id	sid	tid	token	lemma	pos
ihlr-16500	1	1	do	do	AUX
ihlr-16500	1	2	the	the	DET
ihlr-16500	1	3	benefits	benefit	NOUN
ihlr-16500	1	4	outweigh	outweigh	VERB
ihlr-16500	1	5	the	the	DET
ihlr-16500	1	6	risks	risk	NOUN
ihlr-16500	1	7	?	?	PUNCT
ihlr-16500	2	1	the	the	DET
ihlr-16500	2	2	legal	legal	ADJ
ihlr-16500	2	3	,	,	PUNCT
ihlr-16500	2	4	business	business	NOUN
ihlr-16500	2	5	,	,	PUNCT
ihlr-16500	2	6	and	and	CCONJ
ihlr-16500	2	7	etmcal	etmcal	ADJ
ihlr-16500	2	8	ramifications	ramification	NOUN
ihlr-16500	2	9	of	of	ADP
ihlr-16500	2	10	pulling	pull	VERB
ihlr-16500	2	11	a	a	DET
ihlr-16500	2	12	blockbuster	blockbuster	ADJ
ihlr-16500	2	13	drug	drug	NOUN
ihlr-16500	2	14	off	off	ADP
ihlr-16500	2	15	the	the	DET
ihlr-16500	2	16	market	market	NOUN
ihlr-16500	2	17	neil	neil	PROPN
ihlr-16500	2	18	f.	f.	PROPN
ihlr-16500	2	19	hazaray•	hazaray•	ADP
ihlr-16500	2	20	table	table	NOUN
ihlr-16500	2	21	of	of	ADP
ihlr-16500	2	22	contents	content	NOUN
ihlr-16500	2	23	i.	i.	NOUN
ihlr-16500	2	24	introduction	introduction	NOUN
ihlr-16500	2	25	...............................................................................	...............................................................................	PUNCT
ihlr-16500	2	26	116	116	NUM
ihlr-16500	2	27	ii	ii	NOUN
ihlr-16500	2	28	.	.	PUNCT
ihlr-16500	2	29	pharmaceutical	pharmaceutical	PROPN
ihlr-16500	2	30	industry	industry	NOUN
ihlr-16500	2	31	statistics	statistic	NOUN
ihlr-16500	2	32	and	and	CCONJ
ihlr-16500	2	33	the	the	DET
ihlr-16500	2	34	blockbuster	blockbuster	NOUN
ihlr-16500	2	35	drug	drug	NOUN
ihlr-16500	2	36	•	•	PROPN
ihlr-16500	2	37	.....	.....	SYM
ihlr-16500	2	38	••••.••••••	••••.••••••	NOUN
ihlr-16500	2	39	..	..	SYM
ihlr-16500	2	40	•••••	•••••	NOUN
ihlr-16500	2	41	....	....	PUNCT
ihlr-16500	2	42	•••.••••••	•••.••••••	PROPN
ihlr-16500	2	43	..	..	PUNCT
ihlr-16500	2	44	••••••	••••••	NUM
ihlr-16500	2	45	...	...	PUNCT
ihlr-16500	2	46	•	•	NUM
ihlr-16500	2	47	...	...	SYM
ihlr-16500	2	48	•	•	NUM
ihlr-16500	2	49	....	....	PUNCT
ihlr-16500	2	50	•••.	•••.	ADJ
ihlr-16500	2	51	117	117	NUM
ihlr-16500	2	52	a.	a.	NOUN
ihlr-16500	2	53	the	the	DET
ihlr-16500	2	54	blockbuster	blockbuster	NOUN
ihlr-16500	2	55	drug	drug	NOUN
ihlr-16500	2	56	.....	.....	PUNCT
ihlr-16500	2	57	•	•	X
ihlr-16500	2	58	.....................	.....................	SYM
ihlr-16500	2	59	•	•	NUM
ihlr-16500	2	60	......	......	SYM
ihlr-16500	2	61	•	•	NUM
ihlr-16500	2	62	...........................	...........................	SYM
ihlr-16500	2	63	117	117	NUM
ihlr-16500	2	64	b.	b.	NOUN
ihlr-16500	2	65	the	the	DET
ihlr-16500	2	66	drug	drug	NOUN
ihlr-16500	2	67	withdrawal	withdrawal	NOUN
ihlr-16500	2	68	..............................................................	..............................................................	PUNCT
ihlr-16500	2	69	118	118	NUM
ihlr-16500	2	70	c.	c.	NOUN
ihlr-16500	2	71	the	the	DET
ihlr-16500	2	72	pharmaceutical	pharmaceutical	NOUN
ihlr-16500	2	73	industry	industry	NOUN
ihlr-16500	2	74	...................................................	...................................................	PUNCT
ihlr-16500	3	1	118	118	NUM
ihlr-16500	3	2	1	1	NUM
ihlr-16500	3	3	.	.	PUNCT
ihlr-16500	3	4	ongoing	ongoing	ADJ
ihlr-16500	3	5	debate	debate	NOUN
ihlr-16500	3	6	between	between	ADP
ihlr-16500	3	7	pharmaceutical	pharmaceutical	NOUN
ihlr-16500	3	8	industry	industry	NOUN
ihlr-16500	3	9	proponents	proponent	NOUN
ihlr-16500	3	10	and	and	CCONJ
ihlr-16500	3	11	its	its	PRON
ihlr-16500	3	12	critics	critic	NOUN
ihlr-16500	3	13	...................................	...................................	PUNCT
ihlr-16500	4	1	119	119	NUM
ihlr-16500	4	2	2	2	NUM
ihlr-16500	4	3	.	.	PUNCT
ihlr-16500	5	1	the	the	DET
ihlr-16500	5	2	pharmaceutical	pharmaceutical	NOUN
ihlr-16500	5	3	industry	industry	NOUN
ihlr-16500	5	4	's	's	PART
ihlr-16500	5	5	reliance	reliance	NOUN
ihlr-16500	5	6	on	on	ADP
ihlr-16500	5	7	the	the	DET
ihlr-16500	5	8	blockbuster	blockbuster	NOUN
ihlr-16500	5	9	drug	drug	NOUN
ihlr-16500	5	10	....................................................	....................................................	PUNCT
ihlr-16500	5	11	120	120	NUM
ihlr-16500	5	12	3	3	NUM
ihlr-16500	5	13	.	.	PUNCT
ihlr-16500	6	1	the	the	DET
ihlr-16500	6	2	evolving	evolve	VERB
ihlr-16500	6	3	and	and	CCONJ
ihlr-16500	6	4	future	future	ADJ
ihlr-16500	6	5	role	role	NOUN
ihlr-16500	6	6	of	of	ADP
ihlr-16500	6	7	the	the	DET
ihlr-16500	6	8	pharmaceutical	pharmaceutical	NOUN
ihlr-16500	6	9	industry	industry	NOUN
ihlr-16500	6	10	...................................................	...................................................	PUNCT
ihlr-16500	6	11	121	121	NUM
ihlr-16500	6	12	iii	iii	NOUN
ihlr-16500	6	13	.	.	PUNCT
ihlr-16500	7	1	fda	fda	PROPN
ihlr-16500	7	2	drug	drug	PROPN
ihlr-16500	7	3	approval	approval	NOUN
ihlr-16500	7	4	process	process	NOUN
ihlr-16500	7	5	....................................................	....................................................	PUNCT
ihlr-16500	7	6	122	122	NUM
ihlr-16500	7	7	iv	iv	X
ihlr-16500	7	8	.	.	PUNCT
ihlr-16500	8	1	legal	legal	ADJ
ihlr-16500	8	2	ramifications	ramification	NOUN
ihlr-16500	8	3	of	of	ADP
ihlr-16500	8	4	pulling	pull	VERB
ihlr-16500	8	5	a	a	DET
ihlr-16500	8	6	drug	drug	NOUN
ihlr-16500	8	7	off	off	ADP
ihlr-16500	8	8	the	the	DET
ihlr-16500	8	9	market	market	NOUN
ihlr-16500	8	10	.................................................................	.................................................................	PUNCT
ihlr-16500	9	1	125	125	NUM
ihlr-16500	9	2	a.	a.	NOUN
ihlr-16500	9	3	vioxx	vioxx	NOUN
ihlr-16500	9	4	lawsuits	lawsuit	NOUN
ihlr-16500	9	5	:	:	PUNCT
ihlr-16500	9	6	the	the	DET
ihlr-16500	9	7	case	case	NOUN
ihlr-16500	9	8	against	against	ADP
ihlr-16500	9	9	merck	merck	PROPN
ihlr-16500	9	10	................................	................................	PUNCT
ihlr-16500	9	11	126	126	NUM
ihlr-16500	9	12	b.	b.	NOUN
ihlr-16500	9	13	criminal	criminal	ADJ
ihlr-16500	9	14	indictments	indictment	NOUN
ihlr-16500	9	15	and	and	CCONJ
ihlr-16500	9	16	substantial	substantial	ADJ
ihlr-16500	9	17	financial	financial	ADJ
ihlr-16500	9	18	penalties	penalty	NOUN
ihlr-16500	9	19	..................................................................	..................................................................	PUNCT
ihlr-16500	9	20	130	130	NUM
ihlr-16500	9	21	v.	v.	ADP
ihlr-16500	9	22	business	business	NOUN
ihlr-16500	9	23	ramifications	ramification	NOUN
ihlr-16500	9	24	of	of	ADP
ihlr-16500	9	25	pulling	pull	VERB
ihlr-16500	9	26	a	a	DET
ihlr-16500	9	27	drug	drug	NOUN
ihlr-16500	9	28	off	off	ADP
ihlr-16500	9	29	the	the	DET
ihlr-16500	9	30	market	market	NOUN
ihlr-16500	9	31	...........................................................................	...........................................................................	PUNCT
ihlr-16500	9	32	132	132	NUM
ihlr-16500	9	33	vi	vi	NOUN
ihlr-16500	9	34	.	.	PUNCT
ihlr-16500	10	1	etincal	etincal	ADJ
ihlr-16500	10	2	considerations	consideration	NOUN
ihlr-16500	10	3	of	of	ADP
ihlr-16500	10	4	pulling	pull	VERB
ihlr-16500	10	5	a	a	DET
ihlr-16500	10	6	drug	drug	NOUN
ihlr-16500	10	7	off	off	ADP
ihlr-16500	10	8	the	the	DET
ihlr-16500	10	9	market	market	NOUN
ihlr-16500	10	10	...........................................................................	...........................................................................	PUNCT
ihlr-16500	10	11	135	135	NUM
ihlr-16500	10	12	a.	a.	NOUN
ihlr-16500	10	13	ethical	ethical	ADJ
ihlr-16500	10	14	considerations	consideration	NOUN
ihlr-16500	10	15	faced	face	VERB
ihlr-16500	10	16	by	by	ADP
ihlr-16500	10	17	the	the	DET
ihlr-16500	10	18	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	10	19	company	company	NOUN
ihlr-16500	10	20	before	before	ADP
ihlr-16500	10	21	and	and	CCONJ
ihlr-16500	10	22	after	after	ADP
ihlr-16500	10	23	drug	drug	NOUN
ihlr-16500	10	24	withdrawal	withdrawal	NOUN
ihlr-16500	10	25	.............................................................	.............................................................	PUNCT
ihlr-16500	10	26	136	136	NUM
ihlr-16500	10	27	b.	b.	PROPN
ihlr-16500	10	28	a	a	DET
ihlr-16500	10	29	blockbuster	blockbuster	ADJ
ihlr-16500	10	30	drug	drug	NOUN
ihlr-16500	10	31	's	's	PART
ihlr-16500	10	32	withdrawal	withdrawal	NOUN
ihlr-16500	10	33	may	may	AUX
ihlr-16500	10	34	affect	affect	VERB
ihlr-16500	10	35	those	those	DET
ihlr-16500	10	36	patients	patient	NOUN
ihlr-16500	10	37	who	who	PRON
ihlr-16500	10	38	have	have	AUX
ihlr-16500	10	39	not	not	PART
ihlr-16500	10	40	reacted	react	VERB
ihlr-16500	10	41	negatively	negatively	ADV
ihlr-16500	10	42	to	to	ADP
ihlr-16500	10	43	the	the	DET
ihlr-16500	10	44	drug	drug	NOUN
ihlr-16500	10	45	................................................	................................................	PUNCT
ihlr-16500	10	46	139	139	NUM
ihlr-16500	10	47	c.	c.	NOUN
ihlr-16500	10	48	balancing	balance	VERB
ihlr-16500	10	49	ethical	ethical	ADJ
ihlr-16500	10	50	considerations	consideration	NOUN
ihlr-16500	10	51	with	with	ADP
ihlr-16500	10	52	the	the	DET
ihlr-16500	10	53	company	company	NOUN
ihlr-16500	10	54	's	's	PART
ihlr-16500	10	55	stated	state	VERB
ihlr-16500	10	56	goal	goal	NOUN
ihlr-16500	10	57	of	of	ADP
ihlr-16500	10	58	profitability	profitability	NOUN
ihlr-16500	10	59	...................................	...................................	PUNCT
ihlr-16500	10	60	141	141	NUM
ihlr-16500	10	61	vii	vii	NOUN
ihlr-16500	10	62	.	.	PUNCT
ihlr-16500	11	1	considerations	consideration	NOUN
ihlr-16500	11	2	of	of	ADP
ihlr-16500	11	3	culpability	culpability	NOUN
ihlr-16500	11	4	in	in	ADP
ihlr-16500	11	5	pulling	pull	VERB
ihlr-16500	11	6	a	a	DET
ihlr-16500	11	7	drug	drug	NOUN
ihlr-16500	11	8	off	off	ADP
ihlr-16500	11	9	the	the	DET
ihlr-16500	11	10	market	market	NOUN
ihlr-16500	11	11	..............................................................	..............................................................	PUNCT
ihlr-16500	11	12	141	141	NUM
ihlr-16500	11	13	a.	a.	NOUN
ihlr-16500	11	14	to	to	ADP
ihlr-16500	11	15	what	what	DET
ihlr-16500	11	16	extent	extent	NOUN
ihlr-16500	11	17	is	be	AUX
ihlr-16500	11	18	the	the	DET
ihlr-16500	11	19	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	11	20	company	company	NOUN
ihlr-16500	11	21	at	at	ADP
ihlr-16500	11	22	fault	fault	NOUN
ihlr-16500	11	23	?	?	PUNCT
ihlr-16500	12	1	...................................................................	...................................................................	PUNCT
ihlr-16500	13	1	142	142	NUM
ihlr-16500	13	2	b.	b.	NOUN
ihlr-16500	13	3	to	to	ADP
ihlr-16500	13	4	what	what	DET
ihlr-16500	13	5	extent	extent	NOUN
ihlr-16500	13	6	is	be	AUX
ihlr-16500	13	7	the	the	DET
ihlr-16500	13	8	fda	fda	PROPN
ihlr-16500	13	9	at	at	ADP
ihlr-16500	13	10	fault	fault	NOUN
ihlr-16500	13	11	?	?	PUNCT
ihlr-16500	14	1	.......................................	.......................................	PUNCT
ihlr-16500	15	1	143	143	NUM
ihlr-16500	15	2	116	116	NUM
ihlr-16500	15	3	indiana	indiana	PROPN
ihlr-16500	15	4	health	health	PROPN
ihlr-16500	15	5	law	law	PROPN
ihlr-16500	15	6	review	review	NOUN
ihlr-16500	15	7	[	[	X
ihlr-16500	15	8	vol	vol	NOUN
ihlr-16500	15	9	.	.	PUNCT
ihlr-16500	16	1	4:115	4:115	NUM
ihlr-16500	16	2	c.	c.	NOUN
ihlr-16500	16	3	to	to	ADP
ihlr-16500	16	4	what	what	DET
ihlr-16500	16	5	extent	extent	NOUN
ihlr-16500	16	6	is	be	AUX
ihlr-16500	16	7	the	the	DET
ihlr-16500	16	8	health	health	NOUN
ihlr-16500	16	9	care	care	NOUN
ihlr-16500	16	10	professional	professional	ADJ
ihlr-16500	16	11	at	at	ADP
ihlr-16500	16	12	fault	fault	NOUN
ihlr-16500	16	13	?	?	PUNCT
ihlr-16500	17	1	..............................................................	..............................................................	PUNCT
ihlr-16500	18	1	144	144	NUM
ihlr-16500	18	2	d.	d.	PROPN
ihlr-16500	18	3	shared	share	VERB
ihlr-16500	18	4	culpability	culpability	NOUN
ihlr-16500	18	5	among	among	ADP
ihlr-16500	18	6	all	all	DET
ihlr-16500	18	7	parties	party	NOUN
ihlr-16500	18	8	involved	involve	VERB
ihlr-16500	18	9	?	?	PUNCT
ihlr-16500	18	10	....................	....................	PUNCT
ihlr-16500	19	1	145	145	NUM
ihlr-16500	19	2	viii	viii	ADJ
ihlr-16500	19	3	.	.	PUNCT
ihlr-16500	20	1	possmle	possmle	PROPN
ihlr-16500	20	2	solutions	solution	NOUN
ihlr-16500	20	3	.......................	.......................	PUNCT
ihlr-16500	20	4	;	;	PUNCT
ihlr-16500	20	5	.............................................	.............................................	PUNCT
ihlr-16500	20	6	145	145	NUM
ihlr-16500	20	7	a.	a.	NOUN
ihlr-16500	20	8	allow	allow	VERB
ihlr-16500	20	9	the	the	DET
ihlr-16500	20	10	withdrawn	withdraw	VERB
ihlr-16500	20	11	drug	drug	NOUN
ihlr-16500	20	12	to	to	PART
ihlr-16500	20	13	reenter	reenter	VERB
ihlr-16500	20	14	the	the	DET
ihlr-16500	20	15	market	market	NOUN
ihlr-16500	20	16	under	under	ADP
ihlr-16500	20	17	restricted	restricted	ADJ
ihlr-16500	20	18	conditions	condition	NOUN
ihlr-16500	20	19	........................................	........................................	PUNCT
ihlr-16500	20	20	l46	l46	PROPN
ihlr-16500	20	21	b.	b.	PROPN
ihlr-16500	20	22	create	create	VERB
ihlr-16500	20	23	medical	medical	ADJ
ihlr-16500	20	24	liability	liability	NOUN
ihlr-16500	20	25	review	review	NOUN
ihlr-16500	20	26	panels	panel	NOUN
ihlr-16500	20	27	in	in	ADP
ihlr-16500	20	28	order	order	NOUN
ihlr-16500	20	29	to	to	PART
ihlr-16500	20	30	reduce	reduce	VERB
ihlr-16500	20	31	the	the	DET
ihlr-16500	20	32	number	number	NOUN
ihlr-16500	20	33	of	of	ADP
ihlr-16500	20	34	frivolous	frivolous	ADJ
ihlr-16500	20	35	lawsuits	lawsuit	NOUN
ihlr-16500	20	36	................	................	PUNCT
ihlr-16500	21	1	147	147	NUM
ihlr-16500	21	2	c.	c.	NOUN
ihlr-16500	21	3	create	create	VERB
ihlr-16500	21	4	an	an	DET
ihlr-16500	21	5	independent	independent	ADJ
ihlr-16500	21	6	drug	drug	NOUN
ihlr-16500	21	7	monitoring	monitoring	NOUN
ihlr-16500	21	8	board	board	NOUN
ihlr-16500	21	9	......................	......................	PUNCT
ihlr-16500	22	1	14	14	NUM
ihlr-16500	22	2	7	7	NUM
ihlr-16500	22	3	ix	ix	X
ihlr-16500	22	4	.	.	PUNCT
ihlr-16500	22	5	conclusion	conclusion	NOUN
ihlr-16500	22	6	...................................................................................	...................................................................................	PUNCT
ihlr-16500	23	1	l48	l48	PROPN
ihlr-16500	23	2	i.	i.	PROPN
ihlr-16500	23	3	in1roduction	in1roduction	PROPN
ihlr-16500	23	4	the	the	DET
ihlr-16500	23	5	pharmaceutical	pharmaceutical	NOUN
ihlr-16500	23	6	industry	industry	NOUN
ihlr-16500	23	7	has	have	AUX
ihlr-16500	23	8	played	play	VERB
ihlr-16500	23	9	an	an	DET
ihlr-16500	23	10	important	important	ADJ
ihlr-16500	23	11	role	role	NOUN
ihlr-16500	23	12	throughout	throughout	ADP
ihlr-16500	23	13	world	world	NOUN
ihlr-16500	23	14	history	history	NOUN
ihlr-16500	23	15	.	.	PUNCT
ihlr-16500	24	1	this	this	DET
ihlr-16500	24	2	industry	industry	NOUN
ihlr-16500	24	3	is	be	AUX
ihlr-16500	24	4	responsible	responsible	ADJ
ihlr-16500	24	5	for	for	ADP
ihlr-16500	24	6	developing	develop	VERB
ihlr-16500	24	7	,	,	PUNCT
ihlr-16500	24	8	manufacturing	manufacturing	NOUN
ihlr-16500	24	9	,	,	PUNCT
ihlr-16500	24	10	and	and	CCONJ
ihlr-16500	24	11	distributing	distribute	VERB
ihlr-16500	24	12	lifesaving	lifesaving	NOUN
ihlr-16500	24	13	and	and	CCONJ
ihlr-16500	24	14	sustaining	sustain	VERB
ihlr-16500	24	15	medicines	medicine	NOUN
ihlr-16500	24	16	.	.	PUNCT
ihlr-16500	25	1	today	today	NOUN
ihlr-16500	25	2	,	,	PUNCT
ihlr-16500	25	3	due	due	ADP
ihlr-16500	25	4	to	to	ADP
ihlr-16500	25	5	medicines	medicine	NOUN
ihlr-16500	25	6	de­	de­	NOUN
ihlr-16500	25	7	veloped	velope	VERB
ihlr-16500	25	8	by	by	ADP
ihlr-16500	25	9	the	the	DET
ihlr-16500	25	10	pharmaceutical	pharmaceutical	NOUN
ihlr-16500	25	11	industry	industry	NOUN
ihlr-16500	25	12	,	,	PUNCT
ihlr-16500	25	13	human	human	ADJ
ihlr-16500	25	14	beings	being	NOUN
ihlr-16500	25	15	are	be	AUX
ihlr-16500	25	16	living	live	VERB
ihlr-16500	25	17	healthier	healthy	ADJ
ihlr-16500	25	18	and	and	CCONJ
ihlr-16500	25	19	longer	long	ADJ
ihlr-16500	25	20	lives	life	NOUN
ihlr-16500	25	21	.	.	PUNCT
ihlr-16500	26	1	like	like	ADP
ihlr-16500	26	2	most	most	ADJ
ihlr-16500	26	3	industries	industry	NOUN
ihlr-16500	26	4	,	,	PUNCT
ihlr-16500	26	5	however	however	ADV
ihlr-16500	26	6	,	,	PUNCT
ihlr-16500	26	7	the	the	DET
ihlr-16500	26	8	pharmaceutical	pharmaceutical	NOUN
ihlr-16500	26	9	industry	industry	NOUN
ihlr-16500	26	10	has	have	AUX
ihlr-16500	26	11	also	also	ADV
ihlr-16500	26	12	been	be	AUX
ihlr-16500	26	13	plagued	plague	VERB
ihlr-16500	26	14	with	with	ADP
ihlr-16500	26	15	problems	problem	NOUN
ihlr-16500	26	16	in	in	ADP
ihlr-16500	26	17	recent	recent	ADJ
ihlr-16500	26	18	years	year	NOUN
ihlr-16500	26	19	.	.	PUNCT
ihlr-16500	27	1	presently	presently	ADV
ihlr-16500	27	2	,	,	PUNCT
ihlr-16500	27	3	more	more	ADJ
ihlr-16500	27	4	drugs	drug	NOUN
ihlr-16500	27	5	are	be	AUX
ihlr-16500	27	6	being	be	AUX
ihlr-16500	27	7	pulled	pull	VERB
ihlr-16500	27	8	off	off	ADP
ihlr-16500	27	9	the	the	DET
ihlr-16500	27	10	market	market	NOUN
ihlr-16500	27	11	than	than	ADP
ihlr-16500	27	12	ever	ever	ADV
ihlr-16500	27	13	before	before	ADV
ihlr-16500	27	14	because	because	SCONJ
ihlr-16500	27	15	of	of	ADP
ihlr-16500	27	16	safety	safety	NOUN
ihlr-16500	27	17	concerns	concern	NOUN
ihlr-16500	27	18	.	.	PUNCT
ihlr-16500	28	1	this	this	PRON
ihlr-16500	28	2	has	have	AUX
ihlr-16500	28	3	been	be	AUX
ihlr-16500	28	4	followed	follow	VERB
ihlr-16500	28	5	by	by	ADP
ihlr-16500	28	6	a	a	DET
ihlr-16500	28	7	wave	wave	NOUN
ihlr-16500	28	8	oflawsuits	oflawsuit	NOUN
ihlr-16500	28	9	aimed	aim	VERB
ihlr-16500	28	10	at	at	ADP
ihlr-16500	28	11	correcting	correct	VERB
ihlr-16500	28	12	the	the	DET
ihlr-16500	28	13	error	error	NOUN
ihlr-16500	28	14	of	of	ADP
ihlr-16500	28	15	allow­	allow­	PRON
ihlr-16500	28	16	ing	e	VERB
ihlr-16500	28	17	such	such	ADJ
ihlr-16500	28	18	drugs	drug	NOUN
ihlr-16500	28	19	on	on	ADP
ihlr-16500	28	20	the	the	DET
ihlr-16500	28	21	market	market	NOUN
ihlr-16500	28	22	in	in	ADP
ihlr-16500	28	23	the	the	DET
ihlr-16500	28	24	first	first	ADJ
ihlr-16500	28	25	place	place	NOUN
ihlr-16500	28	26	.	.	PUNCT
ihlr-16500	29	1	as	as	ADP
ihlr-16500	29	2	a	a	DET
ihlr-16500	29	3	result	result	NOUN
ihlr-16500	29	4	,	,	PUNCT
ihlr-16500	29	5	the	the	DET
ihlr-16500	29	6	pharmaceutical	pharmaceutical	NOUN
ihlr-16500	29	7	industry	industry	NOUN
ihlr-16500	29	8	has	have	AUX
ihlr-16500	29	9	faced	face	VERB
ihlr-16500	29	10	increasing	increase	VERB
ihlr-16500	29	11	amounts	amount	NOUN
ihlr-16500	29	12	of	of	ADP
ihlr-16500	29	13	negative	negative	ADJ
ihlr-16500	29	14	publicity	publicity	NOUN
ihlr-16500	29	15	and	and	CCONJ
ihlr-16500	29	16	a	a	DET
ihlr-16500	29	17	lack	lack	NOUN
ihlr-16500	29	18	of	of	ADP
ihlr-16500	29	19	confi­	confi­	NOUN
ihlr-16500	29	20	dence	dence	NOUN
ihlr-16500	29	21	from	from	ADP
ihlr-16500	29	22	investors	investor	NOUN
ihlr-16500	29	23	and	and	CCONJ
ihlr-16500	29	24	consumers	consumer	NOUN
ihlr-16500	29	25	alike	alike	ADV
ihlr-16500	29	26	.	.	PUNCT
ihlr-16500	30	1	in	in	ADP
ihlr-16500	30	2	the	the	DET
ihlr-16500	30	3	united	united	PROPN
ihlr-16500	30	4	states	states	PROPN
ihlr-16500	30	5	,	,	PUNCT
ihlr-16500	30	6	most	most	ADJ
ihlr-16500	30	7	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	30	8	companies	company	NOUN
ihlr-16500	30	9	promote	promote	VERB
ihlr-16500	30	10	the	the	DET
ihlr-16500	30	11	dual	dual	ADJ
ihlr-16500	30	12	ob­	ob­	NOUN
ihlr-16500	30	13	jective	jective	NOUN
ihlr-16500	30	14	of	of	ADP
ihlr-16500	30	15	providing	provide	VERB
ihlr-16500	30	16	health	health	NOUN
ihlr-16500	30	17	care	care	NOUN
ihlr-16500	30	18	to	to	ADP
ihlr-16500	30	19	the	the	DET
ihlr-16500	30	20	general	general	ADJ
ihlr-16500	30	21	public	public	NOUN
ihlr-16500	30	22	while	while	SCONJ
ihlr-16500	30	23	making	make	VERB
ihlr-16500	30	24	a	a	DET
ihlr-16500	30	25	profit	profit	NOUN
ihlr-16500	30	26	for	for	ADP
ihlr-16500	30	27	their	their	PRON
ihlr-16500	30	28	shareholders	shareholder	NOUN
ihlr-16500	30	29	.	.	PUNCT
ihlr-16500	31	1	this	this	PRON
ihlr-16500	31	2	is	be	AUX
ihlr-16500	31	3	often	often	ADV
ihlr-16500	31	4	a	a	DET
ihlr-16500	31	5	contentious	contentious	ADJ
ihlr-16500	31	6	proposition	proposition	NOUN
ihlr-16500	31	7	because	because	SCONJ
ihlr-16500	31	8	companies	company	NOUN
ihlr-16500	31	9	will	will	AUX
ihlr-16500	31	10	place	place	VERB
ihlr-16500	31	11	a	a	DET
ihlr-16500	31	12	greater	great	ADJ
ihlr-16500	31	13	priority	priority	NOUN
ihlr-16500	31	14	on	on	ADP
ihlr-16500	31	15	achieving	achieve	VERB
ihlr-16500	31	16	the	the	DET
ihlr-16500	31	17	latter	latter	ADJ
ihlr-16500	31	18	rather	rather	ADV
ihlr-16500	31	19	than	than	ADP
ihlr-16500	31	20	the	the	DET
ihlr-16500	31	21	former	former	NOUN
ihlr-16500	31	22	.	.	PUNCT
ihlr-16500	32	1	moreover	moreover	ADV
ihlr-16500	32	2	,	,	PUNCT
ihlr-16500	32	3	the	the	DET
ihlr-16500	32	4	irony	irony	NOUN
ihlr-16500	32	5	of	of	ADP
ihlr-16500	32	6	this	this	DET
ihlr-16500	32	7	dual	dual	ADJ
ihlr-16500	32	8	objective	objective	NOUN
ihlr-16500	32	9	is	be	AUX
ihlr-16500	32	10	that	that	SCONJ
ihlr-16500	32	11	most	most	ADV
ihlr-16500	32	12	large	large	ADJ
ihlr-16500	32	13	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	32	14	conglomerates	conglomerate	NOUN
ihlr-16500	32	15	,	,	PUNCT
ihlr-16500	32	16	such	such	ADJ
ihlr-16500	32	17	as	as	ADP
ihlr-16500	32	18	merck	merck	NOUN
ihlr-16500	32	19	,	,	PUNCT
ihlr-16500	32	20	pfizer	pfizer	NOUN
ihlr-16500	32	21	,	,	PUNCT
ihlr-16500	32	22	and	and	CCONJ
ihlr-16500	32	23	glaxosmithkline	glaxosmithkline	PROPN
ihlr-16500	32	24	,	,	PUNCT
ihlr-16500	32	25	are	be	AUX
ihlr-16500	32	26	publicly	publicly	ADV
ihlr-16500	32	27	traded	trade	VERB
ihlr-16500	32	28	companies	company	NOUN
ihlr-16500	32	29	.	.	PUNCT
ihlr-16500	32	30	'	'	PUNCT
ihlr-16500	33	1	pharmaceutical	pharmaceutical	NOUN
ihlr-16500	33	2	companies	company	NOUN
ihlr-16500	33	3	aim	aim	VERB
ihlr-16500	33	4	to	to	PART
ihlr-16500	33	5	maximize	maximize	VERB
ihlr-16500	33	6	wealth	wealth	NOUN
ihlr-16500	33	7	for	for	ADP
ihlr-16500	33	8	their	their	PRON
ihlr-16500	33	9	stakeholders	stakeholder	NOUN
ihlr-16500	33	10	(	(	PUNCT
ihlr-16500	33	11	shareholders	shareholder	NOUN
ihlr-16500	33	12	in	in	ADP
ihlr-16500	33	13	the	the	DET
ihlr-16500	33	14	case	case	NOUN
ihlr-16500	33	15	of	of	ADP
ihlr-16500	33	16	a	a	DET
ihlr-16500	33	17	publicly	publicly	ADV
ihlr-16500	33	18	held	hold	VERB
ihlr-16500	33	19	corporation	corporation	NOUN
ihlr-16500	33	20	and	and	CCONJ
ihlr-16500	33	21	owners	owner	NOUN
ihlr-16500	33	22	in	in	ADP
ihlr-16500	33	23	the	the	DET
ihlr-16500	33	24	case	case	NOUN
ihlr-16500	33	25	of	of	ADP
ihlr-16500	33	26	a	a	DET
ihlr-16500	33	27	closely	closely	ADV
ihlr-16500	33	28	held	hold	VERB
ihlr-16500	33	29	corporation	corporation	NOUN
ihlr-16500	33	30	)	)	PUNCT
ihlr-16500	33	31	.	.	PUNCT
ihlr-16500	34	1	therefore	therefore	ADV
ihlr-16500	34	2	,	,	PUNCT
ihlr-16500	34	3	in	in	ADP
ihlr-16500	34	4	order	order	NOUN
ihlr-16500	34	5	to	to	PART
ihlr-16500	34	6	do	do	AUX
ihlr-16500	34	7	so	so	ADV
ihlr-16500	34	8	,	,	PUNCT
ihlr-16500	34	9	*	*	PUNCT
ihlr-16500	34	10	j.d	j.d	PROPN
ihlr-16500	34	11	.	.	PROPN
ihlr-16500	34	12	candidate	candidate	PROPN
ihlr-16500	34	13	,	,	PUNCT
ihlr-16500	34	14	2007	2007	NUM
ihlr-16500	34	15	,	,	PUNCT
ihlr-16500	34	16	indiana	indiana	PROPN
ihlr-16500	34	17	university	university	PROPN
ihlr-16500	34	18	school	school	NOUN
ihlr-16500	34	19	of	of	ADP
ihlr-16500	34	20	law	law	NOUN
ihlr-16500	34	21	,	,	PUNCT
ihlr-16500	34	22	indianapolis	indianapolis	PROPN
ihlr-16500	34	23	,	,	PUNCT
ihlr-16500	34	24	indiana	indiana	PROPN
ihlr-16500	34	25	;	;	PUNCT
ihlr-16500	34	26	m.b.a	m.b.a	ADJ
ihlr-16500	34	27	.	.	PUNCT
ihlr-16500	34	28	candidate	candidate	PROPN
ihlr-16500	34	29	,	,	PUNCT
ihlr-16500	34	30	2007	2007	NUM
ihlr-16500	34	31	,	,	PUNCT
ihlr-16500	34	32	indiana	indiana	PROPN
ihlr-16500	34	33	university	university	PROPN
ihlr-16500	34	34	kelley	kelley	PROPN
ihlr-16500	34	35	school	school	PROPN
ihlr-16500	34	36	of	of	ADP
ihlr-16500	34	37	business	business	NOUN
ihlr-16500	34	38	,	,	PUNCT
ihlr-16500	34	39	indianapolis	indianapolis	PROPN
ihlr-16500	34	40	,	,	PUNCT
ihlr-16500	34	41	indiana	indiana	PROPN
ihlr-16500	34	42	;	;	PUNCT
ihlr-16500	34	43	b.s	b.s	PROPN
ihlr-16500	34	44	.	.	PROPN
ihlr-16500	34	45	,	,	PUNCT
ihlr-16500	34	46	2002	2002	NUM
ihlr-16500	34	47	,	,	PUNCT
ihlr-16500	34	48	indiana	indiana	PROPN
ihlr-16500	34	49	university	university	PROPN
ihlr-16500	34	50	,	,	PUNCT
ihlr-16500	34	51	bloomington	bloomington	PROPN
ihlr-16500	34	52	,	,	PUNCT
ihlr-16500	34	53	indiana	indiana	PROPN
ihlr-16500	34	54	.	.	PUNCT
ihlr-16500	35	1	i	i	PRON
ihlr-16500	35	2	would	would	AUX
ihlr-16500	35	3	especially	especially	ADV
ihlr-16500	35	4	like	like	VERB
ihlr-16500	35	5	to	to	PART
ihlr-16500	35	6	express	express	VERB
ihlr-16500	35	7	my	my	PRON
ihlr-16500	35	8	gratitude	gratitude	NOUN
ihlr-16500	35	9	to	to	ADP
ihlr-16500	35	10	my	my	PRON
ihlr-16500	35	11	mother	mother	NOUN
ihlr-16500	35	12	,	,	PUNCT
ihlr-16500	35	13	father	father	NOUN
ihlr-16500	35	14	,	,	PUNCT
ihlr-16500	35	15	and	and	CCONJ
ihlr-16500	35	16	siblings	sibling	NOUN
ihlr-16500	35	17	,	,	PUNCT
ihlr-16500	35	18	sean	sean	PROPN
ihlr-16500	35	19	and	and	CCONJ
ihlr-16500	35	20	sasha	sasha	PROPN
ihlr-16500	35	21	,	,	PUNCT
ihlr-16500	35	22	for	for	ADP
ihlr-16500	35	23	their	their	PRON
ihlr-16500	35	24	lifelong	lifelong	ADJ
ihlr-16500	35	25	encouragement	encouragement	NOUN
ihlr-16500	35	26	and	and	CCONJ
ihlr-16500	35	27	support	support	NOUN
ihlr-16500	35	28	.	.	PUNCT
ihlr-16500	36	1	i	i	PRON
ihlr-16500	36	2	would	would	AUX
ihlr-16500	36	3	also	also	ADV
ihlr-16500	36	4	like	like	VERB
ihlr-16500	36	5	to	to	PART
ihlr-16500	36	6	thank	thank	VERB
ihlr-16500	36	7	rachel	rachel	PROPN
ihlr-16500	36	8	for	for	ADP
ihlr-16500	36	9	all	all	DET
ihlr-16500	36	10	her	her	PRON
ihlr-16500	36	11	love	love	NOUN
ihlr-16500	36	12	,	,	PUNCT
ihlr-16500	36	13	guidance	guidance	NOUN
ihlr-16500	36	14	,	,	PUNCT
ihlr-16500	36	15	and	and	CCONJ
ihlr-16500	36	16	support	support	NOUN
ihlr-16500	36	17	.	.	PUNCT
ihlr-16500	37	1	in	in	ADP
ihlr-16500	37	2	addi­	addi­	NUM
ihlr-16500	37	3	tion	tion	NOUN
ihlr-16500	37	4	,	,	PUNCT
ihlr-16500	37	5	i	i	PRON
ihlr-16500	37	6	would	would	AUX
ihlr-16500	37	7	like	like	VERB
ihlr-16500	37	8	to	to	PART
ihlr-16500	37	9	thank	thank	VERB
ihlr-16500	37	10	david	david	PROPN
ihlr-16500	37	11	jose	jose	PROPN
ihlr-16500	37	12	for	for	ADP
ihlr-16500	37	13	the	the	DET
ihlr-16500	37	14	helpful	helpful	ADJ
ihlr-16500	37	15	suggestions	suggestion	NOUN
ihlr-16500	37	16	and	and	CCONJ
ihlr-16500	37	17	invaluable	invaluable	ADJ
ihlr-16500	37	18	insight	insight	NOUN
ihlr-16500	37	19	he	he	PRON
ihlr-16500	37	20	pro­	pro­	VERB
ihlr-16500	37	21	vided	vide	VERB
ihlr-16500	37	22	me	i	PRON
ihlr-16500	37	23	as	as	SCONJ
ihlr-16500	37	24	i	i	PRON
ihlr-16500	37	25	wrote	write	VERB
ihlr-16500	37	26	this	this	DET
ihlr-16500	37	27	note	note	NOUN
ihlr-16500	37	28	.	.	PUNCT
ihlr-16500	38	1	1	1	NUM
ihlr-16500	38	2	see	see	VERB
ihlr-16500	38	3	generally	generally	ADV
ihlr-16500	38	4	yahoo	yahoo	PROPN
ihlr-16500	38	5	!	!	PUNCT
ihlr-16500	38	6	finance	finance	PROPN
ihlr-16500	38	7	home	home	NOUN
ihlr-16500	38	8	page	page	NOUN
ihlr-16500	38	9	,	,	PUNCT
ihlr-16500	38	10	http://finance.yahoo.com	http://finance.yahoo.com	X
ihlr-16500	38	11	(	(	PUNCT
ihlr-16500	38	12	last	last	ADJ
ihlr-16500	38	13	visited	visit	VERB
ihlr-16500	38	14	feb	feb	PROPN
ihlr-16500	38	15	.	.	PROPN
ihlr-16500	38	16	15	15	NUM
ihlr-16500	38	17	,	,	PUNCT
ihlr-16500	38	18	2007	2007	NUM
ihlr-16500	38	19	)	)	PUNCT
ihlr-16500	38	20	.	.	PUNCT
ihlr-16500	39	1	merck	merck	PROPN
ihlr-16500	39	2	,	,	PUNCT
ihlr-16500	39	3	glaxosmithkline	glaxosmithkline	PROPN
ihlr-16500	39	4	,	,	PUNCT
ihlr-16500	39	5	and	and	CCONJ
ihlr-16500	39	6	pfizer	pfizer	NOUN
ihlr-16500	39	7	stock	stock	NOUN
ihlr-16500	39	8	are	be	AUX
ihlr-16500	39	9	traded	trade	VERB
ihlr-16500	39	10	on	on	ADP
ihlr-16500	39	11	the	the	DET
ihlr-16500	39	12	new	new	PROPN
ihlr-16500	39	13	york	york	PROPN
ihlr-16500	39	14	stock	stock	PROPN
ihlr-16500	39	15	ex­	ex­	PROPN
ihlr-16500	39	16	change	change	NOUN
ihlr-16500	39	17	.	.	PUNCT
ihlr-16500	40	1	/d	/d	INTJ
ihlr-16500	40	2	.	.	PUNCT
ihlr-16500	41	1	2007	2007	NUM
ihlr-16500	41	2	]	]	PUNCT
ihlr-16500	42	1	pulling	pull	VERB
ihlr-16500	42	2	a	a	DET
ihlr-16500	42	3	blockbuster	blockbuster	ADJ
ihlr-16500	42	4	drug	drug	NOUN
ihlr-16500	42	5	off	off	ADP
ihlr-16500	42	6	the	the	DET
ihlr-16500	42	7	market	market	NOUN
ihlr-16500	42	8	117	117	NUM
ihlr-16500	42	9	the	the	DET
ihlr-16500	42	10	objective	objective	NOUN
ihlr-16500	42	11	of	of	ADP
ihlr-16500	42	12	every	every	DET
ihlr-16500	42	13	major	major	ADJ
ihlr-16500	42	14	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	42	15	company	company	NOUN
ihlr-16500	42	16	is	be	AUX
ihlr-16500	42	17	to	to	PART
ihlr-16500	42	18	produce	produce	VERB
ihlr-16500	42	19	a	a	DET
ihlr-16500	42	20	block­	block­	PROPN
ihlr-16500	42	21	buster	buster	NOUN
ihlr-16500	42	22	drug	drug	NOUN
ihlr-16500	42	23	.	.	PUNCT
ihlr-16500	43	1	because	because	SCONJ
ihlr-16500	43	2	of	of	ADP
ihlr-16500	43	3	the	the	DET
ihlr-16500	43	4	relative	relative	ADJ
ihlr-16500	43	5	importance	importance	NOUN
ihlr-16500	43	6	of	of	ADP
ihlr-16500	43	7	producing	produce	VERB
ihlr-16500	43	8	a	a	DET
ihlr-16500	43	9	blockbuster	blockbuster	ADJ
ihlr-16500	43	10	drug	drug	NOUN
ihlr-16500	43	11	,	,	PUNCT
ihlr-16500	43	12	a	a	DET
ihlr-16500	43	13	withdrawal	withdrawal	NOUN
ihlr-16500	43	14	from	from	ADP
ihlr-16500	43	15	the	the	DET
ihlr-16500	43	16	market	market	NOUN
ihlr-16500	43	17	of	of	ADP
ihlr-16500	43	18	this	this	DET
ihlr-16500	43	19	drug	drug	NOUN
ihlr-16500	43	20	can	can	AUX
ihlr-16500	43	21	have	have	VERB
ihlr-16500	43	22	severe	severe	ADJ
ihlr-16500	43	23	consequences	consequence	NOUN
ihlr-16500	43	24	for	for	ADP
ihlr-16500	43	25	the	the	DET
ihlr-16500	43	26	respective	respective	ADJ
ihlr-16500	43	27	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	43	28	company	company	NOUN
ihlr-16500	43	29	.	.	PUNCT
ihlr-16500	44	1	subsequently	subsequently	ADV
ihlr-16500	44	2	,	,	PUNCT
ihlr-16500	44	3	questions	question	NOUN
ihlr-16500	44	4	arise	arise	VERB
ihlr-16500	44	5	as	as	ADP
ihlr-16500	44	6	to	to	ADP
ihlr-16500	44	7	whether	whether	SCONJ
ihlr-16500	44	8	the	the	DET
ihlr-16500	44	9	lure	lure	NOUN
ihlr-16500	44	10	of	of	ADP
ihlr-16500	44	11	profit	profit	NOUN
ihlr-16500	44	12	blinded	blind	VERB
ihlr-16500	44	13	the	the	DET
ihlr-16500	44	14	company	company	NOUN
ihlr-16500	44	15	into	into	ADP
ihlr-16500	44	16	developing	develop	VERB
ihlr-16500	44	17	a	a	DET
ihlr-16500	44	18	potentially	potentially	ADV
ihlr-16500	44	19	unsafe	unsafe	ADJ
ihlr-16500	44	20	drug	drug	NOUN
ihlr-16500	44	21	.	.	PUNCT
ihlr-16500	45	1	in	in	ADP
ihlr-16500	45	2	answering	answer	VERB
ihlr-16500	45	3	this	this	DET
ihlr-16500	45	4	question	question	NOUN
ihlr-16500	45	5	,	,	PUNCT
ihlr-16500	45	6	it	it	PRON
ihlr-16500	45	7	is	be	AUX
ihlr-16500	45	8	important	important	ADJ
ihlr-16500	45	9	to	to	PART
ihlr-16500	45	10	examine	examine	VERB
ihlr-16500	45	11	the	the	DET
ihlr-16500	45	12	legal	legal	ADJ
ihlr-16500	45	13	,	,	PUNCT
ihlr-16500	45	14	business	business	NOUN
ihlr-16500	45	15	,	,	PUNCT
ihlr-16500	45	16	and	and	CCONJ
ihlr-16500	45	17	ethical	ethical	ADJ
ihlr-16500	45	18	ramifications	ramification	NOUN
ihlr-16500	45	19	for	for	ADP
ihlr-16500	45	20	all	all	DET
ihlr-16500	45	21	parties	party	NOUN
ihlr-16500	45	22	involved	involve	VERB
ihlr-16500	45	23	:	:	PUNCT
ihlr-16500	45	24	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	45	25	companies	company	NOUN
ihlr-16500	45	26	,	,	PUNCT
ihlr-16500	45	27	federal	federal	ADJ
ihlr-16500	45	28	regulatory	regulatory	ADJ
ihlr-16500	45	29	agencies	agency	NOUN
ihlr-16500	45	30	,	,	PUNCT
ihlr-16500	45	31	and	and	CCONJ
ihlr-16500	45	32	patients	patient	NOUN
ihlr-16500	45	33	who	who	PRON
ihlr-16500	45	34	use	use	VERB
ihlr-16500	45	35	the	the	DET
ihlr-16500	45	36	drugs	drug	NOUN
ihlr-16500	45	37	.	.	PUNCT
ihlr-16500	46	1	this	this	DET
ihlr-16500	46	2	note	note	NOUN
ihlr-16500	46	3	will	will	AUX
ihlr-16500	46	4	discuss	discuss	VERB
ihlr-16500	46	5	the	the	DET
ihlr-16500	46	6	significant	significant	ADJ
ihlr-16500	46	7	ramifications	ramification	NOUN
ihlr-16500	46	8	of	of	ADP
ihlr-16500	46	9	withdrawing	withdraw	VERB
ihlr-16500	46	10	a	a	DET
ihlr-16500	46	11	blockbuster	blockbuster	ADJ
ihlr-16500	46	12	drug	drug	NOUN
ihlr-16500	46	13	from	from	ADP
ihlr-16500	46	14	the	the	DET
ihlr-16500	46	15	market	market	NOUN
ihlr-16500	46	16	and	and	CCONJ
ihlr-16500	46	17	how	how	SCONJ
ihlr-16500	46	18	such	such	DET
ihlr-16500	46	19	a	a	DET
ihlr-16500	46	20	decision	decision	NOUN
ihlr-16500	46	21	may	may	AUX
ihlr-16500	46	22	impact	impact	VERB
ihlr-16500	46	23	particu­	particu­	VERB
ihlr-16500	46	24	lar	lar	ADJ
ihlr-16500	46	25	persons	person	NOUN
ihlr-16500	46	26	or	or	CCONJ
ihlr-16500	46	27	entities	entity	NOUN
ihlr-16500	46	28	.	.	PUNCT
ihlr-16500	47	1	part	part	NOUN
ihlr-16500	47	2	ii	ii	PROPN
ihlr-16500	47	3	will	will	AUX
ihlr-16500	47	4	define	define	VERB
ihlr-16500	47	5	a	a	DET
ihlr-16500	47	6	blockbuster	blockbuster	ADJ
ihlr-16500	47	7	drug	drug	NOUN
ihlr-16500	47	8	and	and	CCONJ
ihlr-16500	47	9	a	a	DET
ihlr-16500	47	10	subsequent	subsequent	ADJ
ihlr-16500	47	11	withdrawal	withdrawal	NOUN
ihlr-16500	47	12	from	from	ADP
ihlr-16500	47	13	the	the	DET
ihlr-16500	47	14	market	market	NOUN
ihlr-16500	47	15	.	.	PUNCT
ihlr-16500	48	1	in	in	ADP
ihlr-16500	48	2	addition	addition	NOUN
ihlr-16500	48	3	,	,	PUNCT
ihlr-16500	48	4	it	it	PRON
ihlr-16500	48	5	will	will	AUX
ihlr-16500	48	6	examine	examine	VERB
ihlr-16500	48	7	the	the	DET
ihlr-16500	48	8	recent	recent	ADJ
ihlr-16500	48	9	growth	growth	NOUN
ihlr-16500	48	10	and	and	CCONJ
ihlr-16500	48	11	role	role	NOUN
ihlr-16500	48	12	of	of	ADP
ihlr-16500	48	13	the	the	DET
ihlr-16500	48	14	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	48	15	industry	industry	NOUN
ihlr-16500	48	16	in	in	ADP
ihlr-16500	48	17	the	the	DET
ihlr-16500	48	18	development	development	NOUN
ihlr-16500	48	19	of	of	ADP
ihlr-16500	48	20	novel	novel	ADJ
ihlr-16500	48	21	blockbuster	blockbuster	NOUN
ihlr-16500	48	22	drugs	drug	NOUN
ihlr-16500	48	23	.	.	PUNCT
ihlr-16500	49	1	part	part	NOUN
ihlr-16500	49	2	iii	iii	PRON
ihlr-16500	49	3	will	will	AUX
ihlr-16500	49	4	examine	examine	VERB
ihlr-16500	49	5	the	the	DET
ihlr-16500	49	6	drug	drug	NOUN
ihlr-16500	49	7	approval	approval	NOUN
ihlr-16500	49	8	process	process	NOUN
ihlr-16500	49	9	in	in	ADP
ihlr-16500	49	10	the	the	DET
ihlr-16500	49	11	united	united	PROPN
ihlr-16500	49	12	states	states	PROPN
ihlr-16500	49	13	,	,	PUNCT
ihlr-16500	49	14	specifically	specifically	ADV
ihlr-16500	49	15	the	the	DET
ihlr-16500	49	16	steps	step	NOUN
ihlr-16500	49	17	involved	involve	VERB
ihlr-16500	49	18	in	in	ADP
ihlr-16500	49	19	obtaining	obtain	VERB
ihlr-16500	49	20	food	food	NOUN
ihlr-16500	49	21	and	and	CCONJ
ihlr-16500	49	22	drug	drug	PROPN
ihlr-16500	49	23	administration	administration	NOUN
ihlr-16500	49	24	(	(	PUNCT
ihlr-16500	49	25	"	"	PUNCT
ihlr-16500	49	26	fda	fda	PROPN
ihlr-16500	49	27	"	"	PUNCT
ihlr-16500	49	28	)	)	PUNCT
ihlr-16500	49	29	approval	approval	NOUN
ihlr-16500	49	30	for	for	ADP
ihlr-16500	49	31	a	a	DET
ihlr-16500	49	32	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	49	33	drug	drug	NOUN
ihlr-16500	49	34	owned	own	VERB
ihlr-16500	49	35	by	by	ADP
ihlr-16500	49	36	a	a	DET
ihlr-16500	49	37	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	49	38	com­	com­	NOUN
ihlr-16500	49	39	pany	pany	NOUN
ihlr-16500	49	40	.	.	PUNCT
ihlr-16500	50	1	part	part	NOUN
ihlr-16500	50	2	iv	iv	PRON
ihlr-16500	50	3	will	will	AUX
ihlr-16500	50	4	analyze	analyze	VERB
ihlr-16500	50	5	the	the	DET
ihlr-16500	50	6	legal	legal	ADJ
ihlr-16500	50	7	ramifications	ramification	NOUN
ihlr-16500	50	8	of	of	ADP
ihlr-16500	50	9	withdrawing	withdraw	VERB
ihlr-16500	50	10	a	a	DET
ihlr-16500	50	11	drug	drug	NOUN
ihlr-16500	50	12	from	from	ADP
ihlr-16500	50	13	the	the	DET
ihlr-16500	50	14	market	market	NOUN
ihlr-16500	50	15	,	,	PUNCT
ihlr-16500	50	16	discussing	discuss	VERB
ihlr-16500	50	17	recent	recent	ADJ
ihlr-16500	50	18	court	court	NOUN
ihlr-16500	50	19	decisions	decision	NOUN
ihlr-16500	50	20	involving	involve	VERB
ihlr-16500	50	21	baycol	baycol	NOUN
ihlr-16500	50	22	and	and	CCONJ
ihlr-16500	50	23	vioxx	vioxx	NOUN
ihlr-16500	50	24	.	.	PUNCT
ihlr-16500	51	1	part	part	NOUN
ihlr-16500	51	2	v	v	NOUN
ihlr-16500	51	3	will	will	AUX
ihlr-16500	51	4	examine	examine	VERB
ihlr-16500	51	5	the	the	DET
ihlr-16500	51	6	business	business	NOUN
ihlr-16500	51	7	effects	effect	NOUN
ihlr-16500	51	8	of	of	ADP
ihlr-16500	51	9	such	such	DET
ihlr-16500	51	10	a	a	DET
ihlr-16500	51	11	decision	decision	NOUN
ihlr-16500	51	12	,	,	PUNCT
ihlr-16500	51	13	specifically	specifically	ADV
ihlr-16500	51	14	focusing	focus	VERB
ihlr-16500	51	15	on	on	ADP
ihlr-16500	51	16	how	how	SCONJ
ihlr-16500	51	17	such	such	DET
ihlr-16500	51	18	a	a	DET
ihlr-16500	51	19	decision	decision	NOUN
ihlr-16500	51	20	affects	affect	VERB
ihlr-16500	51	21	the	the	DET
ihlr-16500	51	22	pharmaceutical	pharmaceutical	NOUN
ihlr-16500	51	23	industry	industry	NOUN
ihlr-16500	51	24	and	and	CCONJ
ihlr-16500	51	25	the	the	DET
ihlr-16500	51	26	respective	respective	ADJ
ihlr-16500	51	27	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	51	28	company	company	NOUN
ihlr-16500	51	29	that	that	PRON
ihlr-16500	51	30	is	be	AUX
ihlr-16500	51	31	forced	force	VERB
ihlr-16500	51	32	to	to	PART
ihlr-16500	51	33	make	make	VERB
ihlr-16500	51	34	such	such	DET
ihlr-16500	51	35	a	a	DET
ihlr-16500	51	36	decision	decision	NOUN
ihlr-16500	51	37	.	.	PUNCT
ihlr-16500	52	1	part	part	NOUN
ihlr-16500	52	2	vi	vi	PROPN
ihlr-16500	52	3	will	will	AUX
ihlr-16500	52	4	examine	examine	VERB
ihlr-16500	52	5	the	the	DET
ihlr-16500	52	6	ethical	ethical	ADJ
ihlr-16500	52	7	considerations	consideration	NOUN
ihlr-16500	52	8	that	that	PRON
ihlr-16500	52	9	a	a	DET
ihlr-16500	52	10	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	52	11	company	company	NOUN
ihlr-16500	52	12	must	must	AUX
ihlr-16500	52	13	under­	under­	PROPN
ihlr-16500	52	14	take	take	VERB
ihlr-16500	52	15	before	before	ADP
ihlr-16500	52	16	making	make	VERB
ihlr-16500	52	17	the	the	DET
ihlr-16500	52	18	decision	decision	NOUN
ihlr-16500	52	19	to	to	PART
ihlr-16500	52	20	withdraw	withdraw	VERB
ihlr-16500	52	21	a	a	DET
ihlr-16500	52	22	drug	drug	NOUN
ihlr-16500	52	23	from	from	ADP
ihlr-16500	52	24	the	the	DET
ihlr-16500	52	25	market	market	NOUN
ihlr-16500	52	26	.	.	PUNCT
ihlr-16500	53	1	finally	finally	ADV
ihlr-16500	53	2	,	,	PUNCT
ihlr-16500	53	3	part	part	NOUN
ihlr-16500	53	4	vii	vii	PROPN
ihlr-16500	53	5	and	and	CCONJ
ihlr-16500	53	6	viii	viii	PROPN
ihlr-16500	53	7	will	will	AUX
ihlr-16500	53	8	examine	examine	VERB
ihlr-16500	53	9	those	those	DET
ihlr-16500	53	10	parties	party	NOUN
ihlr-16500	53	11	who	who	PRON
ihlr-16500	53	12	may	may	AUX
ihlr-16500	53	13	be	be	AUX
ihlr-16500	53	14	particularly	particularly	ADV
ihlr-16500	53	15	blame­	blame­	VERB
ihlr-16500	53	16	worthy	worthy	ADJ
ihlr-16500	53	17	in	in	ADP
ihlr-16500	53	18	this	this	DET
ihlr-16500	53	19	saga	saga	NOUN
ihlr-16500	53	20	and	and	CCONJ
ihlr-16500	53	21	identify	identify	VERB
ihlr-16500	53	22	what	what	PRON
ihlr-16500	53	23	,	,	PUNCT
ihlr-16500	53	24	if	if	SCONJ
ihlr-16500	53	25	any	any	PRON
ihlr-16500	53	26	,	,	PUNCT
ihlr-16500	53	27	potential	potential	ADJ
ihlr-16500	53	28	solutions	solution	NOUN
ihlr-16500	53	29	exist	exist	VERB
ihlr-16500	53	30	.	.	PUNCT
ihlr-16500	54	1	ii	ii	PROPN
ihlr-16500	54	2	.	.	PUNCT
ihlr-16500	54	3	pharmaceutical	pharmaceutical	PROPN
ihlr-16500	54	4	industry	industry	NOUN
ihlr-16500	54	5	statistics	statistic	NOUN
ihlr-16500	54	6	and	and	CCONJ
ihlr-16500	54	7	the	the	DET
ihlr-16500	54	8	blockbuster	blockbuster	NOUN
ihlr-16500	54	9	drug	drug	NOUN
ihlr-16500	54	10	the	the	DET
ihlr-16500	54	11	pharmaceutical	pharmaceutical	NOUN
ihlr-16500	54	12	industry	industry	NOUN
ihlr-16500	54	13	is	be	AUX
ihlr-16500	54	14	an	an	DET
ihlr-16500	54	15	ever	ever	ADV
ihlr-16500	54	16	-	-	PUNCT
ihlr-16500	54	17	growing	grow	VERB
ihlr-16500	54	18	industry	industry	NOUN
ihlr-16500	54	19	in	in	ADP
ihlr-16500	54	20	the	the	DET
ihlr-16500	54	21	u.s	u.s	PROPN
ihlr-16500	54	22	.	.	PROPN
ihlr-16500	54	23	in	in	ADP
ihlr-16500	54	24	large	large	ADJ
ihlr-16500	54	25	part	part	NOUN
ihlr-16500	54	26	due	due	ADP
ihlr-16500	54	27	to	to	ADP
ihlr-16500	54	28	the	the	DET
ihlr-16500	54	29	profitability	profitability	NOUN
ihlr-16500	54	30	of	of	ADP
ihlr-16500	54	31	the	the	DET
ihlr-16500	54	32	blockbuster	blockbuster	NOUN
ihlr-16500	54	33	drug	drug	NOUN
ihlr-16500	54	34	.	.	PUNCT
ihlr-16500	55	1	because	because	SCONJ
ihlr-16500	55	2	of	of	ADP
ihlr-16500	55	3	the	the	DET
ihlr-16500	55	4	syn­	syn­	NOUN
ihlr-16500	55	5	ergistic	ergistic	ADJ
ihlr-16500	55	6	effect	effect	NOUN
ihlr-16500	55	7	that	that	SCONJ
ihlr-16500	55	8	both	both	CCONJ
ihlr-16500	55	9	the	the	DET
ihlr-16500	55	10	pharmaceutical	pharmaceutical	NOUN
ihlr-16500	55	11	industry	industry	NOUN
ihlr-16500	55	12	and	and	CCONJ
ihlr-16500	55	13	blockbuster	blockbuster	NOUN
ihlr-16500	55	14	drug	drug	NOUN
ihlr-16500	55	15	have	have	VERB
ihlr-16500	55	16	on	on	ADP
ihlr-16500	55	17	each	each	DET
ihlr-16500	55	18	other	other	ADJ
ihlr-16500	55	19	,	,	PUNCT
ihlr-16500	55	20	it	it	PRON
ihlr-16500	55	21	is	be	AUX
ihlr-16500	55	22	important	important	ADJ
ihlr-16500	55	23	to	to	PART
ihlr-16500	55	24	define	define	VERB
ihlr-16500	55	25	a	a	DET
ihlr-16500	55	26	blockbuster	blockbuster	ADJ
ihlr-16500	55	27	drug	drug	NOUN
ihlr-16500	55	28	and	and	CCONJ
ihlr-16500	55	29	its	its	PRON
ihlr-16500	55	30	withdrawal	withdrawal	NOUN
ihlr-16500	55	31	from	from	ADP
ihlr-16500	55	32	the	the	DET
ihlr-16500	55	33	market	market	NOUN
ihlr-16500	55	34	.	.	PUNCT
ihlr-16500	56	1	it	it	PRON
ihlr-16500	56	2	is	be	AUX
ihlr-16500	56	3	equally	equally	ADV
ihlr-16500	56	4	important	important	ADJ
ihlr-16500	56	5	to	to	PART
ihlr-16500	56	6	examine	examine	VERB
ihlr-16500	56	7	the	the	DET
ihlr-16500	56	8	relative	relative	ADJ
ihlr-16500	56	9	importance	importance	NOUN
ihlr-16500	56	10	of	of	ADP
ihlr-16500	56	11	the	the	DET
ihlr-16500	56	12	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	56	13	industry	industry	NOUN
ihlr-16500	56	14	in	in	ADP
ihlr-16500	56	15	the	the	DET
ihlr-16500	56	16	united	united	PROPN
ihlr-16500	56	17	states	states	PROPN
ihlr-16500	56	18	and	and	CCONJ
ihlr-16500	56	19	its	its	PRON
ihlr-16500	56	20	effect	effect	NOUN
ihlr-16500	56	21	on	on	ADP
ihlr-16500	56	22	the	the	DET
ihlr-16500	56	23	develop­	develop­	NOUN
ihlr-16500	56	24	ment	ment	NOUN
ihlr-16500	56	25	and	and	CCONJ
ihlr-16500	56	26	manufacturing	manufacturing	NOUN
ihlr-16500	56	27	of	of	ADP
ihlr-16500	56	28	blockbuster	blockbuster	ADJ
ihlr-16500	56	29	drugs	drug	NOUN
ihlr-16500	56	30	.	.	PUNCT
ihlr-16500	57	1	a.	a.	NOUN
ihlr-16500	57	2	the	the	DET
ihlr-16500	57	3	blockbuster	blockbuster	ADJ
ihlr-16500	57	4	drog	drog	NOUN
ihlr-16500	57	5	for	for	ADP
ihlr-16500	57	6	the	the	DET
ihlr-16500	57	7	purposes	purpose	NOUN
ihlr-16500	57	8	of	of	ADP
ihlr-16500	57	9	this	this	DET
ihlr-16500	57	10	note	note	NOUN
ihlr-16500	57	11	,	,	PUNCT
ihlr-16500	57	12	a	a	DET
ihlr-16500	57	13	blockbuster	blockbuster	ADJ
ihlr-16500	57	14	drug	drug	NOUN
ihlr-16500	57	15	is	be	AUX
ihlr-16500	57	16	a	a	DET
ihlr-16500	57	17	medicine	medicine	NOUN
ihlr-16500	57	18	that	that	SCONJ
ihlr-16500	57	19	gener­	gener­	PROPN
ihlr-16500	57	20	ates	ates	PROPN
ihlr-16500	57	21	more	more	ADJ
ihlr-16500	57	22	than	than	ADP
ihlr-16500	57	23	one	one	NUM
ihlr-16500	57	24	billion	billion	NUM
ihlr-16500	57	25	dollars	dollar	NOUN
ihlr-16500	57	26	in	in	ADP
ihlr-16500	57	27	sales	sale	NOUN
ihlr-16500	57	28	in	in	ADP
ihlr-16500	57	29	a	a	DET
ihlr-16500	57	30	year.2	year.2	NOUN
ihlr-16500	57	31	in	in	ADP
ihlr-16500	57	32	2003	2003	NUM
ihlr-16500	57	33	,	,	PUNCT
ihlr-16500	57	34	the	the	DET
ihlr-16500	57	35	world	world	NOUN
ihlr-16500	57	36	phar2	phar2	PROPN
ihlr-16500	57	37	visionga1n	visionga1n	NOUN
ihlr-16500	57	38	intewgence	intewgence	NOUN
ihlr-16500	57	39	,	,	PUNCT
ihlr-16500	57	40	blockbuster	blockbuster	ADJ
ihlr-16500	57	41	drugs	drug	NOUN
ihlr-16500	57	42	:	:	PUNCT
ihlr-16500	57	43	a	a	DET
ihlr-16500	57	44	current	current	ADJ
ihlr-16500	57	45	assessment	assessment	NOUN
ihlr-16500	57	46	and	and	CCONJ
ihlr-16500	57	47	118	118	NUM
ihlr-16500	57	48	indiana	indiana	NOUN
ihlr-16500	57	49	heal	heal	PROPN
ihlr-16500	57	50	til	til	PROPN
ihlr-16500	57	51	law	law	NOUN
ihlr-16500	57	52	review	review	NOUN
ihlr-16500	57	53	[	[	X
ihlr-16500	57	54	vol	vol	NOUN
ihlr-16500	57	55	.	.	PUNCT
ihlr-16500	58	1	4:115	4:115	NUM
ihlr-16500	58	2	maceutical	maceutical	ADJ
ihlr-16500	58	3	market	market	NOUN
ihlr-16500	58	4	consisted	consist	VERB
ihlr-16500	58	5	of	of	ADP
ihlr-16500	58	6	sixty	sixty	NUM
ihlr-16500	58	7	-	-	PUNCT
ihlr-16500	58	8	seven	seven	NUM
ihlr-16500	58	9	drugs	drug	NOUN
ihlr-16500	58	10	,	,	PUNCT
ihlr-16500	58	11	which	which	PRON
ihlr-16500	58	12	together	together	ADV
ihlr-16500	58	13	,	,	PUNCT
ihlr-16500	58	14	generated	generate	VERB
ihlr-16500	58	15	over	over	ADP
ihlr-16500	58	16	$	$	SYM
ihlr-16500	58	17	136	136	NUM
ihlr-16500	58	18	billion.3	billion.3	NOUN
ihlr-16500	58	19	between	between	ADP
ihlr-16500	58	20	2004	2004	NUM
ihlr-16500	58	21	and	and	CCONJ
ihlr-16500	58	22	2009	2009	NUM
ihlr-16500	58	23	,	,	PUNCT
ihlr-16500	58	24	experts	expert	NOUN
ihlr-16500	58	25	believe	believe	VERB
ihlr-16500	58	26	that	that	SCONJ
ihlr-16500	58	27	at	at	ADV
ihlr-16500	58	28	least	least	ADJ
ihlr-16500	58	29	twenty	twenty	NUM
ihlr-16500	58	30	-	-	PUNCT
ihlr-16500	58	31	four	four	NUM
ihlr-16500	58	32	new	new	ADJ
ihlr-16500	58	33	blockbuster	blockbuster	NOUN
ihlr-16500	58	34	drugs	drug	NOUN
ihlr-16500	58	35	will	will	AUX
ihlr-16500	58	36	emerge	emerge	VERB
ihlr-16500	58	37	,	,	PUNCT
ihlr-16500	58	38	resulting	result	VERB
ihlr-16500	58	39	in	in	ADP
ihlr-16500	58	40	a	a	DET
ihlr-16500	58	41	total	total	NOUN
ihlr-16500	58	42	ofninety­	ofninety­	PRON
ihlr-16500	58	43	three.4	three.4	ADP
ihlr-16500	58	44	the	the	DET
ihlr-16500	58	45	current	current	ADJ
ihlr-16500	58	46	leading	lead	VERB
ihlr-16500	58	47	blockbuster	blockbuster	NOUN
ihlr-16500	58	48	drug	drug	NOUN
ihlr-16500	58	49	in	in	ADP
ihlr-16500	58	50	tenns	tenn	NOUN
ihlr-16500	58	51	of	of	ADP
ihlr-16500	58	52	total	total	ADJ
ihlr-16500	58	53	sales	sale	NOUN
ihlr-16500	58	54	is	be	AUX
ihlr-16500	58	55	lipitor	lipitor	NOUN
ihlr-16500	58	56	,	,	PUNCT
ihlr-16500	58	57	which	which	PRON
ihlr-16500	58	58	is	be	AUX
ihlr-16500	58	59	owned	own	VERB
ihlr-16500	58	60	and	and	CCONJ
ihlr-16500	58	61	licensed	license	VERB
ihlr-16500	58	62	by	by	ADP
ihlr-16500	58	63	pfizer	pfizer	NOUN
ihlr-16500	58	64	.	.	PUNCT
ihlr-16500	59	1	for	for	ADP
ihlr-16500	59	2	the	the	DET
ihlr-16500	59	3	second	second	ADJ
ihlr-16500	59	4	quarter	quarter	NOUN
ihlr-16500	59	5	of2006	of2006	NOUN
ihlr-16500	59	6	,	,	PUNCT
ihlr-16500	59	7	lipitor	lipitor	NOUN
ihlr-16500	59	8	contributed	contribute	VERB
ihlr-16500	59	9	to	to	ADP
ihlr-16500	59	10	pfizer	pfizer	PROPN
ihlr-16500	59	11	a	a	DET
ihlr-16500	59	12	reported	reported	ADJ
ihlr-16500	59	13	profit	profit	NOUN
ihlr-16500	59	14	of$2.86	of$2.86	NOUN
ihlr-16500	59	15	billion	billion	NUM
ihlr-16500	59	16	.	.	PUNCT
ihlr-16500	60	1	5	5	NUM
ihlr-16500	60	2	in	in	ADP
ihlr-16500	60	3	addition	addition	NOUN
ihlr-16500	61	1	,	,	PUNCT
ihlr-16500	61	2	blockbuster	blockbuster	ADJ
ihlr-16500	61	3	drugs	drug	NOUN
ihlr-16500	61	4	are	be	AUX
ihlr-16500	61	5	heavily	heavily	ADV
ihlr-16500	61	6	marketed	market	VERB
ihlr-16500	61	7	by	by	ADP
ihlr-16500	61	8	their	their	PRON
ihlr-16500	61	9	respective	respective	ADJ
ihlr-16500	61	10	companies	company	NOUN
ihlr-16500	61	11	to	to	ADP
ihlr-16500	61	12	both	both	DET
ihlr-16500	61	13	patients	patient	NOUN
ihlr-16500	61	14	and	and	CCONJ
ihlr-16500	61	15	health	health	NOUN
ihlr-16500	61	16	care	care	NOUN
ihlr-16500	61	17	professionals	professional	NOUN
ihlr-16500	61	18	alike	alike	ADV
ihlr-16500	61	19	.	.	PUNCT
ihlr-16500	62	1	for	for	ADP
ihlr-16500	62	2	instance	instance	NOUN
ihlr-16500	62	3	,	,	PUNCT
ihlr-16500	62	4	as	as	ADP
ihlr-16500	62	5	of2005	of2005	PROPN
ihlr-16500	62	6	,	,	PUNCT
ihlr-16500	62	7	pfizer	pfizer	NOUN
ihlr-16500	62	8	has	have	AUX
ihlr-16500	62	9	spent	spend	VERB
ihlr-16500	62	10	a	a	DET
ihlr-16500	62	11	total	total	ADJ
ihlr-16500	62	12	of$16.99	of$16.99	NOUN
ihlr-16500	62	13	billion	billion	NUM
ihlr-16500	62	14	on	on	ADP
ihlr-16500	62	15	marketing	marketing	NOUN
ihlr-16500	62	16	and	and	CCONJ
ihlr-16500	62	17	administration	administration	NOUN
ihlr-16500	62	18	expenses	expense	NOUN
ihlr-16500	62	19	for	for	ADP
ihlr-16500	62	20	lipitor	lipitor	NOUN
ihlr-16500	62	21	since	since	SCONJ
ihlr-16500	62	22	its	its	PRON
ihlr-16500	62	23	inception	inception	NOUN
ihlr-16500	62	24	in	in	ADP
ihlr-16500	62	25	the	the	DET
ihlr-16500	62	26	u.s	u.s	PROPN
ihlr-16500	62	27	.	.	PROPN
ihlr-16500	62	28	market	market	NOUN
ihlr-16500	62	29	.	.	PUNCT
ihlr-16500	63	1	6	6	NUM
ihlr-16500	63	2	as	as	ADP
ihlr-16500	63	3	a	a	DET
ihlr-16500	63	4	result	result	NOUN
ihlr-16500	63	5	of	of	ADP
ihlr-16500	63	6	this	this	DET
ihlr-16500	63	7	heavy	heavy	ADJ
ihlr-16500	63	8	marketing	marketing	NOUN
ihlr-16500	63	9	,	,	PUNCT
ihlr-16500	63	10	blockbuster	blockbuster	ADJ
ihlr-16500	63	11	drugs	drug	NOUN
ihlr-16500	63	12	such	such	ADJ
ihlr-16500	63	13	as	as	ADP
ihlr-16500	63	14	lipitor	lipitor	NOUN
ihlr-16500	63	15	have	have	AUX
ihlr-16500	63	16	become	become	VERB
ihlr-16500	63	17	well	well	ADV
ihlr-16500	63	18	known	know	VERB
ihlr-16500	63	19	by	by	ADP
ihlr-16500	63	20	the	the	DET
ihlr-16500	63	21	general	general	ADJ
ihlr-16500	63	22	public	public	NOUN
ihlr-16500	63	23	.	.	PUNCT
ihlr-16500	64	1	in	in	ADP
ihlr-16500	64	2	sum	sum	NOUN
ihlr-16500	64	3	,	,	PUNCT
ihlr-16500	64	4	blockbuster	blockbuster	ADJ
ihlr-16500	64	5	drugs	drug	NOUN
ihlr-16500	64	6	are	be	AUX
ihlr-16500	64	7	generally	generally	ADV
ihlr-16500	64	8	heavily	heavily	ADV
ihlr-16500	64	9	marketed	market	VERB
ihlr-16500	64	10	brands	brand	NOUN
ihlr-16500	64	11	that	that	PRON
ihlr-16500	64	12	provide	provide	VERB
ihlr-16500	64	13	patients	patient	NOUN
ihlr-16500	64	14	with	with	ADP
ihlr-16500	64	15	the	the	DET
ihlr-16500	64	16	efficacy	efficacy	NOUN
ihlr-16500	64	17	that	that	PRON
ihlr-16500	64	18	can	can	AUX
ihlr-16500	64	19	not	not	PART
ihlr-16500	64	20	usually	usually	ADV
ihlr-16500	64	21	be	be	AUX
ihlr-16500	64	22	provided	provide	VERB
ihlr-16500	64	23	by	by	ADP
ihlr-16500	64	24	generic	generic	ADJ
ihlr-16500	64	25	and	and	CCONJ
ihlr-16500	64	26	arguably	arguably	ADV
ihlr-16500	64	27	less	less	ADV
ihlr-16500	64	28	efficacious	efficacious	ADJ
ihlr-16500	64	29	brands	brand	NOUN
ihlr-16500	64	30	.	.	PUNCT
ihlr-16500	65	1	b.	b.	PROPN
ihlr-16500	66	1	the	the	DET
ihlr-16500	66	2	drug	drug	NOUN
ihlr-16500	66	3	withdrawal	withdrawal	NOUN
ihlr-16500	66	4	a	a	DET
ihlr-16500	66	5	blockbuster	blockbuster	ADJ
ihlr-16500	66	6	drug	drug	NOUN
ihlr-16500	66	7	withdrawal	withdrawal	NOUN
ihlr-16500	66	8	from	from	ADP
ihlr-16500	66	9	the	the	DET
ihlr-16500	66	10	market	market	NOUN
ihlr-16500	66	11	can	can	AUX
ihlr-16500	66	12	be	be	AUX
ihlr-16500	66	13	devastating	devastating	ADJ
ihlr-16500	66	14	to	to	ADP
ihlr-16500	66	15	the	the	DET
ihlr-16500	66	16	respective	respective	ADJ
ihlr-16500	66	17	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	66	18	company	company	NOUN
ihlr-16500	66	19	,	,	PUNCT
ihlr-16500	66	20	the	the	DET
ihlr-16500	66	21	patients	patient	NOUN
ihlr-16500	66	22	who	who	PRON
ihlr-16500	66	23	use	use	VERB
ihlr-16500	66	24	the	the	DET
ihlr-16500	66	25	drug	drug	NOUN
ihlr-16500	66	26	,	,	PUNCT
ihlr-16500	66	27	and	and	CCONJ
ihlr-16500	66	28	the	the	DET
ihlr-16500	66	29	regulatory	regulatory	ADJ
ihlr-16500	66	30	agencies	agency	NOUN
ihlr-16500	66	31	.	.	PUNCT
ihlr-16500	67	1	a	a	DET
ihlr-16500	67	2	drug	drug	NOUN
ihlr-16500	67	3	withdrawal	withdrawal	NOUN
ihlr-16500	67	4	is	be	AUX
ihlr-16500	67	5	either	either	CCONJ
ihlr-16500	67	6	mandated	mandate	VERB
ihlr-16500	67	7	by	by	ADP
ihlr-16500	67	8	the	the	DET
ihlr-16500	67	9	fda	fda	PROPN
ihlr-16500	67	10	(	(	PUNCT
ihlr-16500	67	11	also	also	ADV
ihlr-16500	67	12	known	know	VERB
ihlr-16500	67	13	as	as	ADP
ihlr-16500	67	14	an	an	DET
ihlr-16500	67	15	involuntary	involuntary	ADJ
ihlr-16500	67	16	withdrawal	withdrawal	NOUN
ihlr-16500	67	17	)	)	PUNCT
ihlr-16500	67	18	or	or	CCONJ
ihlr-16500	67	19	proactively	proactively	ADV
ihlr-16500	67	20	pursued	pursue	VERB
ihlr-16500	67	21	by	by	ADP
ihlr-16500	67	22	the	the	DET
ihlr-16500	67	23	drug	drug	NOUN
ihlr-16500	67	24	's	's	PART
ihlr-16500	67	25	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	67	26	company	company	NOUN
ihlr-16500	67	27	(	(	PUNCT
ihlr-16500	67	28	also	also	ADV
ihlr-16500	67	29	known	know	VERB
ihlr-16500	67	30	as	as	ADP
ihlr-16500	67	31	a	a	DET
ihlr-16500	67	32	voluntary	voluntary	ADJ
ihlr-16500	67	33	withdrawal	withdrawal	NOUN
ihlr-16500	67	34	)	)	PUNCT
ihlr-16500	67	35	.	.	PUNCT
ihlr-16500	68	1	in	in	ADP
ihlr-16500	68	2	the	the	DET
ihlr-16500	68	3	past	past	NOUN
ihlr-16500	68	4	,	,	PUNCT
ihlr-16500	68	5	there	there	PRON
ihlr-16500	68	6	have	have	AUX
ihlr-16500	68	7	been	be	AUX
ihlr-16500	68	8	instances	instance	NOUN
ihlr-16500	68	9	of	of	ADP
ihlr-16500	68	10	both	both	CCONJ
ihlr-16500	68	11	voluntary	voluntary	ADJ
ihlr-16500	68	12	and	and	CCONJ
ihlr-16500	68	13	involuntary	involuntary	ADJ
ihlr-16500	68	14	withdrawals	withdrawal	NOUN
ihlr-16500	68	15	.	.	PUNCT
ihlr-16500	69	1	it	it	PRON
ihlr-16500	69	2	is	be	AUX
ihlr-16500	69	3	important	important	ADJ
ihlr-16500	69	4	to	to	PART
ihlr-16500	69	5	note	note	VERB
ihlr-16500	69	6	,	,	PUNCT
ihlr-16500	69	7	however	however	ADV
ihlr-16500	69	8	,	,	PUNCT
ihlr-16500	69	9	that	that	SCONJ
ihlr-16500	69	10	neither	neither	CCONJ
ihlr-16500	69	11	a	a	DET
ihlr-16500	69	12	voluntary	voluntary	ADJ
ihlr-16500	69	13	withdrawal	withdrawal	NOUN
ihlr-16500	69	14	nor	nor	CCONJ
ihlr-16500	69	15	a	a	DET
ihlr-16500	69	16	fda	fda	PROPN
ihlr-16500	69	17	mandated	mandate	VERB
ihlr-16500	69	18	involuntary	involuntary	ADJ
ihlr-16500	69	19	withdrawal	withdrawal	NOUN
ihlr-16500	69	20	presupposes	presuppose	VERB
ihlr-16500	69	21	any	any	DET
ihlr-16500	69	22	innocence	innocence	NOUN
ihlr-16500	69	23	or	or	CCONJ
ihlr-16500	69	24	guilt	guilt	NOUN
ihlr-16500	69	25	on	on	ADP
ihlr-16500	69	26	the	the	DET
ihlr-16500	69	27	part	part	NOUN
ihlr-16500	69	28	of	of	ADP
ihlr-16500	69	29	the	the	DET
ihlr-16500	69	30	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	69	31	company	company	NOUN
ihlr-16500	69	32	.	.	PUNCT
ihlr-16500	70	1	nevertheless	nevertheless	ADV
ihlr-16500	70	2	,	,	PUNCT
ihlr-16500	70	3	as	as	SCONJ
ihlr-16500	70	4	will	will	AUX
ihlr-16500	70	5	be	be	AUX
ihlr-16500	70	6	discussed	discuss	VERB
ihlr-16500	70	7	later	later	ADV
ihlr-16500	70	8	in	in	ADP
ihlr-16500	70	9	this	this	DET
ihlr-16500	70	10	note7	note7	NOUN
ihlr-16500	70	11	,	,	PUNCT
ihlr-16500	70	12	a	a	DET
ihlr-16500	70	13	voluntary	voluntary	ADJ
ihlr-16500	70	14	withdrawal	withdrawal	NOUN
ihlr-16500	70	15	can	can	AUX
ihlr-16500	70	16	have	have	VERB
ihlr-16500	70	17	much	much	ADV
ihlr-16500	70	18	greater	great	ADJ
ihlr-16500	70	19	consequences	consequence	NOUN
ihlr-16500	70	20	in	in	ADP
ihlr-16500	70	21	tenns	tenn	NOUN
ihlr-16500	70	22	of	of	ADP
ihlr-16500	70	23	investor	investor	NOUN
ihlr-16500	70	24	relations	relation	NOUN
ihlr-16500	70	25	and	and	CCONJ
ihlr-16500	70	26	public	public	ADJ
ihlr-16500	70	27	confidence	confidence	NOUN
ihlr-16500	70	28	for	for	ADP
ihlr-16500	70	29	the	the	DET
ihlr-16500	70	30	respective	respective	ADJ
ihlr-16500	70	31	pharmaceu­	pharmaceu­	NOUN
ihlr-16500	70	32	tical	tical	ADJ
ihlr-16500	70	33	company	company	NOUN
ihlr-16500	70	34	than	than	ADP
ihlr-16500	70	35	an	an	DET
ihlr-16500	70	36	involuntary	involuntary	ADJ
ihlr-16500	70	37	withdrawal	withdrawal	NOUN
ihlr-16500	70	38	.	.	PUNCT
ihlr-16500	71	1	c.	c.	NOUN
ihlr-16500	72	1	the	the	DET
ihlr-16500	72	2	pharmaceutical	pharmaceutical	NOUN
ihlr-16500	72	3	industry	industry	NOUN
ihlr-16500	72	4	the	the	DET
ihlr-16500	72	5	pharmaceutical	pharmaceutical	NOUN
ihlr-16500	72	6	industry	industry	NOUN
ihlr-16500	72	7	's	's	PART
ihlr-16500	72	8	relative	relative	ADJ
ihlr-16500	72	9	importance	importance	NOUN
ihlr-16500	72	10	in	in	ADP
ihlr-16500	72	11	the	the	DET
ihlr-16500	72	12	united	united	PROPN
ihlr-16500	72	13	states	states	PROPN
ihlr-16500	72	14	is	be	AUX
ihlr-16500	72	15	immense	immense	ADJ
ihlr-16500	72	16	.	.	PUNCT
ihlr-16500	73	1	from	from	ADP
ihlr-16500	73	2	2003	2003	NUM
ihlr-16500	73	3	to	to	ADP
ihlr-16500	73	4	2004	2004	NUM
ihlr-16500	73	5	,	,	PUNCT
ihlr-16500	73	6	total	total	ADJ
ihlr-16500	73	7	sales	sale	NOUN
ihlr-16500	73	8	of	of	ADP
ihlr-16500	73	9	prescription	prescription	NOUN
ihlr-16500	73	10	drugs	drug	NOUN
ihlr-16500	73	11	increased	increase	VERB
ihlr-16500	73	12	by	by	ADP
ihlr-16500	73	13	outlook	outlook	NOUN
ihlr-16500	73	14	for	for	ADP
ihlr-16500	73	15	creating	create	VERB
ihlr-16500	73	16	fulurebi	fulurebi	NOUN
ihlr-16500	73	17	..	..	PUNCT
ihlr-16500	73	18	ockbusters	ockbuster	NOUN
ihlr-16500	73	19	(	(	PUNCT
ihlr-16500	73	20	2004	2004	NUM
ihlr-16500	73	21	)	)	PUNCT
ihlr-16500	73	22	,	,	PUNCT
ihlr-16500	73	23	http://www.visiongainintelligence.com	http://www.visiongainintelligence.com	X
ihlr-16500	73	24	/reportdetail.aspx?reportld=	/reportdetail.aspx?reportld=	PROPN
ihlr-16500	74	1	1	1	NUM
ihlr-16500	74	2	088&adselection	088&adselection	NUM
ihlr-16500	74	3	=	=	PROPN
ihlr-16500	74	4	y	y	PROPN
ihlr-16500	74	5	&	&	CCONJ
ihlr-16500	74	6	industryldll	industryldll	PROPN
ihlr-16500	74	7	=	=	PROPN
ihlr-16500	74	8	-1	-1	PROPN
ihlr-16500	74	9	.	.	PUNCT
ihlr-16500	75	1	3	3	NUM
ihlr-16500	76	1	i	i	PRON
ihlr-16500	76	2	d.	d.	NOUN
ihlr-16500	76	3	4	4	NUM
ihlr-16500	76	4	i	i	PROPN
ihlr-16500	76	5	d.	d.	PROPN
ihlr-16500	76	6	5	5	NUM
ihlr-16500	76	7	juliann	juliann	PROPN
ihlr-16500	76	8	walsh	walsh	PROPN
ihlr-16500	76	9	&	&	CCONJ
ihlr-16500	76	10	nicole	nicole	PROPN
ihlr-16500	76	11	ostrow	ostrow	PROPN
ihlr-16500	76	12	,	,	PUNCT
ihlr-16500	76	13	pfizer	pfizer	NOUN
ihlr-16500	76	14	earns	earn	VERB
ihlr-16500	76	15	$	$	SYM
ihlr-16500	76	16	2.86	2.86	NUM
ihlr-16500	76	17	bin	bin	NOUN
ihlr-16500	76	18	on	on	ADP
ihlr-16500	76	19	lipitor	lipitor	NOUN
ihlr-16500	76	20	sales	sale	NOUN
ihlr-16500	76	21	;	;	PUNCT
ihlr-16500	76	22	merck	merck	PROPN
ihlr-16500	76	23	's	's	PART
ihlr-16500	76	24	profit	profit	NOUN
ihlr-16500	76	25	slips	slip	NOUN
ihlr-16500	76	26	,	,	PUNCT
ihlr-16500	76	27	bloomberg.com	bloomberg.com	X
ihlr-16500	76	28	,	,	PUNCT
ihlr-16500	76	29	july	july	PROPN
ihlr-16500	76	30	21	21	NUM
ihlr-16500	76	31	,	,	PUNCT
ihlr-16500	76	32	2004	2004	NUM
ihlr-16500	76	33	,	,	PUNCT
ihlr-16500	76	34	http://quote.bloomberg.com/apps/news	http://quote.bloomberg.com/apps/news	PROPN
ihlr-16500	76	35	?	?	PUNCT
ihlr-16500	77	1	pid	pid	NOUN
ihlr-16500	77	2	=	=	NOUN
ihlr-16500	77	3	l	l	NOUN
ihlr-16500	77	4	0000	0000	NUM
ihlr-16500	77	5	1	1	NUM
ihlr-16500	77	6	03&sid	03&sid	NOUN
ihlr-16500	77	7	=	=	SYM
ihlr-16500	77	8	al	al	PROPN
ihlr-16500	77	9	u3vuxkojwe&refer	u3vuxkojwe&refer	NOUN
ihlr-16500	77	10	=	=	PROPN
ihlr-16500	77	11	us	us	PROPN
ihlr-16500	77	12	.	.	PUNCT
ihlr-16500	77	13	6	6	NUM
ihlr-16500	77	14	the	the	DET
ihlr-16500	77	15	"	"	PUNCT
ihlr-16500	77	16	got	get	VERB
ihlr-16500	77	17	cholesterol	cholesterol	NOUN
ihlr-16500	77	18	?	?	PUNCT
ihlr-16500	77	19	"	"	PUNCT
ihlr-16500	77	20	award	award	NOUN
ihlr-16500	77	21	:	:	PUNCT
ihlr-16500	77	22	foroverpromotingexpensivebrand	foroverpromotingexpensivebrand	ADJ
ihlr-16500	77	23	-	-	PUNCT
ihlr-16500	77	24	namestatins	namestatin	NOUN
ihlr-16500	77	25	,	,	PUNCT
ihlr-16500	77	26	biti'erpll.lawards.org	biti'erpll.lawards.org	NOUN
ihlr-16500	77	27	,	,	PUNCT
ihlr-16500	77	28	apr	apr	PROPN
ihlr-16500	77	29	.	.	PROPN
ihlr-16500	77	30	26	26	NUM
ihlr-16500	77	31	,	,	PUNCT
ihlr-16500	77	32	2006	2006	NUM
ihlr-16500	77	33	,	,	PUNCT
ihlr-16500	77	34	http://www.bitterpillawards.org/crestor-liptor.php	http://www.bitterpillawards.org/crestor-liptor.php	NUM
ihlr-16500	77	35	.	.	PUNCT
ihlr-16500	77	36	7	7	NUM
ihlr-16500	77	37	see	see	VERB
ihlr-16500	77	38	infra	infra	NOUN
ihlr-16500	77	39	part	part	NOUN
ihlr-16500	77	40	v.	v.	ADP
ihlr-16500	77	41	2007	2007	NUM
ihlr-16500	77	42	]	]	PUNCT
ihlr-16500	77	43	pulling	pull	VERB
ihlr-16500	77	44	a	a	DET
ihlr-16500	77	45	blockbuster	blockbuster	ADJ
ihlr-16500	77	46	drug	drug	NOUN
ihlr-16500	77	47	off	off	ADP
ihlr-16500	77	48	the	the	DET
ihlr-16500	77	49	market	market	NOUN
ihlr-16500	77	50	119	119	NUM
ihlr-16500	77	51	8.3	8.3	NUM
ihlr-16500	77	52	%	%	NOUN
ihlr-16500	77	53	.	.	PUNCT
ihlr-16500	78	1	8	8	NUM
ihlr-16500	78	2	not	not	PART
ihlr-16500	78	3	surprisingly	surprisingly	ADV
ihlr-16500	78	4	,	,	PUNCT
ihlr-16500	78	5	every	every	DET
ihlr-16500	78	6	year	year	NOUN
ihlr-16500	78	7	more	more	ADJ
ihlr-16500	78	8	and	and	CCONJ
ihlr-16500	78	9	more	more	ADV
ihlr-16500	78	10	new	new	ADJ
ihlr-16500	78	11	prescriptions	prescription	NOUN
ihlr-16500	78	12	are	be	AUX
ihlr-16500	78	13	being	be	AUX
ihlr-16500	78	14	written	write	VERB
ihlr-16500	78	15	.	.	PUNCT
ihlr-16500	79	1	for	for	ADP
ihlr-16500	79	2	instance	instance	NOUN
ihlr-16500	79	3	,	,	PUNCT
ihlr-16500	79	4	the	the	DET
ihlr-16500	79	5	top	top	ADJ
ihlr-16500	79	6	twenty	twenty	NUM
ihlr-16500	79	7	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	79	8	corporations	corporation	NOUN
ihlr-16500	79	9	and	and	CCONJ
ihlr-16500	79	10	their	their	PRON
ihlr-16500	79	11	re­	re­	PROPN
ihlr-16500	79	12	spective	spective	ADJ
ihlr-16500	79	13	medicines	medicine	NOUN
ihlr-16500	79	14	accounted	account	VERB
ihlr-16500	79	15	for	for	ADP
ihlr-16500	79	16	approximately	approximately	ADV
ihlr-16500	79	17	$	$	SYM
ihlr-16500	79	18	2.5	2.5	NUM
ihlr-16500	79	19	billion	billion	NUM
ihlr-16500	79	20	dispensed	dispense	VERB
ihlr-16500	79	21	pre­	pre­	NOUN
ihlr-16500	79	22	scriptions.9	scriptions.9	VERB
ihlr-16500	79	23	in	in	ADP
ihlr-16500	79	24	addition	addition	NOUN
ihlr-16500	79	25	,	,	PUNCT
ihlr-16500	79	26	the	the	DET
ihlr-16500	79	27	pharmaceutical	pharmaceutical	NOUN
ihlr-16500	79	28	industry	industry	NOUN
ihlr-16500	79	29	netted	net	VERB
ihlr-16500	79	30	a	a	DET
ihlr-16500	79	31	total	total	NOUN
ihlr-16500	79	32	of	of	ADP
ihlr-16500	79	33	$	$	SYM
ihlr-16500	79	34	235	235	NUM
ihlr-16500	79	35	billion	billion	NUM
ihlr-16500	79	36	in	in	ADP
ihlr-16500	79	37	industry	industry	NOUN
ihlr-16500	79	38	sales	sale	NOUN
ihlr-16500	79	39	in	in	ADP
ihlr-16500	79	40	2004	2004	NUM
ihlr-16500	79	41	,	,	PUNCT
ihlr-16500	79	42	which	which	PRON
ihlr-16500	79	43	was	be	AUX
ihlr-16500	79	44	nearly	nearly	ADV
ihlr-16500	79	45	nineteen	nineteen	NUM
ihlr-16500	79	46	billion	billion	NUM
ihlr-16500	79	47	dollars	dollar	NOUN
ihlr-16500	79	48	more	more	ADJ
ihlr-16500	79	49	than	than	ADP
ihlr-16500	79	50	the	the	DET
ihlr-16500	79	51	previous	previous	ADJ
ihlr-16500	79	52	year.10	year.10	NOUN
ihlr-16500	79	53	the	the	DET
ihlr-16500	79	54	desire	desire	NOUN
ihlr-16500	79	55	to	to	PART
ihlr-16500	79	56	obtain	obtain	VERB
ihlr-16500	79	57	a	a	DET
ihlr-16500	79	58	"	"	PUNCT
ihlr-16500	79	59	piece	piece	NOUN
ihlr-16500	79	60	of	of	ADP
ihlr-16500	79	61	this	this	DET
ihlr-16500	79	62	pie	pie	NOUN
ihlr-16500	79	63	"	"	PUNCT
ihlr-16500	79	64	is	be	AUX
ihlr-16500	79	65	motivating	motivate	VERB
ihlr-16500	79	66	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	79	67	companies	company	NOUN
ihlr-16500	79	68	to	to	PART
ihlr-16500	79	69	spend	spend	VERB
ihlr-16500	79	70	more	more	ADJ
ihlr-16500	79	71	in	in	ADP
ihlr-16500	79	72	research	research	NOUN
ihlr-16500	79	73	and	and	CCONJ
ihlr-16500	79	74	development	development	NOUN
ihlr-16500	79	75	than	than	ADP
ihlr-16500	79	76	ever	ever	ADV
ihlr-16500	79	77	before	before	ADV
ihlr-16500	79	78	.	.	PUNCT
ihlr-16500	80	1	11	11	NUM
ihlr-16500	80	2	in	in	ADP
ihlr-16500	80	3	correlation	correlation	NOUN
ihlr-16500	80	4	with	with	ADP
ihlr-16500	80	5	an	an	DET
ihlr-16500	80	6	increase	increase	NOUN
ihlr-16500	80	7	in	in	ADP
ihlr-16500	80	8	research	research	NOUN
ihlr-16500	80	9	and	and	CCONJ
ihlr-16500	80	10	development	development	NOUN
ihlr-16500	80	11	ex­	ex­	PROPN
ihlr-16500	80	12	penditures	penditure	VERB
ihlr-16500	80	13	by	by	ADP
ihlr-16500	80	14	pharmaceutical	pharmaceutical	NOUN
ihlr-16500	80	15	companies	company	NOUN
ihlr-16500	80	16	,	,	PUNCT
ihlr-16500	80	17	retail	retail	ADJ
ihlr-16500	80	18	spending	spending	NOUN
ihlr-16500	80	19	on	on	ADP
ihlr-16500	80	20	prescription	prescription	NOUN
ihlr-16500	80	21	drugs	drug	NOUN
ihlr-16500	80	22	has	have	AUX
ihlr-16500	80	23	increased	increase	VERB
ihlr-16500	80	24	significantly	significantly	ADV
ihlr-16500	80	25	.	.	PUNCT
ihlr-16500	81	1	as	as	ADP
ihlr-16500	81	2	a	a	DET
ihlr-16500	81	3	result	result	NOUN
ihlr-16500	81	4	,	,	PUNCT
ihlr-16500	81	5	"	"	PUNCT
ihlr-16500	81	6	pharmaceuticals	pharmaceutical	NOUN
ihlr-16500	81	7	accounted	account	VERB
ihlr-16500	81	8	for	for	ADP
ihlr-16500	81	9	nearly	nearly	ADV
ihlr-16500	81	10	one	one	NUM
ihlr-16500	81	11	in	in	ADP
ihlr-16500	81	12	every	every	DET
ihlr-16500	81	13	ten	ten	NUM
ihlr-16500	81	14	dollars	dollar	NOUN
ihlr-16500	81	15	spent	spend	VERB
ihlr-16500	81	16	on	on	ADP
ihlr-16500	81	17	health	health	NOUN
ihlr-16500	81	18	care	care	NOUN
ihlr-16500	81	19	,	,	PUNCT
ihlr-16500	81	20	"	"	PUNCT
ihlr-16500	81	21	a	a	DET
ihlr-16500	81	22	number	number	NOUN
ihlr-16500	81	23	that	that	PRON
ihlr-16500	81	24	is	be	AUX
ihlr-16500	81	25	projected	project	VERB
ihlr-16500	81	26	to	to	PART
ihlr-16500	81	27	rise	rise	VERB
ihlr-16500	81	28	to	to	ADP
ihlr-16500	81	29	nearly	nearly	ADV
ihlr-16500	81	30	fourteen	fourteen	NUM
ihlr-16500	81	31	percent	percent	NOUN
ihlr-16500	81	32	of	of	ADP
ihlr-16500	81	33	all	all	DET
ihlr-16500	81	34	health	health	NOUN
ihlr-16500	81	35	care	care	NOUN
ihlr-16500	81	36	costs	cost	NOUN
ihlr-16500	81	37	by	by	ADP
ihlr-16500	81	38	2010.12	2010.12	NUM
ihlr-16500	81	39	1	1	NUM
ihlr-16500	81	40	.	.	PUNCT
ihlr-16500	82	1	ongoing	ongoing	ADJ
ihlr-16500	82	2	debate	debate	NOUN
ihlr-16500	82	3	between	between	ADP
ihlr-16500	82	4	pharmaceutical	pharmaceutical	NOUN
ihlr-16500	82	5	industry	industry	NOUN
ihlr-16500	82	6	proponents	proponent	NOUN
ihlr-16500	82	7	and	and	CCONJ
ihlr-16500	82	8	its	its	PRON
ihlr-16500	82	9	critics	critic	NOUN
ihlr-16500	82	10	proponents	proponent	NOUN
ihlr-16500	82	11	of	of	ADP
ihlr-16500	82	12	the	the	DET
ihlr-16500	82	13	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	82	14	industry	industry	NOUN
ihlr-16500	82	15	claim	claim	VERB
ihlr-16500	82	16	that	that	SCONJ
ihlr-16500	82	17	the	the	DET
ihlr-16500	82	18	industry	industry	NOUN
ihlr-16500	82	19	is	be	AUX
ihlr-16500	82	20	sim­	sim­	ADJ
ihlr-16500	82	21	ply	ply	NOUN
ihlr-16500	82	22	supplying	supply	VERB
ihlr-16500	82	23	the	the	DET
ihlr-16500	82	24	market	market	NOUN
ihlr-16500	82	25	demand	demand	NOUN
ihlr-16500	82	26	for	for	ADP
ihlr-16500	82	27	its	its	PRON
ihlr-16500	82	28	goods	good	NOUN
ihlr-16500	82	29	.	.	PUNCT
ihlr-16500	83	1	critics	critic	NOUN
ihlr-16500	83	2	,	,	PUNCT
ihlr-16500	83	3	however	however	ADV
ihlr-16500	83	4	,	,	PUNCT
ihlr-16500	83	5	point	point	VERB
ihlr-16500	83	6	to	to	ADP
ihlr-16500	83	7	the	the	DET
ihlr-16500	83	8	fact	fact	NOUN
ihlr-16500	83	9	that	that	SCONJ
ihlr-16500	83	10	there	there	PRON
ihlr-16500	83	11	are	be	VERB
ihlr-16500	83	12	several	several	ADJ
ihlr-16500	83	13	competing	compete	VERB
ihlr-16500	83	14	drugs	drug	NOUN
ihlr-16500	83	15	in	in	ADP
ihlr-16500	83	16	each	each	DET
ihlr-16500	83	17	category	category	NOUN
ihlr-16500	83	18	and	and	CCONJ
ihlr-16500	83	19	question	question	NOUN
ihlr-16500	83	20	why	why	SCONJ
ihlr-16500	83	21	the	the	DET
ihlr-16500	83	22	industry	industry	NOUN
ihlr-16500	83	23	produces	produce	VERB
ihlr-16500	83	24	so	so	ADV
ihlr-16500	83	25	many	many	ADJ
ihlr-16500	83	26	duplicates	duplicate	NOUN
ihlr-16500	83	27	,	,	PUNCT
ihlr-16500	83	28	rather	rather	ADV
ihlr-16500	83	29	than	than	ADP
ihlr-16500	83	30	focusing	focus	VERB
ihlr-16500	83	31	on	on	ADP
ihlr-16500	83	32	the	the	DET
ihlr-16500	83	33	develop­	develop­	ADJ
ihlr-16500	83	34	ment	ment	NOUN
ihlr-16500	83	35	of	of	ADP
ihlr-16500	83	36	novel	novel	ADJ
ihlr-16500	83	37	medicines.13	medicines.13	NOUN
ihlr-16500	83	38	critics	critic	NOUN
ihlr-16500	83	39	,	,	PUNCT
ihlr-16500	83	40	including	include	VERB
ihlr-16500	83	41	many	many	ADJ
ihlr-16500	83	42	consumer	consumer	NOUN
ihlr-16500	83	43	advocacy	advocacy	NOUN
ihlr-16500	83	44	and	and	CCONJ
ihlr-16500	83	45	watchdog	watchdog	NOUN
ihlr-16500	83	46	groups	group	NOUN
ihlr-16500	83	47	,	,	PUNCT
ihlr-16500	83	48	point	point	NOUN
ihlr-16500	83	49	to	to	ADP
ihlr-16500	83	50	classes	class	NOUN
ihlr-16500	83	51	of	of	ADP
ihlr-16500	83	52	drugs	drug	NOUN
ihlr-16500	83	53	such	such	ADJ
ihlr-16500	83	54	as	as	ADP
ihlr-16500	83	55	statins	statin	NOUN
ihlr-16500	83	56	,	,	PUNCT
ihlr-16500	83	57	as	as	ADP
ihlr-16500	83	58	the	the	DET
ihlr-16500	83	59	problem.14	problem.14	PROPN
ihlr-16500	83	60	8	8	NUM
ihlr-16500	83	61	2004	2004	NUM
ihlr-16500	83	62	year	year	NOUN
ihlr-16500	83	63	-	-	PUNCT
ihlr-16500	83	64	end	end	NOUN
ihlr-16500	83	65	u.s	u.s	PROPN
ihlr-16500	83	66	.	.	PROPN
ihlr-16500	83	67	prescription	prescription	NOUN
ihlr-16500	83	68	and	and	CCONJ
ihlr-16500	83	69	sales	sale	NOUN
ihlr-16500	83	70	information	information	NOUN
ihlr-16500	83	71	and	and	CCONJ
ihlr-16500	83	72	commentary	commentary	NOUN
ihlr-16500	83	73	,	,	PUNCT
ihlr-16500	83	74	imshealtilcom	imshealtilcom	PROPN
ihlr-16500	83	75	,	,	PUNCT
ihlr-16500	83	76	feb	feb	PROPN
ihlr-16500	83	77	.	.	PROPN
ihlr-16500	83	78	22	22	NUM
ihlr-16500	83	79	,	,	PUNCT
ihlr-16500	83	80	2006	2006	NUM
ihlr-16500	83	81	,	,	PUNCT
ihlr-16500	83	82	http://www.imshealth.com/ims/portallfront/articlec/0,2777	http://www.imshealth.com/ims/portallfront/articlec/0,2777	PROPN
ihlr-16500	83	83	,	,	PUNCT
ihlr-16500	83	84	6599	6599	NUM
ihlr-16500	83	85	_	_	PUNCT
ihlr-16500	83	86	3665	3665	NUM
ihlr-16500	83	87	_	_	PUNCT
ihlr-16500	84	1	69890098,00.html	69890098,00.html	NUM
ihlr-16500	85	1	[	[	X
ihlr-16500	85	2	hereinafter	hereinafter	NOUN
ihlr-16500	85	3	2004	2004	NUM
ihlr-16500	85	4	year	year	NOUN
ihlr-16500	85	5	-	-	PUNCT
ihlr-16500	85	6	end	end	NOUN
ihlr-16500	85	7	]	]	X
ihlr-16500	85	8	.	.	PUNCT
ihlr-16500	86	1	9	9	NUM
ihlr-16500	86	2	imshealth.com	imshealth.com	X
ihlr-16500	86	3	,	,	PUNCT
ihlr-16500	86	4	leading	lead	VERB
ihlr-16500	86	5	20	20	NUM
ihlr-16500	86	6	corporations	corporation	NOUN
ihlr-16500	86	7	by	by	ADP
ihlr-16500	86	8	total	total	ADJ
ihlr-16500	86	9	u.s	u.s	PROPN
ihlr-16500	86	10	.	.	PROPN
ihlr-16500	86	11	dispensed	dispense	VERB
ihlr-16500	86	12	prescriptions	prescription	NOUN
ihlr-16500	86	13	,	,	PUNCT
ihlr-16500	86	14	2005	2005	NUM
ihlr-16500	86	15	,	,	PUNCT
ihlr-16500	86	16	bttp://www.imshealth.com/ims/portal/front/articlec/0,2777,6599	bttp://www.imshealth.com/ims/portal/front/articlec/0,2777,6599	X
ihlr-16500	86	17	_	_	NOUN
ihlr-16500	86	18	73914140_77266121	73914140_77266121	NUM
ihlr-16500	86	19	,	,	PUNCT
ihlr-16500	86	20	oo.btml	oo.btml	X
ihlr-16500	86	21	.	.	PUNCT
ihlr-16500	87	1	10	10	NUM
ihlr-16500	87	2	2004	2004	NUM
ihlr-16500	87	3	year	year	NOUN
ihlr-16500	87	4	-	-	PUNCT
ihlr-16500	87	5	end	end	NOUN
ihlr-16500	87	6	,	,	PUNCT
ihlr-16500	87	7	supra	supra	PROPN
ihlr-16500	87	8	note	note	NOUN
ihlr-16500	87	9	8	8	NUM
ihlr-16500	87	10	.	.	PUNCT
ihlr-16500	88	1	the	the	DET
ihlr-16500	88	2	net	net	ADJ
ihlr-16500	88	3	total	total	ADJ
ihlr-16500	88	4	of$235	of$235	NOUN
ihlr-16500	88	5	billion	billion	NUM
ihlr-16500	88	6	was	be	AUX
ihlr-16500	88	7	calculated	calculate	VERB
ihlr-16500	88	8	by	by	ADP
ihlr-16500	88	9	adding	add	VERB
ihlr-16500	88	10	the	the	DET
ihlr-16500	88	11	following	following	NOUN
ihlr-16500	88	12	:	:	PUNCT
ihlr-16500	88	13	chain	chain	NOUN
ihlr-16500	88	14	stores	store	NOUN
ihlr-16500	88	15	,	,	PUNCT
ihlr-16500	88	16	mail	mail	NOUN
ihlr-16500	88	17	services	service	NOUN
ihlr-16500	88	18	,	,	PUNCT
ihlr-16500	88	19	independent	independent	ADJ
ihlr-16500	88	20	non	non	ADJ
ihlr-16500	88	21	-	-	ADJ
ihlr-16500	88	22	federal	federal	ADJ
ihlr-16500	88	23	facilities	facility	NOUN
ihlr-16500	88	24	.	.	PUNCT
ihlr-16500	89	1	clinics	clinic	NOUN
ihlr-16500	89	2	,	,	PUNCT
ihlr-16500	89	3	food	food	NOUN
ihlr-16500	89	4	stores	store	NOUN
ihlr-16500	89	5	,	,	PUNCT
ihlr-16500	89	6	long	long	ADJ
ihlr-16500	89	7	-	-	PUNCT
ihlr-16500	89	8	term	term	NOUN
ihlr-16500	89	9	care	care	NOUN
ihlr-16500	89	10	,	,	PUNCT
ihlr-16500	89	11	federal	federal	ADJ
ihlr-16500	89	12	facilities	facility	NOUN
ihlr-16500	89	13	,	,	PUNCT
ihlr-16500	89	14	home	home	NOUN
ihlr-16500	89	15	health	health	NOUN
ihlr-16500	89	16	,	,	PUNCT
ihlr-16500	89	17	hmo	hmo	PROPN
ihlr-16500	89	18	,	,	PUNCT
ihlr-16500	89	19	and	and	CCONJ
ihlr-16500	89	20	other	other	ADJ
ihlr-16500	89	21	categories	category	NOUN
ihlr-16500	89	22	.	.	PUNCT
ihlr-16500	90	1	ld	ld	PROPN
ihlr-16500	90	2	.	.	PROPN
ihlr-16500	90	3	11	11	NUM
ihlr-16500	91	1	i	i	PRON
ihlr-16500	91	2	d.	d.	PROPN
ihlr-16500	91	3	in	in	ADP
ihlr-16500	91	4	2005	2005	NUM
ihlr-16500	91	5	,	,	PUNCT
ihlr-16500	91	6	the	the	DET
ihlr-16500	91	7	biopharmaceutical	biopharmaceutical	NOUN
ihlr-16500	91	8	industry	industry	NOUN
ihlr-16500	91	9	spent	spend	VERB
ihlr-16500	91	10	a	a	DET
ihlr-16500	91	11	total	total	ADJ
ihlr-16500	91	12	of$51.3	of$51.3	NUM
ihlr-16500	91	13	billion	billion	NUM
ihlr-16500	91	14	in	in	ADP
ihlr-16500	91	15	research	research	NOUN
ihlr-16500	91	16	and	and	CCONJ
ihlr-16500	91	17	development	development	NOUN
ihlr-16500	91	18	.	.	PUNCT
ihlr-16500	92	1	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	92	2	research	research	PROPN
ihlr-16500	92	3	and	and	CCONJ
ihlr-16500	92	4	ma	ma	PROPN
ihlr-16500	92	5	:	:	PUNCT
ihlr-16500	92	6	nufactijrers	nufactijrer	NOUN
ihlr-16500	92	7	of	of	ADP
ihlr-16500	92	8	america	america	PROPN
ihlr-16500	92	9	,	,	PUNCT
ihlr-16500	92	10	pharmaceutical	pharmaceutical	NOUN
ihlr-16500	92	11	industry	industry	NOUN
ihlr-16500	92	12	profile	profile	NOUN
ihlr-16500	92	13	2006	2006	NUM
ihlr-16500	92	14	10	10	NUM
ihlr-16500	92	15	(	(	PUNCT
ihlr-16500	92	16	2006	2006	NUM
ihlr-16500	92	17	)	)	PUNCT
ihlr-16500	93	1	[	[	X
ihlr-16500	93	2	hereinafter	hereinafter	NOUN
ihlr-16500	93	3	pharmaceutical	pharmaceutical	NOUN
ihlr-16500	93	4	industry	industry	NOUN
ihlr-16500	93	5	profile	profile	NOUN
ihlr-16500	93	6	2006	2006	NUM
ihlr-16500	93	7	)	)	PUNCT
ihlr-16500	93	8	.	.	PUNCT
ihlr-16500	93	9	12	12	NUM
ihlr-16500	93	10	merr1u	merr1u	PROPN
ihlr-16500	93	11	.	.	PUNCT
ihlr-16500	93	12	goozner	goozner	NOUN
ihlr-16500	93	13	,	,	PUNCT
ihlr-16500	93	14	the	the	DET
ihlr-16500	93	15	$	$	SYM
ihlr-16500	93	16	800	800	NUM
ihlr-16500	93	17	mn.lion	mn.lion	NOUN
ihlr-16500	93	18	pill	pill	NOUN
ihlr-16500	93	19	:	:	PUNCT
ihlr-16500	93	20	the	the	DET
ihlr-16500	93	21	truth	truth	NOUN
ihlr-16500	93	22	behind	behind	ADP
ihlr-16500	93	23	the	the	DET
ihlr-16500	93	24	cost	cost	NOUN
ihlr-16500	93	25	of	of	ADP
ihlr-16500	93	26	new	new	ADJ
ihlr-16500	93	27	drugs	drug	NOUN
ihlr-16500	93	28	232	232	NUM
ihlr-16500	93	29	(	(	PUNCT
ihlr-16500	93	30	2004	2004	NUM
ihlr-16500	93	31	)	)	PUNCT
ihlr-16500	93	32	.	.	PUNCT
ihlr-16500	94	1	13	13	NUM
ihlr-16500	94	2	drugs	drug	NOUN
ihlr-16500	94	3	are	be	AUX
ihlr-16500	94	4	often	often	ADV
ihlr-16500	94	5	categorized	categorize	VERB
ihlr-16500	94	6	by	by	ADP
ihlr-16500	94	7	the	the	DET
ihlr-16500	94	8	disease	disease	NOUN
ihlr-16500	94	9	-	-	PUNCT
ihlr-16500	94	10	state	state	NOUN
ihlr-16500	94	11	that	that	SCONJ
ihlr-16500	94	12	they	they	PRON
ihlr-16500	94	13	attempt	attempt	VERB
ihlr-16500	94	14	to	to	PART
ihlr-16500	94	15	treat	treat	VERB
ihlr-16500	94	16	.	.	PUNCT
ihlr-16500	95	1	14	14	NUM
ihlr-16500	95	2	omudbome	omudbome	NOUN
ihlr-16500	95	3	ogbru	ogbru	ADJ
ihlr-16500	95	4	,	,	PUNCT
ihlr-16500	95	5	statins	statin	NOUN
ihlr-16500	95	6	,	,	PUNCT
ihlr-16500	95	7	http://www.medicinenet.com/statins/article.htm	http://www.medicinenet.com/statins/article.htm	PROPN
ihlr-16500	95	8	(	(	PUNCT
ihlr-16500	95	9	last	last	ADJ
ihlr-16500	95	10	vis­	vis­	NOUN
ihlr-16500	95	11	ited	ite	VERB
ihlr-16500	95	12	feb	feb	PROPN
ihlr-16500	95	13	.	.	PROPN
ihlr-16500	95	14	15	15	NUM
ihlr-16500	95	15	,	,	PUNCT
ihlr-16500	95	16	2007	2007	NUM
ihlr-16500	95	17	)	)	PUNCT
ihlr-16500	95	18	.	.	PUNCT
ihlr-16500	95	19	'	'	PUNCT
ihlr-16500	96	1	"	"	PUNCT
ihlr-16500	96	2	statins	statins	PROPN
ihlr-16500	96	3	'	'	PART
ihlr-16500	96	4	are	be	AUX
ihlr-16500	96	5	a	a	DET
ihlr-16500	96	6	class	class	NOUN
ihlr-16500	96	7	of	of	ADP
ihlr-16500	96	8	drugs	drug	NOUN
ihlr-16500	96	9	that	that	PRON
ihlr-16500	96	10	lowers	lower	VERB
ihlr-16500	96	11	the	the	DET
ihlr-16500	96	12	level	level	NOUN
ihlr-16500	96	13	of	of	ADP
ihlr-16500	96	14	cholesterol	cholesterol	NOUN
ihlr-16500	96	15	in	in	ADP
ihlr-16500	96	16	the	the	DET
ihlr-16500	96	17	blood	blood	NOUN
ihlr-16500	96	18	by	by	ADP
ihlr-16500	96	19	reducing	reduce	VERB
ihlr-16500	96	20	the	the	DET
ihlr-16500	96	21	production	production	NOUN
ihlr-16500	96	22	of	of	ADP
ihlr-16500	96	23	cholesterol	cholesterol	NOUN
ihlr-16500	96	24	by	by	ADP
ihlr-16500	96	25	the	the	DET
ihlr-16500	96	26	liver	liver	NOUN
ihlr-16500	96	27	.	.	PUNCT
ihlr-16500	97	1	statins	statin	NOUN
ihlr-16500	97	2	block	block	VERB
ihlr-16500	97	3	the	the	DET
ihlr-16500	97	4	enzyme	enzyme	NOUN
ihlr-16500	97	5	in	in	ADP
ihlr-16500	97	6	the	the	DET
ihlr-16500	97	7	liver	liver	NOUN
ihlr-16500	97	8	that	that	PRON
ihlr-16500	97	9	is	be	AUX
ihlr-16500	97	10	responsible	responsible	ADJ
ihlr-16500	97	11	for	for	ADP
ihlr-16500	97	12	making	make	VERB
ihlr-16500	97	13	cholesterol	cholesterol	NOUN
ihlr-16500	97	14	.	.	PUNCT
ihlr-16500	98	1	•	•	X
ihlr-16500	98	2	..	..	PUNCT
ihlr-16500	98	3	statins	statin	NOUN
ihlr-16500	98	4	are	be	AUX
ihlr-16500	98	5	used	use	VERB
ihlr-16500	98	6	for	for	ADP
ihlr-16500	98	7	preventing	prevent	VERB
ihlr-16500	98	8	and	and	CCONJ
ihlr-16500	98	9	treating	treat	VERB
ihlr-16500	98	10	atherosclerosis	atherosclerosis	NOUN
ihlr-16500	98	11	that	that	PRON
ihlr-16500	98	12	causes	cause	VERB
ihlr-16500	98	13	chest	chest	NOUN
ihlr-16500	98	14	pain	pain	NOUN
ihlr-16500	98	15	,	,	PUNCT
ihlr-16500	98	16	heart	heart	NOUN
ihlr-16500	98	17	attacks	attack	NOUN
ihlr-16500	98	18	,	,	PUNCT
ihlr-16500	98	19	strokes	stroke	NOUN
ihlr-16500	98	20	,	,	PUNCT
ihlr-16500	98	21	and	and	CCONJ
ihlr-16500	98	22	intermittent	intermittent	ADJ
ihlr-16500	98	23	claudication	claudication	NOUN
ihlr-16500	98	24	in	in	ADP
ihlr-16500	98	25	individuals	individual	NOUN
ihlr-16500	98	26	who	who	PRON
ihlr-16500	98	27	have	have	VERB
ihlr-16500	98	28	or	or	CCONJ
ihlr-16500	98	29	are	be	AUX
ihlr-16500	98	30	at	at	ADP
ihlr-16500	98	31	risk	risk	NOUN
ihlr-16500	98	32	for	for	ADP
ihlr-16500	98	33	atherosclerosis	atherosclerosis	NOUN
ihlr-16500	98	34	.	.	PUNCT
ihlr-16500	98	35	"	"	PUNCT
ihlr-16500	99	1	i	i	PRON
ihlr-16500	99	2	d.	d.	VERB
ihlr-16500	99	3	the	the	DET
ihlr-16500	99	4	most	most	ADV
ihlr-16500	99	5	popular	popular	ADJ
ihlr-16500	99	6	statins	statin	NOUN
ihlr-16500	99	7	include	include	VERB
ihlr-16500	99	8	lipitor	lipitor	NOUN
ihlr-16500	99	9	,	,	PUNCT
ihlr-16500	99	10	zocor	zocor	NOUN
ihlr-16500	99	11	and	and	CCONJ
ihlr-16500	99	12	pravachol	pravachol	NOUN
ihlr-16500	99	13	,	,	PUNCT
ihlr-16500	99	14	which	which	PRON
ihlr-16500	99	15	are	be	AUX
ihlr-16500	99	16	also	also	ADV
ihlr-16500	99	17	three	three	NUM
ihlr-16500	99	18	of	of	ADP
ihlr-16500	99	19	the	the	DET
ihlr-16500	99	20	highest	high	ADJ
ihlr-16500	99	21	selling	selling	NOUN
ihlr-16500	99	22	drugs	drug	NOUN
ihlr-16500	99	23	within	within	ADP
ihlr-16500	99	24	the	the	DET
ihlr-16500	99	25	phar­	phar­	ADJ
ihlr-16500	99	26	maceutical	maceutical	ADJ
ihlr-16500	99	27	industry	industry	NOUN
ihlr-16500	99	28	.	.	PUNCT
ihlr-16500	100	1	2004	2004	NUM
ihlr-16500	100	2	year	year	NOUN
ihlr-16500	100	3	-	-	PUNCT
ihlr-16500	100	4	end	end	NOUN
ihlr-16500	100	5	,	,	PUNCT
ihlr-16500	100	6	supra	supra	PROPN
ihlr-16500	100	7	note	note	NOUN
ihlr-16500	100	8	8	8	NUM
ihlr-16500	100	9	.	.	PUNCT
ihlr-16500	101	1	the	the	DET
ihlr-16500	101	2	statio	statio	NOUN
ihlr-16500	101	3	class	class	NOUN
ihlr-16500	101	4	of	of	ADP
ihlr-16500	101	5	drugs	drug	NOUN
ihlr-16500	101	6	currently	currently	ADV
ihlr-16500	101	7	accounts	account	VERB
ihlr-16500	101	8	120	120	NUM
ihlr-16500	101	9	indiana	indiana	PROPN
ihlr-16500	101	10	health	health	NOUN
ihlr-16500	101	11	law	law	NOUN
ihlr-16500	101	12	review	review	NOUN
ihlr-16500	101	13	[	[	X
ihlr-16500	101	14	vol	vol	NOUN
ihlr-16500	101	15	.	.	PUNCT
ihlr-16500	102	1	4:115	4:115	NUM
ihlr-16500	102	2	industry	industry	NOUN
ihlr-16500	102	3	critics	critic	NOUN
ihlr-16500	102	4	believe	believe	VERB
ihlr-16500	102	5	that	that	SCONJ
ihlr-16500	102	6	the	the	DET
ihlr-16500	102	7	lure	lure	NOUN
ihlr-16500	102	8	of	of	ADP
ihlr-16500	102	9	profits	profit	NOUN
ihlr-16500	102	10	and	and	CCONJ
ihlr-16500	102	11	the	the	DET
ihlr-16500	102	12	subsequent	subsequent	ADJ
ihlr-16500	102	13	investor	investor	NOUN
ihlr-16500	102	14	per­	per­	NOUN
ihlr-16500	102	15	ception	ception	PROPN
ihlr-16500	102	16	has	have	AUX
ihlr-16500	102	17	led	lead	VERB
ihlr-16500	102	18	companies	company	NOUN
ihlr-16500	102	19	to	to	PART
ihlr-16500	102	20	produce	produce	VERB
ihlr-16500	102	21	drugs	drug	NOUN
ihlr-16500	102	22	that	that	PRON
ihlr-16500	102	23	increase	increase	VERB
ihlr-16500	102	24	revenues	revenue	NOUN
ihlr-16500	102	25	rather	rather	ADV
ihlr-16500	102	26	than	than	ADP
ihlr-16500	102	27	those	those	PRON
ihlr-16500	102	28	that	that	PRON
ihlr-16500	102	29	benefit	benefit	VERB
ihlr-16500	102	30	the	the	DET
ihlr-16500	102	31	general	general	ADJ
ihlr-16500	102	32	public	public	NOUN
ihlr-16500	102	33	by	by	ADP
ihlr-16500	102	34	treating	treat	VERB
ihlr-16500	102	35	an	an	DET
ihlr-16500	102	36	incurable	incurable	ADJ
ihlr-16500	102	37	or	or	CCONJ
ihlr-16500	102	38	untreatable	untreatable	ADJ
ihlr-16500	102	39	dis­	dis­	NOUN
ihlr-16500	102	40	ease.15	ease.15	NOUN
ihlr-16500	102	41	why	why	SCONJ
ihlr-16500	102	42	else	else	ADV
ihlr-16500	102	43	would	would	AUX
ihlr-16500	102	44	there	there	PRON
ihlr-16500	102	45	be	be	AUX
ihlr-16500	102	46	a	a	DET
ihlr-16500	102	47	number	number	NOUN
ihlr-16500	102	48	of	of	ADP
ihlr-16500	102	49	drugs	drug	NOUN
ihlr-16500	102	50	in	in	ADP
ihlr-16500	102	51	the	the	DET
ihlr-16500	102	52	same	same	ADJ
ihlr-16500	102	53	class	class	NOUN
ihlr-16500	102	54	that	that	PRON
ihlr-16500	102	55	per­	per­	NOUN
ihlr-16500	102	56	form	form	NOUN
ihlr-16500	102	57	virtually	virtually	ADV
ihlr-16500	102	58	the	the	DET
ihlr-16500	102	59	same	same	ADJ
ihlr-16500	102	60	function?16	function?16	PROPN
ihlr-16500	102	61	in	in	ADP
ihlr-16500	102	62	response	response	NOUN
ihlr-16500	102	63	,	,	PUNCT
ihlr-16500	102	64	many	many	ADJ
ihlr-16500	102	65	proponents	proponent	NOUN
ihlr-16500	102	66	of	of	ADP
ihlr-16500	102	67	the	the	DET
ihlr-16500	102	68	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	102	69	industry	industry	NOUN
ihlr-16500	102	70	rebut	rebut	VERB
ihlr-16500	102	71	such	such	DET
ihlr-16500	102	72	a	a	DET
ihlr-16500	102	73	argument	argument	NOUN
ihlr-16500	102	74	by	by	ADP
ihlr-16500	102	75	claiming	claim	VERB
ihlr-16500	102	76	that	that	SCONJ
ihlr-16500	102	77	each	each	DET
ihlr-16500	102	78	drug	drug	NOUN
ihlr-16500	102	79	in	in	ADP
ihlr-16500	102	80	a	a	DET
ihlr-16500	102	81	category	category	NOUN
ihlr-16500	102	82	,	,	PUNCT
ihlr-16500	102	83	although	although	SCONJ
ihlr-16500	102	84	created	create	VERB
ihlr-16500	102	85	to	to	PART
ihlr-16500	102	86	treat	treat	VERB
ihlr-16500	102	87	the	the	DET
ihlr-16500	102	88	same	same	ADJ
ihlr-16500	102	89	disease	disease	NOUN
ihlr-16500	102	90	-	-	PUNCT
ihlr-16500	102	91	state	state	NOUN
ihlr-16500	102	92	,	,	PUNCT
ihlr-16500	102	93	often	often	ADV
ihlr-16500	102	94	has	have	VERB
ihlr-16500	102	95	a	a	DET
ihlr-16500	102	96	different	different	ADJ
ihlr-16500	102	97	mechanism	mechanism	NOUN
ihlr-16500	102	98	of	of	ADP
ihlr-16500	102	99	action	action	NOUN
ihlr-16500	102	100	and	and	CCONJ
ihlr-16500	102	101	as	as	ADP
ihlr-16500	102	102	a	a	DET
ihlr-16500	102	103	result	result	NOUN
ihlr-16500	102	104	is	be	AUX
ihlr-16500	102	105	in	in	ADP
ihlr-16500	102	106	fact	fact	NOUN
ihlr-16500	102	107	a	a	DET
ihlr-16500	102	108	novel	novel	NOUN
ihlr-16500	102	109	drug.17	drug.17	NOUN
ihlr-16500	102	110	the	the	DET
ihlr-16500	102	111	practical	practical	ADJ
ihlr-16500	102	112	answer	answer	NOUN
ihlr-16500	102	113	,	,	PUNCT
ihlr-16500	102	114	however	however	ADV
ihlr-16500	102	115	,	,	PUNCT
ihlr-16500	102	116	is	be	AUX
ihlr-16500	102	117	that	that	SCONJ
ihlr-16500	102	118	each	each	DET
ihlr-16500	102	119	drug	drug	NOUN
ihlr-16500	102	120	makes	make	VERB
ihlr-16500	102	121	a	a	DET
ihlr-16500	102	122	lot	lot	NOUN
ihlr-16500	102	123	of	of	ADP
ihlr-16500	102	124	money.18	money.18	NOUN
ihlr-16500	102	125	as	as	ADP
ihlr-16500	102	126	blockbuster	blockbuster	ADJ
ihlr-16500	102	127	drugs	drug	NOUN
ihlr-16500	102	128	,	,	PUNCT
ihlr-16500	102	129	these	these	DET
ihlr-16500	102	130	drugs	drug	NOUN
ihlr-16500	102	131	can	can	AUX
ihlr-16500	102	132	single	single	ADV
ihlr-16500	102	133	-	-	PUNCT
ihlr-16500	102	134	handedly	handedly	ADV
ihlr-16500	102	135	reverse	reverse	VERB
ihlr-16500	102	136	the	the	DET
ihlr-16500	102	137	fortunes	fortune	NOUN
ihlr-16500	102	138	of	of	ADP
ihlr-16500	102	139	any	any	DET
ihlr-16500	102	140	dwindling	dwindle	VERB
ihlr-16500	102	141	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	102	142	company	company	NOUN
ihlr-16500	102	143	.	.	PUNCT
ihlr-16500	103	1	in	in	ADP
ihlr-16500	103	2	other	other	ADJ
ihlr-16500	103	3	cases	case	NOUN
ihlr-16500	103	4	they	they	PRON
ihlr-16500	103	5	may	may	AUX
ihlr-16500	103	6	further	far	ADV
ihlr-16500	103	7	enhance	enhance	VERB
ihlr-16500	103	8	the	the	DET
ihlr-16500	103	9	profitability	profitability	NOUN
ihlr-16500	103	10	at	at	ADP
ihlr-16500	103	11	a	a	DET
ihlr-16500	103	12	successful	successful	ADJ
ihlr-16500	103	13	phannaceutical	phannaceutical	ADJ
ihlr-16500	103	14	conglomer­	conglomer­	PROPN
ihlr-16500	103	15	ate	ate	NOUN
ihlr-16500	103	16	,	,	PUNCT
ihlr-16500	103	17	certainly	certainly	ADV
ihlr-16500	103	18	increasing	increase	VERB
ihlr-16500	103	19	its	its	PRON
ihlr-16500	103	20	worth	worth	NOUN
ihlr-16500	103	21	on	on	ADP
ihlr-16500	103	22	wall	wall	PROPN
ihlr-16500	103	23	street	street	PROPN
ihlr-16500	103	24	.	.	PUNCT
ihlr-16500	104	1	2	2	X
ihlr-16500	104	2	.	.	X
ihlr-16500	104	3	the	the	DET
ihlr-16500	104	4	pharmaceutical	pharmaceutical	NOUN
ihlr-16500	104	5	industry	industry	NOUN
ihlr-16500	104	6	's	's	PART
ihlr-16500	104	7	reliance	reliance	NOUN
ihlr-16500	104	8	on	on	ADP
ihlr-16500	104	9	the	the	DET
ihlr-16500	104	10	blockbuster	blockbuster	ADJ
ihlr-16500	104	11	drug	drug	NOUN
ihlr-16500	104	12	blockbuster	blockbuster	NOUN
ihlr-16500	104	13	drugs	drug	NOUN
ihlr-16500	104	14	account	account	VERB
ihlr-16500	104	15	for	for	ADP
ihlr-16500	104	16	a	a	DET
ihlr-16500	104	17	large	large	ADJ
ihlr-16500	104	18	percentage	percentage	NOUN
ihlr-16500	104	19	of	of	ADP
ihlr-16500	104	20	the	the	DET
ihlr-16500	104	21	total	total	ADJ
ihlr-16500	104	22	net	net	ADJ
ihlr-16500	104	23	sales	sale	NOUN
ihlr-16500	104	24	pro­	pro­	NOUN
ihlr-16500	104	25	duced	duce	VERB
ihlr-16500	104	26	by	by	ADP
ihlr-16500	104	27	the	the	DET
ihlr-16500	104	28	pharmaceutical	pharmaceutical	NOUN
ihlr-16500	104	29	industry	industry	NOUN
ihlr-16500	104	30	.	.	PUNCT
ihlr-16500	105	1	these	these	DET
ihlr-16500	105	2	drugs	drug	NOUN
ihlr-16500	105	3	dominate	dominate	VERB
ihlr-16500	105	4	the	the	DET
ihlr-16500	105	5	market	market	NOUN
ihlr-16500	105	6	be­	be­	NOUN
ihlr-16500	105	7	cause	cause	NOUN
ihlr-16500	105	8	of	of	ADP
ihlr-16500	105	9	their	their	PRON
ihlr-16500	105	10	relative	relative	ADJ
ihlr-16500	105	11	popularity	popularity	NOUN
ihlr-16500	105	12	and	and	CCONJ
ihlr-16500	105	13	overall	overall	ADJ
ihlr-16500	105	14	efficacy	efficacy	NOUN
ihlr-16500	105	15	and	and	CCONJ
ihlr-16500	105	16	safety	safety	NOUN
ihlr-16500	105	17	.	.	PUNCT
ihlr-16500	106	1	19	19	NUM
ihlr-16500	106	2	in	in	ADP
ihlr-16500	106	3	2004	2004	NUM
ihlr-16500	106	4	,	,	PUNCT
ihlr-16500	106	5	the	the	DET
ihlr-16500	106	6	top	top	ADJ
ihlr-16500	106	7	ten	ten	NUM
ihlr-16500	106	8	blockbuster	blockbuster	ADJ
ihlr-16500	106	9	drugs	drug	NOUN
ihlr-16500	106	10	accounted	account	VERB
ihlr-16500	106	11	for	for	ADP
ihlr-16500	106	12	nearly	nearly	ADV
ihlr-16500	106	13	thirty	thirty	NUM
ihlr-16500	106	14	-	-	PUNCT
ihlr-16500	106	15	eight	eight	NUM
ihlr-16500	106	16	billion	billion	NUM
ihlr-16500	106	17	dollars	dollar	NOUN
ihlr-16500	106	18	of	of	ADP
ihlr-16500	106	19	total	total	ADJ
ihlr-16500	106	20	sales	sale	NOUN
ihlr-16500	106	21	.	.	PUNCT
ihlr-16500	107	1	20	20	NUM
ihlr-16500	107	2	in	in	ADP
ihlr-16500	107	3	2004	2004	NUM
ihlr-16500	107	4	,	,	PUNCT
ihlr-16500	107	5	for	for	ADP
ihlr-16500	107	6	example	example	NOUN
ihlr-16500	107	7	,	,	PUNCT
ihlr-16500	107	8	the	the	DET
ihlr-16500	107	9	top	top	ADJ
ihlr-16500	107	10	ten	ten	NUM
ihlr-16500	107	11	selling	sell	VERB
ihlr-16500	107	12	drugs	drug	NOUN
ihlr-16500	107	13	in	in	ADP
ihlr-16500	107	14	the	the	DET
ihlr-16500	107	15	united	united	PROPN
ihlr-16500	107	16	states	states	PROPN
ihlr-16500	107	17	made	make	VERB
ihlr-16500	107	18	more	more	ADJ
ihlr-16500	107	19	than	than	ADP
ihlr-16500	107	20	two	two	NUM
ihlr-16500	107	21	billion	billion	NUM
ihlr-16500	107	22	dollars	dollar	NOUN
ihlr-16500	107	23	in	in	ADP
ihlr-16500	107	24	sales	sale	NOUN
ihlr-16500	107	25	each	each	PRON
ihlr-16500	107	26	for	for	ADP
ihlr-16500	107	27	their	their	PRON
ihlr-16500	107	28	respective	respective	ADJ
ihlr-16500	107	29	companies	company	NOUN
ihlr-16500	107	30	with	with	ADP
ihlr-16500	107	31	the	the	DET
ihlr-16500	107	32	leader	leader	NOUN
ihlr-16500	107	33	being	be	AUX
ihlr-16500	107	34	pfizer	pfizer	NOUN
ihlr-16500	107	35	's	's	PART
ihlr-16500	107	36	statin	statin	PROPN
ihlr-16500	107	37	,	,	PUNCT
ihlr-16500	107	38	lipitor	lipitor	NOUN
ihlr-16500	107	39	,	,	PUNCT
ihlr-16500	107	40	which	which	PRON
ihlr-16500	107	41	accounted	account	VERB
ihlr-16500	107	42	for	for	ADP
ihlr-16500	107	43	$	$	SYM
ihlr-16500	107	44	7.7	7.7	NUM
ihlr-16500	107	45	billion	billion	NUM
ihlr-16500	107	46	in	in	ADP
ihlr-16500	107	47	sales.21	sales.21	NOUN
ihlr-16500	107	48	these	these	DET
ihlr-16500	107	49	extraordinarily	extraordinarily	ADV
ihlr-16500	107	50	high	high	ADJ
ihlr-16500	107	51	returns	return	NOUN
ihlr-16500	107	52	indicate	indicate	VERB
ihlr-16500	107	53	that	that	SCONJ
ihlr-16500	107	54	the	the	DET
ihlr-16500	107	55	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	107	56	companies	company	NOUN
ihlr-16500	107	57	clearly	clearly	ADV
ihlr-16500	107	58	have	have	VERB
ihlr-16500	107	59	a	a	DET
ihlr-16500	107	60	vested	vested	ADJ
ihlr-16500	107	61	interest	interest	NOUN
ihlr-16500	107	62	in	in	ADP
ihlr-16500	107	63	ensuring	ensure	VERB
ihlr-16500	107	64	that	that	SCONJ
ihlr-16500	107	65	their	their	PRON
ihlr-16500	107	66	blockbuster	blockbuster	ADJ
ihlr-16500	107	67	drugs	drug	NOUN
ihlr-16500	107	68	remain	remain	VERB
ihlr-16500	107	69	on	on	ADP
ihlr-16500	107	70	the	the	DET
ihlr-16500	107	71	market	market	NOUN
ihlr-16500	107	72	.	.	PUNCT
ihlr-16500	108	1	22	22	NUM
ihlr-16500	108	2	there	there	PRON
ihlr-16500	108	3	is	be	VERB
ihlr-16500	108	4	a	a	DET
ihlr-16500	108	5	downside	downside	NOUN
ihlr-16500	108	6	to	to	ADP
ihlr-16500	108	7	keeping	keep	VERB
ihlr-16500	108	8	a	a	DET
ihlr-16500	108	9	problematic	problematic	ADJ
ihlr-16500	108	10	blockbuster	blockbuster	NOUN
ihlr-16500	108	11	drug	drug	NOUN
ihlr-16500	108	12	on	on	ADP
ihlr-16500	108	13	the	the	DET
ihlr-16500	108	14	market	market	NOUN
ihlr-16500	108	15	.	.	PUNCT
ihlr-16500	109	1	keeping	keep	VERB
ihlr-16500	109	2	such	such	DET
ihlr-16500	109	3	a	a	DET
ihlr-16500	109	4	drug	drug	NOUN
ihlr-16500	109	5	on	on	ADP
ihlr-16500	109	6	the	the	DET
ihlr-16500	109	7	market	market	NOUN
ihlr-16500	109	8	may	may	AUX
ihlr-16500	109	9	cost	cost	VERB
ihlr-16500	109	10	the	the	DET
ihlr-16500	109	11	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	109	12	com­	com­	NOUN
ihlr-16500	109	13	pany	pany	NOUN
ihlr-16500	109	14	millions	million	NOUN
ihlr-16500	109	15	,	,	PUNCT
ihlr-16500	109	16	even	even	ADV
ihlr-16500	109	17	billions	billion	NOUN
ihlr-16500	109	18	,	,	PUNCT
ihlr-16500	109	19	of	of	ADP
ihlr-16500	109	20	dollars	dollar	NOUN
ihlr-16500	109	21	in	in	ADP
ihlr-16500	109	22	lawsuits	lawsuit	NOUN
ihlr-16500	109	23	,	,	PUNCT
ihlr-16500	109	24	negative	negative	ADJ
ihlr-16500	109	25	public	public	ADJ
ihlr-16500	109	26	perception	perception	NOUN
ihlr-16500	109	27	,	,	PUNCT
ihlr-16500	109	28	for	for	ADP
ihlr-16500	109	29	the	the	DET
ihlr-16500	109	30	largest	large	ADJ
ihlr-16500	109	31	sales	sale	NOUN
ihlr-16500	109	32	volumes	volume	NOUN
ihlr-16500	109	33	in	in	ADP
ihlr-16500	109	34	the	the	DET
ihlr-16500	109	35	industry	industry	NOUN
ihlr-16500	109	36	.	.	PUNCT
ihlr-16500	110	1	jd	jd	PROPN
ihlr-16500	110	2	15	15	NUM
ihlr-16500	110	3	see	see	VERB
ihlr-16500	110	4	merrill	merrill	PROPN
ihlr-16500	110	5	matthews	matthews	PROPN
ihlr-16500	110	6	,	,	PUNCT
ihlr-16500	110	7	jr	jr	PROPN
ihlr-16500	110	8	.	.	PROPN
ihlr-16500	110	9	,	,	PUNCT
ihlr-16500	110	10	drug	drug	NOUN
ihlr-16500	110	11	company	company	NOUN
ihlr-16500	110	12	profits	profit	NOUN
ihlr-16500	110	13	are	be	AUX
ihlr-16500	110	14	n't	not	PART
ihlr-16500	110	15	a	a	DET
ihlr-16500	110	16	problem	problem	NOUN
ihlr-16500	110	17	-	-	PUNCT
ihlr-16500	110	18	they're	they're	NOUN
ihlr-16500	110	19	the	the	DET
ihlr-16500	110	20	solution	solution	NOUN
ihlr-16500	110	21	,	,	PUNCT
ihlr-16500	110	22	healmcarenews	healmcarenew	NOUN
ihlr-16500	110	23	,	,	PUNCT
ihlr-16500	110	24	july	july	PROPN
ihlr-16500	110	25	1	1	NUM
ihlr-16500	110	26	,	,	PUNCT
ihlr-16500	110	27	2001	2001	NUM
ihlr-16500	110	28	,	,	PUNCT
ihlr-16500	110	29	http://www.heartland.org/article.cfin?artld=640	http://www.heartland.org/article.cfin?artld=640	ADJ
ihlr-16500	110	30	.	.	PUNCT
ihlr-16500	111	1	16	16	NUM
ihlr-16500	111	2	goozner	goozner	NOUN
ihlr-16500	111	3	,	,	PUNCT
ihlr-16500	111	4	supra	supra	PROPN
ihlr-16500	111	5	note	note	NOUN
ihlr-16500	111	6	12	12	NUM
ihlr-16500	111	7	,	,	PUNCT
ihlr-16500	111	8	at	at	ADP
ihlr-16500	111	9	229	229	NUM
ihlr-16500	111	10	.	.	PUNCT
ihlr-16500	112	1	17	17	NUM
ihlr-16500	112	2	ogbru	ogbru	ADJ
ihlr-16500	112	3	,	,	PUNCT
ihlr-16500	112	4	supra	supra	PROPN
ihlr-16500	112	5	note	note	NOUN
ihlr-16500	112	6	14	14	NUM
ihlr-16500	112	7	.	.	PUNCT
ihlr-16500	113	1	for	for	ADP
ihlr-16500	113	2	example	example	NOUN
ihlr-16500	113	3	,	,	PUNCT
ihlr-16500	113	4	''	''	PUNCT
ihlr-16500	113	5	(	(	PUNCT
ihlr-16500	113	6	s]tatins	s]tatin	NOUN
ihlr-16500	113	7	differ	differ	VERB
ihlr-16500	113	8	in	in	ADP
ihlr-16500	113	9	several	several	ADJ
ihlr-16500	113	10	ways	way	NOUN
ihlr-16500	113	11	.	.	PUNCT
ihlr-16500	114	1	the	the	DET
ihlr-16500	114	2	most	most	ADJ
ihlr-16500	114	3	obvi­	obvi­	NOUN
ihlr-16500	114	4	ous	ous	ADJ
ihlr-16500	114	5	difference	difference	NOUN
ihlr-16500	114	6	is	be	AUX
ihlr-16500	114	7	in	in	ADP
ihlr-16500	114	8	their	their	PRON
ihlr-16500	114	9	ability	ability	NOUN
ihlr-16500	114	10	to	to	PART
ihlr-16500	114	11	reduce	reduce	VERB
ihlr-16500	114	12	cholesterol	cholesterol	NOUN
ihlr-16500	114	13	.	.	PUNCT
ihlr-16500	114	14	"	"	PUNCT
ihlr-16500	115	1	jd	jd	PROPN
ihlr-16500	115	2	.	.	PUNCT
ihlr-16500	116	1	they	they	PRON
ihlr-16500	116	2	also	also	ADV
ihlr-16500	116	3	differ	differ	VERB
ihlr-16500	116	4	in	in	ADP
ihlr-16500	116	5	terms	term	NOUN
ihlr-16500	116	6	of	of	ADP
ihlr-16500	116	7	their	their	PRON
ihlr-16500	116	8	mechanism	mechanism	NOUN
ihlr-16500	116	9	of	of	ADP
ihlr-16500	116	10	action	action	NOUN
ihlr-16500	116	11	and	and	CCONJ
ihlr-16500	116	12	chemical	chemical	NOUN
ihlr-16500	116	13	structure	structure	NOUN
ihlr-16500	116	14	.	.	PUNCT
ihlr-16500	117	1	jd	jd	PROPN
ihlr-16500	117	2	.	.	PUNCT
ihlr-16500	118	1	a	a	DET
ihlr-16500	118	2	few	few	ADJ
ihlr-16500	118	3	of	of	ADP
ihlr-16500	118	4	the	the	DET
ihlr-16500	118	5	statins	statin	NOUN
ihlr-16500	118	6	"	"	PUNCT
ihlr-16500	118	7	are	be	AUX
ihlr-16500	118	8	completely	completely	ADV
ihlr-16500	118	9	synthetic	synthetic	ADJ
ihlr-16500	118	10	and	and	CCONJ
ihlr-16500	118	11	have	have	VERB
ihlr-16500	118	12	chemical	chemical	NOUN
ihlr-16500	118	13	structures	structure	NOUN
ihlr-16500	118	14	that	that	PRON
ihlr-16500	118	15	differ	differ	VERB
ihlr-16500	118	16	greatly	greatly	ADV
ihlr-16500	118	17	from	from	ADP
ihlr-16500	118	18	the	the	DET
ihlr-16500	118	19	natural	natural	ADJ
ihlr-16500	118	20	statins	statin	NOUN
ihlr-16500	118	21	.	.	PUNCT
ihlr-16500	118	22	"	"	PUNCT
ihlr-16500	119	1	jd	jd	PROPN
ihlr-16500	119	2	.	.	PROPN
ihlr-16500	119	3	18	18	NUM
ihlr-16500	119	4	walsh	walsh	PROPN
ihlr-16500	119	5	&	&	CCONJ
ihlr-16500	119	6	ostrow	ostrow	PROPN
ihlr-16500	119	7	,	,	PUNCT
ihlr-16500	119	8	supra	supra	ADJ
ihlr-16500	119	9	note	note	NOUN
ihlr-16500	119	10	5	5	NUM
ihlr-16500	119	11	.	.	SYM
ihlr-16500	119	12	19	19	NUM
ihlr-16500	119	13	catherine	catherine	PROPN
ihlr-16500	119	14	arnst	arnst	PROPN
ihlr-16500	119	15	et	et	PROPN
ihlr-16500	119	16	al	al	PROPN
ihlr-16500	119	17	.	.	PROPN
ihlr-16500	119	18	,	,	PUNCT
ihlr-16500	119	19	the	the	DET
ihlr-16500	119	20	waning	waning	NOUN
ihlr-16500	119	21	of	of	ADP
ihlr-16500	119	22	the	the	DET
ihlr-16500	119	23	blockbuster	blockbuster	NOUN
ihlr-16500	119	24	drug	drug	NOUN
ihlr-16500	119	25	,	,	PUNCT
ihlr-16500	119	26	bus	bus	NOUN
ihlr-16500	119	27	.	.	PUNCT
ihlr-16500	120	1	wk	wk	PROPN
ihlr-16500	120	2	.	.	PROPN
ihlr-16500	120	3	online	online	PROPN
ihlr-16500	120	4	,	,	PUNCT
ihlr-16500	120	5	oct	oct	PROPN
ihlr-16500	120	6	.	.	PROPN
ihlr-16500	120	7	18	18	NUM
ihlr-16500	120	8	,	,	PUNCT
ihlr-16500	120	9	2004	2004	NUM
ihlr-16500	120	10	,	,	PUNCT
ihlr-16500	120	11	http://www.businessweek.com/magazinelcontent/04	http://www.businessweek.com/magazinelcontent/04	X
ihlr-16500	121	1	_	_	NOUN
ihlr-16500	121	2	42	42	NUM
ihlr-16500	121	3	/	/	SYM
ihlr-16500	121	4	b3904034	b3904034	NOUN
ihlr-16500	121	5	_	_	PRON
ihlr-16500	121	6	mzo	mzo	NOUN
ihlr-16500	122	1	ll.htm	ll.htm	ADJ
ihlr-16500	122	2	.	.	PROPN
ihlr-16500	123	1	20	20	NUM
ihlr-16500	123	2	2004	2004	NUM
ihlr-16500	123	3	year	year	NOUN
ihlr-16500	123	4	-	-	PUNCT
ihlr-16500	123	5	end	end	NOUN
ihlr-16500	123	6	,	,	PUNCT
ihlr-16500	123	7	supra	supra	PROPN
ihlr-16500	123	8	note	note	NOUN
ihlr-16500	123	9	8	8	NUM
ihlr-16500	123	10	.	.	SYM
ihlr-16500	123	11	21	21	NUM
ihlr-16500	123	12	ld	ld	PROPN
ihlr-16500	123	13	.	.	PROPN
ihlr-16500	124	1	22	22	NUM
ihlr-16500	125	1	it	it	PRON
ihlr-16500	125	2	should	should	AUX
ihlr-16500	125	3	be	be	AUX
ihlr-16500	125	4	noted	note	VERB
ihlr-16500	125	5	that	that	SCONJ
ihlr-16500	125	6	although	although	SCONJ
ihlr-16500	125	7	a	a	DET
ihlr-16500	125	8	blockbuster	blockbuster	ADJ
ihlr-16500	125	9	drug	drug	NOUN
ihlr-16500	125	10	accounts	account	NOUN
ihlr-16500	125	11	for	for	ADP
ihlr-16500	125	12	sales	sale	NOUN
ihlr-16500	125	13	in	in	ADP
ihlr-16500	125	14	excess	excess	NOUN
ihlr-16500	125	15	of	of	ADP
ihlr-16500	125	16	one	one	NUM
ihlr-16500	125	17	billion	billion	NUM
ihlr-16500	125	18	dollars	dollar	NOUN
ihlr-16500	125	19	,	,	PUNCT
ihlr-16500	125	20	it	it	PRON
ihlr-16500	125	21	is	be	AUX
ihlr-16500	125	22	difficult	difficult	ADJ
ihlr-16500	125	23	to	to	PART
ihlr-16500	125	24	compare	compare	VERB
ihlr-16500	125	25	a	a	DET
ihlr-16500	125	26	blockbuster	blockbuster	ADJ
ihlr-16500	125	27	drug	drug	NOUN
ihlr-16500	125	28	to	to	ADP
ihlr-16500	125	29	a	a	DET
ihlr-16500	125	30	non	non	ADJ
ihlr-16500	125	31	-	-	ADJ
ihlr-16500	125	32	blockbuster	blockbuster	ADJ
ihlr-16500	125	33	drug	drug	NOUN
ihlr-16500	125	34	because	because	SCONJ
ihlr-16500	125	35	the	the	DET
ihlr-16500	125	36	latter	latter	NOUN
ihlr-16500	125	37	's	's	PART
ihlr-16500	125	38	sales	sale	NOUN
ihlr-16500	125	39	can	can	AUX
ihlr-16500	125	40	vary	vary	VERB
ihlr-16500	125	41	due	due	ADJ
ihlr-16500	125	42	to	to	ADP
ihlr-16500	125	43	a	a	DET
ihlr-16500	125	44	number	number	NOUN
ihlr-16500	125	45	of	of	ADP
ihlr-16500	125	46	factors	factor	NOUN
ihlr-16500	125	47	,	,	PUNCT
ihlr-16500	125	48	such	such	ADJ
ihlr-16500	125	49	as	as	ADP
ihlr-16500	125	50	with	with	ADP
ihlr-16500	125	51	respect	respect	NOUN
ihlr-16500	125	52	to	to	ADP
ihlr-16500	125	53	its	its	PRON
ihlr-16500	125	54	relative	relative	ADJ
ihlr-16500	125	55	popular­	popular­	PROPN
ihlr-16500	125	56	ity	ity	PROPN
ihlr-16500	125	57	and	and	CCONJ
ihlr-16500	125	58	associated	associated	ADJ
ihlr-16500	125	59	disease	disease	NOUN
ihlr-16500	125	60	-	-	PUNCT
ihlr-16500	125	61	state	state	NOUN
ihlr-16500	125	62	.	.	PUNCT
ihlr-16500	126	1	2007	2007	NUM
ihlr-16500	126	2	]	]	PUNCT
ihlr-16500	127	1	pulling	pull	VERB
ihlr-16500	127	2	a	a	DET
ihlr-16500	127	3	blockbuster	blockbuster	ADJ
ihlr-16500	127	4	drug	drug	NOUN
ihlr-16500	127	5	off	off	ADP
ihlr-16500	127	6	the	the	DET
ihlr-16500	127	7	market	market	NOUN
ihlr-16500	127	8	121	121	NUM
ihlr-16500	127	9	and	and	CCONJ
ihlr-16500	127	10	decreased	decrease	VERB
ihlr-16500	127	11	investor	investor	NOUN
ihlr-16500	127	12	confidence	confidence	NOUN
ihlr-16500	127	13	.	.	PUNCT
ihlr-16500	128	1	more	more	ADV
ihlr-16500	128	2	importantly	importantly	ADV
ihlr-16500	128	3	,	,	PUNCT
ihlr-16500	128	4	the	the	DET
ihlr-16500	128	5	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	128	6	company	company	NOUN
ihlr-16500	128	7	's	's	PART
ihlr-16500	128	8	inaction	inaction	NOUN
ihlr-16500	128	9	may	may	AUX
ihlr-16500	128	10	have	have	VERB
ihlr-16500	128	11	a	a	DET
ihlr-16500	128	12	negative	negative	ADJ
ihlr-16500	128	13	impact	impact	NOUN
ihlr-16500	128	14	on	on	ADP
ihlr-16500	128	15	the	the	DET
ihlr-16500	128	16	health	health	NOUN
ihlr-16500	128	17	of	of	ADP
ihlr-16500	128	18	patients	patient	NOUN
ihlr-16500	128	19	who	who	PRON
ihlr-16500	128	20	use	use	VERB
ihlr-16500	128	21	and	and	CCONJ
ihlr-16500	128	22	rely	rely	VERB
ihlr-16500	128	23	on	on	ADP
ihlr-16500	128	24	the	the	DET
ihlr-16500	128	25	drug	drug	NOUN
ihlr-16500	128	26	in	in	ADP
ihlr-16500	128	27	the	the	DET
ihlr-16500	128	28	first	first	ADJ
ihlr-16500	128	29	place	place	NOUN
ihlr-16500	128	30	.	.	PUNCT
ihlr-16500	129	1	the	the	DET
ihlr-16500	129	2	cost	cost	NOUN
ihlr-16500	129	3	of	of	ADP
ihlr-16500	129	4	a	a	DET
ihlr-16500	129	5	failed	fail	VERB
ihlr-16500	129	6	blockbuster	blockbuster	NOUN
ihlr-16500	129	7	drug	drug	NOUN
ihlr-16500	129	8	can	can	AUX
ihlr-16500	129	9	be	be	AUX
ihlr-16500	129	10	especially	especially	ADV
ihlr-16500	129	11	devastating	devastating	ADJ
ihlr-16500	129	12	for	for	ADP
ihlr-16500	129	13	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	129	14	companies	company	NOUN
ihlr-16500	129	15	that	that	PRON
ihlr-16500	129	16	require	require	VERB
ihlr-16500	129	17	successful	successful	ADJ
ihlr-16500	129	18	blockbuster	blockbuster	NOUN
ihlr-16500	129	19	drugs	drug	NOUN
ihlr-16500	129	20	in	in	ADP
ihlr-16500	129	21	order	order	NOUN
ihlr-16500	129	22	to	to	PART
ihlr-16500	129	23	recoup	recoup	VERB
ihlr-16500	129	24	the	the	DET
ihlr-16500	129	25	high	high	ADJ
ihlr-16500	129	26	cost	cost	NOUN
ihlr-16500	129	27	of	of	ADP
ihlr-16500	129	28	developing	develop	VERB
ihlr-16500	129	29	and	and	CCONJ
ihlr-16500	129	30	manufacturing	manufacture	VERB
ihlr-16500	129	31	these	these	DET
ihlr-16500	129	32	drugs	drug	NOUN
ihlr-16500	129	33	.	.	PUNCT
ihlr-16500	130	1	in	in	ADP
ihlr-16500	130	2	addition	addition	NOUN
ihlr-16500	130	3	,	,	PUNCT
ihlr-16500	130	4	although	although	SCONJ
ihlr-16500	130	5	the	the	DET
ihlr-16500	130	6	pharmaceutical	pharmaceutical	NOUN
ihlr-16500	130	7	industry	industry	NOUN
ihlr-16500	130	8	enjoyed	enjoy	VERB
ihlr-16500	130	9	a	a	DET
ihlr-16500	130	10	5.4	5.4	NUM
ihlr-16500	130	11	%	%	NOUN
ihlr-16500	130	12	increase	increase	NOUN
ihlr-16500	130	13	in	in	ADP
ihlr-16500	130	14	sales	sale	NOUN
ihlr-16500	130	15	in	in	ADP
ihlr-16500	130	16	2005,23	2005,23	NUM
ihlr-16500	130	17	this	this	DET
ihlr-16500	130	18	number	number	NOUN
ihlr-16500	130	19	is	be	AUX
ihlr-16500	130	20	significantly	significantly	ADV
ihlr-16500	130	21	lower	low	ADJ
ihlr-16500	130	22	than	than	ADP
ihlr-16500	130	23	the	the	DET
ihlr-16500	130	24	8.3	8.3	NUM
ihlr-16500	130	25	%	%	NOUN
ihlr-16500	130	26	increase	increase	NOUN
ihlr-16500	130	27	the	the	DET
ihlr-16500	130	28	industry	industry	NOUN
ihlr-16500	130	29	enjoyed	enjoy	VERB
ihlr-16500	130	30	in	in	ADP
ihlr-16500	130	31	2004.24	2004.24	NUM
ihlr-16500	130	32	although	although	SCONJ
ihlr-16500	130	33	the	the	DET
ihlr-16500	130	34	current	current	ADJ
ihlr-16500	130	35	growth	growth	NOUN
ihlr-16500	130	36	rate	rate	NOUN
ihlr-16500	130	37	is	be	AUX
ihlr-16500	130	38	still	still	ADV
ihlr-16500	130	39	a	a	DET
ihlr-16500	130	40	strong	strong	ADJ
ihlr-16500	130	41	number	number	NOUN
ihlr-16500	130	42	,	,	PUNCT
ihlr-16500	130	43	the	the	DET
ihlr-16500	130	44	withdrawal	withdrawal	NOUN
ihlr-16500	130	45	of	of	ADP
ihlr-16500	130	46	blockbuster	blockbuster	ADJ
ihlr-16500	130	47	drugs	drug	NOUN
ihlr-16500	130	48	vioxx	vioxx	NOUN
ihlr-16500	130	49	and	and	CCONJ
ihlr-16500	130	50	bextra	bextra	PROPN
ihlr-16500	130	51	contributed	contribute	VERB
ihlr-16500	130	52	to	to	ADP
ihlr-16500	130	53	the	the	DET
ihlr-16500	130	54	de­	de­	ADJ
ihlr-16500	130	55	clining	clining	NOUN
ihlr-16500	130	56	growth	growth	NOUN
ihlr-16500	130	57	from	from	ADP
ihlr-16500	130	58	previous	previous	ADJ
ihlr-16500	130	59	years.25	years.25	PROPN
ihlr-16500	130	60	therefore	therefore	ADV
ihlr-16500	130	61	,	,	PUNCT
ihlr-16500	130	62	both	both	CCONJ
ihlr-16500	130	63	the	the	DET
ihlr-16500	130	64	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	130	65	in­	in­	NOUN
ihlr-16500	130	66	dustry	dustry	NOUN
ihlr-16500	130	67	and	and	CCONJ
ihlr-16500	130	68	its	its	PRON
ihlr-16500	130	69	companies	company	NOUN
ihlr-16500	130	70	require	require	VERB
ihlr-16500	130	71	a	a	DET
ihlr-16500	130	72	blockbuster	blockbuster	ADJ
ihlr-16500	130	73	drug	drug	NOUN
ihlr-16500	130	74	to	to	PART
ihlr-16500	130	75	succeed	succeed	VERB
ihlr-16500	130	76	commercially	commercially	ADV
ihlr-16500	130	77	,	,	PUNCT
ihlr-16500	130	78	specifically	specifically	ADV
ihlr-16500	130	79	before	before	SCONJ
ihlr-16500	130	80	the	the	DET
ihlr-16500	130	81	company	company	NOUN
ihlr-16500	130	82	loses	lose	VERB
ihlr-16500	130	83	its	its	PRON
ihlr-16500	130	84	right	right	NOUN
ihlr-16500	130	85	to	to	PART
ihlr-16500	130	86	exclusive	exclusive	VERB
ihlr-16500	130	87	marketing	marketing	NOUN
ihlr-16500	130	88	of	of	ADP
ihlr-16500	130	89	the	the	DET
ihlr-16500	130	90	drug26	drug26	ADJ
ihlr-16500	130	91	or	or	CCONJ
ihlr-16500	130	92	the	the	DET
ihlr-16500	130	93	drug	drug	NOUN
ihlr-16500	130	94	's	's	PART
ihlr-16500	130	95	patent	patent	NOUN
ihlr-16500	130	96	expiration27	expiration27	NOUN
ihlr-16500	130	97	,	,	PUNCT
ihlr-16500	130	98	in	in	ADP
ihlr-16500	130	99	order	order	NOUN
ihlr-16500	130	100	for	for	SCONJ
ihlr-16500	130	101	the	the	DET
ihlr-16500	130	102	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	130	103	industry	industry	NOUN
ihlr-16500	130	104	to	to	PART
ihlr-16500	130	105	enjoy	enjoy	VERB
ihlr-16500	130	106	a	a	DET
ihlr-16500	130	107	strong	strong	ADJ
ihlr-16500	130	108	growth	growth	NOUN
ihlr-16500	130	109	rate	rate	NOUN
ihlr-16500	130	110	and	and	CCONJ
ihlr-16500	130	111	for	for	SCONJ
ihlr-16500	130	112	its	its	PRON
ihlr-16500	130	113	companies	company	NOUN
ihlr-16500	130	114	to	to	PART
ihlr-16500	130	115	recoup	recoup	VERB
ihlr-16500	130	116	their	their	PRON
ihlr-16500	130	117	investment	investment	NOUN
ihlr-16500	130	118	in	in	ADP
ihlr-16500	130	119	development	development	NOUN
ihlr-16500	130	120	and	and	CCONJ
ihlr-16500	130	121	manufacturing	manufacturing	NOUN
ihlr-16500	130	122	of	of	ADP
ihlr-16500	130	123	these	these	DET
ihlr-16500	130	124	drugs	drug	NOUN
ihlr-16500	130	125	.	.	PUNCT
ihlr-16500	131	1	3	3	X
ihlr-16500	131	2	.	.	X
ihlr-16500	131	3	the	the	DET
ihlr-16500	131	4	evolving	evolve	VERB
ihlr-16500	131	5	and	and	CCONJ
ihlr-16500	131	6	future	future	ADJ
ihlr-16500	131	7	role	role	NOUN
ihlr-16500	131	8	of	of	ADP
ihlr-16500	131	9	the	the	DET
ihlr-16500	131	10	pharmaceutical	pharmaceutical	NOUN
ihlr-16500	131	11	industry	industry	NOUN
ihlr-16500	131	12	furthermore	furthermore	ADV
ihlr-16500	131	13	,	,	PUNCT
ihlr-16500	131	14	prescription	prescription	NOUN
ihlr-16500	131	15	drugs	drug	NOUN
ihlr-16500	131	16	have	have	AUX
ihlr-16500	131	17	played	play	VERB
ihlr-16500	131	18	an	an	DET
ihlr-16500	131	19	increasingly	increasingly	ADV
ihlr-16500	131	20	important	important	ADJ
ihlr-16500	131	21	role	role	NOUN
ihlr-16500	131	22	over	over	ADP
ihlr-16500	131	23	the	the	DET
ihlr-16500	131	24	years	year	NOUN
ihlr-16500	131	25	,	,	PUNCT
ihlr-16500	131	26	especially	especially	ADV
ihlr-16500	131	27	as	as	ADP
ihlr-16500	131	28	the	the	DET
ihlr-16500	131	29	united	united	PROPN
ihlr-16500	131	30	states	states	PROPN
ihlr-16500	131	31	'	'	PART
ihlr-16500	131	32	population	population	NOUN
ihlr-16500	131	33	ages	age	NOUN
ihlr-16500	131	34	.	.	PUNCT
ihlr-16500	132	1	28	28	NUM
ihlr-16500	133	1	accord­	accord­	ADP
ihlr-16500	133	2	ing	e	VERB
ihlr-16500	133	3	to	to	ADP
ihlr-16500	133	4	the	the	DET
ihlr-16500	133	5	administration	administration	NOUN
ihlr-16500	133	6	on	on	ADP
ihlr-16500	133	7	aging	aging	NOUN
ihlr-16500	133	8	,	,	PUNCT
ihlr-16500	133	9	the	the	DET
ihlr-16500	133	10	older	older	ADV
ihlr-16500	133	11	-	-	PUNCT
ihlr-16500	133	12	aged	aged	ADJ
ihlr-16500	133	13	segment	segment	NOUN
ihlr-16500	133	14	of	of	ADP
ihlr-16500	133	15	the	the	DET
ihlr-16500	133	16	united	united	PROPN
ihlr-16500	133	17	states	states	PROPN
ihlr-16500	133	18	'	'	PART
ihlr-16500	133	19	population	population	NOUN
ihlr-16500	133	20	is	be	AUX
ihlr-16500	133	21	growing	grow	VERB
ihlr-16500	133	22	substantially.29	substantially.29	NOUN
ihlr-16500	133	23	in	in	ADP
ihlr-16500	133	24	addition	addition	NOUN
ihlr-16500	133	25	,	,	PUNCT
ihlr-16500	133	26	many	many	ADJ
ihlr-16500	133	27	of	of	ADP
ihlr-16500	133	28	those	those	PRON
ihlr-16500	133	29	reach­	reach­	VERB
ihlr-16500	133	30	ing	e	VERB
ihlr-16500	133	31	the	the	DET
ihlr-16500	133	32	age	age	NOUN
ihlr-16500	133	33	of	of	ADP
ihlr-16500	133	34	retirement	retirement	NOUN
ihlr-16500	133	35	will	will	AUX
ihlr-16500	133	36	live	live	VERB
ihlr-16500	133	37	18.2	18.2	NUM
ihlr-16500	133	38	years	year	NOUN
ihlr-16500	133	39	longer	long	ADV
ihlr-16500	133	40	than	than	ADP
ihlr-16500	133	41	their	their	PRON
ihlr-16500	133	42	predecessors	predecessor	NOUN
ihlr-16500	133	43	.	.	PUNCT
ihlr-16500	133	44	30	30	NUM
ihlr-16500	134	1	according	accord	VERB
ihlr-16500	134	2	to	to	ADP
ihlr-16500	134	3	these	these	DET
ihlr-16500	134	4	statistics	statistic	NOUN
ihlr-16500	134	5	,	,	PUNCT
ihlr-16500	134	6	medications	medication	NOUN
ihlr-16500	134	7	produced	produce	VERB
ihlr-16500	134	8	by	by	ADP
ihlr-16500	134	9	the	the	DET
ihlr-16500	134	10	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	134	11	in­	in­	NOUN
ihlr-16500	134	12	dustry	dustry	NOUN
ihlr-16500	134	13	have	have	AUX
ihlr-16500	134	14	helped	help	VERB
ihlr-16500	134	15	to	to	PART
ihlr-16500	134	16	sustain	sustain	VERB
ihlr-16500	134	17	the	the	DET
ihlr-16500	134	18	lives	life	NOUN
ihlr-16500	134	19	of	of	ADP
ihlr-16500	134	20	the	the	DET
ihlr-16500	134	21	octogenarian	octogenarian	ADJ
ihlr-16500	134	22	demographic	demographic	NOUN
ihlr-16500	134	23	.	.	PUNCT
ihlr-16500	135	1	there­	there­	NUM
ihlr-16500	135	2	fore	fore	NOUN
ihlr-16500	135	3	,	,	PUNCT
ihlr-16500	135	4	as	as	ADP
ihlr-16500	135	5	a	a	DET
ihlr-16500	135	6	significant	significant	ADJ
ihlr-16500	135	7	portion	portion	NOUN
ihlr-16500	135	8	of	of	ADP
ihlr-16500	135	9	the	the	DET
ihlr-16500	135	10	population	population	NOUN
ihlr-16500	135	11	grows	grow	VERB
ihlr-16500	135	12	older	old	ADJ
ihlr-16500	135	13	,	,	PUNCT
ihlr-16500	135	14	the	the	DET
ihlr-16500	135	15	pharmaceutical	pharmaceutical	NOUN
ihlr-16500	135	16	industry	industry	NOUN
ihlr-16500	135	17	will	will	AUX
ihlr-16500	135	18	be	be	AUX
ihlr-16500	135	19	placed	place	VERB
ihlr-16500	135	20	under	under	ADP
ihlr-16500	135	21	greater	great	ADJ
ihlr-16500	135	22	scrutiny	scrutiny	NOUN
ihlr-16500	135	23	to	to	PART
ihlr-16500	135	24	ensure	ensure	VERB
ihlr-16500	135	25	that	that	SCONJ
ihlr-16500	135	26	the	the	DET
ihlr-16500	135	27	drugs	drug	NOUN
ihlr-16500	135	28	that	that	PRON
ihlr-16500	135	29	are	be	AUX
ihlr-16500	135	30	23	23	NUM
ihlr-16500	135	31	ims	im	NOUN
ihlr-16500	135	32	health	health	NOUN
ihlr-16500	135	33	reports	report	VERB
ihlr-16500	135	34	5.4	5.4	NUM
ihlr-16500	135	35	percent	percent	NOUN
ihlr-16500	135	36	dollar	dollar	NOUN
ihlr-16500	135	37	growth	growth	NOUN
ihlr-16500	135	38	in	in	ADP
ihlr-16500	135	39	2005	2005	NUM
ihlr-16500	135	40	u.s	u.s	PROPN
ihlr-16500	135	41	.	.	PROPN
ihlr-16500	135	42	prescription	prescription	NOUN
ihlr-16500	135	43	sales	sale	NOUN
ihlr-16500	135	44	,	,	PUNCT
ihlr-16500	135	45	imsheal11i.com	imsheal11i.com	X
ihlr-16500	135	46	,	,	PUNCT
ihlr-16500	135	47	feb	feb	PROPN
ihlr-16500	135	48	.	.	PROPN
ihlr-16500	135	49	22	22	NUM
ihlr-16500	135	50	,	,	PUNCT
ihlr-16500	135	51	2006	2006	NUM
ihlr-16500	135	52	,	,	PUNCT
ihlr-16500	135	53	http://www.imshealth.com/ims/portallfron11articlec/0,2777	http://www.imshealth.com/ims/portallfron11articlec/0,2777	PROPN
ihlr-16500	135	54	,	,	PUNCT
ihlr-16500	135	55	6599	6599	NUM
ihlr-16500	136	1	_	_	NOUN
ihlr-16500	136	2	3665	3665	NUM
ihlr-16500	137	1	_	_	NOUN
ihlr-16500	137	2	77180090,00.html	77180090,00.html	X
ihlr-16500	138	1	[	[	X
ihlr-16500	138	2	hereinafter	hereinafter	NOUN
ihlr-16500	138	3	percent	percent	NOUN
ihlr-16500	138	4	dollar	dollar	NOUN
ihlr-16500	138	5	growth	growth	NOUN
ihlr-16500	138	6	]	]	PUNCT
ihlr-16500	138	7	.	.	PUNCT
ihlr-16500	139	1	24	24	NUM
ihlr-16500	139	2	2004	2004	NUM
ihlr-16500	139	3	year	year	NOUN
ihlr-16500	139	4	-	-	PUNCT
ihlr-16500	139	5	end	end	NOUN
ihlr-16500	139	6	,	,	PUNCT
ihlr-16500	139	7	supra	supra	PROPN
ihlr-16500	139	8	note	note	NOUN
ihlr-16500	139	9	8	8	NUM
ihlr-16500	139	10	.	.	SYM
ihlr-16500	139	11	25	25	NUM
ihlr-16500	139	12	percent	percent	NOUN
ihlr-16500	139	13	dollar	dollar	NOUN
ihlr-16500	139	14	growth	growth	NOUN
ihlr-16500	139	15	,	,	PUNCT
ihlr-16500	139	16	supra	supra	PROPN
ihlr-16500	139	17	note	note	NOUN
ihlr-16500	139	18	23	23	NUM
ihlr-16500	139	19	.	.	NUM
ihlr-16500	139	20	26	26	NUM
ihlr-16500	140	1	see2l	see2l	DET
ihlr-16500	140	2	c.f.r	c.f.r	NOUN
ihlr-16500	140	3	.	.	PUNCT
ihlr-16500	141	1	§	§	PROPN
ihlr-16500	141	2	314.108	314.108	NUM
ihlr-16500	141	3	(	(	PUNCT
ihlr-16500	141	4	2006	2006	NUM
ihlr-16500	141	5	)	)	PUNCT
ihlr-16500	141	6	.	.	PUNCT
ihlr-16500	142	1	27	27	NUM
ihlr-16500	142	2	generally	generally	ADV
ihlr-16500	142	3	,	,	PUNCT
ihlr-16500	142	4	a	a	DET
ihlr-16500	142	5	drug	drug	NOUN
ihlr-16500	142	6	's	's	PART
ihlr-16500	142	7	patent	patent	NOUN
ihlr-16500	142	8	expires	expire	VERB
ihlr-16500	142	9	after	after	ADP
ihlr-16500	142	10	twenty	twenty	NUM
ihlr-16500	142	11	years	year	NOUN
ihlr-16500	142	12	,	,	PUNCT
ihlr-16500	142	13	although	although	SCONJ
ihlr-16500	142	14	this	this	DET
ihlr-16500	142	15	number	number	NOUN
ihlr-16500	142	16	can	can	AUX
ihlr-16500	142	17	vary	vary	VERB
ihlr-16500	142	18	due	due	ADJ
ihlr-16500	142	19	to	to	ADP
ihlr-16500	142	20	a	a	DET
ihlr-16500	142	21	host	host	NOUN
ihlr-16500	142	22	of	of	ADP
ihlr-16500	142	23	other	other	ADJ
ihlr-16500	142	24	factors	factor	NOUN
ihlr-16500	142	25	.	.	PUNCT
ihlr-16500	143	1	see	see	VERB
ihlr-16500	143	2	fda.gov	fda.gov	NUM
ihlr-16500	143	3	,	,	PUNCT
ihlr-16500	143	4	frequently	frequently	ADV
ihlr-16500	143	5	asked	ask	VERB
ihlr-16500	143	6	questions	question	NOUN
ihlr-16500	143	7	on	on	ADP
ihlr-16500	143	8	patents	patent	NOUN
ihlr-16500	143	9	and	and	CCONJ
ihlr-16500	143	10	exclu­	exclu­	PROPN
ihlr-16500	143	11	sivity	sivity	NOUN
ihlr-16500	143	12	,	,	PUNCT
ihlr-16500	143	13	http://www.fda.gov/cder/ob/faqs.htm#howo/o20many%20years%20is%20a%20patent%	http://www.fda.gov/cder/ob/faqs.htm#howo/o20many%20years%20is%20a%20patent%	PROPN
ihlr-16500	143	14	20granted%20for	20granted%20for	NUM
ihlr-16500	143	15	?	?	PUNCT
ihlr-16500	144	1	(	(	PUNCT
ihlr-16500	144	2	last	last	ADJ
ihlr-16500	144	3	visited	visit	VERB
ihlr-16500	144	4	feb	feb	PROPN
ihlr-16500	144	5	.	.	PROPN
ihlr-16500	144	6	15	15	NUM
ihlr-16500	144	7	,	,	PUNCT
ihlr-16500	144	8	2007	2007	NUM
ihlr-16500	144	9	)	)	PUNCT
ihlr-16500	144	10	.	.	PUNCT
ihlr-16500	145	1	28	28	NUM
ihlr-16500	145	2	see	see	VERB
ihlr-16500	145	3	generally	generally	ADV
ihlr-16500	145	4	admin	admin	ADJ
ihlr-16500	145	5	.	.	PUNCT
ihlr-16500	146	1	on	on	ADP
ihlr-16500	146	2	aging	aging	NOUN
ihlr-16500	146	3	,	,	PUNCT
ihlr-16500	146	4	u.s	u.s	PROPN
ihlr-16500	146	5	.	.	PROPN
ihlr-16500	146	6	dep't	dep't	NOUN
ihlr-16500	146	7	of	of	ADP
ihlr-16500	146	8	heal	heal	NOUN
ihlr-16500	146	9	til	til	PROPN
ihlr-16500	146	10	&	&	CCONJ
ihlr-16500	146	11	human	human	ADJ
ihlr-16500	146	12	servs	servs	PROPN
ihlr-16500	146	13	.	.	PUNCT
ihlr-16500	146	14	,	,	PUNCT
ihlr-16500	146	15	a	a	DET
ihlr-16500	146	16	profile	profile	NOUN
ihlr-16500	146	17	of	of	ADP
ihlr-16500	146	18	older	old	ADJ
ihlr-16500	146	19	americans	american	NOUN
ihlr-16500	146	20	:	:	PUNCT
ihlr-16500	146	21	2004	2004	NUM
ihlr-16500	146	22	passim	passim	NOUN
ihlr-16500	146	23	(	(	PUNCT
ihlr-16500	146	24	2004	2004	NUM
ihlr-16500	146	25	)	)	PUNCT
ihlr-16500	146	26	,	,	PUNCT
ihlr-16500	146	27	available	available	ADJ
ihlr-16500	146	28	at	at	ADP
ihlr-16500	146	29	http://www.aoa.gov/prof/statistics/	http://www.aoa.gov/prof/statistics/	PROPN
ihlr-16500	146	30	profile/2004/2004profile	profile/2004/2004profile	NOUN
ihlr-16500	146	31	.	.	PUNCT
ihlr-16500	146	32	pdf	pdf	NOUN
ihlr-16500	146	33	.	.	PUNCT
ihlr-16500	146	34	29	29	NUM
ihlr-16500	146	35	/d	/d	PUNCT
ihlr-16500	146	36	.	.	PUNCT
ihlr-16500	147	1	in	in	ADP
ihlr-16500	147	2	2003	2003	NUM
ihlr-16500	147	3	,	,	PUNCT
ihlr-16500	147	4	over	over	ADP
ihlr-16500	147	5	two	two	NUM
ihlr-16500	147	6	million	million	NUM
ihlr-16500	147	7	persons	person	NOUN
ihlr-16500	147	8	reached	reach	VERB
ihlr-16500	147	9	age	age	NOUN
ihlr-16500	147	10	sixty	sixty	NUM
ihlr-16500	147	11	-	-	PUNCT
ihlr-16500	147	12	five	five	NUM
ihlr-16500	147	13	.	.	PUNCT
ihlr-16500	148	1	i	i	PRON
ihlr-16500	148	2	d.	d.	VERB
ihlr-16500	148	3	that	that	DET
ihlr-16500	148	4	same	same	ADJ
ihlr-16500	148	5	year	year	NOUN
ihlr-16500	148	6	,	,	PUNCT
ihlr-16500	148	7	1.8	1.8	NUM
ihlr-16500	148	8	million	million	NUM
ihlr-16500	148	9	persons	person	NOUN
ihlr-16500	148	10	of	of	ADP
ihlr-16500	148	11	age	age	NOUN
ihlr-16500	148	12	sixty	sixty	NUM
ihlr-16500	148	13	-	-	PUNCT
ihlr-16500	148	14	five	five	NUM
ihlr-16500	148	15	or	or	CCONJ
ihlr-16500	148	16	older	old	ADJ
ihlr-16500	148	17	died	die	VERB
ihlr-16500	148	18	,	,	PUNCT
ihlr-16500	148	19	which	which	PRON
ihlr-16500	148	20	resulted	result	VERB
ihlr-16500	148	21	in	in	ADP
ihlr-16500	148	22	an	an	DET
ihlr-16500	148	23	annual	annual	ADJ
ihlr-16500	148	24	net	net	ADJ
ihlr-16500	148	25	increase	increase	NOUN
ihlr-16500	148	26	in	in	ADP
ihlr-16500	148	27	the	the	DET
ihlr-16500	148	28	senior	senior	ADJ
ihlr-16500	148	29	population	population	NOUN
ihlr-16500	148	30	of	of	ADP
ihlr-16500	148	31	over	over	ADP
ihlr-16500	148	32	317,000	317,000	NUM
ihlr-16500	148	33	.	.	PUNCT
ihlr-16500	149	1	/d	/d	INTJ
ihlr-16500	149	2	.	.	PUNCT
ihlr-16500	150	1	3q	3q	NUM
ihlr-16500	150	2	/d	/d	PUNCT
ihlr-16500	150	3	.	.	PROPN
ihlr-16500	151	1	122	122	NUM
ihlr-16500	151	2	indiana	indiana	PROPN
ihlr-16500	151	3	health	health	PROPN
ihlr-16500	151	4	law	law	PROPN
ihlr-16500	151	5	review	review	NOUN
ihlr-16500	151	6	[	[	X
ihlr-16500	151	7	vol	vol	NOUN
ihlr-16500	151	8	.	.	PUNCT
ihlr-16500	152	1	4:115	4:115	PRON
ihlr-16500	152	2	being	be	AUX
ihlr-16500	152	3	produced	produce	VERB
ihlr-16500	152	4	are	be	AUX
ihlr-16500	152	5	safe	safe	ADJ
ihlr-16500	152	6	,	,	PUNCT
ihlr-16500	152	7	as	as	ADV
ihlr-16500	152	8	well	well	ADV
ihlr-16500	152	9	as	as	ADP
ihlr-16500	152	10	efficacious	efficacious	ADJ
ihlr-16500	152	11	.	.	PUNCT
ihlr-16500	153	1	thus	thus	ADV
ihlr-16500	153	2	,	,	PUNCT
ihlr-16500	153	3	as	as	ADP
ihlr-16500	153	4	the	the	DET
ihlr-16500	153	5	number	number	NOUN
ihlr-16500	153	6	of	of	ADP
ihlr-16500	153	7	drug	drug	NOUN
ihlr-16500	153	8	withdrawals	withdrawal	NOUN
ihlr-16500	153	9	increases	increase	NOUN
ihlr-16500	153	10	,	,	PUNCT
ihlr-16500	153	11	this	this	DET
ihlr-16500	153	12	demographic	demographic	NOUN
ihlr-16500	153	13	is	be	AUX
ihlr-16500	153	14	affected	affect	VERB
ihlr-16500	153	15	more	more	ADJ
ihlr-16500	153	16	than	than	ADP
ihlr-16500	153	17	any	any	DET
ihlr-16500	153	18	other	other	ADJ
ihlr-16500	153	19	.	.	PUNCT
ihlr-16500	154	1	iii	iii	X
ihlr-16500	154	2	.	.	PUNCT
ihlr-16500	155	1	fda	fda	PROPN
ihlr-16500	155	2	drug	drug	PROPN
ihlr-16500	155	3	approval	approval	NOUN
ihlr-16500	155	4	process	process	NOUN
ihlr-16500	155	5	presently	presently	ADV
ihlr-16500	155	6	,	,	PUNCT
ihlr-16500	155	7	there	there	PRON
ihlr-16500	155	8	is	be	VERB
ihlr-16500	155	9	mounting	mount	VERB
ihlr-16500	155	10	internal	internal	ADJ
ihlr-16500	155	11	and	and	CCONJ
ihlr-16500	155	12	external	external	ADJ
ihlr-16500	155	13	pressure	pressure	NOUN
ihlr-16500	155	14	placed	place	VERB
ihlr-16500	155	15	on	on	ADP
ihlr-16500	155	16	phar­	phar­	PROPN
ihlr-16500	155	17	maceutical	maceutical	ADJ
ihlr-16500	155	18	companies	company	NOUN
ihlr-16500	155	19	to	to	PART
ihlr-16500	155	20	produce	produce	VERB
ihlr-16500	155	21	blockbuster	blockbuster	NOUN
ihlr-16500	155	22	drugs	drug	NOUN
ihlr-16500	155	23	.	.	PUNCT
ihlr-16500	156	1	internally	internally	ADV
ihlr-16500	156	2	,	,	PUNCT
ihlr-16500	156	3	management	management	NOUN
ihlr-16500	156	4	understands	understand	VERB
ihlr-16500	156	5	that	that	ADV
ihlr-16500	156	6	profitable	profitable	ADJ
ihlr-16500	156	7	drugs	drug	NOUN
ihlr-16500	156	8	are	be	AUX
ihlr-16500	156	9	needed	need	VERB
ihlr-16500	156	10	in	in	ADP
ihlr-16500	156	11	order	order	NOUN
ihlr-16500	156	12	to	to	PART
ihlr-16500	156	13	finance	finance	VERB
ihlr-16500	156	14	other	other	ADJ
ihlr-16500	156	15	opera­	opera­	ADJ
ihlr-16500	156	16	tions	tion	NOUN
ihlr-16500	156	17	,	,	PUNCT
ihlr-16500	156	18	as	as	SCONJ
ihlr-16500	156	19	is	be	AUX
ihlr-16500	156	20	the	the	DET
ihlr-16500	156	21	case	case	NOUN
ihlr-16500	156	22	in	in	ADP
ihlr-16500	156	23	many	many	ADJ
ihlr-16500	156	24	businesses	business	NOUN
ihlr-16500	156	25	.	.	PUNCT
ihlr-16500	157	1	on	on	ADP
ihlr-16500	157	2	the	the	DET
ihlr-16500	157	3	other	other	ADJ
ihlr-16500	157	4	hand	hand	NOUN
ihlr-16500	157	5	,	,	PUNCT
ihlr-16500	157	6	externally	externally	ADV
ihlr-16500	157	7	,	,	PUNCT
ihlr-16500	157	8	share­	share­	PROPN
ihlr-16500	157	9	holders	holder	NOUN
ihlr-16500	157	10	want	want	VERB
ihlr-16500	157	11	novel	novel	ADJ
ihlr-16500	157	12	blockbuster	blockbuster	NOUN
ihlr-16500	157	13	drugs	drug	NOUN
ihlr-16500	157	14	because	because	SCONJ
ihlr-16500	157	15	that	that	PRON
ihlr-16500	157	16	often	often	ADV
ihlr-16500	157	17	corresponds	correspond	VERB
ihlr-16500	157	18	to	to	ADP
ihlr-16500	157	19	increased	increase	VERB
ihlr-16500	157	20	profitability	profitability	NOUN
ihlr-16500	157	21	and	and	CCONJ
ihlr-16500	157	22	as	as	ADP
ihlr-16500	157	23	a	a	DET
ihlr-16500	157	24	result	result	NOUN
ihlr-16500	157	25	a	a	DET
ihlr-16500	157	26	simultaneous	simultaneous	ADJ
ihlr-16500	157	27	increase	increase	NOUN
ihlr-16500	157	28	in	in	ADP
ihlr-16500	157	29	dividend	dividend	NOUN
ihlr-16500	157	30	pay­	pay­	NOUN
ihlr-16500	157	31	ments	ment	NOUN
ihlr-16500	157	32	.	.	PUNCT
ihlr-16500	158	1	because	because	SCONJ
ihlr-16500	158	2	the	the	DET
ihlr-16500	158	3	average	average	ADJ
ihlr-16500	158	4	blockbuster	blockbuster	NOUN
ihlr-16500	158	5	drug	drug	NOUN
ihlr-16500	158	6	's	's	PART
ihlr-16500	158	7	return	return	NOUN
ihlr-16500	158	8	on	on	ADP
ihlr-16500	158	9	investment	investment	NOUN
ihlr-16500	158	10	is	be	AUX
ihlr-16500	158	11	only	only	ADV
ihlr-16500	158	12	five	five	NUM
ihlr-16500	158	13	percent	percent	NOUN
ihlr-16500	158	14	,	,	PUNCT
ihlr-16500	158	15	the	the	DET
ihlr-16500	158	16	large	large	ADJ
ihlr-16500	158	17	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	158	18	conglomerates	conglomerate	NOUN
ihlr-16500	158	19	would	would	AUX
ihlr-16500	158	20	need	need	VERB
ihlr-16500	158	21	to	to	PART
ihlr-16500	158	22	produce	produce	VERB
ihlr-16500	158	23	two	two	NUM
ihlr-16500	158	24	or	or	CCONJ
ihlr-16500	158	25	three	three	NUM
ihlr-16500	158	26	blockbuster	blockbuster	ADJ
ihlr-16500	158	27	drugs	drug	NOUN
ihlr-16500	158	28	per	per	ADP
ihlr-16500	158	29	year	year	NOUN
ihlr-16500	158	30	in	in	ADP
ihlr-16500	158	31	order	order	NOUN
ihlr-16500	158	32	to	to	PART
ihlr-16500	158	33	grow	grow	VERB
ihlr-16500	158	34	sales	sale	NOUN
ihlr-16500	158	35	by	by	ADP
ihlr-16500	158	36	ten	ten	NUM
ihlr-16500	158	37	percent	percent	NOUN
ihlr-16500	158	38	.	.	PUNCT
ihlr-16500	159	1	31	31	NUM
ihlr-16500	160	1	although	although	SCONJ
ihlr-16500	160	2	such	such	DET
ihlr-16500	160	3	a	a	DET
ihlr-16500	160	4	number	number	NOUN
ihlr-16500	160	5	may	may	AUX
ihlr-16500	160	6	seem	seem	VERB
ihlr-16500	160	7	absurd	absurd	ADJ
ihlr-16500	160	8	,	,	PUNCT
ihlr-16500	160	9	especially	especially	ADV
ihlr-16500	160	10	considering	consider	VERB
ihlr-16500	160	11	that	that	SCONJ
ihlr-16500	160	12	it	it	PRON
ihlr-16500	160	13	costs	cost	VERB
ihlr-16500	160	14	hundreds	hundred	NOUN
ihlr-16500	160	15	of	of	ADP
ihlr-16500	160	16	millions	million	NOUN
ihlr-16500	160	17	of	of	ADP
ihlr-16500	160	18	dollars	dollar	NOUN
ihlr-16500	160	19	to	to	PART
ihlr-16500	160	20	produce	produce	VERB
ihlr-16500	160	21	a	a	DET
ihlr-16500	160	22	blockbuster	blockbuster	ADJ
ihlr-16500	160	23	drug	drug	NOUN
ihlr-16500	160	24	,	,	PUNCT
ihlr-16500	160	25	the	the	DET
ihlr-16500	160	26	pharmaceuti­	pharmaceuti­	NOUN
ihlr-16500	160	27	cal	cal	NOUN
ihlr-16500	160	28	industry	industry	NOUN
ihlr-16500	160	29	has	have	AUX
ihlr-16500	160	30	in	in	ADP
ihlr-16500	160	31	fact	fact	NOUN
ihlr-16500	160	32	sustained	sustain	VERB
ihlr-16500	160	33	such	such	DET
ihlr-16500	160	34	a	a	DET
ihlr-16500	160	35	pace	pace	NOUN
ihlr-16500	160	36	.	.	PUNCT
ihlr-16500	161	1	the	the	DET
ihlr-16500	161	2	number	number	NOUN
ihlr-16500	161	3	ofblockbuster	ofblockbuster	NOUN
ihlr-16500	161	4	drugs	drug	NOUN
ihlr-16500	161	5	on	on	ADP
ihlr-16500	161	6	the	the	DET
ihlr-16500	161	7	market	market	NOUN
ihlr-16500	161	8	has	have	AUX
ihlr-16500	161	9	increased	increase	VERB
ihlr-16500	161	10	from	from	ADP
ihlr-16500	161	11	seventeen	seventeen	NUM
ihlr-16500	161	12	in	in	ADP
ihlr-16500	161	13	1995	1995	NUM
ihlr-16500	161	14	to	to	ADP
ihlr-16500	161	15	sixty	sixty	NUM
ihlr-16500	161	16	-	-	PUNCT
ihlr-16500	161	17	seven	seven	NUM
ihlr-16500	161	18	in	in	ADP
ihlr-16500	161	19	2003.32	2003.32	NUM
ihlr-16500	161	20	just	just	ADV
ihlr-16500	161	21	as	as	SCONJ
ihlr-16500	161	22	the	the	DET
ihlr-16500	161	23	number	number	NOUN
ihlr-16500	161	24	of	of	ADP
ihlr-16500	161	25	blockbuster	blockbuster	ADJ
ihlr-16500	161	26	drug	drug	NOUN
ihlr-16500	161	27	brands	brand	NOUN
ihlr-16500	161	28	have	have	AUX
ihlr-16500	161	29	increased	increase	VERB
ihlr-16500	161	30	,	,	PUNCT
ihlr-16500	161	31	so	so	ADV
ihlr-16500	161	32	too	too	ADV
ihlr-16500	161	33	has	have	VERB
ihlr-16500	161	34	the	the	DET
ihlr-16500	161	35	number	number	NOUN
ihlr-16500	161	36	ofblockbuster	ofblockbuster	NOUN
ihlr-16500	161	37	drug	drug	NOUN
ihlr-16500	161	38	withdrawals	withdrawal	NOUN
ihlr-16500	161	39	.	.	PUNCT
ihlr-16500	162	1	as	as	ADP
ihlr-16500	162	2	a	a	DET
ihlr-16500	162	3	result	result	NOUN
ihlr-16500	162	4	,	,	PUNCT
ihlr-16500	162	5	the	the	DET
ihlr-16500	162	6	fda	fda	PROPN
ihlr-16500	162	7	's	's	PART
ihlr-16500	162	8	drug	drug	NOUN
ihlr-16500	162	9	approval	approval	NOUN
ihlr-16500	162	10	process	process	NOUN
ihlr-16500	162	11	has	have	AUX
ihlr-16500	162	12	come	come	VERB
ihlr-16500	162	13	under	under	ADP
ihlr-16500	162	14	scrutiny	scrutiny	NOUN
ihlr-16500	162	15	by	by	ADP
ihlr-16500	162	16	many	many	ADJ
ihlr-16500	162	17	experts	expert	NOUN
ihlr-16500	162	18	.	.	PUNCT
ihlr-16500	163	1	33	33	NUM
ihlr-16500	163	2	even	even	ADV
ihlr-16500	163	3	the	the	DET
ihlr-16500	163	4	agency	agency	NOUN
ihlr-16500	163	5	that	that	PRON
ihlr-16500	163	6	dic­	dic­	PROPN
ihlr-16500	163	7	tates	tat	VERB
ihlr-16500	163	8	whether	whether	SCONJ
ihlr-16500	163	9	a	a	DET
ihlr-16500	163	10	drug	drug	NOUN
ihlr-16500	163	11	is	be	AUX
ihlr-16500	163	12	fit	fit	ADJ
ihlr-16500	163	13	for	for	ADP
ihlr-16500	163	14	introduction	introduction	NOUN
ihlr-16500	163	15	into	into	ADP
ihlr-16500	163	16	the	the	DET
ihlr-16500	163	17	open	open	ADJ
ihlr-16500	163	18	market	market	NOUN
ihlr-16500	163	19	is	be	AUX
ihlr-16500	163	20	not	not	PART
ihlr-16500	163	21	immune	immune	ADJ
ihlr-16500	163	22	from	from	ADP
ihlr-16500	163	23	criticism	criticism	NOUN
ihlr-16500	163	24	,	,	PUNCT
ihlr-16500	163	25	especially	especially	ADV
ihlr-16500	163	26	when	when	SCONJ
ihlr-16500	163	27	its	its	PRON
ihlr-16500	163	28	self	self	NOUN
ihlr-16500	163	29	-	-	PUNCT
ihlr-16500	163	30	acclaimed	acclaim	VERB
ihlr-16500	163	31	stringent	stringent	ADJ
ihlr-16500	163	32	drug	drug	NOUN
ihlr-16500	163	33	approval	approval	NOUN
ihlr-16500	163	34	process	process	NOUN
ihlr-16500	163	35	fails	fail	VERB
ihlr-16500	163	36	to	to	PART
ihlr-16500	163	37	uncover	uncover	VERB
ihlr-16500	163	38	the	the	DET
ihlr-16500	163	39	drug	drug	NOUN
ihlr-16500	163	40	's	's	PART
ihlr-16500	163	41	safety	safety	NOUN
ihlr-16500	163	42	problems	problem	NOUN
ihlr-16500	163	43	.	.	PUNCT
ihlr-16500	164	1	·	·	PUNCT
ihlr-16500	165	1	the	the	DET
ihlr-16500	165	2	drug	drug	NOUN
ihlr-16500	165	3	approval	approval	NOUN
ihlr-16500	165	4	process	process	NOUN
ihlr-16500	165	5	within	within	ADP
ihlr-16500	165	6	the	the	DET
ihlr-16500	165	7	fda	fda	PROPN
ihlr-16500	165	8	is	be	AUX
ihlr-16500	165	9	still	still	ADV
ihlr-16500	165	10	a	a	DET
ihlr-16500	165	11	rigorous	rigorous	ADJ
ihlr-16500	165	12	process	process	NOUN
ihlr-16500	165	13	that	that	PRON
ihlr-16500	165	14	consists	consist	VERB
ihlr-16500	165	15	of	of	ADP
ihlr-16500	165	16	several	several	ADJ
ihlr-16500	165	17	phases	phase	NOUN
ihlr-16500	165	18	of	of	ADP
ihlr-16500	165	19	testing	testing	NOUN
ihlr-16500	165	20	.	.	PUNCT
ihlr-16500	166	1	34	34	NUM
ihlr-16500	166	2	regulation	regulation	NOUN
ihlr-16500	166	3	of	of	ADP
ihlr-16500	166	4	a	a	DET
ihlr-16500	166	5	new	new	ADJ
ihlr-16500	166	6	drug	drug	NOUN
ihlr-16500	166	7	is	be	AUX
ihlr-16500	166	8	performed	perform	VERB
ihlr-16500	166	9	by	by	ADP
ihlr-16500	166	10	the	the	DET
ihlr-16500	166	11	center	center	NOUN
ihlr-16500	166	12	for	for	ADP
ihlr-16500	166	13	drug	drug	NOUN
ihlr-16500	166	14	evaluation	evaluation	NOUN
ihlr-16500	166	15	and	and	CCONJ
ihlr-16500	166	16	research	research	NOUN
ihlr-16500	166	17	,	,	PUNCT
ihlr-16500	166	18	a	a	DET
ihlr-16500	166	19	branch	branch	NOUN
ihlr-16500	166	20	of	of	ADP
ihlr-16500	166	21	the	the	DET
ihlr-16500	166	22	fda	fda	PROPN
ihlr-16500	166	23	.	.	PROPN
ihlr-16500	166	24	35	35	NUM
ihlr-16500	166	25	the	the	DET
ihlr-16500	166	26	process	process	NOUN
ihlr-16500	166	27	for	for	ADP
ihlr-16500	166	28	approval	approval	NOUN
ihlr-16500	166	29	begins	begin	VERB
ihlr-16500	166	30	by	by	ADP
ihlr-16500	166	31	requiring	require	VERB
ihlr-16500	166	32	the	the	DET
ihlr-16500	166	33	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	166	34	company	company	NOUN
ihlr-16500	166	35	to	to	PART
ihlr-16500	166	36	take	take	VERB
ihlr-16500	166	37	steps	step	NOUN
ihlr-16500	166	38	to	to	PART
ihlr-16500	166	39	perform	perform	VERB
ihlr-16500	166	40	pre	pre	ADJ
ihlr-16500	166	41	-	-	ADJ
ihlr-16500	166	42	clinical	clinical	ADJ
ihlr-16500	166	43	screening	screening	NOUN
ihlr-16500	166	44	of	of	ADP
ihlr-16500	166	45	the	the	DET
ihlr-16500	166	46	drug	drug	NOUN
ihlr-16500	166	47	in	in	ADP
ihlr-16500	166	48	order	order	NOUN
ihlr-16500	166	49	to	to	PART
ihlr-16500	166	50	prove	prove	VERB
ihlr-16500	166	51	through	through	ADP
ihlr-16500	166	52	their	their	PRON
ihlr-16500	166	53	subsequent	subsequent	ADJ
ihlr-16500	166	54	submission	submission	NOUN
ihlr-16500	166	55	of	of	ADP
ihlr-16500	166	56	data	datum	NOUN
ihlr-16500	166	57	to	to	ADP
ihlr-16500	166	58	the	the	DET
ihlr-16500	166	59	fda	fda	PROPN
ihlr-16500	166	60	that	that	SCONJ
ihlr-16500	166	61	the	the	DET
ihlr-16500	166	62	drug	drug	NOUN
ihlr-16500	166	63	is	be	AUX
ihlr-16500	166	64	reasonably	reasonably	ADV
ihlr-16500	166	65	safe.36	safe.36	VERB
ihlr-16500	166	66	in	in	ADP
ihlr-16500	166	67	order	order	NOUN
ihlr-16500	166	68	to	to	PART
ihlr-16500	166	69	ensure	ensure	VERB
ihlr-16500	166	70	that	that	SCONJ
ihlr-16500	166	71	the	the	DET
ihlr-16500	166	72	drug	drug	NOUN
ihlr-16500	166	73	is	be	AUX
ihlr-16500	166	74	safe	safe	ADJ
ihlr-16500	166	75	,	,	PUNCT
ihlr-16500	166	76	during	during	ADP
ihlr-16500	166	77	preclinical	preclinical	ADJ
ihlr-16500	166	78	drug	drug	NOUN
ihlr-16500	166	79	develop31	develop31	NOUN
ihlr-16500	166	80	beyond	beyond	ADP
ihlr-16500	166	81	the	the	DET
ihlr-16500	166	82	blockbuster	blockbuster	NOUN
ihlr-16500	166	83	drug	drug	NOUN
ihlr-16500	166	84	:	:	PUNCT
ihlr-16500	166	85	strategies	strategy	NOUN
ihlr-16500	166	86	for	for	ADP
ihlr-16500	166	87	nichebuster	nichebuster	NOUN
ihlr-16500	166	88	drugs	drug	NOUN
ihlr-16500	166	89	,	,	PUNCT
ihlr-16500	166	90	targeted	target	VERB
ihlr-16500	166	91	therapies	therapy	NOUN
ihlr-16500	166	92	and	and	CCONJ
ihlr-16500	166	93	personalized	personalized	ADJ
ihlr-16500	166	94	medicine	medicine	NOUN
ihlr-16500	166	95	,	,	PUNCT
ihlr-16500	166	96	bus	bus	NOUN
ihlr-16500	166	97	.	.	PUNCT
ihlr-16500	167	1	insights	insight	NOUN
ihlr-16500	167	2	,	,	PUNCT
ihlr-16500	167	3	feb	feb	PROPN
ihlr-16500	167	4	.	.	PROPN
ihlr-16500	167	5	2005	2005	NUM
ihlr-16500	167	6	,	,	PUNCT
ihlr-16500	167	7	available	available	ADJ
ihlr-16500	167	8	at	at	ADP
ihlr-16500	167	9	http://www	http://www	PROPN
ihlr-16500	167	10	.researchandmarkets.com	.researchandmarkets.com	PROPN
ihlr-16500	167	11	/	/	SYM
ihlr-16500	167	12	reports/295612	reports/295612	NOUN
ihlr-16500	167	13	.	.	PUNCT
ihlr-16500	168	1	32	32	NUM
ihlr-16500	168	2	visiongain	visiongain	NOUN
ihlr-16500	168	3	,	,	PUNCT
ihlr-16500	168	4	blockbuster	blockbuster	ADJ
ihlr-16500	168	5	drugs	drug	NOUN
ihlr-16500	168	6	expected	expect	VERB
ihlr-16500	168	7	to	to	PART
ihlr-16500	168	8	rise	rise	VERB
ihlr-16500	168	9	by	by	ADP
ihlr-16500	168	10	93%to	93%to	PROPN
ihlr-16500	168	11	$	$	SYM
ihlr-16500	168	12	262	262	NUM
ihlr-16500	168	13	billion	billion	NUM
ihlr-16500	168	14	by	by	ADP
ihlr-16500	168	15	2009	2009	NUM
ihlr-16500	168	16	pre­	pre­	NOUN
ihlr-16500	168	17	dicts	dict	NOUN
ihlr-16500	168	18	visiongain	visiongain	VERB
ihlr-16500	168	19	,	,	PUNCT
ihlr-16500	168	20	pr9.net	pr9.net	NOUN
ihlr-16500	168	21	,	,	PUNCT
ihlr-16500	168	22	nov	nov	PROPN
ihlr-16500	168	23	.	.	PROPN
ihlr-16500	168	24	15,2004	15,2004	NUM
ihlr-16500	168	25	,	,	PUNCT
ihlr-16500	168	26	http://www.pr9.net/health/medicine/1322	http://www.pr9.net/health/medicine/1322	PROPN
ihlr-16500	168	27	novem­	novem­	PART
ihlr-16500	168	28	ber.html	ber.html	PROPN
ihlr-16500	168	29	.	.	PUNCT
ihlr-16500	169	1	33	33	NUM
ihlr-16500	169	2	christopher	christopher	PROPN
ihlr-16500	169	3	placitella	placitella	PROPN
ihlr-16500	169	4	&	&	CCONJ
ihlr-16500	169	5	justin	justin	PROPN
ihlr-16500	169	6	klein	klein	PROPN
ihlr-16500	169	7	,	,	PUNCT
ihlr-16500	169	8	the	the	DET
ihlr-16500	169	9	civil	civil	ADJ
ihlr-16500	169	10	justice	justice	NOUN
ihlr-16500	169	11	system	system	NOUN
ihlr-16500	169	12	bridges	bridge	VERB
ihlr-16500	169	13	the	the	DET
ihlr-16500	169	14	great	great	ADJ
ihlr-16500	169	15	divide	divide	NOUN
ihlr-16500	169	16	in	in	ADP
ihlr-16500	169	17	consumer	consumer	NOUN
ihlr-16500	169	18	protection	protection	NOUN
ihlr-16500	169	19	,	,	PUNCT
ihlr-16500	169	20	43	43	NUM
ihlr-16500	169	21	duq	duq	NOUN
ihlr-16500	169	22	.	.	PUNCT
ihlr-16500	170	1	l.	l.	PROPN
ihlr-16500	170	2	rev	rev	PROPN
ihlr-16500	170	3	.	.	PROPN
ihlr-16500	170	4	219	219	NUM
ihlr-16500	170	5	,	,	PUNCT
ihlr-16500	170	6	220	220	NUM
ihlr-16500	170	7	(	(	PUNCT
ihlr-16500	170	8	2005	2005	NUM
ihlr-16500	170	9	)	)	PUNCT
ihlr-16500	170	10	.	.	PUNCT
ihlr-16500	171	1	34	34	NUM
ihlr-16500	171	2	fooo&drugadmin	fooo&drugadmin	PROPN
ihlr-16500	171	3	.	.	PUNCT
ihlr-16500	171	4	,u.s.dep't.ofhealrn&humanservs	,u.s.dep't.ofhealrn&humanservs	PUNCT
ihlr-16500	171	5	.	.	PUNCT
ihlr-16500	171	6	,centerfordrug	,centerfordrug	PUNCT
ihlr-16500	171	7	evaluation	evaluation	NOUN
ihlr-16500	171	8	and	and	CCONJ
ihlr-16500	171	9	research	research	NOUN
ihlr-16500	171	10	handbook	handbook	NOUN
ihlr-16500	171	11	passim	passim	PROPN
ihlr-16500	171	12	{	{	PUNCT
ihlr-16500	171	13	1998	1998	NUM
ihlr-16500	171	14	)	)	PUNCT
ihlr-16500	171	15	,	,	PUNCT
ihlr-16500	171	16	available	available	ADJ
ihlr-16500	171	17	at	at	ADP
ihlr-16500	171	18	http://www.fda	http://www.fda	PROPN
ihlr-16500	171	19	.	.	PUNCT
ihlr-16500	172	1	gov	gov	PROPN
ihlr-16500	172	2	/	/	SYM
ihlr-16500	172	3	cder	cder	NOUN
ihlr-16500	172	4	/	/	SYM
ihlr-16500	172	5	handbook/.	handbook/.	PROPN
ihlr-16500	172	6	35	35	NUM
ihlr-16500	172	7	jd	jd	NOUN
ihlr-16500	172	8	.	.	PROPN
ihlr-16500	172	9	36	36	NUM
ihlr-16500	173	1	i	i	PRON
ihlr-16500	173	2	d.	d.	PROPN
ihlr-16500	173	3	before	before	SCONJ
ihlr-16500	173	4	the	the	DET
ihlr-16500	173	5	fda	fda	PROPN
ihlr-16500	173	6	allows	allow	VERB
ihlr-16500	173	7	the	the	DET
ihlr-16500	173	8	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	173	9	company	company	NOUN
ihlr-16500	173	10	to	to	PART
ihlr-16500	173	11	use	use	VERB
ihlr-16500	173	12	a	a	DET
ihlr-16500	173	13	drug	drug	NOUN
ihlr-16500	173	14	or	or	CCONJ
ihlr-16500	173	15	compound	compound	NOUN
ihlr-16500	173	16	,	,	PUNCT
ihlr-16500	173	17	in	in	ADP
ihlr-16500	173	18	further	further	ADJ
ihlr-16500	173	19	initial	initial	ADJ
ihlr-16500	173	20	,	,	PUNCT
ihlr-16500	173	21	small	small	ADJ
ihlr-16500	173	22	scale	scale	NOUN
ihlr-16500	173	23	pre	pre	ADJ
ihlr-16500	173	24	-	-	ADJ
ihlr-16500	173	25	clinical	clinical	ADJ
ihlr-16500	173	26	studies	study	NOUN
ihlr-16500	173	27	,	,	PUNCT
ihlr-16500	173	28	the	the	DET
ihlr-16500	173	29	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	173	30	coinpany	coinpany	NOUN
ihlr-16500	173	31	must	must	AUX
ihlr-16500	173	32	put	put	VERB
ihlr-16500	173	33	forth	forth	ADV
ihlr-16500	173	34	2007	2007	NUM
ihlr-16500	173	35	]	]	PUNCT
ihlr-16500	173	36	pulling	pull	VERB
ihlr-16500	173	37	a	a	DET
ihlr-16500	173	38	blockbuster	blockbuster	ADJ
ihlr-16500	173	39	drug	drug	NOUN
ihlr-16500	173	40	off	off	ADP
ihlr-16500	173	41	the	the	DET
ihlr-16500	173	42	market	market	NOUN
ihlr-16500	173	43	123	123	NUM
ihlr-16500	173	44	ment	ment	NOUN
ihlr-16500	173	45	,	,	PUNCT
ihlr-16500	173	46	the	the	DET
ihlr-16500	173	47	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	173	48	company	company	NOUN
ihlr-16500	173	49	must	must	AUX
ihlr-16500	173	50	evaluate	evaluate	VERB
ihlr-16500	173	51	the	the	DET
ihlr-16500	173	52	drug	drug	NOUN
ihlr-16500	173	53	's	's	PART
ihlr-16500	173	54	toxic	toxic	ADJ
ihlr-16500	173	55	and	and	CCONJ
ihlr-16500	173	56	pharma­	pharma­	X
ihlr-16500	173	57	cologic	cologic	ADJ
ihlr-16500	173	58	effects	effect	NOUN
ihlr-16500	173	59	by	by	ADP
ihlr-16500	173	60	conducting	conduct	VERB
ihlr-16500	173	61	shortand	shortand	NOUN
ihlr-16500	173	62	longterm	longterm	PROPN
ihlr-16500	173	63	testing	testing	NOUN
ihlr-16500	173	64	on	on	ADP
ihlr-16500	173	65	animals	animal	NOUN
ihlr-16500	173	66	.	.	PUNCT
ihlr-16500	174	1	only	only	ADV
ihlr-16500	174	2	if	if	SCONJ
ihlr-16500	174	3	the	the	DET
ihlr-16500	174	4	drug	drug	NOUN
ihlr-16500	174	5	passes	pass	VERB
ihlr-16500	174	6	the	the	DET
ihlr-16500	174	7	requirements	requirement	NOUN
ihlr-16500	174	8	of	of	ADP
ihlr-16500	174	9	pre	pre	ADJ
ihlr-16500	174	10	-	-	ADJ
ihlr-16500	174	11	clinical	clinical	ADJ
ihlr-16500	174	12	screening	screening	NOUN
ihlr-16500	174	13	,	,	PUNCT
ihlr-16500	174	14	will	will	AUX
ihlr-16500	174	15	it	it	PRON
ihlr-16500	174	16	undergo	undergo	VERB
ihlr-16500	174	17	a	a	DET
ihlr-16500	174	18	se­	se­	ADJ
ihlr-16500	174	19	ries	rie	NOUN
ihlr-16500	174	20	of	of	ADP
ihlr-16500	174	21	additional	additional	ADJ
ihlr-16500	174	22	screening	screening	NOUN
ihlr-16500	174	23	phases	phase	NOUN
ihlr-16500	174	24	.	.	PUNCT
ihlr-16500	175	1	37	37	NUM
ihlr-16500	175	2	during	during	ADP
ihlr-16500	175	3	the	the	DET
ihlr-16500	175	4	next	next	ADJ
ihlr-16500	175	5	three	three	NUM
ihlr-16500	175	6	phases	phase	NOUN
ihlr-16500	175	7	,	,	PUNCT
ihlr-16500	175	8	the	the	DET
ihlr-16500	175	9	drug	drug	NOUN
ihlr-16500	175	10	is	be	AUX
ihlr-16500	175	11	tested	test	VERB
ihlr-16500	175	12	vigorously	vigorously	ADV
ihlr-16500	175	13	in	in	ADP
ihlr-16500	175	14	order	order	NOUN
ihlr-16500	175	15	to	to	PART
ihlr-16500	175	16	en­	en­	X
ihlr-16500	175	17	sure	sure	ADJ
ihlr-16500	175	18	its	its	PRON
ihlr-16500	175	19	efficacy	efficacy	NOUN
ihlr-16500	175	20	and	and	CCONJ
ihlr-16500	175	21	safety	safety	NOUN
ihlr-16500	175	22	.	.	PUNCT
ihlr-16500	176	1	for	for	ADP
ihlr-16500	176	2	instance	instance	NOUN
ihlr-16500	176	3	,	,	PUNCT
ihlr-16500	176	4	during	during	ADP
ihlr-16500	176	5	the	the	DET
ihlr-16500	176	6	first	first	ADJ
ihlr-16500	176	7	phase	phase	NOUN
ihlr-16500	176	8	,	,	PUNCT
ihlr-16500	176	9	the	the	DET
ihlr-16500	176	10	drug	drug	NOUN
ihlr-16500	176	11	is	be	AUX
ihlr-16500	176	12	in­	in­	NOUN
ihlr-16500	176	13	troduced	troduce	VERB
ihlr-16500	176	14	and	and	CCONJ
ihlr-16500	176	15	administered	administer	VERB
ihlr-16500	176	16	to	to	ADP
ihlr-16500	176	17	humans	human	NOUN
ihlr-16500	176	18	.	.	PUNCT
ihlr-16500	177	1	38	38	NUM
ihlr-16500	177	2	these	these	DET
ihlr-16500	177	3	studies	study	NOUN
ihlr-16500	177	4	are	be	AUX
ihlr-16500	177	5	closely	closely	ADV
ihlr-16500	177	6	monitored	monitor	VERB
ihlr-16500	177	7	and	and	CCONJ
ihlr-16500	177	8	are	be	AUX
ihlr-16500	177	9	usually	usually	ADV
ihlr-16500	177	10	conducted	conduct	VERB
ihlr-16500	177	11	with	with	ADP
ihlr-16500	177	12	healthy	healthy	ADJ
ihlr-16500	177	13	volunteer	volunteer	NOUN
ihlr-16500	177	14	subjects	subject	NOUN
ihlr-16500	177	15	.	.	PUNCT
ihlr-16500	178	1	39	39	NUM
ihlr-16500	178	2	the	the	DET
ihlr-16500	178	3	object	object	NOUN
ihlr-16500	178	4	of	of	ADP
ihlr-16500	178	5	these	these	DET
ihlr-16500	178	6	studies	study	NOUN
ihlr-16500	178	7	is	be	AUX
ihlr-16500	178	8	to	to	PART
ihlr-16500	178	9	determine	determine	VERB
ihlr-16500	178	10	the	the	DET
ihlr-16500	178	11	metabolic	metabolic	NOUN
ihlr-16500	178	12	and	and	CCONJ
ihlr-16500	178	13	pharmacologic	pharmacologic	ADJ
ihlr-16500	178	14	action	action	NOUN
ihlr-16500	178	15	of	of	ADP
ihlr-16500	178	16	the	the	DET
ihlr-16500	178	17	drug	drug	NOUN
ihlr-16500	178	18	in	in	ADP
ihlr-16500	178	19	humans	human	NOUN
ihlr-16500	178	20	,	,	PUNCT
ihlr-16500	178	21	including	include	VERB
ihlr-16500	178	22	any	any	DET
ihlr-16500	178	23	potential	potential	ADJ
ihlr-16500	178	24	side	side	NOUN
ihlr-16500	178	25	effects	effect	NOUN
ihlr-16500	178	26	associated	associate	VERB
ihlr-16500	178	27	with	with	ADP
ihlr-16500	178	28	increasing	increase	VERB
ihlr-16500	178	29	doses	dose	NOUN
ihlr-16500	178	30	(	(	PUNCT
ihlr-16500	178	31	if	if	SCONJ
ihlr-16500	178	32	available	available	ADJ
ihlr-16500	178	33	)	)	PUNCT
ihlr-16500	178	34	.	.	PUNCT
ihlr-16500	179	1	40	40	NUM
ihlr-16500	179	2	during	during	ADP
ihlr-16500	179	3	the	the	DET
ihlr-16500	179	4	second	second	ADJ
ihlr-16500	179	5	phase	phase	NOUN
ihlr-16500	179	6	,	,	PUNCT
ihlr-16500	179	7	early	early	ADV
ihlr-16500	179	8	controlled	control	VERB
ihlr-16500	179	9	clinical	clinical	ADJ
ihlr-16500	179	10	studies	study	NOUN
ihlr-16500	179	11	help	help	VERB
ihlr-16500	179	12	determine	determine	VERB
ihlr-16500	179	13	the	the	DET
ihlr-16500	179	14	common	common	ADJ
ihlr-16500	179	15	side	side	NOUN
ihlr-16500	179	16	effects	effect	NOUN
ihlr-16500	179	17	and	and	CCONJ
ihlr-16500	179	18	risks	risk	NOUN
ihlr-16500	179	19	associated	associate	VERB
ihlr-16500	179	20	with	with	ADP
ihlr-16500	179	21	the	the	DET
ihlr-16500	179	22	drug	drug	NOUN
ihlr-16500	179	23	.	.	PUNCT
ihlr-16500	180	1	41	41	NUM
ihlr-16500	180	2	finally	finally	ADV
ihlr-16500	180	3	,	,	PUNCT
ihlr-16500	180	4	during	during	ADP
ihlr-16500	180	5	the	the	DET
ihlr-16500	180	6	third	third	ADJ
ihlr-16500	180	7	phase	phase	NOUN
ihlr-16500	180	8	,	,	PUNCT
ihlr-16500	180	9	the	the	DET
ihlr-16500	180	10	effectiveness	effectiveness	NOUN
ihlr-16500	180	11	of	of	ADP
ihlr-16500	180	12	the	the	DET
ihlr-16500	180	13	drug	drug	NOUN
ihlr-16500	180	14	and	and	CCONJ
ihlr-16500	180	15	the	the	DET
ihlr-16500	180	16	overall	overall	ADJ
ihlr-16500	180	17	benefit	benefit	NOUN
ihlr-16500	180	18	-	-	PUNCT
ihlr-16500	180	19	risk	risk	NOUN
ihlr-16500	180	20	relationship	relationship	NOUN
ihlr-16500	180	21	of	of	ADP
ihlr-16500	180	22	the	the	DET
ihlr-16500	180	23	drug	drug	NOUN
ihlr-16500	180	24	are	be	AUX
ihlr-16500	180	25	evaluated	evaluate	VERB
ihlr-16500	180	26	.	.	PUNCT
ihlr-16500	181	1	42	42	NUM
ihlr-16500	181	2	although	although	SCONJ
ihlr-16500	181	3	the	the	DET
ihlr-16500	181	4	fda	fda	PROPN
ihlr-16500	181	5	's	's	PART
ihlr-16500	181	6	drug	drug	NOUN
ihlr-16500	181	7	approval	approval	NOUN
ihlr-16500	181	8	process	process	NOUN
ihlr-16500	181	9	is	be	AUX
ihlr-16500	181	10	stringent	stringent	ADJ
ihlr-16500	181	11	,	,	PUNCT
ihlr-16500	181	12	the	the	DET
ihlr-16500	181	13	pressure	pressure	NOUN
ihlr-16500	181	14	to	to	PART
ihlr-16500	181	15	produce	produce	VERB
ihlr-16500	181	16	more	more	ADJ
ihlr-16500	181	17	blockbuster	blockbuster	ADJ
ihlr-16500	181	18	drugs	drug	NOUN
ihlr-16500	181	19	has	have	AUX
ihlr-16500	181	20	caused	cause	VERB
ihlr-16500	181	21	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	181	22	companies	company	NOUN
ihlr-16500	181	23	to	to	PART
ihlr-16500	181	24	sub­	sub­	PROPN
ihlr-16500	181	25	mit	mit	VERB
ihlr-16500	181	26	an	an	DET
ihlr-16500	181	27	increasing	increase	VERB
ihlr-16500	181	28	number	number	NOUN
ihlr-16500	181	29	of	of	ADP
ihlr-16500	181	30	applications	application	NOUN
ihlr-16500	181	31	for	for	ADP
ihlr-16500	181	32	new	new	ADJ
ihlr-16500	181	33	drug	drug	NOUN
ihlr-16500	181	34	approval	approval	NOUN
ihlr-16500	181	35	to	to	ADP
ihlr-16500	181	36	the	the	DET
ihlr-16500	181	37	fda.43	fda.43	NOUN
ihlr-16500	181	38	requiring	require	VERB
ihlr-16500	181	39	a	a	DET
ihlr-16500	181	40	thorough	thorough	ADJ
ihlr-16500	181	41	evaluation	evaluation	NOUN
ihlr-16500	181	42	of	of	ADP
ihlr-16500	181	43	each	each	DET
ihlr-16500	181	44	drug	drug	NOUN
ihlr-16500	181	45	has	have	AUX
ihlr-16500	181	46	put	put	VERB
ihlr-16500	181	47	a	a	DET
ihlr-16500	181	48	considerable	considerable	ADJ
ihlr-16500	181	49	strain	strain	NOUN
ihlr-16500	181	50	on	on	ADP
ihlr-16500	181	51	the	the	DET
ihlr-16500	181	52	fda	fda	PROPN
ihlr-16500	181	53	due	due	ADP
ihlr-16500	181	54	to	to	ADP
ihlr-16500	181	55	its	its	PRON
ihlr-16500	181	56	lack	lack	NOUN
ihlr-16500	181	57	of	of	ADP
ihlr-16500	181	58	resources	resource	NOUN
ihlr-16500	181	59	and	and	CCONJ
ihlr-16500	181	60	manpower.44	manpower.44	NOUN
ihlr-16500	181	61	moreover	moreover	ADV
ihlr-16500	181	62	,	,	PUNCT
ihlr-16500	181	63	lobbying	lobbying	NOUN
ihlr-16500	181	64	ef­	ef­	NOUN
ihlr-16500	181	65	forts	fort	NOUN
ihlr-16500	181	66	by	by	ADP
ihlr-16500	181	67	the	the	DET
ihlr-16500	181	68	pharmaceutical	pharmaceutical	NOUN
ihlr-16500	181	69	industry	industry	NOUN
ihlr-16500	181	70	have	have	AUX
ihlr-16500	181	71	since	since	SCONJ
ihlr-16500	181	72	convinced	convince	VERB
ihlr-16500	181	73	congress	congress	PROPN
ihlr-16500	181	74	to	to	PART
ihlr-16500	181	75	amend	amend	VERB
ihlr-16500	181	76	earlier	early	ADJ
ihlr-16500	181	77	statutes	statute	NOUN
ihlr-16500	181	78	that	that	PRON
ihlr-16500	181	79	previously	previously	ADV
ihlr-16500	181	80	required	require	VERB
ihlr-16500	181	81	nearly	nearly	ADV
ihlr-16500	181	82	fifteen	fifteen	NUM
ihlr-16500	181	83	years	year	NOUN
ihlr-16500	181	84	of	of	ADP
ihlr-16500	181	85	fda	fda	PROPN
ihlr-16500	181	86	testing	testing	NOUN
ihlr-16500	181	87	for	for	ADP
ihlr-16500	181	88	approval	approval	NOUN
ihlr-16500	181	89	of	of	ADP
ihlr-16500	181	90	a	a	DET
ihlr-16500	181	91	new	new	ADJ
ihlr-16500	181	92	drug.45	drug.45	NOUN
ihlr-16500	181	93	for	for	ADP
ihlr-16500	181	94	example	example	NOUN
ihlr-16500	181	95	,	,	PUNCT
ihlr-16500	181	96	in	in	ADP
ihlr-16500	181	97	response	response	NOUN
ihlr-16500	181	98	to	to	ADP
ihlr-16500	181	99	serious	serious	ADJ
ihlr-16500	181	100	epidemics	epidemic	NOUN
ihlr-16500	181	101	such	such	ADJ
ihlr-16500	181	102	as	as	ADP
ihlr-16500	181	103	aids	aid	NOUN
ihlr-16500	181	104	,	,	PUNCT
ihlr-16500	181	105	the	the	DET
ihlr-16500	181	106	fda	fda	PROPN
ihlr-16500	181	107	reduced	reduce	VERB
ihlr-16500	181	108	the	the	DET
ihlr-16500	181	109	amount	amount	NOUN
ihlr-16500	181	110	of	of	ADP
ihlr-16500	181	111	time	time	NOUN
ihlr-16500	181	112	for	for	ADP
ihlr-16500	181	113	reviewing	review	VERB
ihlr-16500	181	114	a	a	DET
ihlr-16500	181	115	new	new	ADJ
ihlr-16500	181	116	drug	drug	NOUN
ihlr-16500	181	117	to	to	ADP
ihlr-16500	181	118	be­	be­	PUNCT
ihlr-16500	181	119	tween	tween	NOUN
ihlr-16500	181	120	six	six	NUM
ihlr-16500	181	121	and	and	CCONJ
ihlr-16500	181	122	twelve	twelve	NUM
ihlr-16500	181	123	months.46	months.46	PROPN
ihlr-16500	181	124	congress	congress	PROPN
ihlr-16500	181	125	officially	officially	ADV
ihlr-16500	181	126	reduced	reduce	VERB
ihlr-16500	181	127	the	the	DET
ihlr-16500	181	128	review	review	NOUN
ihlr-16500	181	129	time	time	NOUN
ihlr-16500	181	130	in	in	ADP
ihlr-16500	181	131	1992	1992	NUM
ihlr-16500	181	132	,	,	PUNCT
ihlr-16500	181	133	when	when	SCONJ
ihlr-16500	181	134	the	the	DET
ihlr-16500	181	135	prescription	prescription	NOUN
ihlr-16500	181	136	drug	drug	NOUN
ihlr-16500	181	137	user	user	NOUN
ihlr-16500	181	138	fee	fee	PROPN
ihlr-16500	181	139	act	act	NOUN
ihlr-16500	181	140	was	be	AUX
ihlr-16500	181	141	passed	pass	VERB
ihlr-16500	181	142	in	in	ADP
ihlr-16500	181	143	order	order	NOUN
ihlr-16500	181	144	to	to	PART
ihlr-16500	181	145	expedite	expedite	VERB
ihlr-16500	181	146	data	datum	NOUN
ihlr-16500	181	147	that	that	PRON
ihlr-16500	181	148	the	the	DET
ihlr-16500	181	149	drug	drug	NOUN
ihlr-16500	181	150	-	-	PUNCT
ihlr-16500	181	151	compound	compound	NOUN
ihlr-16500	181	152	is	be	AUX
ihlr-16500	181	153	reasonably	reasonably	ADV
ihlr-16500	181	154	safe	safe	ADJ
ihlr-16500	181	155	.	.	PUNCT
ihlr-16500	182	1	37	37	NUM
ihlr-16500	182	2	/d	/d	PUNCT
ihlr-16500	182	3	.	.	PUNCT
ihlr-16500	183	1	during	during	ADP
ihlr-16500	183	2	these	these	DET
ihlr-16500	183	3	phases	phase	NOUN
ihlr-16500	183	4	,	,	PUNCT
ihlr-16500	183	5	the	the	DET
ihlr-16500	183	6	new	new	ADJ
ihlr-16500	183	7	drug	drug	NOUN
ihlr-16500	183	8	is	be	AUX
ihlr-16500	183	9	screened	screen	VERB
ihlr-16500	183	10	for	for	ADP
ihlr-16500	183	11	efficacy	efficacy	NOUN
ihlr-16500	183	12	and	and	CCONJ
ihlr-16500	183	13	safety	safety	NOUN
ihlr-16500	183	14	through	through	ADP
ihlr-16500	183	15	a	a	DET
ihlr-16500	183	16	series	series	NOUN
ihlr-16500	183	17	of	of	ADP
ihlr-16500	183	18	clinically	clinically	ADV
ihlr-16500	183	19	monitored	monitor	VERB
ihlr-16500	183	20	trials	trial	NOUN
ihlr-16500	183	21	.	.	PUNCT
ihlr-16500	184	1	/d	/d	INTJ
ihlr-16500	184	2	.	.	PUNCT
ihlr-16500	185	1	"	"	PUNCT
ihlr-16500	185	2	a	a	DET
ihlr-16500	185	3	clinical	clinical	ADJ
ihlr-16500	185	4	trial	trial	NOUN
ihlr-16500	185	5	is	be	AUX
ihlr-16500	185	6	a	a	DET
ihlr-16500	185	7	research	research	NOUN
ihlr-16500	185	8	study	study	NOUN
ihlr-16500	185	9	designed	design	VERB
ihlr-16500	185	10	to	to	PART
ihlr-16500	185	11	answer	answer	VERB
ihlr-16500	185	12	specific	specific	ADJ
ihlr-16500	185	13	questions	question	NOUN
ihlr-16500	185	14	about	about	ADP
ihlr-16500	185	15	vaccines	vaccine	NOUN
ihlr-16500	185	16	or	or	CCONJ
ihlr-16500	185	17	new	new	ADJ
ihlr-16500	185	18	therapies	therapy	NOUN
ihlr-16500	185	19	or	or	CCONJ
ihlr-16500	185	20	new	new	ADJ
ihlr-16500	185	21	ways	way	NOUN
ihlr-16500	185	22	of	of	ADP
ihlr-16500	185	23	using	use	VERB
ihlr-16500	185	24	known	known	ADJ
ihlr-16500	185	25	treatments	treatment	NOUN
ihlr-16500	185	26	.	.	PUNCT
ihlr-16500	185	27	"	"	PUNCT
ihlr-16500	186	1	the	the	DET
ihlr-16500	186	2	open	open	ADJ
ihlr-16500	186	3	door	door	NOUN
ihlr-16500	186	4	clinic	clinic	NOUN
ihlr-16500	186	5	,	,	PUNCT
ihlr-16500	186	6	definitions	definition	VERB
ihlr-16500	186	7	ofhiv	ofhiv	ADJ
ihlr-16500	186	8	glossary	glossary	NOUN
ihlr-16500	186	9	,	,	PUNCT
ihlr-16500	186	10	www.opendoorclinic.org/hivglossary.htm	www.opendoorclinic.org/hivglossary.htm	PROPN
ihlr-16500	186	11	(	(	PUNCT
ihlr-16500	186	12	last	last	ADJ
ihlr-16500	186	13	visited	visit	VERB
ihlr-16500	186	14	feb	feb	PROPN
ihlr-16500	186	15	.	.	PROPN
ihlr-16500	186	16	16	16	NUM
ihlr-16500	186	17	,	,	PUNCT
ihlr-16500	186	18	2007	2007	NUM
ihlr-16500	186	19	)	)	PUNCT
ihlr-16500	186	20	.	.	PUNCT
ihlr-16500	187	1	in	in	ADP
ihlr-16500	187	2	essence	essence	NOUN
ihlr-16500	187	3	,	,	PUNCT
ihlr-16500	187	4	"	"	PUNCT
ihlr-16500	187	5	[	[	X
ihlr-16500	187	6	c]linical	c]linical	ADJ
ihlr-16500	187	7	trials	trial	NOUN
ihlr-16500	187	8	(	(	PUNCT
ihlr-16500	187	9	also	also	ADV
ihlr-16500	187	10	called	call	VERB
ihlr-16500	187	11	medical	medical	ADJ
ihlr-16500	187	12	research	research	NOUN
ihlr-16500	187	13	andre­	andre­	PROPN
ihlr-16500	187	14	search	search	NOUN
ihlr-16500	187	15	studies	study	NOUN
ihlr-16500	187	16	)	)	PUNCT
ihlr-16500	187	17	are	be	AUX
ihlr-16500	187	18	used	use	VERB
ihlr-16500	187	19	to	to	PART
ihlr-16500	187	20	determine	determine	VERB
ihlr-16500	187	21	whether	whether	SCONJ
ihlr-16500	187	22	new	new	ADJ
ihlr-16500	187	23	drugs	drug	NOUN
ihlr-16500	187	24	or	or	CCONJ
ihlr-16500	187	25	treatments	treatment	NOUN
ihlr-16500	187	26	are	be	AUX
ihlr-16500	187	27	both	both	ADV
ihlr-16500	187	28	safe	safe	ADJ
ihlr-16500	187	29	and	and	CCONJ
ihlr-16500	187	30	effec­	effec­	X
ihlr-16500	187	31	tive	tive	NOUN
ihlr-16500	187	32	.	.	PUNCT
ihlr-16500	188	1	carefully	carefully	ADV
ihlr-16500	188	2	conducted	conduct	VERB
ihlr-16500	188	3	clinical	clinical	ADJ
ihlr-16500	188	4	trials	trial	NOUN
ihlr-16500	188	5	are	be	AUX
ihlr-16500	188	6	the	the	DET
ihlr-16500	188	7	fastest	fast	ADJ
ihlr-16500	188	8	and	and	CCONJ
ihlr-16500	188	9	safest	safest	ADJ
ihlr-16500	188	10	way	way	NOUN
ihlr-16500	188	11	to	to	PART
ihlr-16500	188	12	find	find	VERB
ihlr-16500	188	13	treatments	treatment	NOUN
ihlr-16500	188	14	that	that	PRON
ihlr-16500	188	15	work	work	VERB
ihlr-16500	188	16	in	in	ADP
ihlr-16500	188	17	people	people	NOUN
ihlr-16500	188	18	.	.	PUNCT
ihlr-16500	188	19	"	"	PUNCT
ihlr-16500	189	1	/d	/d	PUNCT
ihlr-16500	189	2	.	.	PUNCT
ihlr-16500	190	1	38	38	NUM
ihlr-16500	190	2	rickng	rickng	NOUN
ihlr-16500	190	3	,	,	PUNCT
ihlr-16500	190	4	drugs	drug	NOUN
ihlr-16500	190	5	:	:	PUNCT
ihlr-16500	190	6	from	from	ADP
ihlr-16500	190	7	discovery	discovery	NOUN
ihlr-16500	190	8	to	to	ADP
ihlr-16500	190	9	approval	approval	NOUN
ihlr-16500	190	10	144	144	NUM
ihlr-16500	190	11	(	(	PUNCT
ihlr-16500	190	12	2004	2004	NUM
ihlr-16500	190	13	)	)	PUNCT
ihlr-16500	190	14	;	;	PUNCT
ihlr-16500	190	15	see	see	VERB
ihlr-16500	190	16	also	also	ADV
ihlr-16500	190	17	food	food	PROPN
ihlr-16500	190	18	&	&	CCONJ
ihlr-16500	190	19	drug	drug	PROPN
ihlr-16500	190	20	admin	admin	PROPN
ihlr-16500	190	21	.	.	PROPN
ihlr-16500	190	22	,	,	PUNCT
ihlr-16500	190	23	supra	supra	PROPN
ihlr-16500	190	24	note	note	VERB
ihlr-16500	190	25	34	34	NUM
ihlr-16500	190	26	.	.	NOUN
ihlr-16500	190	27	39	39	NUM
ihlr-16500	190	28	food	food	NOUN
ihlr-16500	190	29	&	&	CCONJ
ihlr-16500	190	30	drug	drug	PROPN
ihlr-16500	190	31	admin	admin	PROPN
ihlr-16500	190	32	.	.	PROPN
ihlr-16500	190	33	,	,	PUNCT
ihlr-16500	190	34	supra	supra	PROPN
ihlr-16500	190	35	note	note	VERB
ihlr-16500	190	36	34	34	NUM
ihlr-16500	190	37	.	.	NOUN
ihlr-16500	190	38	40	40	NUM
ihlr-16500	190	39	/d	/d	PUNCT
ihlr-16500	190	40	.	.	PROPN
ihlr-16500	191	1	41	41	NUM
ihlr-16500	191	2	ng	ng	PROPN
ihlr-16500	191	3	,	,	PUNCT
ihlr-16500	191	4	supra	supra	PROPN
ihlr-16500	191	5	note	note	PROPN
ihlr-16500	191	6	38	38	NUM
ihlr-16500	191	7	,	,	PUNCT
ihlr-16500	191	8	at	at	ADP
ihlr-16500	191	9	145	145	NUM
ihlr-16500	191	10	-	-	SYM
ihlr-16500	191	11	46	46	NUM
ihlr-16500	191	12	;	;	PUNCT
ihlr-16500	191	13	see	see	VERB
ihlr-16500	191	14	also	also	ADV
ihlr-16500	191	15	food	food	PROPN
ihlr-16500	191	16	&	&	CCONJ
ihlr-16500	191	17	drug	drug	NOUN
ihlr-16500	191	18	admin	admin	PROPN
ihlr-16500	191	19	.	.	PROPN
ihlr-16500	191	20	,	,	PUNCT
ihlr-16500	191	21	supra	supra	PROPN
ihlr-16500	191	22	note	note	VERB
ihlr-16500	191	23	34	34	NUM
ihlr-16500	191	24	.	.	NOUN
ihlr-16500	191	25	42	42	NUM
ihlr-16500	191	26	ng	ng	PROPN
ihlr-16500	191	27	,	,	PUNCT
ihlr-16500	191	28	supra	supra	PROPN
ihlr-16500	191	29	note	note	PROPN
ihlr-16500	191	30	38	38	NUM
ihlr-16500	191	31	,	,	PUNCT
ihlr-16500	191	32	at	at	ADP
ihlr-16500	191	33	146	146	NUM
ihlr-16500	191	34	;	;	PUNCT
ihlr-16500	191	35	see	see	VERB
ihlr-16500	191	36	also	also	ADV
ihlr-16500	191	37	food	food	PROPN
ihlr-16500	191	38	&	&	CCONJ
ihlr-16500	191	39	drug	drug	PROPN
ihlr-16500	191	40	admin	admin	PROPN
ihlr-16500	191	41	.	.	PROPN
ihlr-16500	191	42	,	,	PUNCT
ihlr-16500	191	43	supra	supra	PROPN
ihlr-16500	191	44	note	note	VERB
ihlr-16500	192	1	34	34	NUM
ihlr-16500	192	2	.	.	NOUN
ihlr-16500	193	1	43	43	NUM
ihlr-16500	193	2	see	see	VERB
ihlr-16500	193	3	deborah	deborah	PROPN
ihlr-16500	193	4	g.	g.	PROPN
ihlr-16500	193	5	parver	parver	PROPN
ihlr-16500	193	6	,	,	PUNCT
ihlr-16500	193	7	note	note	NOUN
ihlr-16500	193	8	&	&	CCONJ
ihlr-16500	193	9	comment	comment	NOUN
ihlr-16500	193	10	,	,	PUNCT
ihlr-16500	193	11	expediting	expedite	VERB
ihlr-16500	193	12	the	the	DET
ihlr-16500	193	13	drug	drug	NOUN
ihlr-16500	193	14	approval	approval	NOUN
ihlr-16500	193	15	process	process	NOUN
ihlr-16500	193	16	:	:	PUNCT
ihlr-16500	193	17	an	an	DET
ihlr-16500	193	18	analysis	analysis	NOUN
ihlr-16500	193	19	of	of	ADP
ihlr-16500	193	20	the	the	DET
ihlr-16500	193	21	fda	fda	PROPN
ihlr-16500	193	22	modernization	modernization	PROPN
ihlr-16500	193	23	act	act	NOUN
ihlr-16500	193	24	of	of	ADP
ihlr-16500	193	25	1997	1997	NUM
ihlr-16500	193	26	,	,	PUNCT
ihlr-16500	193	27	51	51	NUM
ihlr-16500	193	28	admin	admin	ADJ
ihlr-16500	193	29	.	.	PUNCT
ihlr-16500	194	1	l.	l.	PROPN
ihlr-16500	194	2	rev	rev	PROPN
ihlr-16500	194	3	.	.	PROPN
ihlr-16500	194	4	1249	1249	NUM
ihlr-16500	194	5	,	,	PUNCT
ihlr-16500	194	6	1249	1249	NUM
ihlr-16500	194	7	-	-	SYM
ihlr-16500	194	8	53	53	NUM
ihlr-16500	194	9	(	(	PUNCT
ihlr-16500	194	10	1999	1999	NUM
ihlr-16500	194	11	)	)	PUNCT
ihlr-16500	194	12	.	.	PUNCT
ihlr-16500	195	1	44	44	NUM
ihlr-16500	195	2	see	see	VERB
ihlr-16500	195	3	i	i	PRON
ihlr-16500	195	4	d.	d.	PROPN
ihlr-16500	195	5	at	at	ADP
ihlr-16500	195	6	1255	1255	NUM
ihlr-16500	195	7	.	.	PUNCT
ihlr-16500	196	1	45	45	NUM
ihlr-16500	196	2	see	see	VERB
ihlr-16500	196	3	i	i	PRON
ihlr-16500	196	4	d.	d.	PROPN
ihlr-16500	196	5	at	at	ADP
ihlr-16500	196	6	1253	1253	NUM
ihlr-16500	196	7	,	,	PUNCT
ihlr-16500	196	8	1255	1255	NUM
ihlr-16500	196	9	.	.	PUNCT
ihlr-16500	197	1	46	46	NUM
ihlr-16500	197	2	ng	ng	PROPN
ihlr-16500	197	3	,	,	PUNCT
ihlr-16500	197	4	supranote	supranote	VERB
ihlr-16500	197	5	38	38	NUM
ihlr-16500	197	6	,	,	PUNCT
ihlr-16500	197	7	at	at	ADP
ihlr-16500	197	8	164(statingthatmerck'saidsdrug.crixivan	164(statingthatmerck'saidsdrug.crixivan	NUM
ihlr-16500	197	9	,	,	PUNCT
ihlr-16500	197	10	was	be	AUX
ihlr-16500	197	11	approved	approve	VERB
ihlr-16500	197	12	in	in	ADP
ihlr-16500	197	13	just	just	ADV
ihlr-16500	197	14	forty	forty	NUM
ihlr-16500	197	15	-	-	PUNCT
ihlr-16500	197	16	two	two	NUM
ihlr-16500	197	17	days	day	NOUN
ihlr-16500	197	18	)	)	PUNCT
ihlr-16500	197	19	.	.	PUNCT
ihlr-16500	198	1	124	124	NUM
ihlr-16500	198	2	indiana	indiana	PROPN
ihlr-16500	198	3	health	health	PROPN
ihlr-16500	198	4	law	law	PROPN
ihlr-16500	198	5	review	review	NOUN
ihlr-16500	198	6	[	[	X
ihlr-16500	198	7	vol	vol	NOUN
ihlr-16500	198	8	.	.	PUNCT
ihlr-16500	198	9	4:115	4:115	NUM
ihlr-16500	199	1	the	the	DET
ihlr-16500	199	2	drug	drug	NOUN
ihlr-16500	199	3	approval	approval	NOUN
ihlr-16500	199	4	process.47	process.47	NOUN
ihlr-16500	199	5	curiously	curiously	ADV
ihlr-16500	199	6	,	,	PUNCT
ihlr-16500	199	7	although	although	SCONJ
ihlr-16500	199	8	the	the	DET
ihlr-16500	199	9	amount	amount	NOUN
ihlr-16500	199	10	of	of	ADP
ihlr-16500	199	11	time	time	NOUN
ihlr-16500	199	12	required	require	VERB
ihlr-16500	199	13	to	to	PART
ihlr-16500	199	14	review	review	VERB
ihlr-16500	199	15	a	a	DET
ihlr-16500	199	16	drug	drug	NOUN
ihlr-16500	199	17	has	have	AUX
ihlr-16500	199	18	decreased	decrease	VERB
ihlr-16500	199	19	,	,	PUNCT
ihlr-16500	199	20	the	the	DET
ihlr-16500	199	21	number	number	NOUN
ihlr-16500	199	22	of	of	ADP
ihlr-16500	199	23	drug	drug	NOUN
ihlr-16500	199	24	withdrawals	withdrawal	NOUN
ihlr-16500	199	25	has	have	AUX
ihlr-16500	199	26	continued	continue	VERB
ihlr-16500	199	27	to	to	PART
ihlr-16500	199	28	rise	rise	VERB
ihlr-16500	199	29	.	.	PUNCT
ihlr-16500	200	1	the	the	DET
ihlr-16500	200	2	remaining	remain	VERB
ihlr-16500	200	3	question	question	NOUN
ihlr-16500	200	4	is	be	AUX
ihlr-16500	200	5	whether	whether	SCONJ
ihlr-16500	200	6	there	there	PRON
ihlr-16500	200	7	is	be	VERB
ihlr-16500	200	8	a	a	DET
ihlr-16500	200	9	direct	direct	ADJ
ihlr-16500	200	10	correlation	correlation	NOUN
ihlr-16500	200	11	between	between	ADP
ihlr-16500	200	12	the	the	DET
ihlr-16500	200	13	reduced	reduce	VERB
ihlr-16500	200	14	amount	amount	NOUN
ihlr-16500	200	15	of	of	ADP
ihlr-16500	200	16	review	review	NOUN
ihlr-16500	200	17	time	time	NOUN
ihlr-16500	200	18	and	and	CCONJ
ihlr-16500	200	19	the	the	DET
ihlr-16500	200	20	increased	increase	VERB
ihlr-16500	200	21	number	number	NOUN
ihlr-16500	200	22	of	of	ADP
ihlr-16500	200	23	drug	drug	NOUN
ihlr-16500	200	24	with­	with­	PROPN
ihlr-16500	200	25	drawals	drawal	NOUN
ihlr-16500	200	26	in	in	ADP
ihlr-16500	200	27	recent	recent	ADJ
ihlr-16500	200	28	years	year	NOUN
ihlr-16500	200	29	.	.	PUNCT
ihlr-16500	201	1	according	accord	VERB
ihlr-16500	201	2	to	to	ADP
ihlr-16500	201	3	the	the	DET
ihlr-16500	201	4	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	201	5	research	research	NOUN
ihlr-16500	201	6	and	and	CCONJ
ihlr-16500	201	7	manufacturers	manufacturer	NOUN
ihlr-16500	201	8	association	association	NOUN
ihlr-16500	201	9	(	(	PUNCT
ihlr-16500	201	10	"	"	PUNCT
ihlr-16500	201	11	phrma	phrma	NOUN
ihlr-16500	201	12	"	"	PUNCT
ihlr-16500	201	13	)	)	PUNCT
ihlr-16500	201	14	,	,	PUNCT
ihlr-16500	201	15	an	an	DET
ihlr-16500	201	16	organization	organization	NOUN
ihlr-16500	201	17	comprised	comprise	VERB
ihlr-16500	201	18	of	of	ADP
ihlr-16500	201	19	representatives	representative	NOUN
ihlr-16500	201	20	from	from	ADP
ihlr-16500	201	21	a	a	DET
ihlr-16500	201	22	number	number	NOUN
ihlr-16500	201	23	of	of	ADP
ihlr-16500	201	24	pharmaceutical	pharmaceutical	NOUN
ihlr-16500	201	25	companies	company	NOUN
ihlr-16500	201	26	,	,	PUNCT
ihlr-16500	201	27	there	there	PRON
ihlr-16500	201	28	are	be	VERB
ihlr-16500	201	29	significant	significant	ADJ
ihlr-16500	201	30	costs	cost	NOUN
ihlr-16500	201	31	associated	associate	VERB
ihlr-16500	201	32	with	with	ADP
ihlr-16500	201	33	producing	produce	VERB
ihlr-16500	201	34	a	a	DET
ihlr-16500	201	35	blockbuster	blockbuster	ADJ
ihlr-16500	201	36	drug	drug	NOUN
ihlr-16500	201	37	and	and	CCONJ
ihlr-16500	201	38	bringing	bring	VERB
ihlr-16500	201	39	it	it	PRON
ihlr-16500	201	40	to	to	ADP
ihlr-16500	201	41	market.48	market.48	NOUN
ihlr-16500	201	42	generally	generally	ADV
ihlr-16500	201	43	,	,	PUNCT
ihlr-16500	201	44	the	the	DET
ihlr-16500	201	45	industry	industry	NOUN
ihlr-16500	201	46	responds	respond	VERB
ihlr-16500	201	47	to	to	PART
ihlr-16500	201	48	claims	claim	NOUN
ihlr-16500	201	49	that	that	SCONJ
ihlr-16500	201	50	the	the	DET
ihlr-16500	201	51	drug	drug	NOUN
ihlr-16500	201	52	approval	approval	NOUN
ihlr-16500	201	53	process	process	NOUN
ihlr-16500	201	54	is	be	AUX
ihlr-16500	201	55	not	not	PART
ihlr-16500	201	56	stringent	stringent	ADJ
ihlr-16500	201	57	enough	enough	ADV
ihlr-16500	201	58	by	by	ADP
ihlr-16500	201	59	pointing	point	VERB
ihlr-16500	201	60	to	to	ADP
ihlr-16500	201	61	the	the	DET
ihlr-16500	201	62	substantial	substantial	ADJ
ihlr-16500	201	63	amount	amount	NOUN
ihlr-16500	201	64	of	of	ADP
ihlr-16500	201	65	resources	resource	NOUN
ihlr-16500	201	66	invested	invest	VERB
ihlr-16500	201	67	in	in	ADP
ihlr-16500	201	68	producing	produce	VERB
ihlr-16500	201	69	a	a	DET
ihlr-16500	201	70	blockbuster	blockbuster	NOUN
ihlr-16500	201	71	drug.49	drug.49	PROPN
ihlr-16500	201	72	the	the	DET
ihlr-16500	201	73	industry	industry	NOUN
ihlr-16500	201	74	claims	claim	VERB
ihlr-16500	201	75	that	that	SCONJ
ihlr-16500	201	76	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	201	77	companies	company	NOUN
ihlr-16500	201	78	have	have	VERB
ihlr-16500	201	79	a	a	DET
ihlr-16500	201	80	considerable	considerable	ADJ
ihlr-16500	201	81	stake	stake	NOUN
ihlr-16500	201	82	in	in	ADP
ihlr-16500	201	83	producing	produce	VERB
ihlr-16500	201	84	a	a	DET
ihlr-16500	201	85	drug	drug	NOUN
ihlr-16500	201	86	that	that	PRON
ihlr-16500	201	87	is	be	AUX
ihlr-16500	201	88	both	both	ADV
ihlr-16500	201	89	safe	safe	ADJ
ihlr-16500	201	90	and	and	CCONJ
ihlr-16500	201	91	efficacious	efficacious	ADJ
ihlr-16500	201	92	.	.	PUNCT
ihlr-16500	202	1	for	for	ADP
ihlr-16500	202	2	instance	instance	NOUN
ihlr-16500	202	3	,	,	PUNCT
ihlr-16500	202	4	a	a	DET
ihlr-16500	202	5	block­	block­	PROPN
ihlr-16500	202	6	buster	buster	NOUN
ihlr-16500	202	7	drug	drug	NOUN
ihlr-16500	202	8	costs	cost	VERB
ihlr-16500	202	9	a	a	DET
ihlr-16500	202	10	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	202	11	company	company	NOUN
ihlr-16500	202	12	an	an	DET
ihlr-16500	202	13	average	average	NOUN
ihlr-16500	202	14	of	of	ADP
ihlr-16500	202	15	over	over	ADP
ihlr-16500	202	16	$	$	SYM
ihlr-16500	202	17	800	800	NUM
ihlr-16500	202	18	million	million	NUM
ihlr-16500	202	19	dollars	dollar	NOUN
ihlr-16500	202	20	to	to	PART
ihlr-16500	202	21	develop	develop	VERB
ihlr-16500	202	22	from	from	ADP
ihlr-16500	202	23	its	its	PRON
ihlr-16500	202	24	infancy	infancy	NOUN
ihlr-16500	202	25	as	as	ADP
ihlr-16500	202	26	a	a	DET
ihlr-16500	202	27	molecule	molecule	NOUN
ihlr-16500	202	28	.	.	PUNCT
ihlr-16500	203	1	5	5	NUM
ihlr-16500	203	2	°	°	NOUN
ihlr-16500	203	3	in	in	ADP
ihlr-16500	203	4	addition	addition	NOUN
ihlr-16500	203	5	,	,	PUNCT
ihlr-16500	203	6	of	of	ADP
ihlr-16500	203	7	the	the	DET
ihlr-16500	203	8	five	five	NUM
ihlr-16500	203	9	to	to	PART
ihlr-16500	203	10	ten	ten	NUM
ihlr-16500	203	11	thousand	thousand	NUM
ihlr-16500	203	12	chemically	chemically	ADV
ihlr-16500	203	13	synthesized	synthesize	VERB
ihlr-16500	203	14	molecules	molecule	NOUN
ihlr-16500	203	15	examined	examine	VERB
ihlr-16500	203	16	by	by	ADP
ihlr-16500	203	17	the	the	DET
ihlr-16500	203	18	fda	fda	PROPN
ihlr-16500	203	19	,	,	PUNCT
ihlr-16500	203	20	only	only	ADV
ihlr-16500	203	21	one	one	NUM
ihlr-16500	203	22	ever	ever	ADV
ihlr-16500	203	23	becomes	become	VERB
ihlr-16500	203	24	an	an	DET
ihlr-16500	203	25	approved	approve	VERB
ihlr-16500	203	26	drug	drug	NOUN
ihlr-16500	203	27	.	.	PUNCT
ihlr-16500	204	1	51	51	NUM
ihlr-16500	204	2	therefore	therefore	ADV
ihlr-16500	204	3	,	,	PUNCT
ihlr-16500	204	4	it	it	PRON
ihlr-16500	204	5	could	could	AUX
ihlr-16500	204	6	be	be	AUX
ihlr-16500	204	7	argued	argue	VERB
ihlr-16500	204	8	that	that	SCONJ
ihlr-16500	204	9	the	the	DET
ihlr-16500	204	10	phar­	phar­	PROPN
ihlr-16500	204	11	maceutical	maceutical	ADJ
ihlr-16500	204	12	industry	industry	NOUN
ihlr-16500	204	13	is	be	AUX
ihlr-16500	204	14	more	more	ADV
ihlr-16500	204	15	than	than	ADP
ihlr-16500	204	16	committed	commit	VERB
ihlr-16500	204	17	to	to	ADP
ihlr-16500	204	18	producing	produce	VERB
ihlr-16500	204	19	safe	safe	ADJ
ihlr-16500	204	20	drugs	drug	NOUN
ihlr-16500	204	21	,	,	PUNCT
ihlr-16500	204	22	which	which	PRON
ihlr-16500	204	23	can	can	AUX
ihlr-16500	204	24	be	be	AUX
ihlr-16500	204	25	directly	directly	ADV
ihlr-16500	204	26	attributed	attribute	VERB
ihlr-16500	204	27	to	to	ADP
ihlr-16500	204	28	the	the	DET
ihlr-16500	204	29	great	great	ADJ
ihlr-16500	204	30	number	number	NOUN
ihlr-16500	204	31	of	of	ADP
ihlr-16500	204	32	drugs	drug	NOUN
ihlr-16500	204	33	that	that	PRON
ihlr-16500	204	34	are	be	AUX
ihlr-16500	204	35	discarded	discard	VERB
ihlr-16500	204	36	due	due	ADP
ihlr-16500	204	37	to	to	ADP
ihlr-16500	204	38	problems	problem	NOUN
ihlr-16500	204	39	in	in	ADP
ihlr-16500	204	40	the	the	DET
ihlr-16500	204	41	earlier	early	ADJ
ihlr-16500	204	42	stages	stage	NOUN
ihlr-16500	204	43	of	of	ADP
ihlr-16500	204	44	development	development	NOUN
ihlr-16500	204	45	.	.	PUNCT
ihlr-16500	205	1	regardless	regardless	ADV
ihlr-16500	205	2	of	of	ADP
ihlr-16500	205	3	these	these	DET
ihlr-16500	205	4	statistics	statistic	NOUN
ihlr-16500	205	5	,	,	PUNCT
ihlr-16500	205	6	however	however	ADV
ihlr-16500	205	7	,	,	PUNCT
ihlr-16500	205	8	the	the	DET
ihlr-16500	205	9	alarming	alarming	ADJ
ihlr-16500	205	10	rise	rise	NOUN
ihlr-16500	205	11	in	in	ADP
ihlr-16500	205	12	the	the	DET
ihlr-16500	205	13	number	number	NOUN
ihlr-16500	205	14	of	of	ADP
ihlr-16500	205	15	blockbuster	blockbuster	ADJ
ihlr-16500	205	16	drug	drug	NOUN
ihlr-16500	205	17	withdrawals	withdrawal	NOUN
ihlr-16500	205	18	has	have	AUX
ihlr-16500	205	19	caused	cause	VERB
ihlr-16500	205	20	many	many	ADJ
ihlr-16500	205	21	critics	critic	NOUN
ihlr-16500	205	22	to	to	PART
ihlr-16500	205	23	"	"	PUNCT
ihlr-16500	205	24	point	point	VERB
ihlr-16500	205	25	the	the	DET
ihlr-16500	205	26	finger	finger	NOUN
ihlr-16500	205	27	''	''	PUNCT
ihlr-16500	205	28	at	at	ADP
ihlr-16500	205	29	the	the	DET
ihlr-16500	205	30	fda	fda	PROPN
ihlr-16500	205	31	's	's	PART
ihlr-16500	205	32	reduced	reduce	VERB
ihlr-16500	205	33	review	review	NOUN
ihlr-16500	205	34	time	time	NOUN
ihlr-16500	205	35	.	.	PUNCT
ihlr-16500	206	1	during	during	ADP
ihlr-16500	206	2	the	the	DET
ihlr-16500	206	3	2004	2004	NUM
ihlr-16500	206	4	senate	senate	PROPN
ihlr-16500	206	5	finance	finance	PROPN
ihlr-16500	206	6	committee	committee	NOUN
ihlr-16500	206	7	hearings	hearing	NOUN
ihlr-16500	206	8	concerning	concern	VERB
ihlr-16500	206	9	the	the	DET
ihlr-16500	206	10	drug	drug	NOUN
ihlr-16500	206	11	vioxx	vioxx	NOUN
ihlr-16500	206	12	,	,	PUNCT
ihlr-16500	206	13	doctor	doctor	NOUN
ihlr-16500	206	14	david	david	PROPN
ihlr-16500	206	15	graham	graham	PROPN
ihlr-16500	206	16	,	,	PUNCT
ihlr-16500	206	17	the	the	DET
ihlr-16500	206	18	associate	associate	ADJ
ihlr-16500	206	19	di­	di­	ADJ
ihlr-16500	206	20	rector	rector	NOUN
ihlr-16500	206	21	for	for	ADP
ihlr-16500	206	22	science	science	NOUN
ihlr-16500	206	23	and	and	CCONJ
ihlr-16500	206	24	medicine	medicine	NOUN
ihlr-16500	206	25	in	in	ADP
ihlr-16500	206	26	the	the	DET
ihlr-16500	206	27	fda	fda	PROPN
ihlr-16500	206	28	's	's	PART
ihlr-16500	206	29	office	office	NOUN
ihlr-16500	206	30	of	of	ADP
ihlr-16500	206	31	drug	drug	NOUN
ihlr-16500	206	32	safety	safety	NOUN
ihlr-16500	206	33	,	,	PUNCT
ihlr-16500	206	34	called	call	VERB
ihlr-16500	206	35	the	the	DET
ihlr-16500	206	36	fda	fda	PROPN
ihlr-16500	206	37	incapable	incapable	ADJ
ihlr-16500	206	38	of	of	ADP
ihlr-16500	206	39	protecting	protect	VERB
ihlr-16500	206	40	the	the	DET
ihlr-16500	206	41	american	american	ADJ
ihlr-16500	206	42	public	public	NOUN
ihlr-16500	206	43	from	from	ADP
ihlr-16500	206	44	another	another	DET
ihlr-16500	206	45	blockbuster	blockbuster	NOUN
ihlr-16500	206	46	withdrawal	withdrawal	NOUN
ihlr-16500	206	47	such	such	ADJ
ihlr-16500	206	48	as	as	ADP
ihlr-16500	206	49	vioxx.52	vioxx.52	PROPN
ihlr-16500	206	50	he	he	PRON
ihlr-16500	206	51	claimed	claim	VERB
ihlr-16500	206	52	that	that	SCONJ
ihlr-16500	206	53	fda	fda	PROPN
ihlr-16500	206	54	officials	official	NOUN
ihlr-16500	206	55	pandered	pander	VERB
ihlr-16500	206	56	to	to	ADP
ihlr-16500	206	57	the	the	DET
ihlr-16500	206	58	47	47	NUM
ihlr-16500	206	59	/d	/d	PUNCT
ihlr-16500	206	60	.	.	PUNCT
ihlr-16500	206	61	;	;	PUNCT
ihlr-16500	206	62	see	see	VERB
ihlr-16500	206	63	also	also	ADV
ihlr-16500	206	64	ctr	ctr	PROPN
ihlr-16500	206	65	.	.	PUNCT
ihlr-16500	207	1	for	for	ADP
ihlr-16500	207	2	drug	drug	NOUN
ihlr-16500	207	3	evaluation	evaluation	NOUN
ihlr-16500	207	4	&	&	CCONJ
ihlr-16500	207	5	research	research	PROPN
ihlr-16500	207	6	,	,	PUNCT
ihlr-16500	207	7	u.s	u.s	PROPN
ihlr-16500	207	8	.	.	PROPN
ihlr-16500	207	9	food	food	PROPN
ihlr-16500	207	10	&	&	CCONJ
ihlr-16500	207	11	drug	drug	PROPN
ihlr-16500	207	12	admin	admin	PROPN
ihlr-16500	207	13	.	.	PROPN
ihlr-16500	207	14	,	,	PUNCT
ihlr-16500	207	15	pdufa	pdufa	NOUN
ihlr-16500	207	16	reautiiorjzation	reautiiorjzation	NOUN
ihlr-16500	207	17	performance	performance	NOUN
ihlr-16500	207	18	goals	goal	NOUN
ihlr-16500	207	19	and	and	CCONJ
ihlr-16500	207	20	procedures	procedure	NOUN
ihlr-16500	207	21	(	(	PUNCT
ihlr-16500	207	22	2005	2005	NUM
ihlr-16500	207	23	)	)	PUNCT
ihlr-16500	207	24	,	,	PUNCT
ihlr-16500	207	25	available	available	ADJ
ihlr-16500	207	26	at	at	ADP
ihlr-16500	207	27	http://www.fda.gov/cder/news/pdufagoals.htm	http://www.fda.gov/cder/news/pdufagoals.htm	PROPN
ihlr-16500	207	28	.	.	PUNCT
ihlr-16500	208	1	the	the	DET
ihlr-16500	208	2	prescription	prescription	NOUN
ihlr-16500	208	3	drug	drug	NOUN
ihlr-16500	208	4	fee	fee	NOUN
ihlr-16500	208	5	act	act	NOUN
ihlr-16500	208	6	required	require	VERB
ihlr-16500	208	7	phar­	phar­	NUM
ihlr-16500	208	8	maceutical	maceutical	ADJ
ihlr-16500	208	9	companies	company	NOUN
ihlr-16500	208	10	to	to	PART
ihlr-16500	208	11	pay	pay	VERB
ihlr-16500	208	12	a	a	DET
ihlr-16500	208	13	fee	fee	NOUN
ihlr-16500	208	14	to	to	ADP
ihlr-16500	208	15	the	the	DET
ihlr-16500	208	16	fda	fda	PROPN
ihlr-16500	208	17	before	before	ADP
ihlr-16500	208	18	commencement	commencement	NOUN
ihlr-16500	208	19	of	of	ADP
ihlr-16500	208	20	a	a	DET
ihlr-16500	208	21	review	review	NOUN
ihlr-16500	208	22	of	of	ADP
ihlr-16500	208	23	the	the	DET
ihlr-16500	208	24	respec­	respec­	PROPN
ihlr-16500	208	25	tive	tive	PROPN
ihlr-16500	208	26	company	company	NOUN
ihlr-16500	208	27	's	's	PART
ihlr-16500	208	28	new	new	ADJ
ihlr-16500	208	29	drug	drug	NOUN
ihlr-16500	208	30	application	application	NOUN
ihlr-16500	208	31	.	.	PUNCT
ihlr-16500	209	1	this	this	DET
ihlr-16500	209	2	fee	fee	NOUN
ihlr-16500	209	3	was	be	AUX
ihlr-16500	209	4	used	use	VERB
ihlr-16500	209	5	to	to	PART
ihlr-16500	209	6	hire	hire	VERB
ihlr-16500	209	7	more	more	ADJ
ihlr-16500	209	8	reviewers	reviewer	NOUN
ihlr-16500	209	9	and	and	CCONJ
ihlr-16500	209	10	scientists	scientist	NOUN
ihlr-16500	209	11	in	in	ADP
ihlr-16500	209	12	an	an	DET
ihlr-16500	209	13	effort	effort	NOUN
ihlr-16500	209	14	to	to	PART
ihlr-16500	209	15	streamline	streamline	VERB
ihlr-16500	209	16	the	the	DET
ihlr-16500	209	17	process	process	NOUN
ihlr-16500	209	18	and	and	CCONJ
ihlr-16500	209	19	resulted	result	VERB
ihlr-16500	209	20	in	in	ADP
ihlr-16500	209	21	a	a	DET
ihlr-16500	209	22	new	new	ADJ
ihlr-16500	209	23	timeline	timeline	NOUN
ihlr-16500	209	24	for	for	ADP
ihlr-16500	209	25	review	review	NOUN
ihlr-16500	209	26	consisting	consist	VERB
ihlr-16500	209	27	of	of	ADP
ihlr-16500	209	28	only	only	ADV
ihlr-16500	209	29	seven	seven	NUM
ihlr-16500	209	30	years	year	NOUN
ihlr-16500	209	31	.	.	PUNCT
ihlr-16500	210	1	/d	/d	PUNCT
ihlr-16500	210	2	.	.	PUNCT
ihlr-16500	211	1	48	48	NUM
ihlr-16500	211	2	pharmaceutical	pharmaceutical	NOUN
ihlr-16500	211	3	industry	industry	NOUN
ihlr-16500	211	4	profile	profile	NOUN
ihlr-16500	211	5	2006	2006	NUM
ihlr-16500	211	6	,	,	PUNCT
ihlr-16500	211	7	supra	supra	PROPN
ihlr-16500	211	8	note	note	NOUN
ihlr-16500	211	9	ll	ll	AUX
ihlr-16500	211	10	.	.	PUNCT
ihlr-16500	211	11	49	49	NUM
ihlr-16500	211	12	/d	/d	PUNCT
ihlr-16500	211	13	.	.	PUNCT
ihlr-16500	211	14	;	;	PUNCT
ihlr-16500	211	15	but	but	CCONJ
ihlr-16500	211	16	cf	cf	NOUN
ihlr-16500	211	17	marcia	marcia	PROPN
ihlr-16500	211	18	angell	angell	PROPN
ihlr-16500	211	19	,	,	PUNCT
ihlr-16500	211	20	the	the	DET
ihlr-16500	211	21	truth	truth	NOUN
ihlr-16500	211	22	about	about	ADP
ihlr-16500	211	23	the	the	DET
ihlr-16500	211	24	drug	drug	NOUN
ihlr-16500	211	25	companies	company	NOUN
ihlr-16500	211	26	,	,	PUNCT
ihlr-16500	211	27	the	the	DET
ihlr-16500	211	28	n.y	n.y	PROPN
ihlr-16500	211	29	.	.	PROPN
ihlr-16500	211	30	rev	rev	PROPN
ihlr-16500	211	31	.	.	PROPN
ihlr-16500	211	32	of	of	ADP
ihlr-16500	211	33	bks	bks	PROPN
ihlr-16500	211	34	.	.	PROPN
ihlr-16500	211	35	,	,	PUNCT
ihlr-16500	211	36	july	july	PROPN
ihlr-16500	211	37	15	15	NUM
ihlr-16500	211	38	,	,	PUNCT
ihlr-16500	211	39	2004	2004	NUM
ihlr-16500	211	40	,	,	PUNCT
ihlr-16500	211	41	available	available	ADJ
ihlr-16500	211	42	at	at	ADP
ihlr-16500	211	43	http://www	http://www	PROPN
ihlr-16500	211	44	.nybooks.comlarticles/17244	.nybooks.comlarticles/17244	PROPN
ihlr-16500	212	1	(	(	PUNCT
ihlr-16500	212	2	claiming	claim	VERB
ihlr-16500	212	3	the	the	DET
ihlr-16500	212	4	cost	cost	NOUN
ihlr-16500	212	5	to	to	PART
ihlr-16500	212	6	develop	develop	VERB
ihlr-16500	212	7	a	a	DET
ihlr-16500	212	8	blockbuster	blockbuster	ADJ
ihlr-16500	212	9	drug	drug	NOUN
ihlr-16500	212	10	is	be	AUX
ihlr-16500	212	11	not	not	PART
ihlr-16500	212	12	as	as	ADV
ihlr-16500	212	13	great	great	ADJ
ihlr-16500	212	14	as	as	SCONJ
ihlr-16500	212	15	is	be	AUX
ihlr-16500	212	16	claimed	claim	VERB
ihlr-16500	212	17	by	by	ADP
ihlr-16500	212	18	the	the	DET
ihlr-16500	212	19	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	212	20	industry	industry	NOUN
ihlr-16500	212	21	)	)	PUNCT
ihlr-16500	212	22	.	.	PUNCT
ihlr-16500	213	1	50	50	NUM
ihlr-16500	213	2	pharmaceutical	pharmaceutical	NOUN
ihlr-16500	213	3	industry	industry	NOUN
ihlr-16500	213	4	profile	profile	NOUN
ihlr-16500	213	5	2006	2006	NUM
ihlr-16500	213	6	,	,	PUNCT
ihlr-16500	213	7	supra	supra	PROPN
ihlr-16500	213	8	note	note	PROPN
ihlr-16500	213	9	11	11	NUM
ihlr-16500	213	10	;	;	PUNCT
ihlr-16500	213	11	contra	contra	PROPN
ihlr-16500	213	12	angell	angell	PROPN
ihlr-16500	213	13	,	,	PUNCT
ihlr-16500	213	14	supra	supra	PROPN
ihlr-16500	213	15	note	note	NOUN
ihlr-16500	213	16	49	49	NUM
ihlr-16500	213	17	.	.	PUNCT
ihlr-16500	214	1	st	st	PROPN
ihlr-16500	214	2	j.	j.	PROPN
ihlr-16500	214	3	michael	michael	PROPN
ihlr-16500	214	4	hayes	hayes	PROPN
ihlr-16500	214	5	,	,	PUNCT
ihlr-16500	214	6	the	the	DET
ihlr-16500	214	7	united	united	PROPN
ihlr-16500	214	8	states	states	PROPN
ihlr-16500	214	9	drug	drug	NOUN
ihlr-16500	214	10	approval	approval	NOUN
ihlr-16500	214	11	process	process	NOUN
ihlr-16500	214	12	,	,	PUNCT
ihlr-16500	214	13	at	at	ADP
ihlr-16500	214	14	3	3	NUM
ihlr-16500	214	15	,	,	PUNCT
ihlr-16500	214	16	http://www	http://www	PROPN
ihlr-16500	214	17	.	.	PUNCT
ihlr-16500	215	1	conti­	conti­	PROPN
ihlr-16500	215	2	nuingeducation.comlpharmtechldrapproval/drapproval.pdf?x=	nuingeducation.comlpharmtechldrapproval/drapproval.pdf?x=	PRON
ihlr-16500	215	3	1141768340&t=	1141768340&t=	NOUN
ihlr-16500	215	4	(	(	PUNCT
ihlr-16500	215	5	last	last	ADJ
ihlr-16500	215	6	visited	visit	VERB
ihlr-16500	215	7	feb	feb	PROPN
ihlr-16500	215	8	.	.	PROPN
ihlr-16500	215	9	16	16	NUM
ihlr-16500	215	10	,	,	PUNCT
ihlr-16500	215	11	2007	2007	NUM
ihlr-16500	215	12	)	)	PUNCT
ihlr-16500	215	13	.	.	PUNCT
ihlr-16500	216	1	all	all	DET
ihlr-16500	216	2	drugs	drug	NOUN
ihlr-16500	216	3	are	be	AUX
ihlr-16500	216	4	created	create	VERB
ihlr-16500	216	5	from	from	ADP
ihlr-16500	216	6	chemically	chemically	ADV
ihlr-16500	216	7	synthesized	synthesize	VERB
ihlr-16500	216	8	molecules	molecule	NOUN
ihlr-16500	216	9	.	.	PUNCT
ihlr-16500	217	1	/d	/d	PUNCT
ihlr-16500	217	2	.	.	PUNCT
ihlr-16500	218	1	the	the	DET
ihlr-16500	218	2	mechanism	mechanism	NOUN
ihlr-16500	218	3	of	of	ADP
ihlr-16500	218	4	action	action	NOUN
ihlr-16500	218	5	of	of	ADP
ihlr-16500	218	6	a	a	DET
ihlr-16500	218	7	molecule	molecule	NOUN
ihlr-16500	218	8	differs	differ	VERB
ihlr-16500	218	9	from	from	ADP
ihlr-16500	218	10	one	one	NUM
ihlr-16500	218	11	drug	drug	NOUN
ihlr-16500	218	12	to	to	ADP
ihlr-16500	218	13	another	another	PRON
ihlr-16500	218	14	,	,	PUNCT
ihlr-16500	218	15	even	even	ADV
ihlr-16500	218	16	if	if	SCONJ
ihlr-16500	218	17	they	they	PRON
ihlr-16500	218	18	are	be	AUX
ihlr-16500	218	19	from	from	ADP
ihlr-16500	218	20	the	the	DET
ihlr-16500	218	21	same	same	ADJ
ihlr-16500	218	22	class	class	NOUN
ihlr-16500	218	23	of	of	ADP
ihlr-16500	218	24	drugs	drug	NOUN
ihlr-16500	218	25	.	.	PUNCT
ihlr-16500	219	1	see	see	VERB
ihlr-16500	219	2	i	i	PRON
ihlr-16500	219	3	d.	d.	PROPN
ihlr-16500	219	4	52	52	NUM
ihlr-16500	219	5	placitella	placitella	PROPN
ihlr-16500	219	6	&	&	CCONJ
ihlr-16500	219	7	klein	klein	PROPN
ihlr-16500	219	8	,	,	PUNCT
ihlr-16500	219	9	supra	supra	PROPN
ihlr-16500	219	10	note	note	VERB
ihlr-16500	219	11	33	33	NUM
ihlr-16500	219	12	.	.	PUNCT
ihlr-16500	219	13	2007	2007	NUM
ihlr-16500	219	14	]	]	PUNCT
ihlr-16500	220	1	pulling	pull	VERB
ihlr-16500	220	2	a	a	DET
ihlr-16500	220	3	blockbuster	blockbuster	ADJ
ihlr-16500	220	4	drug	drug	NOUN
ihlr-16500	220	5	off	off	ADP
ihlr-16500	220	6	the	the	DET
ihlr-16500	220	7	market	market	NOUN
ihlr-16500	220	8	125	125	NUM
ihlr-16500	220	9	wishes	wish	NOUN
ihlr-16500	220	10	ofbig	ofbig	ADJ
ihlr-16500	220	11	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	220	12	companies	company	NOUN
ihlr-16500	220	13	,	,	PUNCT
ihlr-16500	220	14	even	even	ADV
ihlr-16500	220	15	so	so	ADV
ihlr-16500	220	16	far	far	ADV
ihlr-16500	220	17	as	as	ADP
ihlr-16500	220	18	allegedly	allegedly	ADV
ihlr-16500	220	19	attempting	attempt	VERB
ihlr-16500	220	20	to	to	PART
ihlr-16500	220	21	pressure	pressure	VERB
ihlr-16500	220	22	him	he	PRON
ihlr-16500	220	23	into	into	ADP
ihlr-16500	220	24	changing	change	VERB
ihlr-16500	220	25	his	his	PRON
ihlr-16500	220	26	scientific	scientific	ADJ
ihlr-16500	220	27	conclusions	conclusion	NOUN
ihlr-16500	220	28	and	and	CCONJ
ihlr-16500	220	29	recommendations	recommendation	NOUN
ihlr-16500	220	30	regarding	regard	VERB
ihlr-16500	220	31	certain	certain	ADJ
ihlr-16500	220	32	drugs.53	drugs.53	NOUN
ihlr-16500	220	33	the	the	DET
ihlr-16500	220	34	journal	journal	NOUN
ihlr-16500	220	35	of	of	ADP
ihlr-16500	220	36	the	the	DET
ihlr-16500	220	37	american	american	PROPN
ihlr-16500	220	38	medical	medical	PROPN
ihlr-16500	220	39	association	association	PROPN
ihlr-16500	220	40	(	(	PUNCT
ihlr-16500	220	41	"	"	PUNCT
ihlr-16500	220	42	jama	jama	X
ihlr-16500	220	43	''	''	PUNCT
ihlr-16500	220	44	)	)	PUNCT
ihlr-16500	220	45	agreed	agree	VERB
ihlr-16500	220	46	with	with	ADP
ihlr-16500	220	47	doctor	doctor	NOUN
ihlr-16500	220	48	graham	graham	PROPN
ihlr-16500	220	49	and	and	CCONJ
ihlr-16500	220	50	claimed	claim	VERB
ihlr-16500	220	51	that	that	SCONJ
ihlr-16500	220	52	the	the	DET
ihlr-16500	220	53	fda	fda	PROPN
ihlr-16500	220	54	's	's	PART
ihlr-16500	220	55	post­	post­	NOUN
ihlr-16500	220	56	market	market	NOUN
ihlr-16500	220	57	-	-	PUNCT
ihlr-16500	220	58	approval	approval	NOUN
ihlr-16500	220	59	-	-	PUNCT
ihlr-16500	220	60	surveillance	surveillance	NOUN
ihlr-16500	220	61	system	system	NOUN
ihlr-16500	220	62	was	be	AUX
ihlr-16500	220	63	underfunded	underfunded	ADJ
ihlr-16500	220	64	and	and	CCONJ
ihlr-16500	220	65	understaffed	understaffed	ADJ
ihlr-16500	220	66	.	.	PUNCT
ihlr-16500	221	1	this	this	DET
ihlr-16500	221	2	shortage	shortage	NOUN
ihlr-16500	221	3	of	of	ADP
ihlr-16500	221	4	adequate	adequate	ADJ
ihlr-16500	221	5	finances	finance	NOUN
ihlr-16500	221	6	and	and	CCONJ
ihlr-16500	221	7	manpower	manpower	NOUN
ihlr-16500	221	8	has	have	AUX
ihlr-16500	221	9	led	lead	VERB
ihlr-16500	221	10	to	to	ADP
ihlr-16500	221	11	thousands	thousand	NOUN
ihlr-16500	221	12	of	of	ADP
ihlr-16500	221	13	deaths	death	NOUN
ihlr-16500	221	14	each	each	DET
ihlr-16500	221	15	year	year	NOUN
ihlr-16500	221	16	by	by	ADP
ihlr-16500	221	17	drugs	drug	NOUN
ihlr-16500	221	18	that	that	PRON
ihlr-16500	221	19	should	should	AUX
ihlr-16500	221	20	have	have	AUX
ihlr-16500	221	21	been	be	AUX
ihlr-16500	221	22	withdrawn	withdraw	VERB
ihlr-16500	221	23	in	in	ADP
ihlr-16500	221	24	the	the	DET
ihlr-16500	221	25	first	first	ADJ
ihlr-16500	221	26	place	place	NOUN
ihlr-16500	221	27	.	.	PUNCT
ihlr-16500	222	1	54	54	NUM
ihlr-16500	222	2	further	further	ADJ
ihlr-16500	222	3	proof	proof	NOUN
ihlr-16500	222	4	can	can	AUX
ihlr-16500	222	5	be	be	AUX
ihlr-16500	222	6	found	find	VERB
ihlr-16500	222	7	by	by	ADP
ihlr-16500	222	8	examining	examine	VERB
ihlr-16500	222	9	the	the	DET
ihlr-16500	222	10	fda	fda	PROPN
ihlr-16500	222	11	drug	drug	PROPN
ihlr-16500	222	12	approval	approval	NOUN
ihlr-16500	222	13	process	process	NOUN
ihlr-16500	222	14	,	,	PUNCT
ihlr-16500	222	15	which	which	PRON
ihlr-16500	222	16	would	would	AUX
ihlr-16500	222	17	reveal	reveal	VERB
ihlr-16500	222	18	that	that	SCONJ
ihlr-16500	222	19	although	although	SCONJ
ihlr-16500	222	20	the	the	DET
ihlr-16500	222	21	process	process	NOUN
ihlr-16500	222	22	is	be	AUX
ihlr-16500	222	23	stringent	stringent	ADJ
ihlr-16500	222	24	,	,	PUNCT
ihlr-16500	222	25	in	in	ADP
ihlr-16500	222	26	the	the	DET
ihlr-16500	222	27	past	past	NOUN
ihlr-16500	222	28	it	it	PRON
ihlr-16500	222	29	has	have	AUX
ihlr-16500	222	30	failed	fail	VERB
ihlr-16500	222	31	to	to	PART
ihlr-16500	222	32	weed	weed	VERB
ihlr-16500	222	33	out	out	ADP
ihlr-16500	222	34	those	those	DET
ihlr-16500	222	35	drugs	drug	NOUN
ihlr-16500	222	36	that	that	PRON
ihlr-16500	222	37	were	be	AUX
ihlr-16500	222	38	unsafe	unsafe	ADJ
ihlr-16500	222	39	to	to	ADP
ihlr-16500	222	40	place	place	NOUN
ihlr-16500	222	41	on	on	ADP
ihlr-16500	222	42	the	the	DET
ihlr-16500	222	43	market	market	NOUN
ihlr-16500	222	44	.	.	PUNCT
ihlr-16500	223	1	in	in	ADP
ihlr-16500	223	2	addi­	addi­	NUM
ihlr-16500	223	3	tion	tion	NOUN
ihlr-16500	223	4	,	,	PUNCT
ihlr-16500	223	5	the	the	DET
ihlr-16500	223	6	heavy	heavy	ADJ
ihlr-16500	223	7	price	price	NOUN
ihlr-16500	223	8	tag	tag	NOUN
ihlr-16500	223	9	placed	place	VERB
ihlr-16500	223	10	on	on	ADP
ihlr-16500	223	11	the	the	DET
ihlr-16500	223	12	development	development	NOUN
ihlr-16500	223	13	of	of	ADP
ihlr-16500	223	14	each	each	DET
ihlr-16500	223	15	molecule	molecule	NOUN
ihlr-16500	223	16	increases	increase	VERB
ihlr-16500	223	17	the	the	DET
ihlr-16500	223	18	incentive	incentive	NOUN
ihlr-16500	223	19	for	for	SCONJ
ihlr-16500	223	20	the	the	DET
ihlr-16500	223	21	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	223	22	company	company	NOUN
ihlr-16500	223	23	to	to	PART
ihlr-16500	223	24	push	push	VERB
ihlr-16500	223	25	the	the	DET
ihlr-16500	223	26	drug	drug	NOUN
ihlr-16500	223	27	to	to	ADP
ihlr-16500	223	28	market	market	NOUN
ihlr-16500	223	29	,	,	PUNCT
ihlr-16500	223	30	espe­	espe­	VERB
ihlr-16500	223	31	cially	cially	ADV
ihlr-16500	223	32	if	if	SCONJ
ihlr-16500	223	33	the	the	DET
ihlr-16500	223	34	drug	drug	NOUN
ihlr-16500	223	35	is	be	AUX
ihlr-16500	223	36	in	in	ADP
ihlr-16500	223	37	the	the	DET
ihlr-16500	223	38	third	third	ADJ
ihlr-16500	223	39	phase	phase	NOUN
ihlr-16500	223	40	of	of	ADP
ihlr-16500	223	41	testing	testing	NOUN
ihlr-16500	223	42	.	.	PUNCT
ihlr-16500	224	1	often	often	ADV
ihlr-16500	224	2	times	time	NOUN
ihlr-16500	224	3	in	in	ADP
ihlr-16500	224	4	the	the	DET
ihlr-16500	224	5	third	third	ADJ
ihlr-16500	224	6	phase	phase	NOUN
ihlr-16500	224	7	,	,	PUNCT
ihlr-16500	224	8	the	the	DET
ihlr-16500	224	9	drug	drug	NOUN
ihlr-16500	224	10	is	be	AUX
ihlr-16500	224	11	viewed	view	VERB
ihlr-16500	224	12	as	as	ADP
ihlr-16500	224	13	an	an	DET
ihlr-16500	224	14	eventual	eventual	ADJ
ihlr-16500	224	15	release	release	NOUN
ihlr-16500	224	16	to	to	ADP
ihlr-16500	224	17	the	the	DET
ihlr-16500	224	18	market	market	NOUN
ihlr-16500	224	19	and	and	CCONJ
ihlr-16500	224	20	is	be	AUX
ihlr-16500	224	21	often	often	ADV
ihlr-16500	224	22	portrayed	portray	VERB
ihlr-16500	224	23	as	as	ADP
ihlr-16500	224	24	such	such	ADJ
ihlr-16500	224	25	by	by	ADP
ihlr-16500	224	26	the	the	DET
ihlr-16500	224	27	company	company	NOUN
ihlr-16500	224	28	.	.	PUNCT
ihlr-16500	225	1	in	in	ADP
ihlr-16500	225	2	doing	do	VERB
ihlr-16500	225	3	so	so	ADV
ihlr-16500	225	4	,	,	PUNCT
ihlr-16500	225	5	the	the	DET
ihlr-16500	225	6	company	company	NOUN
ihlr-16500	225	7	's	's	PART
ihlr-16500	225	8	stock	stock	NOUN
ihlr-16500	225	9	price	price	NOUN
ihlr-16500	225	10	increases	increase	NOUN
ihlr-16500	225	11	as	as	SCONJ
ihlr-16500	225	12	the	the	DET
ihlr-16500	225	13	company	company	NOUN
ihlr-16500	225	14	is	be	AUX
ihlr-16500	225	15	viewed	view	VERB
ihlr-16500	225	16	as	as	ADP
ihlr-16500	225	17	having	have	VERB
ihlr-16500	225	18	a	a	DET
ihlr-16500	225	19	strong	strong	ADJ
ihlr-16500	225	20	pipeline	pipeline	NOUN
ihlr-16500	225	21	that	that	PRON
ihlr-16500	225	22	may	may	AUX
ihlr-16500	225	23	lead	lead	VERB
ihlr-16500	225	24	to	to	ADP
ihlr-16500	225	25	a	a	DET
ihlr-16500	225	26	more	more	ADV
ihlr-16500	225	27	finan­	finan­	ADJ
ihlr-16500	225	28	cially	cially	ADV
ihlr-16500	225	29	prosperous	prosperous	ADJ
ihlr-16500	225	30	future	future	NOUN
ihlr-16500	225	31	.	.	PUNCT
ihlr-16500	226	1	conversely	conversely	ADV
ihlr-16500	226	2	,	,	PUNCT
ihlr-16500	226	3	loss	loss	NOUN
ihlr-16500	226	4	of	of	ADP
ihlr-16500	226	5	such	such	DET
ihlr-16500	226	6	a	a	DET
ihlr-16500	226	7	drug	drug	NOUN
ihlr-16500	226	8	during	during	ADP
ihlr-16500	226	9	the	the	DET
ihlr-16500	226	10	third	third	ADJ
ihlr-16500	226	11	phase	phase	NOUN
ihlr-16500	226	12	can	can	AUX
ihlr-16500	226	13	be	be	AUX
ihlr-16500	226	14	devastating	devastate	VERB
ihlr-16500	226	15	financially	financially	ADV
ihlr-16500	226	16	and	and	CCONJ
ihlr-16500	226	17	publicly	publicly	ADV
ihlr-16500	226	18	for	for	ADP
ihlr-16500	226	19	the	the	DET
ihlr-16500	226	20	company	company	NOUN
ihlr-16500	226	21	and	and	CCONJ
ihlr-16500	226	22	its	its	PRON
ihlr-16500	226	23	shareholders	shareholder	NOUN
ihlr-16500	226	24	.	.	PUNCT
ihlr-16500	227	1	in	in	ADP
ihlr-16500	227	2	recent	recent	ADJ
ihlr-16500	227	3	years	year	NOUN
ihlr-16500	227	4	,	,	PUNCT
ihlr-16500	227	5	several	several	ADJ
ihlr-16500	227	6	high	high	ADJ
ihlr-16500	227	7	profile	profile	NOUN
ihlr-16500	227	8	drugs	drug	NOUN
ihlr-16500	227	9	have	have	AUX
ihlr-16500	227	10	been	be	AUX
ihlr-16500	227	11	pulled	pull	VERB
ihlr-16500	227	12	off	off	ADP
ihlr-16500	227	13	the	the	DET
ihlr-16500	227	14	market	market	NOUN
ihlr-16500	227	15	due	due	ADP
ihlr-16500	227	16	to	to	ADP
ihlr-16500	227	17	safety	safety	NOUN
ihlr-16500	227	18	con­	con­	NOUN
ihlr-16500	227	19	cerns	cern	NOUN
ihlr-16500	227	20	.	.	PUNCT
ihlr-16500	228	1	a	a	DET
ihlr-16500	228	2	withdrawal	withdrawal	NOUN
ihlr-16500	228	3	of	of	ADP
ihlr-16500	228	4	a	a	DET
ihlr-16500	228	5	blockbuster	blockbuster	ADJ
ihlr-16500	228	6	drug	drug	NOUN
ihlr-16500	228	7	may	may	AUX
ihlr-16500	228	8	not	not	PART
ihlr-16500	228	9	only	only	ADV
ihlr-16500	228	10	affect	affect	VERB
ihlr-16500	228	11	the	the	DET
ihlr-16500	228	12	company	company	NOUN
ihlr-16500	228	13	fmancially	fmancially	ADV
ihlr-16500	228	14	and	and	CCONJ
ihlr-16500	228	15	legally	legally	ADV
ihlr-16500	228	16	,	,	PUNCT
ihlr-16500	228	17	but	but	CCONJ
ihlr-16500	228	18	can	can	AUX
ihlr-16500	228	19	also	also	ADV
ihlr-16500	228	20	affect	affect	VERB
ihlr-16500	228	21	its	its	PRON
ihlr-16500	228	22	public	public	ADJ
ihlr-16500	228	23	image	image	NOUN
ihlr-16500	228	24	.	.	PUNCT
ihlr-16500	229	1	therefore	therefore	ADV
ihlr-16500	229	2	,	,	PUNCT
ihlr-16500	229	3	the	the	DET
ihlr-16500	229	4	withdrawal	withdrawal	NOUN
ihlr-16500	229	5	of	of	ADP
ihlr-16500	229	6	a	a	DET
ihlr-16500	229	7	blockbuster	blockbuster	ADJ
ihlr-16500	229	8	drug	drug	NOUN
ihlr-16500	229	9	from	from	ADP
ihlr-16500	229	10	the	the	DET
ihlr-16500	229	11	market	market	NOUN
ihlr-16500	229	12	can	can	AUX
ihlr-16500	229	13	have	have	VERB
ihlr-16500	229	14	a	a	DET
ihlr-16500	229	15	direct	direct	ADJ
ihlr-16500	229	16	effect	effect	NOUN
ihlr-16500	229	17	on	on	ADP
ihlr-16500	229	18	not	not	PART
ihlr-16500	229	19	only	only	ADV
ihlr-16500	229	20	the	the	DET
ihlr-16500	229	21	respective	respective	ADJ
ihlr-16500	229	22	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	229	23	company	company	NOUN
ihlr-16500	229	24	and	and	CCONJ
ihlr-16500	229	25	its	its	PRON
ihlr-16500	229	26	con­	con­	NOUN
ihlr-16500	229	27	sumers	sumer	NOUN
ihlr-16500	229	28	,	,	PUNCT
ihlr-16500	229	29	but	but	CCONJ
ihlr-16500	229	30	also	also	ADV
ihlr-16500	229	31	the	the	DET
ihlr-16500	229	32	fda	fda	PROPN
ihlr-16500	229	33	and	and	CCONJ
ihlr-16500	229	34	other	other	ADJ
ihlr-16500	229	35	agencies	agency	NOUN
ihlr-16500	229	36	that	that	PRON
ihlr-16500	229	37	failed	fail	VERB
ihlr-16500	229	38	to	to	PART
ihlr-16500	229	39	prevent	prevent	VERB
ihlr-16500	229	40	the	the	DET
ihlr-16500	229	41	drug	drug	NOUN
ihlr-16500	229	42	from	from	ADP
ihlr-16500	229	43	being	be	AUX
ihlr-16500	229	44	introduced	introduce	VERB
ihlr-16500	229	45	on	on	ADP
ihlr-16500	229	46	the	the	DET
ihlr-16500	229	47	open	open	ADJ
ihlr-16500	229	48	market	market	NOUN
ihlr-16500	229	49	.	.	PUNCT
ihlr-16500	230	1	it	it	PRON
ihlr-16500	230	2	seems	seem	VERB
ihlr-16500	230	3	apparent	apparent	ADJ
ihlr-16500	230	4	from	from	ADP
ihlr-16500	230	5	recent	recent	ADJ
ihlr-16500	230	6	drug	drug	NOUN
ihlr-16500	230	7	withdrawals	withdrawal	NOUN
ihlr-16500	230	8	that	that	SCONJ
ihlr-16500	230	9	as	as	SCONJ
ihlr-16500	230	10	the	the	DET
ihlr-16500	230	11	number	number	NOUN
ihlr-16500	230	12	of	of	ADP
ihlr-16500	230	13	blockbuster	blockbuster	ADJ
ihlr-16500	230	14	drugs	drug	NOUN
ihlr-16500	230	15	pulled	pull	VERB
ihlr-16500	230	16	off	off	ADP
ihlr-16500	230	17	the	the	DET
ihlr-16500	230	18	market	market	NOUN
ihlr-16500	230	19	in­	in­	NOUN
ihlr-16500	230	20	creases	crease	NOUN
ihlr-16500	230	21	,	,	PUNCT
ihlr-16500	230	22	the	the	DET
ihlr-16500	230	23	fda	fda	PROPN
ihlr-16500	230	24	's	's	PART
ihlr-16500	230	25	drug	drug	NOUN
ihlr-16500	230	26	approval	approval	NOUN
ihlr-16500	230	27	process	process	NOUN
ihlr-16500	230	28	will	will	AUX
ihlr-16500	230	29	come	come	VERB
ihlr-16500	230	30	under	under	ADP
ihlr-16500	230	31	continued	continued	ADJ
ihlr-16500	230	32	scrutiny	scrutiny	NOUN
ihlr-16500	230	33	.	.	PUNCT
ihlr-16500	231	1	this	this	PRON
ihlr-16500	231	2	may	may	AUX
ihlr-16500	231	3	ultimately	ultimately	ADV
ihlr-16500	231	4	lead	lead	VERB
ihlr-16500	231	5	to	to	ADP
ihlr-16500	231	6	significant	significant	ADJ
ihlr-16500	231	7	changes	change	NOUN
ihlr-16500	231	8	in	in	ADP
ihlr-16500	231	9	the	the	DET
ihlr-16500	231	10	way	way	NOUN
ihlr-16500	231	11	the	the	DET
ihlr-16500	231	12	fda	fda	PROPN
ihlr-16500	231	13	handles	handle	VERB
ihlr-16500	231	14	new	new	ADJ
ihlr-16500	231	15	drug	drug	NOUN
ihlr-16500	231	16	applications	application	NOUN
ihlr-16500	231	17	.	.	PUNCT
ihlr-16500	232	1	n.	n.	ADJ
ihlr-16500	232	2	legal	legal	ADJ
ihlr-16500	232	3	ramifications	ramification	NOUN
ihlr-16500	232	4	of	of	ADP
ihlr-16500	232	5	pulling	pull	VERB
ihlr-16500	232	6	a	a	DET
ihlr-16500	232	7	drug	drug	NOUN
ihlr-16500	232	8	off	off	ADP
ihlr-16500	232	9	the	the	DET
ihlr-16500	232	10	market	market	NOUN
ihlr-16500	232	11	when	when	SCONJ
ihlr-16500	232	12	a	a	DET
ihlr-16500	232	13	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	232	14	company	company	NOUN
ihlr-16500	232	15	pulls	pull	VERB
ihlr-16500	232	16	a	a	DET
ihlr-16500	232	17	drug	drug	NOUN
ihlr-16500	232	18	off	off	ADP
ihlr-16500	232	19	the	the	DET
ihlr-16500	232	20	market	market	NOUN
ihlr-16500	232	21	as	as	ADP
ihlr-16500	232	22	a	a	DET
ihlr-16500	232	23	result	result	NOUN
ihlr-16500	232	24	of	of	ADP
ihlr-16500	232	25	an	an	DET
ihlr-16500	232	26	fda	fda	PROPN
ihlr-16500	232	27	mandate	mandate	NOUN
ihlr-16500	232	28	,	,	PUNCT
ihlr-16500	232	29	it	it	PRON
ihlr-16500	232	30	is	be	AUX
ihlr-16500	232	31	in	in	ADP
ihlr-16500	232	32	many	many	ADJ
ihlr-16500	232	33	cases	case	NOUN
ihlr-16500	232	34	conceding	concede	VERB
ihlr-16500	232	35	that	that	SCONJ
ihlr-16500	232	36	the	the	DET
ihlr-16500	232	37	drug	drug	NOUN
ihlr-16500	232	38	was	be	AUX
ihlr-16500	232	39	somehow	somehow	ADV
ihlr-16500	232	40	flawed	flawed	ADJ
ihlr-16500	232	41	.	.	PUNCT
ihlr-16500	233	1	usually	usually	ADV
ihlr-16500	233	2	the	the	DET
ihlr-16500	233	3	flaw	flaw	NOUN
ihlr-16500	233	4	or	or	CCONJ
ihlr-16500	233	5	flaws	flaw	NOUN
ihlr-16500	233	6	in	in	ADP
ihlr-16500	233	7	a	a	DET
ihlr-16500	233	8	prescription	prescription	NOUN
ihlr-16500	233	9	drug	drug	NOUN
ihlr-16500	233	10	pulled	pull	VERB
ihlr-16500	233	11	off	off	ADP
ihlr-16500	233	12	the	the	DET
ihlr-16500	233	13	market	market	NOUN
ihlr-16500	233	14	can	can	AUX
ihlr-16500	233	15	be	be	AUX
ihlr-16500	233	16	attributed	attribute	VERB
ihlr-16500	233	17	to	to	ADP
ihlr-16500	233	18	safety	safety	NOUN
ihlr-16500	233	19	concerns	concern	NOUN
ihlr-16500	233	20	.	.	PUNCT
ihlr-16500	234	1	in	in	ADP
ihlr-16500	234	2	recent	recent	ADJ
ihlr-16500	234	3	years	year	NOUN
ihlr-16500	234	4	,	,	PUNCT
ihlr-16500	234	5	several	several	ADJ
ihlr-16500	234	6	high	high	ADJ
ihlr-16500	234	7	profile	profile	NOUN
ihlr-16500	234	8	block­	block­	AUX
ihlr-16500	234	9	buster	buster	NOUN
ihlr-16500	234	10	drugs	drug	NOUN
ihlr-16500	234	11	,	,	PUNCT
ihlr-16500	234	12	such	such	ADJ
ihlr-16500	234	13	as	as	ADP
ihlr-16500	234	14	rezulin	rezulin	NOUN
ihlr-16500	234	15	and	and	CCONJ
ihlr-16500	234	16	baycol	baycol	NOUN
ihlr-16500	234	17	,	,	PUNCT
ihlr-16500	234	18	have	have	AUX
ihlr-16500	234	19	been	be	AUX
ihlr-16500	234	20	pulled	pull	VERB
ihlr-16500	234	21	off	off	ADP
ihlr-16500	234	22	the	the	DET
ihlr-16500	234	23	market	market	NOUN
ihlr-16500	234	24	for	for	ADP
ihlr-16500	234	25	just	just	ADV
ihlr-16500	234	26	this	this	DET
ihlr-16500	234	27	reason	reason	NOUN
ihlr-16500	234	28	.	.	PUNCT
ihlr-16500	235	1	55	55	NUM
ihlr-16500	235	2	many	many	ADJ
ihlr-16500	235	3	of	of	ADP
ihlr-16500	235	4	these	these	DET
ihlr-16500	235	5	recently	recently	ADV
ihlr-16500	235	6	withdrawn	withdraw	VERB
ihlr-16500	235	7	drugs	drug	NOUN
ihlr-16500	235	8	were	be	AUX
ihlr-16500	235	9	used	use	VERB
ihlr-16500	235	10	to	to	PART
ihlr-16500	235	11	treat	treat	VERB
ihlr-16500	235	12	a	a	DET
ihlr-16500	235	13	53	53	NUM
ihlr-16500	235	14	/d	/d	PUNCT
ihlr-16500	235	15	.	.	PUNCT
ihlr-16500	236	1	at	at	ADP
ihlr-16500	236	2	220	220	NUM
ihlr-16500	236	3	-	-	SYM
ihlr-16500	236	4	21	21	NUM
ihlr-16500	236	5	.	.	PUNCT
ihlr-16500	237	1	54	54	NUM
ihlr-16500	238	1	i	i	PRON
ihlr-16500	238	2	d.	d.	VERB
ihlr-16500	238	3	at	at	ADP
ihlr-16500	238	4	221	221	NUM
ihlr-16500	238	5	.	.	PUNCT
ihlr-16500	239	1	55	55	NUM
ihlr-16500	239	2	parke	parke	NOUN
ihlr-16500	239	3	-	-	PUNCT
ihlr-16500	239	4	davis	davis	PROPN
ihlr-16500	239	5	/	/	SYM
ihlr-16500	239	6	warner	warner	PROPN
ihlr-16500	239	7	-	-	PUNCT
ihlr-16500	239	8	lambert	lambert	PROPN
ihlr-16500	239	9	inc	inc	PROPN
ihlr-16500	239	10	.	.	PROPN
ihlr-16500	239	11	(	(	PUNCT
ihlr-16500	239	12	currently	currently	ADV
ihlr-16500	239	13	owned	own	VERB
ihlr-16500	239	14	by	by	ADP
ihlr-16500	239	15	pfizer	pfizer	NOUN
ihlr-16500	239	16	)	)	PUNCT
ihlr-16500	239	17	voluntarily	voluntarily	ADV
ihlr-16500	239	18	withdrew	withdraw	VERB
ihlr-16500	239	19	rezulin	rezulin	ADV
ihlr-16500	239	20	from	from	ADP
ihlr-16500	239	21	the	the	DET
ihlr-16500	239	22	u.s	u.s	PROPN
ihlr-16500	239	23	.	.	PROPN
ihlr-16500	239	24	market	market	NOUN
ihlr-16500	239	25	in	in	ADP
ihlr-16500	239	26	2000	2000	NUM
ihlr-16500	239	27	.	.	PUNCT
ihlr-16500	240	1	jim	jim	PROPN
ihlr-16500	240	2	morris	morris	PROPN
ihlr-16500	240	3	,	,	PUNCT
ihlr-16500	240	4	diabetes	diabete	VERB
ihlr-16500	240	5	drug	drug	NOUN
ihlr-16500	240	6	rezulin	rezulin	NOUN
ihlr-16500	240	7	taken	take	VERB
ihlr-16500	240	8	off	off	ADP
ihlr-16500	240	9	market	market	NOUN
ihlr-16500	240	10	:	:	PUNCT
ihlr-16500	240	11	126	126	NUM
ihlr-16500	240	12	indiana	indiana	PROPN
ihlr-16500	240	13	health	health	PROPN
ihlr-16500	240	14	law	law	PROPN
ihlr-16500	240	15	review	review	NOUN
ihlr-16500	240	16	(	(	PUNCT
ihlr-16500	240	17	vol	vol	NOUN
ihlr-16500	240	18	.	.	PUNCT
ihlr-16500	241	1	4:115	4:115	NUM
ihlr-16500	241	2	wide	wide	ADJ
ihlr-16500	241	3	variety	variety	NOUN
ihlr-16500	241	4	of	of	ADP
ihlr-16500	241	5	disease	disease	NOUN
ihlr-16500	241	6	-	-	PUNCT
ihlr-16500	241	7	states	state	NOUN
ihlr-16500	241	8	.	.	PUNCT
ihlr-16500	242	1	56	56	NUM
ihlr-16500	242	2	in	in	ADP
ihlr-16500	242	3	such	such	ADJ
ihlr-16500	242	4	cases	case	NOUN
ihlr-16500	242	5	,	,	PUNCT
ihlr-16500	242	6	patients	patient	NOUN
ihlr-16500	242	7	and	and	CCONJ
ihlr-16500	242	8	health	health	NOUN
ihlr-16500	242	9	care	care	NOUN
ihlr-16500	242	10	profes­	profes­	NOUN
ihlr-16500	242	11	sionals	sional	NOUN
ihlr-16500	242	12	had	have	VERB
ihlr-16500	242	13	to	to	PART
ihlr-16500	242	14	find	find	VERB
ihlr-16500	242	15	alternatives	alternative	NOUN
ihlr-16500	242	16	to	to	PART
ihlr-16500	242	17	treat	treat	VERB
ihlr-16500	242	18	these	these	DET
ihlr-16500	242	19	life	life	NOUN
ihlr-16500	242	20	altering	alter	VERB
ihlr-16500	242	21	diseases	disease	NOUN
ihlr-16500	242	22	.	.	PUNCT
ihlr-16500	243	1	conversely	conversely	ADV
ihlr-16500	243	2	,	,	PUNCT
ihlr-16500	243	3	the	the	DET
ihlr-16500	243	4	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	243	5	companies	company	NOUN
ihlr-16500	243	6	that	that	PRON
ihlr-16500	243	7	manufactured	manufacture	VERB
ihlr-16500	243	8	drugs	drug	NOUN
ihlr-16500	243	9	,	,	PUNCT
ihlr-16500	243	10	such	such	ADJ
ihlr-16500	243	11	as	as	ADP
ihlr-16500	243	12	rezulin	rezulin	NOUN
ihlr-16500	243	13	and	and	CCONJ
ihlr-16500	243	14	baycol	baycol	NOUN
ihlr-16500	243	15	,	,	PUNCT
ihlr-16500	243	16	57	57	NUM
ihlr-16500	243	17	were	be	AUX
ihlr-16500	243	18	inundated	inundate	VERB
ihlr-16500	243	19	by	by	ADP
ihlr-16500	243	20	a	a	DET
ihlr-16500	243	21	number	number	NOUN
ihlr-16500	243	22	of	of	ADP
ihlr-16500	243	23	lawsuits	lawsuit	NOUN
ihlr-16500	243	24	.	.	PUNCT
ihlr-16500	244	1	both	both	DET
ihlr-16500	244	2	companies	company	NOUN
ihlr-16500	244	3	are	be	AUX
ihlr-16500	244	4	cur­	cur­	ADJ
ihlr-16500	244	5	rently	rently	ADV
ihlr-16500	244	6	fighting	fight	VERB
ihlr-16500	244	7	the	the	DET
ihlr-16500	244	8	majority	majority	NOUN
ihlr-16500	244	9	of	of	ADP
ihlr-16500	244	10	these	these	DET
ihlr-16500	244	11	lawsuits	lawsuit	NOUN
ihlr-16500	244	12	domestically	domestically	ADV
ihlr-16500	244	13	and	and	CCONJ
ihlr-16500	244	14	globally	globally	ADV
ihlr-16500	244	15	.	.	PUNCT
ihlr-16500	245	1	the	the	DET
ihlr-16500	245	2	legal	legal	ADJ
ihlr-16500	245	3	ramifications	ramification	NOUN
ihlr-16500	245	4	of	of	ADP
ihlr-16500	245	5	pulling	pull	VERB
ihlr-16500	245	6	a	a	DET
ihlr-16500	245	7	blockbuster	blockbuster	ADJ
ihlr-16500	245	8	drug	drug	NOUN
ihlr-16500	245	9	off	off	ADP
ihlr-16500	245	10	the	the	DET
ihlr-16500	245	11	market	market	NOUN
ihlr-16500	245	12	may	may	AUX
ihlr-16500	245	13	be	be	AUX
ihlr-16500	245	14	significant	significant	ADJ
ihlr-16500	245	15	for	for	ADP
ihlr-16500	245	16	both	both	CCONJ
ihlr-16500	245	17	the	the	DET
ihlr-16500	245	18	plaintiff	plaintiff	NOUN
ihlr-16500	245	19	and	and	CCONJ
ihlr-16500	245	20	the	the	DET
ihlr-16500	245	21	defendant	defendant	NOUN
ihlr-16500	245	22	-	-	PUNCT
ihlr-16500	245	23	pharmaceutical	pharmaceutical	NOUN
ihlr-16500	245	24	company	company	NOUN
ihlr-16500	245	25	.	.	PUNCT
ihlr-16500	246	1	first	first	ADV
ihlr-16500	246	2	,	,	PUNCT
ihlr-16500	246	3	a	a	DET
ihlr-16500	246	4	verdict	verdict	NOUN
ihlr-16500	246	5	against	against	ADP
ihlr-16500	246	6	a	a	DET
ihlr-16500	246	7	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	246	8	company	company	NOUN
ihlr-16500	246	9	can	can	AUX
ihlr-16500	246	10	lead	lead	VERB
ihlr-16500	246	11	to	to	ADP
ihlr-16500	246	12	large	large	ADJ
ihlr-16500	246	13	jury	jury	NOUN
ihlr-16500	246	14	awards	award	NOUN
ihlr-16500	246	15	,	,	PUNCT
ihlr-16500	246	16	specifically	specifically	ADV
ihlr-16500	246	17	punitive	punitive	ADJ
ihlr-16500	246	18	damages	damage	NOUN
ihlr-16500	246	19	.	.	PUNCT
ihlr-16500	247	1	a	a	DET
ihlr-16500	247	2	pattern	pattern	NOUN
ihlr-16500	247	3	of	of	ADP
ihlr-16500	247	4	such	such	ADJ
ihlr-16500	247	5	losses	loss	NOUN
ihlr-16500	247	6	and	and	CCONJ
ihlr-16500	247	7	large	large	ADJ
ihlr-16500	247	8	awards	award	NOUN
ihlr-16500	247	9	can	can	AUX
ihlr-16500	247	10	lead	lead	VERB
ihlr-16500	247	11	to	to	ADP
ihlr-16500	247	12	more	more	ADJ
ihlr-16500	247	13	lawsuits	lawsuit	NOUN
ihlr-16500	247	14	,	,	PUNCT
ihlr-16500	247	15	including	include	VERB
ihlr-16500	247	16	class	class	NOUN
ihlr-16500	247	17	action	action	NOUN
ihlr-16500	247	18	lawsuits	lawsuit	NOUN
ihlr-16500	247	19	,	,	PUNCT
ihlr-16500	247	20	which	which	PRON
ihlr-16500	247	21	may	may	AUX
ihlr-16500	247	22	financially	financially	ADV
ihlr-16500	247	23	burden	burden	VERB
ihlr-16500	247	24	the	the	DET
ihlr-16500	247	25	company	company	NOUN
ihlr-16500	247	26	for	for	ADP
ihlr-16500	247	27	a	a	DET
ihlr-16500	247	28	long	long	ADJ
ihlr-16500	247	29	time	time	NOUN
ihlr-16500	247	30	.	.	PUNCT
ihlr-16500	248	1	it	it	PRON
ihlr-16500	248	2	may	may	AUX
ihlr-16500	248	3	also	also	ADV
ihlr-16500	248	4	lead	lead	VERB
ihlr-16500	248	5	to	to	ADP
ihlr-16500	248	6	a	a	DET
ihlr-16500	248	7	global	global	ADJ
ihlr-16500	248	8	settlement	settlement	NOUN
ihlr-16500	248	9	in	in	ADP
ihlr-16500	248	10	order	order	NOUN
ihlr-16500	248	11	to	to	PART
ihlr-16500	248	12	prevent	prevent	VERB
ihlr-16500	248	13	the	the	DET
ihlr-16500	248	14	company	company	NOUN
ihlr-16500	248	15	from	from	ADP
ihlr-16500	248	16	going	go	VERB
ihlr-16500	248	17	bankrupt	bankrupt	ADJ
ihlr-16500	248	18	.	.	PUNCT
ihlr-16500	249	1	58	58	NUM
ihlr-16500	250	1	conversely	conversely	ADV
ihlr-16500	250	2	,	,	PUNCT
ihlr-16500	250	3	if	if	SCONJ
ihlr-16500	250	4	the	the	DET
ihlr-16500	250	5	plain­	plain­	PROPN
ihlr-16500	250	6	tiffloses	tifflose	NOUN
ihlr-16500	250	7	,	,	PUNCT
ihlr-16500	250	8	usually	usually	ADV
ihlr-16500	250	9	after	after	ADP
ihlr-16500	250	10	filing	file	VERB
ihlr-16500	250	11	several	several	ADJ
ihlr-16500	250	12	appeals	appeal	NOUN
ihlr-16500	250	13	,	,	PUNCT
ihlr-16500	250	14	there	there	PRON
ihlr-16500	250	15	is	be	VERB
ihlr-16500	250	16	very	very	ADV
ihlr-16500	250	17	little	little	ADJ
ihlr-16500	250	18	recourse	recourse	NOUN
ihlr-16500	250	19	to	to	PART
ihlr-16500	250	20	seek	seek	VERB
ihlr-16500	250	21	compensation	compensation	NOUN
ihlr-16500	250	22	for	for	ADP
ihlr-16500	250	23	the	the	DET
ihlr-16500	250	24	sacrifice	sacrifice	NOUN
ihlr-16500	250	25	of	of	ADP
ihlr-16500	250	26	time	time	NOUN
ihlr-16500	250	27	spent	spend	VERB
ihlr-16500	250	28	and	and	CCONJ
ihlr-16500	250	29	expenses	expense	NOUN
ihlr-16500	250	30	incuited	incuite	VERB
ihlr-16500	250	31	as	as	ADP
ihlr-16500	250	32	a	a	DET
ihlr-16500	250	33	result	result	NOUN
ihlr-16500	250	34	of	of	ADP
ihlr-16500	250	35	attorney	attorney	NOUN
ihlr-16500	250	36	's	's	PART
ihlr-16500	250	37	fees	fee	NOUN
ihlr-16500	250	38	and	and	CCONJ
ihlr-16500	250	39	court	court	NOUN
ihlr-16500	250	40	costs	cost	NOUN
ihlr-16500	250	41	.	.	PUNCT
ihlr-16500	251	1	this	this	PRON
ihlr-16500	251	2	is	be	AUX
ihlr-16500	251	3	even	even	ADV
ihlr-16500	251	4	more	more	ADV
ihlr-16500	251	5	demoralizing	demoralizing	ADJ
ihlr-16500	251	6	to	to	ADP
ihlr-16500	251	7	the	the	DET
ihlr-16500	251	8	individ­	individ­	ADJ
ihlr-16500	251	9	ual	ual	ADJ
ihlr-16500	251	10	plaintiff	plaintiff	NOUN
ihlr-16500	251	11	than	than	ADP
ihlr-16500	251	12	to	to	ADP
ihlr-16500	251	13	its	its	PRON
ihlr-16500	251	14	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	251	15	counterpart	counterpart	NOUN
ihlr-16500	251	16	because	because	SCONJ
ihlr-16500	251	17	the	the	DET
ihlr-16500	251	18	latter	latter	NOUN
ihlr-16500	251	19	can	can	AUX
ihlr-16500	251	20	dig	dig	VERB
ihlr-16500	251	21	into	into	ADP
ihlr-16500	251	22	its	its	PRON
ihlr-16500	251	23	deep	deep	ADJ
ihlr-16500	251	24	pockets	pocket	NOUN
ihlr-16500	251	25	and	and	CCONJ
ihlr-16500	251	26	come	come	VERB
ihlr-16500	251	27	out	out	ADP
ihlr-16500	251	28	of	of	ADP
ihlr-16500	251	29	such	such	ADJ
ihlr-16500	251	30	litigation	litigation	NOUN
ihlr-16500	251	31	essentially	essentially	ADV
ihlr-16500	251	32	unscathed	unscathed	ADJ
ihlr-16500	251	33	,	,	PUNCT
ihlr-16500	251	34	aside	aside	ADV
ihlr-16500	251	35	from	from	ADP
ihlr-16500	251	36	its	its	PRON
ihlr-16500	251	37	attorney	attorney	NOUN
ihlr-16500	251	38	's	's	PART
ihlr-16500	251	39	fees	fee	NOUN
ihlr-16500	251	40	and	and	CCONJ
ihlr-16500	251	41	court	court	NOUN
ihlr-16500	251	42	costs	cost	NOUN
ihlr-16500	251	43	.	.	PUNCT
ihlr-16500	252	1	second	second	ADV
ihlr-16500	252	2	,	,	PUNCT
ihlr-16500	252	3	there	there	PRON
ihlr-16500	252	4	may	may	AUX
ihlr-16500	252	5	be	be	AUX
ihlr-16500	252	6	criminal	criminal	ADJ
ihlr-16500	252	7	penalties	penalty	NOUN
ihlr-16500	252	8	.	.	PUNCT
ihlr-16500	253	1	if	if	SCONJ
ihlr-16500	253	2	the	the	DET
ihlr-16500	253	3	plaintiff	plaintiff	NOUN
ihlr-16500	253	4	can	can	AUX
ihlr-16500	253	5	prove	prove	VERB
ihlr-16500	253	6	that	that	SCONJ
ihlr-16500	253	7	the	the	DET
ihlr-16500	253	8	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	253	9	company	company	NOUN
ihlr-16500	253	10	knew	know	VERB
ihlr-16500	253	11	of	of	ADP
ihlr-16500	253	12	the	the	DET
ihlr-16500	253	13	drug	drug	NOUN
ihlr-16500	253	14	's	's	PART
ihlr-16500	253	15	safety	safety	NOUN
ihlr-16500	253	16	defects	defect	NOUN
ihlr-16500	253	17	and	and	CCONJ
ihlr-16500	253	18	continued	continue	VERB
ihlr-16500	253	19	to	to	PART
ihlr-16500	253	20	market	market	VERB
ihlr-16500	253	21	and	and	CCONJ
ihlr-16500	253	22	sell	sell	VERB
ihlr-16500	253	23	it	it	PRON
ihlr-16500	253	24	,	,	PUNCT
ihlr-16500	253	25	the	the	DET
ihlr-16500	253	26	company	company	NOUN
ihlr-16500	253	27	and	and	CCONJ
ihlr-16500	253	28	its	its	PRON
ihlr-16500	253	29	principals	principal	NOUN
ihlr-16500	253	30	may	may	AUX
ihlr-16500	253	31	face	face	VERB
ihlr-16500	253	32	criminal	criminal	ADJ
ihlr-16500	253	33	prosecu­	prosecu­	PROPN
ihlr-16500	253	34	tion	tion	NOUN
ihlr-16500	253	35	.	.	PUNCT
ihlr-16500	254	1	those	those	PRON
ihlr-16500	254	2	within	within	ADP
ihlr-16500	254	3	the	the	DET
ihlr-16500	254	4	company	company	NOUN
ihlr-16500	254	5	who	who	PRON
ihlr-16500	254	6	knew	know	VERB
ihlr-16500	254	7	of	of	ADP
ihlr-16500	254	8	the	the	DET
ihlr-16500	254	9	drug	drug	NOUN
ihlr-16500	254	10	's	's	PART
ihlr-16500	254	11	problems	problem	NOUN
ihlr-16500	254	12	and	and	CCONJ
ihlr-16500	254	13	failed	fail	VERB
ihlr-16500	254	14	to	to	PART
ihlr-16500	254	15	disclose	disclose	VERB
ihlr-16500	254	16	such	such	ADJ
ihlr-16500	254	17	concerns	concern	NOUN
ihlr-16500	254	18	may	may	AUX
ihlr-16500	254	19	even	even	ADV
ihlr-16500	254	20	face	face	VERB
ihlr-16500	254	21	possible	possible	ADJ
ihlr-16500	254	22	jail	jail	NOUN
ihlr-16500	254	23	time	time	NOUN
ihlr-16500	254	24	.	.	PUNCT
ihlr-16500	255	1	this	this	PRON
ihlr-16500	255	2	may	may	AUX
ihlr-16500	255	3	also	also	ADV
ihlr-16500	255	4	result	result	VERB
ihlr-16500	255	5	in	in	ADP
ihlr-16500	255	6	class	class	NOUN
ihlr-16500	255	7	action	action	NOUN
ihlr-16500	255	8	lawsuits	lawsuit	NOUN
ihlr-16500	255	9	against	against	ADP
ihlr-16500	255	10	the	the	DET
ihlr-16500	255	11	company	company	NOUN
ihlr-16500	255	12	and	and	CCONJ
ihlr-16500	255	13	may	may	AUX
ihlr-16500	255	14	lead	lead	VERB
ihlr-16500	255	15	to	to	ADP
ihlr-16500	255	16	large	large	ADJ
ihlr-16500	255	17	fines	fine	NOUN
ihlr-16500	255	18	from	from	ADP
ihlr-16500	255	19	the	the	DET
ihlr-16500	255	20	fda	fda	PROPN
ihlr-16500	255	21	.	.	PUNCT
ihlr-16500	256	1	a.	a.	PROPN
ihlr-16500	256	2	vioxx	vioxx	PROPN
ihlr-16500	256	3	lawsuits	lawsuit	NOUN
ihlr-16500	256	4	:	:	PUNCT
ihlr-16500	256	5	the	the	DET
ihlr-16500	256	6	case	case	NOUN
ihlr-16500	256	7	against	against	ADP
ihlr-16500	256	8	merck	merck	NOUN
ihlr-16500	256	9	in	in	ADP
ihlr-16500	256	10	2004	2004	NUM
ihlr-16500	256	11	,	,	PUNCT
ihlr-16500	256	12	vioxx	vioxx	PROPN
ihlr-16500	256	13	was	be	AUX
ihlr-16500	256	14	pulled	pull	VERB
ihlr-16500	256	15	off	off	ADP
ihlr-16500	256	16	the	the	DET
ihlr-16500	256	17	market	market	NOUN
ihlr-16500	256	18	for	for	ADP
ihlr-16500	256	19	safety	safety	NOUN
ihlr-16500	256	20	reasons	reason	NOUN
ihlr-16500	256	21	;	;	PUNCT
ihlr-16500	256	22	at	at	ADP
ihlr-16500	256	23	the	the	DET
ihlr-16500	256	24	time	time	NOUN
ihlr-16500	256	25	,	,	PUNCT
ihlr-16500	256	26	vioxx	vioxx	PROPN
ihlr-16500	256	27	was	be	AUX
ihlr-16500	256	28	the	the	DET
ihlr-16500	256	29	most	most	ADV
ihlr-16500	256	30	profitable	profitable	ADJ
ihlr-16500	256	31	drug	drug	NOUN
ihlr-16500	256	32	ever	ever	ADV
ihlr-16500	256	33	to	to	PART
ihlr-16500	256	34	be	be	AUX
ihlr-16500	256	35	withdrawn	withdraw	VERB
ihlr-16500	256	36	from	from	ADP
ihlr-16500	256	37	the	the	DET
ihlr-16500	256	38	market	market	NOUN
ihlr-16500	256	39	in	in	ADP
ihlr-16500	256	40	united	united	PROPN
ihlr-16500	256	41	states	states	PROPN
ihlr-16500	256	42	history	history	NOUN
ihlr-16500	256	43	.	.	PUNCT
ihlr-16500	257	1	59	59	NUM
ihlr-16500	257	2	merck	merck	NOUN
ihlr-16500	257	3	withdrew	withdraw	VERB
ihlr-16500	257	4	vioxx	vioxx	NOUN
ihlr-16500	257	5	from	from	ADP
ihlr-16500	257	6	the	the	DET
ihlr-16500	257	7	market	market	NOUN
ihlr-16500	257	8	after	after	SCONJ
ihlr-16500	257	9	the	the	DET
ihlr-16500	257	10	datapill	datapill	NOUN
ihlr-16500	257	11	linked	link	VERB
ihlr-16500	257	12	to	to	ADP
ihlr-16500	257	13	63	63	NUM
ihlr-16500	257	14	liver	liver	NOUN
ihlr-16500	257	15	-	-	PUNCT
ihlr-16500	257	16	poisoning	poison	VERB
ihlr-16500	257	17	deaths	death	NOUN
ihlr-16500	257	18	,	,	PUNCT
ihlr-16500	257	19	cnn.com	cnn.com	X
ihlr-16500	257	20	,	,	PUNCT
ihlr-16500	257	21	mar	mar	PROPN
ihlr-16500	257	22	.	.	PROPN
ihlr-16500	257	23	23	23	NUM
ihlr-16500	257	24	,	,	PUNCT
ihlr-16500	257	25	2000	2000	NUM
ihlr-16500	257	26	,	,	PUNCT
ihlr-16500	257	27	http://archives.cnn.com	http://archives.cnn.com	PROPN
ihlr-16500	257	28	/2000	/2000	PUNCT
ihlr-16500	257	29	/	/	SYM
ihlr-16500	257	30	heal	heal	VERB
ihlr-16500	257	31	th/03/22	th/03/22	PROPN
ihlr-16500	257	32	/diabetes.drug.01	/diabetes.drug.01	NOUN
ihlr-16500	257	33	/	/	SYM
ihlr-16500	257	34	index.html	index.html	PROPN
ihlr-16500	257	35	.	.	PUNCT
ihlr-16500	258	1	bayer	bayer	PROPN
ihlr-16500	258	2	voluntarily	voluntarily	ADV
ihlr-16500	258	3	withdrew	withdraw	VERB
ihlr-16500	258	4	baycol	baycol	NOUN
ihlr-16500	258	5	from	from	ADP
ihlr-16500	258	6	the	the	DET
ihlr-16500	258	7	market	market	NOUN
ihlr-16500	258	8	in	in	ADP
ihlr-16500	258	9	2001	2001	NUM
ihlr-16500	258	10	.	.	PUNCT
ihlr-16500	259	1	david	david	PROPN
ihlr-16500	259	2	brown	brown	PROPN
ihlr-16500	259	3	,	,	PUNCT
ihlr-16500	259	4	baycol	baycol	PROPN
ihlr-16500	259	5	pulled	pull	VERB
ihlr-16500	259	6	from	from	ADP
ihlr-16500	259	7	market	market	NOUN
ihlr-16500	259	8	as	as	ADP
ihlr-16500	259	9	numerous	numerous	ADJ
ihlr-16500	259	10	deaths	death	NOUN
ihlr-16500	259	11	linked	link	VERB
ihlr-16500	259	12	to	to	ADP
ihlr-16500	259	13	it	it	PRON
ihlr-16500	259	14	,	,	PUNCT
ihlr-16500	259	15	wash	wash	NOUN
ihlr-16500	259	16	.	.	PUNCT
ihlr-16500	260	1	post	post	NOUN
ihlr-16500	260	2	,	,	PUNCT
ihlr-16500	260	3	aug	aug	PROPN
ihlr-16500	260	4	.	.	PROPN
ihlr-16500	260	5	9	9	NUM
ihlr-16500	260	6	,	,	PUNCT
ihlr-16500	260	7	2001	2001	NUM
ihlr-16500	260	8	,	,	PUNCT
ihlr-16500	260	9	at	at	ADP
ihlr-16500	260	10	aol	aol	NOUN
ihlr-16500	260	11	.	.	PUNCT
ihlr-16500	261	1	56	56	NUM
ihlr-16500	261	2	some	some	PRON
ihlr-16500	261	3	of	of	ADP
ihlr-16500	261	4	the	the	DET
ihlr-16500	261	5	blockbuster	blockbuster	ADJ
ihlr-16500	261	6	drugs	drug	NOUN
ihlr-16500	261	7	pulled	pull	VERB
ihlr-16500	261	8	off	off	ADP
ihlr-16500	261	9	the	the	DET
ihlr-16500	261	10	market	market	NOUN
ihlr-16500	261	11	recently	recently	ADV
ihlr-16500	261	12	,	,	PUNCT
ihlr-16500	261	13	such	such	ADJ
ihlr-16500	261	14	as	as	ADP
ihlr-16500	261	15	rezulin	rezulin	NOUN
ihlr-16500	261	16	,	,	PUNCT
ihlr-16500	261	17	baycol	baycol	NOUN
ihlr-16500	261	18	,	,	PUNCT
ihlr-16500	261	19	and	and	CCONJ
ihlr-16500	261	20	vioxx	vioxx	NOUN
ihlr-16500	261	21	,	,	PUNCT
ihlr-16500	261	22	treated	treat	VERB
ihlr-16500	261	23	disease	disease	NOUN
ihlr-16500	261	24	-	-	PUNCT
ihlr-16500	261	25	states	state	NOUN
ihlr-16500	261	26	such	such	ADJ
ihlr-16500	261	27	as	as	ADP
ihlr-16500	261	28	diabetes	diabetes	NOUN
ihlr-16500	261	29	,	,	PUNCT
ihlr-16500	261	30	heart	heart	NOUN
ihlr-16500	261	31	disease	disease	NOUN
ihlr-16500	261	32	,	,	PUNCT
ihlr-16500	261	33	and	and	CCONJ
ihlr-16500	261	34	osteo	osteo	NOUN
ihlr-16500	261	35	-	-	PUNCT
ihlr-16500	261	36	arthritis	arthritis	NOUN
ihlr-16500	261	37	respectively	respectively	ADV
ihlr-16500	261	38	.	.	PUNCT
ihlr-16500	262	1	57	57	NUM
ihlr-16500	262	2	rezulin	rezulin	NOUN
ihlr-16500	262	3	and	and	CCONJ
ihlr-16500	262	4	baycol	baycol	NOUN
ihlr-16500	262	5	were	be	AUX
ihlr-16500	262	6	manufactured	manufacture	VERB
ihlr-16500	262	7	by	by	ADP
ihlr-16500	262	8	pfizer	pfizer	NOUN
ihlr-16500	262	9	and	and	CCONJ
ihlr-16500	262	10	bayer	bayer	PROPN
ihlr-16500	262	11	respectively	respectively	ADV
ihlr-16500	262	12	.	.	PUNCT
ihlr-16500	263	1	58	58	NUM
ihlr-16500	263	2	an	an	DET
ihlr-16500	263	3	example	example	NOUN
ihlr-16500	263	4	of	of	ADP
ihlr-16500	263	5	a	a	DET
ihlr-16500	263	6	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	263	7	global	global	ADJ
ihlr-16500	263	8	settlement	settlement	NOUN
ihlr-16500	263	9	occurred	occur	VERB
ihlr-16500	263	10	in	in	ADP
ihlr-16500	263	11	november	november	PROPN
ihlr-16500	263	12	,	,	PUNCT
ihlr-16500	263	13	200	200	NUM
ihlr-16500	263	14	i	i	PRON
ihlr-16500	263	15	,	,	PUNCT
ihlr-16500	263	16	when	when	SCONJ
ihlr-16500	263	17	tap	tap	PROPN
ihlr-16500	263	18	pharmaceuticals	pharmaceuticals	PROPN
ihlr-16500	263	19	inc	inc	PROPN
ihlr-16500	263	20	.	.	PUNCT
ihlr-16500	263	21	"	"	PUNCT
ihlr-16500	263	22	agreed	agree	VERB
ihlr-16500	263	23	to	to	PART
ihlr-16500	263	24	pay	pay	VERB
ihlr-16500	263	25	a	a	DET
ihlr-16500	263	26	total	total	ADJ
ihlr-16500	263	27	of$875	of$875	NUM
ihlr-16500	263	28	million	million	NUM
ihlr-16500	263	29	to	to	PART
ihlr-16500	263	30	resolve	resolve	VERB
ihlr-16500	263	31	alleged	allege	VERB
ihlr-16500	263	32	violations	violation	NOUN
ihlr-16500	263	33	of	of	ADP
ihlr-16500	263	34	the	the	DET
ihlr-16500	263	35	prescription	prescription	NOUN
ihlr-16500	263	36	drug	drug	NOUN
ihlr-16500	263	37	marketing	marketing	NOUN
ihlr-16500	263	38	act	act	NOUN
ihlr-16500	263	39	(	(	PUNCT
ihlr-16500	263	40	pdma	pdma	NOUN
ihlr-16500	263	41	)	)	PUNCT
ihlr-16500	263	42	and	and	CCONJ
ihlr-16500	263	43	criminal	criminal	ADJ
ihlr-16500	263	44	and	and	CCONJ
ihlr-16500	263	45	civil	civil	ADJ
ihlr-16500	263	46	allegations	allegation	NOUN
ihlr-16500	263	47	of	of	ADP
ihlr-16500	263	48	:	:	PUNCT
ihlr-16500	263	49	fraudulent	fraudulent	ADJ
ihlr-16500	263	50	drug	drug	NOUN
ihlr-16500	263	51	pricing	pricing	NOUN
ihlr-16500	263	52	and	and	CCONJ
ihlr-16500	263	53	marketing	marketing	NOUN
ihlr-16500	263	54	conduct	conduct	NOUN
ihlr-16500	263	55	.	.	PUNCT
ihlr-16500	263	56	"	"	PUNCT
ihlr-16500	264	1	judith	judith	PROPN
ihlr-16500	264	2	a.	a.	NOUN
ihlr-16500	264	3	waltz	waltz	PROPN
ihlr-16500	264	4	,	,	PUNCT
ihlr-16500	264	5	multimillion	multimillion	NOUN
ihlr-16500	264	6	dollar	dollar	NOUN
ihlr-16500	264	7	settlement	settlement	NOUN
ihlr-16500	264	8	signals	signal	VERB
ihlr-16500	264	9	government	government	NOUN
ihlr-16500	264	10	's	's	PART
ihlr-16500	264	11	increased	increase	VERB
ihlr-16500	264	12	scrutiny	scrutiny	NOUN
ihlr-16500	264	13	of	of	ADP
ihlr-16500	264	14	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	264	15	industry	industry	NOUN
ihlr-16500	264	16	,	,	PUNCT
ihlr-16500	264	17	drug	drug	NOUN
ihlr-16500	264	18	benefit	benefit	NOUN
ihlr-16500	264	19	trends	trend	NOUN
ihlr-16500	264	20	,	,	PUNCT
ihlr-16500	264	21	nov	nov	PROPN
ihlr-16500	264	22	.	.	PROPN
ihlr-16500	264	23	2001	2001	NUM
ihlr-16500	264	24	,	,	PUNCT
ihlr-16500	264	25	at	at	ADP
ihlr-16500	264	26	15	15	NUM
ihlr-16500	264	27	-	-	SYM
ihlr-16500	264	28	16	16	NUM
ihlr-16500	264	29	,	,	PUNCT
ihlr-16500	264	30	available	available	ADJ
ihlr-16500	264	31	at	at	ADP
ihlr-16500	264	32	http	http	ADJ
ihlr-16500	264	33	:	:	PUNCT
ihlr-16500	264	34	llwww.medscape.com	llwww.medscape.com	PROPN
ihlr-16500	264	35	/	/	SYM
ihlr-16500	264	36	viewarticle/41490	viewarticle/41490	PROPN
ihlr-16500	264	37	1	1	NUM
ihlr-16500	264	38	.	.	NUM
ihlr-16500	264	39	59	59	NUM
ihlr-16500	264	40	vioxx	vioxx	NOUN
ihlr-16500	264	41	withdrawn	withdraw	VERB
ihlr-16500	264	42	after	after	SCONJ
ihlr-16500	264	43	study	study	NOUN
ihlr-16500	264	44	suggests	suggest	VERB
ihlr-16500	264	45	it	it	PRON
ihlr-16500	264	46	.may	.may	PUNCT
ihlr-16500	264	47	double	double	VERB
ihlr-16500	264	48	the	the	DET
ihlr-16500	264	49	risk	risk	NOUN
ihlr-16500	264	50	of	of	ADP
ihlr-16500	264	51	heart	heart	NOUN
ihlr-16500	264	52	attack	attack	NOUN
ihlr-16500	264	53	,	,	PUNCT
ihlr-16500	264	54	seniorjournal.com	seniorjournal.com	X
ihlr-16500	264	55	,	,	PUNCT
ihlr-16500	264	56	sept	sept	PROPN
ihlr-16500	264	57	30	30	NUM
ihlr-16500	264	58	,	,	PUNCT
ihlr-16500	264	59	2004	2004	NUM
ihlr-16500	264	60	,	,	PUNCT
ihlr-16500	264	61	http://www.seniorjournal.com/news/health/4-092007	http://www.seniorjournal.com/news/health/4-092007	ADP
ihlr-16500	264	62	]	]	PUNCT
ihlr-16500	264	63	pulling	pull	VERB
ihlr-16500	264	64	a	a	DET
ihlr-16500	264	65	blockbuster	blockbuster	ADJ
ihlr-16500	264	66	drug	drug	NOUN
ihlr-16500	264	67	off	off	ADP
ihlr-16500	264	68	the	the	DET
ihlr-16500	264	69	market	market	NOUN
ihlr-16500	264	70	127	127	NUM
ihlr-16500	264	71	safety	safety	NOUN
ihlr-16500	264	72	-	-	PUNCT
ihlr-16500	264	73	monitoring	monitor	VERB
ihlr-16500	264	74	board	board	NOUN
ihlr-16500	264	75	,	,	PUNCT
ihlr-16500	264	76	which	which	PRON
ihlr-16500	264	77	oversaw	oversee	VERB
ihlr-16500	264	78	a	a	DET
ihlr-16500	264	79	long	long	ADJ
ihlr-16500	264	80	-	-	PUNCT
ihlr-16500	264	81	term	term	NOUN
ihlr-16500	264	82	study	study	NOUN
ihlr-16500	264	83	of	of	ADP
ihlr-16500	264	84	the	the	DET
ihlr-16500	264	85	drug	drug	NOUN
ihlr-16500	264	86	,	,	PUNCT
ihlr-16500	264	87	recom­	recom­	PROPN
ihlr-16500	264	88	mended	mend	VERB
ihlr-16500	264	89	that	that	SCONJ
ihlr-16500	264	90	the	the	DET
ihlr-16500	264	91	study	study	NOUN
ihlr-16500	264	92	be	be	AUX
ihlr-16500	264	93	halted.60	halted.60	ADJ
ihlr-16500	264	94	in	in	ADP
ihlr-16500	264	95	essence	essence	NOUN
ihlr-16500	264	96	,	,	PUNCT
ihlr-16500	264	97	patients	patient	NOUN
ihlr-16500	264	98	in	in	ADP
ihlr-16500	264	99	the	the	DET
ihlr-16500	264	100	study	study	NOUN
ihlr-16500	264	101	had	have	VERB
ihlr-16500	264	102	an	an	DET
ihlr-16500	264	103	in­	in­	ADJ
ihlr-16500	264	104	creased	creased	ADJ
ihlr-16500	264	105	risk	risk	NOUN
ihlr-16500	264	106	of	of	ADP
ihlr-16500	264	107	developing	develop	VERB
ihlr-16500	264	108	serious	serious	ADJ
ihlr-16500	264	109	cardiovascular	cardiovascular	ADJ
ihlr-16500	264	110	events	event	NOUN
ihlr-16500	264	111	,	,	PUNCT
ihlr-16500	264	112	such	such	ADJ
ihlr-16500	264	113	as	as	ADP
ihlr-16500	264	114	heart	heart	NOUN
ihlr-16500	264	115	attacks	attack	NOUN
ihlr-16500	264	116	and	and	CCONJ
ihlr-16500	264	117	strokes	stroke	NOUN
ihlr-16500	264	118	,	,	PUNCT
ihlr-16500	264	119	because	because	SCONJ
ihlr-16500	264	120	of	of	ADP
ihlr-16500	264	121	their	their	PRON
ihlr-16500	264	122	continued	continue	VERB
ihlr-16500	264	123	use	use	NOUN
ihlr-16500	264	124	of	of	ADP
ihlr-16500	264	125	the	the	DET
ihlr-16500	264	126	vioxx	vioxx	NOUN
ihlr-16500	264	127	fifty	fifty	NUM
ihlr-16500	264	128	milligram	milligram	NOUN
ihlr-16500	264	129	tablet	tablet	NOUN
ihlr-16500	264	130	,	,	PUNCT
ihlr-16500	264	131	as	as	SCONJ
ihlr-16500	264	132	compared	compare	VERB
ihlr-16500	264	133	to	to	ADP
ihlr-16500	264	134	those	those	DET
ihlr-16500	264	135	patients	patient	NOUN
ihlr-16500	264	136	simply	simply	ADV
ihlr-16500	264	137	taking	take	VERB
ihlr-16500	264	138	a	a	DET
ihlr-16500	264	139	placebo	placebo	NOUN
ihlr-16500	264	140	.	.	PUNCT
ihlr-16500	265	1	61	61	NUM
ihlr-16500	265	2	the	the	DET
ihlr-16500	265	3	fda	fda	PROPN
ihlr-16500	265	4	responded	respond	VERB
ihlr-16500	265	5	to	to	ADP
ihlr-16500	265	6	merck	merck	PROPN
ihlr-16500	265	7	's	's	PART
ihlr-16500	265	8	stunning	stunning	ADJ
ihlr-16500	265	9	announcement	announcement	NOUN
ihlr-16500	265	10	by	by	ADP
ihlr-16500	265	11	stating	state	VERB
ihlr-16500	265	12	that	that	SCONJ
ihlr-16500	265	13	"	"	PUNCT
ihlr-16500	265	14	merck	merck	PROPN
ihlr-16500	265	15	did	do	VERB
ihlr-16500	265	16	the	the	DET
ihlr-16500	265	17	right	right	ADJ
ihlr-16500	265	18	thing	thing	NOUN
ihlr-16500	265	19	by	by	ADP
ihlr-16500	265	20	promptly	promptly	ADV
ihlr-16500	265	21	reporting	report	VERB
ihlr-16500	265	22	these	these	DET
ihlr-16500	265	23	findings	finding	NOUN
ihlr-16500	265	24	to	to	ADP
ihlr-16500	265	25	the	the	DET
ihlr-16500	265	26	fda	fda	PROPN
ihlr-16500	265	27	and	and	CCONJ
ihlr-16500	265	28	voluntarily	voluntarily	ADV
ihlr-16500	265	29	withdrawing	withdraw	VERB
ihlr-16500	265	30	the	the	DET
ihlr-16500	265	31	product	product	NOUN
ihlr-16500	265	32	from	from	ADP
ihlr-16500	265	33	the	the	DET
ihlr-16500	265	34	market:.62	market:.62	NOUN
ihlr-16500	265	35	the	the	DET
ihlr-16500	265	36	legal	legal	ADJ
ihlr-16500	265	37	ramifica­	ramifica­	NOUN
ihlr-16500	265	38	tions	tion	NOUN
ihlr-16500	265	39	of	of	ADP
ihlr-16500	265	40	such	such	DET
ihlr-16500	265	41	a	a	DET
ihlr-16500	265	42	withdrawal	withdrawal	NOUN
ihlr-16500	265	43	were	be	AUX
ihlr-16500	265	44	unprecedented	unprecedented	ADJ
ihlr-16500	265	45	and	and	CCONJ
ihlr-16500	265	46	over	over	ADP
ihlr-16500	265	47	the	the	DET
ihlr-16500	265	48	next	next	ADJ
ihlr-16500	265	49	few	few	ADJ
ihlr-16500	265	50	weeks	week	NOUN
ihlr-16500	265	51	and	and	CCONJ
ihlr-16500	265	52	months	month	NOUN
ihlr-16500	265	53	,	,	PUNCT
ihlr-16500	265	54	injury	injury	NOUN
ihlr-16500	265	55	lawyers	lawyer	NOUN
ihlr-16500	265	56	across	across	ADP
ihlr-16500	265	57	the	the	DET
ihlr-16500	265	58	country	country	NOUN
ihlr-16500	265	59	postured	posture	VERB
ihlr-16500	265	60	for	for	ADP
ihlr-16500	265	61	position	position	NOUN
ihlr-16500	265	62	in	in	ADP
ihlr-16500	265	63	an	an	DET
ihlr-16500	265	64	at­	at­	ADV
ihlr-16500	265	65	tempt	tempt	ADJ
ihlr-16500	265	66	to	to	PART
ihlr-16500	265	67	sue	sue	VERB
ihlr-16500	265	68	merck	merck	NOUN
ihlr-16500	265	69	and	and	CCONJ
ihlr-16500	265	70	obtain	obtain	VERB
ihlr-16500	265	71	a	a	DET
ihlr-16500	265	72	piece	piece	NOUN
ihlr-16500	265	73	of	of	ADP
ihlr-16500	265	74	the	the	DET
ihlr-16500	265	75	vioxx	vioxx	NOUN
ihlr-16500	265	76	injury	injury	NOUN
ihlr-16500	265	77	pie	pie	NOUN
ihlr-16500	265	78	.	.	PUNCT
ihlr-16500	266	1	the	the	DET
ihlr-16500	266	2	legal	legal	ADJ
ihlr-16500	266	3	consequences	consequence	NOUN
ihlr-16500	266	4	of	of	ADP
ihlr-16500	266	5	the	the	DET
ihlr-16500	266	6	vioxx	vioxx	NOUN
ihlr-16500	266	7	withdrawal	withdrawal	NOUN
ihlr-16500	266	8	were	be	AUX
ihlr-16500	266	9	immense	immense	ADJ
ihlr-16500	266	10	.	.	PUNCT
ihlr-16500	267	1	in	in	ADP
ihlr-16500	267	2	the	the	DET
ihlr-16500	267	3	united	united	PROPN
ihlr-16500	267	4	states	states	PROPN
ihlr-16500	267	5	alone	alone	ADV
ihlr-16500	267	6	4,300	4,300	NUM
ihlr-16500	267	7	lawsuits	lawsuit	NOUN
ihlr-16500	267	8	were	be	AUX
ihlr-16500	267	9	filed	file	VERB
ihlr-16500	267	10	against	against	ADP
ihlr-16500	267	11	merck	merck	NOUN
ihlr-16500	267	12	,	,	PUNCT
ihlr-16500	267	13	citing	cite	VERB
ihlr-16500	267	14	vioxx	vioxx	NOUN
ihlr-16500	267	15	as	as	ADP
ihlr-16500	267	16	the	the	DET
ihlr-16500	267	17	cause	cause	NOUN
ihlr-16500	267	18	of	of	ADP
ihlr-16500	267	19	an	an	DET
ihlr-16500	267	20	injury	injury	NOUN
ihlr-16500	267	21	.	.	PUNCT
ihlr-16500	268	1	63	63	NUM
ihlr-16500	268	2	there	there	PRON
ihlr-16500	268	3	may	may	AUX
ihlr-16500	268	4	be	be	AUX
ihlr-16500	268	5	several	several	ADJ
ihlr-16500	268	6	reasons	reason	NOUN
ihlr-16500	268	7	why	why	SCONJ
ihlr-16500	268	8	such	such	DET
ihlr-16500	268	9	a	a	DET
ihlr-16500	268	10	large	large	ADJ
ihlr-16500	268	11	num­	num­	ADJ
ihlr-16500	268	12	ber	ber	NOUN
ihlr-16500	268	13	oflawsuits	oflawsuit	NOUN
ihlr-16500	268	14	were	be	AUX
ihlr-16500	268	15	filed	file	VERB
ihlr-16500	268	16	.	.	PUNCT
ihlr-16500	269	1	first	first	ADV
ihlr-16500	269	2	,	,	PUNCT
ihlr-16500	269	3	plaintiffs	plaintiff	NOUN
ihlr-16500	269	4	'	'	PART
ihlr-16500	269	5	attorneys	attorney	NOUN
ihlr-16500	269	6	targeted	target	VERB
ihlr-16500	269	7	large	large	ADJ
ihlr-16500	269	8	pharmaceu­	pharmaceu­	NOUN
ihlr-16500	269	9	tical	tical	ADJ
ihlr-16500	269	10	companies	company	NOUN
ihlr-16500	269	11	,	,	PUNCT
ihlr-16500	269	12	and	and	CCONJ
ihlr-16500	269	13	many	many	ADJ
ihlr-16500	269	14	of	of	ADP
ihlr-16500	269	15	them	they	PRON
ihlr-16500	269	16	used	use	VERB
ihlr-16500	269	17	this	this	DET
ihlr-16500	269	18	opportunity	opportunity	NOUN
ihlr-16500	269	19	to	to	PART
ihlr-16500	269	20	show	show	VERB
ihlr-16500	269	21	prospective	prospective	ADJ
ihlr-16500	269	22	clients	client	NOUN
ihlr-16500	269	23	that	that	SCONJ
ihlr-16500	269	24	trial	trial	NOUN
ihlr-16500	269	25	lawyers	lawyer	NOUN
ihlr-16500	269	26	can	can	AUX
ihlr-16500	269	27	sue	sue	VERB
ihlr-16500	269	28	big	big	ADJ
ihlr-16500	269	29	conglomerates	conglomerate	NOUN
ihlr-16500	269	30	like	like	ADP
ihlr-16500	269	31	merck	merck	NOUN
ihlr-16500	269	32	and	and	CCONJ
ihlr-16500	269	33	hold	hold	VERB
ihlr-16500	269	34	them	they	PRON
ihlr-16500	269	35	accountable	accountable	ADJ
ihlr-16500	269	36	.	.	PUNCT
ihlr-16500	270	1	64	64	NUM
ihlr-16500	270	2	second	second	ADJ
ihlr-16500	270	3	,	,	PUNCT
ihlr-16500	270	4	a	a	DET
ihlr-16500	270	5	significant	significant	ADJ
ihlr-16500	270	6	number	number	NOUN
ihlr-16500	270	7	of	of	ADP
ihlr-16500	270	8	the	the	DET
ihlr-16500	270	9	cases	case	NOUN
ihlr-16500	270	10	were	be	AUX
ihlr-16500	270	11	to	to	PART
ihlr-16500	270	12	be	be	AUX
ihlr-16500	270	13	tried	try	VERB
ihlr-16500	270	14	in	in	ADP
ihlr-16500	270	15	jurisdictions	jurisdiction	NOUN
ihlr-16500	270	16	that	that	PRON
ihlr-16500	270	17	fail	fail	VERB
ihlr-16500	270	18	to	to	PART
ihlr-16500	270	19	cap	cap	VERB
ihlr-16500	270	20	punitive	punitive	ADJ
ihlr-16500	270	21	damages	damage	NOUN
ihlr-16500	270	22	.	.	PUNCT
ihlr-16500	271	1	65	65	NUM
ihlr-16500	271	2	as	as	ADP
ihlr-16500	271	3	a	a	DET
ihlr-16500	271	4	result	result	NOUN
ihlr-16500	271	5	,	,	PUNCT
ihlr-16500	271	6	plaintiffs	plaintiff	NOUN
ihlr-16500	271	7	'	'	PART
ihlr-16500	271	8	lawyers	lawyer	NOUN
ihlr-16500	271	9	were	be	AUX
ihlr-16500	271	10	hoping	hope	VERB
ihlr-16500	271	11	that	that	SCONJ
ihlr-16500	271	12	the	the	DET
ihlr-16500	271	13	advent	advent	NOUN
ihlr-16500	271	14	of	of	ADP
ihlr-16500	271	15	big	big	ADJ
ihlr-16500	271	16	-	-	PUNCT
ihlr-16500	271	17	ticket	ticket	NOUN
ihlr-16500	271	18	verdicts	verdict	NOUN
ihlr-16500	271	19	against	against	ADP
ihlr-16500	271	20	the	the	DET
ihlr-16500	271	21	company	company	NOUN
ihlr-16500	271	22	would	would	AUX
ihlr-16500	271	23	result	result	VERB
ihlr-16500	271	24	in	in	ADP
ihlr-16500	271	25	the	the	DET
ihlr-16500	271	26	filing	filing	NOUN
ihlr-16500	271	27	of	of	ADP
ihlr-16500	271	28	more	more	ADJ
ihlr-16500	271	29	lawsuits.66	lawsuits.66	NOUN
ihlr-16500	271	30	similar	similar	ADJ
ihlr-16500	271	31	to	to	ADP
ihlr-16500	271	32	cases	case	NOUN
ihlr-16500	271	33	involving	involve	VERB
ihlr-16500	271	34	claims	claim	NOUN
ihlr-16500	271	35	against	against	ADP
ihlr-16500	271	36	asbestos	asbestos	NOUN
ihlr-16500	271	37	and	and	CCONJ
ihlr-16500	271	38	breast	breast	NOUN
ihlr-16500	271	39	implants	implant	NOUN
ihlr-16500	271	40	,	,	PUNCT
ihlr-16500	271	41	plaintiffs	plaintiff	NOUN
ihlr-16500	271	42	'	'	PART
ihlr-16500	271	43	lawyers	lawyer	NOUN
ihlr-16500	271	44	hoped	hope	VERB
ihlr-16500	271	45	that	that	SCONJ
ihlr-16500	271	46	this	this	PRON
ihlr-16500	271	47	marked	mark	VERB
ihlr-16500	271	48	the	the	DET
ihlr-16500	271	49	be­	be­	NOUN
ihlr-16500	271	50	ginning	gin	VERB
ihlr-16500	271	51	of	of	ADP
ihlr-16500	271	52	a	a	DET
ihlr-16500	271	53	long	long	ADJ
ihlr-16500	271	54	road	road	NOUN
ihlr-16500	271	55	oflitigation.67	oflitigation.67	ADJ
ihlr-16500	271	56	finally	finally	ADV
ihlr-16500	271	57	,	,	PUNCT
ihlr-16500	271	58	a	a	DET
ihlr-16500	271	59	defeat	defeat	NOUN
ihlr-16500	271	60	in	in	ADP
ihlr-16500	271	61	the	the	DET
ihlr-16500	271	62	courtroom	courtroom	NOUN
ihlr-16500	271	63	might	might	AUX
ihlr-16500	271	64	be	be	AUX
ihlr-16500	271	65	the	the	DET
ihlr-16500	271	66	ultimate	ultimate	ADJ
ihlr-16500	271	67	consequence	consequence	NOUN
ihlr-16500	271	68	of	of	ADP
ihlr-16500	271	69	the	the	DET
ihlr-16500	271	70	withdrawal	withdrawal	NOUN
ihlr-16500	271	71	because	because	SCONJ
ihlr-16500	271	72	it	it	PRON
ihlr-16500	271	73	can	can	AUX
ihlr-16500	271	74	lead	lead	VERB
ihlr-16500	271	75	to	to	ADP
ihlr-16500	271	76	substantial	substantial	ADJ
ihlr-16500	271	77	jury	jury	NOUN
ihlr-16500	271	78	awards	award	NOUN
ihlr-16500	271	79	and	and	CCONJ
ihlr-16500	271	80	a	a	DET
ihlr-16500	271	81	considerable	considerable	ADJ
ihlr-16500	271	82	number	number	NOUN
ihlr-16500	271	83	of	of	ADP
ihlr-16500	271	84	subsequent	subsequent	ADJ
ihlr-16500	271	85	lawsuits	lawsuit	NOUN
ihlr-16500	271	86	.	.	PUNCT
ihlr-16500	272	1	additionally	additionally	ADV
ihlr-16500	272	2	,	,	PUNCT
ihlr-16500	272	3	in	in	ADP
ihlr-16500	272	4	2005	2005	NUM
ihlr-16500	272	5	,	,	PUNCT
ihlr-16500	272	6	three	three	NUM
ihlr-16500	272	7	highly	highly	ADV
ihlr-16500	272	8	publicized	publicize	VERB
ihlr-16500	272	9	vioxx	vioxx	NOUN
ihlr-16500	272	10	trials	trial	NOUN
ihlr-16500	272	11	set	set	VERB
ihlr-16500	272	12	the	the	DET
ihlr-16500	272	13	tone	tone	NOUN
ihlr-16500	272	14	for	for	ADP
ihlr-16500	272	15	30vioxx.htm	30vioxx.htm	NUM
ihlr-16500	272	16	.	.	PUNCT
ihlr-16500	273	1	vioxx	vioxx	PROPN
ihlr-16500	273	2	was	be	AUX
ihlr-16500	273	3	a	a	DET
ihlr-16500	273	4	non	non	ADJ
ihlr-16500	273	5	-	-	ADJ
ihlr-16500	273	6	steroidal	steroidal	ADJ
ihlr-16500	273	7	anti	anti	ADJ
ihlr-16500	273	8	-	-	ADJ
ihlr-16500	273	9	inflammatory	inflammatory	ADJ
ihlr-16500	273	10	drug	drug	NOUN
ihlr-16500	273	11	within	within	ADP
ihlr-16500	273	12	the	the	DET
ihlr-16500	273	13	category	category	NOUN
ihlr-16500	273	14	of	of	ADP
ihlr-16500	273	15	drugs	drug	NOUN
ihlr-16500	273	16	known	know	VERB
ihlr-16500	273	17	as	as	ADP
ihlr-16500	273	18	cox-2	cox-2	ADJ
ihlr-16500	273	19	inhibitors	inhibitor	NOUN
ihlr-16500	273	20	.	.	PUNCT
ihlr-16500	274	1	i	i	PRON
ihlr-16500	274	2	d.	d.	VERB
ihlr-16500	274	3	it	it	PRON
ihlr-16500	274	4	was	be	AUX
ihlr-16500	274	5	prescribed	prescribe	VERB
ihlr-16500	274	6	by	by	ADP
ihlr-16500	274	7	both	both	DET
ihlr-16500	274	8	specialists	specialist	NOUN
ihlr-16500	274	9	and	and	CCONJ
ihlr-16500	274	10	general	general	ADJ
ihlr-16500	274	11	practitioners	practitioner	NOUN
ihlr-16500	274	12	for	for	ADP
ihlr-16500	274	13	pain	pain	NOUN
ihlr-16500	274	14	associated	associate	VERB
ihlr-16500	274	15	with	with	ADP
ihlr-16500	274	16	osteoarthritis	osteoarthritis	NOUN
ihlr-16500	274	17	.	.	PUNCT
ihlr-16500	275	1	/d	/d	PUNCT
ihlr-16500	275	2	.	.	PUNCT
ihlr-16500	276	1	also	also	ADV
ihlr-16500	276	2	,	,	PUNCT
ihlr-16500	276	3	since	since	SCONJ
ihlr-16500	276	4	vioxx	vioxx	NOUN
ihlr-16500	276	5	was	be	AUX
ihlr-16500	276	6	marketed	market	VERB
ihlr-16500	276	7	for	for	ADP
ihlr-16500	276	8	the	the	DET
ihlr-16500	276	9	treatment	treatment	NOUN
ihlr-16500	276	10	of	of	ADP
ihlr-16500	276	11	pain	pain	NOUN
ihlr-16500	276	12	,	,	PUNCT
ihlr-16500	276	13	many	many	ADJ
ihlr-16500	276	14	physicians	physician	NOUN
ihlr-16500	276	15	prescribed	prescribe	VERB
ihlr-16500	276	16	it	it	PRON
ihlr-16500	276	17	to	to	ADP
ihlr-16500	276	18	octogenarians	octogenarian	NOUN
ihlr-16500	276	19	.	.	PUNCT
ihlr-16500	277	1	60	60	NUM
ihlr-16500	277	2	/d	/d	X
ihlr-16500	277	3	.	.	PROPN
ihlr-16500	278	1	6	6	NUM
ihlr-16500	278	2	t	t	NOUN
ihlr-16500	279	1	i	i	PRON
ihlr-16500	279	2	d.	d.	PROPN
ihlr-16500	279	3	62	62	NUM
ihlr-16500	279	4	/d	/d	PUNCT
ihlr-16500	279	5	.	.	PUNCT
ihlr-16500	280	1	acting	act	VERB
ihlr-16500	280	2	fda	fda	PROPN
ihlr-16500	280	3	commissioner	commissioner	PROPN
ihlr-16500	280	4	dr	dr	PROPN
ihlr-16500	280	5	.	.	PROPN
ihlr-16500	280	6	lester	lester	PROPN
ihlr-16500	280	7	m.	m.	PROPN
ihlr-16500	280	8	crawford	crawford	PROPN
ihlr-16500	280	9	also	also	ADV
ihlr-16500	280	10	stated	state	VERB
ihlr-16500	280	11	that	that	SCONJ
ihlr-16500	280	12	"	"	PUNCT
ihlr-16500	280	13	[	[	PUNCT
ihlr-16500	280	14	a]lthough	a]lthough	SCONJ
ihlr-16500	280	15	the	the	DET
ihlr-16500	280	16	risk	risk	NOUN
ihlr-16500	280	17	that	that	PRON
ihlr-16500	280	18	an	an	DET
ihlr-16500	280	19	individual	individual	ADJ
ihlr-16500	280	20	patient	patient	NOUN
ihlr-16500	280	21	would	would	AUX
ihlr-16500	280	22	have	have	AUX
ihlr-16500	280	23	a	a	DET
ihlr-16500	280	24	heart	heart	NOUN
ihlr-16500	280	25	attack	attack	NOUN
ihlr-16500	280	26	or	or	CCONJ
ihlr-16500	280	27	stroke	stroke	NOUN
ihlr-16500	280	28	related	relate	VERB
ihlr-16500	280	29	to	to	ADP
ihlr-16500	280	30	vioxx	vioxx	NOUN
ihlr-16500	280	31	is	be	AUX
ihlr-16500	280	32	very	very	ADV
ihlr-16500	280	33	small	small	ADJ
ihlr-16500	280	34	,	,	PUNCT
ihlr-16500	280	35	the	the	DET
ihlr-16500	280	36	study	study	NOUN
ihlr-16500	280	37	that	that	PRON
ihlr-16500	280	38	was	be	AUX
ihlr-16500	280	39	halted	halt	VERB
ihlr-16500	280	40	suggests	suggest	VERB
ihlr-16500	280	41	that	that	SCONJ
ihlr-16500	280	42	,	,	PUNCT
ihlr-16500	280	43	overall	overall	ADV
ihlr-16500	280	44	,	,	PUNCT
ihlr-16500	280	45	patients	patient	NOUN
ihlr-16500	280	46	taking	take	VERB
ihlr-16500	280	47	the	the	DET
ihlr-16500	280	48	drug	drug	NOUN
ihlr-16500	280	49	chronically	chronically	ADV
ihlr-16500	280	50	face	face	VERB
ihlr-16500	280	51	twice	twice	DET
ihlr-16500	280	52	the	the	DET
ihlr-16500	280	53	risk	risk	NOUN
ihlr-16500	280	54	of	of	ADP
ihlr-16500	280	55	a	a	DET
ihlr-16500	280	56	heart	heart	NOUN
ihlr-16500	280	57	attack	attack	NOUN
ihlr-16500	280	58	compared	compare	VERB
ihlr-16500	280	59	to	to	ADP
ihlr-16500	280	60	patients	patient	NOUN
ihlr-16500	280	61	receiving	receive	VERB
ihlr-16500	280	62	a	a	DET
ihlr-16500	280	63	placebo	placebo	NOUN
ihlr-16500	280	64	.	.	PUNCT
ihlr-16500	280	65	"	"	PUNCT
ihlr-16500	280	66	!	!	PUNCT
ihlr-16500	281	1	d.	d.	PROPN
ihlr-16500	281	2	63	63	NUM
ihlr-16500	281	3	anthony	anthony	PROPN
ihlr-16500	281	4	j.	j.	PROPN
ihlr-16500	281	5	sebok	sebok	PROPN
ihlr-16500	281	6	,	,	PUNCT
ihlr-16500	281	7	what'snextfor	what'snextfor	ADP
ihlr-16500	281	8	merckanditslawyers	merckanditslawyer	NOUN
ihlr-16500	281	9	?	?	PUNCT
ihlr-16500	282	1	vioxx	vioxx	NOUN
ihlr-16500	282	2	verdict	verdict	NOUN
ihlr-16500	282	3	likely	likely	ADJ
ihlr-16500	282	4	to	to	PART
ihlr-16500	282	5	be	be	AUX
ihlr-16500	282	6	reduced	reduce	VERB
ihlr-16500	282	7	but	but	CCONJ
ihlr-16500	282	8	could	could	AUX
ihlr-16500	282	9	impact	impact	VERB
ihlr-16500	282	10	other	other	ADJ
ihlr-16500	282	11	cases	case	NOUN
ihlr-16500	282	12	,	,	PUNCT
ihlr-16500	282	13	cnn.com	cnn.com	X
ihlr-16500	282	14	,	,	PUNCT
ihlr-16500	282	15	aug	aug	PROPN
ihlr-16500	282	16	.	.	PROPN
ihlr-16500	282	17	23	23	NUM
ihlr-16500	282	18	,	,	PUNCT
ihlr-16500	282	19	2005	2005	NUM
ihlr-16500	282	20	,	,	PUNCT
ihlr-16500	282	21	http://www	http://www	PROPN
ihlr-16500	282	22	.cnn.com/2005	.cnn.com/2005	PUNCT
ihlr-16500	282	23	/	/	SYM
ihlr-16500	282	24	la	la	PROPN
ihlr-16500	282	25	w	w	PROPN
ihlr-16500	282	26	/08/23	/08/23	PUNCT
ihlr-16500	282	27	/	/	SYM
ihlr-16500	282	28	sebok	sebok	PROPN
ihlr-16500	282	29	.	.	PUNCT
ihlr-16500	283	1	vioxxlindex.html	vioxxlindex.html	PROPN
ihlr-16500	283	2	.	.	PUNCT
ihlr-16500	284	1	64	64	NUM
ihlr-16500	284	2	sebok	sebok	NOUN
ihlr-16500	284	3	,	,	PUNCT
ihlr-16500	284	4	supra	supra	PROPN
ihlr-16500	284	5	note	note	PROPN
ihlr-16500	284	6	63	63	NUM
ihlr-16500	284	7	;	;	PUNCT
ihlr-16500	284	8	jerry	jerry	NOUN
ihlr-16500	284	9	avorn	avorn	PROPN
ihlr-16500	284	10	,	,	PUNCT
ihlr-16500	284	11	powerful	powerful	ADJ
ihlr-16500	284	12	medicines	medicine	NOUN
ihlr-16500	284	13	:	:	PUNCT
ihlr-16500	284	14	the	the	DET
ihlr-16500	284	15	benefits	benefit	NOUN
ihlr-16500	284	16	,	,	PUNCT
ihlr-16500	284	17	risks	risk	NOUN
ihlr-16500	284	18	,	,	PUNCT
ihlr-16500	284	19	and	and	CCONJ
ihlr-16500	284	20	costs	cost	NOUN
ihlr-16500	284	21	of	of	ADP
ihlr-16500	284	22	prescription	prescription	NOUN
ihlr-16500	284	23	drugs	drug	NOUN
ihlr-16500	284	24	371	371	NUM
ihlr-16500	284	25	(	(	PUNCT
ihlr-16500	284	26	2004	2004	NUM
ihlr-16500	284	27	)	)	PUNCT
ihlr-16500	284	28	.	.	PUNCT
ihlr-16500	285	1	65	65	NUM
ihlr-16500	285	2	sebok	sebok	PROPN
ihlr-16500	285	3	,	,	PUNCT
ihlr-16500	285	4	supra	supra	PROPN
ihlr-16500	285	5	note	note	PROPN
ihlr-16500	285	6	63	63	NUM
ihlr-16500	285	7	.	.	PUNCT
ihlr-16500	286	1	66	66	NUM
ihlr-16500	287	1	i	i	PRON
ihlr-16500	287	2	d.	d.	PROPN
ihlr-16500	287	3	67	67	NUM
ihlr-16500	288	1	i	i	PRON
ihlr-16500	288	2	d.	d.	PROPN
ihlr-16500	288	3	a	a	DET
ihlr-16500	288	4	drawn	draw	VERB
ihlr-16500	288	5	out	out	ADP
ihlr-16500	288	6	litigation	litigation	NOUN
ihlr-16500	288	7	process	process	NOUN
ihlr-16500	288	8	means	mean	VERB
ihlr-16500	288	9	that	that	SCONJ
ihlr-16500	288	10	the	the	DET
ihlr-16500	288	11	company	company	NOUN
ihlr-16500	288	12	will	will	AUX
ihlr-16500	288	13	likely	likely	ADV
ihlr-16500	288	14	settle	settle	VERB
ihlr-16500	288	15	,	,	PUNCT
ihlr-16500	288	16	even	even	ADV
ihlr-16500	288	17	those	those	DET
ihlr-16500	288	18	cases	case	NOUN
ihlr-16500	288	19	it	it	PRON
ihlr-16500	288	20	might	might	AUX
ihlr-16500	288	21	win	win	VERB
ihlr-16500	288	22	,	,	PUNCT
ihlr-16500	288	23	in	in	ADP
ihlr-16500	288	24	an	an	DET
ihlr-16500	288	25	attempt	attempt	NOUN
ihlr-16500	288	26	to	to	PART
ihlr-16500	288	27	avoid	avoid	VERB
ihlr-16500	288	28	a	a	DET
ihlr-16500	288	29	string	string	NOUN
ihlr-16500	288	30	of	of	ADP
ihlr-16500	288	31	defeats	defeat	NOUN
ihlr-16500	288	32	that	that	PRON
ihlr-16500	288	33	would	would	AUX
ihlr-16500	288	34	provide	provide	VERB
ihlr-16500	288	35	other	other	ADJ
ihlr-16500	288	36	po­	po­	NOUN
ihlr-16500	288	37	tential	tential	ADJ
ihlr-16500	288	38	victims	victim	NOUN
ihlr-16500	288	39	the	the	DET
ihlr-16500	288	40	incentive	incentive	NOUN
ihlr-16500	288	41	to	to	PART
ihlr-16500	288	42	sue	sue	VERB
ihlr-16500	288	43	.	.	PUNCT
ihlr-16500	289	1	i	i	PRON
ihlr-16500	289	2	d.	d.	VERB
ihlr-16500	289	3	it	it	PRON
ihlr-16500	289	4	also	also	ADV
ihlr-16500	289	5	could	could	AUX
ihlr-16500	289	6	lead	lead	VERB
ihlr-16500	289	7	to	to	ADP
ihlr-16500	289	8	forum	forum	PROPN
ihlr-16500	289	9	shopping	shopping	NOUN
ihlr-16500	289	10	,	,	PUNCT
ihlr-16500	289	11	resulting	result	VERB
ihlr-16500	289	12	in	in	ADP
ihlr-16500	289	13	ad­	ad­	ADJ
ihlr-16500	289	14	verse	verse	NOUN
ihlr-16500	289	15	publicity	publicity	NOUN
ihlr-16500	289	16	for	for	ADP
ihlr-16500	289	17	the	the	DET
ihlr-16500	289	18	company	company	NOUN
ihlr-16500	289	19	in	in	ADP
ihlr-16500	289	20	multiple	multiple	ADJ
ihlr-16500	289	21	jurisdictions	jurisdiction	NOUN
ihlr-16500	289	22	.	.	PUNCT
ihlr-16500	290	1	..	..	PUNCT
ihlr-16500	291	1	128	128	NUM
ihlr-16500	291	2	indiana	indiana	PROPN
ihlr-16500	291	3	health	health	PROPN
ihlr-16500	291	4	law	law	PROPN
ihlr-16500	291	5	review	review	NOUN
ihlr-16500	291	6	[	[	X
ihlr-16500	291	7	vol	vol	NOUN
ihlr-16500	291	8	.	.	PUNCT
ihlr-16500	292	1	4:115	4:115	NUM
ihlr-16500	292	2	future	future	ADJ
ihlr-16500	292	3	litigation	litigation	NOUN
ihlr-16500	292	4	that	that	PRON
ihlr-16500	292	5	would	would	AUX
ihlr-16500	292	6	be	be	AUX
ihlr-16500	292	7	sure	sure	ADJ
ihlr-16500	292	8	to	to	PART
ihlr-16500	292	9	follow	follow	VERB
ihlr-16500	292	10	.	.	PUNCT
ihlr-16500	293	1	each	each	PRON
ihlr-16500	293	2	of	of	ADP
ihlr-16500	293	3	these	these	DET
ihlr-16500	293	4	trials	trial	NOUN
ihlr-16500	293	5	presented	present	VERB
ihlr-16500	293	6	a	a	DET
ihlr-16500	293	7	unique	unique	ADJ
ihlr-16500	293	8	opportunity	opportunity	NOUN
ihlr-16500	293	9	to	to	PART
ihlr-16500	293	10	examine	examine	VERB
ihlr-16500	293	11	the	the	DET
ihlr-16500	293	12	legal	legal	ADJ
ihlr-16500	293	13	consequences	consequence	NOUN
ihlr-16500	293	14	of	of	ADP
ihlr-16500	293	15	pulling	pull	VERB
ihlr-16500	293	16	a	a	DET
ihlr-16500	293	17	blockbuster	blockbuster	ADJ
ihlr-16500	293	18	drug	drug	NOUN
ihlr-16500	293	19	off	off	ADP
ihlr-16500	293	20	the	the	DET
ihlr-16500	293	21	market	market	NOUN
ihlr-16500	293	22	.	.	PUNCT
ihlr-16500	294	1	so	so	ADV
ihlr-16500	294	2	far	far	ADV
ihlr-16500	294	3	there	there	PRON
ihlr-16500	294	4	is	be	VERB
ihlr-16500	294	5	no	no	DET
ihlr-16500	294	6	clear	clear	ADJ
ihlr-16500	294	7	winner	winner	NOUN
ihlr-16500	294	8	as	as	SCONJ
ihlr-16500	294	9	the	the	DET
ihlr-16500	294	10	decisions	decision	NOUN
ihlr-16500	294	11	sometimes	sometimes	ADV
ihlr-16500	294	12	favor	favor	VERB
ihlr-16500	294	13	merck	merck	NOUN
ihlr-16500	294	14	and	and	CCONJ
ihlr-16500	294	15	other	other	ADJ
ihlr-16500	294	16	times	time	NOUN
ihlr-16500	294	17	favor	favor	VERB
ihlr-16500	294	18	the	the	DET
ihlr-16500	294	19	plaintiff	plaintiff	NOUN
ihlr-16500	294	20	.	.	PUNCT
ihlr-16500	295	1	the	the	DET
ihlr-16500	295	2	first	first	ADJ
ihlr-16500	295	3	trial	trial	NOUN
ihlr-16500	295	4	occurred	occur	VERB
ihlr-16500	295	5	in	in	ADP
ihlr-16500	295	6	the	the	DET
ihlr-16500	295	7	texas	texas	PROPN
ihlr-16500	295	8	case	case	NOUN
ihlr-16500	295	9	,	,	PUNCT
ihlr-16500	295	10	ernst	ernst	PROPN
ihlr-16500	295	11	v.	v.	CCONJ
ihlr-16500	295	12	merck,68	merck,68	NUM
ihlr-16500	295	13	in	in	ADP
ihlr-16500	295	14	which	which	PRON
ihlr-16500	295	15	the	the	DET
ihlr-16500	295	16	widow	widow	NOUN
ihlr-16500	295	17	of	of	ADP
ihlr-16500	295	18	the	the	DET
ihlr-16500	295	19	decedent	decedent	NOUN
ihlr-16500	295	20	who	who	PRON
ihlr-16500	295	21	used	use	VERB
ihlr-16500	295	22	vioxx	vioxx	NOUN
ihlr-16500	295	23	for	for	ADP
ihlr-16500	295	24	several	several	ADJ
ihlr-16500	295	25	months	month	NOUN
ihlr-16500	295	26	,	,	PUNCT
ihlr-16500	295	27	claiming	claim	VERB
ihlr-16500	295	28	that	that	SCONJ
ihlr-16500	295	29	vi­	vi­	PROPN
ihlr-16500	295	30	oxx	oxx	PROPN
ihlr-16500	295	31	contributed	contribute	VERB
ihlr-16500	295	32	to	to	ADP
ihlr-16500	295	33	the	the	DET
ihlr-16500	295	34	decedent	decedent	NOUN
ihlr-16500	295	35	's	's	PART
ihlr-16500	295	36	death	death	NOUN
ihlr-16500	295	37	,	,	PUNCT
ihlr-16500	295	38	sued	sue	VERB
ihlr-16500	295	39	merck	merck	NOUN
ihlr-16500	295	40	for	for	ADP
ihlr-16500	295	41	negligence	negligence	NOUN
ihlr-16500	295	42	in	in	ADP
ihlr-16500	295	43	the	the	DET
ihlr-16500	295	44	de­	de­	ADJ
ihlr-16500	295	45	sign	sign	NOUN
ihlr-16500	295	46	of	of	ADP
ihlr-16500	295	47	their	their	PRON
ihlr-16500	295	48	blockbuster	blockbuster	ADJ
ihlr-16500	295	49	anti	anti	ADJ
ihlr-16500	295	50	-	-	ADJ
ihlr-16500	295	51	arthritic	arthritic	ADJ
ihlr-16500	295	52	drug	drug	NOUN
ihlr-16500	295	53	.	.	PUNCT
ihlr-16500	296	1	69	69	NUM
ihlr-16500	297	1	the	the	DET
ihlr-16500	297	2	jury	jury	NOUN
ihlr-16500	297	3	awarded	award	VERB
ihlr-16500	297	4	a	a	DET
ihlr-16500	297	5	verdict	verdict	NOUN
ihlr-16500	297	6	in	in	ADP
ihlr-16500	297	7	favor	favor	NOUN
ihlr-16500	297	8	of	of	ADP
ihlr-16500	297	9	the	the	DET
ihlr-16500	297	10	plaintiff	plaintiff	NOUN
ihlr-16500	297	11	for	for	ADP
ihlr-16500	297	12	$	$	SYM
ihlr-16500	297	13	253	253	NUM
ihlr-16500	297	14	million	million	NUM
ihlr-16500	297	15	,	,	PUNCT
ihlr-16500	297	16	including	include	VERB
ihlr-16500	297	17	$	$	SYM
ihlr-16500	297	18	229	229	NUM
ihlr-16500	297	19	million	million	NUM
ihlr-16500	297	20	in	in	ADP
ihlr-16500	297	21	punitive	punitive	ADJ
ihlr-16500	297	22	dam­	dam­	NOUN
ihlr-16500	297	23	ages	age	NOUN
ihlr-16500	297	24	.	.	PUNCT
ihlr-16500	298	1	70	70	NUM
ihlr-16500	299	1	the	the	DET
ihlr-16500	299	2	jury	jury	NOUN
ihlr-16500	299	3	determined	determine	VERB
ihlr-16500	299	4	that	that	SCONJ
ihlr-16500	299	5	merck	merck	PROPN
ihlr-16500	299	6	acted	act	VERB
ihlr-16500	299	7	with	with	ADP
ihlr-16500	299	8	malice	malice	NOUN
ihlr-16500	299	9	,	,	PUNCT
ihlr-16500	299	10	which	which	PRON
ihlr-16500	299	11	was	be	AUX
ihlr-16500	299	12	defined	define	VERB
ihlr-16500	299	13	as	as	ADP
ihlr-16500	299	14	"	"	PUNCT
ihlr-16500	299	15	an	an	DET
ihlr-16500	299	16	extreme	extreme	ADJ
ihlr-16500	299	17	degree	degree	NOUN
ihlr-16500	299	18	of	of	ADP
ihlr-16500	299	19	risk	risk	NOUN
ihlr-16500	299	20	and	and	CCONJ
ihlr-16500	299	21	conscious	conscious	ADJ
ihlr-16500	299	22	indifference	indifference	NOUN
ihlr-16500	299	23	to	to	ADP
ihlr-16500	299	24	the	the	DET
ihlr-16500	299	25	rights	right	NOUN
ihlr-16500	299	26	,	,	PUNCT
ihlr-16500	299	27	safety	safety	NOUN
ihlr-16500	299	28	or	or	CCONJ
ihlr-16500	299	29	welfare	welfare	NOUN
ihlr-16500	299	30	of	of	ADP
ihlr-16500	299	31	others	other	NOUN
ihlr-16500	299	32	.	.	PUNCT
ihlr-16500	300	1	"71	"71	PROPN
ihlr-16500	300	2	this	this	DET
ihlr-16500	300	3	large	large	ADJ
ihlr-16500	300	4	award	award	NOUN
ihlr-16500	300	5	has	have	VERB
ihlr-16500	300	6	several	several	ADJ
ihlr-16500	300	7	implications	implication	NOUN
ihlr-16500	300	8	.	.	PUNCT
ihlr-16500	301	1	first	first	ADV
ihlr-16500	301	2	,	,	PUNCT
ihlr-16500	301	3	as	as	ADP
ihlr-16500	301	4	the	the	DET
ihlr-16500	301	5	largest	large	ADJ
ihlr-16500	301	6	award	award	NOUN
ihlr-16500	301	7	against	against	ADP
ihlr-16500	301	8	a	a	DET
ihlr-16500	301	9	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	301	10	company	company	NOUN
ihlr-16500	301	11	in	in	ADP
ihlr-16500	301	12	u.s	u.s	PROPN
ihlr-16500	301	13	.	.	PROPN
ihlr-16500	301	14	history	history	NOUN
ihlr-16500	301	15	,	,	PUNCT
ihlr-16500	301	16	it	it	PRON
ihlr-16500	301	17	attracted	attract	VERB
ihlr-16500	301	18	hundreds	hundred	NOUN
ihlr-16500	301	19	of	of	ADP
ihlr-16500	301	20	new	new	ADJ
ihlr-16500	301	21	lawsuits	lawsuit	NOUN
ihlr-16500	301	22	against	against	ADP
ihlr-16500	301	23	merck	merck	NOUN
ihlr-16500	301	24	filed	file	VERB
ihlr-16500	301	25	by	by	ADP
ihlr-16500	301	26	plaintiffs	plaintiff	NOUN
ihlr-16500	301	27	'	'	PART
ihlr-16500	301	28	attorneys	attorney	NOUN
ihlr-16500	301	29	who	who	PRON
ihlr-16500	301	30	wanted	want	VERB
ihlr-16500	301	31	a	a	DET
ihlr-16500	301	32	piece	piece	NOUN
ihlr-16500	301	33	of	of	ADP
ihlr-16500	301	34	the	the	DET
ihlr-16500	301	35	pie	pie	NOUN
ihlr-16500	301	36	.	.	PUNCT
ihlr-16500	302	1	second	second	ADJ
ihlr-16500	302	2	,	,	PUNCT
ihlr-16500	302	3	the	the	DET
ihlr-16500	302	4	award	award	NOUN
ihlr-16500	302	5	sent	send	VERB
ihlr-16500	302	6	a	a	DET
ihlr-16500	302	7	clear	clear	ADJ
ihlr-16500	302	8	message	message	NOUN
ihlr-16500	302	9	to	to	ADP
ihlr-16500	302	10	the	the	DET
ihlr-16500	302	11	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	302	12	industry	industry	NOUN
ihlr-16500	302	13	that	that	SCONJ
ihlr-16500	302	14	pulling	pull	VERB
ihlr-16500	302	15	a	a	DET
ihlr-16500	302	16	blockbuster	blockbuster	ADJ
ihlr-16500	302	17	drug	drug	NOUN
ihlr-16500	302	18	off	off	ADP
ihlr-16500	302	19	the	the	DET
ihlr-16500	302	20	market	market	NOUN
ihlr-16500	302	21	could	could	AUX
ihlr-16500	302	22	lead	lead	VERB
ihlr-16500	302	23	to	to	ADP
ihlr-16500	302	24	crippling	crippling	ADJ
ihlr-16500	302	25	damage	damage	NOUN
ihlr-16500	302	26	awards	award	NOUN
ihlr-16500	302	27	.	.	PUNCT
ihlr-16500	303	1	third	third	ADV
ihlr-16500	303	2	,	,	PUNCT
ihlr-16500	303	3	merck	merck	PROPN
ihlr-16500	303	4	was	be	AUX
ihlr-16500	303	5	dealt	deal	VERB
ihlr-16500	303	6	a	a	DET
ihlr-16500	303	7	serious	serious	ADJ
ihlr-16500	303	8	blow	blow	NOUN
ihlr-16500	303	9	since	since	SCONJ
ihlr-16500	303	10	this	this	PRON
ihlr-16500	303	11	was	be	AUX
ihlr-16500	303	12	only	only	ADV
ihlr-16500	303	13	the	the	DET
ihlr-16500	303	14	first	first	ADJ
ihlr-16500	303	15	of	of	ADP
ihlr-16500	303	16	thousands	thousand	NOUN
ihlr-16500	303	17	oflawsuits	oflawsuit	NOUN
ihlr-16500	303	18	that	that	SCONJ
ihlr-16500	303	19	it	it	PRON
ihlr-16500	303	20	would	would	AUX
ihlr-16500	303	21	face	face	VERB
ihlr-16500	303	22	,	,	PUNCT
ihlr-16500	303	23	and	and	CCONJ
ihlr-16500	303	24	such	such	DET
ihlr-16500	303	25	a	a	DET
ihlr-16500	303	26	verdict	verdict	NOUN
ihlr-16500	303	27	and	and	CCONJ
ihlr-16500	303	28	award	award	NOUN
ihlr-16500	303	29	set	set	VERB
ihlr-16500	303	30	a	a	DET
ihlr-16500	303	31	very	very	ADV
ihlr-16500	303	32	negative	negative	ADJ
ihlr-16500	303	33	precedent	precedent	NOUN
ihlr-16500	303	34	.	.	PUNCT
ihlr-16500	304	1	finally	finally	ADV
ihlr-16500	304	2	,	,	PUNCT
ihlr-16500	304	3	such	such	DET
ihlr-16500	304	4	a	a	DET
ihlr-16500	304	5	verdict	verdict	NOUN
ihlr-16500	304	6	not	not	PART
ihlr-16500	304	7	only	only	ADV
ihlr-16500	304	8	encouraged	encourage	VERB
ihlr-16500	304	9	plaintiffs	plaintiff	NOUN
ihlr-16500	304	10	to	to	PART
ihlr-16500	304	11	file	file	VERB
ihlr-16500	304	12	more	more	ADJ
ihlr-16500	304	13	lawsuits	lawsuit	NOUN
ihlr-16500	304	14	,	,	PUNCT
ihlr-16500	304	15	it	it	PRON
ihlr-16500	304	16	also	also	ADV
ihlr-16500	304	17	discouraged	discourage	VERB
ihlr-16500	304	18	plaintiffs	plaintiff	NOUN
ihlr-16500	304	19	from	from	ADP
ihlr-16500	304	20	settling	settle	VERB
ihlr-16500	304	21	their	their	PRON
ihlr-16500	304	22	cases	case	NOUN
ihlr-16500	304	23	,	,	PUNCT
ihlr-16500	304	24	hoping	hope	VERB
ihlr-16500	304	25	for	for	ADP
ihlr-16500	304	26	a	a	DET
ihlr-16500	304	27	similar	similar	ADJ
ihlr-16500	304	28	outcome	outcome	NOUN
ihlr-16500	304	29	by	by	ADP
ihlr-16500	304	30	taking	take	VERB
ihlr-16500	304	31	their	their	PRON
ihlr-16500	304	32	cases	case	NOUN
ihlr-16500	304	33	to	to	ADP
ihlr-16500	304	34	trial	trial	NOUN
ihlr-16500	304	35	.	.	PUNCT
ihlr-16500	305	1	the	the	DET
ihlr-16500	305	2	second	second	ADJ
ihlr-16500	305	3	trial	trial	NOUN
ihlr-16500	305	4	occurred	occur	VERB
ihlr-16500	305	5	in	in	ADP
ihlr-16500	305	6	the	the	DET
ihlr-16500	305	7	new	new	PROPN
ihlr-16500	305	8	jersey	jersey	PROPN
ihlr-16500	305	9	case	case	NOUN
ihlr-16500	305	10	,	,	PUNCT
ihlr-16500	305	11	humeston	humeston	NOUN
ihlr-16500	305	12	v.	v.	PROPN
ihlr-16500	305	13	merck/2	merck/2	PROPN
ihlr-16500	305	14	and	and	CCONJ
ihlr-16500	305	15	resulted	result	VERB
ihlr-16500	305	16	in	in	ADP
ihlr-16500	305	17	the	the	DET
ihlr-16500	305	18	pendulum	pendulum	NOUN
ihlr-16500	305	19	swinging	swinge	VERB
ihlr-16500	305	20	back	back	ADV
ihlr-16500	305	21	in	in	ADP
ihlr-16500	305	22	merck	merck	PROPN
ihlr-16500	305	23	's	's	PART
ihlr-16500	305	24	favor	favor	NOUN
ihlr-16500	305	25	.	.	PUNCT
ihlr-16500	306	1	this	this	DET
ihlr-16500	306	2	case	case	NOUN
ihlr-16500	306	3	proved	prove	VERB
ihlr-16500	306	4	that	that	SCONJ
ihlr-16500	306	5	winning	win	VERB
ihlr-16500	306	6	a	a	DET
ihlr-16500	306	7	lawsuit	lawsuit	NOUN
ihlr-16500	306	8	against	against	ADP
ihlr-16500	306	9	a	a	DET
ihlr-16500	306	10	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	306	11	company	company	NOUN
ihlr-16500	306	12	that	that	PRON
ihlr-16500	306	13	has	have	AUX
ihlr-16500	306	14	vol­	vol­	VERB
ihlr-16500	306	15	untarily	untarily	ADV
ihlr-16500	306	16	withdrawn	withdraw	VERB
ihlr-16500	306	17	a	a	DET
ihlr-16500	306	18	blockbuster	blockbuster	NOUN
ihlr-16500	306	19	drug	drug	NOUN
ihlr-16500	306	20	because	because	SCONJ
ihlr-16500	306	21	of	of	ADP
ihlr-16500	306	22	safety	safety	NOUN
ihlr-16500	306	23	concerns	concern	NOUN
ihlr-16500	306	24	is	be	AUX
ihlr-16500	306	25	an	an	DET
ihlr-16500	306	26	unlikely	unlikely	ADJ
ihlr-16500	306	27	proposition	proposition	NOUN
ihlr-16500	306	28	and	and	CCONJ
ihlr-16500	306	29	is	be	AUX
ihlr-16500	306	30	a	a	DET
ihlr-16500	306	31	great	great	ADJ
ihlr-16500	306	32	risk	risk	NOUN
ihlr-16500	306	33	for	for	ADP
ihlr-16500	306	34	the	the	DET
ihlr-16500	306	35	plaintiff	plaintiff	NOUN
ihlr-16500	306	36	.	.	PUNCT
ihlr-16500	307	1	in	in	ADP
ihlr-16500	307	2	this	this	DET
ihlr-16500	307	3	case	case	NOUN
ihlr-16500	307	4	,	,	PUNCT
ihlr-16500	307	5	even	even	ADV
ihlr-16500	307	6	though	though	SCONJ
ihlr-16500	307	7	the	the	DET
ihlr-16500	307	8	jury	jury	NOUN
ihlr-16500	307	9	verdict	verdict	NOUN
ihlr-16500	307	10	was	be	AUX
ihlr-16500	307	11	not	not	PART
ihlr-16500	307	12	permitted	permit	VERB
ihlr-16500	307	13	to	to	PART
ihlr-16500	307	14	address	address	VERB
ihlr-16500	307	15	whether	whether	SCONJ
ihlr-16500	307	16	vioxx	vioxx	NOUN
ihlr-16500	307	17	caused	cause	VERB
ihlr-16500	307	18	a	a	DET
ihlr-16500	307	19	heart	heart	NOUN
ihlr-16500	307	20	attack	attack	NOUN
ihlr-16500	307	21	,	,	PUNCT
ihlr-16500	307	22	the	the	DET
ihlr-16500	307	23	jurors	juror	NOUN
ihlr-16500	307	24	had	have	AUX
ihlr-16500	307	25	determined	determine	VERB
ihlr-16500	307	26	that	that	SCONJ
ihlr-16500	307	27	other	other	ADJ
ihlr-16500	307	28	risk	risk	NOUN
ihlr-16500	307	29	factors	factor	NOUN
ihlr-16500	307	30	and	and	CCONJ
ihlr-16500	307	31	job	job	NOUN
ihlr-16500	307	32	stress	stress	NOUN
ihlr-16500	307	33	were	be	AUX
ihlr-16500	307	34	contributing	contribute	VERB
ihlr-16500	307	35	factors	factor	NOUN
ihlr-16500	307	36	.	.	PUNCT
ihlr-16500	308	1	73	73	NUM
ihlr-16500	309	1	the	the	DET
ihlr-16500	309	2	jury	jury	NOUN
ihlr-16500	309	3	determined	determine	VERB
ihlr-16500	309	4	that	that	SCONJ
ihlr-16500	309	5	merck	merck	PROPN
ihlr-16500	309	6	provided	provide	VERB
ihlr-16500	309	7	adequate	adequate	ADJ
ihlr-16500	309	8	warning	warning	NOUN
ihlr-16500	309	9	to	to	ADP
ihlr-16500	309	10	prescribing	prescribing	NOUN
ihlr-16500	309	11	physicians.74	physicians.74	NOUN
ihlr-16500	309	12	this	this	DET
ihlr-16500	309	13	verdict	verdict	NOUN
ihlr-16500	309	14	was	be	AUX
ihlr-16500	309	15	a	a	DET
ihlr-16500	309	16	giant	giant	ADJ
ihlr-16500	309	17	setback	setback	NOUN
ihlr-16500	309	18	for	for	ADP
ihlr-16500	309	19	many	many	ADJ
ihlr-16500	309	20	plaintiffs	plaintiff	NOUN
ihlr-16500	309	21	because	because	SCONJ
ihlr-16500	309	22	it	it	PRON
ihlr-16500	309	23	occurred	occur	VERB
ihlr-16500	309	24	in	in	ADP
ihlr-16500	309	25	new	new	PROPN
ihlr-16500	309	26	jersey	jersey	PROPN
ihlr-16500	309	27	,	,	PUNCT
ihlr-16500	309	28	the	the	DET
ihlr-16500	309	29	loca68	loca68	PROPN
ihlr-16500	309	30	texas	texas	PROPN
ihlr-16500	309	31	jury	jury	PROPN
ihlr-16500	309	32	awards	award	VERB
ihlr-16500	309	33	$	$	SYM
ihlr-16500	309	34	250	250	NUM
ihlr-16500	309	35	million	million	NUM
ihlr-16500	309	36	in	in	ADP
ihlr-16500	309	37	jm	jm	PROPN
ihlr-16500	309	38	vioxx	vioxx	PROPN
ihlr-16500	309	39	trial	trial	NOUN
ihlr-16500	309	40	,	,	PUNCT
ihlr-16500	309	41	mealey	mealey	PROPN
ihlr-16500	309	42	's	's	PART
ihlr-16500	309	43	prod	prod	NOUN
ihlr-16500	309	44	.	.	PUNCT
ihlr-16500	310	1	liab	liab	PROPN
ihlr-16500	310	2	.	.	PUNCT
ihlr-16500	311	1	&	&	CCONJ
ihlr-16500	311	2	risk	risk	PROPN
ihlr-16500	311	3	,	,	PUNCT
ihlr-16500	311	4	sept	sept	PROPN
ihlr-16500	311	5	.	.	PROPN
ihlr-16500	311	6	5	5	NUM
ihlr-16500	311	7	,	,	PUNCT
ihlr-16500	311	8	2005	2005	NUM
ihlr-16500	311	9	,	,	PUNCT
ihlr-16500	311	10	at	at	ADP
ihlr-16500	311	11	23	23	NUM
ihlr-16500	311	12	,	,	PUNCT
ihlr-16500	311	13	23	23	NUM
ihlr-16500	312	1	[	[	X
ihlr-16500	312	2	hereinafter	hereinafter	NOUN
ihlr-16500	312	3	texas	texas	PROPN
ihlr-16500	312	4	jury	jury	PROPN
ihlr-16500	312	5	awards	award	NOUN
ihlr-16500	312	6	$	$	SYM
ihlr-16500	312	7	250	250	NUM
ihlr-16500	312	8	million	million	NUM
ihlr-16500	312	9	in	in	ADP
ihlr-16500	312	10	i	i	PROPN
ihlr-16500	312	11	m	m	VERB
ihlr-16500	312	12	vioxx	vioxx	NOUN
ihlr-16500	312	13	trial	trial	NOUN
ihlr-16500	312	14	]	]	PUNCT
ihlr-16500	312	15	.	.	PUNCT
ihlr-16500	313	1	69	69	NUM
ihlr-16500	313	2	texas	texas	PROPN
ihlr-16500	313	3	jury	jury	NOUN
ihlr-16500	313	4	awards	award	NOUN
ihlr-16500	313	5	$	$	SYM
ihlr-16500	313	6	250	250	NUM
ihlr-16500	313	7	million	million	NUM
ihlr-16500	313	8	in	in	ADP
ihlr-16500	313	9	jm	jm	PROPN
ihlr-16500	313	10	vioxx	vioxx	PROPN
ihlr-16500	313	11	trial	trial	NOUN
ihlr-16500	313	12	,	,	PUNCT
ihlr-16500	313	13	supra	supra	PROPN
ihlr-16500	313	14	note	note	NOUN
ihlr-16500	313	15	68	68	NUM
ihlr-16500	313	16	.	.	PUNCT
ihlr-16500	314	1	70	70	NUM
ihlr-16500	314	2	aaron	aaron	PROPN
ihlr-16500	314	3	smith	smith	PROPN
ihlr-16500	314	4	,	,	PUNCT
ihlr-16500	314	5	jury	jury	NOUN
ihlr-16500	314	6	:	:	PUNCT
ihlr-16500	314	7	merck	merck	PROPN
ihlr-16500	314	8	negligent	negligent	ADJ
ihlr-16500	314	9	:	:	PUNCT
ihlr-16500	314	10	merck	merck	PROPN
ihlr-16500	314	11	blamed	blame	VERB
ihlr-16500	314	12	for	for	ADP
ihlr-16500	314	13	death	death	NOUN
ihlr-16500	314	14	in	in	ADP
ihlr-16500	314	15	vioxx	vioxx	NOUN
ihlr-16500	314	16	suit	suit	NOUN
ihlr-16500	314	17	;	;	PUNCT
ihlr-16500	314	18	jury	jury	NOUN
ihlr-16500	314	19	awards	award	NOUN
ihlr-16500	314	20	$	$	SYM
ihlr-16500	314	21	253	253	NUM
ihlr-16500	314	22	million	million	NUM
ihlr-16500	314	23	in	in	ADP
ihlr-16500	314	24	damages	damage	NOUN
ihlr-16500	314	25	.	.	PUNCT
ihlr-16500	315	1	drug	drug	NOUN
ihlr-16500	315	2	giant	giant	NOUN
ihlr-16500	315	3	to	to	PART
ihlr-16500	315	4	appeal	appeal	VERB
ihlr-16500	315	5	.	.	PUNCT
ihlr-16500	315	6	,	,	PUNCT
ihlr-16500	315	7	cnnmoney.com	cnnmoney.com	X
ihlr-16500	315	8	,	,	PUNCT
ihlr-16500	315	9	aug	aug	PROPN
ihlr-16500	315	10	.	.	PROPN
ihlr-16500	315	11	19	19	NUM
ihlr-16500	315	12	,	,	PUNCT
ihlr-16500	315	13	2005	2005	NUM
ihlr-16500	315	14	,	,	PUNCT
ihlr-16500	315	15	http://money.cnn.com/2005/08/191news/fortune500/vioxx	http://money.cnn.com/2005/08/191news/fortune500/vioxx	ADV
ihlr-16500	315	16	.	.	PUNCT
ihlr-16500	316	1	71	71	NUM
ihlr-16500	316	2	texas	texas	PROPN
ihlr-16500	316	3	jury	jury	NOUN
ihlr-16500	316	4	awards	award	NOUN
ihlr-16500	316	5	$	$	SYM
ihlr-16500	316	6	250	250	NUM
ihlr-16500	316	7	million	million	NUM
ihlr-16500	316	8	in	in	ADP
ihlr-16500	316	9	181	181	NUM
ihlr-16500	316	10	vioxx	vioxx	NOUN
ihlr-16500	316	11	trial	trial	NOUN
ihlr-16500	316	12	,	,	PUNCT
ihlr-16500	316	13	supra	supra	PROPN
ihlr-16500	316	14	note	note	NOUN
ihlr-16500	316	15	68	68	NUM
ihlr-16500	316	16	.	.	PUNCT
ihlr-16500	316	17	72	72	NUM
ihlr-16500	316	18	new	new	PROPN
ihlr-16500	316	19	jersey	jersey	PROPN
ihlr-16500	316	20	jury	jury	NOUN
ihlr-16500	316	21	finds	find	VERB
ihlr-16500	316	22	vioxx	vioxx	NOUN
ihlr-16500	316	23	warnings	warning	NOUN
ihlr-16500	316	24	were	be	AUX
ihlr-16500	316	25	adequate	adequate	ADJ
ihlr-16500	316	26	,	,	PUNCT
ihlr-16500	316	27	mealey	mealey	PROPN
ihlr-16500	316	28	's	's	PART
ihlr-16500	316	29	prod	prod	NOUN
ihlr-16500	316	30	.	.	PUNCT
ihlr-16500	317	1	liab	liab	PROPN
ihlr-16500	317	2	.	.	PUNCT
ihlr-16500	318	1	&	&	CCONJ
ihlr-16500	318	2	risk	risk	PROPN
ihlr-16500	318	3	,	,	PUNCT
ihlr-16500	318	4	dec	dec	PROPN
ihlr-16500	318	5	.	.	PROPN
ihlr-16500	318	6	2	2	NUM
ihlr-16500	318	7	,	,	PUNCT
ihlr-16500	318	8	2005	2005	NUM
ihlr-16500	318	9	,	,	PUNCT
ihlr-16500	318	10	at	at	ADP
ihlr-16500	318	11	29	29	NUM
ihlr-16500	318	12	,	,	PUNCT
ihlr-16500	318	13	29	29	NUM
ihlr-16500	319	1	[	[	X
ihlr-16500	319	2	hereinafter	hereinafter	NOUN
ihlr-16500	319	3	new	new	PROPN
ihlr-16500	319	4	jersey	jersey	PROPN
ihlr-16500	319	5	jury	jury	NOUN
ihlr-16500	319	6	finds	find	VERB
ihlr-16500	319	7	vioxx	vioxx	NOUN
ihlr-16500	319	8	warnings	warning	NOUN
ihlr-16500	319	9	were	be	AUX
ihlr-16500	319	10	ade­	ade­	ADJ
ihlr-16500	319	11	quate	quate	NOUN
ihlr-16500	319	12	]	]	PUNCT
ihlr-16500	319	13	.	.	PUNCT
ihlr-16500	320	1	73	73	NUM
ihlr-16500	320	2	new	new	ADJ
ihlr-16500	320	3	jersey	jersey	PROPN
ihlr-16500	320	4	jury	jury	NOUN
ihlr-16500	320	5	finds	find	VERB
ihlr-16500	320	6	vioxx	vioxx	NOUN
ihlr-16500	320	7	warnings	warning	NOUN
ihlr-16500	320	8	were	be	AUX
ihlr-16500	320	9	adequate	adequate	ADJ
ihlr-16500	320	10	,	,	PUNCT
ihlr-16500	320	11	supra	supra	PROPN
ihlr-16500	320	12	note	note	NOUN
ihlr-16500	320	13	72	72	NUM
ihlr-16500	320	14	.	.	X
ihlr-16500	321	1	74	74	NUM
ihlr-16500	322	1	i	i	PRON
ihlr-16500	322	2	d.	d.	NOUN
ihlr-16500	322	3	2007	2007	NUM
ihlr-16500	322	4	]	]	PUNCT
ihlr-16500	322	5	pulling	pull	VERB
ihlr-16500	322	6	a	a	DET
ihlr-16500	322	7	blockbuster	blockbuster	ADJ
ihlr-16500	322	8	drug	drug	NOUN
ihlr-16500	322	9	off	off	ADP
ihlr-16500	322	10	the	the	DET
ihlr-16500	322	11	market	market	NOUN
ihlr-16500	322	12	129	129	NUM
ihlr-16500	322	13	tion	tion	NOUN
ihlr-16500	322	14	of	of	ADP
ihlr-16500	322	15	merck	merck	NOUN
ihlr-16500	322	16	's	's	PART
ihlr-16500	322	17	corporate	corporate	ADJ
ihlr-16500	322	18	headquarters	headquarter	NOUN
ihlr-16500	322	19	and	and	CCONJ
ihlr-16500	322	20	the	the	DET
ihlr-16500	322	21	location	location	NOUN
ihlr-16500	322	22	of	of	ADP
ihlr-16500	322	23	more	more	ADJ
ihlr-16500	322	24	than	than	ADP
ihlr-16500	322	25	2,700	2,700	NUM
ihlr-16500	322	26	other	other	ADJ
ihlr-16500	322	27	filed	file	VERB
ihlr-16500	322	28	lawsuits	lawsuit	NOUN
ihlr-16500	322	29	.	.	PUNCT
ihlr-16500	323	1	7s	7	NOUN
ihlr-16500	323	2	nevertheless	nevertheless	ADV
ihlr-16500	323	3	,	,	PUNCT
ihlr-16500	323	4	this	this	DET
ihlr-16500	323	5	victory	victory	NOUN
ihlr-16500	323	6	proved	prove	VERB
ihlr-16500	323	7	that	that	SCONJ
ihlr-16500	323	8	in	in	ADP
ihlr-16500	323	9	any	any	DET
ihlr-16500	323	10	lawsuit	lawsuit	NOUN
ihlr-16500	323	11	against	against	ADP
ihlr-16500	323	12	a	a	DET
ihlr-16500	323	13	major	major	ADJ
ihlr-16500	323	14	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	323	15	company	company	NOUN
ihlr-16500	323	16	(	(	PUNCT
ihlr-16500	323	17	with	with	ADP
ihlr-16500	323	18	deep	deep	ADJ
ihlr-16500	323	19	pockets	pocket	NOUN
ihlr-16500	323	20	and	and	CCONJ
ihlr-16500	323	21	even	even	ADV
ihlr-16500	323	22	deeper	deep	ADJ
ihlr-16500	323	23	resources	resource	NOUN
ihlr-16500	323	24	)	)	PUNCT
ihlr-16500	323	25	,	,	PUNCT
ihlr-16500	323	26	wins	win	NOUN
ihlr-16500	323	27	and	and	CCONJ
ihlr-16500	323	28	losses	loss	NOUN
ihlr-16500	323	29	during	during	ADP
ihlr-16500	323	30	the	the	DET
ihlr-16500	323	31	course	course	NOUN
ihlr-16500	323	32	of	of	ADP
ihlr-16500	323	33	the	the	DET
ihlr-16500	323	34	litigation	litigation	NOUN
ihlr-16500	323	35	process	process	NOUN
ihlr-16500	323	36	depend	depend	VERB
ihlr-16500	323	37	on	on	ADP
ihlr-16500	323	38	the	the	DET
ihlr-16500	323	39	facts	fact	NOUN
ihlr-16500	323	40	as	as	SCONJ
ihlr-16500	323	41	presented	present	VERB
ihlr-16500	323	42	in	in	ADP
ihlr-16500	323	43	individual	individual	ADJ
ihlr-16500	323	44	cases	case	NOUN
ihlr-16500	323	45	.	.	PUNCT
ihlr-16500	324	1	76	76	NUM
ihlr-16500	324	2	the	the	DET
ihlr-16500	324	3	third	third	ADJ
ihlr-16500	324	4	vioxx	vioxx	NOUN
ihlr-16500	324	5	trial	trial	NOUN
ihlr-16500	324	6	and	and	CCONJ
ihlr-16500	324	7	first	first	ADJ
ihlr-16500	324	8	federal	federal	ADJ
ihlr-16500	324	9	trial	trial	NOUN
ihlr-16500	324	10	,	,	PUNCT
ihlr-16500	324	11	plunkett	plunkett	PROPN
ihlr-16500	324	12	v.	v.	PROPN
ihlr-16500	324	13	merck	merck	PROPN
ihlr-16500	324	14	,	,	PUNCT
ihlr-16500	324	15	took	take	VERB
ihlr-16500	324	16	place	place	NOUN
ihlr-16500	324	17	in	in	ADP
ihlr-16500	324	18	houston	houston	PROPN
ihlr-16500	324	19	,	,	PUNCT
ihlr-16500	324	20	texas	texas	PROPN
ihlr-16500	324	21	,	,	PUNCT
ihlr-16500	324	22	and	and	CCONJ
ihlr-16500	324	23	resulted	result	VERB
ihlr-16500	324	24	in	in	ADP
ihlr-16500	324	25	a	a	DET
ihlr-16500	324	26	mistrial	mistrial	NOUN
ihlr-16500	324	27	.	.	PUNCT
ihlr-16500	325	1	77	77	NUM
ihlr-16500	325	2	in	in	ADP
ihlr-16500	325	3	plunkett	plunkett	PROPN
ihlr-16500	326	1	,	,	PUNCT
ihlr-16500	326	2	the	the	DET
ihlr-16500	326	3	trial	trial	NOUN
ihlr-16500	326	4	ended	end	VERB
ihlr-16500	326	5	in	in	ADP
ihlr-16500	326	6	a	a	DET
ihlr-16500	326	7	mistrial	mistrial	NOUN
ihlr-16500	326	8	after	after	SCONJ
ihlr-16500	326	9	the	the	DET
ihlr-16500	326	10	jury	jury	NOUN
ihlr-16500	326	11	could	could	AUX
ihlr-16500	326	12	not	not	PART
ihlr-16500	326	13	reach	reach	VERB
ihlr-16500	326	14	a	a	DET
ihlr-16500	326	15	conclusive	conclusive	ADJ
ihlr-16500	326	16	verdict	verdict	NOUN
ihlr-16500	326	17	after	after	ADP
ihlr-16500	326	18	nearly	nearly	ADV
ihlr-16500	326	19	two	two	NUM
ihlr-16500	326	20	and	and	CCONJ
ihlr-16500	326	21	a	a	DET
ihlr-16500	326	22	half	half	NOUN
ihlr-16500	326	23	days	day	NOUN
ihlr-16500	326	24	of	of	ADP
ihlr-16500	326	25	deliberation	deliberation	NOUN
ihlr-16500	326	26	.	.	PUNCT
ihlr-16500	327	1	78	78	NUM
ihlr-16500	328	1	the	the	DET
ihlr-16500	328	2	judge	judge	NOUN
ihlr-16500	328	3	stated	state	VERB
ihlr-16500	328	4	that	that	SCONJ
ihlr-16500	328	5	"	"	PUNCT
ihlr-16500	328	6	the	the	DET
ihlr-16500	328	7	jury	jury	NOUN
ihlr-16500	328	8	was	be	AUX
ihlr-16500	328	9	split	split	VERB
ihlr-16500	328	10	and	and	CCONJ
ihlr-16500	328	11	unable	unable	ADJ
ihlr-16500	328	12	to	to	PART
ihlr-16500	328	13	agree	agree	VERB
ihlr-16500	328	14	on	on	ADP
ihlr-16500	328	15	a	a	DET
ihlr-16500	328	16	verdict	verdict	NOUN
ihlr-16500	328	17	.	.	PUNCT
ihlr-16500	329	1	"79	"79	PROPN
ihlr-16500	330	1	once	once	ADV
ihlr-16500	330	2	again	again	ADV
ihlr-16500	330	3	,	,	PUNCT
ihlr-16500	330	4	the	the	DET
ihlr-16500	330	5	outcome	outcome	NOUN
ihlr-16500	330	6	of	of	ADP
ihlr-16500	330	7	the	the	DET
ihlr-16500	330	8	trial	trial	NOUN
ihlr-16500	330	9	rested	rest	VERB
ihlr-16500	330	10	on	on	ADP
ihlr-16500	330	11	facts	fact	NOUN
ihlr-16500	330	12	that	that	PRON
ihlr-16500	330	13	ultimately	ultimately	ADV
ihlr-16500	330	14	left	leave	VERB
ihlr-16500	330	15	the	the	DET
ihlr-16500	330	16	jurors	juror	NOUN
ihlr-16500	330	17	deadlocked	deadlocke	VERB
ihlr-16500	330	18	.	.	PUNCT
ihlr-16500	331	1	the	the	DET
ihlr-16500	331	2	three	three	NUM
ihlr-16500	331	3	vioxx	vioxx	NOUN
ihlr-16500	331	4	trials	trial	NOUN
ihlr-16500	331	5	proved	prove	VERB
ihlr-16500	331	6	that	that	SCONJ
ihlr-16500	331	7	pulling	pull	VERB
ihlr-16500	331	8	a	a	DET
ihlr-16500	331	9	blockbuster	blockbuster	ADJ
ihlr-16500	331	10	drug	drug	NOUN
ihlr-16500	331	11	off	off	ADP
ihlr-16500	331	12	the	the	DET
ihlr-16500	331	13	mar­	mar­	NOUN
ihlr-16500	331	14	ket	ket	NOUN
ihlr-16500	331	15	can	can	AUX
ihlr-16500	331	16	have	have	VERB
ihlr-16500	331	17	significant	significant	ADJ
ihlr-16500	331	18	and	and	CCONJ
ihlr-16500	331	19	unpredictable	unpredictable	ADJ
ihlr-16500	331	20	legal	legal	ADJ
ihlr-16500	331	21	consequences	consequence	NOUN
ihlr-16500	331	22	for	for	ADP
ihlr-16500	331	23	both	both	CCONJ
ihlr-16500	331	24	the	the	DET
ihlr-16500	331	25	plaintiff	plaintiff	NOUN
ihlr-16500	331	26	and	and	CCONJ
ihlr-16500	331	27	the	the	DET
ihlr-16500	331	28	defendant	defendant	NOUN
ihlr-16500	331	29	.	.	PUNCT
ihlr-16500	332	1	these	these	DET
ihlr-16500	332	2	trials	trial	NOUN
ihlr-16500	332	3	also	also	ADV
ihlr-16500	332	4	proved	prove	VERB
ihlr-16500	332	5	that	that	SCONJ
ihlr-16500	332	6	extraneous	extraneous	ADJ
ihlr-16500	332	7	factors	factor	NOUN
ihlr-16500	332	8	can	can	AUX
ihlr-16500	332	9	dictate	dictate	VERB
ihlr-16500	332	10	the	the	DET
ihlr-16500	332	11	outcome	outcome	NOUN
ihlr-16500	332	12	of	of	ADP
ihlr-16500	332	13	the	the	DET
ihlr-16500	332	14	trial	trial	NOUN
ihlr-16500	332	15	.	.	PUNCT
ihlr-16500	333	1	for	for	ADP
ihlr-16500	333	2	instance	instance	NOUN
ihlr-16500	333	3	,	,	PUNCT
ihlr-16500	333	4	in	in	ADP
ihlr-16500	333	5	all	all	DET
ihlr-16500	333	6	three	three	NUM
ihlr-16500	333	7	trials	trial	NOUN
ihlr-16500	333	8	,	,	PUNCT
ihlr-16500	333	9	the	the	DET
ihlr-16500	333	10	facts	fact	NOUN
ihlr-16500	333	11	played	play	VERB
ihlr-16500	333	12	a	a	DET
ihlr-16500	333	13	critical	critical	ADJ
ihlr-16500	333	14	role	role	NOUN
ihlr-16500	333	15	in	in	ADP
ihlr-16500	333	16	swaying	sway	VERB
ihlr-16500	333	17	or	or	CCONJ
ihlr-16500	333	18	deadlocking	deadlocke	VERB
ihlr-16500	333	19	the	the	DET
ihlr-16500	333	20	respective	respective	ADJ
ihlr-16500	333	21	juries.80	juries.80	NOUN
ihlr-16500	333	22	in	in	ADP
ihlr-16500	333	23	both	both	CCONJ
ihlr-16500	333	24	the	the	DET
ihlr-16500	333	25	sec­	sec­	ADJ
ihlr-16500	333	26	ond	ond	NOUN
ihlr-16500	333	27	and	and	CCONJ
ihlr-16500	333	28	third	third	ADJ
ihlr-16500	333	29	trials	trial	NOUN
ihlr-16500	333	30	,	,	PUNCT
ihlr-16500	333	31	the	the	DET
ihlr-16500	333	32	individual	individual	ADJ
ihlr-16500	333	33	facts	fact	NOUN
ihlr-16500	333	34	of	of	ADP
ihlr-16500	333	35	each	each	DET
ihlr-16500	333	36	case	case	NOUN
ihlr-16500	333	37	dictated	dictate	VERB
ihlr-16500	333	38	the	the	DET
ihlr-16500	333	39	outcome	outcome	NOUN
ihlr-16500	333	40	in	in	ADP
ihlr-16500	333	41	merck	merck	PROPN
ihlr-16500	333	42	's	's	PART
ihlr-16500	333	43	favor	favor	NOUN
ihlr-16500	333	44	.	.	PUNCT
ihlr-16500	334	1	in	in	ADP
ihlr-16500	334	2	product	product	NOUN
ihlr-16500	334	3	liability	liability	NOUN
ihlr-16500	334	4	cases	case	NOUN
ihlr-16500	334	5	,	,	PUNCT
ihlr-16500	334	6	often	often	ADV
ihlr-16500	334	7	the	the	DET
ihlr-16500	334	8	specific	specific	ADJ
ihlr-16500	334	9	facts	fact	NOUN
ihlr-16500	334	10	,	,	PUNCT
ihlr-16500	334	11	such	such	ADJ
ihlr-16500	334	12	as	as	ADP
ihlr-16500	334	13	the	the	DET
ihlr-16500	334	14	patient	patient	NOUN
ihlr-16500	334	15	's	's	PART
ihlr-16500	334	16	administration	administration	NOUN
ihlr-16500	334	17	of	of	ADP
ihlr-16500	334	18	the	the	DET
ihlr-16500	334	19	pill	pill	NOUN
ihlr-16500	334	20	or	or	CCONJ
ihlr-16500	334	21	the	the	DET
ihlr-16500	334	22	patient	patient	NOUN
ihlr-16500	334	23	's	's	PART
ihlr-16500	334	24	understanding	understanding	NOUN
ihlr-16500	334	25	of	of	ADP
ihlr-16500	334	26	the	the	DET
ihlr-16500	334	27	pre­	pre­	NOUN
ihlr-16500	334	28	scribing	scribe	VERB
ihlr-16500	334	29	information	information	NOUN
ihlr-16500	334	30	,	,	PUNCT
ihlr-16500	334	31	can	can	AUX
ihlr-16500	334	32	play	play	VERB
ihlr-16500	334	33	a	a	DET
ihlr-16500	334	34	pivotal	pivotal	ADJ
ihlr-16500	334	35	role	role	NOUN
ihlr-16500	334	36	in	in	ADP
ihlr-16500	334	37	swaying	sway	VERB
ihlr-16500	334	38	the	the	DET
ihlr-16500	334	39	jury	jury	NOUN
ihlr-16500	334	40	one	one	NUM
ihlr-16500	334	41	way	way	NOUN
ihlr-16500	334	42	or	or	CCONJ
ihlr-16500	334	43	an­	an­	VERB
ihlr-16500	334	44	other.81	other.81	NOUN
ihlr-16500	334	45	another	another	DET
ihlr-16500	334	46	critical	critical	ADJ
ihlr-16500	334	47	factor	factor	NOUN
ihlr-16500	334	48	in	in	ADP
ihlr-16500	334	49	determining	determine	VERB
ihlr-16500	334	50	the	the	DET
ihlr-16500	334	51	outcome	outcome	NOUN
ihlr-16500	334	52	was	be	AUX
ihlr-16500	334	53	the	the	DET
ihlr-16500	334	54	jurisdictional	jurisdictional	ADJ
ihlr-16500	334	55	location	location	NOUN
ihlr-16500	334	56	of	of	ADP
ihlr-16500	334	57	the	the	DET
ihlr-16500	334	58	lawsuit	lawsuit	NOUN
ihlr-16500	334	59	.	.	PUNCT
ihlr-16500	335	1	for	for	ADP
ihlr-16500	335	2	instance	instance	NOUN
ihlr-16500	335	3	,	,	PUNCT
ihlr-16500	335	4	the	the	DET
ihlr-16500	335	5	large	large	ADJ
ihlr-16500	335	6	award	award	NOUN
ihlr-16500	335	7	in	in	ADP
ihlr-16500	335	8	the	the	DET
ihlr-16500	335	9	first	first	ADJ
ihlr-16500	335	10	trial	trial	NOUN
ihlr-16500	335	11	was	be	AUX
ihlr-16500	335	12	not	not	PART
ihlr-16500	335	13	unusual	unusual	ADJ
ihlr-16500	335	14	for	for	ADP
ihlr-16500	335	15	texas	texas	PROPN
ihlr-16500	335	16	.	.	PUNCT
ihlr-16500	336	1	moreover	moreover	ADV
ihlr-16500	336	2	,	,	PUNCT
ihlr-16500	336	3	the	the	DET
ihlr-16500	336	4	second	second	ADJ
ihlr-16500	336	5	trial	trial	NOUN
ihlr-16500	336	6	was	be	AUX
ihlr-16500	336	7	held	hold	VERB
ihlr-16500	336	8	in	in	ADP
ihlr-16500	336	9	new	new	PROPN
ihlr-16500	336	10	jersey	jersey	PROPN
ihlr-16500	336	11	where	where	SCONJ
ihlr-16500	336	12	merck	merck	PROPN
ihlr-16500	336	13	was	be	AUX
ihlr-16500	336	14	incorporated	incorporate	VERB
ihlr-16500	336	15	;	;	PUNCT
ihlr-16500	336	16	therefore	therefore	ADV
ihlr-16500	336	17	,	,	PUNCT
ihlr-16500	336	18	finding	find	VERB
ihlr-16500	336	19	an	an	DET
ihlr-16500	336	20	unbiased	unbiased	ADJ
ihlr-16500	336	21	jury	jury	NOUN
ihlr-16500	336	22	may	may	AUX
ihlr-16500	336	23	have	have	AUX
ihlr-16500	336	24	proven	prove	VERB
ihlr-16500	336	25	difficult	difficult	ADJ
ihlr-16500	336	26	for	for	ADP
ihlr-16500	336	27	the	the	DET
ihlr-16500	336	28	plaintiff	plaintiff	NOUN
ihlr-16500	336	29	.	.	PUNCT
ihlr-16500	337	1	finally	finally	ADV
ihlr-16500	337	2	,	,	PUNCT
ihlr-16500	337	3	all	all	DET
ihlr-16500	337	4	three	three	NUM
ihlr-16500	337	5	trials	trial	NOUN
ihlr-16500	337	6	proved	prove	VERB
ihlr-16500	337	7	that	that	SCONJ
ihlr-16500	337	8	a	a	DET
ihlr-16500	337	9	blockbuster	blockbuster	ADJ
ihlr-16500	337	10	drug	drug	NOUN
ihlr-16500	337	11	being	be	AUX
ihlr-16500	337	12	pulled	pull	VERB
ihlr-16500	337	13	off	off	ADP
ihlr-16500	337	14	the	the	DET
ihlr-16500	337	15	market	market	NOUN
ihlr-16500	337	16	delineates	delineate	VERB
ihlr-16500	337	17	the	the	DET
ihlr-16500	337	18	beginning	beginning	NOUN
ihlr-16500	337	19	of	of	ADP
ihlr-16500	337	20	a	a	DET
ihlr-16500	337	21	long	long	ADJ
ihlr-16500	337	22	road	road	NOUN
ihlr-16500	337	23	oflitigation	oflitigation	NOUN
ihlr-16500	337	24	for	for	ADP
ihlr-16500	337	25	both	both	DET
ihlr-16500	337	26	parties	party	NOUN
ihlr-16500	337	27	.	.	PUNCT
ihlr-16500	338	1	thus	thus	ADV
ihlr-16500	338	2	,	,	PUNCT
ihlr-16500	338	3	much	much	ADJ
ihlr-16500	338	4	like	like	ADP
ihlr-16500	338	5	a	a	DET
ihlr-16500	338	6	boxing	boxing	NOUN
ihlr-16500	338	7	match	match	NOUN
ihlr-16500	338	8	,	,	PUNCT
ihlr-16500	338	9	a	a	DET
ihlr-16500	338	10	resounding	resounding	ADJ
ihlr-16500	338	11	win	win	NOUN
ihlr-16500	338	12	in	in	ADP
ihlr-16500	338	13	any	any	DET
ihlr-16500	338	14	one	one	NUM
ihlr-16500	338	15	round	round	NOUN
ihlr-16500	338	16	can	can	AUX
ihlr-16500	338	17	be	be	AUX
ihlr-16500	338	18	easily	easily	ADV
ihlr-16500	338	19	reversed	reverse	VERB
ihlr-16500	338	20	in	in	ADP
ihlr-16500	338	21	subsequent	subsequent	ADJ
ihlr-16500	338	22	rounds	round	NOUN
ihlr-16500	338	23	.	.	PUNCT
ihlr-16500	339	1	these	these	DET
ihlr-16500	339	2	three	three	NUM
ihlr-16500	339	3	cases	case	NOUN
ihlr-16500	339	4	are	be	AUX
ihlr-16500	339	5	only	only	ADV
ihlr-16500	339	6	a	a	DET
ihlr-16500	339	7	small	small	ADJ
ihlr-16500	339	8	sample	sample	NOUN
ihlr-16500	339	9	of	of	ADP
ihlr-16500	339	10	the	the	DET
ihlr-16500	339	11	cases	case	NOUN
ihlr-16500	339	12	that	that	PRON
ihlr-16500	339	13	merck	merck	NOUN
ihlr-16500	339	14	will	will	AUX
ihlr-16500	339	15	face	face	VERB
ihlr-16500	339	16	75	75	NUM
ihlr-16500	339	17	ld	ld	NOUN
ihlr-16500	339	18	.	.	PROPN
ihlr-16500	339	19	76	76	NUM
ihlr-16500	339	20	/d	/d	PUNCT
ihlr-16500	339	21	.	.	PUNCT
ihlr-16500	340	1	at	at	ADP
ihlr-16500	340	2	the	the	DET
ihlr-16500	340	3	time	time	NOUN
ihlr-16500	340	4	of	of	ADP
ihlr-16500	340	5	the	the	DET
ihlr-16500	340	6	verdict	verdict	NOUN
ihlr-16500	340	7	in	in	ADP
ihlr-16500	340	8	merck	merck	PROPN
ihlr-16500	340	9	's	's	PART
ihlr-16500	340	10	favor	favor	NOUN
ihlr-16500	340	11	,	,	PUNCT
ihlr-16500	340	12	there	there	PRON
ihlr-16500	340	13	were	be	VERB
ihlr-16500	340	14	6,400	6,400	NUM
ihlr-16500	340	15	other	other	ADJ
ihlr-16500	340	16	lawsuits	lawsuit	NOUN
ihlr-16500	340	17	that	that	PRON
ihlr-16500	340	18	had	have	AUX
ihlr-16500	340	19	been	be	AUX
ihlr-16500	340	20	filed	file	VERB
ihlr-16500	340	21	against	against	ADP
ihlr-16500	340	22	merck	merck	PROPN
ihlr-16500	340	23	.	.	PROPN
ihlr-16500	340	24	merck	merck	PROPN
ihlr-16500	340	25	acquitted	acquit	VERB
ihlr-16500	340	26	in	in	ADP
ihlr-16500	340	27	second	second	ADJ
ihlr-16500	340	28	vioxx	vioxx	NOUN
ihlr-16500	340	29	suit	suit	NOUN
ihlr-16500	340	30	,	,	PUNCT
ihlr-16500	340	31	injury	injury	NOUN
ihlr-16500	340	32	help	help	NOUN
ihlr-16500	340	33	line	line	NOUN
ihlr-16500	340	34	,	,	PUNCT
ihlr-16500	340	35	nov	nov	PROPN
ihlr-16500	340	36	.	.	PROPN
ihlr-16500	340	37	10,2005	10,2005	NUM
ihlr-16500	340	38	,	,	PUNCT
ihlr-16500	340	39	http://www.injuryhe1pline.com/index.rwl?category=news&section=phannaceutical	http://www.injuryhe1pline.com/index.rwl?category=news&section=phannaceutical	PROPN
ihlr-16500	340	40	&	&	CCONJ
ihlr-16500	340	41	article	article	NOUN
ihlr-16500	340	42	=	=	NOUN
ihlr-16500	340	43	merck+acquitted+in+second+vioxx+suit&id=	merck+acquitted+in+second+vioxx+suit&id=	PROPN
ihlr-16500	340	44	1901	1901	NUM
ihlr-16500	340	45	.	.	PUNCT
ihlr-16500	341	1	77	77	NUM
ihlr-16500	341	2	jill	jill	PROPN
ihlr-16500	341	3	federal	federal	PROPN
ihlr-16500	341	4	vioxx	vioxx	PROPN
ihlr-16500	341	5	trail	trail	NOUN
ihlr-16500	341	6	ends	end	VERB
ihlr-16500	341	7	in	in	ADP
ihlr-16500	341	8	mzstrial	mzstrial	ADJ
ihlr-16500	341	9	;	;	PUNCT
ihlr-16500	341	10	jury	jury	NOUN
ihlr-16500	341	11	split	split	NOUN
ihlr-16500	341	12	,	,	PUNCT
ihlr-16500	341	13	mealey	mealey	PROPN
ihlr-16500	341	14	's	's	PART
ihlr-16500	341	15	prod	prod	NOUN
ihlr-16500	341	16	.	.	PUNCT
ihlr-16500	342	1	liab	liab	PROPN
ihlr-16500	342	2	.	.	PUNCT
ihlr-16500	343	1	&	&	CCONJ
ihlr-16500	343	2	risk	risk	NOUN
ihlr-16500	343	3	.	.	PUNCT
ihlr-16500	344	1	dec	dec	PROPN
ihlr-16500	344	2	.	.	PROPN
ihlr-16500	344	3	16	16	NUM
ihlr-16500	344	4	,	,	PUNCT
ihlr-16500	344	5	2005	2005	NUM
ihlr-16500	344	6	,	,	PUNCT
ihlr-16500	344	7	at	at	ADP
ihlr-16500	344	8	24	24	NUM
ihlr-16500	344	9	,	,	PUNCT
ihlr-16500	344	10	24	24	NUM
ihlr-16500	344	11	[	[	X
ihlr-16500	344	12	hereinafter	hereinafter	NOUN
ihlr-16500	344	13	jill	jill	PROPN
ihlr-16500	344	14	federal	federal	PROPN
ihlr-16500	344	15	vioxx	vioxx	PROPN
ihlr-16500	344	16	trail	trail	NOUN
ihlr-16500	344	17	ends	end	VERB
ihlr-16500	344	18	in	in	ADP
ihlr-16500	344	19	mzstrial	mzstrial	ADJ
ihlr-16500	344	20	;	;	PUNCT
ihlr-16500	344	21	jury	jury	NOUN
ihlr-16500	344	22	split	split	NOUN
ihlr-16500	344	23	]	]	PUNCT
ihlr-16500	344	24	.	.	PUNCT
ihlr-16500	345	1	78	78	NUM
ihlr-16500	345	2	ld	ld	PROPN
ihlr-16500	345	3	.	.	PROPN
ihlr-16500	345	4	79	79	NUM
ihlr-16500	346	1	jd	jd	PROPN
ihlr-16500	346	2	.	.	PROPN
ihlr-16500	346	3	80	80	NUM
ihlr-16500	346	4	texas	texas	PROPN
ihlr-16500	346	5	jury	jury	NOUN
ihlr-16500	346	6	awards	award	NOUN
ihlr-16500	346	7	$	$	SYM
ihlr-16500	346	8	250	250	NUM
ihlr-16500	346	9	million	million	NUM
ihlr-16500	346	10	in	in	ADP
ihlr-16500	346	11	jill	jill	PROPN
ihlr-16500	346	12	vioxx	vioxx	PROPN
ihlr-16500	346	13	trial	trial	NOUN
ihlr-16500	346	14	,	,	PUNCT
ihlr-16500	346	15	supra	supra	PROPN
ihlr-16500	346	16	note	note	PROPN
ihlr-16500	346	17	68	68	NUM
ihlr-16500	346	18	;	;	PUNCT
ihlr-16500	346	19	new	new	PROPN
ihlr-16500	346	20	jersey	jersey	PROPN
ihlr-16500	346	21	jury	jury	NOUN
ihlr-16500	346	22	finds	find	VERB
ihlr-16500	346	23	vioxx	vioxx	NOUN
ihlr-16500	346	24	warnings	warning	NOUN
ihlr-16500	346	25	were	be	AUX
ihlr-16500	346	26	adequate	adequate	ADJ
ihlr-16500	346	27	,	,	PUNCT
ihlr-16500	346	28	supra	supra	PROPN
ihlr-16500	346	29	note	note	PROPN
ihlr-16500	346	30	72	72	NUM
ihlr-16500	346	31	;	;	PUNCT
ihlr-16500	346	32	jill	jill	PROPN
ihlr-16500	346	33	federal	federal	PROPN
ihlr-16500	346	34	vioxx	vioxx	PROPN
ihlr-16500	346	35	trail	trail	NOUN
ihlr-16500	346	36	ends	end	VERB
ihlr-16500	346	37	in	in	ADP
ihlr-16500	346	38	mistrial	mistrial	NOUN
ihlr-16500	346	39	;	;	PUNCT
ihlr-16500	346	40	jury	jury	NOUN
ihlr-16500	346	41	split	split	NOUN
ihlr-16500	346	42	,	,	PUNCT
ihlr-16500	346	43	supra	supra	PROPN
ihlr-16500	346	44	note	note	NOUN
ihlr-16500	346	45	77	77	NUM
ihlr-16500	346	46	.	.	PUNCT
ihlr-16500	347	1	81	81	NUM
ihlr-16500	348	1	it	it	PRON
ihlr-16500	348	2	should	should	AUX
ihlr-16500	348	3	be	be	AUX
ihlr-16500	348	4	noted	note	VERB
ihlr-16500	348	5	that	that	SCONJ
ihlr-16500	348	6	this	this	PRON
ihlr-16500	348	7	is	be	AUX
ihlr-16500	348	8	not	not	PART
ihlr-16500	348	9	true	true	ADJ
ihlr-16500	348	10	in	in	ADP
ihlr-16500	348	11	every	every	DET
ihlr-16500	348	12	case	case	NOUN
ihlr-16500	348	13	but	but	CCONJ
ihlr-16500	348	14	seemed	seem	VERB
ihlr-16500	348	15	to	to	PART
ihlr-16500	348	16	matter	matter	VERB
ihlr-16500	348	17	in	in	ADP
ihlr-16500	348	18	these	these	DET
ihlr-16500	348	19	early	early	ADJ
ihlr-16500	348	20	vioxx	vioxx	NOUN
ihlr-16500	348	21	cases	case	NOUN
ihlr-16500	348	22	.	.	PUNCT
ihlr-16500	349	1	130	130	NUM
ihlr-16500	349	2	indiana	indiana	PROPN
ihlr-16500	349	3	heal	heal	NOUN
ihlr-16500	349	4	til	til	SCONJ
ihlr-16500	349	5	law	law	NOUN
ihlr-16500	349	6	review	review	NOUN
ihlr-16500	349	7	[	[	X
ihlr-16500	349	8	vol	vol	NOUN
ihlr-16500	349	9	.	.	PUNCT
ihlr-16500	349	10	4:115	4:115	NUM
ihlr-16500	349	11	in	in	ADP
ihlr-16500	349	12	the	the	DET
ihlr-16500	349	13	next	next	ADJ
ihlr-16500	349	14	ten	ten	NUM
ihlr-16500	349	15	years	year	NOUN
ihlr-16500	349	16	.	.	PUNCT
ihlr-16500	350	1	82	82	NUM
ihlr-16500	351	1	these	these	DET
ihlr-16500	351	2	cases	case	NOUN
ihlr-16500	351	3	prove	prove	VERB
ihlr-16500	351	4	that	that	SCONJ
ihlr-16500	351	5	the	the	DET
ihlr-16500	351	6	determining	determine	VERB
ihlr-16500	351	7	factors	factor	NOUN
ihlr-16500	351	8	will	will	AUX
ihlr-16500	351	9	be	be	AUX
ihlr-16500	351	10	the	the	DET
ihlr-16500	351	11	merits	merit	NOUN
ihlr-16500	351	12	of	of	ADP
ihlr-16500	351	13	the	the	DET
ihlr-16500	351	14	respective	respective	ADJ
ihlr-16500	351	15	case	case	NOUN
ihlr-16500	351	16	,	,	PUNCT
ihlr-16500	351	17	the	the	DET
ihlr-16500	351	18	jurisdiction	jurisdiction	NOUN
ihlr-16500	351	19	in	in	ADP
ihlr-16500	351	20	which	which	PRON
ihlr-16500	351	21	the	the	DET
ihlr-16500	351	22	case	case	NOUN
ihlr-16500	351	23	is	be	AUX
ihlr-16500	351	24	tried	try	VERB
ihlr-16500	351	25	,	,	PUNCT
ihlr-16500	351	26	and	and	CCONJ
ihlr-16500	351	27	the	the	DET
ihlr-16500	351	28	trial	trial	NOUN
ihlr-16500	351	29	strategies	strategy	NOUN
ihlr-16500	351	30	employed	employ	VERB
ihlr-16500	351	31	by	by	ADP
ihlr-16500	351	32	the	the	DET
ihlr-16500	351	33	parties	party	NOUN
ihlr-16500	351	34	.	.	PUNCT
ihlr-16500	352	1	a	a	DET
ihlr-16500	352	2	resounding	resounding	ADJ
ihlr-16500	352	3	victory	victory	NOUN
ihlr-16500	352	4	in	in	ADP
ihlr-16500	352	5	one	one	NUM
ihlr-16500	352	6	part	part	NOUN
ihlr-16500	352	7	of	of	ADP
ihlr-16500	352	8	the	the	DET
ihlr-16500	352	9	country	country	NOUN
ihlr-16500	352	10	may	may	AUX
ihlr-16500	352	11	be	be	AUX
ihlr-16500	352	12	inconsequential	inconsequential	ADJ
ihlr-16500	352	13	to	to	ADP
ihlr-16500	352	14	potential	potential	ADJ
ihlr-16500	352	15	plaintiffs	plaintiff	NOUN
ihlr-16500	352	16	in	in	ADP
ihlr-16500	352	17	other	other	ADJ
ihlr-16500	352	18	parts	part	NOUN
ihlr-16500	352	19	of	of	ADP
ihlr-16500	352	20	the	the	DET
ihlr-16500	352	21	country	country	NOUN
ihlr-16500	352	22	.	.	PUNCT
ihlr-16500	353	1	nevertheless	nevertheless	ADV
ihlr-16500	353	2	,	,	PUNCT
ihlr-16500	353	3	the	the	DET
ihlr-16500	353	4	legal	legal	ADJ
ihlr-16500	353	5	consequences	consequence	NOUN
ihlr-16500	353	6	can	can	AUX
ihlr-16500	353	7	greatly	greatly	ADV
ihlr-16500	353	8	affect	affect	VERB
ihlr-16500	353	9	all	all	DET
ihlr-16500	353	10	pharmaceu­	pharmaceu­	PART
ihlr-16500	353	11	tical	tical	ADJ
ihlr-16500	353	12	companies	company	NOUN
ihlr-16500	353	13	and	and	CCONJ
ihlr-16500	353	14	plaintiffs	plaintiff	NOUN
ihlr-16500	353	15	who	who	PRON
ihlr-16500	353	16	use	use	VERB
ihlr-16500	353	17	blockbuster	blockbuster	ADJ
ihlr-16500	353	18	drugs	drug	NOUN
ihlr-16500	353	19	in	in	ADP
ihlr-16500	353	20	the	the	DET
ihlr-16500	353	21	foreseeable	foreseeable	ADJ
ihlr-16500	353	22	fu­	fu­	PROPN
ihlr-16500	353	23	ture	ture	PROPN
ihlr-16500	353	24	.	.	PUNCT
ihlr-16500	354	1	b.	b.	PROPN
ihlr-16500	354	2	criminal	criminal	ADJ
ihlr-16500	354	3	indictments	indictment	NOUN
ihlr-16500	354	4	and	and	CCONJ
ihlr-16500	354	5	substantial	substantial	ADJ
ihlr-16500	354	6	financial	financial	ADJ
ihlr-16500	354	7	penalties	penalty	NOUN
ihlr-16500	354	8	a	a	DET
ihlr-16500	354	9	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	354	10	company	company	NOUN
ihlr-16500	354	11	that	that	PRON
ihlr-16500	354	12	pulls	pull	VERB
ihlr-16500	354	13	a	a	DET
ihlr-16500	354	14	blockbuster	blockbuster	ADJ
ihlr-16500	354	15	drug	drug	NOUN
ihlr-16500	354	16	off	off	ADP
ihlr-16500	354	17	the	the	DET
ihlr-16500	354	18	market	market	NOUN
ihlr-16500	354	19	ei­	ei­	AUX
ihlr-16500	354	20	ther	ther	ADV
ihlr-16500	354	21	voluntarily	voluntarily	ADV
ihlr-16500	354	22	or	or	CCONJ
ihlr-16500	354	23	involuntarily	involuntarily	ADV
ihlr-16500	354	24	is	be	AUX
ihlr-16500	354	25	likely	likely	ADJ
ihlr-16500	354	26	to	to	PART
ihlr-16500	354	27	receive	receive	VERB
ihlr-16500	354	28	major	major	ADJ
ihlr-16500	354	29	media	medium	NOUN
ihlr-16500	354	30	attention	attention	NOUN
ihlr-16500	354	31	.	.	PUNCT
ihlr-16500	355	1	most	most	ADJ
ihlr-16500	355	2	drugs	drug	NOUN
ihlr-16500	355	3	are	be	AUX
ihlr-16500	355	4	pulled	pull	VERB
ihlr-16500	355	5	off	off	ADP
ihlr-16500	355	6	the	the	DET
ihlr-16500	355	7	market	market	NOUN
ihlr-16500	355	8	because	because	SCONJ
ihlr-16500	355	9	there	there	PRON
ihlr-16500	355	10	is	be	VERB
ihlr-16500	355	11	indisputable	indisputable	ADJ
ihlr-16500	355	12	evidence	evidence	NOUN
ihlr-16500	355	13	that	that	SCONJ
ihlr-16500	355	14	the	the	DET
ihlr-16500	355	15	drug	drug	NOUN
ihlr-16500	355	16	has	have	AUX
ihlr-16500	355	17	caused	cause	VERB
ihlr-16500	355	18	health	health	NOUN
ihlr-16500	355	19	problems	problem	NOUN
ihlr-16500	355	20	in	in	ADP
ihlr-16500	355	21	those	those	PRON
ihlr-16500	355	22	who	who	PRON
ihlr-16500	355	23	used	use	VERB
ihlr-16500	355	24	the	the	DET
ihlr-16500	355	25	drug	drug	NOUN
ihlr-16500	355	26	.	.	PUNCT
ihlr-16500	356	1	as	as	ADP
ihlr-16500	356	2	a	a	DET
ihlr-16500	356	3	result	result	NOUN
ihlr-16500	356	4	,	,	PUNCT
ihlr-16500	356	5	the	the	DET
ihlr-16500	356	6	next	next	ADJ
ihlr-16500	356	7	logical	logical	ADJ
ihlr-16500	356	8	step	step	NOUN
ihlr-16500	356	9	is	be	AUX
ihlr-16500	356	10	to	to	PART
ihlr-16500	356	11	question	question	VERB
ihlr-16500	356	12	those	those	PRON
ihlr-16500	356	13	involved	involve	VERB
ihlr-16500	356	14	in	in	ADP
ihlr-16500	356	15	the	the	DET
ihlr-16500	356	16	development	development	NOUN
ihlr-16500	356	17	and	and	CCONJ
ihlr-16500	356	18	manufac­	manufac­	PROPN
ihlr-16500	356	19	turing	turing	NOUN
ihlr-16500	356	20	of	of	ADP
ihlr-16500	356	21	the	the	DET
ihlr-16500	356	22	drug	drug	NOUN
ihlr-16500	356	23	and	and	CCONJ
ihlr-16500	356	24	to	to	PART
ihlr-16500	356	25	determine	determine	VERB
ihlr-16500	356	26	if	if	SCONJ
ihlr-16500	356	27	such	such	ADJ
ihlr-16500	356	28	information	information	NOUN
ihlr-16500	356	29	could	could	AUX
ihlr-16500	356	30	have	have	AUX
ihlr-16500	356	31	been	be	AUX
ihlr-16500	356	32	re­	re­	AUX
ihlr-16500	356	33	vealed	veale	VERB
ihlr-16500	356	34	earlier	early	ADV
ihlr-16500	356	35	.	.	PUNCT
ihlr-16500	357	1	accordingly	accordingly	ADV
ihlr-16500	357	2	,	,	PUNCT
ihlr-16500	357	3	if	if	SCONJ
ihlr-16500	357	4	personnel	personnel	NOUN
ihlr-16500	357	5	within	within	ADP
ihlr-16500	357	6	the	the	DET
ihlr-16500	357	7	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	357	8	company	company	NOUN
ihlr-16500	357	9	had	have	VERB
ihlr-16500	357	10	the	the	DET
ihlr-16500	357	11	information	information	NOUN
ihlr-16500	357	12	and	and	CCONJ
ihlr-16500	357	13	failed	fail	VERB
ihlr-16500	357	14	to	to	PART
ihlr-16500	357	15	reveal	reveal	VERB
ihlr-16500	357	16	its	its	PRON
ihlr-16500	357	17	contents	content	NOUN
ihlr-16500	357	18	to	to	ADP
ihlr-16500	357	19	the	the	DET
ihlr-16500	357	20	fda	fda	PROPN
ihlr-16500	357	21	or	or	CCONJ
ihlr-16500	357	22	to	to	ADP
ihlr-16500	357	23	decision	decision	NOUN
ihlr-16500	357	24	makers	maker	NOUN
ihlr-16500	357	25	within	within	ADP
ihlr-16500	357	26	the	the	DET
ihlr-16500	357	27	company	company	NOUN
ihlr-16500	357	28	,	,	PUNCT
ihlr-16500	357	29	not	not	PART
ihlr-16500	357	30	only	only	ADV
ihlr-16500	357	31	is	be	AUX
ihlr-16500	357	32	the	the	DET
ihlr-16500	357	33	company	company	NOUN
ihlr-16500	357	34	subject	subject	ADJ
ihlr-16500	357	35	to	to	ADP
ihlr-16500	357	36	civil	civil	ADJ
ihlr-16500	357	37	lawsuits	lawsuit	NOUN
ihlr-16500	357	38	,	,	PUNCT
ihlr-16500	357	39	but	but	CCONJ
ihlr-16500	357	40	those	those	PRON
ihlr-16500	357	41	who	who	PRON
ihlr-16500	357	42	failed	fail	VERB
ihlr-16500	357	43	to	to	PART
ihlr-16500	357	44	disclose	disclose	VERB
ihlr-16500	357	45	the	the	DET
ihlr-16500	357	46	information	information	NOUN
ihlr-16500	357	47	may	may	AUX
ihlr-16500	357	48	be	be	AUX
ihlr-16500	357	49	criminally	criminally	ADV
ihlr-16500	357	50	prosecuted	prosecute	VERB
ihlr-16500	357	51	and	and	CCONJ
ihlr-16500	357	52	the	the	DET
ihlr-16500	357	53	company	company	NOUN
ihlr-16500	357	54	may	may	AUX
ihlr-16500	357	55	be	be	AUX
ihlr-16500	357	56	penalized	penalize	VERB
ihlr-16500	357	57	through	through	ADP
ihlr-16500	357	58	large	large	ADJ
ihlr-16500	357	59	fines	fine	NOUN
ihlr-16500	357	60	.	.	PUNCT
ihlr-16500	358	1	in	in	ADP
ihlr-16500	358	2	such	such	DET
ihlr-16500	358	3	a	a	DET
ihlr-16500	358	4	case	case	NOUN
ihlr-16500	358	5	,	,	PUNCT
ihlr-16500	358	6	criminal	criminal	ADJ
ihlr-16500	358	7	indictments	indictment	NOUN
ihlr-16500	358	8	will	will	AUX
ihlr-16500	358	9	probably	probably	ADV
ihlr-16500	358	10	be	be	AUX
ihlr-16500	358	11	filed	file	VERB
ihlr-16500	358	12	because	because	SCONJ
ihlr-16500	358	13	of	of	ADP
ihlr-16500	358	14	the	the	DET
ihlr-16500	358	15	potential	potential	ADJ
ihlr-16500	358	16	severity	severity	NOUN
ihlr-16500	358	17	of	of	ADP
ihlr-16500	358	18	such	such	DET
ihlr-16500	358	19	a	a	DET
ihlr-16500	358	20	situation	situation	NOUN
ihlr-16500	358	21	.	.	PUNCT
ihlr-16500	359	1	it	it	PRON
ihlr-16500	359	2	is	be	AUX
ihlr-16500	359	3	inexcusable	inexcusable	ADJ
ihlr-16500	359	4	for	for	SCONJ
ihlr-16500	359	5	a	a	DET
ihlr-16500	359	6	company	company	NOUN
ihlr-16500	359	7	to	to	PART
ihlr-16500	359	8	withhold	withhold	VERB
ihlr-16500	359	9	information	information	NOUN
ihlr-16500	359	10	proving	prove	VERB
ihlr-16500	359	11	that	that	SCONJ
ihlr-16500	359	12	a	a	DET
ihlr-16500	359	13	drug	drug	NOUN
ihlr-16500	359	14	could	could	AUX
ihlr-16500	359	15	be	be	AUX
ihlr-16500	359	16	potentially	potentially	ADV
ihlr-16500	359	17	harmful	harmful	ADJ
ihlr-16500	359	18	to	to	ADP
ihlr-16500	359	19	those	those	DET
ihlr-16500	359	20	patients	patient	NOUN
ihlr-16500	359	21	whom	whom	PRON
ihlr-16500	359	22	it	it	PRON
ihlr-16500	359	23	is	be	AUX
ihlr-16500	359	24	intended	intend	VERB
ihlr-16500	359	25	to	to	PART
ihlr-16500	359	26	benefit	benefit	VERB
ihlr-16500	359	27	.	.	PUNCT
ihlr-16500	360	1	a	a	DET
ihlr-16500	360	2	little	little	ADJ
ihlr-16500	360	3	over	over	ADP
ihlr-16500	360	4	a	a	PRON
ihlr-16500	360	5	month	month	NOUN
ihlr-16500	360	6	after	after	ADP
ihlr-16500	360	7	pulling	pull	VERB
ihlr-16500	360	8	vioxx	vioxx	NOUN
ihlr-16500	360	9	off	off	ADP
ihlr-16500	360	10	the	the	DET
ihlr-16500	360	11	market	market	NOUN
ihlr-16500	360	12	,	,	PUNCT
ihlr-16500	360	13	merck	merck	PROPN
ihlr-16500	360	14	revealed	reveal	VERB
ihlr-16500	360	15	that	that	SCONJ
ihlr-16500	360	16	it	it	PRON
ihlr-16500	360	17	had	have	AUX
ihlr-16500	360	18	been	be	AUX
ihlr-16500	360	19	subpoenaed	subpoena	VERB
ihlr-16500	360	20	by	by	ADP
ihlr-16500	360	21	the	the	DET
ihlr-16500	360	22	justice	justice	PROPN
ihlr-16500	360	23	department	department	PROPN
ihlr-16500	360	24	concerning	concern	VERB
ihlr-16500	360	25	an	an	DET
ihlr-16500	360	26	investiga­	investiga­	ADJ
ihlr-16500	360	27	tion	tion	NOUN
ihlr-16500	360	28	into	into	ADP
ihlr-16500	360	29	the	the	DET
ihlr-16500	360	30	methods	method	NOUN
ihlr-16500	360	31	merck	merck	PROPN
ihlr-16500	360	32	had	have	AUX
ihlr-16500	360	33	used	use	VERB
ihlr-16500	360	34	to	to	PART
ihlr-16500	360	35	market	market	VERB
ihlr-16500	360	36	and	and	CCONJ
ihlr-16500	360	37	sell	sell	VERB
ihlr-16500	360	38	vioxx	vioxx	NOUN
ihlr-16500	360	39	.	.	PUNCT
ihlr-16500	361	1	83	83	NUM
ihlr-16500	361	2	in	in	ADP
ihlr-16500	361	3	subse­	subse­	PROPN
ihlr-16500	361	4	quent	quent	PROPN
ihlr-16500	361	5	cases	case	NOUN
ihlr-16500	361	6	against	against	ADP
ihlr-16500	361	7	merck	merck	PROPN
ihlr-16500	361	8	,	,	PUNCT
ihlr-16500	361	9	plaintiffs	plaintiff	NOUN
ihlr-16500	361	10	'	'	PART
ihlr-16500	361	11	attorneys	attorney	NOUN
ihlr-16500	361	12	are	be	AUX
ihlr-16500	361	13	likely	likely	ADJ
ihlr-16500	361	14	to	to	PART
ihlr-16500	361	15	point	point	VERB
ihlr-16500	361	16	to	to	ADP
ihlr-16500	361	17	internal	internal	ADJ
ihlr-16500	361	18	merck	merck	NOUN
ihlr-16500	361	19	memoranda	memoranda	NOUN
ihlr-16500	361	20	that	that	PRON
ihlr-16500	361	21	had	have	VERB
ihlr-16500	361	22	at	at	ADV
ihlr-16500	361	23	least	least	ADV
ihlr-16500	361	24	three	three	NUM
ihlr-16500	361	25	programs	program	NOUN
ihlr-16500	361	26	to	to	PART
ihlr-16500	361	27	train	train	VERB
ihlr-16500	361	28	sales	sale	NOUN
ihlr-16500	361	29	representatives	representative	NOUN
ihlr-16500	361	30	"	"	PUNCT
ihlr-16500	361	31	to	to	PART
ihlr-16500	361	32	misstate	misstate	VERB
ihlr-16500	361	33	and	and	CCONJ
ihlr-16500	361	34	misrepresent	misrepresent	VERB
ihlr-16500	361	35	the	the	DET
ihlr-16500	361	36	truly	truly	ADV
ihlr-16500	361	37	dangerous	dangerous	ADJ
ihlr-16500	361	38	nature	nature	NOUN
ihlr-16500	361	39	ofvioxx	ofvioxx	ADV
ihlr-16500	361	40	to	to	PART
ihlr-16500	361	41	prescrib­	prescrib­	VERB
ihlr-16500	361	42	ing	ing	ADJ
ihlr-16500	361	43	physicians	physician	NOUN
ihlr-16500	361	44	,	,	PUNCT
ihlr-16500	361	45	"	"	PUNCT
ihlr-16500	361	46	including	include	VERB
ihlr-16500	361	47	a	a	DET
ihlr-16500	361	48	company	company	NOUN
ihlr-16500	361	49	document	document	NOUN
ihlr-16500	361	50	that	that	PRON
ihlr-16500	361	51	alerted	alert	VERB
ihlr-16500	361	52	sales	sale	NOUN
ihlr-16500	361	53	reps	rep	NOUN
ihlr-16500	361	54	to	to	PART
ihlr-16500	361	55	dodge	dodge	VERB
ihlr-16500	361	56	tough	tough	ADJ
ihlr-16500	361	57	questions	question	NOUN
ihlr-16500	361	58	from	from	ADP
ihlr-16500	361	59	physicians.84	physicians.84	PROPN
ihlr-16500	361	60	in	in	ADP
ihlr-16500	361	61	addition	addition	NOUN
ihlr-16500	361	62	,	,	PUNCT
ihlr-16500	361	63	plaintiffs	plaintiff	NOUN
ihlr-16500	361	64	'	'	PART
ihlr-16500	361	65	attorneys	attorney	NOUN
ihlr-16500	361	66	will	will	AUX
ihlr-16500	361	67	also	also	ADV
ihlr-16500	361	68	use	use	VERB
ihlr-16500	361	69	internal	internal	ADJ
ihlr-16500	361	70	merck	merck	NOUN
ihlr-16500	361	71	e	e	NOUN
ihlr-16500	361	72	-	-	NOUN
ihlr-16500	361	73	mails	mail	NOUN
ihlr-16500	361	74	and	and	CCONJ
ihlr-16500	361	75	marketing	marketing	NOUN
ihlr-16500	361	76	materials	material	NOUN
ihlr-16500	361	77	as	as	ADV
ihlr-16500	361	78	well	well	ADV
ihlr-16500	361	79	as	as	ADP
ihlr-16500	361	80	interviews	interview	NOUN
ihlr-16500	361	81	with	with	ADP
ihlr-16500	361	82	outside	outside	ADJ
ihlr-16500	361	83	scientists	scientist	NOUN
ihlr-16500	361	84	to	to	PART
ihlr-16500	361	85	show	show	VERB
ihlr-16500	361	86	that	that	SCONJ
ihlr-16500	361	87	the	the	DET
ihlr-16500	361	88	company	company	NOUN
ihlr-16500	361	89	fought	fight	VERB
ihlr-16500	361	90	hard	hard	ADV
ihlr-16500	361	91	to	to	PART
ihlr-16500	361	92	keep	keep	VERB
ihlr-16500	361	93	safety	safety	NOUN
ihlr-16500	361	94	concerns	concern	NOUN
ihlr-16500	361	95	82	82	NUM
ihlr-16500	361	96	there	there	PRON
ihlr-16500	361	97	have	have	AUX
ihlr-16500	361	98	been	be	AUX
ihlr-16500	361	99	several	several	ADJ
ihlr-16500	361	100	cases	case	NOUN
ihlr-16500	361	101	following	follow	VERB
ihlr-16500	361	102	the	the	DET
ihlr-16500	361	103	initial	initial	ADJ
ihlr-16500	361	104	three	three	NUM
ihlr-16500	361	105	publicized	publicize	VERB
ihlr-16500	361	106	cases	case	NOUN
ihlr-16500	361	107	.	.	PUNCT
ihlr-16500	362	1	see	see	VERB
ihlr-16500	362	2	brooks	brooks	PROPN
ihlr-16500	362	3	v.	v.	PROPN
ihlr-16500	362	4	merck	merck	PROPN
ihlr-16500	362	5	&	&	CCONJ
ihlr-16500	362	6	co.	co.	PROPN
ihlr-16500	362	7	inc	inc	PROPN
ihlr-16500	362	8	.	.	PROPN
ihlr-16500	362	9	,	,	PUNCT
ihlr-16500	362	10	443	443	NUM
ihlr-16500	362	11	f.	f.	PROPN
ihlr-16500	362	12	supp	supp	PROPN
ihlr-16500	362	13	.	.	PUNCT
ihlr-16500	363	1	2d	2d	NOUN
ihlr-16500	363	2	994	994	NUM
ihlr-16500	363	3	(	(	PUNCT
ihlr-16500	363	4	s.d.lll	s.d.lll	PROPN
ihlr-16500	363	5	.	.	PUNCT
ihlr-16500	364	1	2006	2006	NUM
ihlr-16500	364	2	)	)	PUNCT
ihlr-16500	365	1	;	;	PUNCT
ihlr-16500	365	2	see	see	VERB
ihlr-16500	365	3	also	also	ADV
ihlr-16500	365	4	melton	melton	PROPN
ihlr-16500	365	5	v.	v.	PROPN
ihlr-16500	365	6	merck	merck	PROPN
ihlr-16500	365	7	&	&	CCONJ
ihlr-16500	365	8	co.	co.	PROPN
ihlr-16500	365	9	inc	inc	PROPN
ihlr-16500	365	10	,	,	PUNCT
ihlr-16500	365	11	2006	2006	NUM
ihlr-16500	365	12	u.s	u.s	PROPN
ihlr-16500	365	13	.	.	PROPN
ihlr-16500	365	14	dist	dist	PROPN
ihlr-16500	365	15	.	.	PUNCT
ihlr-16500	366	1	lexis	lexis	NOUN
ihlr-16500	366	2	37376	37376	NUM
ihlr-16500	366	3	(	(	PUNCT
ihlr-16500	366	4	b.d	b.d	PROPN
ihlr-16500	366	5	.	.	PROPN
ihlr-16500	366	6	ky	ky	PROPN
ihlr-16500	366	7	.	.	PROPN
ihlr-16500	367	1	june	june	PROPN
ihlr-16500	367	2	l	l	PROPN
ihlr-16500	367	3	,	,	PUNCT
ihlr-16500	367	4	2006	2006	NUM
ihlr-16500	367	5	)	)	PUNCT
ihlr-16500	367	6	;	;	PUNCT
ihlr-16500	367	7	see	see	VERB
ihlr-16500	367	8	also	also	ADV
ihlr-16500	367	9	salinas	salinas	PROPN
ihlr-16500	367	10	v.	v.	PROPN
ihlr-16500	367	11	merck	merck	PROPN
ihlr-16500	367	12	&	&	CCONJ
ihlr-16500	367	13	co.	co.	PROPN
ihlr-16500	367	14	inc	inc	PROPN
ihlr-16500	367	15	.	.	PROPN
ihlr-16500	367	16	,	,	PUNCT
ihlr-16500	367	17	2006	2006	NUM
ihlr-16500	367	18	u.s	u.s	PROPN
ihlr-16500	367	19	.	.	PROPN
ihlr-16500	367	20	dist	dist	PROPN
ihlr-16500	367	21	.	.	PUNCT
ihlr-16500	368	1	lexis	lexis	PROPN
ihlr-16500	368	2	12196	12196	NUM
ihlr-16500	368	3	(	(	PUNCT
ihlr-16500	368	4	s.d	s.d	PROPN
ihlr-16500	368	5	.	.	PUNCT
ihlr-16500	369	1	tex	tex	PROPN
ihlr-16500	369	2	.	.	PROPN
ihlr-16500	369	3	mar	mar	PROPN
ihlr-16500	369	4	.	.	PROPN
ihlr-16500	369	5	7	7	NUM
ihlr-16500	369	6	,	,	PUNCT
ihlr-16500	369	7	2006	2006	NUM
ihlr-16500	369	8	)	)	PUNCT
ihlr-16500	369	9	.	.	PUNCT
ihlr-16500	370	1	83	83	NUM
ihlr-16500	370	2	amy	amy	PROPN
ihlr-16500	370	3	barrett	barrett	PROPN
ihlr-16500	370	4	,	,	PUNCT
ihlr-16500	370	5	merck	merck	PROPN
ihlr-16500	370	6	:	:	PUNCT
ihlr-16500	370	7	how	how	SCONJ
ihlr-16500	370	8	much	much	ADJ
ihlr-16500	370	9	misery	misery	NOUN
ihlr-16500	370	10	after	after	ADP
ihlr-16500	370	11	vioxx	vioxx	NOUN
ihlr-16500	370	12	?	?	PUNCT
ihlr-16500	371	1	bankruptcy	bankruptcy	NOUN
ihlr-16500	371	2	seems	seem	VERB
ihlr-16500	371	3	unlikely	unlikely	ADJ
ihlr-16500	371	4	,	,	PUNCT
ihlr-16500	371	5	but	but	CCONJ
ihlr-16500	371	6	lawsuits	lawsuit	NOUN
ihlr-16500	371	7	could	could	AUX
ihlr-16500	371	8	be	be	AUX
ihlr-16500	371	9	a	a	DET
ihlr-16500	371	10	drain	drain	NOUN
ihlr-16500	371	11	for	for	ADP
ihlr-16500	371	12	years	year	NOUN
ihlr-16500	371	13	,	,	PUNCT
ihlr-16500	371	14	bus	bus	NOUN
ihlr-16500	371	15	.	.	PUNCT
ihlr-16500	372	1	wk	wk	INTJ
ihlr-16500	372	2	.	.	PROPN
ihlr-16500	372	3	onune	onune	PROPN
ihlr-16500	372	4	,	,	PUNCT
ihlr-16500	372	5	nov	nov	PROPN
ihlr-16500	372	6	.	.	PROPN
ihlr-16500	372	7	22	22	NUM
ihlr-16500	372	8	,	,	PUNCT
ihlr-16500	372	9	2004	2004	NUM
ihlr-16500	372	10	,	,	PUNCT
ihlr-16500	372	11	http://www.businessweek.com/magazine/content/04	http://www.businessweek.com/magazine/content/04	X
ihlr-16500	372	12	_	_	PROPN
ihlr-16500	372	13	47	47	NUM
ihlr-16500	372	14	/	/	SYM
ihlr-16500	372	15	b3909051_mz011.htm?chan	b3909051_mz011.htm?chan	NOUN
ihlr-16500	372	16	=	=	NOUN
ihlr-16500	372	17	search	search	NOUN
ihlr-16500	372	18	.	.	PUNCT
ihlr-16500	373	1	84	84	NUM
ihlr-16500	373	2	cindi	cindi	PROPN
ihlr-16500	373	3	solomon	solomon	PROPN
ihlr-16500	373	4	&	&	CCONJ
ihlr-16500	373	5	sandy	sandy	PROPN
ihlr-16500	373	6	summers	summer	NOUN
ihlr-16500	373	7	,	,	PUNCT
ihlr-16500	373	8	vioxx	vioxx	NOUN
ihlr-16500	373	9	:	:	PUNCT
ihlr-16500	373	10	birth	birth	NOUN
ihlr-16500	373	11	and	and	CCONJ
ihlr-16500	373	12	death	death	NOUN
ihlr-16500	373	13	of	of	ADP
ihlr-16500	373	14	a	a	DET
ihlr-16500	373	15	super	super	ADJ
ihlr-16500	373	16	aspirin	aspirin	NOUN
ihlr-16500	373	17	,	,	PUNCT
ihlr-16500	373	18	1	1	NUM
ihlr-16500	373	19	-	-	SYM
ihlr-16500	373	20	6	6	NUM
ihlr-16500	373	21	mealey	mealey	NOUN
ihlr-16500	373	22	's	's	PART
ihlr-16500	373	23	lmg	lmg	PROPN
ihlr-16500	373	24	.	.	PUNCT
ihlr-16500	373	25	rep	rep	PROPN
ihlr-16500	373	26	.	.	PROPN
ihlr-16500	373	27	a	a	DET
ihlr-16500	373	28	:	:	PUNCT
ihlr-16500	373	29	r1hritis	r1hritis	ADJ
ihlr-16500	373	30	drugs	drug	NOUN
ihlr-16500	373	31	15	15	NUM
ihlr-16500	373	32	(	(	PUNCT
ihlr-16500	373	33	2004	2004	NUM
ihlr-16500	373	34	)	)	PUNCT
ihlr-16500	373	35	.	.	PUNCT
ihlr-16500	374	1	2007	2007	NUM
ihlr-16500	374	2	]	]	PUNCT
ihlr-16500	374	3	pulling	pull	VERB
ihlr-16500	374	4	a	a	DET
ihlr-16500	374	5	blockbuster	blockbuster	ADJ
ihlr-16500	374	6	drug	drug	NOUN
ihlr-16500	374	7	off	off	ADP
ihlr-16500	374	8	the	the	DET
ihlr-16500	374	9	market	market	NOUN
ihlr-16500	374	10	131	131	NUM
ihlr-16500	374	11	from	from	ADP
ihlr-16500	374	12	destroying	destroy	VERB
ihlr-16500	374	13	the	the	DET
ihlr-16500	374	14	drug	drug	NOUN
ihlr-16500	374	15	's	's	PART
ihlr-16500	374	16	profit.8s	profit.8s	PROPN
ihlr-16500	374	17	furthermore	furthermore	ADV
ihlr-16500	374	18	,	,	PUNCT
ihlr-16500	374	19	in	in	ADP
ihlr-16500	374	20	2005	2005	NUM
ihlr-16500	374	21	,	,	PUNCT
ihlr-16500	374	22	the	the	DET
ihlr-16500	374	23	new	new	PROPN
ihlr-16500	374	24	england	england	PROPN
ihlr-16500	374	25	journal	journal	PROPN
ihlr-16500	374	26	of	of	ADP
ihlr-16500	374	27	medicine	medicine	NOUN
ihlr-16500	374	28	claimed	claim	VERB
ihlr-16500	374	29	that	that	SCONJ
ihlr-16500	374	30	the	the	DET
ihlr-16500	374	31	authors	author	NOUN
ihlr-16500	374	32	of	of	ADP
ihlr-16500	374	33	vigor	vigor	NOUN
ihlr-16500	374	34	,	,	PUNCT
ihlr-16500	374	35	a	a	DET
ihlr-16500	374	36	landmark	landmark	NOUN
ihlr-16500	374	37	vioxx	vioxx	NOUN
ihlr-16500	374	38	clinical	clinical	ADJ
ihlr-16500	374	39	outcomes	outcome	NOUN
ihlr-16500	374	40	trial	trial	NOUN
ihlr-16500	374	41	,	,	PUNCT
ihlr-16500	374	42	erased	erase	VERB
ihlr-16500	374	43	data	datum	NOUN
ihlr-16500	374	44	suggesting	suggest	VERB
ihlr-16500	374	45	that	that	SCONJ
ihlr-16500	374	46	three	three	NUM
ihlr-16500	374	47	patients	patient	NOUN
ihlr-16500	374	48	who	who	PRON
ihlr-16500	374	49	took	take	VERB
ihlr-16500	374	50	vi­	vi­	NOUN
ihlr-16500	374	51	oxx	oxx	PROPN
ihlr-16500	374	52	in	in	ADP
ihlr-16500	374	53	the	the	DET
ihlr-16500	374	54	trial	trial	NOUN
ihlr-16500	374	55	suffered	suffer	VERB
ihlr-16500	374	56	heart	heart	NOUN
ihlr-16500	374	57	attacks	attack	NOUN
ihlr-16500	374	58	.	.	PUNCT
ihlr-16500	375	1	86	86	NUM
ihlr-16500	376	1	although	although	SCONJ
ihlr-16500	376	2	there	there	PRON
ihlr-16500	376	3	is	be	VERB
ihlr-16500	376	4	mounting	mount	VERB
ihlr-16500	376	5	evidence	evidence	NOUN
ihlr-16500	376	6	that	that	PRON
ihlr-16500	376	7	merck	merck	PROPN
ihlr-16500	376	8	employees	employee	NOUN
ihlr-16500	376	9	knew	know	VERB
ihlr-16500	376	10	about	about	ADP
ihlr-16500	376	11	vioxx	vioxx	NOUN
ihlr-16500	376	12	's	's	PART
ihlr-16500	376	13	safety	safety	NOUN
ihlr-16500	376	14	problems	problem	NOUN
ihlr-16500	376	15	,	,	PUNCT
ihlr-16500	376	16	the	the	DET
ihlr-16500	376	17	justice	justice	NOUN
ihlr-16500	376	18	de­	de­	VERB
ihlr-16500	376	19	partment	partment	NOUN
ihlr-16500	376	20	has	have	VERB
ihlr-16500	376	21	yet	yet	ADV
ihlr-16500	376	22	to	to	PART
ihlr-16500	376	23	file	file	VERB
ihlr-16500	376	24	any	any	DET
ihlr-16500	376	25	criminal	criminal	ADJ
ihlr-16500	376	26	indictments	indictment	NOUN
ihlr-16500	376	27	against	against	ADP
ihlr-16500	376	28	merck	merck	PROPN
ihlr-16500	376	29	.	.	PUNCT
ihlr-16500	377	1	in	in	ADP
ihlr-16500	377	2	the	the	DET
ihlr-16500	377	3	past	past	NOUN
ihlr-16500	377	4	,	,	PUNCT
ihlr-16500	377	5	a	a	DET
ihlr-16500	377	6	company	company	NOUN
ihlr-16500	377	7	's	's	PART
ihlr-16500	377	8	voluntary	voluntary	ADJ
ihlr-16500	377	9	withdrawal	withdrawal	NOUN
ihlr-16500	377	10	of	of	ADP
ihlr-16500	377	11	a	a	DET
ihlr-16500	377	12	blockbuster	blockbuster	ADJ
ihlr-16500	377	13	drug	drug	NOUN
ihlr-16500	377	14	did	do	AUX
ihlr-16500	377	15	not	not	PART
ihlr-16500	377	16	result	result	VERB
ihlr-16500	377	17	in	in	ADP
ihlr-16500	377	18	criminal	criminal	ADJ
ihlr-16500	377	19	indictments	indictment	NOUN
ihlr-16500	377	20	against	against	ADP
ihlr-16500	377	21	decision	decision	NOUN
ihlr-16500	377	22	makers	maker	NOUN
ihlr-16500	377	23	within	within	ADP
ihlr-16500	377	24	the	the	DET
ihlr-16500	377	25	company	company	NOUN
ihlr-16500	377	26	because	because	SCONJ
ihlr-16500	377	27	in	in	ADP
ihlr-16500	377	28	doing	do	VERB
ihlr-16500	377	29	so	so	ADV
ihlr-16500	377	30	the	the	DET
ihlr-16500	377	31	company	company	NOUN
ihlr-16500	377	32	conceded	concede	VERB
ihlr-16500	377	33	the	the	DET
ihlr-16500	377	34	drug	drug	NOUN
ihlr-16500	377	35	's	's	PART
ihlr-16500	377	36	lack	lack	NOUN
ihlr-16500	377	37	of	of	ADP
ihlr-16500	377	38	safety	safety	NOUN
ihlr-16500	377	39	and	and	CCONJ
ihlr-16500	377	40	as	as	ADP
ihlr-16500	377	41	a	a	DET
ihlr-16500	377	42	result	result	NOUN
ihlr-16500	377	43	attempted	attempt	VERB
ihlr-16500	377	44	to	to	PART
ihlr-16500	377	45	rectify	rectify	VERB
ihlr-16500	377	46	such	such	DET
ihlr-16500	377	47	a	a	DET
ihlr-16500	377	48	problem	problem	NOUN
ihlr-16500	377	49	.	.	PUNCT
ihlr-16500	378	1	87	87	NUM
ihlr-16500	378	2	as	as	SCONJ
ihlr-16500	378	3	more	more	ADJ
ihlr-16500	378	4	pharmaceutical	pharmaceutical	NOUN
ihlr-16500	378	5	compa­	compa­	NOUN
ihlr-16500	378	6	nies	ny	NOUN
ihlr-16500	378	7	require	require	VERB
ihlr-16500	378	8	successful	successful	ADJ
ihlr-16500	378	9	blockbuster	blockbuster	NOUN
ihlr-16500	378	10	drugs	drug	NOUN
ihlr-16500	378	11	in	in	ADP
ihlr-16500	378	12	order	order	NOUN
ihlr-16500	378	13	to	to	PART
ihlr-16500	378	14	offset	offset	VERB
ihlr-16500	378	15	the	the	DET
ihlr-16500	378	16	ever	ever	ADV
ihlr-16500	378	17	increasing	increase	VERB
ihlr-16500	378	18	research	research	NOUN
ihlr-16500	378	19	,	,	PUNCT
ihlr-16500	378	20	development	development	NOUN
ihlr-16500	378	21	,	,	PUNCT
ihlr-16500	378	22	and	and	CCONJ
ihlr-16500	378	23	litigation	litigation	NOUN
ihlr-16500	378	24	costs	cost	NOUN
ihlr-16500	378	25	,	,	PUNCT
ihlr-16500	378	26	executives	executive	NOUN
ihlr-16500	378	27	are	be	AUX
ihlr-16500	378	28	faced	face	VERB
ihlr-16500	378	29	with	with	ADP
ihlr-16500	378	30	increasing	increase	VERB
ihlr-16500	378	31	pressure	pressure	NOUN
ihlr-16500	378	32	to	to	PART
ihlr-16500	378	33	circumvent	circumvent	VERB
ihlr-16500	378	34	any	any	DET
ihlr-16500	378	35	problems	problem	NOUN
ihlr-16500	378	36	with	with	ADP
ihlr-16500	378	37	potential	potential	ADJ
ihlr-16500	378	38	blockbuster	blockbuster	ADJ
ihlr-16500	378	39	drugs	drug	NOUN
ihlr-16500	378	40	that	that	PRON
ihlr-16500	378	41	may	may	AUX
ihlr-16500	378	42	arise	arise	VERB
ihlr-16500	378	43	.	.	PUNCT
ihlr-16500	379	1	in	in	ADP
ihlr-16500	379	2	doing	do	VERB
ihlr-16500	379	3	so	so	ADV
ihlr-16500	379	4	,	,	PUNCT
ihlr-16500	379	5	it	it	PRON
ihlr-16500	379	6	is	be	AUX
ihlr-16500	379	7	likely	likely	ADJ
ihlr-16500	379	8	that	that	SCONJ
ihlr-16500	379	9	these	these	DET
ihlr-16500	379	10	executives	executive	NOUN
ihlr-16500	379	11	might	might	AUX
ihlr-16500	379	12	face	face	VERB
ihlr-16500	379	13	criminal	criminal	ADJ
ihlr-16500	379	14	prosecu­	prosecu­	PROPN
ihlr-16500	379	15	tion	tion	NOUN
ihlr-16500	379	16	for	for	ADP
ihlr-16500	379	17	attempting	attempt	VERB
ihlr-16500	379	18	to	to	PART
ihlr-16500	379	19	hide	hide	VERB
ihlr-16500	379	20	concerns	concern	NOUN
ihlr-16500	379	21	that	that	PRON
ihlr-16500	379	22	might	might	AUX
ihlr-16500	379	23	jeopardize	jeopardize	VERB
ihlr-16500	379	24	the	the	DET
ihlr-16500	379	25	drug	drug	NOUN
ihlr-16500	379	26	's	's	PART
ihlr-16500	379	27	commer­	commer­	PROPN
ihlr-16500	379	28	cial	cial	ADJ
ihlr-16500	379	29	future	future	NOUN
ihlr-16500	379	30	.	.	PUNCT
ihlr-16500	380	1	another	another	DET
ihlr-16500	380	2	consequence	consequence	NOUN
ihlr-16500	380	3	of	of	ADP
ihlr-16500	380	4	concealing	conceal	VERB
ihlr-16500	380	5	information	information	NOUN
ihlr-16500	380	6	that	that	PRON
ihlr-16500	380	7	may	may	AUX
ihlr-16500	380	8	reveal	reveal	VERB
ihlr-16500	380	9	a	a	DET
ihlr-16500	380	10	block­	block­	PROPN
ihlr-16500	380	11	buster	buster	NOUN
ihlr-16500	380	12	drug	drug	NOUN
ihlr-16500	380	13	's	's	PART
ihlr-16500	380	14	safety	safety	NOUN
ihlr-16500	380	15	problems	problem	NOUN
ihlr-16500	380	16	is	be	AUX
ihlr-16500	380	17	the	the	DET
ihlr-16500	380	18	imposition	imposition	NOUN
ihlr-16500	380	19	of	of	ADP
ihlr-16500	380	20	substantial	substantial	ADJ
ihlr-16500	380	21	financial	financial	ADJ
ihlr-16500	380	22	penalties	penalty	NOUN
ihlr-16500	380	23	on	on	ADP
ihlr-16500	380	24	the	the	DET
ihlr-16500	380	25	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	380	26	company	company	NOUN
ihlr-16500	380	27	that	that	PRON
ihlr-16500	380	28	owns	own	VERB
ihlr-16500	380	29	the	the	DET
ihlr-16500	380	30	drug	drug	NOUN
ihlr-16500	380	31	.	.	PUNCT
ihlr-16500	381	1	for	for	ADP
ihlr-16500	381	2	instance	instance	NOUN
ihlr-16500	381	3	,	,	PUNCT
ihlr-16500	381	4	in	in	ADP
ihlr-16500	381	5	1996	1996	NUM
ihlr-16500	381	6	,	,	PUNCT
ihlr-16500	381	7	warner	warner	PROPN
ihlr-16500	381	8	-	-	PUNCT
ihlr-16500	381	9	lambert	lambert	PROPN
ihlr-16500	381	10	pharmaceuticals	pharmaceutical	NOUN
ihlr-16500	381	11	,	,	PUNCT
ihlr-16500	381	12	before	before	ADP
ihlr-16500	381	13	being	be	AUX
ihlr-16500	381	14	acquired	acquire	VERB
ihlr-16500	381	15	by	by	ADP
ihlr-16500	381	16	pfizer	pfizer	NOUN
ihlr-16500	381	17	,	,	PUNCT
ihlr-16500	381	18	submitted	submit	VERB
ihlr-16500	381	19	rezulin	rezulin	NOUN
ihlr-16500	381	20	,	,	PUNCT
ihlr-16500	381	21	a	a	DET
ihlr-16500	381	22	drug	drug	NOUN
ihlr-16500	381	23	aimed	aim	VERB
ihlr-16500	381	24	at	at	ADP
ihlr-16500	381	25	treating	treat	VERB
ihlr-16500	381	26	patients	patient	NOUN
ihlr-16500	381	27	with	with	ADP
ihlr-16500	381	28	diabetes	diabetes	NOUN
ihlr-16500	381	29	,	,	PUNCT
ihlr-16500	381	30	to	to	ADP
ihlr-16500	381	31	the	the	DET
ihlr-16500	381	32	fda	fda	PROPN
ihlr-16500	381	33	.	.	PROPN
ihlr-16500	381	34	88	88	NUM
ihlr-16500	381	35	during	during	ADP
ihlr-16500	381	36	the	the	DET
ihlr-16500	381	37	drug	drug	NOUN
ihlr-16500	381	38	approval	approval	NOUN
ihlr-16500	381	39	process	process	NOUN
ihlr-16500	381	40	,	,	PUNCT
ihlr-16500	381	41	warner	warner	PROPN
ihlr-16500	381	42	-	-	PUNCT
ihlr-16500	381	43	lambert	lambert	PROPN
ihlr-16500	381	44	pressured	pressure	VERB
ihlr-16500	381	45	the	the	DET
ihlr-16500	381	46	fda	fda	PROPN
ihlr-16500	381	47	into	into	ADP
ihlr-16500	381	48	approving	approve	VERB
ihlr-16500	381	49	rezulin	rezulin	NOUN
ihlr-16500	381	50	,	,	PUNCT
ihlr-16500	381	51	a	a	DET
ihlr-16500	381	52	drug	drug	NOUN
ihlr-16500	381	53	with	with	ADP
ihlr-16500	381	54	known	know	VERB
ihlr-16500	381	55	side	side	NOUN
ihlr-16500	381	56	-	-	PUNCT
ihlr-16500	381	57	effects	effect	NOUN
ihlr-16500	381	58	,	,	PUNCT
ihlr-16500	381	59	which	which	PRON
ihlr-16500	381	60	were	be	AUX
ihlr-16500	381	61	fatal	fatal	ADJ
ihlr-16500	381	62	in	in	ADP
ihlr-16500	381	63	some	some	DET
ihlr-16500	381	64	cases	case	NOUN
ihlr-16500	381	65	.	.	PUNCT
ihlr-16500	382	1	89	89	NUM
ihlr-16500	382	2	this	this	DET
ihlr-16500	382	3	decision	decision	NOUN
ihlr-16500	382	4	to	to	PART
ihlr-16500	382	5	approve	approve	VERB
ihlr-16500	382	6	the	the	DET
ihlr-16500	382	7	drug	drug	NOUN
ihlr-16500	382	8	was	be	AUX
ihlr-16500	382	9	ill	ill	ADV
ihlr-16500	382	10	-	-	PUNCT
ihlr-16500	382	11	fated	fate	VERB
ihlr-16500	382	12	as	as	SCONJ
ihlr-16500	382	13	the	the	DET
ihlr-16500	382	14	drug	drug	NOUN
ihlr-16500	382	15	was	be	AUX
ihlr-16500	382	16	allegedly	allegedly	ADV
ihlr-16500	382	17	related	relate	VERB
ihlr-16500	382	18	to	to	ADP
ihlr-16500	382	19	the	the	DET
ihlr-16500	382	20	deaths	death	NOUN
ihlr-16500	382	21	of	of	ADP
ihlr-16500	382	22	391	391	NUM
ihlr-16500	382	23	people	people	NOUN
ihlr-16500	382	24	by	by	ADP
ihlr-16500	382	25	the	the	DET
ihlr-16500	382	26	time	time	NOUN
ihlr-16500	382	27	it	it	PRON
ihlr-16500	382	28	was	be	AUX
ihlr-16500	382	29	pulled	pull	VERB
ihlr-16500	382	30	from	from	ADP
ihlr-16500	382	31	the	the	DET
ihlr-16500	382	32	market	market	NOUN
ihlr-16500	382	33	.	.	PUNCT
ihlr-16500	383	1	90	90	NUM
ihlr-16500	383	2	prior	prior	ADV
ihlr-16500	383	3	to	to	ADP
ihlr-16500	383	4	its	its	PRON
ihlr-16500	383	5	submission	submission	NOUN
ihlr-16500	383	6	ofrezulin	ofrezulin	NOUN
ihlr-16500	383	7	to	to	ADP
ihlr-16500	383	8	the	the	DET
ihlr-16500	383	9	fda	fda	PROPN
ihlr-16500	383	10	,	,	PUNCT
ihlr-16500	383	11	warner	warner	PROPN
ihlr-16500	383	12	-	-	PUNCT
ihlr-16500	383	13	lambert	lambert	PROPN
ihlr-16500	383	14	was	be	AUX
ihlr-16500	383	15	al­	al­	PROPN
ihlr-16500	383	16	ready	ready	ADJ
ihlr-16500	383	17	being	be	AUX
ihlr-16500	383	18	investigated	investigate	VERB
ihlr-16500	383	19	by	by	ADP
ihlr-16500	383	20	the	the	DET
ihlr-16500	383	21	fda	fda	PROPN
ihlr-16500	383	22	and	and	CCONJ
ihlr-16500	383	23	the	the	DET
ihlr-16500	383	24	justice	justice	PROPN
ihlr-16500	383	25	department	department	PROPN
ihlr-16500	383	26	for	for	ADP
ihlr-16500	383	27	its	its	PRON
ihlr-16500	383	28	con­	con­	NOUN
ihlr-16500	383	29	cealment	cealment	NOUN
ihlr-16500	383	30	of	of	ADP
ihlr-16500	383	31	key	key	ADJ
ihlr-16500	383	32	information	information	NOUN
ihlr-16500	383	33	and	and	CCONJ
ihlr-16500	383	34	actions	action	NOUN
ihlr-16500	383	35	during	during	ADP
ihlr-16500	383	36	the	the	DET
ihlr-16500	383	37	drug	drug	NOUN
ihlr-16500	383	38	approval	approval	NOUN
ihlr-16500	383	39	process	process	NOUN
ihlr-16500	383	40	.	.	PUNCT
ihlr-16500	384	1	91	91	NUM
ihlr-16500	385	1	eventually	eventually	ADV
ihlr-16500	385	2	,	,	PUNCT
ihlr-16500	385	3	warner	warner	PROPN
ihlr-16500	385	4	-	-	PUNCT
ihlr-16500	385	5	lambert	lambert	PROPN
ihlr-16500	385	6	pled	plead	VERB
ihlr-16500	385	7	guilty	guilty	ADJ
ihlr-16500	385	8	in	in	ADP
ihlr-16500	385	9	1995	1995	NUM
ihlr-16500	385	10	for	for	ADP
ihlr-16500	385	11	"	"	PUNCT
ihlr-16500	385	12	concealing	conceal	VERB
ihlr-16500	385	13	quality	quality	NOUN
ihlr-16500	385	14	-	-	PUNCT
ihlr-16500	385	15	control	control	NOUN
ihlr-16500	385	16	problems	problem	NOUN
ihlr-16500	385	17	in	in	ADP
ihlr-16500	385	18	its	its	PRON
ihlr-16500	385	19	drug	drug	NOUN
ihlr-16500	385	20	manufacturing	manufacturing	NOUN
ihlr-16500	385	21	"	"	PUNCT
ihlr-16500	385	22	processes	process	NOUN
ihlr-16500	385	23	and	and	CCONJ
ihlr-16500	385	24	received	receive	VERB
ihlr-16500	385	25	a	a	DET
ihlr-16500	385	26	ten	ten	NUM
ihlr-16500	385	27	million	million	NUM
ihlr-16500	385	28	dollar	dollar	NOUN
ihlr-16500	385	29	85	85	NUM
ihlr-16500	385	30	alex	alex	PROPN
ihlr-16500	385	31	berenson	berenson	PROPN
ihlr-16500	385	32	,	,	PUNCT
ihlr-16500	385	33	in	in	ADP
ihlr-16500	385	34	training	training	NOUN
ihlr-16500	385	35	video	video	NOUN
ihlr-16500	385	36	,	,	PUNCT
ihlr-16500	385	37	merck	merck	PROPN
ihlr-16500	385	38	said	say	VERB
ihlr-16500	385	39	vioxx	vioxx	NOUN
ihlr-16500	385	40	did	do	AUX
ihlr-16500	385	41	not	not	PART
ihlr-16500	385	42	increase	increase	VERB
ihlr-16500	385	43	risk	risk	NOUN
ihlr-16500	385	44	of	of	ADP
ihlr-16500	385	45	heart	heart	NOUN
ihlr-16500	385	46	attack	attack	NOUN
ihlr-16500	385	47	,	,	PUNCT
ihlr-16500	385	48	n.y	n.y	PROPN
ihlr-16500	385	49	.	.	PROPN
ihlr-16500	385	50	times	times	PROPN
ihlr-16500	385	51	,	,	PUNCT
ihlr-16500	385	52	july	july	PROPN
ihlr-16500	385	53	21	21	NUM
ihlr-16500	385	54	,	,	PUNCT
ihlr-16500	385	55	2005	2005	NUM
ihlr-16500	385	56	,	,	PUNCT
ihlr-16500	385	57	at	at	ADP
ihlr-16500	385	58	c4	c4	NOUN
ihlr-16500	385	59	,	,	PUNCT
ihlr-16500	385	60	available	available	ADJ
ihlr-16500	385	61	at	at	ADP
ihlr-16500	385	62	http://www.vioxx-recall-lawsuit.com	http://www.vioxx-recall-lawsuit.com	X
ihlr-16500	385	63	/news	/news	SYM
ihlr-16500	385	64	/	/	SYM
ihlr-16500	385	65	video.pdf	video.pdf	PROPN
ihlr-16500	385	66	.	.	PUNCT
ihlr-16500	386	1	86	86	NUM
ihlr-16500	386	2	chris	chris	PROPN
ihlr-16500	386	3	rangel	rangel	PROPN
ihlr-16500	386	4	,	,	PUNCT
ihlr-16500	386	5	unprecedented	unprecedented	ADJ
ihlr-16500	386	6	!	!	PUNCT
ihlr-16500	387	1	the	the	DET
ihlr-16500	387	2	new	new	PROPN
ihlr-16500	387	3	england	england	PROPN
ihlr-16500	387	4	journal	journal	PROPN
ihlr-16500	387	5	accuses	accuse	VERB
ihlr-16500	387	6	vioxx	vioxx	PROPN
ihlr-16500	387	7	study	study	NOUN
ihlr-16500	387	8	au­	au­	ADP
ihlr-16500	387	9	thors	thor	NOUN
ihlr-16500	387	10	of	of	ADP
ihlr-16500	387	11	cover	cover	NOUN
ihlr-16500	387	12	-	-	PUNCT
ihlr-16500	387	13	up	up	NOUN
ihlr-16500	387	14	!	!	PUNCT
ihlr-16500	387	15	,	,	PUNCT
ihlr-16500	387	16	ranoelmd.com	ranoelmd.com	X
ihlr-16500	387	17	,	,	PUNCT
ihlr-16500	387	18	dec	dec	PROPN
ihlr-16500	387	19	.	.	PROPN
ihlr-16500	387	20	9	9	NUM
ihlr-16500	387	21	,	,	PUNCT
ihlr-16500	387	22	2005	2005	NUM
ihlr-16500	387	23	,	,	PUNCT
ihlr-16500	387	24	http://www.rangelmd.com/2005112/new­	http://www.rangelmd.com/2005112/new­	PROPN
ihlr-16500	387	25	england	england	PROPN
ihlr-16500	387	26	-	-	PUNCT
ihlr-16500	387	27	journal	journal	NOUN
ihlr-16500	387	28	-	-	PUNCT
ihlr-16500	387	29	fingers	finger	NOUN
ihlr-16500	387	30	-	-	PUNCT
ihlr-16500	387	31	vioxx.h1ml	vioxx.h1ml	NOUN
ihlr-16500	387	32	.	.	PUNCT
ihlr-16500	388	1	87	87	NUM
ihlr-16500	388	2	a	a	DET
ihlr-16500	388	3	company	company	NOUN
ihlr-16500	388	4	can	can	AUX
ihlr-16500	388	5	rectify	rectify	VERB
ihlr-16500	388	6	such	such	DET
ihlr-16500	388	7	a	a	DET
ihlr-16500	388	8	problem	problem	NOUN
ihlr-16500	388	9	by	by	ADP
ihlr-16500	388	10	further	further	ADJ
ihlr-16500	388	11	testing	test	VERB
ihlr-16500	388	12	the	the	DET
ihlr-16500	388	13	drug	drug	NOUN
ihlr-16500	388	14	or	or	CCONJ
ihlr-16500	388	15	settling	settle	VERB
ihlr-16500	388	16	lawsuits	lawsuit	NOUN
ihlr-16500	388	17	with	with	ADP
ihlr-16500	388	18	any	any	DET
ihlr-16500	388	19	adverse	adverse	ADJ
ihlr-16500	388	20	party	party	NOUN
ihlr-16500	388	21	.	.	PUNCT
ihlr-16500	389	1	88	88	NUM
ihlr-16500	389	2	melissa	melissa	PROPN
ihlr-16500	389	3	marie	marie	PROPN
ihlr-16500	389	4	bean	bean	PROPN
ihlr-16500	389	5	,	,	PUNCT
ihlr-16500	389	6	fatal	fatal	ADJ
ihlr-16500	389	7	flaws	flaw	NOUN
ihlr-16500	389	8	in	in	ADP
ihlr-16500	389	9	the	the	DET
ihlr-16500	389	10	food	food	NOUN
ihlr-16500	389	11	and	and	CCONJ
ihlr-16500	389	12	drug	drug	PROPN
ihlr-16500	389	13	administration	administration	NOUN
ihlr-16500	389	14	's	's	PART
ihlr-16500	389	15	drug­	drug­	NOUN
ihlr-16500	389	16	approval	approval	NOUN
ihlr-16500	389	17	formula	formula	NOUN
ihlr-16500	389	18	,	,	PUNCT
ihlr-16500	389	19	2003	2003	NUM
ihlr-16500	389	20	utahl	utahl	NOUN
ihlr-16500	389	21	.	.	PUNCT
ihlr-16500	390	1	rev	rev	PROPN
ihlr-16500	390	2	.	.	PROPN
ihlr-16500	390	3	881,904,908	881,904,908	NUM
ihlr-16500	390	4	(	(	PUNCT
ihlr-16500	390	5	2003	2003	NUM
ihlr-16500	390	6	)	)	PUNCT
ihlr-16500	390	7	.	.	PUNCT
ihlr-16500	391	1	rezulin	rezulin	NOUN
ihlr-16500	391	2	was	be	AUX
ihlr-16500	391	3	approved	approve	VERB
ihlr-16500	391	4	to	to	PART
ihlr-16500	391	5	lower	lower	VERB
ihlr-16500	391	6	blood	blood	NOUN
ihlr-16500	391	7	sugar	sugar	NOUN
ihlr-16500	391	8	,	,	PUNCT
ihlr-16500	391	9	which	which	PRON
ihlr-16500	391	10	is	be	AUX
ihlr-16500	391	11	critically	critically	ADV
ihlr-16500	391	12	important	important	ADJ
ihlr-16500	391	13	to	to	ADP
ihlr-16500	391	14	diabetic	diabetic	ADJ
ihlr-16500	391	15	patients	patient	NOUN
ihlr-16500	391	16	because	because	SCONJ
ihlr-16500	391	17	it	it	PRON
ihlr-16500	391	18	helps	help	VERB
ihlr-16500	391	19	the	the	DET
ihlr-16500	391	20	body	body	NOUN
ihlr-16500	391	21	process	process	NOUN
ihlr-16500	391	22	insulin	insulin	NOUN
ihlr-16500	391	23	.	.	PUNCT
ihlr-16500	392	1	/d	/d	INTJ
ihlr-16500	392	2	.	.	PUNCT
ihlr-16500	393	1	at	at	ADP
ihlr-16500	393	2	903	903	NUM
ihlr-16500	393	3	.	.	PUNCT
ihlr-16500	393	4	89	89	NUM
ihlr-16500	393	5	/d	/d	PUNCT
ihlr-16500	393	6	.	.	PUNCT
ihlr-16500	394	1	at	at	ADP
ihlr-16500	394	2	904	904	NUM
ihlr-16500	394	3	-	-	SYM
ihlr-16500	394	4	05	05	NUM
ihlr-16500	394	5	.	.	PROPN
ihlr-16500	394	6	90	90	NUM
ihlr-16500	394	7	/d	/d	PUNCT
ihlr-16500	394	8	.	.	PUNCT
ihlr-16500	395	1	at	at	ADP
ihlr-16500	395	2	903	903	NUM
ihlr-16500	395	3	.	.	PUNCT
ihlr-16500	395	4	91	91	NUM
ihlr-16500	395	5	!	!	PUNCT
ihlr-16500	395	6	d.	d.	PROPN
ihlr-16500	395	7	at	at	ADP
ihlr-16500	395	8	904	904	NUM
ihlr-16500	395	9	.	.	PUNCT
ihlr-16500	396	1	132	132	NUM
ihlr-16500	396	2	indiana	indiana	PROPN
ihlr-16500	396	3	h	h	PROPN
ihlr-16500	396	4	:	:	PUNCT
ihlr-16500	396	5	ealtii	ealtii	PROPN
ihlr-16500	396	6	law	law	NOUN
ihlr-16500	396	7	review	review	NOUN
ihlr-16500	397	1	[	[	X
ihlr-16500	397	2	vol	vol	NOUN
ihlr-16500	397	3	.	.	PUNCT
ihlr-16500	398	1	4:115	4:115	NUM
ihlr-16500	398	2	fine	fine	ADJ
ihlr-16500	398	3	;	;	PUNCT
ihlr-16500	398	4	at	at	ADP
ihlr-16500	398	5	the	the	DET
ihlr-16500	398	6	time	time	NOUN
ihlr-16500	398	7	,	,	PUNCT
ihlr-16500	398	8	this	this	PRON
ihlr-16500	398	9	was	be	AUX
ihlr-16500	398	10	one	one	NUM
ihlr-16500	398	11	of	of	ADP
ihlr-16500	398	12	the	the	DET
ihlr-16500	398	13	largest	large	ADJ
ihlr-16500	398	14	fines	fine	NOUN
ihlr-16500	398	15	ever	ever	ADV
ihlr-16500	398	16	imposed	impose	VERB
ihlr-16500	398	17	on	on	ADP
ihlr-16500	398	18	a	a	DET
ihlr-16500	398	19	drug	drug	NOUN
ihlr-16500	398	20	manu­	manu­	ADJ
ihlr-16500	398	21	facturer	facturer	NOUN
ihlr-16500	398	22	.	.	PUNCT
ihlr-16500	399	1	92	92	NUM
ihlr-16500	400	1	although	although	SCONJ
ihlr-16500	400	2	that	that	DET
ihlr-16500	400	3	number	number	NOUN
ihlr-16500	400	4	may	may	AUX
ihlr-16500	400	5	not	not	PART
ihlr-16500	400	6	seem	seem	VERB
ihlr-16500	400	7	significant	significant	ADJ
ihlr-16500	400	8	for	for	ADP
ihlr-16500	400	9	a	a	DET
ihlr-16500	400	10	large	large	ADJ
ihlr-16500	400	11	pharma­	pharma­	PRON
ihlr-16500	400	12	ceutical	ceutical	ADJ
ihlr-16500	400	13	conglomerate	conglomerate	NOUN
ihlr-16500	400	14	with	with	ADP
ihlr-16500	400	15	deep	deep	ADJ
ihlr-16500	400	16	pockets	pocket	NOUN
ihlr-16500	400	17	,	,	PUNCT
ihlr-16500	400	18	the	the	DET
ihlr-16500	400	19	fine	fine	NOUN
ihlr-16500	400	20	represented	represent	VERB
ihlr-16500	400	21	the	the	DET
ihlr-16500	400	22	determination	determination	NOUN
ihlr-16500	400	23	by	by	ADP
ihlr-16500	400	24	governmental	governmental	ADJ
ihlr-16500	400	25	agencies	agency	NOUN
ihlr-16500	400	26	that	that	SCONJ
ihlr-16500	400	27	the	the	DET
ihlr-16500	400	28	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	400	29	company	company	NOUN
ihlr-16500	400	30	erred	err	VERB
ihlr-16500	400	31	in	in	ADP
ihlr-16500	400	32	its	its	PRON
ihlr-16500	400	33	manu­	manu­	PROPN
ihlr-16500	400	34	facturing	facturing	NOUN
ihlr-16500	400	35	of	of	ADP
ihlr-16500	400	36	the	the	DET
ihlr-16500	400	37	drug	drug	NOUN
ihlr-16500	400	38	.	.	PUNCT
ihlr-16500	401	1	in	in	ADP
ihlr-16500	401	2	tum	tum	PROPN
ihlr-16500	401	3	,	,	PUNCT
ihlr-16500	401	4	such	such	DET
ihlr-16500	401	5	a	a	DET
ihlr-16500	401	6	finding	finding	NOUN
ihlr-16500	401	7	could	could	AUX
ihlr-16500	401	8	be	be	AUX
ihlr-16500	401	9	used	use	VERB
ihlr-16500	401	10	by	by	ADP
ihlr-16500	401	11	plaintiffs	plaintiff	NOUN
ihlr-16500	401	12	'	'	PART
ihlr-16500	401	13	attor­	attor­	NOUN
ihlr-16500	401	14	neys	ney	NOUN
ihlr-16500	401	15	in	in	ADP
ihlr-16500	401	16	subsequent	subsequent	ADJ
ihlr-16500	401	17	civil	civil	ADJ
ihlr-16500	401	18	lawsuits	lawsuit	NOUN
ihlr-16500	401	19	.	.	PUNCT
ihlr-16500	402	1	v.	v.	ADP
ihlr-16500	402	2	business	business	NOUN
ihlr-16500	402	3	ramifications	ramification	NOUN
ihlr-16500	402	4	of	of	ADP
ihlr-16500	402	5	pulling	pull	VERB
ihlr-16500	402	6	a	a	DET
ihlr-16500	402	7	drug	drug	NOUN
ihlr-16500	402	8	off	off	ADP
ihlr-16500	402	9	the	the	DET
ihlr-16500	402	10	market	market	NOUN
ihlr-16500	402	11	in	in	ADP
ihlr-16500	402	12	addition	addition	NOUN
ihlr-16500	402	13	to	to	ADP
ihlr-16500	402	14	legal	legal	ADJ
ihlr-16500	402	15	consequences	consequence	NOUN
ihlr-16500	402	16	,	,	PUNCT
ihlr-16500	402	17	such	such	ADJ
ihlr-16500	402	18	as	as	ADP
ihlr-16500	402	19	civil	civil	ADJ
ihlr-16500	402	20	lawsuits	lawsuit	NOUN
ihlr-16500	402	21	and	and	CCONJ
ihlr-16500	402	22	criminal	criminal	ADJ
ihlr-16500	402	23	in­	in­	NOUN
ihlr-16500	402	24	dictments	dictment	NOUN
ihlr-16500	402	25	,	,	PUNCT
ihlr-16500	402	26	a	a	DET
ihlr-16500	402	27	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	402	28	company	company	NOUN
ihlr-16500	402	29	can	can	AUX
ihlr-16500	402	30	also	also	ADV
ihlr-16500	402	31	face	face	VERB
ihlr-16500	402	32	business	business	NOUN
ihlr-16500	402	33	consequences	consequence	NOUN
ihlr-16500	402	34	as	as	ADP
ihlr-16500	402	35	a	a	DET
ihlr-16500	402	36	result	result	NOUN
ihlr-16500	402	37	of	of	ADP
ihlr-16500	402	38	a	a	DET
ihlr-16500	402	39	blockbuster	blockbuster	ADJ
ihlr-16500	402	40	drug	drug	NOUN
ihlr-16500	402	41	withdrawal	withdrawal	NOUN
ihlr-16500	402	42	from	from	ADP
ihlr-16500	402	43	the	the	DET
ihlr-16500	402	44	market	market	NOUN
ihlr-16500	402	45	.	.	PUNCT
ihlr-16500	403	1	one	one	NUM
ihlr-16500	403	2	of	of	ADP
ihlr-16500	403	3	these	these	DET
ihlr-16500	403	4	conse­	conse­	PROPN
ihlr-16500	403	5	quences	quence	NOUN
ihlr-16500	403	6	is	be	AUX
ihlr-16500	403	7	the	the	DET
ihlr-16500	403	8	loss	loss	NOUN
ihlr-16500	403	9	of	of	ADP
ihlr-16500	403	10	an	an	DET
ihlr-16500	403	11	asset	asset	NOUN
ihlr-16500	403	12	that	that	PRON
ihlr-16500	403	13	produces	produce	VERB
ihlr-16500	403	14	a	a	DET
ihlr-16500	403	15	significant	significant	ADJ
ihlr-16500	403	16	amount	amount	NOUN
ihlr-16500	403	17	of	of	ADP
ihlr-16500	403	18	revenue	revenue	NOUN
ihlr-16500	403	19	for	for	ADP
ihlr-16500	403	20	the	the	DET
ihlr-16500	403	21	company	company	NOUN
ihlr-16500	403	22	.	.	PUNCT
ihlr-16500	404	1	another	another	PRON
ihlr-16500	404	2	is	be	AUX
ihlr-16500	404	3	the	the	DET
ihlr-16500	404	4	myriad	myriad	NOUN
ihlr-16500	404	5	of	of	ADP
ihlr-16500	404	6	lawsuits	lawsuit	NOUN
ihlr-16500	404	7	and	and	CCONJ
ihlr-16500	404	8	the	the	DET
ihlr-16500	404	9	significant	significant	ADJ
ihlr-16500	404	10	amount	amount	NOUN
ihlr-16500	404	11	of	of	ADP
ihlr-16500	404	12	capital	capital	NOUN
ihlr-16500	404	13	required	require	VERB
ihlr-16500	404	14	for	for	ADP
ihlr-16500	404	15	their	their	PRON
ihlr-16500	404	16	defense	defense	NOUN
ihlr-16500	404	17	.	.	PUNCT
ihlr-16500	405	1	also	also	ADV
ihlr-16500	405	2	,	,	PUNCT
ihlr-16500	405	3	the	the	DET
ihlr-16500	405	4	company	company	NOUN
ihlr-16500	405	5	can	can	AUX
ihlr-16500	405	6	face	face	VERB
ihlr-16500	405	7	a	a	DET
ihlr-16500	405	8	decrease	decrease	NOUN
ihlr-16500	405	9	in	in	ADP
ihlr-16500	405	10	the	the	DET
ihlr-16500	405	11	market	market	NOUN
ihlr-16500	405	12	's	's	PART
ihlr-16500	405	13	valuation	valuation	NOUN
ihlr-16500	405	14	of	of	ADP
ihlr-16500	405	15	the	the	DET
ihlr-16500	405	16	company	company	NOUN
ihlr-16500	405	17	,	,	PUNCT
ihlr-16500	405	18	specifically	specifically	ADV
ihlr-16500	405	19	in	in	ADP
ihlr-16500	405	20	its	its	PRON
ihlr-16500	405	21	stock	stock	NOUN
ihlr-16500	405	22	price	price	NOUN
ihlr-16500	405	23	,	,	PUNCT
ihlr-16500	405	24	which	which	PRON
ihlr-16500	405	25	can	can	AUX
ihlr-16500	405	26	affect	affect	VERB
ihlr-16500	405	27	perception	perception	NOUN
ihlr-16500	405	28	and	and	CCONJ
ihlr-16500	405	29	investor	investor	NOUN
ihlr-16500	405	30	confidence	confidence	NOUN
ihlr-16500	405	31	in	in	ADP
ihlr-16500	405	32	the	the	DET
ihlr-16500	405	33	company	company	NOUN
ihlr-16500	405	34	's	's	PART
ihlr-16500	405	35	ability	ability	NOUN
ihlr-16500	405	36	to	to	PART
ihlr-16500	405	37	bounce	bounce	VERB
ihlr-16500	405	38	back	back	ADV
ihlr-16500	405	39	from	from	ADP
ihlr-16500	405	40	such	such	DET
ihlr-16500	405	41	a	a	DET
ihlr-16500	405	42	setback	setback	NOUN
ihlr-16500	405	43	.	.	PUNCT
ihlr-16500	406	1	nevertheless	nevertheless	ADV
ihlr-16500	406	2	,	,	PUNCT
ihlr-16500	406	3	regardless	regardless	ADV
ihlr-16500	406	4	of	of	ADP
ihlr-16500	406	5	the	the	DET
ihlr-16500	406	6	reason	reason	NOUN
ihlr-16500	406	7	,	,	PUNCT
ihlr-16500	406	8	the	the	DET
ihlr-16500	406	9	loss	loss	NOUN
ihlr-16500	406	10	in	in	ADP
ihlr-16500	406	11	.	.	PUNCT
ihlr-16500	407	1	profit	profit	NOUN
ihlr-16500	407	2	and	and	CCONJ
ihlr-16500	407	3	future	future	ADJ
ihlr-16500	407	4	revenues	revenue	NOUN
ihlr-16500	407	5	can	can	AUX
ihlr-16500	407	6	be	be	AUX
ihlr-16500	407	7	devastating	devastating	ADJ
ihlr-16500	407	8	for	for	ADP
ihlr-16500	407	9	any	any	DET
ihlr-16500	407	10	company	company	NOUN
ihlr-16500	407	11	,	,	PUNCT
ihlr-16500	407	12	especially	especially	ADV
ihlr-16500	407	13	ifthe	ifthe	NOUN
ihlr-16500	407	14	drug	drug	NOUN
ihlr-16500	407	15	is	be	AUX
ihlr-16500	407	16	a	a	DET
ihlr-16500	407	17	significant	significant	ADJ
ihlr-16500	407	18	asset	asset	NOUN
ihlr-16500	407	19	within	within	ADP
ihlr-16500	407	20	its	its	PRON
ihlr-16500	407	21	product	product	NOUN
ihlr-16500	407	22	line	line	NOUN
ihlr-16500	407	23	.	.	PUNCT
ihlr-16500	408	1	bayer	bayer	PROPN
ihlr-16500	408	2	pharmaceuticals	pharmaceutical	NOUN
ihlr-16500	408	3	faced	face	VERB
ihlr-16500	408	4	the	the	DET
ihlr-16500	408	5	business	business	NOUN
ihlr-16500	408	6	ramifications	ramification	NOUN
ihlr-16500	408	7	of	of	ADP
ihlr-16500	408	8	pulling	pull	VERB
ihlr-16500	408	9	a	a	DET
ihlr-16500	408	10	block­	block­	PROPN
ihlr-16500	408	11	buster	buster	NOUN
ihlr-16500	408	12	drug	drug	NOUN
ihlr-16500	408	13	off	off	ADP
ihlr-16500	408	14	the	the	DET
ihlr-16500	408	15	market	market	NOUN
ihlr-16500	408	16	when	when	SCONJ
ihlr-16500	408	17	,	,	PUNCT
ihlr-16500	408	18	in	in	ADP
ihlr-16500	408	19	2001	2001	NUM
ihlr-16500	408	20	,	,	PUNCT
ihlr-16500	408	21	it	it	PRON
ihlr-16500	408	22	pulled	pull	VERB
ihlr-16500	408	23	baycol,93	baycol,93	X
ihlr-16500	408	24	one	one	NUM
ihlr-16500	408	25	of	of	ADP
ihlr-16500	408	26	its	its	PRON
ihlr-16500	408	27	most	most	ADV
ihlr-16500	408	28	profitable	profitable	ADJ
ihlr-16500	408	29	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	408	30	drugs	drug	NOUN
ihlr-16500	408	31	used	use	VERB
ihlr-16500	408	32	to	to	PART
ihlr-16500	408	33	treat	treat	VERB
ihlr-16500	408	34	high	high	ADJ
ihlr-16500	408	35	cholesterol	cholesterol	NOUN
ihlr-16500	408	36	,	,	PUNCT
ihlr-16500	408	37	off	off	ADP
ihlr-16500	408	38	the	the	DET
ihlr-16500	408	39	market	market	NOUN
ihlr-16500	408	40	.	.	PUNCT
ihlr-16500	409	1	as	as	ADP
ihlr-16500	409	2	a	a	DET
ihlr-16500	409	3	result	result	NOUN
ihlr-16500	409	4	,	,	PUNCT
ihlr-16500	409	5	bayer	bayer	PROPN
ihlr-16500	409	6	had	have	VERB
ihlr-16500	409	7	to	to	PART
ihlr-16500	409	8	prepare	prepare	VERB
ihlr-16500	409	9	itself	itself	PRON
ihlr-16500	409	10	for	for	ADP
ihlr-16500	409	11	the	the	DET
ihlr-16500	409	12	long	long	ADJ
ihlr-16500	409	13	road	road	NOUN
ihlr-16500	409	14	of	of	ADP
ihlr-16500	409	15	litigation	litigation	NOUN
ihlr-16500	409	16	by	by	ADP
ihlr-16500	409	17	stock­	stock­	NOUN
ihlr-16500	409	18	piling	pile	VERB
ihlr-16500	409	19	a	a	DET
ihlr-16500	409	20	significant	significant	ADJ
ihlr-16500	409	21	amount	amount	NOUN
ihlr-16500	409	22	of	of	ADP
ihlr-16500	409	23	capital	capital	NOUN
ihlr-16500	409	24	to	to	PART
ihlr-16500	409	25	fight	fight	VERB
ihlr-16500	409	26	lawsuits.94	lawsuits.94	NOUN
ihlr-16500	409	27	unlike	unlike	ADP
ihlr-16500	409	28	its	its	PRON
ihlr-16500	409	29	statin	statin	PROPN
ihlr-16500	409	30	coun­	coun­	NOUN
ihlr-16500	409	31	terparts	terpart	NOUN
ihlr-16500	409	32	,	,	PUNCT
ihlr-16500	409	33	zocor	zocor	PROPN
ihlr-16500	409	34	,	,	PUNCT
ihlr-16500	409	35	lipitor	lipitor	NOUN
ihlr-16500	409	36	and	and	CCONJ
ihlr-16500	409	37	pravacol	pravacol	NOUN
ihlr-16500	409	38	,	,	PUNCT
ihlr-16500	409	39	bayer	bayer	PROPN
ihlr-16500	409	40	's	's	PART
ihlr-16500	409	41	baycol	baycol	NOUN
ihlr-16500	409	42	was	be	AUX
ihlr-16500	409	43	related	relate	VERB
ihlr-16500	409	44	to	to	ADP
ihlr-16500	409	45	the	the	DET
ihlr-16500	409	46	deaths	death	NOUN
ihlr-16500	409	47	of	of	ADP
ihlr-16500	409	48	nearly	nearly	ADV
ihlr-16500	409	49	one	one	NUM
ihlr-16500	409	50	hundred	hundred	NUM
ihlr-16500	409	51	people	people	NOUN
ihlr-16500	409	52	and	and	CCONJ
ihlr-16500	409	53	was	be	AUX
ihlr-16500	409	54	associated	associate	VERB
ihlr-16500	409	55	with	with	ADP
ihlr-16500	409	56	causing	cause	VERB
ihlr-16500	409	57	painful	painful	ADJ
ihlr-16500	409	58	side	side	NOUN
ihlr-16500	409	59	ef­	ef­	NOUN
ihlr-16500	409	60	fects	fect	NOUN
ihlr-16500	409	61	,	,	PUNCT
ihlr-16500	409	62	such	such	ADJ
ihlr-16500	409	63	as	as	ADP
ihlr-16500	409	64	rhabdomyolosis	rhabdomyolosis	NOUN
ihlr-16500	409	65	,	,	PUNCT
ihlr-16500	409	66	which	which	PRON
ihlr-16500	409	67	causes	cause	VERB
ihlr-16500	409	68	weakening	weaken	VERB
ihlr-16500	409	69	of	of	ADP
ihlr-16500	409	70	the	the	DET
ihlr-16500	409	71	muscles.95	muscles.95	NOUN
ihlr-16500	409	72	since	since	SCONJ
ihlr-16500	409	73	its	its	PRON
ihlr-16500	409	74	withdrawal	withdrawal	NOUN
ihlr-16500	409	75	,	,	PUNCT
ihlr-16500	409	76	many	many	ADJ
ihlr-16500	409	77	plaintiffs	plaintiff	NOUN
ihlr-16500	409	78	'	'	PART
ihlr-16500	409	79	attorneys	attorney	NOUN
ihlr-16500	409	80	had	have	AUX
ihlr-16500	409	81	been	be	AUX
ihlr-16500	409	82	critical	critical	ADJ
ihlr-16500	409	83	of	of	ADP
ihlr-16500	409	84	bayer	bayer	PROPN
ihlr-16500	409	85	's	's	PART
ihlr-16500	409	86	handling	handling	NOUN
ihlr-16500	409	87	of	of	ADP
ihlr-16500	409	88	the	the	DET
ihlr-16500	409	89	drug	drug	NOUN
ihlr-16500	409	90	,	,	PUNCT
ihlr-16500	409	91	even	even	ADV
ihlr-16500	409	92	claiming	claim	VERB
ihlr-16500	409	93	that	that	SCONJ
ihlr-16500	409	94	bayer	bayer	PROPN
ihlr-16500	409	95	's	's	PART
ihlr-16500	409	96	litigation	litigation	NOUN
ihlr-16500	409	97	costs	cost	NOUN
ihlr-16500	409	98	(	(	PUNCT
ihlr-16500	409	99	due	due	ADP
ihlr-16500	409	100	to	to	ADP
ihlr-16500	409	101	the	the	DET
ihlr-16500	409	102	withdrawal	withdrawal	NOUN
ihlr-16500	409	103	of	of	ADP
ihlr-16500	409	104	baycol	baycol	NOUN
ihlr-16500	409	105	)	)	PUNCT
ihlr-16500	409	106	would	would	AUX
ihlr-16500	409	107	ultimately	ultimately	ADV
ihlr-16500	409	108	cost	cost	VERB
ihlr-16500	409	109	fifty	fifty	NUM
ihlr-16500	409	110	billion	billion	NUM
ihlr-16500	409	111	dollars	dollar	NOUN
ihlr-16500	409	112	in	in	ADP
ihlr-16500	409	113	settlements	settlement	NOUN
ihlr-16500	409	114	and	and	CCONJ
ihlr-16500	409	115	judgments	judgment	NOUN
ihlr-16500	409	116	before	before	SCONJ
ihlr-16500	409	117	it	it	PRON
ihlr-16500	409	118	was	be	AUX
ihlr-16500	409	119	over.%	over.%	ADJ
ihlr-16500	409	120	as	as	ADP
ihlr-16500	409	121	a	a	DET
ihlr-16500	409	122	result	result	NOUN
ihlr-16500	409	123	of	of	ADP
ihlr-16500	409	124	the	the	DET
ihlr-16500	409	125	negative	negative	ADJ
ihlr-16500	409	126	press	press	NOUN
ihlr-16500	409	127	it	it	PRON
ihlr-16500	409	128	received	receive	VERB
ihlr-16500	409	129	and	and	CCONJ
ihlr-16500	409	130	the	the	DET
ihlr-16500	409	131	numerous	numerous	ADJ
ihlr-16500	409	132	lawsuits	lawsuit	NOUN
ihlr-16500	409	133	that	that	PRON
ihlr-16500	409	134	were	be	AUX
ihlr-16500	409	135	filed	file	VERB
ihlr-16500	409	136	against	against	ADP
ihlr-16500	409	137	it	it	PRON
ihlr-16500	409	138	,	,	PUNCT
ihlr-16500	409	139	bayer	bayer	PROPN
ihlr-16500	409	140	faced	face	VERB
ihlr-16500	409	141	a	a	DET
ihlr-16500	409	142	significant	significant	ADJ
ihlr-16500	409	143	financial	financial	ADJ
ihlr-16500	409	144	setback	setback	NOUN
ihlr-16500	409	145	due	due	ADP
ihlr-16500	409	146	to	to	ADP
ihlr-16500	409	147	baycol	baycol	VERB
ihlr-16500	409	148	'	'	PART
ihlr-16500	409	149	s	s	PART
ihlr-16500	409	150	withdrawal	withdrawal	NOUN
ihlr-16500	409	151	.	.	PUNCT
ihlr-16500	410	1	at	at	ADP
ihlr-16500	410	2	first	first	ADV
ihlr-16500	410	3	,	,	PUNCT
ihlr-16500	410	4	bayer	bayer	PROPN
ihlr-16500	410	5	settled	settle	VERB
ihlr-16500	410	6	2,312	2,312	NUM
ihlr-16500	410	7	cases	case	NOUN
ihlr-16500	410	8	for	for	ADP
ihlr-16500	410	9	$	$	SYM
ihlr-16500	410	10	872	872	NUM
ihlr-16500	410	11	million	million	NUM
ihlr-16500	410	12	,	,	PUNCT
ihlr-16500	410	13	including	include	VERB
ihlr-16500	410	14	sev­	sev­	NOUN
ihlr-16500	410	15	eral	eral	ADJ
ihlr-16500	410	16	settlements	settlement	NOUN
ihlr-16500	410	17	of	of	ADP
ihlr-16500	410	18	one	one	NUM
ihlr-16500	410	19	million	million	NUM
ihlr-16500	410	20	dollars	dollar	NOUN
ihlr-16500	410	21	for	for	ADP
ihlr-16500	410	22	the	the	DET
ihlr-16500	410	23	roughly	roughly	ADV
ihlr-16500	410	24	100	100	NUM
ihlr-16500	410	25	death	death	NOUN
ihlr-16500	410	26	cases.97	cases.97	NOUN
ihlr-16500	410	27	in	in	ADP
ihlr-16500	410	28	or92	or92	PROPN
ihlr-16500	410	29	/d	/d	PUNCT
ihlr-16500	410	30	.	.	PUNCT
ihlr-16500	411	1	93	93	NUM
ihlr-16500	411	2	baycol	baycol	PROPN
ihlr-16500	411	3	was	be	AUX
ihlr-16500	411	4	a	a	DET
ihlr-16500	411	5	cholesterol	cholesterol	NOUN
ihlr-16500	411	6	lowering	lower	VERB
ihlr-16500	411	7	drug	drug	NOUN
ihlr-16500	411	8	within	within	ADP
ihlr-16500	411	9	the	the	DET
ihlr-16500	411	10	category	category	NOUN
ihlr-16500	411	11	of	of	ADP
ihlr-16500	411	12	drugs	drug	NOUN
ihlr-16500	411	13	known	know	VERB
ihlr-16500	411	14	as	as	ADP
ihlr-16500	411	15	statins	statin	NOUN
ihlr-16500	411	16	.	.	PUNCT
ihlr-16500	412	1	94	94	NUM
ihlr-16500	412	2	monica	monica	PROPN
ihlr-16500	412	3	langley	langley	PROPN
ihlr-16500	412	4	,	,	PUNCT
ihlr-16500	412	5	bayer	bayer	PROPN
ihlr-16500	412	6	,	,	PUNCT
ihlr-16500	412	7	pressed	press	VERB
ihlr-16500	412	8	to	to	PART
ihlr-16500	412	9	settle	settle	VERB
ihlr-16500	412	10	a	a	DET
ihlr-16500	412	11	flood	flood	NOUN
ihlr-16500	412	12	of	of	ADP
ihlr-16500	412	13	suits	suit	NOUN
ihlr-16500	412	14	over	over	ADP
ihlr-16500	412	15	drug	drug	NOUN
ihlr-16500	412	16	,	,	PUNCT
ihlr-16500	412	17	fights	fight	VERB
ihlr-16500	412	18	back	back	ADV
ihlr-16500	412	19	,	,	PUNCT
ihlr-16500	413	1	wall	wall	PROPN
ihlr-16500	413	2	st	st	PROPN
ihlr-16500	413	3	.	.	PROPN
ihlr-16500	413	4	j.	j.	PROPN
ihlr-16500	413	5	,	,	PUNCT
ihlr-16500	413	6	may	may	AUX
ihlr-16500	413	7	4	4	NUM
ihlr-16500	413	8	,	,	PUNCT
ihlr-16500	413	9	2004	2004	NUM
ihlr-16500	413	10	,	,	PUNCT
ihlr-16500	413	11	at	at	ADP
ihlr-16500	413	12	al	al	PROPN
ihlr-16500	413	13	,	,	PUNCT
ihlr-16500	413	14	availableatbttp://webreprints.djreprints.com/1220931162452	availableatbttp://webreprints.djreprints.com/1220931162452	PROPN
ihlr-16500	413	15	.httnl	.httnl	PRON
ihlr-16500	413	16	.	.	PUNCT
ihlr-16500	414	1	9s	9s	NUM
ihlr-16500	415	1	i	i	PRON
ihlr-16500	415	2	d.	d.	PROPN
ihlr-16500	415	3	96	96	NUM
ihlr-16500	416	1	i	i	PRON
ihlr-16500	416	2	d.	d.	PROPN
ihlr-16500	416	3	97	97	NUM
ihlr-16500	416	4	!	!	PUNCT
ihlr-16500	417	1	d.	d.	PROPN
ihlr-16500	417	2	2007	2007	NUM
ihlr-16500	417	3	]	]	PUNCT
ihlr-16500	418	1	puujng	puujng	X
ihlr-16500	418	2	a	a	DET
ihlr-16500	418	3	blockbuster	blockbuster	ADJ
ihlr-16500	418	4	drug	drug	NOUN
ihlr-16500	418	5	off	off	ADP
ihlr-16500	418	6	the	the	DET
ihlr-16500	418	7	market	market	NOUN
ihlr-16500	418	8	133	133	NUM
ihlr-16500	418	9	der	der	NOUN
ihlr-16500	418	10	to	to	PART
ihlr-16500	418	11	cover	cover	VERB
ihlr-16500	418	12	the	the	DET
ihlr-16500	418	13	legal	legal	ADJ
ihlr-16500	418	14	costs	cost	NOUN
ihlr-16500	418	15	associated	associate	VERB
ihlr-16500	418	16	with	with	ADP
ihlr-16500	418	17	the	the	DET
ihlr-16500	418	18	nearly	nearly	ADV
ihlr-16500	418	19	9,278	9,278	NUM
ihlr-16500	418	20	lawsuits	lawsuit	NOUN
ihlr-16500	418	21	pending	pende	VERB
ihlr-16500	418	22	since	since	SCONJ
ihlr-16500	418	23	baycol	baycol	PROPN
ihlr-16500	418	24	was	be	AUX
ihlr-16500	418	25	pulled	pull	VERB
ihlr-16500	418	26	:	:	PUNCT
ihlr-16500	418	27	from	from	ADP
ihlr-16500	418	28	the	the	DET
ihlr-16500	418	29	market	market	NOUN
ihlr-16500	418	30	,	,	PUNCT
ihlr-16500	418	31	bayer	bayer	PROPN
ihlr-16500	418	32	set	set	VERB
ihlr-16500	418	33	aside	aside	ADV
ihlr-16500	418	34	nearly	nearly	ADV
ihlr-16500	418	35	$	$	SYM
ihlr-16500	418	36	1.2	1.2	NUM
ihlr-16500	418	37	billion	billion	NUM
ihlr-16500	418	38	,	,	PUNCT
ihlr-16500	418	39	mostly	mostly	ADV
ihlr-16500	418	40	provided	provide	VERB
ihlr-16500	418	41	by	by	ADP
ihlr-16500	418	42	insurers	insurer	NOUN
ihlr-16500	418	43	.	.	PUNCT
ihlr-16500	419	1	98	98	NUM
ihlr-16500	419	2	furthermore	furthermore	ADV
ihlr-16500	419	3	,	,	PUNCT
ihlr-16500	419	4	bayer	bayer	PROPN
ihlr-16500	419	5	had	have	VERB
ihlr-16500	419	6	to	to	PART
ihlr-16500	419	7	plan	plan	VERB
ihlr-16500	419	8	for	for	ADP
ihlr-16500	419	9	any	any	DET
ihlr-16500	419	10	possible	possible	ADJ
ihlr-16500	419	11	losses	loss	NOUN
ihlr-16500	419	12	in	in	ADP
ihlr-16500	419	13	such	such	ADJ
ihlr-16500	419	14	cases	case	NOUN
ihlr-16500	419	15	or	or	CCONJ
ihlr-16500	419	16	in	in	ADP
ihlr-16500	419	17	settlement	settlement	NOUN
ihlr-16500	419	18	of	of	ADP
ihlr-16500	419	19	some	some	PRON
ihlr-16500	419	20	of	of	ADP
ihlr-16500	419	21	the	the	DET
ihlr-16500	419	22	lawsuits	lawsuit	NOUN
ihlr-16500	419	23	.	.	PUNCT
ihlr-16500	420	1	from	from	ADP
ihlr-16500	420	2	its	its	PRON
ihlr-16500	420	3	initial	initial	ADJ
ihlr-16500	420	4	withdrawal	withdrawal	NOUN
ihlr-16500	420	5	ofbaycol	ofbaycol	PRON
ihlr-16500	420	6	until2004	until2004	NOUN
ihlr-16500	420	7	,	,	PUNCT
ihlr-16500	420	8	bayer	bayer	PROPN
ihlr-16500	420	9	had	have	AUX
ihlr-16500	420	10	settled	settle	VERB
ihlr-16500	420	11	2,312	2,312	NUM
ihlr-16500	420	12	lawsuits	lawsuit	NOUN
ihlr-16500	420	13	and	and	CCONJ
ihlr-16500	420	14	as	as	SCONJ
ihlr-16500	420	15	are­	are­	PROPN
ihlr-16500	420	16	sult	sult	PROPN
ihlr-16500	420	17	paid	pay	VERB
ihlr-16500	420	18	nearly	nearly	ADV
ihlr-16500	420	19	$	$	SYM
ihlr-16500	420	20	872	872	NUM
ihlr-16500	420	21	million	million	NUM
ihlr-16500	420	22	.	.	PUNCT
ihlr-16500	421	1	99	99	NUM
ihlr-16500	422	1	there	there	PRON
ihlr-16500	422	2	were	be	VERB
ihlr-16500	422	3	over	over	ADP
ihlr-16500	422	4	9,000	9,000	NUM
ihlr-16500	422	5	lawsuits	lawsuit	NOUN
ihlr-16500	422	6	pending	pende	VERB
ihlr-16500	422	7	,	,	PUNCT
ihlr-16500	422	8	which	which	PRON
ihlr-16500	422	9	plaintiffs	plaintiff	NOUN
ihlr-16500	422	10	'	'	PART
ihlr-16500	422	11	attorneys	attorney	NOUN
ihlr-16500	422	12	,	,	PUNCT
ihlr-16500	422	13	such	such	ADJ
ihlr-16500	422	14	as	as	ADP
ihlr-16500	422	15	mikal	mikal	PROPN
ihlr-16500	422	16	watts	watts	PROPN
ihlr-16500	422	17	,	,	PUNCT
ihlr-16500	422	18	believe	believe	VERB
ihlr-16500	422	19	will	will	AUX
ihlr-16500	422	20	end	end	VERB
ihlr-16500	422	21	up	up	ADP
ihlr-16500	422	22	costing	cost	VERB
ihlr-16500	422	23	the	the	DET
ihlr-16500	422	24	com­	com­	NOUN
ihlr-16500	422	25	pany	pany	NOUN
ihlr-16500	422	26	in	in	ADP
ihlr-16500	422	27	excess	excess	NOUN
ihlr-16500	422	28	of	of	ADP
ihlr-16500	422	29	fifty	fifty	NUM
ihlr-16500	422	30	billion	billion	NUM
ihlr-16500	422	31	dollars.100	dollars.100	NOUN
ihlr-16500	422	32	therefore	therefore	ADV
ihlr-16500	422	33	,	,	PUNCT
ihlr-16500	422	34	not	not	PART
ihlr-16500	422	35	only	only	ADV
ihlr-16500	422	36	did	do	AUX
ihlr-16500	422	37	bayer	bayer	PROPN
ihlr-16500	422	38	lose	lose	VERB
ihlr-16500	422	39	one	one	NUM
ihlr-16500	422	40	of	of	ADP
ihlr-16500	422	41	its	its	PRON
ihlr-16500	422	42	most	most	ADV
ihlr-16500	422	43	profitable	profitable	ADJ
ihlr-16500	422	44	products	product	NOUN
ihlr-16500	422	45	,	,	PUNCT
ihlr-16500	422	46	but	but	CCONJ
ihlr-16500	422	47	it	it	PRON
ihlr-16500	422	48	was	be	AUX
ihlr-16500	422	49	faced	face	VERB
ihlr-16500	422	50	with	with	ADP
ihlr-16500	422	51	the	the	DET
ihlr-16500	422	52	prospect	prospect	NOUN
ihlr-16500	422	53	of	of	ADP
ihlr-16500	422	54	using	use	VERB
ihlr-16500	422	55	capi­	capi­	NOUN
ihlr-16500	422	56	tal	tal	PROPN
ihlr-16500	422	57	that	that	SCONJ
ihlr-16500	422	58	it	it	PRON
ihlr-16500	422	59	had	have	AUX
ihlr-16500	422	60	reserved	reserve	VERB
ihlr-16500	422	61	for	for	ADP
ihlr-16500	422	62	research	research	NOUN
ihlr-16500	422	63	and	and	CCONJ
ihlr-16500	422	64	development	development	NOUN
ihlr-16500	422	65	of	of	ADP
ihlr-16500	422	66	other	other	ADJ
ihlr-16500	422	67	compounds	compound	NOUN
ihlr-16500	422	68	to	to	PART
ihlr-16500	422	69	fend	fend	VERB
ihlr-16500	422	70	off	off	ADP
ihlr-16500	422	71	plaintiffs	plaintiff	NOUN
ihlr-16500	422	72	'	'	PART
ihlr-16500	422	73	attorneys	attorney	NOUN
ihlr-16500	422	74	who	who	PRON
ihlr-16500	422	75	wanted	want	VERB
ihlr-16500	422	76	a	a	DET
ihlr-16500	422	77	piece	piece	NOUN
ihlr-16500	422	78	of	of	ADP
ihlr-16500	422	79	the	the	DET
ihlr-16500	422	80	ever	ever	ADV
ihlr-16500	422	81	-	-	PUNCT
ihlr-16500	422	82	increasing	increase	VERB
ihlr-16500	422	83	lawsuit	lawsuit	NOUN
ihlr-16500	422	84	pie	pie	NOUN
ihlr-16500	422	85	.	.	PUNCT
ihlr-16500	423	1	another	another	DET
ihlr-16500	423	2	possible	possible	ADJ
ihlr-16500	423	3	fmancial	fmancial	ADJ
ihlr-16500	423	4	consequence	consequence	NOUN
ihlr-16500	423	5	of	of	ADP
ihlr-16500	423	6	pulling	pull	VERB
ihlr-16500	423	7	a	a	DET
ihlr-16500	423	8	drug	drug	NOUN
ihlr-16500	423	9	off	off	ADP
ihlr-16500	423	10	the	the	DET
ihlr-16500	423	11	market	market	NOUN
ihlr-16500	423	12	is	be	AUX
ihlr-16500	423	13	the	the	DET
ihlr-16500	423	14	stock	stock	NOUN
ihlr-16500	423	15	market	market	NOUN
ihlr-16500	423	16	's	's	PART
ihlr-16500	423	17	downward	downward	ADJ
ihlr-16500	423	18	valuation	valuation	NOUN
ihlr-16500	423	19	of	of	ADP
ihlr-16500	423	20	the	the	DET
ihlr-16500	423	21	company	company	NOUN
ihlr-16500	423	22	in	in	ADP
ihlr-16500	423	23	terms	term	NOUN
ihlr-16500	423	24	of	of	ADP
ihlr-16500	423	25	its	its	PRON
ihlr-16500	423	26	stock	stock	NOUN
ihlr-16500	423	27	price	price	NOUN
ihlr-16500	423	28	.	.	PUNCT
ihlr-16500	424	1	in	in	ADP
ihlr-16500	424	2	bayer	bayer	PROPN
ihlr-16500	424	3	's	's	PART
ihlr-16500	424	4	case	case	NOUN
ihlr-16500	424	5	,	,	PUNCT
ihlr-16500	424	6	as	as	ADP
ihlr-16500	424	7	a	a	DET
ihlr-16500	424	8	result	result	NOUN
ihlr-16500	424	9	of	of	ADP
ihlr-16500	424	10	the	the	DET
ihlr-16500	424	11	thousands	thousand	NOUN
ihlr-16500	424	12	of	of	ADP
ihlr-16500	424	13	lawsuits	lawsuit	NOUN
ihlr-16500	424	14	that	that	PRON
ihlr-16500	424	15	had	have	AUX
ihlr-16500	424	16	been	be	AUX
ihlr-16500	424	17	filed	file	VERB
ihlr-16500	424	18	against	against	ADP
ihlr-16500	424	19	the	the	DET
ihlr-16500	424	20	company	company	NOUN
ihlr-16500	424	21	and	and	CCONJ
ihlr-16500	424	22	the	the	DET
ihlr-16500	424	23	long	long	ADJ
ihlr-16500	424	24	road	road	NOUN
ihlr-16500	424	25	oflitigation	oflitigation	NOUN
ihlr-16500	424	26	ahead	ahead	ADV
ihlr-16500	424	27	which	which	PRON
ihlr-16500	424	28	the	the	DET
ihlr-16500	424	29	com­	com­	NOUN
ihlr-16500	424	30	pany	pany	NOUN
ihlr-16500	424	31	would	would	AUX
ihlr-16500	424	32	inevitably	inevitably	ADV
ihlr-16500	424	33	have	have	VERB
ihlr-16500	424	34	to	to	PART
ihlr-16500	424	35	face	face	VERB
ihlr-16500	424	36	over	over	ADP
ihlr-16500	424	37	the	the	DET
ihlr-16500	424	38	next	next	ADJ
ihlr-16500	424	39	decade	decade	NOUN
ihlr-16500	424	40	,	,	PUNCT
ihlr-16500	424	41	the	the	DET
ihlr-16500	424	42	company	company	NOUN
ihlr-16500	424	43	saw	see	VERB
ihlr-16500	424	44	a	a	DET
ihlr-16500	424	45	significant	significant	ADJ
ihlr-16500	424	46	setback	setback	NOUN
ihlr-16500	424	47	in	in	ADP
ihlr-16500	424	48	its	its	PRON
ihlr-16500	424	49	stock	stock	NOUN
ihlr-16500	424	50	price.101	price.101	PROPN
ihlr-16500	424	51	the	the	DET
ihlr-16500	424	52	lack	lack	NOUN
ihlr-16500	424	53	of	of	ADP
ihlr-16500	424	54	market	market	NOUN
ihlr-16500	424	55	confidence	confidence	NOUN
ihlr-16500	424	56	in	in	ADP
ihlr-16500	424	57	bayer	bayer	PROPN
ihlr-16500	424	58	remained	remain	VERB
ihlr-16500	424	59	even	even	ADV
ihlr-16500	424	60	though	though	SCONJ
ihlr-16500	424	61	bayer	bayer	PROPN
ihlr-16500	424	62	produced	produce	VERB
ihlr-16500	424	63	several	several	ADJ
ihlr-16500	424	64	high	high	ADJ
ihlr-16500	424	65	profile	profile	NOUN
ihlr-16500	424	66	blockbuster	blockbuster	NOUN
ihlr-16500	424	67	drugs	drug	NOUN
ihlr-16500	424	68	after	after	ADP
ihlr-16500	424	69	baycol	baycol	NOUN
ihlr-16500	424	70	's	's	PART
ihlr-16500	424	71	withdrawal	withdrawal	NOUN
ihlr-16500	424	72	,	,	PUNCT
ihlr-16500	424	73	including	include	VERB
ihlr-16500	424	74	levitra	levitra	PROPN
ihlr-16500	424	75	,	,	PUNCT
ihlr-16500	424	76	a	a	DET
ihlr-16500	424	77	drug	drug	NOUN
ihlr-16500	424	78	used	use	VERB
ihlr-16500	424	79	to	to	PART
ihlr-16500	424	80	treat	treat	VERB
ihlr-16500	424	81	erectile	erectile	ADJ
ihlr-16500	424	82	dys­	dys­	PROPN
ihlr-16500	424	83	function	function	NOUN
ihlr-16500	424	84	.	.	PUNCT
ihlr-16500	425	1	another	another	DET
ihlr-16500	425	2	example	example	NOUN
ihlr-16500	425	3	of	of	ADP
ihlr-16500	425	4	a	a	DET
ihlr-16500	425	5	company	company	NOUN
ihlr-16500	425	6	's	's	PART
ihlr-16500	425	7	stock	stock	NOUN
ihlr-16500	425	8	devaluation	devaluation	NOUN
ihlr-16500	425	9	due	due	ADP
ihlr-16500	425	10	to	to	ADP
ihlr-16500	425	11	a	a	DET
ihlr-16500	425	12	drug	drug	NOUN
ihlr-16500	425	13	with­	with­	PROPN
ihlr-16500	425	14	drawal	drawal	NOUN
ihlr-16500	425	15	occurred	occur	VERB
ihlr-16500	425	16	when	when	SCONJ
ihlr-16500	425	17	merck	merck	PROPN
ihlr-16500	425	18	voluntarily	voluntarily	ADV
ihlr-16500	425	19	withdrew	withdraw	VERB
ihlr-16500	425	20	vioxx	vioxx	NOUN
ihlr-16500	425	21	from	from	ADP
ihlr-16500	425	22	the	the	DET
ihlr-16500	425	23	market	market	NOUN
ihlr-16500	425	24	.	.	PUNCT
ihlr-16500	426	1	arguably	arguably	ADV
ihlr-16500	426	2	,	,	PUNCT
ihlr-16500	426	3	no	no	DET
ihlr-16500	426	4	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	426	5	company	company	NOUN
ihlr-16500	426	6	has	have	AUX
ihlr-16500	426	7	faced	face	VERB
ihlr-16500	426	8	wall	wall	PROPN
ihlr-16500	426	9	street	street	PROPN
ihlr-16500	426	10	's	's	PART
ihlr-16500	426	11	wrath	wrath	NOUN
ihlr-16500	426	12	quite	quite	ADV
ihlr-16500	426	13	like	like	ADP
ihlr-16500	426	14	merck	merck	NOUN
ihlr-16500	426	15	,	,	PUNCT
ihlr-16500	426	16	which	which	PRON
ihlr-16500	426	17	faced	face	VERB
ihlr-16500	426	18	a	a	DET
ihlr-16500	426	19	significant	significant	ADJ
ihlr-16500	426	20	decrease	decrease	NOUN
ihlr-16500	426	21	in	in	ADP
ihlr-16500	426	22	stock	stock	NOUN
ihlr-16500	426	23	price	price	NOUN
ihlr-16500	426	24	after	after	ADP
ihlr-16500	426	25	pulling	pull	VERB
ihlr-16500	426	26	vioxx	vioxx	NOUN
ihlr-16500	426	27	off	off	ADP
ihlr-16500	426	28	the	the	DET
ihlr-16500	426	29	market	market	NOUN
ihlr-16500	426	30	because	because	SCONJ
ihlr-16500	426	31	of	of	ADP
ihlr-16500	426	32	impending	impend	VERB
ihlr-16500	426	33	litigation.102	litigation.102	NOUN
ihlr-16500	426	34	it	it	PRON
ihlr-16500	426	35	is	be	AUX
ihlr-16500	426	36	easy	easy	ADJ
ihlr-16500	426	37	to	to	PART
ihlr-16500	426	38	see	see	VERB
ihlr-16500	426	39	how	how	SCONJ
ihlr-16500	426	40	investor	investor	NOUN
ihlr-16500	426	41	faith	faith	NOUN
ihlr-16500	426	42	in	in	ADP
ihlr-16500	426	43	the	the	DET
ihlr-16500	426	44	pharmaceutical	pharmaceutical	NOUN
ihlr-16500	426	45	industry	industry	NOUN
ihlr-16500	426	46	has	have	AUX
ihlr-16500	426	47	begun	begin	VERB
ihlr-16500	426	48	to	to	PART
ihlr-16500	426	49	wane	wane	VERB
ihlr-16500	426	50	as	as	ADP
ihlr-16500	426	51	a	a	DET
ihlr-16500	426	52	result	result	NOUN
ihlr-16500	426	53	of	of	ADP
ihlr-16500	426	54	continual	continual	ADJ
ihlr-16500	426	55	litigation103	litigation103	PROPN
ihlr-16500	426	56	and	and	CCONJ
ihlr-16500	426	57	the	the	DET
ihlr-16500	426	58	fact	fact	NOUN
ihlr-16500	426	59	that	that	SCONJ
ihlr-16500	426	60	vioxx	vioxx	NOUN
ihlr-16500	426	61	was	be	AUX
ihlr-16500	426	62	the	the	DET
ihlr-16500	426	63	ninth	ninth	ADJ
ihlr-16500	426	64	prescription	prescription	NOUN
ihlr-16500	426	65	drug	drug	NOUN
ihlr-16500	426	66	to	to	PART
ihlr-16500	426	67	be	be	AUX
ihlr-16500	426	68	invol­	invol­	AUX
ihlr-16500	426	69	untarily	untarily	ADV
ihlr-16500	426	70	withdrawn	withdraw	VERB
ihlr-16500	426	71	from	from	ADP
ihlr-16500	426	72	the	the	DET
ihlr-16500	426	73	market	market	NOUN
ihlr-16500	426	74	due	due	ADP
ihlr-16500	426	75	to	to	ADP
ihlr-16500	426	76	death	death	NOUN
ihlr-16500	426	77	or	or	CCONJ
ihlr-16500	426	78	injury	injury	NOUN
ihlr-16500	426	79	in	in	ADP
ihlr-16500	426	80	the	the	DET
ihlr-16500	426	81	last	last	ADJ
ihlr-16500	426	82	seven	seven	NUM
ihlr-16500	426	83	years	year	NOUN
ihlr-16500	426	84	.	.	PUNCT
ihlr-16500	427	1	104	104	NUM
ihlr-16500	427	2	also	also	ADV
ihlr-16500	427	3	,	,	PUNCT
ihlr-16500	427	4	vioxx	vioxx	PROPN
ihlr-16500	427	5	was	be	AUX
ihlr-16500	427	6	a	a	DET
ihlr-16500	427	7	different	different	ADJ
ihlr-16500	427	8	type	type	NOUN
ihlr-16500	427	9	of	of	ADP
ihlr-16500	427	10	blockbuster	blockbuster	ADJ
ihlr-16500	427	11	drug	drug	NOUN
ihlr-16500	427	12	:	:	PUNCT
ihlr-16500	427	13	vioxx	vioxx	NOUN
ihlr-16500	427	14	was	be	AUX
ihlr-16500	427	15	a	a	DET
ihlr-16500	427	16	98	98	NUM
ihlr-16500	427	17	/d	/d	PUNCT
ihlr-16500	427	18	.	.	PROPN
ihlr-16500	427	19	99	99	NUM
ihlr-16500	428	1	/d	/d	PUNCT
ihlr-16500	428	2	.	.	PROPN
ihlr-16500	428	3	100	100	NUM
ihlr-16500	428	4	/d	/d	PUNCT
ihlr-16500	428	5	..	..	PUNCT
ihlr-16500	428	6	101	101	NUM
ihlr-16500	428	7	yahoo	yahoo	PROPN
ihlr-16500	428	8	!	!	PUNCT
ihlr-16500	428	9	finance	finance	PROPN
ihlr-16500	428	10	,	,	PUNCT
ihlr-16500	428	11	bayer	bayer	PROPN
ihlr-16500	428	12	historical	historical	ADJ
ihlr-16500	428	13	prices	price	NOUN
ihlr-16500	428	14	,	,	PUNCT
ihlr-16500	428	15	date	date	NOUN
ihlr-16500	428	16	range	range	NOUN
ihlr-16500	428	17	:	:	PUNCT
ihlr-16500	428	18	nov	nov	PROPN
ihlr-16500	428	19	.	.	PROPN
ihlr-16500	428	20	18	18	NUM
ihlr-16500	428	21	,	,	PUNCT
ihlr-16500	428	22	2000	2000	NUM
ihlr-16500	428	23	to	to	ADP
ihlr-16500	428	24	jan	jan	PROPN
ihlr-16500	428	25	.	.	PROPN
ihlr-16500	428	26	4	4	NUM
ihlr-16500	428	27	,	,	PUNCT
ihlr-16500	428	28	2003	2003	NUM
ihlr-16500	428	29	,	,	PUNCT
ihlr-16500	428	30	http://finance.yahoo.com/qlhp?s=bay&a=lo&b=18&c=2000&d=oo&e=4&f=2003&g=m	http://finance.yahoo.com/qlhp?s=bay&a=lo&b=18&c=2000&d=oo&e=4&f=2003&g=m	PROPN
ihlr-16500	428	31	(	(	PUNCT
ihlr-16500	428	32	last	last	ADV
ihlr-16500	428	33	visited	visit	VERB
ihlr-16500	428	34	feb	feb	PROPN
ihlr-16500	428	35	.	.	PROPN
ihlr-16500	428	36	20	20	NUM
ihlr-16500	428	37	,	,	PUNCT
ihlr-16500	428	38	2007	2007	NUM
ihlr-16500	428	39	)	)	PUNCT
ihlr-16500	428	40	.	.	PUNCT
ihlr-16500	429	1	from	from	ADP
ihlr-16500	429	2	2001	2001	NUM
ihlr-16500	429	3	to	to	ADP
ihlr-16500	429	4	2003	2003	NUM
ihlr-16500	429	5	,	,	PUNCT
ihlr-16500	429	6	bayer	bayer	PROPN
ihlr-16500	429	7	's	's	PART
ihlr-16500	429	8	stock	stock	NOUN
ihlr-16500	429	9	price	price	NOUN
ihlr-16500	429	10	decreased	decrease	VERB
ihlr-16500	429	11	by	by	ADP
ihlr-16500	429	12	approximately	approximately	ADV
ihlr-16500	429	13	eighteen	eighteen	NUM
ihlr-16500	429	14	dollars	dollar	NOUN
ihlr-16500	429	15	,	,	PUNCT
ihlr-16500	429	16	in	in	ADP
ihlr-16500	429	17	large	large	ADJ
ihlr-16500	429	18	part	part	NOUN
ihlr-16500	429	19	due	due	ADP
ihlr-16500	429	20	to	to	ADP
ihlr-16500	429	21	the	the	DET
ihlr-16500	429	22	damage	damage	NOUN
ihlr-16500	429	23	caused	cause	VERB
ihlr-16500	429	24	by	by	ADP
ihlr-16500	429	25	the	the	DET
ihlr-16500	429	26	withdrawal	withdrawal	NOUN
ihlr-16500	429	27	ofbaycol	ofbaycol	NOUN
ihlr-16500	429	28	from	from	ADP
ihlr-16500	429	29	the	the	DET
ihlr-16500	429	30	market	market	NOUN
ihlr-16500	429	31	and	and	CCONJ
ihlr-16500	429	32	a	a	DET
ihlr-16500	429	33	lack	lack	NOUN
ihlr-16500	429	34	of	of	ADP
ihlr-16500	429	35	confidence	confidence	NOUN
ihlr-16500	429	36	from	from	ADP
ihlr-16500	429	37	investors	investor	NOUN
ihlr-16500	429	38	that	that	SCONJ
ihlr-16500	429	39	the	the	DET
ihlr-16500	429	40	company	company	NOUN
ihlr-16500	429	41	would	would	AUX
ihlr-16500	429	42	bounce	bounce	VERB
ihlr-16500	429	43	back	back	ADV
ihlr-16500	429	44	in	in	ADP
ihlr-16500	429	45	the	the	DET
ihlr-16500	429	46	wake	wake	NOUN
ihlr-16500	429	47	of	of	ADP
ihlr-16500	429	48	impending	impend	VERB
ihlr-16500	429	49	litigation	litigation	NOUN
ihlr-16500	429	50	.	.	PUNCT
ihlr-16500	430	1	102	102	NUM
ihlr-16500	430	2	yahoo	yahoo	PROPN
ihlr-16500	430	3	!	!	PUNCT
ihlr-16500	430	4	finance	finance	PROPN
ihlr-16500	430	5	,	,	PUNCT
ihlr-16500	430	6	merck	merck	PROPN
ihlr-16500	430	7	historical	historical	ADJ
ihlr-16500	430	8	prices	price	NOUN
ihlr-16500	430	9	,	,	PUNCT
ihlr-16500	430	10	date	date	NOUN
ihlr-16500	430	11	range	range	NOUN
ihlr-16500	430	12	:	:	PUNCT
ihlr-16500	430	13	aug	aug	PROPN
ihlr-16500	430	14	.	.	PROPN
ihlr-16500	430	15	2	2	NUM
ihlr-16500	430	16	,	,	PUNCT
ihlr-16500	430	17	2004	2004	NUM
ihlr-16500	430	18	to	to	ADP
ihlr-16500	430	19	nov	nov	PROPN
ihlr-16500	430	20	.	.	PROPN
ihlr-16500	430	21	4	4	NUM
ihlr-16500	430	22	,	,	PUNCT
ihlr-16500	430	23	2004	2004	NUM
ihlr-16500	430	24	,	,	PUNCT
ihlr-16500	430	25	http://finance.yahoo.com/qlhp?s=mrk&a=07&b=2&c=2004&d=10&e=4&f=2004&g=d	http://finance.yahoo.com/qlhp?s=mrk&a=07&b=2&c=2004&d=10&e=4&f=2004&g=d	NOUN
ihlr-16500	430	26	(	(	PUNCT
ihlr-16500	430	27	last	last	ADJ
ihlr-16500	430	28	visited	visit	VERB
ihlr-16500	430	29	feb	feb	PROPN
ihlr-16500	430	30	.	.	PROPN
ihlr-16500	430	31	20	20	NUM
ihlr-16500	430	32	,	,	PUNCT
ihlr-16500	430	33	2007	2007	NUM
ihlr-16500	430	34	)	)	PUNCT
ihlr-16500	430	35	.	.	PUNCT
ihlr-16500	431	1	in	in	ADP
ihlr-16500	431	2	a	a	DET
ihlr-16500	431	3	span	span	NOUN
ihlr-16500	431	4	of	of	ADP
ihlr-16500	431	5	three	three	NUM
ihlr-16500	431	6	months	month	NOUN
ihlr-16500	431	7	,	,	PUNCT
ihlr-16500	431	8	from	from	ADP
ihlr-16500	431	9	august	august	PROPN
ihlr-16500	431	10	2004	2004	NUM
ihlr-16500	431	11	to	to	ADP
ihlr-16500	431	12	october	october	PROPN
ihlr-16500	431	13	2004	2004	NUM
ihlr-16500	431	14	,	,	PUNCT
ihlr-16500	431	15	merck	merck	PROPN
ihlr-16500	431	16	's	's	PART
ihlr-16500	431	17	stock	stock	NOUN
ihlr-16500	431	18	price	price	NOUN
ihlr-16500	431	19	dropped	drop	VERB
ihlr-16500	431	20	by	by	ADP
ihlr-16500	431	21	approximately	approximately	ADV
ihlr-16500	431	22	sixteen	sixteen	NUM
ihlr-16500	431	23	dollars	dollar	NOUN
ihlr-16500	431	24	due	due	ADP
ihlr-16500	431	25	to	to	ADP
ihlr-16500	431	26	the	the	DET
ihlr-16500	431	27	voluntary	voluntary	ADJ
ihlr-16500	431	28	withdrawal	withdrawal	NOUN
ihlr-16500	431	29	ofvioxx	ofvioxx	ADV
ihlr-16500	431	30	.	.	PUNCT
ihlr-16500	432	1	103	103	NUM
ihlr-16500	432	2	/d	/d	PUNCT
ihlr-16500	432	3	.	.	PUNCT
ihlr-16500	433	1	104	104	NUM
ihlr-16500	433	2	placitella	placitella	PROPN
ihlr-16500	433	3	&	&	CCONJ
ihlr-16500	433	4	klein	klein	PROPN
ihlr-16500	433	5	,	,	PUNCT
ihlr-16500	433	6	supra	supra	PROPN
ihlr-16500	433	7	note	note	PROPN
ihlr-16500	433	8	33	33	NUM
ihlr-16500	433	9	,	,	PUNCT
ihlr-16500	433	10	at	at	ADP
ihlr-16500	433	11	222	222	NUM
ihlr-16500	433	12	.	.	PUNCT
ihlr-16500	434	1	134	134	NUM
ihlr-16500	434	2	indiana	indiana	PROPN
ihlr-16500	434	3	health	health	PROPN
ihlr-16500	434	4	law	law	NOUN
ihlr-16500	434	5	review	review	NOUN
ihlr-16500	434	6	[	[	X
ihlr-16500	434	7	vol	vol	NOUN
ihlr-16500	434	8	.	.	PUNCT
ihlr-16500	434	9	4:115	4:115	NUM
ihlr-16500	434	10	veritable	veritable	ADJ
ihlr-16500	434	11	super	super	ADV
ihlr-16500	434	12	blockbuster	blockbuster	ADJ
ihlr-16500	434	13	drug	drug	NOUN
ihlr-16500	434	14	,	,	PUNCT
ihlr-16500	434	15	if	if	SCONJ
ihlr-16500	434	16	such	such	DET
ihlr-16500	434	17	a	a	DET
ihlr-16500	434	18	term	term	NOUN
ihlr-16500	434	19	exists	exist	VERB
ihlr-16500	434	20	.	.	PUNCT
ihlr-16500	435	1	it	it	PRON
ihlr-16500	435	2	had	have	AUX
ihlr-16500	435	3	entered	enter	VERB
ihlr-16500	435	4	the	the	DET
ihlr-16500	435	5	mar­	mar­	NOUN
ihlr-16500	435	6	ket	ket	NOUN
ihlr-16500	435	7	to	to	ADP
ihlr-16500	435	8	much	much	ADJ
ihlr-16500	435	9	hype	hype	NOUN
ihlr-16500	435	10	in	in	ADP
ihlr-16500	435	11	1999	1999	NUM
ihlr-16500	435	12	and	and	CCONJ
ihlr-16500	435	13	became	become	VERB
ihlr-16500	435	14	an	an	DET
ihlr-16500	435	15	instant	instant	ADJ
ihlr-16500	435	16	success	success	NOUN
ihlr-16500	435	17	,	,	PUNCT
ihlr-16500	435	18	grossing	gross	VERB
ihlr-16500	435	19	over	over	ADP
ihlr-16500	435	20	one	one	NUM
ihlr-16500	435	21	hundred	hundred	NUM
ihlr-16500	435	22	million	million	NUM
ihlr-16500	435	23	prescriptions	prescription	NOUN
ihlr-16500	435	24	,	,	PUNCT
ihlr-16500	435	25	including	include	VERB
ihlr-16500	435	26	twenty	twenty	NUM
ihlr-16500	435	27	million	million	NUM
ihlr-16500	435	28	users	user	NOUN
ihlr-16500	435	29	,	,	PUNCT
ihlr-16500	435	30	and	and	CCONJ
ihlr-16500	435	31	about	about	ADV
ihlr-16500	435	32	$	$	SYM
ihlr-16500	435	33	2.5	2.5	NUM
ihlr-16500	435	34	billion	billion	NUM
ihlr-16500	435	35	in	in	ADP
ihlr-16500	435	36	annual	annual	ADJ
ihlr-16500	435	37	sales	sale	NOUN
ihlr-16500	435	38	.	.	PUNCT
ihlr-16500	436	1	105	105	NUM
ihlr-16500	436	2	the	the	DET
ihlr-16500	436	3	fact	fact	NOUN
ihlr-16500	436	4	that	that	SCONJ
ihlr-16500	436	5	vioxx	vioxx	NOUN
ihlr-16500	436	6	was	be	AUX
ihlr-16500	436	7	such	such	DET
ihlr-16500	436	8	a	a	DET
ihlr-16500	436	9	highly	highly	ADV
ihlr-16500	436	10	advertised	advertise	VERB
ihlr-16500	436	11	drug	drug	NOUN
ihlr-16500	436	12	led	lead	VERB
ihlr-16500	436	13	to	to	ADP
ihlr-16500	436	14	a	a	DET
ihlr-16500	436	15	firestorm	firestorm	NOUN
ihlr-16500	436	16	of	of	ADP
ihlr-16500	436	17	publicity	publicity	NOUN
ihlr-16500	436	18	and	and	CCONJ
ihlr-16500	436	19	made	make	VERB
ihlr-16500	436	20	it	it	PRON
ihlr-16500	436	21	all	all	DET
ihlr-16500	436	22	the	the	PRON
ihlr-16500	436	23	more	more	ADV
ihlr-16500	436	24	vulnerable	vulnerable	ADJ
ihlr-16500	436	25	to	to	ADP
ihlr-16500	436	26	indi­	indi­	ADJ
ihlr-16500	436	27	vidual	vidual	ADJ
ihlr-16500	436	28	plaintiff	plaintiff	NOUN
ihlr-16500	436	29	and	and	CCONJ
ihlr-16500	436	30	class	class	NOUN
ihlr-16500	436	31	action	action	NOUN
ihlr-16500	436	32	lawsuits	lawsuit	NOUN
ihlr-16500	436	33	,	,	PUNCT
ihlr-16500	436	34	such	such	ADJ
ihlr-16500	436	35	as	as	ADP
ihlr-16500	436	36	personal	personal	ADJ
ihlr-16500	436	37	injury	injury	NOUN
ihlr-16500	436	38	tort	tort	NOUN
ihlr-16500	436	39	actions	action	NOUN
ihlr-16500	436	40	,	,	PUNCT
ihlr-16500	436	41	derivative	derivative	ADJ
ihlr-16500	436	42	lawsuits	lawsuit	NOUN
ihlr-16500	436	43	,	,	PUNCT
ihlr-16500	436	44	congressional	congressional	ADJ
ihlr-16500	436	45	investigations	investigation	NOUN
ihlr-16500	436	46	,	,	PUNCT
ihlr-16500	436	47	and	and	CCONJ
ihlr-16500	436	48	securities	security	NOUN
ihlr-16500	436	49	and	and	CCONJ
ihlr-16500	436	50	exchange	exchange	PROPN
ihlr-16500	436	51	commission	commission	PROPN
ihlr-16500	436	52	inquiries.106	inquiries.106	PRON
ihlr-16500	436	53	subsequently	subsequently	ADV
ihlr-16500	436	54	,	,	PUNCT
ihlr-16500	436	55	on	on	ADP
ihlr-16500	436	56	the	the	DET
ihlr-16500	436	57	day	day	NOUN
ihlr-16500	436	58	vioxx	vioxx	NOUN
ihlr-16500	436	59	's	's	PART
ihlr-16500	436	60	withdrawal	withdrawal	NOUN
ihlr-16500	436	61	was	be	AUX
ihlr-16500	436	62	announced	announce	VERB
ihlr-16500	436	63	,	,	PUNCT
ihlr-16500	436	64	merck	merck	PROPN
ihlr-16500	436	65	shares	share	NOUN
ihlr-16500	436	66	lost	lose	VERB
ihlr-16500	436	67	more	more	ADJ
ihlr-16500	436	68	than	than	ADP
ihlr-16500	436	69	twelve	twelve	NUM
ihlr-16500	436	70	dollars	dollar	NOUN
ihlr-16500	436	71	per	per	ADP
ihlr-16500	436	72	share	share	NOUN
ihlr-16500	436	73	,	,	PUNCT
ihlr-16500	436	74	dropping	drop	VERB
ihlr-16500	436	75	from	from	ADP
ihlr-16500	436	76	forty	forty	NUM
ihlr-16500	436	77	-	-	PUNCT
ihlr-16500	436	78	five	five	NUM
ihlr-16500	436	79	to	to	PART
ihlr-16500	436	80	thirty	thirty	NUM
ihlr-16500	436	81	-	-	PUNCT
ihlr-16500	436	82	three	three	NUM
ihlr-16500	436	83	dollars	dollar	NOUN
ihlr-16500	436	84	per	per	ADP
ihlr-16500	436	85	share	share	NOUN
ihlr-16500	436	86	,	,	PUNCT
ihlr-16500	436	87	later	later	ADV
ihlr-16500	436	88	stabilizing	stabilize	VERB
ihlr-16500	436	89	to	to	ADP
ihlr-16500	436	90	around	around	ADP
ihlr-16500	436	91	thirty	thirty	NUM
ihlr-16500	436	92	dollars	dollar	NOUN
ihlr-16500	436	93	per	per	ADP
ihlr-16500	436	94	share.107	share.107	NOUN
ihlr-16500	436	95	the	the	DET
ihlr-16500	436	96	withdrawal	withdrawal	NOUN
ihlr-16500	436	97	ofvioxx	ofvioxx	ADV
ihlr-16500	436	98	also	also	ADV
ihlr-16500	436	99	caused	cause	VERB
ihlr-16500	436	100	merck	merck	PROPN
ihlr-16500	436	101	,	,	PUNCT
ihlr-16500	436	102	the	the	DET
ihlr-16500	436	103	nation	nation	NOUN
ihlr-16500	436	104	's	's	PART
ihlr-16500	436	105	third	third	ADV
ihlr-16500	436	106	largest	large	ADJ
ihlr-16500	436	107	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	436	108	company	company	NOUN
ihlr-16500	436	109	,	,	PUNCT
ihlr-16500	436	110	to	to	PART
ihlr-16500	436	111	be	be	AUX
ihlr-16500	436	112	thought	think	VERB
ihlr-16500	436	113	of	of	ADP
ihlr-16500	436	114	as	as	ADP
ihlr-16500	436	115	a	a	DET
ihlr-16500	436	116	potential	potential	ADJ
ihlr-16500	436	117	merger	merger	NOUN
ihlr-16500	436	118	target.108	target.108	NOUN
ihlr-16500	436	119	in	in	ADP
ihlr-16500	436	120	fact	fact	NOUN
ihlr-16500	436	121	,	,	PUNCT
ihlr-16500	436	122	in	in	ADP
ihlr-16500	436	123	the	the	DET
ihlr-16500	436	124	months	month	NOUN
ihlr-16500	436	125	to	to	PART
ihlr-16500	436	126	follow	follow	VERB
ihlr-16500	436	127	,	,	PUNCT
ihlr-16500	436	128	merck	merck	PROPN
ihlr-16500	436	129	's	's	PART
ihlr-16500	436	130	board	board	NOUN
ihlr-16500	436	131	of	of	ADP
ihlr-16500	436	132	directors	director	NOUN
ihlr-16500	436	133	offered	offer	VERB
ihlr-16500	436	134	special	special	ADJ
ihlr-16500	436	135	bo­	bo­	PROPN
ihlr-16500	436	136	nuses	nuse	NOUN
ihlr-16500	436	137	to	to	ADP
ihlr-16500	436	138	230	230	NUM
ihlr-16500	436	139	of	of	ADP
ihlr-16500	436	140	its	its	PRON
ihlr-16500	436	141	most	most	ADV
ihlr-16500	436	142	senior	senior	ADJ
ihlr-16500	436	143	managers	manager	NOUN
ihlr-16500	436	144	,	,	PUNCT
ihlr-16500	436	145	which	which	PRON
ihlr-16500	436	146	would	would	AUX
ihlr-16500	436	147	be	be	AUX
ihlr-16500	436	148	triggered	trigger	VERB
ihlr-16500	436	149	if	if	SCONJ
ihlr-16500	436	150	either	either	CCONJ
ihlr-16500	436	151	the	the	DET
ihlr-16500	436	152	company	company	NOUN
ihlr-16500	436	153	was	be	AUX
ihlr-16500	436	154	taken	take	VERB
ihlr-16500	436	155	over	over	ADP
ihlr-16500	436	156	by	by	ADP
ihlr-16500	436	157	another	another	DET
ihlr-16500	436	158	firm	firm	NOUN
ihlr-16500	436	159	or	or	CCONJ
ihlr-16500	436	160	if	if	SCONJ
ihlr-16500	436	161	some	some	DET
ihlr-16500	436	162	other	other	ADJ
ihlr-16500	436	163	firm	firm	NOUN
ihlr-16500	436	164	acquired	acquire	VERB
ihlr-16500	436	165	twenty	twenty	NUM
ihlr-16500	436	166	percent	percent	NOUN
ihlr-16500	436	167	of	of	ADP
ihlr-16500	436	168	its	its	PRON
ihlr-16500	436	169	outstanding	outstanding	ADJ
ihlr-16500	436	170	shares	share	NOUN
ihlr-16500	436	171	.	.	PUNCT
ihlr-16500	437	1	ul9	ul9	NOUN
ihlr-16500	437	2	the	the	DET
ihlr-16500	437	3	vioxx	vioxx	NOUN
ihlr-16500	437	4	episode	episode	NOUN
ihlr-16500	437	5	proved	prove	VERB
ihlr-16500	437	6	that	that	SCONJ
ihlr-16500	437	7	not	not	PART
ihlr-16500	437	8	only	only	ADV
ihlr-16500	437	9	is	be	AUX
ihlr-16500	437	10	the	the	DET
ihlr-16500	437	11	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	437	12	company	company	NOUN
ihlr-16500	437	13	susceptible	susceptible	ADJ
ihlr-16500	437	14	to	to	ADP
ihlr-16500	437	15	a	a	DET
ihlr-16500	437	16	drop	drop	NOUN
ihlr-16500	437	17	in	in	ADP
ihlr-16500	437	18	stock	stock	NOUN
ihlr-16500	437	19	price	price	NOUN
ihlr-16500	437	20	,	,	PUNCT
ihlr-16500	437	21	but	but	CCONJ
ihlr-16500	437	22	as	as	ADP
ihlr-16500	437	23	a	a	DET
ihlr-16500	437	24	result	result	NOUN
ihlr-16500	437	25	,	,	PUNCT
ihlr-16500	437	26	the	the	DET
ihlr-16500	437	27	company	company	NOUN
ihlr-16500	437	28	may	may	AUX
ihlr-16500	437	29	also	also	ADV
ihlr-16500	437	30	face	face	VERB
ihlr-16500	437	31	a	a	DET
ihlr-16500	437	32	hostile	hostile	ADJ
ihlr-16500	437	33	takeover	takeover	NOUN
ihlr-16500	437	34	by	by	ADP
ihlr-16500	437	35	another	another	DET
ihlr-16500	437	36	company	company	NOUN
ihlr-16500	437	37	,	,	PUNCT
ihlr-16500	437	38	greatly	greatly	ADV
ihlr-16500	437	39	affecting	affect	VERB
ihlr-16500	437	40	investor	investor	NOUN
ihlr-16500	437	41	confidence	confidence	NOUN
ihlr-16500	437	42	in	in	ADP
ihlr-16500	437	43	the	the	DET
ihlr-16500	437	44	company	company	NOUN
ihlr-16500	437	45	.	.	PUNCT
ihlr-16500	438	1	nevertheless	nevertheless	ADV
ihlr-16500	438	2	,	,	PUNCT
ihlr-16500	438	3	any	any	DET
ihlr-16500	438	4	company	company	NOUN
ihlr-16500	438	5	that	that	PRON
ihlr-16500	438	6	wished	wish	VERB
ihlr-16500	438	7	to	to	PART
ihlr-16500	438	8	take	take	VERB
ihlr-16500	438	9	over	over	ADP
ihlr-16500	438	10	merck	merck	NOUN
ihlr-16500	438	11	would	would	AUX
ihlr-16500	438	12	also	also	ADV
ihlr-16500	438	13	have	have	VERB
ihlr-16500	438	14	to	to	PART
ihlr-16500	438	15	take	take	VERB
ihlr-16500	438	16	on	on	ADP
ihlr-16500	438	17	the	the	DET
ihlr-16500	438	18	thousands	thousand	NOUN
ihlr-16500	438	19	oflawsuits	oflawsuit	NOUN
ihlr-16500	438	20	that	that	PRON
ihlr-16500	438	21	merck	merck	NOUN
ihlr-16500	438	22	faced	face	VERB
ihlr-16500	438	23	as	as	ADP
ihlr-16500	438	24	are­	are­	PROPN
ihlr-16500	438	25	sult	sult	PROPN
ihlr-16500	438	26	ofvioxx	ofvioxx	PROPN
ihlr-16500	438	27	's	's	PART
ihlr-16500	438	28	withdrawal	withdrawal	NOUN
ihlr-16500	438	29	.	.	PUNCT
ihlr-16500	439	1	furthermore	furthermore	ADV
ihlr-16500	439	2	,	,	PUNCT
ihlr-16500	439	3	vioxx	vioxx	NOUN
ihlr-16500	439	4	'	'	PUNCT
ihlr-16500	439	5	s	s	NOUN
ihlr-16500	439	6	withdrawal	withdrawal	NOUN
ihlr-16500	439	7	cost	cost	VERB
ihlr-16500	439	8	many	many	ADJ
ihlr-16500	439	9	merck	merck	NOUN
ihlr-16500	439	10	employees	employee	NOUN
ihlr-16500	439	11	their	their	PRON
ihlr-16500	439	12	jobs	job	NOUN
ihlr-16500	439	13	.	.	PUNCT
ihlr-16500	440	1	since	since	SCONJ
ihlr-16500	440	2	the	the	DET
ihlr-16500	440	3	withdrawal	withdrawal	NOUN
ihlr-16500	440	4	,	,	PUNCT
ihlr-16500	440	5	merck	merck	PROPN
ihlr-16500	440	6	has	have	AUX
ihlr-16500	440	7	planned	plan	VERB
ihlr-16500	440	8	to	to	PART
ihlr-16500	440	9	layoff	layoff	VERB
ihlr-16500	440	10	nearly	nearly	ADV
ihlr-16500	440	11	7,000	7,000	NUM
ihlr-16500	440	12	employees	employee	NOUN
ihlr-16500	440	13	,	,	PUNCT
ihlr-16500	440	14	most	most	ADJ
ihlr-16500	440	15	of	of	ADP
ihlr-16500	440	16	whom	whom	PRON
ihlr-16500	440	17	held	hold	VERB
ihlr-16500	440	18	production	production	NOUN
ihlr-16500	440	19	plantjobs.110	plantjobs.110	NOUN
ihlr-16500	440	20	in	in	ADP
ihlr-16500	440	21	addition	addition	NOUN
ihlr-16500	440	22	,	,	PUNCT
ihlr-16500	440	23	top	top	ADJ
ihlr-16500	440	24	executives	executive	NOUN
ihlr-16500	440	25	are	be	AUX
ihlr-16500	440	26	not	not	PART
ihlr-16500	440	27	often	often	ADV
ihlr-16500	440	28	spared	spare	VERB
ihlr-16500	440	29	after	after	ADP
ihlr-16500	440	30	a	a	DET
ihlr-16500	440	31	major	major	ADJ
ihlr-16500	440	32	drug	drug	NOUN
ihlr-16500	440	33	withdrawal	withdrawal	NOUN
ihlr-16500	440	34	.	.	PUNCT
ihlr-16500	441	1	for	for	ADP
ihlr-16500	441	2	instance	instance	NOUN
ihlr-16500	441	3	,	,	PUNCT
ihlr-16500	441	4	merck	merck	PROPN
ihlr-16500	441	5	's	's	PART
ihlr-16500	441	6	chairman	chairman	NOUN
ihlr-16500	441	7	and	and	CCONJ
ihlr-16500	441	8	chief	chief	ADJ
ihlr-16500	441	9	executive	executive	ADJ
ihlr-16500	441	10	officer	officer	NOUN
ihlr-16500	441	11	,	,	PUNCT
ihlr-16500	441	12	raymond	raymond	PROPN
ihlr-16500	441	13	gilmartin	gilmartin	PROPN
ihlr-16500	441	14	,	,	PUNCT
ihlr-16500	441	15	abruptly	abruptly	ADV
ihlr-16500	441	16	resigned	resign	VERB
ihlr-16500	441	17	shortly	shortly	ADV
ihlr-16500	441	18	after	after	SCONJ
ihlr-16500	441	19	vioxx	vioxx	NOUN
ihlr-16500	441	20	was	be	AUX
ihlr-16500	441	21	withdrawn	withdraw	VERB
ihlr-16500	441	22	from	from	ADP
ihlr-16500	441	23	the	the	DET
ihlr-16500	441	24	u.s	u.s	PROPN
ihlr-16500	441	25	.	.	PROPN
ihlr-16500	441	26	market.m	market.m	X
ihlr-16500	441	27	therefore	therefore	ADV
ihlr-16500	441	28	,	,	PUNCT
ihlr-16500	441	29	the	the	DET
ihlr-16500	441	30	business	business	NOUN
ihlr-16500	441	31	105	105	NUM
ihlr-16500	441	32	richard	richard	PROPN
ihlr-16500	441	33	a.	a.	PROPN
ihlr-16500	441	34	epstein	epstein	PROPN
ihlr-16500	441	35	,	,	PUNCT
ihlr-16500	441	36	regulatory	regulatory	ADJ
ihlr-16500	441	37	paternalism	paternalism	NOUN
ihlr-16500	441	38	in	in	ADP
ihlr-16500	441	39	the	the	DET
ihlr-16500	441	40	market	market	NOUN
ihlr-16500	441	41	for	for	ADP
ihlr-16500	441	42	drugs	drug	NOUN
ihlr-16500	441	43	:	:	PUNCT
ihlr-16500	441	44	lessons	lesson	NOUN
ihlr-16500	441	45	from	from	ADP
ihlr-16500	441	46	vioxx	vioxx	NOUN
ihlr-16500	441	47	and	and	CCONJ
ihlr-16500	441	48	celebrex	celebrex	PROPN
ihlr-16500	441	49	,	,	PUNCT
ihlr-16500	441	50	5	5	NUM
ihlr-16500	441	51	yalej	yalej	NOUN
ihlr-16500	441	52	.	.	PUNCT
ihlr-16500	442	1	heal1hpol'yl	heal1hpol'yl	PROPN
ihlr-16500	442	2	.	.	PROPN
ihlr-16500	442	3	&	&	CCONJ
ihlr-16500	442	4	e1hlcs	e1hlc	VERB
ihlr-16500	442	5	741,741	741,741	NUM
ihlr-16500	442	6	(	(	PUNCT
ihlr-16500	442	7	2005	2005	NUM
ihlr-16500	442	8	)	)	PUNCT
ihlr-16500	442	9	.	.	PUNCT
ihlr-16500	443	1	106	106	NUM
ihlr-16500	444	1	i	i	PRON
ihlr-16500	444	2	d.	d.	NOUN
ihlr-16500	444	3	at	at	ADP
ihlr-16500	444	4	742	742	NUM
ihlr-16500	444	5	;	;	PUNCT
ihlr-16500	444	6	see	see	VERB
ihlr-16500	444	7	also	also	ADV
ihlr-16500	444	8	congressional	congressional	ADJ
ihlr-16500	444	9	hearing	hearing	NOUN
ihlr-16500	444	10	focuses	focus	VERB
ihlr-16500	444	11	on	on	ADP
ihlr-16500	444	12	merck	merck	PROPN
ihlr-16500	444	13	's	's	PART
ihlr-16500	444	14	marketing	marketing	NOUN
ihlr-16500	444	15	/	/	SYM
ihlr-16500	444	16	or	or	CCONJ
ihlr-16500	444	17	cox-2	cox-2	ADJ
ihlr-16500	444	18	drug	drug	NOUN
ihlr-16500	444	19	vioxx	vioxx	NOUN
ihlr-16500	444	20	,	,	PUNCT
ihlr-16500	444	21	the	the	DET
ihlr-16500	444	22	kaiser	kaiser	PROPN
ihlr-16500	444	23	family	family	PROPN
ihlr-16500	444	24	found	find	VERB
ihlr-16500	444	25	.	.	PUNCT
ihlr-16500	445	1	daily	daily	ADJ
ihlr-16500	445	2	reports	report	NOUN
ihlr-16500	445	3	,	,	PUNCT
ihlr-16500	445	4	may	may	AUX
ihlr-16500	445	5	6	6	NUM
ihlr-16500	445	6	,	,	PUNCT
ihlr-16500	445	7	2005	2005	NUM
ihlr-16500	445	8	,	,	PUNCT
ihlr-16500	445	9	http://www	http://www	PROPN
ihlr-16500	445	10	.	.	PUNCT
ihlr-16500	446	1	kaisemetwork.orgldaily	kaisemetwork.orgldaily	ADV
ihlr-16500	446	2	_	_	ADJ
ihlr-16500	446	3	reports	report	NOUN
ihlr-16500	446	4	/	/	SYM
ihlr-16500	446	5	rep	rep	NOUN
ihlr-16500	446	6	_	_	PROPN
ihlr-16500	446	7	index.cfin?hint=3&dr	index.cfin?hint=3&dr	PROPN
ihlr-16500	446	8	_	_	PUNCT
ihlr-16500	446	9	id=29882	id=29882	PROPN
ihlr-16500	446	10	.	.	PUNCT
ihlr-16500	447	1	107	107	NUM
ihlr-16500	447	2	epstein	epstein	PROPN
ihlr-16500	447	3	,	,	PUNCT
ihlr-16500	447	4	supra	supra	PROPN
ihlr-16500	447	5	note	note	NOUN
ihlr-16500	447	6	i	i	PRON
ihlr-16500	447	7	05	05	NUM
ihlr-16500	447	8	,	,	PUNCT
ihlr-16500	447	9	at	at	ADP
ihlr-16500	447	10	743	743	NUM
ihlr-16500	447	11	;	;	PUNCT
ihlr-16500	447	12	see	see	VERB
ihlr-16500	447	13	also	also	ADV
ihlr-16500	447	14	aaron	aaron	PROPN
ihlr-16500	447	15	smith	smith	PROPN
ihlr-16500	447	16	,	,	PUNCT
ihlr-16500	447	17	canadian	canadian	ADJ
ihlr-16500	447	18	vioxx	vioxx	PROPN
ihlr-16500	447	19	study	study	NOUN
ihlr-16500	447	20	chal­	chal­	PROPN
ihlr-16500	447	21	lenges	lenge	NOUN
ihlr-16500	447	22	merck	merck	NOUN
ihlr-16500	447	23	:	:	PUNCT
ihlr-16500	447	24	vioxx	vioxx	NOUN
ihlr-16500	447	25	increases	increase	VERB
ihlr-16500	447	26	heart	heart	NOUN
ihlr-16500	447	27	attack	attack	NOUN
ihlr-16500	447	28	risk	risk	NOUN
ihlr-16500	447	29	in	in	ADP
ihlr-16500	447	30	first	first	ADJ
ihlr-16500	447	31	few	few	ADJ
ihlr-16500	447	32	weeks	week	NOUN
ihlr-16500	447	33	ofuse	ofuse	NOUN
ihlr-16500	447	34	,	,	PUNCT
ihlr-16500	447	35	study	study	NOUN
ihlr-16500	447	36	says	say	VERB
ihlr-16500	447	37	;	;	PUNCT
ihlr-16500	447	38	merck	merck	PROPN
ihlr-16500	447	39	dismisses	dismiss	VERB
ihlr-16500	447	40	findings	finding	NOUN
ihlr-16500	447	41	.	.	PUNCT
ihlr-16500	447	42	,	,	PUNCT
ihlr-16500	447	43	cnnmoney.com	cnnmoney.com	X
ihlr-16500	447	44	,	,	PUNCT
ihlr-16500	447	45	may	may	AUX
ihlr-16500	447	46	3	3	NUM
ihlr-16500	447	47	,	,	PUNCT
ihlr-16500	447	48	2006	2006	NUM
ihlr-16500	447	49	,	,	PUNCT
ihlr-16500	447	50	http:/lm.oney.cnn.com/2006/05/03	http:/lm.oney.cnn.com/2006/05/03	NOUN
ihlr-16500	447	51	/	/	SYM
ihlr-16500	447	52	news	news	NOUN
ihlr-16500	447	53	/companieslvioxx	/companieslvioxx	NOUN
ihlr-16500	447	54	/	/	SYM
ihlr-16500	447	55	index.htm	index.htm	NOUN
ihlr-16500	447	56	.	.	NOUN
ihlr-16500	447	57	108	108	NUM
ihlr-16500	447	58	epstein	epstein	PROPN
ihlr-16500	447	59	,	,	PUNCT
ihlr-16500	447	60	supra	supra	PROPN
ihlr-16500	447	61	note	note	PROPN
ihlr-16500	447	62	105	105	NUM
ihlr-16500	447	63	,	,	PUNCT
ihlr-16500	447	64	at	at	ADP
ihlr-16500	447	65	743	743	NUM
ihlr-16500	447	66	.	.	PUNCT
ihlr-16500	448	1	109	109	NUM
ihlr-16500	448	2	i	i	PROPN
ihlr-16500	448	3	d.	d.	PROPN
ihlr-16500	448	4	110	110	NUM
ihlr-16500	448	5	joseph	joseph	PROPN
ihlr-16500	448	6	kay	kay	PROPN
ihlr-16500	448	7	,	,	PUNCT
ihlr-16500	448	8	merck	merck	PROPN
ihlr-16500	448	9	announces	announce	VERB
ihlr-16500	448	10	7,000	7,000	NUM
ihlr-16500	448	11	layoffscontinued	layoffscontinue	VERB
ihlr-16500	448	12	attack	attack	NOUN
ihlr-16500	448	13	on	on	ADP
ihlr-16500	448	14	jobs	job	NOUN
ihlr-16500	448	15	and	and	CCONJ
ihlr-16500	448	16	wages	wage	NOUN
ihlr-16500	448	17	in	in	ADP
ihlr-16500	448	18	us	we	PRON
ihlr-16500	448	19	,	,	PUNCT
ihlr-16500	448	20	world	world	NOUN
ihlr-16500	448	21	socialist	socialist	ADJ
ihlr-16500	448	22	web	web	NOUN
ihlr-16500	448	23	site	site	NOUN
ihlr-16500	448	24	,	,	PUNCT
ihlr-16500	448	25	dec	dec	PROPN
ihlr-16500	448	26	.	.	PROPN
ihlr-16500	448	27	2	2	NUM
ihlr-16500	448	28	,	,	PUNCT
ihlr-16500	448	29	2005	2005	NUM
ihlr-16500	448	30	,	,	PUNCT
ihlr-16500	448	31	http://www.wsws.orglarticles/2005/	http://www.wsws.orglarticles/2005/	NOUN
ihlr-16500	448	32	dec2005	dec2005	NOUN
ihlr-16500	448	33	/	/	SYM
ihlr-16500	448	34	jobs	job	NOUN
ihlr-16500	448	35	-	-	PUNCT
ihlr-16500	448	36	d02.shtml	d02.shtml	PROPN
ihlr-16500	448	37	.	.	NOUN
ihlr-16500	448	38	111	111	NUM
ihlr-16500	448	39	'	'	NUM
ihlr-16500	448	40	phil	phil	PROPN
ihlr-16500	448	41	taylor	taylor	PROPN
ihlr-16500	448	42	,	,	PUNCT
ihlr-16500	448	43	manufacturing	manufacturing	NOUN
ihlr-16500	448	44	head	head	NOUN
ihlr-16500	448	45	takes	take	VERB
ihlr-16500	448	46	merck	merck	NOUN
ihlr-16500	448	47	top	top	ADJ
ihlr-16500	448	48	spot	spot	NOUN
ihlr-16500	448	49	as	as	ADP
ihlr-16500	448	50	gilmartin	gilmartin	NOUN
ihlr-16500	448	51	quits	quit	NOUN
ihlr-16500	448	52	,	,	PUNCT
ihlr-16500	448	53	drugresearcher.com	drugresearcher.com	X
ihlr-16500	448	54	,	,	PUNCT
ihlr-16500	448	55	sept	sept	PROPN
ihlr-16500	448	56	.	.	PROPN
ihlr-16500	448	57	5	5	NUM
ihlr-16500	448	58	,	,	PUNCT
ihlr-16500	448	59	2005	2005	NUM
ihlr-16500	448	60	,	,	PUNCT
ihlr-16500	448	61	ht1p://www.drugresearcher.com/news/ng	ht1p://www.drugresearcher.com/news/ng	NOUN
ihlr-16500	448	62	.asp?n=598442007	.asp?n=598442007	PUNCT
ihlr-16500	448	63	]	]	X
ihlr-16500	448	64	pulling	pull	VERB
ihlr-16500	448	65	a	a	DET
ihlr-16500	448	66	blockbuster	blockbuster	ADJ
ihlr-16500	448	67	drug	drug	NOUN
ihlr-16500	448	68	off	off	ADP
ihlr-16500	448	69	the	the	DET
ihlr-16500	448	70	market	market	NOUN
ihlr-16500	448	71	135	135	NUM
ihlr-16500	448	72	ramifications	ramification	NOUN
ihlr-16500	448	73	of	of	ADP
ihlr-16500	448	74	pulling	pull	VERB
ihlr-16500	448	75	a	a	DET
ihlr-16500	448	76	drug	drug	NOUN
ihlr-16500	448	77	from	from	ADP
ihlr-16500	448	78	the	the	DET
ihlr-16500	448	79	market	market	NOUN
ihlr-16500	448	80	can	can	AUX
ihlr-16500	448	81	affect	affect	VERB
ihlr-16500	448	82	all	all	PRON
ihlr-16500	448	83	of	of	ADP
ihlr-16500	448	84	a	a	DET
ihlr-16500	448	85	company	company	NOUN
ihlr-16500	448	86	's	's	PART
ihlr-16500	448	87	divisions	division	NOUN
ihlr-16500	448	88	,	,	PUNCT
ihlr-16500	448	89	from	from	ADP
ihlr-16500	448	90	the	the	DET
ihlr-16500	448	91	boardroom	boardroom	NOUN
ihlr-16500	448	92	to	to	ADP
ihlr-16500	448	93	the	the	DET
ihlr-16500	448	94	factory	factory	NOUN
ihlr-16500	448	95	floor	floor	NOUN
ihlr-16500	448	96	.	.	PUNCT
ihlr-16500	449	1	finally	finally	ADV
ihlr-16500	449	2	,	,	PUNCT
ihlr-16500	449	3	it	it	PRON
ihlr-16500	449	4	should	should	AUX
ihlr-16500	449	5	be	be	AUX
ihlr-16500	449	6	noted	note	VERB
ihlr-16500	449	7	that	that	SCONJ
ihlr-16500	449	8	once	once	SCONJ
ihlr-16500	449	9	the	the	DET
ihlr-16500	449	10	patent	patent	NOUN
ihlr-16500	449	11	on	on	ADP
ihlr-16500	449	12	a	a	DET
ihlr-16500	449	13	blockbuster	blockbuster	ADJ
ihlr-16500	449	14	drug	drug	NOUN
ihlr-16500	449	15	ex­	ex­	NOUN
ihlr-16500	449	16	pires	pire	NOUN
ihlr-16500	449	17	,	,	PUNCT
ihlr-16500	449	18	other	other	ADJ
ihlr-16500	449	19	companies	company	NOUN
ihlr-16500	449	20	can	can	AUX
ihlr-16500	449	21	use	use	VERB
ihlr-16500	449	22	the	the	DET
ihlr-16500	449	23	same	same	ADJ
ihlr-16500	449	24	drug	drug	NOUN
ihlr-16500	449	25	's	's	PART
ihlr-16500	449	26	formula	formula	NOUN
ihlr-16500	449	27	to	to	PART
ihlr-16500	449	28	create	create	VERB
ihlr-16500	449	29	generic	generic	ADJ
ihlr-16500	449	30	drugs	drug	NOUN
ihlr-16500	449	31	.	.	PUNCT
ihlr-16500	450	1	the	the	DET
ihlr-16500	450	2	proliferation	proliferation	NOUN
ihlr-16500	450	3	of	of	ADP
ihlr-16500	450	4	generic	generic	ADJ
ihlr-16500	450	5	drugs	drug	NOUN
ihlr-16500	450	6	often	often	ADV
ihlr-16500	450	7	cannibalizes	cannibalize	VERB
ihlr-16500	450	8	the	the	DET
ihlr-16500	450	9	market	market	NOUN
ihlr-16500	450	10	for	for	ADP
ihlr-16500	450	11	the	the	DET
ihlr-16500	450	12	original	original	ADJ
ihlr-16500	450	13	blockbuster	blockbuster	NOUN
ihlr-16500	450	14	drug	drug	NOUN
ihlr-16500	450	15	.	.	PUNCT
ihlr-16500	451	1	therefore	therefore	ADV
ihlr-16500	451	2	,	,	PUNCT
ihlr-16500	451	3	for	for	ADP
ihlr-16500	451	4	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	451	5	companies	company	NOUN
ihlr-16500	451	6	that	that	PRON
ihlr-16500	451	7	possess	possess	VERB
ihlr-16500	451	8	multi­	multi­	PROPN
ihlr-16500	451	9	ple	ple	ADJ
ihlr-16500	451	10	blockbuster	blockbuster	NOUN
ihlr-16500	451	11	drugs	drug	NOUN
ihlr-16500	451	12	,	,	PUNCT
ihlr-16500	451	13	one	one	NUM
ihlr-16500	451	14	of	of	ADP
ihlr-16500	451	15	the	the	DET
ihlr-16500	451	16	drugs	drug	NOUN
ihlr-16500	451	17	whose	whose	DET
ihlr-16500	451	18	patent	patent	NOUN
ihlr-16500	451	19	may	may	AUX
ihlr-16500	451	20	be	be	AUX
ihlr-16500	451	21	close	close	ADJ
ihlr-16500	451	22	to	to	ADP
ihlr-16500	451	23	its	its	PRON
ihlr-16500	451	24	expira­	expira­	DET
ihlr-16500	451	25	tion	tion	NOUN
ihlr-16500	451	26	,	,	PUNCT
ihlr-16500	451	27	a	a	DET
ihlr-16500	451	28	drug	drug	NOUN
ihlr-16500	451	29	withdrawal	withdrawal	NOUN
ihlr-16500	451	30	of	of	ADP
ihlr-16500	451	31	the	the	DET
ihlr-16500	451	32	other	other	ADJ
ihlr-16500	451	33	drug	drug	NOUN
ihlr-16500	451	34	or	or	CCONJ
ihlr-16500	451	35	drugs	drug	NOUN
ihlr-16500	451	36	may	may	AUX
ihlr-16500	451	37	be	be	AUX
ihlr-16500	451	38	financially	financially	ADV
ihlr-16500	451	39	crippling	crippling	ADJ
ihlr-16500	451	40	.	.	PUNCT
ihlr-16500	452	1	as	as	ADP
ihlr-16500	452	2	a	a	DET
ihlr-16500	452	3	result	result	NOUN
ihlr-16500	452	4	,	,	PUNCT
ihlr-16500	452	5	this	this	PRON
ihlr-16500	452	6	may	may	AUX
ihlr-16500	452	7	lead	lead	VERB
ihlr-16500	452	8	to	to	ADP
ihlr-16500	452	9	increasing	increase	VERB
ihlr-16500	452	10	motivation	motivation	NOUN
ihlr-16500	452	11	on	on	ADP
ihlr-16500	452	12	the	the	DET
ihlr-16500	452	13	part	part	NOUN
ihlr-16500	452	14	of	of	ADP
ihlr-16500	452	15	the	the	DET
ihlr-16500	452	16	respective	respective	ADJ
ihlr-16500	452	17	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	452	18	company	company	NOUN
ihlr-16500	452	19	to	to	PART
ihlr-16500	452	20	produce	produce	VERB
ihlr-16500	452	21	more	more	ADJ
ihlr-16500	452	22	blockbuster	blockbuster	ADJ
ihlr-16500	452	23	drugs	drug	NOUN
ihlr-16500	452	24	in	in	ADP
ihlr-16500	452	25	order	order	NOUN
ihlr-16500	452	26	to	to	PART
ihlr-16500	452	27	make	make	VERB
ihlr-16500	452	28	up	up	ADP
ihlr-16500	452	29	for	for	ADP
ihlr-16500	452	30	the	the	DET
ihlr-16500	452	31	loss	loss	NOUN
ihlr-16500	452	32	of	of	ADP
ihlr-16500	452	33	these	these	DET
ihlr-16500	452	34	profitable	profitable	ADJ
ihlr-16500	452	35	assets.112	assets.112	PROPN
ihlr-16500	452	36	vi	vi	PROPN
ihlr-16500	452	37	.	.	PUNCT
ihlr-16500	453	1	ethical	ethical	ADJ
ihlr-16500	453	2	considerations	consideration	NOUN
ihlr-16500	453	3	of	of	ADP
ihlr-16500	453	4	pulling	pull	VERB
ihlr-16500	453	5	a	a	DET
ihlr-16500	453	6	drug	drug	NOUN
ihlr-16500	453	7	off	off	ADP
ihlr-16500	453	8	the	the	DET
ihlr-16500	453	9	market	market	NOUN
ihlr-16500	453	10	the	the	DET
ihlr-16500	453	11	decision	decision	NOUN
ihlr-16500	453	12	to	to	PART
ihlr-16500	453	13	withdraw	withdraw	VERB
ihlr-16500	453	14	a	a	DET
ihlr-16500	453	15	blockbuster	blockbuster	ADJ
ihlr-16500	453	16	drug	drug	NOUN
ihlr-16500	453	17	from	from	ADP
ihlr-16500	453	18	the	the	DET
ihlr-16500	453	19	market	market	NOUN
ihlr-16500	453	20	can	can	AUX
ihlr-16500	453	21	present	present	VERB
ihlr-16500	453	22	ethical	ethical	ADJ
ihlr-16500	453	23	dilemmas	dilemma	NOUN
ihlr-16500	453	24	to	to	ADP
ihlr-16500	453	25	the	the	DET
ihlr-16500	453	26	following	follow	VERB
ihlr-16500	453	27	parties	party	NOUN
ihlr-16500	453	28	:	:	PUNCT
ihlr-16500	453	29	the	the	DET
ihlr-16500	453	30	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	453	31	company	company	NOUN
ihlr-16500	453	32	,	,	PUNCT
ihlr-16500	453	33	the	the	DET
ihlr-16500	453	34	regulatory	regulatory	ADJ
ihlr-16500	453	35	agencies	agency	NOUN
ihlr-16500	453	36	,	,	PUNCT
ihlr-16500	453	37	such	such	ADJ
ihlr-16500	453	38	as	as	ADP
ihlr-16500	453	39	the	the	DET
ihlr-16500	453	40	fda	fda	PROPN
ihlr-16500	453	41	,	,	PUNCT
ihlr-16500	453	42	and	and	CCONJ
ihlr-16500	453	43	the	the	DET
ihlr-16500	453	44	pharmaceutical	pharmaceutical	NOUN
ihlr-16500	453	45	industry	industry	NOUN
ihlr-16500	453	46	as	as	ADP
ihlr-16500	453	47	a	a	DET
ihlr-16500	453	48	whole	whole	NOUN
ihlr-16500	453	49	.	.	PUNCT
ihlr-16500	454	1	for	for	ADP
ihlr-16500	454	2	instance	instance	NOUN
ihlr-16500	454	3	,	,	PUNCT
ihlr-16500	454	4	before	before	ADP
ihlr-16500	454	5	pursuing	pursue	VERB
ihlr-16500	454	6	a	a	DET
ihlr-16500	454	7	withdrawal	withdrawal	NOUN
ihlr-16500	454	8	,	,	PUNCT
ihlr-16500	454	9	the	the	DET
ihlr-16500	454	10	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	454	11	com­	com­	NOUN
ihlr-16500	454	12	pany	pany	NOUN
ihlr-16500	454	13	must	must	AUX
ihlr-16500	454	14	take	take	VERB
ihlr-16500	454	15	into	into	ADP
ihlr-16500	454	16	account	account	NOUN
ihlr-16500	454	17	that	that	SCONJ
ihlr-16500	454	18	there	there	PRON
ihlr-16500	454	19	are	be	VERB
ihlr-16500	454	20	patients	patient	NOUN
ihlr-16500	454	21	who	who	PRON
ihlr-16500	454	22	may	may	AUX
ihlr-16500	454	23	be	be	AUX
ihlr-16500	454	24	dependent	dependent	ADJ
ihlr-16500	454	25	on	on	ADP
ihlr-16500	454	26	these	these	DET
ihlr-16500	454	27	arguably	arguably	ADJ
ihlr-16500	454	28	life	life	NOUN
ihlr-16500	454	29	altering	alter	VERB
ihlr-16500	454	30	drugs	drug	NOUN
ihlr-16500	454	31	,	,	PUNCT
ihlr-16500	454	32	such	such	ADJ
ihlr-16500	454	33	as	as	ADP
ihlr-16500	454	34	vioxx	vioxx	NOUN
ihlr-16500	454	35	and	and	CCONJ
ihlr-16500	454	36	lipitor.113	lipitor.113	VERB
ihlr-16500	454	37	in	in	ADP
ihlr-16500	454	38	addition	addition	NOUN
ihlr-16500	454	39	,	,	PUNCT
ihlr-16500	454	40	the	the	DET
ihlr-16500	454	41	pharmaceutical	pharmaceutical	NOUN
ihlr-16500	454	42	industry	industry	NOUN
ihlr-16500	454	43	is	be	AUX
ihlr-16500	454	44	forced	force	VERB
ihlr-16500	454	45	to	to	PART
ihlr-16500	454	46	consider	consider	VERB
ihlr-16500	454	47	that	that	SCONJ
ihlr-16500	454	48	many	many	ADJ
ihlr-16500	454	49	patients	patient	NOUN
ihlr-16500	454	50	are	be	AUX
ihlr-16500	454	51	"	"	PUNCT
ihlr-16500	454	52	counting	count	VERB
ihlr-16500	454	53	on	on	ADP
ihlr-16500	454	54	industry	industry	NOUN
ihlr-16500	454	55	research	research	NOUN
ihlr-16500	454	56	to	to	PART
ihlr-16500	454	57	produce	produce	VERB
ihlr-16500	454	58	new	new	ADJ
ihlr-16500	454	59	treatments	treatment	NOUN
ihlr-16500	454	60	for	for	ADP
ihlr-16500	454	61	diseases	disease	NOUN
ihlr-16500	454	62	like	like	ADP
ihlr-16500	454	63	rheumatoid	rheumatoid	VERB
ihlr-16500	454	64	arthritis	arthritis	NOUN
ihlr-16500	454	65	and	and	CCONJ
ihlr-16500	454	66	diabetes	diabetes	NOUN
ihlr-16500	454	67	.	.	PUNCT
ihlr-16500	455	1	"114	"114	PROPN
ihlr-16500	455	2	finally	finally	ADV
ihlr-16500	455	3	,	,	PUNCT
ihlr-16500	455	4	regulatory	regulatory	ADJ
ihlr-16500	455	5	agencies	agency	NOUN
ihlr-16500	455	6	such	such	ADJ
ihlr-16500	455	7	as	as	ADP
ihlr-16500	455	8	the	the	DET
ihlr-16500	455	9	fda	fda	PROPN
ihlr-16500	455	10	have	have	AUX
ihlr-16500	455	11	begun	begin	VERB
ihlr-16500	455	12	to	to	PART
ihlr-16500	455	13	carefully	carefully	ADV
ihlr-16500	455	14	scrutinize	scrutinize	VERB
ihlr-16500	455	15	ethical	ethical	ADJ
ihlr-16500	455	16	considerations	consideration	NOUN
ihlr-16500	455	17	because	because	SCONJ
ihlr-16500	455	18	"	"	PUNCT
ihlr-16500	455	19	nobody	nobody	PRON
ihlr-16500	455	20	wants	want	VERB
ihlr-16500	455	21	to	to	PART
ihlr-16500	455	22	be	be	AUX
ihlr-16500	455	23	on	on	ADP
ihlr-16500	455	24	60	60	NUM
ihlr-16500	455	25	minutes	minute	NOUN
ihlr-16500	455	26	being	be	AUX
ihlr-16500	455	27	asked	ask	VERB
ihlr-16500	455	28	why	why	SCONJ
ihlr-16500	455	29	a	a	DET
ihlr-16500	455	30	dangero\!-s	dangero\!-s	NOUN
ihlr-16500	455	31	drug	drug	NOUN
ihlr-16500	455	32	·	·	PUNCT
ihlr-16500	455	33	was	be	AUX
ihlr-16500	455	34	approved	approve	VERB
ihlr-16500	455	35	"	"	PUNCT
ihlr-16500	455	36	and	and	CCONJ
ihlr-16500	455	37	whether	whether	SCONJ
ihlr-16500	455	38	the	the	DET
ihlr-16500	455	39	fda	fda	PROPN
ihlr-16500	455	40	took	take	VERB
ihlr-16500	455	41	into	into	ADP
ihlr-16500	455	42	account	account	NOUN
ihlr-16500	455	43	that	that	SCONJ
ihlr-16500	455	44	countless	countless	ADJ
ihlr-16500	455	45	americans	americans	PROPN
ihlr-16500	455	46	that	that	PRON
ihlr-16500	455	47	would	would	AUX
ihlr-16500	455	48	be	be	AUX
ihlr-16500	455	49	negatively	negatively	ADV
ihlr-16500	455	50	affected	affect	VERB
ihlr-16500	455	51	due	due	ADP
ihlr-16500	455	52	to	to	ADP
ihlr-16500	455	53	side	side	ADJ
ihlr-16500	455	54	effects	effect	NOUN
ihlr-16500	455	55	and	and	CCONJ
ihlr-16500	455	56	many	many	ADJ
ihlr-16500	455	57	more	more	ADJ
ihlr-16500	455	58	would	would	AUX
ihlr-16500	455	59	be	be	AUX
ihlr-16500	455	60	left	leave	VERB
ihlr-16500	455	61	without	without	ADP
ihlr-16500	455	62	a	a	DET
ihlr-16500	455	63	viable	viable	ADJ
ihlr-16500	455	64	alternative	alternative	NOUN
ihlr-16500	455	65	once	once	SCONJ
ihlr-16500	455	66	that	that	DET
ihlr-16500	455	67	drug	drug	NOUN
ihlr-16500	455	68	was	be	AUX
ihlr-16500	455	69	withdrawn	withdraw	VERB
ihlr-16500	455	70	from	from	ADP
ihlr-16500	455	71	the	the	DET
ihlr-16500	455	72	market.115	market.115	PROPN
ihlr-16500	455	73	subsequently	subsequently	ADV
ihlr-16500	455	74	,	,	PUNCT
ihlr-16500	455	75	all	all	PRON
ihlr-16500	455	76	of	of	ADP
ihlr-16500	455	77	the	the	DET
ihlr-16500	455	78	players	player	NOUN
ihlr-16500	455	79	in	in	ADP
ihlr-16500	455	80	this	this	DET
ihlr-16500	455	81	drama	drama	NOUN
ihlr-16500	455	82	have	have	AUX
ihlr-16500	455	83	begun	begin	VERB
ihlr-16500	455	84	to	to	PART
ihlr-16500	455	85	take	take	VERB
ihlr-16500	455	86	into	into	ADP
ihlr-16500	455	87	con­	con­	NOUN
ihlr-16500	455	88	sidemtiem	sidemtiem	NOUN
ihlr-16500	455	89	how	how	SCONJ
ihlr-16500	455	90	a	a	DET
ihlr-16500	455	91	drug	drug	NOUN
ihlr-16500	455	92	withdrawal	withdrawal	NOUN
ihlr-16500	455	93	may	may	AUX
ihlr-16500	455	94	affect	affect	VERB
ihlr-16500	455	95	not	not	PART
ihlr-16500	455	96	just	just	ADV
ihlr-16500	455	97	their	their	PRON
ihlr-16500	455	98	respective	respective	ADJ
ihlr-16500	455	99	entities	entity	NOUN
ihlr-16500	455	100	,	,	PUNCT
ihlr-16500	455	101	but	but	CCONJ
ihlr-16500	455	102	also	also	ADV
ihlr-16500	455	103	the	the	DET
ihlr-16500	455	104	lives	life	NOUN
ihlr-16500	455	105	of	of	ADP
ihlr-16500	455	106	many	many	ADJ
ihlr-16500	455	107	patients	patient	NOUN
ihlr-16500	455	108	.	.	PUNCT
ihlr-16500	456	1	the	the	DET
ihlr-16500	456	2	most	most	ADV
ihlr-16500	456	3	prominent	prominent	ADJ
ihlr-16500	456	4	player	player	NOUN
ihlr-16500	456	5	in	in	ADP
ihlr-16500	456	6	this	this	DET
ihlr-16500	456	7	drama	drama	NOUN
ihlr-16500	456	8	,	,	PUNCT
ihlr-16500	456	9	however	however	ADV
ihlr-16500	456	10	,	,	PUNCT
ihlr-16500	456	11	is	be	AUX
ihlr-16500	456	12	the	the	DET
ihlr-16500	456	13	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	456	14	company	company	NOUN
ihlr-16500	456	15	,	,	PUNCT
ihlr-16500	456	16	and	and	CCONJ
ihlr-16500	456	17	although	although	SCONJ
ihlr-16500	456	18	the	the	DET
ihlr-16500	456	19	fda	fda	PROPN
ihlr-16500	456	20	and	and	CCONJ
ihlr-16500	456	21	the	the	DET
ihlr-16500	456	22	phar­	phar­	PROPN
ihlr-16500	456	23	maceutical	maceutical	ADJ
ihlr-16500	456	24	industry	industry	NOUN
ihlr-16500	456	25	also	also	ADV
ihlr-16500	456	26	face	face	VERB
ihlr-16500	456	27	certain	certain	ADJ
ihlr-16500	456	28	ethical	ethical	ADJ
ihlr-16500	456	29	issues	issue	NOUN
ihlr-16500	456	30	,	,	PUNCT
ihlr-16500	456	31	most	most	ADJ
ihlr-16500	456	32	of	of	ADP
ihlr-16500	456	33	these	these	DET
ihlr-16500	456	34	issues	issue	NOUN
ihlr-16500	456	35	are	be	AUX
ihlr-16500	456	36	a	a	DET
ihlr-16500	456	37	by	by	ADP
ihlr-16500	456	38	-	-	PUNCT
ihlr-16500	456	39	product	product	NOUN
ihlr-16500	456	40	of	of	ADP
ihlr-16500	456	41	those	those	PRON
ihlr-16500	456	42	faced	face	VERB
ihlr-16500	456	43	by	by	ADP
ihlr-16500	456	44	the	the	DET
ihlr-16500	456	45	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	456	46	company	company	NOUN
ihlr-16500	456	47	.	.	PUNCT
ihlr-16500	457	1	as	as	ADP
ihlr-16500	457	2	a	a	DET
ihlr-16500	457	3	result	result	NOUN
ihlr-16500	457	4	,	,	PUNCT
ihlr-16500	457	5	for	for	ADP
ihlr-16500	457	6	the	the	DET
ihlr-16500	457	7	purposes	purpose	NOUN
ihlr-16500	457	8	of	of	ADP
ihlr-16500	457	9	this	this	DET
ihlr-16500	457	10	note	note	NOUN
ihlr-16500	457	11	,	,	PUNCT
ihlr-16500	457	12	the	the	DET
ihlr-16500	457	13	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	457	14	company	company	NOUN
ihlr-16500	457	15	's	's	PART
ihlr-16500	457	16	ethical	ethical	ADJ
ihlr-16500	457	17	considerations	consideration	NOUN
ihlr-16500	457	18	or	or	CCONJ
ihlr-16500	457	19	lack	lack	NOUN
ihlr-16500	457	20	thereof	thereof	ADV
ihlr-16500	457	21	will	will	AUX
ihlr-16500	457	22	be	be	AUX
ihlr-16500	457	23	examined	examine	VERB
ihlr-16500	457	24	and	and	CCONJ
ihlr-16500	457	25	scrutinized	scrutinize	VERB
ihlr-16500	457	26	.	.	PUNCT
ihlr-16500	458	1	manufacturing	manufacturing	NOUN
ihlr-16500	458	2	-	-	PUNCT
ihlr-16500	458	3	head	head	NOUN
ihlr-16500	458	4	-	-	PUNCT
ihlr-16500	458	5	takes	take	NOUN
ihlr-16500	458	6	.	.	PUNCT
ihlr-16500	459	1	112	112	NUM
ihlr-16500	459	2	greg	greg	PROPN
ihlr-16500	459	3	radinsky	radinsky	NOUN
ihlr-16500	459	4	,	,	PUNCT
ihlr-16500	459	5	the	the	DET
ihlr-16500	459	6	spotlight	spotlight	NOUN
ihlr-16500	459	7	on	on	ADP
ihlr-16500	459	8	pbms	pbms	ADJ
ihlr-16500	459	9	:	:	PUNCT
ihlr-16500	459	10	federal	federal	ADJ
ihlr-16500	459	11	enforcement	enforcement	NOUN
ihlr-16500	459	12	of	of	ADP
ihlr-16500	459	13	the	the	DET
ihlr-16500	459	14	anti	anti	ADJ
ihlr-16500	459	15	-	-	ADJ
ihlr-16500	459	16	kickback	kickback	ADJ
ihlr-16500	459	17	statute	statute	NOUN
ihlr-16500	459	18	on	on	ADP
ihlr-16500	459	19	the	the	DET
ihlr-16500	459	20	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	459	21	benefit	benefit	NOUN
ihlr-16500	459	22	management	management	NOUN
ihlr-16500	459	23	industry	industry	NOUN
ihlr-16500	459	24	,	,	PUNCT
ihlr-16500	459	25	2	2	NUM
ihlr-16500	459	26	j.	j.	PROPN
ihlr-16500	459	27	healml	healml	PROPN
ihlr-16500	459	28	.	.	PUNCT
ihlr-16500	460	1	213	213	NUM
ihlr-16500	460	2	(	(	PUNCT
ihlr-16500	460	3	2003	2003	NUM
ihlr-16500	460	4	)	)	PUNCT
ihlr-16500	460	5	.	.	PUNCT
ihlr-16500	461	1	113	113	NUM
ihlr-16500	461	2	alex	alex	PROPN
ihlr-16500	461	3	berenson	berenson	PROPN
ihlr-16500	461	4	,	,	PUNCT
ihlr-16500	461	5	big	big	ADJ
ihlr-16500	461	6	drug	drug	NOUN
ihlr-16500	461	7	malrers	malrer	NOUN
ihlr-16500	461	8	see	see	VERB
ihlr-16500	461	9	sales	sale	NOUN
ihlr-16500	461	10	erode	erode	VERB
ihlr-16500	461	11	with	with	ADP
ihlr-16500	461	12	their	their	PRON
ihlr-16500	461	13	image	image	NOUN
ihlr-16500	461	14	,	,	PUNCT
ihlr-16500	461	15	n.y	n.y	PROPN
ihlr-16500	461	16	.	.	PROPN
ihlr-16500	461	17	t1mes	t1mes	PROPN
ihlr-16500	461	18	,	,	PUNCT
ihlr-16500	461	19	nov	nov	PROPN
ihlr-16500	461	20	.	.	PROPN
ihlr-16500	461	21	14,2005	14,2005	NUM
ihlr-16500	461	22	,	,	PUNCT
ihlr-16500	461	23	atal	atal	PROPN
ihlr-16500	461	24	.	.	PUNCT
ihlr-16500	462	1	114	114	NUM
ihlr-16500	462	2	ld	ld	NOUN
ihlr-16500	462	3	lis	li	NOUN
ihlr-16500	462	4	/d	/d	PUNCT
ihlr-16500	462	5	.	.	PROPN
ihlr-16500	462	6	136	136	NUM
ihlr-16500	462	7	indiana	indiana	NOUN
ihlr-16500	462	8	ileal	ileal	NOUN
ihlr-16500	462	9	til	til	SCONJ
ihlr-16500	462	10	law	law	NOUN
ihlr-16500	462	11	review	review	NOUN
ihlr-16500	462	12	[	[	X
ihlr-16500	462	13	vol	vol	NOUN
ihlr-16500	462	14	.	.	PUNCT
ihlr-16500	462	15	4:115	4:115	NUM
ihlr-16500	462	16	a.	a.	NOUN
ihlr-16500	462	17	ethical	ethical	ADJ
ihlr-16500	462	18	considerations	consideration	NOUN
ihlr-16500	462	19	faced	face	VERB
ihlr-16500	462	20	by	by	ADP
ihlr-16500	462	21	the	the	DET
ihlr-16500	462	22	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	462	23	company	company	NOUN
ihlr-16500	462	24	before	before	ADP
ihlr-16500	462	25	and	and	CCONJ
ihlr-16500	462	26	after	after	ADP
ihlr-16500	462	27	drug	drug	NOUN
ihlr-16500	462	28	withdrawal	withdrawal	NOUN
ihlr-16500	462	29	although	although	SCONJ
ihlr-16500	462	30	a	a	DET
ihlr-16500	462	31	withdrawal	withdrawal	NOUN
ihlr-16500	462	32	might	might	AUX
ihlr-16500	462	33	be	be	AUX
ihlr-16500	462	34	in	in	ADP
ihlr-16500	462	35	the	the	DET
ihlr-16500	462	36	best	good	ADJ
ihlr-16500	462	37	interests	interest	NOUN
ihlr-16500	462	38	of	of	ADP
ihlr-16500	462	39	the	the	DET
ihlr-16500	462	40	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	462	41	company	company	NOUN
ihlr-16500	462	42	,	,	PUNCT
ihlr-16500	462	43	it	it	PRON
ihlr-16500	462	44	is	be	AUX
ihlr-16500	462	45	often	often	ADV
ihlr-16500	462	46	not	not	PART
ihlr-16500	462	47	in	in	ADP
ihlr-16500	462	48	the	the	DET
ihlr-16500	462	49	best	good	ADJ
ihlr-16500	462	50	interests	interest	NOUN
ihlr-16500	462	51	of	of	ADP
ihlr-16500	462	52	the	the	DET
ihlr-16500	462	53	patients	patient	NOUN
ihlr-16500	462	54	who	who	PRON
ihlr-16500	462	55	use	use	VERB
ihlr-16500	462	56	the	the	DET
ihlr-16500	462	57	drug	drug	NOUN
ihlr-16500	462	58	and	and	CCONJ
ihlr-16500	462	59	are	be	AUX
ihlr-16500	462	60	dependent	dependent	ADJ
ihlr-16500	462	61	on	on	ADP
ihlr-16500	462	62	it	it	PRON
ihlr-16500	462	63	for	for	ADP
ihlr-16500	462	64	their	their	PRON
ihlr-16500	462	65	daily	daily	ADJ
ihlr-16500	462	66	activities	activity	NOUN
ihlr-16500	462	67	.	.	PUNCT
ihlr-16500	463	1	therefore	therefore	ADV
ihlr-16500	463	2	,	,	PUNCT
ihlr-16500	463	3	this	this	DET
ihlr-16500	463	4	section	section	NOUN
ihlr-16500	463	5	of	of	ADP
ihlr-16500	463	6	the	the	DET
ihlr-16500	463	7	note	note	NOUN
ihlr-16500	463	8	will	will	AUX
ihlr-16500	463	9	examine	examine	VERB
ihlr-16500	463	10	the	the	DET
ihlr-16500	463	11	ethical	ethical	ADJ
ihlr-16500	463	12	considerations	consideration	NOUN
ihlr-16500	463	13	that	that	PRON
ihlr-16500	463	14	a	a	DET
ihlr-16500	463	15	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	463	16	company	company	NOUN
ihlr-16500	463	17	must	must	AUX
ihlr-16500	463	18	undertake	undertake	VERB
ihlr-16500	463	19	before	before	ADV
ihlr-16500	463	20	and	and	CCONJ
ihlr-16500	463	21	after	after	ADP
ihlr-16500	463	22	a	a	DET
ihlr-16500	463	23	drug	drug	NOUN
ihlr-16500	463	24	withdrawal	withdrawal	NOUN
ihlr-16500	463	25	.	.	PUNCT
ihlr-16500	464	1	116	116	NUM
ihlr-16500	464	2	obviously	obviously	ADV
ihlr-16500	464	3	from	from	ADP
ihlr-16500	464	4	the	the	DET
ihlr-16500	464	5	perspective	perspective	NOUN
ihlr-16500	464	6	of	of	ADP
ihlr-16500	464	7	a	a	DET
ihlr-16500	464	8	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	464	9	company	company	NOUN
ihlr-16500	464	10	,	,	PUNCT
ihlr-16500	464	11	a.	a.	NOUN
ihlr-16500	464	12	drug	drug	PROPN
ihlr-16500	464	13	withdrawal	withdrawal	NOUN
ihlr-16500	464	14	is	be	AUX
ihlr-16500	464	15	not	not	PART
ihlr-16500	464	16	an	an	DET
ihlr-16500	464	17	ideal	ideal	ADJ
ihlr-16500	464	18	solution	solution	NOUN
ihlr-16500	464	19	because	because	SCONJ
ihlr-16500	464	20	it	it	PRON
ihlr-16500	464	21	leads	lead	VERB
ihlr-16500	464	22	to	to	ADP
ihlr-16500	464	23	negative	negative	ADJ
ihlr-16500	464	24	public	public	ADJ
ihlr-16500	464	25	percep­	percep­	PROPN
ihlr-16500	464	26	tion	tion	NOUN
ihlr-16500	464	27	,	,	PUNCT
ihlr-16500	464	28	strained	strained	ADJ
ihlr-16500	464	29	investor	investor	NOUN
ihlr-16500	464	30	relations	relation	NOUN
ihlr-16500	464	31	,	,	PUNCT
ihlr-16500	464	32	and	and	CCONJ
ihlr-16500	464	33	loss	loss	NOUN
ihlr-16500	464	34	of	of	ADP
ihlr-16500	464	35	a	a	DET
ihlr-16500	464	36	valuable	valuable	ADJ
ihlr-16500	464	37	asset	asset	NOUN
ihlr-16500	464	38	.	.	PUNCT
ihlr-16500	465	1	117	117	NUM
ihlr-16500	465	2	in	in	ADP
ihlr-16500	465	3	short	short	ADJ
ihlr-16500	465	4	,	,	PUNCT
ihlr-16500	465	5	there	there	PRON
ihlr-16500	465	6	are	be	VERB
ihlr-16500	465	7	rarely	rarely	ADV
ihlr-16500	465	8	any	any	DET
ihlr-16500	465	9	positive	positive	ADJ
ihlr-16500	465	10	aspects	aspect	NOUN
ihlr-16500	465	11	to	to	ADP
ihlr-16500	465	12	a	a	DET
ihlr-16500	465	13	drug	drug	NOUN
ihlr-16500	465	14	withdrawal	withdrawal	NOUN
ihlr-16500	465	15	.	.	PUNCT
ihlr-16500	466	1	before	before	SCONJ
ihlr-16500	466	2	a	a	DET
ihlr-16500	466	3	drug	drug	NOUN
ihlr-16500	466	4	withdrawal	withdrawal	NOUN
ihlr-16500	466	5	has	have	AUX
ihlr-16500	466	6	transpired	transpire	VERB
ihlr-16500	466	7	,	,	PUNCT
ihlr-16500	466	8	however	however	ADV
ihlr-16500	466	9	,	,	PUNCT
ihlr-16500	466	10	it	it	PRON
ihlr-16500	466	11	is	be	AUX
ihlr-16500	466	12	important	important	ADJ
ihlr-16500	466	13	for	for	SCONJ
ihlr-16500	466	14	a	a	DET
ihlr-16500	466	15	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	466	16	company	company	NOUN
ihlr-16500	466	17	to	to	PART
ihlr-16500	466	18	note	note	VERB
ihlr-16500	466	19	that	that	SCONJ
ihlr-16500	466	20	it	it	PRON
ihlr-16500	466	21	can	can	AUX
ihlr-16500	466	22	minimize	minimize	VERB
ihlr-16500	466	23	the	the	DET
ihlr-16500	466	24	negative	negative	ADJ
ihlr-16500	466	25	aspects	aspect	NOUN
ihlr-16500	466	26	of	of	ADP
ihlr-16500	466	27	a	a	DET
ihlr-16500	466	28	drug	drug	NOUN
ihlr-16500	466	29	withdrawal	withdrawal	NOUN
ihlr-16500	466	30	with	with	ADP
ihlr-16500	466	31	a	a	DET
ihlr-16500	466	32	proper	proper	ADJ
ihlr-16500	466	33	handling	handling	NOUN
ihlr-16500	466	34	of	of	ADP
ihlr-16500	466	35	the	the	DET
ihlr-16500	466	36	situation	situation	NOUN
ihlr-16500	466	37	.	.	PUNCT
ihlr-16500	467	1	therefore	therefore	ADV
ihlr-16500	467	2	,	,	PUNCT
ihlr-16500	467	3	a	a	DET
ihlr-16500	467	4	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	467	5	company	company	NOUN
ihlr-16500	467	6	's	's	PART
ihlr-16500	467	7	evaluation	evaluation	NOUN
ihlr-16500	467	8	of	of	ADP
ihlr-16500	467	9	the	the	DET
ihlr-16500	467	10	ethical	ethical	ADJ
ihlr-16500	467	11	considerations	consideration	NOUN
ihlr-16500	467	12	before	before	SCONJ
ihlr-16500	467	13	a	a	DET
ihlr-16500	467	14	drug	drug	NOUN
ihlr-16500	467	15	withdrawal	withdrawal	NOUN
ihlr-16500	467	16	may	may	AUX
ihlr-16500	467	17	mitigate	mitigate	VERB
ihlr-16500	467	18	the	the	DET
ihlr-16500	467	19	negative	negative	ADJ
ihlr-16500	467	20	public	public	ADJ
ihlr-16500	467	21	perception	perception	NOUN
ihlr-16500	467	22	and	and	CCONJ
ihlr-16500	467	23	strained	strained	ADJ
ihlr-16500	467	24	investor	investor	NOUN
ihlr-16500	467	25	relationship	relationship	NOUN
ihlr-16500	467	26	it	it	PRON
ihlr-16500	467	27	is	be	AUX
ihlr-16500	467	28	sure	sure	ADJ
ihlr-16500	467	29	to	to	PART
ihlr-16500	467	30	face	face	VERB
ihlr-16500	467	31	.	.	PUNCT
ihlr-16500	468	1	the	the	DET
ihlr-16500	468	2	stakes	stake	NOUN
ihlr-16500	468	3	for	for	ADP
ihlr-16500	468	4	all	all	PRON
ihlr-16500	468	5	involved	involve	VERB
ihlr-16500	468	6	in	in	ADP
ihlr-16500	468	7	a	a	DET
ihlr-16500	468	8	drug	drug	NOUN
ihlr-16500	468	9	withdrawal	withdrawal	NOUN
ihlr-16500	468	10	,	,	PUNCT
ihlr-16500	468	11	whether	whether	SCONJ
ihlr-16500	468	12	voluntary	voluntary	ADJ
ihlr-16500	468	13	or	or	CCONJ
ihlr-16500	468	14	in­	in­	NOUN
ihlr-16500	468	15	voluntary	voluntary	ADJ
ihlr-16500	468	16	,	,	PUNCT
ihlr-16500	468	17	are	be	AUX
ihlr-16500	468	18	enormous	enormous	ADJ
ihlr-16500	468	19	.	.	PUNCT
ihlr-16500	469	1	as	as	ADP
ihlr-16500	469	2	a	a	DET
ihlr-16500	469	3	result	result	NOUN
ihlr-16500	469	4	,	,	PUNCT
ihlr-16500	469	5	before	before	SCONJ
ihlr-16500	469	6	a	a	DET
ihlr-16500	469	7	decision	decision	NOUN
ihlr-16500	469	8	is	be	AUX
ihlr-16500	469	9	made	make	VERB
ihlr-16500	469	10	as	as	ADP
ihlr-16500	469	11	to	to	ADP
ihlr-16500	469	12	whether	whether	SCONJ
ihlr-16500	469	13	a	a	DET
ihlr-16500	469	14	blockbuster	blockbuster	ADJ
ihlr-16500	469	15	drug	drug	NOUN
ihlr-16500	469	16	will	will	AUX
ihlr-16500	469	17	be	be	AUX
ihlr-16500	469	18	withdrawn	withdraw	VERB
ihlr-16500	469	19	from	from	ADP
ihlr-16500	469	20	the	the	DET
ihlr-16500	469	21	market	market	NOUN
ihlr-16500	469	22	,	,	PUNCT
ihlr-16500	469	23	the	the	DET
ihlr-16500	469	24	respective	respective	ADJ
ihlr-16500	469	25	pharmaceu­	pharmaceu­	NOUN
ihlr-16500	469	26	tical	tical	ADJ
ihlr-16500	469	27	company	company	NOUN
ihlr-16500	469	28	must	must	AUX
ihlr-16500	469	29	evaluate	evaluate	VERB
ihlr-16500	469	30	how	how	SCONJ
ihlr-16500	469	31	such	such	DET
ihlr-16500	469	32	an	an	DET
ihlr-16500	469	33	announcement	announcement	NOUN
ihlr-16500	469	34	will	will	AUX
ihlr-16500	469	35	affect	affect	VERB
ihlr-16500	469	36	the	the	DET
ihlr-16500	469	37	count­	count­	NOUN
ihlr-16500	469	38	less	less	ADJ
ihlr-16500	469	39	number	number	NOUN
ihlr-16500	469	40	of	of	ADP
ihlr-16500	469	41	patients	patient	NOUN
ihlr-16500	469	42	who	who	PRON
ihlr-16500	469	43	are	be	AUX
ihlr-16500	469	44	counting	count	VERB
ihlr-16500	469	45	on	on	ADP
ihlr-16500	469	46	the	the	DET
ihlr-16500	469	47	drug	drug	NOUN
ihlr-16500	469	48	to	to	PART
ihlr-16500	469	49	treat	treat	VERB
ihlr-16500	469	50	a	a	DET
ihlr-16500	469	51	life	life	NOUN
ihlr-16500	469	52	-	-	PUNCT
ihlr-16500	469	53	altering	alter	VERB
ihlr-16500	469	54	ailment	ailment	NOUN
ihlr-16500	469	55	.	.	PUNCT
ihlr-16500	470	1	in	in	ADP
ihlr-16500	470	2	addition	addition	NOUN
ihlr-16500	470	3	,	,	PUNCT
ihlr-16500	470	4	such	such	DET
ihlr-16500	470	5	an	an	DET
ihlr-16500	470	6	announcement	announcement	NOUN
ihlr-16500	470	7	also	also	ADV
ihlr-16500	470	8	forces	force	VERB
ihlr-16500	470	9	health	health	NOUN
ihlr-16500	470	10	care	care	NOUN
ihlr-16500	470	11	profession­	profession­	NOUN
ihlr-16500	470	12	als	als	VERB
ihlr-16500	470	13	to	to	PART
ihlr-16500	470	14	face	face	VERB
ihlr-16500	470	15	the	the	DET
ihlr-16500	470	16	prospect	prospect	NOUN
ihlr-16500	470	17	of	of	ADP
ihlr-16500	470	18	finding	find	VERB
ihlr-16500	470	19	alternative	alternative	ADJ
ihlr-16500	470	20	forms	form	NOUN
ihlr-16500	470	21	of	of	ADP
ihlr-16500	470	22	relief	relief	NOUN
ihlr-16500	470	23	for	for	ADP
ihlr-16500	470	24	patients	patient	NOUN
ihlr-16500	470	25	who	who	PRON
ihlr-16500	470	26	can	can	AUX
ihlr-16500	470	27	no	no	ADV
ihlr-16500	470	28	longer	long	ADV
ihlr-16500	470	29	use	use	VERB
ihlr-16500	470	30	the	the	DET
ihlr-16500	470	31	withdrawn	withdraw	VERB
ihlr-16500	470	32	blockbuster	blockbuster	NOUN
ihlr-16500	470	33	drug	drug	NOUN
ihlr-16500	470	34	.	.	PUNCT
ihlr-16500	471	1	in	in	ADP
ihlr-16500	471	2	the	the	DET
ihlr-16500	471	3	case	case	NOUN
ihlr-16500	471	4	of	of	ADP
ihlr-16500	471	5	voluntary	voluntary	ADJ
ihlr-16500	471	6	withdrawal	withdrawal	NOUN
ihlr-16500	471	7	,	,	PUNCT
ihlr-16500	471	8	the	the	DET
ihlr-16500	471	9	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	471	10	company	company	NOUN
ihlr-16500	471	11	can	can	AUX
ihlr-16500	471	12	balance	balance	VERB
ihlr-16500	471	13	such	such	ADJ
ihlr-16500	471	14	ethical	ethical	ADJ
ihlr-16500	471	15	considera­	considera­	NOUN
ihlr-16500	471	16	tions	tion	NOUN
ihlr-16500	471	17	with	with	ADP
ihlr-16500	471	18	the	the	DET
ihlr-16500	471	19	fact	fact	NOUN
ihlr-16500	471	20	that	that	SCONJ
ihlr-16500	471	21	they	they	PRON
ihlr-16500	471	22	must	must	AUX
ihlr-16500	471	23	ensure	ensure	VERB
ihlr-16500	471	24	the	the	DET
ihlr-16500	471	25	safety	safety	NOUN
ihlr-16500	471	26	of	of	ADP
ihlr-16500	471	27	the	the	DET
ihlr-16500	471	28	general	general	ADJ
ihlr-16500	471	29	public	public	NOUN
ihlr-16500	471	30	.	.	PUNCT
ihlr-16500	472	1	also	also	ADV
ihlr-16500	472	2	,	,	PUNCT
ihlr-16500	472	3	the	the	DET
ihlr-16500	472	4	company	company	NOUN
ihlr-16500	472	5	can	can	AUX
ihlr-16500	472	6	fall	fall	VERB
ihlr-16500	472	7	back	back	ADV
ihlr-16500	472	8	on	on	ADP
ihlr-16500	472	9	the	the	DET
ihlr-16500	472	10	fact	fact	NOUN
ihlr-16500	472	11	that	that	SCONJ
ihlr-16500	472	12	it	it	PRON
ihlr-16500	472	13	took	take	VERB
ihlr-16500	472	14	all	all	DET
ihlr-16500	472	15	the	the	DET
ihlr-16500	472	16	necessary	necessary	ADJ
ihlr-16500	472	17	precautions	precaution	NOUN
ihlr-16500	472	18	,	,	PUNCT
ihlr-16500	472	19	such	such	ADJ
ihlr-16500	472	20	as	as	ADP
ihlr-16500	472	21	adding	add	VERB
ihlr-16500	472	22	warning	warning	NOUN
ihlr-16500	472	23	labels	label	NOUN
ihlr-16500	472	24	as	as	SCONJ
ihlr-16500	472	25	required	require	VERB
ihlr-16500	472	26	by	by	ADP
ihlr-16500	472	27	the	the	DET
ihlr-16500	472	28	fda	fda	PROPN
ihlr-16500	472	29	,	,	PUNCT
ihlr-16500	472	30	but	but	CCONJ
ihlr-16500	472	31	in	in	ADP
ihlr-16500	472	32	such	such	DET
ihlr-16500	472	33	a	a	DET
ihlr-16500	472	34	case	case	NOUN
ihlr-16500	472	35	,	,	PUNCT
ihlr-16500	472	36	the	the	DET
ihlr-16500	472	37	risk	risk	NOUN
ihlr-16500	472	38	outweighed	outweigh	VERB
ihlr-16500	472	39	any	any	DET
ihlr-16500	472	40	potential	potential	ADJ
ihlr-16500	472	41	benefit	benefit	NOUN
ihlr-16500	472	42	that	that	PRON
ihlr-16500	472	43	the	the	DET
ihlr-16500	472	44	blockbuster	blockbuster	NOUN
ihlr-16500	472	45	drug	drug	NOUN
ihlr-16500	472	46	provided.118	provided.118	VERB
ihlr-16500	472	47	conversely	conversely	ADV
ihlr-16500	472	48	,	,	PUNCT
ihlr-16500	472	49	the	the	DET
ihlr-16500	472	50	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	472	51	company	company	NOUN
ihlr-16500	472	52	is	be	AUX
ihlr-16500	472	53	faced	face	VERB
ihlr-16500	472	54	with	with	ADP
ihlr-16500	472	55	the	the	DET
ihlr-16500	472	56	prospect	prospect	NOUN
ihlr-16500	472	57	of	of	ADP
ihlr-16500	472	58	continuing	continue	VERB
ihlr-16500	472	59	to	to	PART
ihlr-16500	472	60	market	market	VERB
ihlr-16500	472	61	and	and	CCONJ
ihlr-16500	472	62	manufacture	manufacture	VERB
ihlr-16500	472	63	a	a	DET
ihlr-16500	472	64	defective	defective	ADJ
ihlr-16500	472	65	product	product	NOUN
ihlr-16500	472	66	,	,	PUNCT
ihlr-16500	472	67	particularly	particularly	ADV
ihlr-16500	472	68	,	,	PUNCT
ihlr-16500	472	69	one	one	NUM
ihlr-16500	472	70	that	that	PRON
ihlr-16500	472	71	posed	pose	VERB
ihlr-16500	472	72	a	a	DET
ihlr-16500	472	73	danger	danger	NOUN
ihlr-16500	472	74	to	to	ADP
ihlr-16500	472	75	those	those	DET
ihlr-16500	472	76	patients	patient	NOUN
ihlr-16500	472	77	who	who	PRON
ihlr-16500	472	78	used	use	VERB
ihlr-16500	472	79	it	it	PRON
ihlr-16500	472	80	.	.	PUNCT
ihlr-16500	473	1	in	in	ADP
ihlr-16500	473	2	addition	addition	NOUN
ihlr-16500	473	3	,	,	PUNCT
ihlr-16500	473	4	the	the	DET
ihlr-16500	473	5	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	473	6	company	company	NOUN
ihlr-16500	473	7	also	also	ADV
ihlr-16500	473	8	must	must	AUX
ihlr-16500	473	9	consider	consider	VERB
ihlr-16500	473	10	the	the	DET
ihlr-16500	473	11	ethics	ethic	NOUN
ihlr-16500	473	12	of	of	ADP
ihlr-16500	473	13	continuing	continue	VERB
ihlr-16500	473	14	to	to	PART
ihlr-16500	473	15	market	market	VERB
ihlr-16500	473	16	a	a	DET
ihlr-16500	473	17	product	product	NOUN
ihlr-16500	473	18	whose	whose	DET
ihlr-16500	473	19	·	·	SYM
ihlr-16500	473	20	failures	failure	NOUN
ihlr-16500	473	21	are	be	AUX
ihlr-16500	473	22	delineated	delineate	VERB
ihlr-16500	473	23	in	in	ADP
ihlr-16500	473	24	clinical	clinical	ADJ
ihlr-16500	473	25	outcomes	outcome	NOUN
ihlr-16500	473	26	studies	study	NOUN
ihlr-16500	473	27	.	.	PUNCT
ihlr-16500	474	1	as	as	ADP
ihlr-16500	474	2	a	a	DET
ihlr-16500	474	3	result	result	NOUN
ihlr-16500	474	4	,	,	PUNCT
ihlr-16500	474	5	the	the	DET
ihlr-16500	474	6	pharmaceu­	pharmaceu­	NOUN
ihlr-16500	474	7	tical	tical	ADJ
ihlr-16500	474	8	company	company	NOUN
ihlr-16500	474	9	's	's	PART
ihlr-16500	474	10	failure	failure	NOUN
ihlr-16500	474	11	to	to	PART
ihlr-16500	474	12	act	act	VERB
ihlr-16500	474	13	may	may	AUX
ihlr-16500	474	14	have	have	AUX
ihlr-16500	474	15	led	lead	VERB
ihlr-16500	474	16	to	to	ADP
ihlr-16500	474	17	countless	countless	ADJ
ihlr-16500	474	18	more	more	ADJ
ihlr-16500	474	19	deaths	death	NOUN
ihlr-16500	474	20	that	that	PRON
ihlr-16500	474	21	may	may	AUX
ihlr-16500	474	22	have	have	AUX
ihlr-16500	474	23	been	be	AUX
ihlr-16500	474	24	avoided	avoid	VERB
ihlr-16500	474	25	through	through	ADP
ihlr-16500	474	26	both	both	DET
ihlr-16500	474	27	the	the	DET
ihlr-16500	474	28	drug	drug	NOUN
ihlr-16500	474	29	's	's	PART
ihlr-16500	474	30	withdrawal	withdrawal	NOUN
ihlr-16500	474	31	from	from	ADP
ihlr-16500	474	32	the	the	DET
ihlr-16500	474	33	market	market	NOUN
ihlr-16500	474	34	and	and	CCONJ
ihlr-16500	474	35	timely	timely	ADJ
ihlr-16500	474	36	notice	notice	NOUN
ihlr-16500	474	37	of	of	ADP
ihlr-16500	474	38	the	the	DET
ihlr-16500	474	39	drug	drug	NOUN
ihlr-16500	474	40	's	's	PART
ihlr-16500	474	41	withdrawal	withdrawal	NOUN
ihlr-16500	474	42	to	to	ADP
ihlr-16500	474	43	physicians	physician	NOUN
ihlr-16500	474	44	and	and	CCONJ
ihlr-16500	474	45	patients.119	patients.119	PROPN
ihlr-16500	474	46	therefore	therefore	ADV
ihlr-16500	474	47	,	,	PUNCT
ihlr-16500	474	48	116	116	NUM
ihlr-16500	474	49	epstein	epstein	NOUN
ihlr-16500	474	50	,	,	PUNCT
ihlr-16500	474	51	supra	supra	PROPN
ihlr-16500	474	52	note	note	PROPN
ihlr-16500	474	53	105	105	NUM
ihlr-16500	474	54	,	,	PUNCT
ihlr-16500	474	55	at	at	ADP
ihlr-16500	474	56	745	745	NUM
ihlr-16500	474	57	.	.	PUNCT
ihlr-16500	475	1	117	117	NUM
ihlr-16500	475	2	aaron	aaron	PROPN
ihlr-16500	475	3	smith	smith	PROPN
ihlr-16500	475	4	,	,	PUNCT
ihlr-16500	475	5	drug	drug	NOUN
ihlr-16500	475	6	company	company	NOUN
ihlr-16500	475	7	could	could	AUX
ihlr-16500	475	8	use	use	VERB
ihlr-16500	475	9	a	a	DET
ihlr-16500	475	10	face	face	NOUN
ihlr-16500	475	11	lift	lift	NOUN
ihlr-16500	475	12	,	,	PUNCT
ihlr-16500	475	13	cnnmoney.com	cnnmoney.com	X
ihlr-16500	475	14	,	,	PUNCT
ihlr-16500	475	15	aug	aug	PROPN
ihlr-16500	475	16	.	.	PROPN
ihlr-16500	475	17	19	19	NUM
ihlr-16500	475	18	,	,	PUNCT
ihlr-16500	475	19	2005	2005	NUM
ihlr-16500	475	20	,	,	PUNCT
ihlr-16500	475	21	http://money.cnn.com/2005/08/16/newslfortune500/drugindustryfmdex.htm?section=	http://money.cnn.com/2005/08/16/newslfortune500/drugindustryfmdex.htm?section=	VERB
ihlr-16500	475	22	money	money	NOUN
ihlr-16500	475	23	_	_	PUNCT
ihlr-16500	475	24	latest	late	ADJ
ihlr-16500	475	25	.	.	PUNCT
ihlr-16500	476	1	lis	lis	PROPN
ihlr-16500	476	2	jd	jd	PROPN
ihlr-16500	476	3	.	.	PROPN
ihlr-16500	476	4	119	119	NUM
ihlr-16500	476	5	see	see	VERB
ihlr-16500	476	6	bean	bean	NOUN
ihlr-16500	476	7	,	,	PUNCT
ihlr-16500	476	8	supra	supra	PROPN
ihlr-16500	476	9	note	note	NOUN
ihlr-16500	476	10	88	88	NUM
ihlr-16500	476	11	.	.	PUNCT
ihlr-16500	476	12	2007	2007	NUM
ihlr-16500	476	13	]	]	PUNCT
ihlr-16500	477	1	pulling	pull	VERB
ihlr-16500	477	2	a	a	DET
ihlr-16500	477	3	blockbuster	blockbuster	ADJ
ihlr-16500	477	4	drug	drug	NOUN
ihlr-16500	477	5	off	off	ADP
ihlr-16500	477	6	the	the	DET
ihlr-16500	477	7	market	market	NOUN
ihlr-16500	477	8	137	137	NUM
ihlr-16500	477	9	a	a	DET
ihlr-16500	477	10	failure	failure	NOUN
ihlr-16500	477	11	to	to	PART
ihlr-16500	477	12	take	take	VERB
ihlr-16500	477	13	into	into	ADP
ihlr-16500	477	14	account	account	NOUN
ihlr-16500	477	15	these	these	DET
ihlr-16500	477	16	important	important	ADJ
ihlr-16500	477	17	ethical	ethical	ADJ
ihlr-16500	477	18	considerations	consideration	NOUN
ihlr-16500	477	19	can	can	AUX
ihlr-16500	477	20	lead	lead	VERB
ihlr-16500	477	21	to	to	ADP
ihlr-16500	477	22	devastating	devastating	ADJ
ihlr-16500	477	23	consequences	consequence	NOUN
ihlr-16500	477	24	including	include	VERB
ihlr-16500	477	25	a	a	DET
ihlr-16500	477	26	fda	fda	PROPN
ihlr-16500	477	27	mandated	mandate	VERB
ihlr-16500	477	28	withdrawal	withdrawal	NOUN
ihlr-16500	477	29	,	,	PUNCT
ihlr-16500	477	30	negative	negative	ADJ
ihlr-16500	477	31	public	public	ADJ
ihlr-16500	477	32	perception	perception	NOUN
ihlr-16500	477	33	,	,	PUNCT
ihlr-16500	477	34	and	and	CCONJ
ihlr-16500	477	35	strained	strained	ADJ
ihlr-16500	477	36	investor	investor	NOUN
ihlr-16500	477	37	relationships	relationship	NOUN
ihlr-16500	477	38	.	.	PUNCT
ihlr-16500	478	1	every	every	DET
ihlr-16500	478	2	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	478	3	company	company	NOUN
ihlr-16500	478	4	must	must	AUX
ihlr-16500	478	5	balance	balance	VERB
ihlr-16500	478	6	the	the	DET
ihlr-16500	478	7	benefits	benefit	NOUN
ihlr-16500	478	8	of	of	ADP
ihlr-16500	478	9	producing	produce	VERB
ihlr-16500	478	10	a	a	DET
ihlr-16500	478	11	blockbuster	blockbuster	ADJ
ihlr-16500	478	12	drug	drug	NOUN
ihlr-16500	478	13	with	with	ADP
ihlr-16500	478	14	the	the	DET
ihlr-16500	478	15	risk	risk	NOUN
ihlr-16500	478	16	of	of	ADP
ihlr-16500	478	17	loss	loss	NOUN
ihlr-16500	478	18	of	of	ADP
ihlr-16500	478	19	life	life	NOUN
ihlr-16500	478	20	or	or	CCONJ
ihlr-16500	478	21	serious	serious	ADJ
ihlr-16500	478	22	injury	injury	NOUN
ihlr-16500	478	23	that	that	PRON
ihlr-16500	478	24	may	may	AUX
ihlr-16500	478	25	result	result	VERB
ihlr-16500	478	26	due	due	ADP
ihlr-16500	478	27	to	to	ADP
ihlr-16500	478	28	an	an	DET
ihlr-16500	478	29	adverse	adverse	ADJ
ihlr-16500	478	30	event	event	NOUN
ihlr-16500	478	31	or	or	CCONJ
ihlr-16500	478	32	other	other	ADJ
ihlr-16500	478	33	usage	usage	NOUN
ihlr-16500	478	34	problem	problem	NOUN
ihlr-16500	478	35	.	.	PUNCT
ihlr-16500	479	1	in	in	ADP
ihlr-16500	479	2	addition	addition	NOUN
ihlr-16500	479	3	,	,	PUNCT
ihlr-16500	479	4	every	every	DET
ihlr-16500	479	5	pharmaceu­	pharmaceu­	PART
ihlr-16500	479	6	tical	tical	ADJ
ihlr-16500	479	7	company	company	NOUN
ihlr-16500	479	8	,	,	PUNCT
ihlr-16500	479	9	through	through	ADP
ihlr-16500	479	10	their	their	PRON
ihlr-16500	479	11	membership	membership	NOUN
ihlr-16500	479	12	in	in	ADP
ihlr-16500	479	13	phrma	phrma	NOUN
ihlr-16500	479	14	,	,	PUNCT
ihlr-16500	479	15	understands	understand	VERB
ihlr-16500	479	16	that	that	SCONJ
ihlr-16500	479	17	they	they	PRON
ihlr-16500	479	18	have	have	VERB
ihlr-16500	479	19	an	an	DET
ihlr-16500	479	20	important	important	ADJ
ihlr-16500	479	21	duty	duty	NOUN
ihlr-16500	479	22	to	to	PART
ihlr-16500	479	23	treat	treat	VERB
ihlr-16500	479	24	patients	patient	NOUN
ihlr-16500	479	25	on	on	ADP
ihlr-16500	479	26	their	their	PRON
ihlr-16500	479	27	road	road	NOUN
ihlr-16500	479	28	to	to	ADP
ihlr-16500	479	29	recovery	recovery	NOUN
ihlr-16500	479	30	.	.	PUNCT
ihlr-16500	480	1	120	120	NUM
ihlr-16500	480	2	neverthe­	neverthe­	NOUN
ihlr-16500	480	3	less	less	ADJ
ihlr-16500	480	4	,	,	PUNCT
ihlr-16500	480	5	given	give	VERB
ihlr-16500	480	6	the	the	DET
ihlr-16500	480	7	ethical	ethical	ADJ
ihlr-16500	480	8	duties	duty	NOUN
ihlr-16500	480	9	voluntarily	voluntarily	ADV
ihlr-16500	480	10	undertaken	undertake	VERB
ihlr-16500	480	11	by	by	ADP
ihlr-16500	480	12	the	the	DET
ihlr-16500	480	13	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	480	14	in­	in­	NOUN
ihlr-16500	480	15	dustry	dustry	NOUN
ihlr-16500	480	16	and	and	CCONJ
ihlr-16500	480	17	its	its	PRON
ihlr-16500	480	18	companies	company	NOUN
ihlr-16500	480	19	,	,	PUNCT
ihlr-16500	480	20	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	480	21	companies	company	NOUN
ihlr-16500	480	22	are	be	AUX
ihlr-16500	480	23	continually	continually	ADV
ihlr-16500	480	24	faced	face	VERB
ihlr-16500	480	25	with	with	ADP
ihlr-16500	480	26	accusations	accusation	NOUN
ihlr-16500	480	27	from	from	ADP
ihlr-16500	480	28	the	the	DET
ihlr-16500	480	29	public	public	NOUN
ihlr-16500	480	30	,	,	PUNCT
ihlr-16500	480	31	government	government	NOUN
ihlr-16500	480	32	officials	official	NOUN
ihlr-16500	480	33	,	,	PUNCT
ihlr-16500	480	34	and	and	CCONJ
ihlr-16500	480	35	regulatory	regulatory	ADJ
ihlr-16500	480	36	officials	official	NOUN
ihlr-16500	480	37	that	that	SCONJ
ihlr-16500	480	38	they	they	PRON
ihlr-16500	480	39	failed	fail	VERB
ihlr-16500	480	40	to	to	PART
ihlr-16500	480	41	take	take	VERB
ihlr-16500	480	42	into	into	ADP
ihlr-16500	480	43	account	account	NOUN
ihlr-16500	480	44	the	the	DET
ihlr-16500	480	45	ethical	ethical	ADJ
ihlr-16500	480	46	consideration	consideration	NOUN
ihlr-16500	480	47	of	of	ADP
ihlr-16500	480	48	continuing	continue	VERB
ihlr-16500	480	49	to	to	ADP
ihlr-16500	480	50	manu­	manu­	PROPN
ihlr-16500	480	51	facture	facture	VERB
ihlr-16500	480	52	a	a	DET
ihlr-16500	480	53	drug	drug	NOUN
ihlr-16500	480	54	whose	whose	DET
ihlr-16500	480	55	safety	safety	NOUN
ihlr-16500	480	56	problems	problem	NOUN
ihlr-16500	480	57	were	be	AUX
ihlr-16500	480	58	readily	readily	ADV
ihlr-16500	480	59	ascertained	ascertain	VERB
ihlr-16500	480	60	from	from	ADP
ihlr-16500	480	61	ongoing	ongoing	ADJ
ihlr-16500	480	62	clinical	clinical	ADJ
ihlr-16500	480	63	-	-	PUNCT
ihlr-16500	480	64	outcomes	outcome	NOUN
ihlr-16500	480	65	studies	study	NOUN
ihlr-16500	480	66	.	.	PUNCT
ihlr-16500	481	1	121	121	NUM
ihlr-16500	481	2	in	in	ADP
ihlr-16500	481	3	addition	addition	NOUN
ihlr-16500	481	4	,	,	PUNCT
ihlr-16500	481	5	although	although	SCONJ
ihlr-16500	481	6	in	in	ADP
ihlr-16500	481	7	recent	recent	ADJ
ihlr-16500	481	8	years	year	NOUN
ihlr-16500	481	9	,	,	PUNCT
ihlr-16500	481	10	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	481	11	companies	company	NOUN
ihlr-16500	481	12	have	have	AUX
ihlr-16500	481	13	been	be	AUX
ihlr-16500	481	14	forced	force	VERB
ihlr-16500	481	15	to	to	PART
ihlr-16500	481	16	withdraw	withdraw	VERB
ihlr-16500	481	17	an	an	DET
ihlr-16500	481	18	increasing	increase	VERB
ihlr-16500	481	19	number	number	NOUN
ihlr-16500	481	20	of	of	ADP
ihlr-16500	481	21	blockbuster	blockbuster	ADJ
ihlr-16500	481	22	drugs	drug	NOUN
ihlr-16500	481	23	,	,	PUNCT
ihlr-16500	481	24	many	many	ADJ
ihlr-16500	481	25	of	of	ADP
ihlr-16500	481	26	these	these	DET
ihlr-16500	481	27	drugs	drug	NOUN
ihlr-16500	481	28	have	have	AUX
ihlr-16500	481	29	been	be	AUX
ihlr-16500	481	30	withdrawn	withdraw	VERB
ihlr-16500	481	31	after	after	ADP
ihlr-16500	481	32	a	a	DET
ihlr-16500	481	33	significant	significant	ADJ
ihlr-16500	481	34	number	number	NOUN
ihlr-16500	481	35	of	of	ADP
ihlr-16500	481	36	patient	patient	ADJ
ihlr-16500	481	37	deaths	death	NOUN
ihlr-16500	481	38	.	.	PUNCT
ihlr-16500	482	1	for	for	ADP
ihlr-16500	482	2	instance	instance	NOUN
ihlr-16500	482	3	,	,	PUNCT
ihlr-16500	482	4	from	from	ADP
ihlr-16500	482	5	1997	1997	NUM
ihlr-16500	482	6	until200	until200	PROPN
ihlr-16500	482	7	1	1	NUM
ihlr-16500	482	8	,	,	PUNCT
ihlr-16500	482	9	thirteen	thirteen	NUM
ihlr-16500	482	10	drugs	drug	NOUN
ihlr-16500	482	11	were	be	AUX
ihlr-16500	482	12	pulled	pull	VERB
ihlr-16500	482	13	off	off	ADP
ihlr-16500	482	14	the	the	DET
ihlr-16500	482	15	market	market	NOUN
ihlr-16500	482	16	,	,	PUNCT
ihlr-16500	482	17	hav­	hav­	ADV
ihlr-16500	482	18	ing	ing	NOUN
ihlr-16500	482	19	been	be	AUX
ihlr-16500	482	20	linked	link	VERB
ihlr-16500	482	21	to	to	ADP
ihlr-16500	482	22	consumer	consumer	NOUN
ihlr-16500	482	23	deaths	death	NOUN
ihlr-16500	482	24	and	and	CCONJ
ihlr-16500	482	25	severe	severe	ADJ
ihlr-16500	482	26	side	side	NOUN
ihlr-16500	482	27	effects	effect	NOUN
ihlr-16500	482	28	.	.	PUNCT
ihlr-16500	483	1	122	122	NUM
ihlr-16500	483	2	several	several	ADJ
ihlr-16500	483	3	of	of	ADP
ihlr-16500	483	4	these	these	DET
ihlr-16500	483	5	thirteen	thirteen	NUM
ihlr-16500	483	6	drugs	drug	NOUN
ihlr-16500	483	7	were	be	AUX
ihlr-16500	483	8	on	on	ADP
ihlr-16500	483	9	the	the	DET
ihlr-16500	483	10	market	market	NOUN
ihlr-16500	483	11	for	for	ADP
ihlr-16500	483	12	many	many	ADJ
ihlr-16500	483	13	years	year	NOUN
ihlr-16500	483	14	before	before	SCONJ
ihlr-16500	483	15	they	they	PRON
ihlr-16500	483	16	were	be	AUX
ihlr-16500	483	17	withdrawn	withdraw	VERB
ihlr-16500	483	18	,	,	PUNCT
ihlr-16500	483	19	begging	beg	VERB
ihlr-16500	483	20	the	the	DET
ihlr-16500	483	21	question	question	NOUN
ihlr-16500	483	22	whether	whether	SCONJ
ihlr-16500	483	23	the	the	DET
ihlr-16500	483	24	respective	respective	ADJ
ihlr-16500	483	25	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	483	26	company	company	NOUN
ihlr-16500	483	27	should	should	AUX
ihlr-16500	483	28	have	have	AUX
ihlr-16500	483	29	been	be	AUX
ihlr-16500	483	30	allowed	allow	VERB
ihlr-16500	483	31	to	to	PART
ihlr-16500	483	32	wait	wait	VERB
ihlr-16500	483	33	for	for	ADP
ihlr-16500	483	34	evidence	evidence	NOUN
ihlr-16500	483	35	of	of	ADP
ihlr-16500	483	36	the	the	DET
ihlr-16500	483	37	drugs	drug	NOUN
ihlr-16500	483	38	'	'	PART
ihlr-16500	483	39	safety	safety	NOUN
ihlr-16500	483	40	problems	problem	NOUN
ihlr-16500	483	41	to	to	PART
ihlr-16500	483	42	accu­	accu­	PROPN
ihlr-16500	483	43	mulate	mulate	VERB
ihlr-16500	483	44	before	before	ADP
ihlr-16500	483	45	finally	finally	ADV
ihlr-16500	483	46	being	be	AUX
ihlr-16500	483	47	forced	force	VERB
ihlr-16500	483	48	to	to	PART
ihlr-16500	483	49	withdraw	withdraw	VERB
ihlr-16500	483	50	the	the	DET
ihlr-16500	483	51	drug	drug	NOUN
ihlr-16500	483	52	,	,	PUNCT
ihlr-16500	483	53	especially	especially	ADV
ihlr-16500	483	54	in	in	ADP
ihlr-16500	483	55	light	light	NOUN
ihlr-16500	483	56	of	of	ADP
ihlr-16500	483	57	their	their	PRON
ihlr-16500	483	58	ethical	ethical	ADJ
ihlr-16500	483	59	obligation	obligation	NOUN
ihlr-16500	483	60	to	to	PART
ihlr-16500	483	61	improve	improve	VERB
ihlr-16500	483	62	patients	patient	NOUN
ihlr-16500	483	63	'	'	PART
ihlr-16500	483	64	well	well	ADV
ihlr-16500	483	65	-	-	PUNCT
ihlr-16500	483	66	being	being	NOUN
ihlr-16500	483	67	.	.	PUNCT
ihlr-16500	484	1	123	123	NUM
ihlr-16500	484	2	a	a	DET
ihlr-16500	484	3	more	more	ADV
ihlr-16500	484	4	recent	recent	ADJ
ihlr-16500	484	5	example	example	NOUN
ihlr-16500	484	6	of	of	ADP
ihlr-16500	484	7	a	a	DET
ihlr-16500	484	8	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	484	9	company	company	NOUN
ihlr-16500	484	10	's	's	PART
ihlr-16500	484	11	alleged	allege	VERB
ihlr-16500	484	12	failure	failure	NOUN
ihlr-16500	484	13	to	to	PART
ihlr-16500	484	14	withdraw	withdraw	VERB
ihlr-16500	484	15	a	a	DET
ihlr-16500	484	16	drug	drug	NOUN
ihlr-16500	484	17	from	from	ADP
ihlr-16500	484	18	the	the	DET
ihlr-16500	484	19	market	market	NOUN
ihlr-16500	484	20	despite	despite	SCONJ
ihlr-16500	484	21	the	the	DET
ihlr-16500	484	22	proof	proof	NOUN
ihlr-16500	484	23	of	of	ADP
ihlr-16500	484	24	its	its	PRON
ihlr-16500	484	25	safety	safety	NOUN
ihlr-16500	484	26	problems	problem	NOUN
ihlr-16500	484	27	was	be	AUX
ihlr-16500	484	28	the	the	DET
ihlr-16500	484	29	vioxx	vioxx	NOUN
ihlr-16500	484	30	drug	drug	NOUN
ihlr-16500	484	31	withdrawal	withdrawal	PROPN
ihlr-16500	484	32	.	.	PUNCT
ihlr-16500	485	1	several	several	ADJ
ihlr-16500	485	2	notable	notable	ADJ
ihlr-16500	485	3	medical	medical	ADJ
ihlr-16500	485	4	journals	journal	NOUN
ihlr-16500	485	5	,	,	PUNCT
ihlr-16500	485	6	including	include	VERB
ihlr-16500	485	7	the	the	DET
ihlr-16500	485	8	120	120	NUM
ihlr-16500	485	9	pharmaceutical	pharmaceutical	NOUN
ihlr-16500	485	10	research	research	NOUN
ihlr-16500	485	11	&	&	CCONJ
ihlr-16500	485	12	manufacturers	manufacturer	NOUN
ihlr-16500	485	13	of	of	ADP
ihlr-16500	485	14	am	am	PROPN
ihlr-16500	485	15	.	.	PUNCT
ihlr-16500	485	16	,	,	PUNCT
ihlr-16500	485	17	about	about	ADP
ihlr-16500	485	18	phrma	phrma	NOUN
ihlr-16500	485	19	,	,	PUNCT
ihlr-16500	485	20	http://www.phnna.org/about_phnna/	http://www.phnna.org/about_phnna/	NOUN
ihlr-16500	485	21	(	(	PUNCT
ihlr-16500	485	22	last	last	ADV
ihlr-16500	485	23	visited	visit	VERB
ihlr-16500	485	24	feb	feb	PROPN
ihlr-16500	485	25	.	.	PROPN
ihlr-16500	485	26	20	20	NUM
ihlr-16500	485	27	,	,	PUNCT
ihlr-16500	485	28	2007	2007	NUM
ihlr-16500	485	29	)	)	PUNCT
ihlr-16500	485	30	.	.	PUNCT
ihlr-16500	486	1	phrma	phrma	PROPN
ihlr-16500	486	2	is	be	AUX
ihlr-16500	486	3	an	an	DET
ihlr-16500	486	4	association	association	NOUN
ihlr-16500	486	5	of	of	ADP
ihlr-16500	486	6	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	486	7	companies	company	NOUN
ihlr-16500	486	8	that	that	PRON
ihlr-16500	486	9	helps	help	VERB
ihlr-16500	486	10	regulate	regulate	VERB
ihlr-16500	486	11	the	the	DET
ihlr-16500	486	12	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	486	13	industry	industry	NOUN
ihlr-16500	486	14	.	.	PUNCT
ihlr-16500	487	1	i	i	PRON
ihlr-16500	487	2	d.	d.	PROPN
ihlr-16500	487	3	"	"	PUNCT
ihlr-16500	487	4	phrma	phrma	PROPN
ihlr-16500	487	5	'	'	PART
ihlr-16500	487	6	s	s	PROPN
ihlr-16500	487	7	mis­	mis­	PROPN
ihlr-16500	487	8	sion	sion	PROPN
ihlr-16500	487	9	is	be	AUX
ihlr-16500	487	10	winning	win	VERB
ihlr-16500	487	11	advocacy	advocacy	NOUN
ihlr-16500	487	12	for	for	ADP
ihlr-16500	487	13	public	public	ADJ
ihlr-16500	487	14	policies	policy	NOUN
ihlr-16500	487	15	that	that	PRON
ihlr-16500	487	16	encourage	encourage	VERB
ihlr-16500	487	17	the	the	DET
ihlr-16500	487	18	discovery	discovery	NOUN
ihlr-16500	487	19	oflife	oflife	NOUN
ihlr-16500	487	20	-	-	PUNCT
ihlr-16500	487	21	saving	save	VERB
ihlr-16500	487	22	and	and	CCONJ
ihlr-16500	487	23	life	life	NOUN
ihlr-16500	487	24	enhancing	enhance	VERB
ihlr-16500	487	25	new	new	ADJ
ihlr-16500	487	26	medicines	medicine	NOUN
ihlr-16500	487	27	for	for	ADP
ihlr-16500	487	28	patients	patient	NOUN
ihlr-16500	487	29	by	by	ADP
ihlr-16500	487	30	pharmaceutical	pharmaceutical	NOUN
ihlr-16500	487	31	/	/	SYM
ihlr-16500	487	32	biotechnology	biotechnology	NOUN
ihlr-16500	487	33	research	research	NOUN
ihlr-16500	487	34	companies	company	NOUN
ihlr-16500	487	35	.	.	PUNCT
ihlr-16500	487	36	"	"	PUNCT
ihlr-16500	488	1	pharmaceutical	pharmaceutical	NOUN
ihlr-16500	488	2	research	research	NOUN
ihlr-16500	488	3	&	&	CCONJ
ihlr-16500	488	4	manufacturers	manufacturer	NOUN
ihlr-16500	488	5	of	of	ADP
ihlr-16500	488	6	am	am	PROPN
ihlr-16500	488	7	.	.	PUNCT
ihlr-16500	488	8	,	,	PUNCT
ihlr-16500	488	9	mission	mission	NOUN
ihlr-16500	488	10	statement	statement	NOUN
ihlr-16500	488	11	,	,	PUNCT
ihlr-16500	488	12	http:/	http:/	PROPN
ihlr-16500	488	13	/www.phrma.org	/www.phrma.org	SYM
ihlr-16500	488	14	/	/	SYM
ihlr-16500	488	15	mission	mission	NOUN
ihlr-16500	488	16	_	_	NOUN
ihlr-16500	488	17	statement	statement	NOUN
ihlr-16500	488	18	!	!	PUNCT
ihlr-16500	488	19	.	.	PUNCT
ihlr-16500	489	1	121	121	NUM
ihlr-16500	489	2	the	the	DET
ihlr-16500	489	3	baycol	baycol	NOUN
ihlr-16500	489	4	/	/	SYM
ihlr-16500	489	5	lipobayscandal	lipobayscandal	ADJ
ihlr-16500	489	6	:	:	PUNCT
ihlr-16500	489	7	first	first	ADJ
ihlr-16500	489	8	trial	trial	NOUN
ihlr-16500	489	9	set	set	VERB
ihlr-16500	489	10	to	to	PART
ihlr-16500	489	11	start	start	VERB
ihlr-16500	489	12	for	for	ADP
ihlr-16500	489	13	bayer	bayer	PROPN
ihlr-16500	489	14	's	's	PART
ihlr-16500	489	15	baycol	baycol	NOUN
ihlr-16500	489	16	,	,	PUNCT
ihlr-16500	489	17	drratif­	drratif­	PROPN
ihlr-16500	489	18	foundation.org	foundation.org	X
ihlr-16500	489	19	,	,	PUNCT
ihlr-16500	489	20	feb	feb	PROPN
ihlr-16500	489	21	.	.	PROPN
ihlr-16500	489	22	18,2003	18,2003	NUM
ihlr-16500	489	23	,	,	PUNCT
ihlr-16500	489	24	http://www4.dr-rath-foundation.org/pharmaceutical	http://www4.dr-rath-foundation.org/pharmaceutical	ADJ
ihlr-16500	489	25	_	_	PRON
ihlr-16500	489	26	business/	business/	NUM
ihlr-16500	489	27	baycol!baycol08.htm	baycol!baycol08.htm	X
ihlr-16500	489	28	.	.	PUNCT
ihlr-16500	490	1	the	the	DET
ihlr-16500	490	2	dr	dr	PROPN
ihlr-16500	490	3	.	.	PROPN
ihlr-16500	490	4	rath	rath	PROPN
ihlr-16500	490	5	health	health	PROPN
ihlr-16500	490	6	foundation	foundation	PROPN
ihlr-16500	490	7	is	be	AUX
ihlr-16500	490	8	a	a	DET
ihlr-16500	490	9	leading	lead	VERB
ihlr-16500	490	10	website	website	NOUN
ihlr-16500	490	11	providing	provide	VERB
ihlr-16500	490	12	information	information	NOUN
ihlr-16500	490	13	on	on	ADP
ihlr-16500	490	14	natural	natural	ADJ
ihlr-16500	490	15	health	health	NOUN
ihlr-16500	490	16	.	.	PUNCT
ihlr-16500	491	1	i	i	PRON
ihlr-16500	491	2	d.	d.	VERB
ihlr-16500	491	3	during	during	ADP
ihlr-16500	491	4	a	a	DET
ihlr-16500	491	5	trial	trial	NOUN
ihlr-16500	491	6	against	against	ADP
ihlr-16500	491	7	bayer	bayer	NOUN
ihlr-16500	491	8	,	,	PUNCT
ihlr-16500	491	9	the	the	DET
ihlr-16500	491	10	plaintiff	plaintiff	NOUN
ihlr-16500	491	11	attempted	attempt	VERB
ihlr-16500	491	12	to	to	PART
ihlr-16500	491	13	show	show	VERB
ihlr-16500	491	14	that	that	SCONJ
ihlr-16500	491	15	"	"	PUNCT
ihlr-16500	491	16	bayer	bayer	PROPN
ihlr-16500	491	17	withheld	withhold	VERB
ihlr-16500	491	18	from	from	ADP
ihlr-16500	491	19	the	the	DET
ihlr-16500	491	20	fda	fda	PROPN
ihlr-16500	491	21	negative	negative	ADJ
ihlr-16500	491	22	results	result	NOUN
ihlr-16500	491	23	ofbaycol	ofbaycol	PRON
ihlr-16500	491	24	's	's	PART
ihlr-16500	491	25	clinical	clinical	ADJ
ihlr-16500	491	26	trials	trial	NOUN
ihlr-16500	491	27	.	.	PUNCT
ihlr-16500	491	28	"	"	PUNCT
ihlr-16500	492	1	i	i	PRON
ihlr-16500	492	2	d.	d.	PROPN
ihlr-16500	492	3	122	122	NUM
ihlr-16500	492	4	safety	safety	NOUN
ihlr-16500	492	5	-	-	PUNCT
ihlr-16500	492	6	based	base	VERB
ihlr-16500	492	7	drog	drog	NOUN
ihlr-16500	492	8	withdrawals	withdrawal	NOUN
ihlr-16500	492	9	(	(	PUNCT
ihlr-16500	492	10	1997	1997	NUM
ihlr-16500	492	11	-	-	SYM
ihlr-16500	492	12	2001	2001	NUM
ihlr-16500	492	13	)	)	PUNCT
ihlr-16500	492	14	,	,	PUNCT
ihlr-16500	492	15	fda	fda	PROPN
ihlr-16500	492	16	consumer	consumer	PROPN
ihlr-16500	492	17	mag	mag	PROPN
ihlr-16500	492	18	.	.	PROPN
ihlr-16500	492	19	,	,	PUNCT
ihlr-16500	492	20	jan.-feb	jan.-feb	PROPN
ihlr-16500	492	21	.	.	PROPN
ihlr-16500	492	22	2002	2002	NUM
ihlr-16500	492	23	,	,	PUNCT
ihlr-16500	492	24	available	available	ADJ
ihlr-16500	492	25	at	at	ADP
ihlr-16500	492	26	http://www.fda.gov/fdac/features/2002/chrtwithdrawals.html	http://www.fda.gov/fdac/features/2002/chrtwithdrawals.html	PROPN
ihlr-16500	492	27	.	.	PUNCT
ihlr-16500	493	1	the	the	DET
ihlr-16500	493	2	thirteen	thirteen	NUM
ihlr-16500	493	3	with­	with­	PROPN
ihlr-16500	493	4	drawn	draw	VERB
ihlr-16500	493	5	drugs	drug	NOUN
ihlr-16500	493	6	include	include	VERB
ihlr-16500	493	7	baycol	baycol	NOUN
ihlr-16500	493	8	,	,	PUNCT
ihlr-16500	493	9	raplon	raplon	NOUN
ihlr-16500	493	10	,	,	PUNCT
ihlr-16500	493	11	lotronex	lotronex	NOUN
ihlr-16500	493	12	.	.	PUNCT
ihlr-16500	494	1	propulsid	propulsid	PROPN
ihlr-16500	494	2	,	,	PUNCT
ihlr-16500	494	3	phenylprpanolamine	phenylprpanolamine	ADJ
ihlr-16500	494	4	,	,	PUNCT
ihlr-16500	494	5	rezulin	rezulin	PROPN
ihlr-16500	494	6	,	,	PUNCT
ihlr-16500	494	7	his­	his­	PROPN
ihlr-16500	494	8	mana	mana	PROPN
ihlr-16500	494	9	!	!	PROPN
ihlr-16500	494	10	,	,	PUNCT
ihlr-16500	494	11	raxar	raxar	NOUN
ihlr-16500	494	12	,	,	PUNCT
ihlr-16500	494	13	posicor	posicor	PROPN
ihlr-16500	494	14	,	,	PUNCT
ihlr-16500	494	15	duract	duract	ADJ
ihlr-16500	494	16	,	,	PUNCT
ihlr-16500	494	17	seldane	seldane	ADJ
ihlr-16500	494	18	and	and	CCONJ
ihlr-16500	494	19	seldane	seldane	PROPN
ihlr-16500	494	20	-	-	PUNCT
ihlr-16500	494	21	d	d	PROPN
ihlr-16500	494	22	,	,	PUNCT
ihlr-16500	494	23	pondimin	pondimin	NOUN
ihlr-16500	494	24	,	,	PUNCT
ihlr-16500	494	25	and	and	CCONJ
ihlr-16500	494	26	redux	redux	PROPN
ihlr-16500	494	27	.	.	PUNCT
ihlr-16500	495	1	i	i	PRON
ihlr-16500	495	2	d.	d.	PROPN
ihlr-16500	495	3	123	123	NUM
ihlr-16500	496	1	i	i	PROPN
ihlr-16500	496	2	d.	d.	PROPN
ihlr-16500	496	3	138	138	NUM
ihlr-16500	496	4	indiana	indiana	PROPN
ihlr-16500	496	5	heal1h	heal1h	PROPN
ihlr-16500	496	6	law	law	NOUN
ihlr-16500	496	7	review	review	NOUN
ihlr-16500	496	8	[	[	X
ihlr-16500	496	9	vol	vol	NOUN
ihlr-16500	496	10	.	.	PUNCT
ihlr-16500	497	1	4:115	4:115	NUM
ihlr-16500	497	2	lancet	lancet	PROPN
ihlr-16500	497	3	,	,	PUNCT
ihlr-16500	497	4	124	124	NUM
ihlr-16500	497	5	criticized	criticize	VERB
ihlr-16500	497	6	merck	merck	PROPN
ihlr-16500	497	7	's	's	PART
ihlr-16500	497	8	handling	handling	NOUN
ihlr-16500	497	9	of	of	ADP
ihlr-16500	497	10	the	the	DET
ihlr-16500	497	11	vioxx	vioxx	NOUN
ihlr-16500	497	12	situation	situation	NOUN
ihlr-16500	497	13	,	,	PUNCT
ihlr-16500	497	14	specifically	specifically	ADV
ihlr-16500	497	15	,	,	PUNCT
ihlr-16500	497	16	its	its	PRON
ihlr-16500	497	17	failure	failure	NOUN
ihlr-16500	497	18	to	to	PART
ihlr-16500	497	19	withdraw	withdraw	VERB
ihlr-16500	497	20	the	the	DET
ihlr-16500	497	21	drug	drug	NOUN
ihlr-16500	497	22	when	when	SCONJ
ihlr-16500	497	23	the	the	DET
ihlr-16500	497	24	existence	existence	NOUN
ihlr-16500	497	25	of	of	ADP
ihlr-16500	497	26	safety	safety	NOUN
ihlr-16500	497	27	issues	issue	NOUN
ihlr-16500	497	28	became	become	VERB
ihlr-16500	497	29	obvi­	obvi­	NOUN
ihlr-16500	497	30	ous	ous	ADJ
ihlr-16500	497	31	.	.	PUNCT
ihlr-16500	498	1	125	125	NUM
ihlr-16500	498	2	during	during	ADP
ihlr-16500	498	3	the	the	DET
ihlr-16500	498	4	vioxx	vioxx	NOUN
ihlr-16500	498	5	senate	senate	PROPN
ihlr-16500	498	6	hearings	hearing	NOUN
ihlr-16500	498	7	months	month	NOUN
ihlr-16500	498	8	after	after	ADP
ihlr-16500	498	9	the	the	DET
ihlr-16500	498	10	withdrawal	withdrawal	NOUN
ihlr-16500	498	11	,	,	PUNCT
ihlr-16500	498	12	asso­	asso­	PROPN
ihlr-16500	498	13	ciate	ciate	PROPN
ihlr-16500	498	14	director	director	NOUN
ihlr-16500	498	15	for	for	ADP
ihlr-16500	498	16	science	science	NOUN
ihlr-16500	498	17	and	and	CCONJ
ihlr-16500	498	18	medicine	medicine	NOUN
ihlr-16500	498	19	in	in	ADP
ihlr-16500	498	20	the	the	DET
ihlr-16500	498	21	fda	fda	PROPN
ihlr-16500	498	22	's	's	PART
ihlr-16500	498	23	office	office	NOUN
ihlr-16500	498	24	of	of	ADP
ihlr-16500	498	25	drug	drug	NOUN
ihlr-16500	498	26	safety	safety	NOUN
ihlr-16500	498	27	,	,	PUNCT
ihlr-16500	498	28	doctor	doctor	NOUN
ihlr-16500	498	29	david	david	PROPN
ihlr-16500	498	30	graham	graham	PROPN
ihlr-16500	498	31	,	,	PUNCT
ihlr-16500	498	32	"	"	PUNCT
ihlr-16500	498	33	explained	explain	VERB
ihlr-16500	498	34	that	that	SCONJ
ihlr-16500	498	35	vioxx	vioxx	NOUN
ihlr-16500	498	36	is	be	AUX
ihlr-16500	498	37	a	a	DET
ihlr-16500	498	38	prime	prime	ADJ
ihlr-16500	498	39	example	example	NOUN
ihlr-16500	498	40	of	of	ADP
ihlr-16500	498	41	the	the	DET
ihlr-16500	498	42	na­	na­	PROPN
ihlr-16500	498	43	tional	tional	PROPN
ihlr-16500	498	44	tragedy	tragedy	NOUN
ihlr-16500	498	45	that	that	PRON
ihlr-16500	498	46	occurs	occur	VERB
ihlr-16500	498	47	when	when	SCONJ
ihlr-16500	498	48	the	the	DET
ihlr-16500	498	49	fda	fda	PROPN
ihlr-16500	498	50	and	and	CCONJ
ihlr-16500	498	51	the	the	DET
ihlr-16500	498	52	manufacturer	manufacturer	NOUN
ihlr-16500	498	53	''	''	PUNCT
ihlr-16500	498	54	do	do	AUX
ihlr-16500	498	55	not	not	PART
ihlr-16500	498	56	take	take	VERB
ihlr-16500	498	57	into	into	ADP
ihlr-16500	498	58	consideration	consideration	NOUN
ihlr-16500	498	59	the	the	DET
ihlr-16500	498	60	effect	effect	NOUN
ihlr-16500	498	61	a	a	DET
ihlr-16500	498	62	failure	failure	NOUN
ihlr-16500	498	63	to	to	PART
ihlr-16500	498	64	withdraw	withdraw	VERB
ihlr-16500	498	65	the	the	DET
ihlr-16500	498	66	drug	drug	NOUN
ihlr-16500	498	67	might	might	AUX
ihlr-16500	498	68	have	have	VERB
ihlr-16500	498	69	on	on	ADP
ihlr-16500	498	70	prospec­	prospec­	NOUN
ihlr-16500	498	71	tive	tive	NOUN
ihlr-16500	498	72	and	and	CCONJ
ihlr-16500	498	73	current	current	ADJ
ihlr-16500	498	74	patients	patient	NOUN
ihlr-16500	498	75	.	.	PUNCT
ihlr-16500	499	1	126	126	NUM
ihlr-16500	499	2	he	he	PRON
ihlr-16500	499	3	stated	state	VERB
ihlr-16500	499	4	that	that	SCONJ
ihlr-16500	499	5	,	,	PUNCT
ihlr-16500	499	6	"	"	PUNCT
ihlr-16500	499	7	vioxx	vioxx	NOUN
ihlr-16500	499	8	•may	•may	PROPN
ihlr-16500	499	9	be	be	AUX
ihlr-16500	499	10	the	the	DET
ihlr-16500	499	11	single	single	ADJ
ihlr-16500	499	12	greatest	great	ADJ
ihlr-16500	499	13	drug	drug	NOUN
ihlr-16500	499	14	safety	safety	NOUN
ihlr-16500	499	15	catastrophe	catastrophe	NOUN
ihlr-16500	499	16	in	in	ADP
ihlr-16500	499	17	the	the	DET
ihlr-16500	499	18	history	history	NOUN
ihlr-16500	499	19	of	of	ADP
ihlr-16500	499	20	this	this	DET
ihlr-16500	499	21	country	country	NOUN
ihlr-16500	499	22	'	'	PUNCT
ihlr-16500	499	23	that	that	PRON
ihlr-16500	499	24	•largely	•largely	PRON
ihlr-16500	499	25	could	could	AUX
ihlr-16500	499	26	have	have	AUX
ihlr-16500	499	27	been	be	AUX
ihlr-16500	499	28	avoided	avoid	VERB
ihlr-16500	499	29	but	but	CCONJ
ihlr-16500	499	30	wasn't	wasn't	PROPN
ihlr-16500	499	31	.	.	PUNCT
ihlr-16500	499	32	"'127	"'127	PUNCT
ihlr-16500	500	1	furthermore	furthermore	ADV
ihlr-16500	500	2	,	,	PUNCT
ihlr-16500	500	3	"	"	PUNCT
ihlr-16500	500	4	doctor	doctor	NOUN
ihlr-16500	500	5	graham	graham	PROPN
ihlr-16500	500	6	estimated	estimate	VERB
ihlr-16500	500	7	that	that	SCONJ
ihlr-16500	500	8	88,000	88,000	NUM
ihlr-16500	500	9	to	to	PART
ihlr-16500	500	10	139,000	139,000	NUM
ihlr-16500	500	11	americans	american	NOUN
ihlr-16500	500	12	were	be	AUX
ihlr-16500	500	13	injured	injure	VERB
ihlr-16500	500	14	by	by	ADP
ihlr-16500	500	15	vioxx	vioxx	NOUN
ihlr-16500	500	16	"	"	PUNCT
ihlr-16500	500	17	and	and	CCONJ
ihlr-16500	500	18	that	that	SCONJ
ihlr-16500	500	19	thirty	thirty	NUM
ihlr-16500	500	20	to	to	PART
ihlr-16500	500	21	forty	forty	NUM
ihlr-16500	500	22	percent	percent	NOUN
ihlr-16500	500	23	of	of	ADP
ihlr-16500	500	24	them	they	PRON
ihlr-16500	500	25	probably	probably	ADV
ihlr-16500	500	26	died	die	VERB
ihlr-16500	500	27	,	,	PUNCT
ihlr-16500	500	28	analogizing	analogize	VERB
ihlr-16500	500	29	the	the	DET
ihlr-16500	500	30	magnitude	magnitude	NOUN
ihlr-16500	500	31	of	of	ADP
ihlr-16500	500	32	the	the	DET
ihlr-16500	500	33	harm	harm	NOUN
ihlr-16500	500	34	to	to	ADP
ihlr-16500	500	35	"	"	PUNCT
ihlr-16500	500	36	the	the	DET
ihlr-16500	500	37	rough	rough	ADJ
ihlr-16500	500	38	equivalent	equivalent	NOUN
ihlr-16500	500	39	of	of	ADP
ihlr-16500	500	40	500	500	NUM
ihlr-16500	500	41	to	to	PART
ihlr-16500	500	42	900	900	NUM
ihlr-16500	500	43	aircraft	aircraft	NOUN
ihlr-16500	500	44	[	[	X
ihlr-16500	500	45	sic	sic	ADJ
ihlr-16500	500	46	]	]	PUNCT
ihlr-16500	500	47	dropping	drop	VERB
ihlr-16500	500	48	from	from	ADP
ihlr-16500	500	49	the	the	DET
ihlr-16500	500	50	sky	sky	NOUN
ihlr-16500	500	51	.	.	PUNCT
ihlr-16500	500	52	"	"	PUNCT
ihlr-16500	501	1	128	128	NUM
ihlr-16500	501	2	many	many	ADJ
ihlr-16500	501	3	prominent	prominent	ADJ
ihlr-16500	501	4	members	member	NOUN
ihlr-16500	501	5	of	of	ADP
ihlr-16500	501	6	the	the	DET
ihlr-16500	501	7	medical	medical	ADJ
ihlr-16500	501	8	community	community	NOUN
ihlr-16500	501	9	agreed	agree	VERB
ihlr-16500	501	10	with	with	ADP
ihlr-16500	501	11	doctor	doctor	NOUN
ihlr-16500	501	12	graham	graham	PROPN
ihlr-16500	501	13	that	that	SCONJ
ihlr-16500	501	14	countless	countless	ADJ
ihlr-16500	501	15	deaths	death	NOUN
ihlr-16500	501	16	and	and	CCONJ
ihlr-16500	501	17	much	much	ADJ
ihlr-16500	501	18	suffering	suffering	NOUN
ihlr-16500	501	19	could	could	AUX
ihlr-16500	501	20	have	have	AUX
ihlr-16500	501	21	been	be	AUX
ihlr-16500	501	22	avoided	avoid	VERB
ihlr-16500	501	23	had	have	AUX
ihlr-16500	501	24	vioxx	vioxx	NOUN
ihlr-16500	501	25	been	be	AUX
ihlr-16500	501	26	recalled	recall	VERB
ihlr-16500	501	27	four	four	NUM
ihlr-16500	501	28	years	year	NOUN
ihlr-16500	501	29	earlier	early	ADV
ihlr-16500	501	30	.	.	PUNCT
ihlr-16500	502	1	this	this	DET
ihlr-16500	502	2	opinion	opinion	NOUN
ihlr-16500	502	3	was	be	AUX
ihlr-16500	502	4	supported	support	VERB
ihlr-16500	502	5	by	by	ADP
ihlr-16500	502	6	an	an	DET
ihlr-16500	502	7	editorial	editorial	NOUN
ihlr-16500	502	8	appear­	appear­	VERB
ihlr-16500	502	9	ing	ing	NOUN
ihlr-16500	502	10	in	in	ADP
ihlr-16500	502	11	the	the	DET
ihlr-16500	502	12	the	the	DET
ihlr-16500	502	13	lancet.129	lancet.129	NOUN
ihlr-16500	502	14	in	in	ADP
ihlr-16500	502	15	the	the	DET
ihlr-16500	502	16	article	article	NOUN
ihlr-16500	502	17	,	,	PUNCT
ihlr-16500	502	18	the	the	DET
ihlr-16500	502	19	author	author	NOUN
ihlr-16500	502	20	commented	comment	VERB
ihlr-16500	502	21	that	that	SCONJ
ihlr-16500	502	22	both	both	PRON
ihlr-16500	502	23	"	"	PUNCT
ihlr-16500	502	24	merck	merck	PROPN
ihlr-16500	502	25	and	and	CCONJ
ihlr-16500	502	26	the	the	DET
ihlr-16500	502	27	fda	fda	PROPN
ihlr-16500	502	28	acted	act	VERB
ihlr-16500	502	29	out	out	ADP
ihlr-16500	502	30	of	of	ADP
ihlr-16500	502	31	ruthless	ruthless	ADJ
ihlr-16500	502	32	,	,	PUNCT
ihlr-16500	502	33	short	short	ADJ
ihlr-16500	502	34	-	-	PUNCT
ihlr-16500	502	35	sighted	sighted	ADJ
ihlr-16500	502	36	,	,	PUNCT
ihlr-16500	502	37	and	and	CCONJ
ihlr-16500	502	38	irresponsible	irresponsible	ADJ
ihlr-16500	502	39	self­	self­	NOUN
ihlr-16500	502	40	interest	interest	NOUN
ihlr-16500	502	41	.	.	PUNCT
ihlr-16500	503	1	"130	"130	PROPN
ihlr-16500	503	2	merck	merck	PROPN
ihlr-16500	503	3	was	be	AUX
ihlr-16500	503	4	not	not	PART
ihlr-16500	503	5	the	the	DET
ihlr-16500	503	6	only	only	ADJ
ihlr-16500	503	7	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	503	8	company	company	NOUN
ihlr-16500	503	9	in	in	ADP
ihlr-16500	503	10	recent	recent	ADJ
ihlr-16500	503	11	years	year	NOUN
ihlr-16500	503	12	that	that	PRON
ihlr-16500	503	13	failed	fail	VERB
ihlr-16500	503	14	to	to	PART
ihlr-16500	503	15	take	take	VERB
ihlr-16500	503	16	into	into	ADP
ihlr-16500	503	17	account	account	NOUN
ihlr-16500	503	18	the	the	DET
ihlr-16500	503	19	ethical	ethical	ADJ
ihlr-16500	503	20	ramifications	ramification	NOUN
ihlr-16500	503	21	of	of	ADP
ihlr-16500	503	22	pulling	pull	VERB
ihlr-16500	503	23	a	a	DET
ihlr-16500	503	24	drug	drug	NOUN
ihlr-16500	503	25	off	off	ADP
ihlr-16500	503	26	the	the	DET
ihlr-16500	503	27	124	124	NUM
ihlr-16500	503	28	the	the	DET
ihlr-16500	503	29	lancet	lancet	NOUN
ihlr-16500	503	30	is	be	AUX
ihlr-16500	503	31	a	a	DET
ihlr-16500	503	32	medical	medical	ADJ
ihlr-16500	503	33	journal	journal	NOUN
ihlr-16500	503	34	originally	originally	ADV
ihlr-16500	503	35	foooded	fooode	VERB
ihlr-16500	503	36	in	in	ADP
ihlr-16500	503	37	1823	1823	NUM
ihlr-16500	503	38	.	.	PUNCT
ihlr-16500	504	1	thelancet.com	thelancet.com	X
ihlr-16500	504	2	,	,	PUNCT
ihlr-16500	504	3	about	about	ADP
ihlr-16500	504	4	the	the	DET
ihlr-16500	504	5	lancet	lancet	NOUN
ihlr-16500	504	6	,	,	PUNCT
ihlr-16500	504	7	http://www.thelancet.com/about	http://www.thelancet.com/about	PRON
ihlr-16500	504	8	(	(	PUNCT
ihlr-16500	504	9	last	last	ADJ
ihlr-16500	504	10	visited	visit	VERB
ihlr-16500	504	11	feb	feb	PROPN
ihlr-16500	504	12	.	.	PROPN
ihlr-16500	504	13	20	20	NUM
ihlr-16500	504	14	,	,	PUNCT
ihlr-16500	504	15	2007	2007	NUM
ihlr-16500	504	16	)	)	PUNCT
ihlr-16500	504	17	.	.	PUNCT
ihlr-16500	505	1	it	it	PRON
ihlr-16500	505	2	publishes	publish	VERB
ihlr-16500	505	3	clinical	clinical	ADJ
ihlr-16500	505	4	trials	trial	NOUN
ihlr-16500	505	5	and	and	CCONJ
ihlr-16500	505	6	opinions	opinion	NOUN
ihlr-16500	505	7	of	of	ADP
ihlr-16500	505	8	notable	notable	ADJ
ihlr-16500	505	9	health	health	NOUN
ihlr-16500	505	10	care	care	NOUN
ihlr-16500	505	11	professionals	professional	NOUN
ihlr-16500	505	12	.	.	PUNCT
ihlr-16500	506	1	i	i	PRON
ihlr-16500	506	2	d.	d.	VERB
ihlr-16500	506	3	it	it	PRON
ihlr-16500	506	4	claims	claim	VERB
ihlr-16500	506	5	not	not	PART
ihlr-16500	506	6	to	to	PART
ihlr-16500	506	7	be	be	AUX
ihlr-16500	506	8	affiliated	affiliate	VERB
ihlr-16500	506	9	with	with	ADP
ihlr-16500	506	10	any	any	DET
ihlr-16500	506	11	medical	medical	ADJ
ihlr-16500	506	12	organization	organization	NOUN
ihlr-16500	506	13	.	.	PUNCT
ihlr-16500	507	1	ld	ld	PROPN
ihlr-16500	507	2	125	125	NUM
ihlr-16500	507	3	tom	tom	PROPN
ihlr-16500	507	4	armitage	armitage	PROPN
ihlr-16500	507	5	,	,	PUNCT
ihlr-16500	507	6	merck	merck	PROPN
ihlr-16500	507	7	should	should	AUX
ihlr-16500	507	8	have	have	AUX
ihlr-16500	507	9	pulled	pull	VERB
ihlr-16500	507	10	vioxx	vioxx	NOUN
ihlr-16500	507	11	in	in	ADP
ihlr-16500	507	12	2000study	2000study	NUM
ihlr-16500	507	13	,	,	PUNCT
ihlr-16500	507	14	reuters	reuters	PROPN
ihlr-16500	507	15	,	,	PUNCT
ihlr-16500	507	16	nov	nov	PROPN
ihlr-16500	507	17	.	.	PROPN
ihlr-16500	507	18	4	4	NUM
ihlr-16500	507	19	,	,	PUNCT
ihlr-16500	507	20	2004	2004	NUM
ihlr-16500	507	21	,	,	PUNCT
ihlr-16500	507	22	available	available	ADJ
ihlr-16500	507	23	at	at	ADP
ihlr-16500	507	24	http://www.lexisnexis.com	http://www.lexisnexis.com	X
ihlr-16500	507	25	(	(	PUNCT
ihlr-16500	507	26	click	click	VERB
ihlr-16500	507	27	on	on	ADP
ihlr-16500	507	28	news	news	NOUN
ihlr-16500	507	29	and	and	CCONJ
ihlr-16500	507	30	business	business	NOUN
ihlr-16500	507	31	,	,	PUNCT
ihlr-16500	507	32	click	click	VERB
ihlr-16500	507	33	on	on	ADP
ihlr-16500	507	34	individual	individual	ADJ
ihlr-16500	507	35	publications	publication	NOUN
ihlr-16500	507	36	,	,	PUNCT
ihlr-16500	507	37	click	click	VERB
ihlr-16500	507	38	on	on	ADP
ihlr-16500	507	39	r	r	NOUN
ihlr-16500	507	40	,	,	PUNCT
ihlr-16500	507	41	click	click	VERB
ihlr-16500	507	42	on	on	ADP
ihlr-16500	507	43	reuters	reuters	PROPN
ihlr-16500	507	44	news	news	PROPN
ihlr-16500	507	45	)	)	PUNCT
ihlr-16500	507	46	(	(	PUNCT
ihlr-16500	507	47	arguing	argue	VERB
ihlr-16500	507	48	that	that	SCONJ
ihlr-16500	507	49	merck	merck	PROPN
ihlr-16500	507	50	executives	executive	NOUN
ihlr-16500	507	51	should	should	AUX
ihlr-16500	507	52	have	have	AUX
ihlr-16500	507	53	withdrawn	withdraw	VERB
ihlr-16500	507	54	vioxx	vioxx	NOUN
ihlr-16500	507	55	from	from	ADP
ihlr-16500	507	56	the	the	DET
ihlr-16500	507	57	market	market	NOUN
ihlr-16500	507	58	in	in	ADP
ihlr-16500	507	59	2000	2000	NUM
ihlr-16500	507	60	while	while	SCONJ
ihlr-16500	507	61	citing	cite	VERB
ihlr-16500	507	62	a	a	DET
ihlr-16500	507	63	report	report	NOUN
ihlr-16500	507	64	in	in	ADP
ihlr-16500	507	65	the	the	DET
ihlr-16500	507	66	british	british	PROPN
ihlr-16500	507	67	medical	medical	PROPN
ihlr-16500	507	68	journal	journal	PROPN
ihlr-16500	507	69	,	,	PUNCT
ihlr-16500	507	70	"	"	PUNCT
ihlr-16500	507	71	the	the	DET
ihlr-16500	507	72	lancet	lancet	NOUN
ihlr-16500	507	73	"	"	PUNCT
ihlr-16500	507	74	.	.	PUNCT
ihlr-16500	508	1	in	in	ADP
ihlr-16500	508	2	that	that	DET
ihlr-16500	508	3	report	report	NOUN
ihlr-16500	508	4	,	,	PUNCT
ihlr-16500	508	5	''	''	PUNCT
ihlr-16500	508	6	researchers	researcher	NOUN
ihlr-16500	508	7	at	at	ADP
ihlr-16500	508	8	the	the	DET
ihlr-16500	508	9	university	university	PROPN
ihlr-16500	508	10	of	of	ADP
ihlr-16500	508	11	berne	berne	PROPN
ihlr-16500	508	12	said	say	VERB
ihlr-16500	508	13	there	there	PRON
ihlr-16500	508	14	was	be	VERB
ihlr-16500	508	15	substantial	substantial	ADJ
ihlr-16500	508	16	evidence	evidence	NOUN
ihlr-16500	508	17	of	of	ADP
ihlr-16500	508	18	the	the	DET
ihlr-16500	508	19	dangerous	dangerous	ADJ
ihlr-16500	508	20	side	side	NOUN
ihlr-16500	508	21	effects	effect	NOUN
ihlr-16500	508	22	of	of	ADP
ihlr-16500	508	23	the	the	DET
ihlr-16500	508	24	drug	drug	NOUN
ihlr-16500	508	25	by	by	ADP
ihlr-16500	508	26	the	the	DET
ihlr-16500	508	27	end	end	NOUN
ihlr-16500	508	28	of2000	of2000	ADJ
ihlr-16500	508	29	,	,	PUNCT
ihlr-16500	508	30	but	but	CCONJ
ihlr-16500	508	31	the	the	DET
ihlr-16500	508	32	moooting	mooote	VERB
ihlr-16500	508	33	data	datum	NOUN
ihlr-16500	508	34	was	be	AUX
ihlr-16500	508	35	not	not	PART
ihlr-16500	508	36	analyzed	analyze	VERB
ihlr-16500	508	37	properly	properly	ADV
ihlr-16500	508	38	"	"	PUNCT
ihlr-16500	508	39	)	)	PUNCT
ihlr-16500	508	40	;	;	PUNCT
ihlr-16500	508	41	see	see	VERB
ihlr-16500	508	42	also	also	ADV
ihlr-16500	508	43	richard	richard	PROPN
ihlr-16500	508	44	horton	horton	PROPN
ihlr-16500	508	45	,	,	PUNCT
ihlr-16500	508	46	vioxx	vioxx	PROPN
ihlr-16500	508	47	,	,	PUNCT
ihlr-16500	508	48	the	the	DET
ihlr-16500	508	49	implosion	implosion	NOUN
ihlr-16500	508	50	of	of	ADP
ihlr-16500	508	51	merck	merck	NOUN
ihlr-16500	508	52	,	,	PUNCT
ihlr-16500	508	53	and	and	CCONJ
ihlr-16500	508	54	after­	after­	NOUN
ihlr-16500	508	55	shocks	shock	NOUN
ihlr-16500	508	56	at	at	ADP
ihlr-16500	508	57	the	the	DET
ihlr-16500	508	58	fda	fda	PROPN
ihlr-16500	508	59	,	,	PUNCT
ihlr-16500	508	60	364	364	NUM
ihlr-16500	508	61	the	the	DET
ihlr-16500	508	62	lancer	lancer	PROPN
ihlr-16500	508	63	1995	1995	NUM
ihlr-16500	508	64	,	,	PUNCT
ihlr-16500	508	65	1995	1995	NUM
ihlr-16500	508	66	-	-	SYM
ihlr-16500	508	67	1996(2004)(citingacumulativemeta	1996(2004)(citingacumulativemeta	NUM
ihlr-16500	508	68	-	-	PUNCT
ihlr-16500	508	69	analysis	analysis	NOUN
ihlr-16500	508	70	showing	show	VERB
ihlr-16500	508	71	the	the	DET
ihlr-16500	508	72	cardiovascular	cardiovascular	ADJ
ihlr-16500	508	73	risks	risk	NOUN
ihlr-16500	508	74	ofvioxx	ofvioxx	ADV
ihlr-16500	508	75	as	as	ADV
ihlr-16500	508	76	early	early	ADV
ihlr-16500	508	77	as	as	ADP
ihlr-16500	508	78	2000	2000	NUM
ihlr-16500	508	79	)	)	PUNCT
ihlr-16500	508	80	;	;	PUNCT
ihlr-16500	509	1	contra	contra	PROPN
ihlr-16500	509	2	peters	peters	PROPN
ihlr-16500	509	3	.	.	PUNCT
ihlr-16500	510	1	kim	kim	PROPN
ihlr-16500	510	2	&	&	CCONJ
ihlr-16500	510	3	alise	alise	PROPN
ihlr-16500	510	4	s.	s.	PROPN
ihlr-16500	510	5	reicin	reicin	PROPN
ihlr-16500	510	6	,	,	PUNCT
ihlr-16500	510	7	discontinuation	discontinuation	NOUN
ihlr-16500	510	8	ofvioxx	ofvioxx	NOUN
ihlr-16500	510	9	,	,	PUNCT
ihlr-16500	510	10	365	365	NUM
ihlr-16500	510	11	the	the	DET
ihlr-16500	510	12	lancet	lancet	PROPN
ihlr-16500	510	13	23,23	23,23	PROPN
ihlr-16500	510	14	(	(	PUNCT
ihlr-16500	510	15	2004	2004	NUM
ihlr-16500	510	16	)	)	PUNCT
ihlr-16500	510	17	(	(	PUNCT
ihlr-16500	510	18	arguing	argue	VERB
ihlr-16500	510	19	analyses	analysis	NOUN
ihlr-16500	510	20	by	by	ADP
ihlr-16500	510	21	juni	juni	PROPN
ihlr-16500	510	22	and	and	CCONJ
ihlr-16500	510	23	horton	horton	PROPN
ihlr-16500	510	24	of	of	ADP
ihlr-16500	510	25	past	past	ADJ
ihlr-16500	510	26	vioxx	vioxx	NOUN
ihlr-16500	510	27	meta	meta	VERB
ihlr-16500	510	28	-	-	PUNCT
ihlr-16500	510	29	analyses	analysis	NOUN
ihlr-16500	510	30	reached	reach	VERB
ihlr-16500	510	31	flawed	flawed	ADJ
ihlr-16500	510	32	conclusions	conclusion	NOUN
ihlr-16500	510	33	)	)	PUNCT
ihlr-16500	510	34	.	.	PUNCT
ihlr-16500	511	1	126	126	NUM
ihlr-16500	511	2	placitella	placitella	NOUN
ihlr-16500	511	3	&	&	CCONJ
ihlr-16500	511	4	klein	klein	PROPN
ihlr-16500	511	5	,	,	PUNCT
ihlr-16500	511	6	supra	supra	PROPN
ihlr-16500	511	7	note	note	PROPN
ihlr-16500	511	8	33	33	NUM
ihlr-16500	511	9	,	,	PUNCT
ihlr-16500	511	10	at	at	ADP
ihlr-16500	511	11	221	221	NUM
ihlr-16500	511	12	;	;	PUNCT
ihlr-16500	511	13	see	see	VERB
ihlr-16500	511	14	also	also	ADV
ihlr-16500	511	15	testimony	testimony	NOUN
ihlr-16500	511	16	of	of	ADP
ihlr-16500	511	17	david	david	PROPN
ihlr-16500	511	18	j.	j.	PROPN
ihlr-16500	511	19	graham	graham	PROPN
ihlr-16500	511	20	,	,	PUNCT
ihlr-16500	511	21	md	md	PROPN
ihlr-16500	511	22	,	,	PUNCT
ihlr-16500	511	23	mph	mph	PROPN
ihlr-16500	511	24	:	:	PUNCT
ihlr-16500	511	25	november	november	PROPN
ihlr-16500	511	26	18	18	NUM
ihlr-16500	511	27	,	,	PUNCT
ihlr-16500	511	28	2004	2004	NUM
ihlr-16500	511	29	,	,	PUNCT
ihlr-16500	511	30	available	available	ADJ
ihlr-16500	511	31	at	at	ADP
ihlr-16500	511	32	http://www.mercola.com/2005/mar/2	http://www.mercola.com/2005/mar/2	PROPN
ihlr-16500	511	33	/david_graham_testimonial.htm	/david_graham_testimonial.htm	PROPN
ihlr-16500	511	34	,	,	PUNCT
ihlr-16500	511	35	cited	cite	VERB
ihlr-16500	511	36	in	in	ADP
ihlr-16500	511	37	joseph	joseph	PROPN
ihlr-16500	511	38	mercola	mercola	PROPN
ihlr-16500	511	39	,	,	PUNCT
ihlr-16500	511	40	vioxx	vioxx	PROPN
ihlr-16500	511	41	reapproved	reapprove	VERB
ihlr-16500	511	42	by	by	ADP
ihlr-16500	511	43	fda	fda	PROPN
ihlr-16500	511	44	panel	panel	NOUN
ihlr-16500	511	45	members	member	NOUN
ihlr-16500	511	46	with	with	ADP
ihlr-16500	511	47	ties	tie	NOUN
ihlr-16500	511	48	to	to	ADP
ihlr-16500	511	49	drug	drug	NOUN
ihlr-16500	511	50	companies	company	NOUN
ihlr-16500	511	51	,	,	PUNCT
ihlr-16500	511	52	eiieai.rnv	eiieai.rnv	X
ihlr-16500	511	53	news	news	NOUN
ihlr-16500	511	54	you	you	PRON
ihlr-16500	511	55	can	can	AUX
ihlr-16500	511	56	use	use	VERB
ihlr-16500	511	57	,	,	PUNCT
ihlr-16500	511	58	mar	mar	PROPN
ihlr-16500	511	59	.	.	PROPN
ihlr-16500	511	60	2	2	NUM
ihlr-16500	511	61	,	,	PUNCT
ihlr-16500	511	62	2005	2005	NUM
ihlr-16500	511	63	,	,	PUNCT
ihlr-16500	511	64	http://www.mercola.com/2005/mar/2/vioxx	http://www.mercola.com/2005/mar/2/vioxx	X
ihlr-16500	512	1	_	_	PRON
ihlr-16500	512	2	fda.htm	fda.htm	NUM
ihlr-16500	512	3	.	.	PUNCT
ihlr-16500	513	1	127	127	NUM
ihlr-16500	513	2	placitella	placitella	NOUN
ihlr-16500	513	3	&	&	CCONJ
ihlr-16500	513	4	klein	klein	PROPN
ihlr-16500	513	5	,	,	PUNCT
ihlr-16500	513	6	supra	supra	PROPN
ihlr-16500	513	7	note	note	PROPN
ihlr-16500	513	8	33	33	NUM
ihlr-16500	513	9	,	,	PUNCT
ihlr-16500	513	10	at	at	ADP
ihlr-16500	513	11	221	221	NUM
ihlr-16500	513	12	.	.	PUNCT
ihlr-16500	513	13	12s	12	NOUN
ihlr-16500	514	1	i	i	PRON
ihlr-16500	514	2	d.	d.	PROPN
ihlr-16500	514	3	129	129	NUM
ihlr-16500	514	4	mike	mike	PROPN
ihlr-16500	514	5	adams	adams	PROPN
ihlr-16500	514	6	,	,	PUNCT
ihlr-16500	514	7	reputation	reputation	NOUN
ihlr-16500	514	8	of	of	ADP
ihlr-16500	514	9	the	the	DET
ihlr-16500	514	10	fda	fda	PROPN
ihlr-16500	514	11	in	in	ADP
ihlr-16500	514	12	shambles	shamble	NOUN
ihlr-16500	514	13	after	after	ADP
ihlr-16500	514	14	vioxx	vioxx	NOUN
ihlr-16500	514	15	scandal	scandal	NOUN
ihlr-16500	514	16	;	;	PUNCT
ihlr-16500	514	17	calls	call	VERB
ihlr-16500	514	18	for	for	ADP
ihlr-16500	514	19	wholesale	wholesale	ADJ
ihlr-16500	514	20	fda	fda	PROPN
ihlr-16500	514	21	reform	reform	NOUN
ihlr-16500	514	22	gain	gain	VERB
ihlr-16500	514	23	momentum	momentum	NOUN
ihlr-16500	514	24	,	,	PUNCT
ihlr-16500	514	25	newstarget.com	newstarget.com	X
ihlr-16500	514	26	.	.	PUNCT
ihlr-16500	515	1	nov	nov	PROPN
ihlr-16500	515	2	.	.	PROPN
ihlr-16500	515	3	6	6	NUM
ihlr-16500	515	4	,	,	PUNCT
ihlr-16500	515	5	2004	2004	NUM
ihlr-16500	515	6	,	,	PUNCT
ihlr-16500	515	7	http://www	http://www	PROPN
ihlr-16500	515	8	.	.	PROPN
ihlr-16500	515	9	newstarget.com/002157	newstarget.com/002157	PROPN
ihlr-16500	515	10	.html	.html	PUNCT
ihlr-16500	515	11	.	.	PUNCT
ihlr-16500	516	1	130	130	NUM
ihlr-16500	517	1	i	i	PRON
ihlr-16500	517	2	d.	d.	NOUN
ihlr-16500	517	3	2007	2007	NUM
ihlr-16500	517	4	]	]	PUNCT
ihlr-16500	517	5	pulling	pull	VERB
ihlr-16500	517	6	a	a	DET
ihlr-16500	517	7	blockbuster	blockbuster	ADJ
ihlr-16500	517	8	drug	drug	NOUN
ihlr-16500	517	9	off	off	ADP
ihlr-16500	517	10	the	the	DET
ihlr-16500	517	11	market	market	NOUN
ihlr-16500	517	12	139	139	NUM
ihlr-16500	517	13	market	market	NOUN
ihlr-16500	517	14	.	.	PUNCT
ihlr-16500	518	1	in	in	ADP
ihlr-16500	518	2	2001	2001	NUM
ihlr-16500	518	3	,	,	PUNCT
ihlr-16500	518	4	baycol	baycol	PROPN
ihlr-16500	518	5	was	be	AUX
ihlr-16500	518	6	withdrawn	withdraw	VERB
ihlr-16500	518	7	from	from	ADP
ihlr-16500	518	8	the	the	DET
ihlr-16500	518	9	market	market	NOUN
ihlr-16500	518	10	,	,	PUNCT
ihlr-16500	518	11	but	but	CCONJ
ihlr-16500	518	12	only	only	ADV
ihlr-16500	518	13	after	after	SCONJ
ihlr-16500	518	14	it	it	PRON
ihlr-16500	518	15	had	have	AUX
ihlr-16500	518	16	been	be	AUX
ihlr-16500	518	17	linked	link	VERB
ihlr-16500	518	18	to	to	ADP
ihlr-16500	518	19	thirty	thirty	NUM
ihlr-16500	518	20	-	-	PUNCT
ihlr-16500	518	21	one	one	NUM
ihlr-16500	518	22	deaths	death	NOUN
ihlr-16500	518	23	.	.	PUNCT
ihlr-16500	519	1	131	131	NUM
ihlr-16500	519	2	bayer	bayer	PROPN
ihlr-16500	519	3	claimed	claim	VERB
ihlr-16500	519	4	that	that	SCONJ
ihlr-16500	519	5	the	the	DET
ihlr-16500	519	6	drug	drug	NOUN
ihlr-16500	519	7	was	be	AUX
ihlr-16500	519	8	safe	safe	ADJ
ihlr-16500	519	9	,	,	PUNCT
ihlr-16500	519	10	but	but	CCONJ
ihlr-16500	519	11	"	"	PUNCT
ihlr-16500	519	12	[	[	X
ihlr-16500	519	13	t]he	t]he	X
ihlr-16500	519	14	industry	industry	NOUN
ihlr-16500	519	15	's	's	PART
ihlr-16500	519	16	focus	focus	NOUN
ihlr-16500	519	17	on	on	ADP
ihlr-16500	519	18	producing	produce	VERB
ihlr-16500	519	19	drugs	drug	NOUN
ihlr-16500	519	20	for	for	ADP
ihlr-16500	519	21	chronic	chronic	ADJ
ihlr-16500	519	22	conditions	condition	NOUN
ihlr-16500	519	23	like	like	ADP
ihlr-16500	519	24	depres­	depres­	PRON
ihlr-16500	519	25	sion	sion	NOUN
ihlr-16500	519	26	and	and	CCONJ
ihlr-16500	519	27	diabetes	diabetes	NOUN
ihlr-16500	519	28	has	have	AUX
ihlr-16500	519	29	vastly	vastly	ADV
ihlr-16500	519	30	increased	increase	VERB
ihlr-16500	519	31	the	the	DET
ihlr-16500	519	32	pool	pool	NOUN
ihlr-16500	519	33	of	of	ADP
ihlr-16500	519	34	potential	potential	ADJ
ihlr-16500	519	35	plaintiffs	plaintiff	NOUN
ihlr-16500	519	36	,	,	PUNCT
ihlr-16500	519	37	because	because	SCONJ
ihlr-16500	519	38	medicines	medicine	NOUN
ihlr-16500	519	39	for	for	ADP
ihlr-16500	519	40	those	those	DET
ihlr-16500	519	41	diseases	disease	NOUN
ihlr-16500	519	42	are	be	AUX
ihlr-16500	519	43	taken	take	VERB
ihlr-16500	519	44	by	by	ADP
ihlr-16500	519	45	millions	million	NOUN
ihlr-16500	519	46	of	of	ADP
ihlr-16500	519	47	people	people	NOUN
ihlr-16500	519	48	.	.	PUNCT
ihlr-16500	520	1	"132	"132	PROPN
ihlr-16500	521	1	moreover	moreover	ADV
ihlr-16500	521	2	,	,	PUNCT
ihlr-16500	521	3	"	"	PUNCT
ihlr-16500	521	4	because	because	SCONJ
ihlr-16500	521	5	clinical	clinical	ADJ
ihlr-16500	521	6	trials	trial	NOUN
ihlr-16500	521	7	for	for	ADP
ihlr-16500	521	8	new	new	ADJ
ihlr-16500	521	9	drugs	drug	NOUN
ihlr-16500	521	10	are	be	AUX
ihlr-16500	521	11	conducted	conduct	VERB
ihlr-16500	521	12	on	on	ADP
ihlr-16500	521	13	only	only	ADV
ihlr-16500	521	14	a	a	DET
ihlr-16500	521	15	few	few	ADJ
ihlr-16500	521	16	thousand	thousand	NUM
ihlr-16500	521	17	subjects	subject	NOUN
ihlr-16500	521	18	,	,	PUNCT
ihlr-16500	521	19	the	the	DET
ihlr-16500	521	20	tests	test	NOUN
ihlr-16500	521	21	do	do	AUX
ihlr-16500	521	22	not	not	PART
ihlr-16500	521	23	always	always	ADV
ihlr-16500	521	24	discover	discover	VERB
ihlr-16500	521	25	...	...	PUNCT
ihlr-16500	521	26	dangerous	dangerous	ADJ
ihlr-16500	521	27	side	side	NOUN
ihlr-16500	521	28	effects	effect	NOUN
ihlr-16500	521	29	.	.	PUNCT
ihlr-16500	522	1	"133	"133	PROPN
ihlr-16500	522	2	bayer	bayer	PROPN
ihlr-16500	522	3	's	's	PART
ihlr-16500	522	4	argument	argument	NOUN
ihlr-16500	522	5	can	can	AUX
ihlr-16500	522	6	be	be	AUX
ihlr-16500	522	7	criticized	criticize	VERB
ihlr-16500	522	8	for	for	ADP
ihlr-16500	522	9	several	several	ADJ
ihlr-16500	522	10	reasons	reason	NOUN
ihlr-16500	522	11	.	.	PUNCT
ihlr-16500	523	1	first	first	ADV
ihlr-16500	523	2	,	,	PUNCT
ihlr-16500	523	3	more	more	ADJ
ihlr-16500	523	4	testing	testing	NOUN
ihlr-16500	523	5	should	should	AUX
ihlr-16500	523	6	have	have	AUX
ihlr-16500	523	7	been	be	AUX
ihlr-16500	523	8	performed	perform	VERB
ihlr-16500	523	9	,	,	PUNCT
ihlr-16500	523	10	especially	especially	ADV
ihlr-16500	523	11	when	when	SCONJ
ihlr-16500	523	12	the	the	DET
ihlr-16500	523	13	drug	drug	NOUN
ihlr-16500	523	14	is	be	AUX
ihlr-16500	523	15	being	be	AUX
ihlr-16500	523	16	mass	mass	ADV
ihlr-16500	523	17	produced	produce	VERB
ihlr-16500	523	18	and	and	CCONJ
ihlr-16500	523	19	marketed	market	VERB
ihlr-16500	523	20	to	to	ADP
ihlr-16500	523	21	a	a	DET
ihlr-16500	523	22	wide	wide	ADJ
ihlr-16500	523	23	number	number	NOUN
ihlr-16500	523	24	of	of	ADP
ihlr-16500	523	25	patients	patient	NOUN
ihlr-16500	523	26	and	and	CCONJ
ihlr-16500	523	27	physicians	physician	NOUN
ihlr-16500	523	28	.	.	PUNCT
ihlr-16500	524	1	134	134	NUM
ihlr-16500	524	2	second	second	ADJ
ihlr-16500	524	3	,	,	PUNCT
ihlr-16500	524	4	the	the	DET
ihlr-16500	524	5	drug	drug	NOUN
ihlr-16500	524	6	was	be	AUX
ihlr-16500	524	7	withdrawn	withdraw	VERB
ihlr-16500	524	8	after	after	SCONJ
ihlr-16500	524	9	thirty	thirty	NUM
ihlr-16500	524	10	people	people	NOUN
ihlr-16500	524	11	died	die	VERB
ihlr-16500	524	12	during	during	ADP
ihlr-16500	524	13	post	post	ADJ
ihlr-16500	524	14	-	-	ADJ
ihlr-16500	524	15	marketing	marketing	ADJ
ihlr-16500	524	16	surveillance	surveillance	NOUN
ihlr-16500	524	17	,	,	PUNCT
ihlr-16500	524	18	a	a	DET
ihlr-16500	524	19	number	number	NOUN
ihlr-16500	524	20	that	that	PRON
ihlr-16500	524	21	seems	seem	VERB
ihlr-16500	524	22	much	much	ADV
ihlr-16500	524	23	too	too	ADV
ihlr-16500	524	24	high	high	ADJ
ihlr-16500	524	25	given	give	VERB
ihlr-16500	524	26	the	the	DET
ihlr-16500	524	27	fact	fact	NOUN
ihlr-16500	524	28	that	that	SCONJ
ihlr-16500	524	29	this	this	DET
ihlr-16500	524	30	drug	drug	NOUN
ihlr-16500	524	31	was	be	AUX
ihlr-16500	524	32	used	use	VERB
ihlr-16500	524	33	to	to	ADP
ihlr-16500	524	34	pre­	pre­	NOUN
ihlr-16500	524	35	vent	vent	VERB
ihlr-16500	524	36	heart	heart	NOUN
ihlr-16500	524	37	attacks	attack	NOUN
ihlr-16500	524	38	and	and	CCONJ
ihlr-16500	524	39	strokes	stroke	NOUN
ihlr-16500	524	40	.	.	PUNCT
ihlr-16500	525	1	135	135	NUM
ihlr-16500	525	2	in	in	ADP
ihlr-16500	525	3	sum	sum	NOUN
ihlr-16500	525	4	,	,	PUNCT
ihlr-16500	525	5	more	more	ADJ
ihlr-16500	525	6	consideration	consideration	NOUN
ihlr-16500	525	7	should	should	AUX
ihlr-16500	525	8	have	have	AUX
ihlr-16500	525	9	been	be	AUX
ihlr-16500	525	10	given	give	VERB
ihlr-16500	525	11	to	to	ADP
ihlr-16500	525	12	the	the	DET
ihlr-16500	525	13	fact	fact	NOUN
ihlr-16500	525	14	that	that	SCONJ
ihlr-16500	525	15	the	the	DET
ihlr-16500	525	16	drug	drug	NOUN
ihlr-16500	525	17	was	be	AUX
ihlr-16500	525	18	not	not	PART
ihlr-16500	525	19	properly	properly	ADV
ihlr-16500	525	20	tested	test	VERB
ihlr-16500	525	21	and	and	CCONJ
ihlr-16500	525	22	could	could	AUX
ihlr-16500	525	23	negatively	negatively	ADV
ihlr-16500	525	24	af­	af­	ADJ
ihlr-16500	525	25	fect	fect	NOUN
ihlr-16500	525	26	many	many	ADJ
ihlr-16500	525	27	of	of	ADP
ihlr-16500	525	28	the	the	DET
ihlr-16500	525	29	patients	patient	NOUN
ihlr-16500	525	30	for	for	ADP
ihlr-16500	525	31	whom	whom	PRON
ihlr-16500	525	32	it	it	PRON
ihlr-16500	525	33	was	be	AUX
ihlr-16500	525	34	prescribed	prescribe	VERB
ihlr-16500	525	35	.	.	PUNCT
ihlr-16500	526	1	b.	b.	PROPN
ihlr-16500	526	2	a	a	DET
ihlr-16500	526	3	blockbuster	blockbuster	ADJ
ihlr-16500	526	4	drug	drug	NOUN
ihlr-16500	526	5	's	's	PART
ihlr-16500	526	6	withdrawal	withdrawal	NOUN
ihlr-16500	526	7	may	may	AUX
ihlr-16500	526	8	affect	affect	VERB
ihlr-16500	526	9	those	those	DET
ihlr-16500	526	10	patients	patient	NOUN
ihlr-16500	526	11	who	who	PRON
ihlr-16500	526	12	have	have	AUX
ihlr-16500	526	13	not	not	PART
ihlr-16500	526	14	reacted	react	VERB
ihlr-16500	526	15	negatively	negatively	ADV
ihlr-16500	526	16	to	to	ADP
ihlr-16500	526	17	the	the	DET
ihlr-16500	526	18	drug	drug	NOUN
ihlr-16500	526	19	another	another	DET
ihlr-16500	526	20	ethical	ethical	ADJ
ihlr-16500	526	21	consideration	consideration	NOUN
ihlr-16500	526	22	that	that	SCONJ
ihlr-16500	526	23	a	a	DET
ihlr-16500	526	24	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	526	25	company	company	NOUN
ihlr-16500	526	26	must	must	AUX
ihlr-16500	526	27	con­	con­	VERB
ihlr-16500	526	28	sider	sider	NOUN
ihlr-16500	526	29	when	when	SCONJ
ihlr-16500	526	30	deciding	decide	VERB
ihlr-16500	526	31	whether	whether	SCONJ
ihlr-16500	526	32	to	to	PART
ihlr-16500	526	33	withdraw	withdraw	VERB
ihlr-16500	526	34	a	a	DET
ihlr-16500	526	35	blockbuster	blockbuster	ADJ
ihlr-16500	526	36	drug	drug	NOUN
ihlr-16500	526	37	from	from	ADP
ihlr-16500	526	38	the	the	DET
ihlr-16500	526	39	market	market	NOUN
ihlr-16500	526	40	is	be	AUX
ihlr-16500	526	41	how	how	SCONJ
ihlr-16500	526	42	such	such	DET
ihlr-16500	526	43	a	a	DET
ihlr-16500	526	44	withdrawal	withdrawal	NOUN
ihlr-16500	526	45	will	will	AUX
ihlr-16500	526	46	affect	affect	VERB
ihlr-16500	526	47	current	current	ADJ
ihlr-16500	526	48	patients.136	patients.136	NOUN
ihlr-16500	526	49	many	many	ADJ
ihlr-16500	526	50	patients	patient	NOUN
ihlr-16500	526	51	depend	depend	VERB
ihlr-16500	526	52	on	on	ADP
ihlr-16500	526	53	drugs	drug	NOUN
ihlr-16500	526	54	such	such	ADJ
ihlr-16500	526	55	as	as	ADP
ihlr-16500	526	56	vioxx	vioxx	NOUN
ihlr-16500	526	57	and	and	CCONJ
ihlr-16500	526	58	bextra	bextra	NOUN
ihlr-16500	526	59	,	,	PUNCT
ihlr-16500	526	60	not	not	PART
ihlr-16500	526	61	only	only	ADV
ihlr-16500	526	62	for	for	ADP
ihlr-16500	526	63	their	their	PRON
ihlr-16500	526	64	pain	pain	NOUN
ihlr-16500	526	65	relief	relief	NOUN
ihlr-16500	526	66	properties	property	NOUN
ihlr-16500	526	67	,	,	PUNCT
ihlr-16500	526	68	but	but	CCONJ
ihlr-16500	526	69	also	also	ADV
ihlr-16500	526	70	because	because	SCONJ
ihlr-16500	526	71	these	these	DET
ihlr-16500	526	72	drugs	drug	NOUN
ihlr-16500	526	73	give	give	VERB
ihlr-16500	526	74	patients	patient	NOUN
ihlr-16500	526	75	the	the	DET
ihlr-16500	526	76	ability	ability	NOUN
ihlr-16500	526	77	to	to	PART
ihlr-16500	526	78	perform	perform	VERB
ihlr-16500	526	79	activities	activity	NOUN
ihlr-16500	526	80	that	that	PRON
ihlr-16500	526	81	oth­	oth­	NOUN
ihlr-16500	526	82	erwise	erwise	ADV
ihlr-16500	526	83	would	would	AUX
ihlr-16500	526	84	not	not	PART
ihlr-16500	526	85	be	be	AUX
ihlr-16500	526	86	possible	possible	ADJ
ihlr-16500	526	87	without	without	ADP
ihlr-16500	526	88	pain	pain	NOUN
ihlr-16500	526	89	.	.	PUNCT
ihlr-16500	527	1	137	137	NUM
ihlr-16500	527	2	as	as	ADP
ihlr-16500	527	3	a	a	DET
ihlr-16500	527	4	result	result	NOUN
ihlr-16500	527	5	,	,	PUNCT
ihlr-16500	527	6	due	due	ADP
ihlr-16500	527	7	to	to	ADP
ihlr-16500	527	8	the	the	DET
ihlr-16500	527	9	with­	with­	PROPN
ihlr-16500	527	10	drawal	drawal	NOUN
ihlr-16500	527	11	,	,	PUNCT
ihlr-16500	527	12	these	these	DET
ihlr-16500	527	13	patients	patient	NOUN
ihlr-16500	527	14	are	be	AUX
ihlr-16500	527	15	not	not	PART
ihlr-16500	527	16	afforded	afford	VERB
ihlr-16500	527	17	the	the	DET
ihlr-16500	527	18	chance	chance	NOUN
ihlr-16500	527	19	to	to	PART
ihlr-16500	527	20	determine	determine	VERB
ihlr-16500	527	21	whether	whether	SCONJ
ihlr-16500	527	22	continued	continue	VERB
ihlr-16500	527	23	use	use	NOUN
ihlr-16500	527	24	of	of	ADP
ihlr-16500	527	25	the	the	DET
ihlr-16500	527	26	withdrawn	withdraw	VERB
ihlr-16500	527	27	drug	drug	NOUN
ihlr-16500	527	28	and	and	CCONJ
ihlr-16500	527	29	any	any	DET
ihlr-16500	527	30	possible	possible	ADJ
ihlr-16500	527	31	associated	associated	ADJ
ihlr-16500	527	32	health	health	NOUN
ihlr-16500	527	33	risks	risk	NOUN
ihlr-16500	527	34	131	131	NUM
ihlr-16500	527	35	posting	posting	NOUN
ihlr-16500	527	36	of	of	ADP
ihlr-16500	527	37	louise	louise	PROPN
ihlr-16500	527	38	mckichan	mckichan	PROPN
ihlr-16500	527	39	,	,	PUNCT
ihlr-16500	527	40	baycol	baycol	PROPN
ihlr-16500	527	41	killed	kill	VERB
ihlr-16500	527	42	140	140	NUM
ihlr-16500	527	43	people	people	NOUN
ihlr-16500	527	44	taking	take	VERB
ihlr-16500	527	45	its	its	PRON
ihlr-16500	527	46	statin	statin	NOUN
ihlr-16500	527	47	,	,	PUNCT
ihlr-16500	527	48	to	to	ADP
ihlr-16500	527	49	http://www.rxlist.com/rxboard/pravachol.pl?read=143	http://www.rxlist.com/rxboard/pravachol.pl?read=143	PROPN
ihlr-16500	527	50	(	(	PUNCT
ihlr-16500	527	51	feb	feb	PROPN
ihlr-16500	527	52	.	.	PROPN
ihlr-16500	527	53	26	26	NUM
ihlr-16500	527	54	,	,	PUNCT
ihlr-16500	527	55	2005	2005	NUM
ihlr-16500	527	56	,	,	PUNCT
ihlr-16500	527	57	15:28	15:28	NUM
ihlr-16500	527	58	est	est	X
ihlr-16500	527	59	)	)	PUNCT
ihlr-16500	527	60	.	.	PUNCT
ihlr-16500	528	1	132	132	NUM
ihlr-16500	528	2	alex	alex	PROPN
ihlr-16500	528	3	berenson	berenson	PROPN
ihlr-16500	528	4	,	,	PUNCT
ihlr-16500	528	5	trial	trial	NOUN
ihlr-16500	528	6	lawyers	lawyer	NOUN
ihlr-16500	528	7	now	now	ADV
ihlr-16500	528	8	take	take	VERB
ihlr-16500	528	9	aim	aim	NOUN
ihlr-16500	528	10	at	at	ADP
ihlr-16500	528	11	drug	drug	NOUN
ihlr-16500	528	12	makers	maker	NOUN
ihlr-16500	528	13	,	,	PUNCT
ihlr-16500	528	14	n.y	n.y	PROPN
ihlr-16500	528	15	.	.	PROPN
ihlr-16500	528	16	times	times	PROPN
ihlr-16500	528	17	,	,	PUNCT
ihlr-16500	528	18	may	may	AUX
ihlr-16500	528	19	18	18	NUM
ihlr-16500	528	20	,	,	PUNCT
ihlr-16500	528	21	2003	2003	NUM
ihlr-16500	528	22	,	,	PUNCT
ihlr-16500	528	23	ata6	ata6	PROPN
ihlr-16500	528	24	.	.	PUNCT
ihlr-16500	529	1	133	133	NUM
ihlr-16500	530	1	i	i	PRON
ihlr-16500	530	2	d.	d.	PROPN
ihlr-16500	530	3	134	134	NUM
ihlr-16500	530	4	see	see	VERB
ihlr-16500	530	5	ben	ben	PROPN
ihlr-16500	530	6	harder	hard	ADV
ihlr-16500	530	7	,	,	PUNCT
ihlr-16500	530	8	dangerous	dangerous	ADJ
ihlr-16500	530	9	practices	practice	NOUN
ihlr-16500	530	10	:	:	PUNCT
ihlr-16500	530	11	critics	critic	NOUN
ihlr-16500	530	12	see	see	VERB
ihlr-16500	530	13	flaws	flaw	NOUN
ihlr-16500	530	14	in	in	ADP
ihlr-16500	530	15	drug	drug	NOUN
ihlr-16500	530	16	-	-	PUNCT
ihlr-16500	530	17	safety	safety	NOUN
ihlr-16500	530	18	monitoring	monitoring	NOUN
ihlr-16500	530	19	,	,	PUNCT
ihlr-16500	530	20	sci	sci	PROPN
ihlr-16500	530	21	.	.	PUNCT
ihlr-16500	531	1	news	news	PROPN
ihlr-16500	531	2	onune	onune	PROPN
ihlr-16500	531	3	,	,	PUNCT
ihlr-16500	531	4	feb	feb	PROPN
ihlr-16500	531	5	.	.	PROPN
ihlr-16500	531	6	5	5	NUM
ihlr-16500	531	7	,	,	PUNCT
ihlr-16500	531	8	2005	2005	NUM
ihlr-16500	531	9	,	,	PUNCT
ihlr-16500	531	10	http://www.sciencenews.org/articles/20050205/boblo.asp	http://www.sciencenews.org/articles/20050205/boblo.asp	NUM
ihlr-16500	531	11	.	.	PUNCT
ihlr-16500	532	1	critics	critic	NOUN
ihlr-16500	532	2	of	of	ADP
ihlr-16500	532	3	bayer	bayer	PROPN
ihlr-16500	532	4	claim	claim	VERB
ihlr-16500	532	5	that	that	SCONJ
ihlr-16500	532	6	the	the	DET
ihlr-16500	532	7	company	company	NOUN
ihlr-16500	532	8	had	have	AUX
ihlr-16500	532	9	become	become	VERB
ihlr-16500	532	10	aware	aware	ADJ
ihlr-16500	532	11	of	of	ADP
ihlr-16500	532	12	the	the	DET
ihlr-16500	532	13	hazards	hazard	NOUN
ihlr-16500	532	14	even	even	ADV
ihlr-16500	532	15	as	as	SCONJ
ihlr-16500	532	16	it	it	PRON
ihlr-16500	532	17	continued	continue	VERB
ihlr-16500	532	18	to	to	PART
ihlr-16500	532	19	sell	sell	VERB
ihlr-16500	532	20	baycol	baycol	NOUN
ihlr-16500	532	21	and	and	CCONJ
ihlr-16500	532	22	that	that	SCONJ
ihlr-16500	532	23	it	it	PRON
ihlr-16500	532	24	imperiled	imperil	VERB
ihlr-16500	532	25	its	its	PRON
ihlr-16500	532	26	customers	customer	NOUN
ihlr-16500	532	27	by	by	ADP
ihlr-16500	532	28	choosing	choose	VERB
ihlr-16500	532	29	not	not	PART
ihlr-16500	532	30	to	to	PART
ihlr-16500	532	31	disclose	disclose	VERB
ihlr-16500	532	32	those	those	DET
ihlr-16500	532	33	risks	risk	NOUN
ihlr-16500	532	34	fully	fully	ADV
ihlr-16500	532	35	.	.	PUNCT
ihlr-16500	533	1	several	several	ADJ
ihlr-16500	533	2	thousand	thousand	NUM
ihlr-16500	533	3	lawsuits	lawsuit	NOUN
ihlr-16500	533	4	have	have	AUX
ihlr-16500	533	5	been	be	AUX
ihlr-16500	533	6	brought	bring	VERB
ihlr-16500	533	7	against	against	ADP
ihlr-16500	533	8	the	the	DET
ihlr-16500	533	9	company	company	NOUN
ihlr-16500	533	10	.	.	PUNCT
ihlr-16500	534	1	four	four	NUM
ihlr-16500	534	2	researchers	researcher	NOUN
ihlr-16500	534	3	who	who	PRON
ihlr-16500	534	4	were	be	AUX
ihlr-16500	534	5	paid	pay	VERB
ihlr-16500	534	6	by	by	ADP
ihlr-16500	534	7	prosecutors	prosecutor	NOUN
ihlr-16500	534	8	to	to	PART
ihlr-16500	534	9	testify	testify	VERB
ihlr-16500	534	10	as	as	SCONJ
ihlr-16500	534	11	expert	expert	NOUN
ihlr-16500	534	12	witnesses	witness	NOUN
ihlr-16500	534	13	studied	study	VERB
ihlr-16500	534	14	the	the	DET
ihlr-16500	534	15	medical	medical	ADJ
ihlr-16500	534	16	literature	literature	NOUN
ihlr-16500	534	17	and	and	CCONJ
ihlr-16500	534	18	internal	internal	ADJ
ihlr-16500	534	19	company	company	NOUN
ihlr-16500	534	20	documents	document	NOUN
ihlr-16500	534	21	that	that	PRON
ihlr-16500	534	22	were	be	AUX
ihlr-16500	534	23	made	make	VERB
ihlr-16500	534	24	public	public	ADJ
ihlr-16500	534	25	during	during	ADP
ihlr-16500	534	26	the	the	DET
ihlr-16500	534	27	legal	legal	ADJ
ihlr-16500	534	28	proceedings	proceeding	NOUN
ihlr-16500	534	29	.	.	PUNCT
ihlr-16500	535	1	reporting	report	VERB
ihlr-16500	535	2	in	in	ADP
ihlr-16500	535	3	the	the	DET
ihlr-16500	535	4	same	same	ADJ
ihlr-16500	535	5	issue	issue	NOUN
ihlr-16500	535	6	of	of	ADP
ihlr-16500	535	7	jama	jama	PROPN
ihlr-16500	535	8	in	in	ADP
ihlr-16500	535	9	which	which	PRON
ihlr-16500	535	10	graham	graham	PROPN
ihlr-16500	535	11	's	's	PART
ihlr-16500	535	12	report	report	NOUN
ihlr-16500	535	13	appears	appear	VERB
ihlr-16500	535	14	,	,	PUNCT
ihlr-16500	535	15	they	they	PRON
ihlr-16500	535	16	conclude	conclude	VERB
ihlr-16500	535	17	that	that	SCONJ
ihlr-16500	535	18	the	the	DET
ihlr-16500	535	19	data	data	NOUN
ihlr-16500	535	20	bayer	bayer	NOUN
ihlr-16500	535	21	released	release	VERB
ihlr-16500	535	22	while	while	SCONJ
ihlr-16500	535	23	marketing	marketing	NOUN
ihlr-16500	535	24	baycol	baycol	NOUN
ihlr-16500	535	25	did	do	AUX
ihlr-16500	535	26	not	not	PART
ihlr-16500	535	27	tell	tell	VERB
ihlr-16500	535	28	the	the	DET
ihlr-16500	535	29	whole	whole	ADJ
ihlr-16500	535	30	truth	truth	NOUN
ihlr-16500	535	31	about	about	ADP
ihlr-16500	535	32	the	the	DET
ihlr-16500	535	33	drug	drug	NOUN
ihlr-16500	535	34	.	.	PUNCT
ihlr-16500	536	1	/d	/d	PUNCT
ihlr-16500	536	2	.	.	PROPN
ihlr-16500	536	3	135	135	NUM
ihlr-16500	536	4	/d	/d	X
ihlr-16500	536	5	.	.	PROPN
ihlr-16500	536	6	136	136	NUM
ihlr-16500	536	7	see	see	VERB
ihlr-16500	536	8	julie	julie	PROPN
ihlr-16500	536	9	appleby	appleby	PROPN
ihlr-16500	536	10	&	&	CCONJ
ihlr-16500	536	11	anita	anita	PROPN
ihlr-16500	536	12	manning	manning	PROPN
ihlr-16500	536	13	,	,	PUNCT
ihlr-16500	536	14	for	for	ADP
ihlr-16500	536	15	those	those	PRON
ihlr-16500	536	16	in	in	ADP
ihlr-16500	536	17	pain	pain	NOUN
ihlr-16500	536	18	,	,	PUNCT
ihlr-16500	536	19	relief	relief	NOUN
ihlr-16500	536	20	trumps	trump	VERB
ihlr-16500	536	21	risks	risk	NOUN
ihlr-16500	536	22	of	of	ADP
ihlr-16500	536	23	banned	ban	VERB
ihlr-16500	536	24	painkillers	painkiller	NOUN
ihlr-16500	536	25	,	,	PUNCT
ihlr-16500	536	26	usa	usa	PROPN
ihlr-16500	536	27	today	today	NOUN
ihlr-16500	536	28	,	,	PUNCT
ihlr-16500	536	29	jan	jan	PROPN
ihlr-16500	536	30	.	.	PROPN
ihlr-16500	536	31	4	4	NUM
ihlr-16500	536	32	,	,	PUNCT
ihlr-16500	536	33	2005	2005	NUM
ihlr-16500	536	34	,	,	PUNCT
ihlr-16500	536	35	at	at	ADP
ihlr-16500	536	36	la	la	ADV
ihlr-16500	536	37	,	,	PUNCT
ihlr-16500	536	38	available	available	ADJ
ihlr-16500	536	39	at	at	ADP
ihlr-16500	536	40	http://www.usatoday.com/newsl	http://www.usatoday.com/newsl	ADP
ihlr-16500	536	41	health/2005	health/2005	NOUN
ihlr-16500	536	42	-	-	SYM
ihlr-16500	536	43	0	0	NUM
ihlr-16500	536	44	1	1	NUM
ihlr-16500	536	45	-	-	PUNCT
ihlr-16500	536	46	04	04	NUM
ihlr-16500	536	47	-	-	PUNCT
ihlr-16500	536	48	painkillers	painkiller	NOUN
ihlr-16500	536	49	_	_	NOUN
ihlr-16500	537	1	x.htm	x.htm	PUNCT
ihlr-16500	537	2	.	.	PUNCT
ihlr-16500	538	1	137	137	NUM
ihlr-16500	538	2	see	see	VERB
ihlr-16500	538	3	i	i	PROPN
ihlr-16500	538	4	d.	d.	PROPN
ihlr-16500	538	5	140	140	NUM
ihlr-16500	538	6	indiana	indiana	PROPN
ihlr-16500	538	7	health	health	PROPN
ihlr-16500	538	8	law	law	PROPN
ihlr-16500	538	9	review	review	NOUN
ihlr-16500	538	10	[	[	X
ihlr-16500	538	11	vol	vol	NOUN
ihlr-16500	538	12	.	.	PUNCT
ihlr-16500	539	1	4:115	4:115	PRON
ihlr-16500	539	2	may	may	AUX
ihlr-16500	539	3	be	be	AUX
ihlr-16500	539	4	worth	worth	ADJ
ihlr-16500	539	5	the	the	DET
ihlr-16500	539	6	risk	risk	NOUN
ihlr-16500	539	7	,	,	PUNCT
ihlr-16500	539	8	given	give	VERB
ihlr-16500	539	9	the	the	DET
ihlr-16500	539	10	very	very	ADV
ihlr-16500	539	11	real	real	ADJ
ihlr-16500	539	12	possibility	possibility	NOUN
ihlr-16500	539	13	that	that	SCONJ
ihlr-16500	539	14	without	without	ADP
ihlr-16500	539	15	these	these	DET
ihlr-16500	539	16	drugs	drug	NOUN
ihlr-16500	539	17	,	,	PUNCT
ihlr-16500	539	18	their	their	PRON
ihlr-16500	539	19	quality	quality	NOUN
ihlr-16500	539	20	of	of	ADP
ihlr-16500	539	21	life	life	NOUN
ihlr-16500	539	22	would	would	AUX
ihlr-16500	539	23	be	be	AUX
ihlr-16500	539	24	substantially	substantially	ADV
ihlr-16500	539	25	diminished	diminish	VERB
ihlr-16500	539	26	.	.	PUNCT
ihlr-16500	540	1	138	138	NUM
ihlr-16500	540	2	subsequently	subsequently	ADV
ihlr-16500	540	3	,	,	PUNCT
ihlr-16500	540	4	without	without	ADP
ihlr-16500	540	5	these	these	DET
ihlr-16500	540	6	drugs	drug	NOUN
ihlr-16500	540	7	many	many	ADJ
ihlr-16500	540	8	patients	patient	NOUN
ihlr-16500	540	9	are	be	AUX
ihlr-16500	540	10	forced	force	VERB
ihlr-16500	540	11	to	to	PART
ihlr-16500	540	12	use	use	VERB
ihlr-16500	540	13	substi­	substi­	NOUN
ihlr-16500	540	14	tute	tute	NOUN
ihlr-16500	540	15	drugs	drug	NOUN
ihlr-16500	540	16	that	that	PRON
ihlr-16500	540	17	are	be	AUX
ihlr-16500	540	18	often	often	ADV
ihlr-16500	540	19	not	not	PART
ihlr-16500	540	20	as	as	ADV
ihlr-16500	540	21	efficacious	efficacious	ADJ
ihlr-16500	540	22	or	or	CCONJ
ihlr-16500	540	23	potent	potent	ADJ
ihlr-16500	540	24	.	.	PUNCT
ihlr-16500	541	1	139	139	NUM
ihlr-16500	541	2	in	in	ADP
ihlr-16500	541	3	some	some	DET
ihlr-16500	541	4	cases	case	NOUN
ihlr-16500	541	5	,	,	PUNCT
ihlr-16500	541	6	the	the	DET
ihlr-16500	541	7	sub­	sub­	PROPN
ihlr-16500	541	8	stitute	stitute	PROPN
ihlr-16500	541	9	drugs	drug	NOUN
ihlr-16500	541	10	can	can	AUX
ihlr-16500	541	11	also	also	ADV
ihlr-16500	541	12	cause	cause	VERB
ihlr-16500	541	13	distress	distress	NOUN
ihlr-16500	541	14	and	and	CCONJ
ihlr-16500	541	15	side	side	NOUN
ihlr-16500	541	16	effects.140	effects.140	NOUN
ihlr-16500	541	17	for	for	ADP
ihlr-16500	541	18	instance	instance	NOUN
ihlr-16500	541	19	,	,	PUNCT
ihlr-16500	541	20	with	with	ADP
ihlr-16500	541	21	the	the	DET
ihlr-16500	541	22	withdrawal	withdrawal	NOUN
ihlr-16500	541	23	of	of	ADP
ihlr-16500	541	24	vioxx	vioxx	NOUN
ihlr-16500	541	25	and	and	CCONJ
ihlr-16500	541	26	bextra	bextra	NOUN
ihlr-16500	541	27	,	,	PUNCT
ihlr-16500	541	28	many	many	ADJ
ihlr-16500	541	29	patients	patient	NOUN
ihlr-16500	541	30	were	be	AUX
ihlr-16500	541	31	forced	force	VERB
ihlr-16500	541	32	to	to	PART
ihlr-16500	541	33	use	use	VERB
ihlr-16500	541	34	over	over	ADP
ihlr-16500	541	35	-	-	PUNCT
ihlr-16500	541	36	the­	the­	NOUN
ihlr-16500	541	37	counter	counter	NOUN
ihlr-16500	541	38	drugs	drug	NOUN
ihlr-16500	541	39	such	such	ADJ
ihlr-16500	541	40	as	as	ADP
ihlr-16500	541	41	advil	advil	NOUN
ihlr-16500	541	42	and	and	CCONJ
ihlr-16500	541	43	aleve	aleve	VERB
ihlr-16500	541	44	,	,	PUNCT
ihlr-16500	541	45	both	both	PRON
ihlr-16500	541	46	of	of	ADP
ihlr-16500	541	47	which	which	PRON
ihlr-16500	541	48	can	can	AUX
ihlr-16500	541	49	also	also	ADV
ihlr-16500	541	50	cause	cause	VERB
ihlr-16500	541	51	cardio­	cardio­	NOUN
ihlr-16500	541	52	vascular	vascular	ADJ
ihlr-16500	541	53	problems	problem	NOUN
ihlr-16500	541	54	and	and	CCONJ
ihlr-16500	541	55	digestive	digestive	ADJ
ihlr-16500	541	56	distress	distress	NOUN
ihlr-16500	541	57	,	,	PUNCT
ihlr-16500	541	58	although	although	SCONJ
ihlr-16500	541	59	at	at	ADP
ihlr-16500	541	60	a	a	DET
ihlr-16500	541	61	much	much	ADV
ihlr-16500	541	62	lower	low	ADJ
ihlr-16500	541	63	rate	rate	NOUN
ihlr-16500	541	64	than	than	ADP
ihlr-16500	541	65	the	the	DET
ihlr-16500	541	66	cox-2	cox-2	ADJ
ihlr-16500	541	67	inhibitors.141	inhibitors.141	NOUN
ihlr-16500	541	68	furthermore	furthermore	ADV
ihlr-16500	541	69	,	,	PUNCT
ihlr-16500	541	70	withdrawal	withdrawal	VERB
ihlr-16500	541	71	ofmanyofthe	ofmanyofthe	DET
ihlr-16500	541	72	blockbuster	blockbuster	NOUN
ihlr-16500	541	73	drugs	drug	NOUN
ihlr-16500	541	74	does	do	AUX
ihlr-16500	541	75	not	not	PART
ihlr-16500	541	76	affect	affect	VERB
ihlr-16500	541	77	all	all	DET
ihlr-16500	541	78	patients	patient	NOUN
ihlr-16500	541	79	negatively	negatively	ADV
ihlr-16500	541	80	,	,	PUNCT
ihlr-16500	541	81	causing	cause	VERB
ihlr-16500	541	82	many	many	ADJ
ihlr-16500	541	83	patients	patient	NOUN
ihlr-16500	541	84	to	to	PART
ihlr-16500	541	85	wonder	wonder	VERB
ihlr-16500	541	86	why	why	SCONJ
ihlr-16500	541	87	they	they	PRON
ihlr-16500	541	88	have	have	AUX
ihlr-16500	541	89	been	be	AUX
ihlr-16500	541	90	deprived	deprive	VERB
ihlr-16500	541	91	of	of	ADP
ihlr-16500	541	92	effective	effective	ADJ
ihlr-16500	541	93	treatment	treatment	NOUN
ihlr-16500	541	94	.	.	PUNCT
ihlr-16500	542	1	in	in	ADP
ihlr-16500	542	2	most	most	ADJ
ihlr-16500	542	3	drug	drug	NOUN
ihlr-16500	542	4	withdrawal	withdrawal	NOUN
ihlr-16500	542	5	cases	case	NOUN
ihlr-16500	542	6	,	,	PUNCT
ihlr-16500	542	7	the	the	DET
ihlr-16500	542	8	vast	vast	ADJ
ihlr-16500	542	9	majority	majority	NOUN
ihlr-16500	542	10	of	of	ADP
ihlr-16500	542	11	patients	patient	NOUN
ihlr-16500	542	12	are	be	AUX
ihlr-16500	542	13	not	not	PART
ihlr-16500	542	14	at	at	ADP
ihlr-16500	542	15	risk	risk	NOUN
ihlr-16500	542	16	for	for	ADP
ihlr-16500	542	17	any	any	PRON
ihlr-16500	542	18	of	of	ADP
ihlr-16500	542	19	the	the	DET
ihlr-16500	542	20	side	side	NOUN
ihlr-16500	542	21	effects	effect	NOUN
ihlr-16500	542	22	listed.142	listed.142	VERB
ihlr-16500	542	23	in	in	ADP
ihlr-16500	542	24	fact	fact	NOUN
ihlr-16500	542	25	,	,	PUNCT
ihlr-16500	542	26	an	an	DET
ihlr-16500	542	27	fda	fda	PROPN
ihlr-16500	542	28	advisory	advisory	PROPN
ihlr-16500	542	29	panel	panel	NOUN
ihlr-16500	542	30	even	even	ADV
ihlr-16500	542	31	concluded	conclude	VERB
ihlr-16500	542	32	that	that	SCONJ
ihlr-16500	542	33	vioxx	vioxx	NOUN
ihlr-16500	542	34	was	be	AUX
ihlr-16500	542	35	safe	safe	ADJ
ihlr-16500	542	36	enough	enough	ADV
ihlr-16500	542	37	to	to	PART
ihlr-16500	542	38	be	be	AUX
ihlr-16500	542	39	returned	return	VERB
ihlr-16500	542	40	to	to	ADP
ihlr-16500	542	41	the	the	DET
ihlr-16500	542	42	market	market	NOUN
ihlr-16500	542	43	as	as	ADV
ihlr-16500	542	44	long	long	ADV
ihlr-16500	542	45	as	as	SCONJ
ihlr-16500	542	46	patients	patient	NOUN
ihlr-16500	542	47	were	be	AUX
ihlr-16500	542	48	better	well	ADV
ihlr-16500	542	49	warned	warn	VERB
ihlr-16500	542	50	of	of	ADP
ihlr-16500	542	51	the	the	DET
ihlr-16500	542	52	risks.143	risks.143	NOUN
ihlr-16500	542	53	furthermore	furthermore	ADV
ihlr-16500	542	54	,	,	PUNCT
ihlr-16500	542	55	these	these	DET
ihlr-16500	542	56	patients	patient	NOUN
ihlr-16500	542	57	might	might	AUX
ihlr-16500	542	58	actually	actually	ADV
ihlr-16500	542	59	be	be	AUX
ihlr-16500	542	60	more	more	ADV
ihlr-16500	542	61	at	at	ADP
ihlr-16500	542	62	risk	risk	NOUN
ihlr-16500	542	63	from	from	ADP
ihlr-16500	542	64	substitute	substitute	ADJ
ihlr-16500	542	65	drugs	drug	NOUN
ihlr-16500	542	66	than	than	ADP
ihlr-16500	542	67	from	from	ADP
ihlr-16500	542	68	the	the	DET
ihlr-16500	542	69	withdrawn	withdraw	VERB
ihlr-16500	542	70	drugs	drug	NOUN
ihlr-16500	542	71	.	.	PUNCT
ihlr-16500	543	1	therefore	therefore	ADV
ihlr-16500	543	2	,	,	PUNCT
ihlr-16500	543	3	many	many	ADJ
ihlr-16500	543	4	patients	patient	NOUN
ihlr-16500	543	5	are	be	AUX
ihlr-16500	543	6	left	leave	VERB
ihlr-16500	543	7	to	to	PART
ihlr-16500	543	8	wonder	wonder	VERB
ihlr-16500	543	9	138	138	NUM
ihlr-16500	543	10	see	see	VERB
ihlr-16500	543	11	i	i	PROPN
ihlr-16500	543	12	d.	d.	PROPN
ihlr-16500	543	13	;	;	PUNCT
ihlr-16500	543	14	see	see	VERB
ihlr-16500	543	15	also	also	ADV
ihlr-16500	543	16	life	life	NOUN
ihlr-16500	543	17	without	without	ADP
ihlr-16500	543	18	vioxx	vioxx	NOUN
ihlr-16500	543	19	:	:	PUNCT
ihlr-16500	543	20	what	what	PRON
ihlr-16500	543	21	's	be	AUX
ihlr-16500	543	22	a	a	DET
ihlr-16500	543	23	patient	patient	NOUN
ihlr-16500	543	24	to	to	PART
ihlr-16500	543	25	do	do	VERB
ihlr-16500	543	26	?	?	PUNCT
ihlr-16500	543	27	,	,	PUNCT
ihlr-16500	543	28	consumeraffairs	consumeraffair	NOUN
ihlr-16500	543	29	.	.	PUNCT
ihlr-16500	544	1	com	com	NOUN
ihlr-16500	544	2	,	,	PUNCT
ihlr-16500	544	3	oct	oct	PROPN
ihlr-16500	544	4	.	.	PROPN
ihlr-16500	544	5	1	1	NUM
ihlr-16500	544	6	,	,	PUNCT
ihlr-16500	544	7	2004	2004	NUM
ihlr-16500	544	8	,	,	PUNCT
ihlr-16500	544	9	http://www.consumeraffairs.comfnews04	http://www.consumeraffairs.comfnews04	ADV
ihlr-16500	544	10	/	/	SYM
ihlr-16500	544	11	vioxx_alternatives.html	vioxx_alternatives.html	PUNCT
ihlr-16500	544	12	.	.	PUNCT
ihlr-16500	545	1	139	139	NUM
ihlr-16500	545	2	see	see	VERB
ihlr-16500	545	3	life	life	NOUN
ihlr-16500	545	4	without	without	ADP
ihlr-16500	545	5	vioxx	vioxx	NOUN
ihlr-16500	545	6	:	:	PUNCT
ihlr-16500	545	7	what	what	PRON
ihlr-16500	545	8	's	be	AUX
ihlr-16500	545	9	a	a	DET
ihlr-16500	545	10	patient	patient	NOUN
ihlr-16500	545	11	to	to	PART
ihlr-16500	545	12	do	do	VERB
ihlr-16500	545	13	?	?	PUNCT
ihlr-16500	545	14	,	,	PUNCT
ihlr-16500	545	15	supra	supra	PROPN
ihlr-16500	545	16	note	note	PROPN
ihlr-16500	545	17	138	138	NUM
ihlr-16500	545	18	.	.	PUNCT
ihlr-16500	545	19	140	140	NUM
ihlr-16500	545	20	mayo	mayo	NOUN
ihlr-16500	545	21	clinic	clinic	NOUN
ihlr-16500	545	22	staff	staff	NOUN
ihlr-16500	545	23	,	,	PUNCT
ihlr-16500	545	24	nsaids	nsaid	VERB
ihlr-16500	545	25	:	:	PUNCT
ihlr-16500	545	26	how	how	SCONJ
ihlr-16500	545	27	to	to	PART
ihlr-16500	545	28	avoid	avoid	VERB
ihlr-16500	545	29	side	side	ADJ
ihlr-16500	545	30	effects	effect	NOUN
ihlr-16500	545	31	,	,	PUNCT
ihlr-16500	545	32	apr	apr	NOUN
ihlr-16500	545	33	.	.	PROPN
ihlr-16500	545	34	3	3	NUM
ihlr-16500	545	35	,	,	PUNCT
ihlr-16500	545	36	2006	2006	NUM
ihlr-16500	545	37	[	[	X
ihlr-16500	545	38	hereinafter	hereinafter	NOUN
ihlr-16500	545	39	nsaids	nsaid	VERB
ihlr-16500	545	40	:	:	PUNCT
ihlr-16500	545	41	how	how	SCONJ
ihlr-16500	545	42	to	to	PART
ihlr-16500	545	43	avoid	avoid	VERB
ihlr-16500	545	44	side	side	ADJ
ihlr-16500	545	45	effects	effect	NOUN
ihlr-16500	545	46	]	]	PUNCT
ihlr-16500	545	47	(	(	PUNCT
ihlr-16500	545	48	on	on	ADP
ihlr-16500	545	49	file	file	NOUN
ihlr-16500	545	50	with	with	ADP
ihlr-16500	545	51	author	author	NOUN
ihlr-16500	545	52	)	)	PUNCT
ihlr-16500	545	53	.	.	PUNCT
ihlr-16500	546	1	aspirin	aspirin	NOUN
ihlr-16500	546	2	and	and	CCONJ
ihlr-16500	546	3	advil	advil	NOUN
ihlr-16500	546	4	are	be	AUX
ihlr-16500	546	5	categorized	categorize	VERB
ihlr-16500	546	6	as	as	ADP
ihlr-16500	546	7	non	non	ADJ
ihlr-16500	546	8	-	-	ADJ
ihlr-16500	546	9	steroidal	steroidal	ADJ
ihlr-16500	546	10	anti	anti	ADJ
ihlr-16500	546	11	-	-	ADJ
ihlr-16500	546	12	inflammatory	inflammatory	ADJ
ihlr-16500	546	13	drugs	drug	NOUN
ihlr-16500	546	14	(	(	PUNCT
ihlr-16500	546	15	"	"	PUNCT
ihlr-16500	546	16	nsaids	nsaids	PROPN
ihlr-16500	546	17	"	"	PUNCT
ihlr-16500	546	18	)	)	PUNCT
ihlr-16500	546	19	,	,	PUNCT
ihlr-16500	546	20	which	which	PRON
ihlr-16500	546	21	are	be	AUX
ihlr-16500	546	22	known	know	VERB
ihlr-16500	546	23	to	to	PART
ihlr-16500	546	24	cause	cause	VERB
ihlr-16500	546	25	stomach	stomach	NOUN
ihlr-16500	546	26	ulcers	ulcer	NOUN
ihlr-16500	546	27	and	and	CCONJ
ihlr-16500	546	28	other	other	ADJ
ihlr-16500	546	29	gastrointestinal	gastrointestinal	ADJ
ihlr-16500	546	30	side	side	NOUN
ihlr-16500	546	31	effects	effect	NOUN
ihlr-16500	546	32	.	.	PUNCT
ihlr-16500	547	1	see	see	VERB
ihlr-16500	547	2	mayoclinic.com	mayoclinic.com	X
ihlr-16500	547	3	,	,	PUNCT
ihlr-16500	547	4	anti	anti	ADJ
ihlr-16500	547	5	-	-	ADJ
ihlr-16500	547	6	inflammatory	inflammatory	ADJ
ihlr-16500	547	7	drugs	drug	NOUN
ihlr-16500	547	8	,	,	PUNCT
ihlr-16500	547	9	nonsteroidal	nonsteroidal	NOUN
ihlr-16500	547	10	(	(	PUNCT
ihlr-16500	547	11	systemic	systemic	ADJ
ihlr-16500	547	12	)	)	PUNCT
ihlr-16500	547	13	,	,	PUNCT
ihlr-16500	547	14	http://www.mayoclinic.com/health/drug-information/dr202743	http://www.mayoclinic.com/health/drug-information/dr202743	PROPN
ihlr-16500	547	15	(	(	PUNCT
ihlr-16500	547	16	last	last	ADJ
ihlr-16500	547	17	visited	visit	VERB
ihlr-16500	547	18	feb	feb	PROPN
ihlr-16500	547	19	.	.	PROPN
ihlr-16500	547	20	24	24	NUM
ihlr-16500	547	21	,	,	PUNCT
ihlr-16500	547	22	2007	2007	NUM
ihlr-16500	547	23	)	)	PUNCT
ihlr-16500	547	24	.	.	PUNCT
ihlr-16500	548	1	other	other	ADJ
ihlr-16500	548	2	classes	class	NOUN
ihlr-16500	548	3	ofnsaids	ofnsaid	NOUN
ihlr-16500	548	4	can	can	AUX
ihlr-16500	548	5	also	also	ADV
ihlr-16500	548	6	cause	cause	VERB
ihlr-16500	548	7	cardiovascular	cardiovascular	ADJ
ihlr-16500	548	8	problems	problem	NOUN
ihlr-16500	548	9	.	.	PUNCT
ihlr-16500	549	1	nsaids	nsaid	NOUN
ihlr-16500	549	2	:	:	PUNCT
ihlr-16500	549	3	how	how	SCONJ
ihlr-16500	549	4	to	to	PART
ihlr-16500	549	5	avoid	avoid	VERB
ihlr-16500	549	6	side	side	ADJ
ihlr-16500	549	7	effects	effect	NOUN
ihlr-16500	549	8	,	,	PUNCT
ihlr-16500	549	9	supra	supra	NOUN
ihlr-16500	549	10	.	.	PUNCT
ihlr-16500	550	1	141	141	NUM
ihlr-16500	550	2	see	see	VERB
ihlr-16500	550	3	life	life	NOUN
ihlr-16500	550	4	without	without	ADP
ihlr-16500	550	5	vioxx	vioxx	NOUN
ihlr-16500	550	6	:	:	PUNCT
ihlr-16500	550	7	what	what	PRON
ihlr-16500	550	8	's	be	AUX
ihlr-16500	550	9	a	a	DET
ihlr-16500	550	10	patient	patient	NOUN
ihlr-16500	550	11	to	to	PART
ihlr-16500	550	12	do	do	VERB
ihlr-16500	550	13	?	?	PUNCT
ihlr-16500	550	14	,	,	PUNCT
ihlr-16500	550	15	supra	supra	PROPN
ihlr-16500	550	16	note	note	PROPN
ihlr-16500	550	17	138	138	NUM
ihlr-16500	550	18	.	.	PUNCT
ihlr-16500	551	1	142	142	NUM
ihlr-16500	551	2	see	see	VERB
ihlr-16500	551	3	painconcem.com	painconcem.com	X
ihlr-16500	551	4	,	,	PUNCT
ihlr-16500	551	5	how	how	SCONJ
ihlr-16500	551	6	safe	safe	ADJ
ihlr-16500	551	7	are	be	AUX
ihlr-16500	551	8	my	my	PRON
ihlr-16500	551	9	pills	pill	NOUN
ihlr-16500	551	10	?	?	PUNCT
ihlr-16500	551	11	,	,	PUNCT
ihlr-16500	551	12	mar	mar	PROPN
ihlr-16500	551	13	.	.	PROPN
ihlr-16500	551	14	3	3	NUM
ihlr-16500	551	15	,	,	PUNCT
ihlr-16500	551	16	2005	2005	NUM
ihlr-16500	551	17	,	,	PUNCT
ihlr-16500	551	18	http://www	http://www	PROPN
ihlr-16500	551	19	.	.	PUNCT
ihlr-16500	552	1	painconcem.org.uk/pages/page62.php	painconcem.org.uk/pages/page62.php	VERB
ihlr-16500	552	2	.	.	PUNCT
ihlr-16500	553	1	in	in	ADP
ihlr-16500	553	2	a	a	DET
ihlr-16500	553	3	recent	recent	ADJ
ihlr-16500	553	4	study	study	NOUN
ihlr-16500	553	5	,	,	PUNCT
ihlr-16500	553	6	the	the	DET
ihlr-16500	553	7	united	united	PROPN
ihlr-16500	553	8	states	states	PROPN
ihlr-16500	553	9	food	food	NOUN
ihlr-16500	553	10	and	and	CCONJ
ihlr-16500	553	11	drug	drug	NOUN
ihlr-16500	553	12	ad­	ad­	ADJ
ihlr-16500	553	13	ministration	ministration	NOUN
ihlr-16500	553	14	(	(	PUNCT
ihlr-16500	553	15	"	"	PUNCT
ihlr-16500	553	16	fda	fda	PROPN
ihlr-16500	553	17	"	"	PUNCT
ihlr-16500	553	18	)	)	PUNCT
ihlr-16500	553	19	examined	examine	VERB
ihlr-16500	553	20	heart	heart	NOUN
ihlr-16500	553	21	attack	attack	NOUN
ihlr-16500	553	22	risk	risk	NOUN
ihlr-16500	553	23	in	in	ADP
ihlr-16500	553	24	patients	patient	NOUN
ihlr-16500	553	25	who	who	PRON
ihlr-16500	553	26	used	use	VERB
ihlr-16500	553	27	vioxx	vioxx	NOUN
ihlr-16500	553	28	.	.	PUNCT
ihlr-16500	553	29	!	!	PUNCT
ihlr-16500	554	1	d.	d.	PROPN
ihlr-16500	554	2	the	the	DET
ihlr-16500	554	3	fda	fda	PROPN
ihlr-16500	554	4	studied	study	VERB
ihlr-16500	554	5	a	a	DET
ihlr-16500	554	6	total	total	NOUN
ihlr-16500	554	7	of	of	ADP
ihlr-16500	554	8	1.4	1.4	NUM
ihlr-16500	554	9	million	million	NUM
ihlr-16500	554	10	californians	californian	NOUN
ihlr-16500	554	11	who	who	PRON
ihlr-16500	554	12	were	be	AUX
ihlr-16500	554	13	using	use	VERB
ihlr-16500	554	14	painkillers	painkiller	NOUN
ihlr-16500	554	15	,	,	PUNCT
ihlr-16500	554	16	including	include	VERB
ihlr-16500	554	17	1,000,000	1,000,000	NUM
ihlr-16500	554	18	pa­	pa­	ADJ
ihlr-16500	554	19	tients	tient	NOUN
ihlr-16500	554	20	who	who	PRON
ihlr-16500	554	21	were	be	AUX
ihlr-16500	554	22	using	use	VERB
ihlr-16500	554	23	ibuprofen	ibuprofen	NOUN
ihlr-16500	554	24	,	,	PUNCT
ihlr-16500	554	25	400,000	400,000	NUM
ihlr-16500	554	26	using	use	VERB
ihlr-16500	554	27	naproxen	naproxen	NOUN
ihlr-16500	554	28	,	,	PUNCT
ihlr-16500	554	29	40,000	40,000	NUM
ihlr-16500	554	30	using	use	VERB
ihlr-16500	554	31	celecoxib	celecoxib	NOUN
ihlr-16500	554	32	,	,	PUNCT
ihlr-16500	554	33	and	and	CCONJ
ihlr-16500	554	34	27,000	27,000	NUM
ihlr-16500	554	35	using	use	VERB
ihlr-16500	554	36	vioxx	vioxx	NOUN
ihlr-16500	554	37	.	.	PUNCT
ihlr-16500	555	1	i	i	PRON
ihlr-16500	555	2	d	d	PROPN
ihlr-16500	555	3	additionally	additionally	ADV
ihlr-16500	555	4	,	,	PUNCT
ihlr-16500	555	5	among	among	ADP
ihlr-16500	555	6	the	the	DET
ihlr-16500	555	7	1.4	1.4	NUM
ihlr-16500	555	8	million	million	NUM
ihlr-16500	555	9	patients	patient	NOUN
ihlr-16500	555	10	,	,	PUNCT
ihlr-16500	555	11	the	the	DET
ihlr-16500	555	12	total	total	ADJ
ihlr-16500	555	13	number	number	NOUN
ihlr-16500	555	14	with	with	ADP
ihlr-16500	555	15	coronary	coronary	ADJ
ihlr-16500	555	16	heart	heart	NOUN
ihlr-16500	555	17	disease	disease	NOUN
ihlr-16500	555	18	was	be	AUX
ihlr-16500	555	19	8,1	8,1	NUM
ihlr-16500	555	20	00	00	NUM
ihlr-16500	555	21	.	.	PUNCT
ihlr-16500	556	1	/d	/d	PUNCT
ihlr-16500	556	2	.	.	PUNCT
ihlr-16500	557	1	"	"	PUNCT
ihlr-16500	557	2	[	[	X
ihlr-16500	557	3	b]ut	b]ut	X
ihlr-16500	557	4	when	when	SCONJ
ihlr-16500	557	5	the	the	DET
ihlr-16500	557	6	incidence	incidence	NOUN
ihlr-16500	557	7	of	of	ADP
ihlr-16500	557	8	coronary	coronary	ADJ
ihlr-16500	557	9	heart	heart	NOUN
ihlr-16500	557	10	disease	disease	NOUN
ihlr-16500	557	11	was	be	AUX
ihlr-16500	557	12	compared	compare	VERB
ihlr-16500	557	13	with	with	ADP
ihlr-16500	557	14	individual	individual	ADJ
ihlr-16500	557	15	drugs	drug	NOUN
ihlr-16500	557	16	they	they	PRON
ihlr-16500	557	17	found	find	VERB
ihlr-16500	557	18	a	a	DET
ihlr-16500	557	19	1.6x	1.6x	NUM
ihlr-16500	557	20	higher	high	ADJ
ihlr-16500	557	21	risk	risk	NOUN
ihlr-16500	557	22	,	,	PUNCT
ihlr-16500	557	23	i.e.	i.e.	X
ihlr-16500	557	24	1	1	NUM
ihlr-16500	557	25	%	%	NOUN
ihlr-16500	557	26	in	in	ADP
ihlr-16500	557	27	patients	patient	NOUN
ihlr-16500	557	28	using	use	VERB
ihlr-16500	557	29	vioxx	vioxx	NOUN
ihlr-16500	557	30	.	.	PUNCT
ihlr-16500	558	1	so	so	ADV
ihlr-16500	558	2	if	if	SCONJ
ihlr-16500	558	3	you	you	PRON
ihlr-16500	558	4	are	be	AUX
ihlr-16500	558	5	a	a	DET
ihlr-16500	558	6	doctor	doctor	NOUN
ihlr-16500	558	7	in	in	ADP
ihlr-16500	558	8	california	california	PROPN
ihlr-16500	558	9	and	and	CCONJ
ihlr-16500	558	10	you	you	PRON
ihlr-16500	558	11	have	have	VERB
ihlr-16500	558	12	1000	1000	NUM
ihlr-16500	558	13	patients	patient	NOUN
ihlr-16500	558	14	on	on	ADP
ihlr-16500	558	15	painkillers	painkiller	NOUN
ihlr-16500	558	16	other	other	ADJ
ihlr-16500	558	17	than	than	ADP
ihlr-16500	558	18	vioxx	vioxx	NOUN
ihlr-16500	558	19	,	,	PUNCT
ihlr-16500	558	20	you	you	PRON
ihlr-16500	558	21	might	might	AUX
ihlr-16500	558	22	find	find	VERB
ihlr-16500	558	23	that	that	SCONJ
ihlr-16500	558	24	6	6	NUM
ihlr-16500	558	25	of	of	ADP
ihlr-16500	558	26	them	they	PRON
ihlr-16500	558	27	have	have	VERB
ihlr-16500	558	28	coronary	coronary	ADJ
ihlr-16500	558	29	heart	heart	NOUN
ihlr-16500	558	30	disease	disease	NOUN
ihlr-16500	558	31	.	.	PUNCT
ihlr-16500	559	1	and	and	CCONJ
ihlr-16500	559	2	if	if	SCONJ
ihlr-16500	559	3	you	you	PRON
ihlr-16500	559	4	have	have	VERB
ihlr-16500	559	5	1000	1000	NUM
ihlr-16500	559	6	patients	patient	NOUN
ihlr-16500	559	7	on	on	ADP
ihlr-16500	559	8	vioxx	vioxx	NOUN
ihlr-16500	559	9	you	you	PRON
ihlr-16500	559	10	might	might	AUX
ihlr-16500	559	11	find	find	VERB
ihlr-16500	559	12	that	that	SCONJ
ihlr-16500	559	13	10	10	NUM
ihlr-16500	559	14	have	have	VERB
ihlr-16500	559	15	heart	heart	NOUN
ihlr-16500	559	16	disease	disease	NOUN
ihlr-16500	559	17	.	.	PUNCT
ihlr-16500	560	1	that	that	PRON
ihlr-16500	560	2	's	be	AUX
ihlr-16500	560	3	the	the	DET
ihlr-16500	560	4	problem	problem	NOUN
ihlr-16500	560	5	.	.	PUNCT
ihlr-16500	561	1	how	how	SCONJ
ihlr-16500	561	2	do	do	AUX
ihlr-16500	561	3	you	you	PRON
ihlr-16500	561	4	decide	decide	VERB
ihlr-16500	561	5	if	if	SCONJ
ihlr-16500	561	6	such	such	DET
ihlr-16500	561	7	a	a	DET
ihlr-16500	561	8	smau	smau	NOUN
ihlr-16500	561	9	increase	increase	NOUN
ihlr-16500	561	10	is	be	AUX
ihlr-16500	561	11	chance	chance	NOUN
ihlr-16500	561	12	or	or	CCONJ
ihlr-16500	561	13	genuinely	genuinely	ADV
ihlr-16500	561	14	due	due	ADJ
ihlr-16500	561	15	to	to	ADP
ihlr-16500	561	16	the	the	DET
ihlr-16500	561	17	drug	drug	NOUN
ihlr-16500	561	18	?	?	PUNCT
ihlr-16500	561	19	''	''	PUNCT
ihlr-16500	562	1	/d	/d	PUNCT
ihlr-16500	562	2	.	.	PUNCT
ihlr-16500	563	1	143	143	NUM
ihlr-16500	563	2	fda	fda	PROPN
ihlr-16500	563	3	panel	panel	NOUN
ihlr-16500	563	4	concludes	conclude	VERB
ihlr-16500	563	5	vioxx	vioxx	NOUN
ihlr-16500	563	6	safe	safe	ADJ
ihlr-16500	563	7	enough	enough	ADV
ihlr-16500	563	8	to	to	PART
ihlr-16500	563	9	return	return	VERB
ihlr-16500	563	10	to	to	ADP
ihlr-16500	563	11	market	market	NOUN
ihlr-16500	563	12	,	,	PUNCT
ihlr-16500	563	13	newstarget.com	newstarget.com	X
ihlr-16500	563	14	,	,	PUNCT
ihlr-16500	563	15	feb	feb	PROPN
ihlr-16500	563	16	.	.	PROPN
ihlr-16500	563	17	28	28	NUM
ihlr-16500	563	18	,	,	PUNCT
ihlr-16500	563	19	2005	2005	NUM
ihlr-16500	563	20	,	,	PUNCT
ihlr-16500	563	21	http://www	http://www	PROPN
ihlr-16500	563	22	.newstarget.comf005033.html	.newstarget.comf005033.html	PROPN
ihlr-16500	563	23	;	;	PUNCT
ihlr-16500	563	24	vioxx	vioxx	NOUN
ihlr-16500	563	25	could	could	AUX
ihlr-16500	563	26	be	be	AUX
ihlr-16500	563	27	sold	sell	VERB
ihlr-16500	563	28	again	again	ADV
ihlr-16500	563	29	,	,	PUNCT
ihlr-16500	563	30	mealey	mealey	PROPN
ihlr-16500	563	31	's	's	PART
ihlr-16500	563	32	lmo	lmo	PROPN
ihlr-16500	563	33	.	.	PUNCT
ihlr-16500	563	34	rep	rep	PROPN
ihlr-16500	563	35	.	.	PROPN
ihlr-16500	563	36	artiiritis	artiiritis	PROPN
ihlr-16500	563	37	drugs	drug	NOUN
ihlr-16500	563	38	,	,	PUNCT
ihlr-16500	563	39	feb	feb	PROPN
ihlr-16500	563	40	.	.	PROPN
ihlr-16500	563	41	1	1	NUM
ihlr-16500	563	42	,	,	PUNCT
ihlr-16500	563	43	2005	2005	NUM
ihlr-16500	563	44	,	,	PUNCT
ihlr-16500	563	45	at	at	ADP
ihlr-16500	563	46	8	8	NUM
ihlr-16500	563	47	,	,	PUNCT
ihlr-16500	563	48	11	11	NUM
ihlr-16500	563	49	[	[	X
ihlr-16500	563	50	hereinafter	hereinafter	NOUN
ihlr-16500	563	51	vioxx	vioxx	NOUN
ihlr-16500	563	52	could	could	AUX
ihlr-16500	563	53	be	be	AUX
ihlr-16500	563	54	sold	sell	VERB
ihlr-16500	563	55	again	again	ADV
ihlr-16500	563	56	]	]	PUNCT
ihlr-16500	563	57	.	.	PUNCT
ihlr-16500	564	1	with	with	ADP
ihlr-16500	564	2	the	the	DET
ihlr-16500	564	3	approval	approval	NOUN
ihlr-16500	564	4	of	of	ADP
ihlr-16500	564	5	a	a	DET
ihlr-16500	564	6	closely	closely	ADV
ihlr-16500	564	7	divided	divide	VERB
ihlr-16500	564	8	joint	joint	ADJ
ihlr-16500	564	9	advisory	advisory	ADJ
ihlr-16500	564	10	committee	committee	NOUN
ihlr-16500	564	11	of	of	ADP
ihlr-16500	564	12	the	the	DET
ihlr-16500	564	13	fda	fda	PROPN
ihlr-16500	564	14	that	that	PRON
ihlr-16500	564	15	also	also	ADV
ihlr-16500	564	16	voted	vote	VERB
ihlr-16500	564	17	to	to	PART
ihlr-16500	564	18	keep	keep	VERB
ihlr-16500	564	19	competitors	competitor	NOUN
ihlr-16500	564	20	celebrex	celebrex	PROPN
ihlr-16500	564	21	and	and	CCONJ
ihlr-16500	564	22	bextra	bextra	PROPN
ihlr-16500	564	23	available	available	ADJ
ihlr-16500	564	24	,	,	PUNCT
ihlr-16500	564	25	vioxx	vioxx	PROPN
ihlr-16500	564	26	could	could	AUX
ihlr-16500	564	27	re	re	VERB
ihlr-16500	564	28	-	-	VERB
ihlr-16500	564	29	enter	enter	VERB
ihlr-16500	564	30	the	the	DET
ihlr-16500	564	31	pharmaceutical	pharmaceutical	NOUN
ihlr-16500	564	32	mar­	mar­	NOUN
ihlr-16500	564	33	ketplace	ketplace	NOUN
ihlr-16500	564	34	.	.	PUNCT
ihlr-16500	565	1	a	a	DET
ihlr-16500	565	2	joint	joint	ADJ
ihlr-16500	565	3	committee	committee	NOUN
ihlr-16500	565	4	of	of	ADP
ihlr-16500	565	5	thirty	thirty	NUM
ihlr-16500	565	6	-	-	PUNCT
ihlr-16500	565	7	two	two	NUM
ihlr-16500	565	8	expertsconvenedbythefda	expertsconvenedbythefda	NOUN
ihlr-16500	565	9	voted	vote	VERB
ihlr-16500	565	10	17	17	NUM
ihlr-16500	565	11	-	-	SYM
ihlr-16500	565	12	15	15	NUM
ihlr-16500	565	13	onfeb.18	onfeb.18	ADJ
ihlr-16500	565	14	,	,	PUNCT
ihlr-16500	565	15	2005	2005	NUM
ihlr-16500	565	16	,	,	PUNCT
ihlr-16500	565	17	that	that	DET
ihlr-16500	565	18	vioxx	vioxx	NOUN
ihlr-16500	565	19	should	should	AUX
ihlr-16500	565	20	be	be	AUX
ihlr-16500	565	21	permitted	permit	VERB
ihlr-16500	565	22	back	back	ADV
ihlr-16500	565	23	on	on	ADP
ihlr-16500	565	24	the	the	DET
ihlr-16500	565	25	market	market	NOUN
ihlr-16500	565	26	.	.	PUNCT
ihlr-16500	566	1	the	the	DET
ihlr-16500	566	2	committee	committee	NOUN
ihlr-16500	566	3	voted	vote	VERB
ihlr-16500	566	4	31	31	NUM
ihlr-16500	566	5	-	-	SYM
ihlr-16500	566	6	1	1	NUM
ihlr-16500	566	7	in	in	ADP
ihlr-16500	566	8	favor	favor	NOUN
ihlr-16500	566	9	of	of	ADP
ihlr-16500	566	10	ce1ebrex	ce1ebrex	PROPN
ihlr-16500	566	11	and	and	CCONJ
ihlr-16500	566	12	17	17	NUM
ihlr-16500	566	13	-	-	SYM
ihlr-16500	566	14	13	13	NUM
ihlr-16500	566	15	with	with	ADP
ihlr-16500	566	16	two	two	NUM
ihlr-16500	566	17	abstentions	abstention	NOUN
ihlr-16500	566	18	for	for	ADP
ihlr-16500	566	19	bextra	bextra	NOUN
ihlr-16500	566	20	.	.	PUNCT
ihlr-16500	567	1	vioxx	vioxx	PROPN
ihlr-16500	567	2	could	could	AUX
ihlr-16500	567	3	be	be	AUX
ihlr-16500	567	4	sold	sell	VERB
ihlr-16500	567	5	again	again	ADV
ihlr-16500	567	6	,	,	PUNCT
ihlr-16500	567	7	supra	supra	PROPN
ihlr-16500	567	8	.	.	PUNCT
ihlr-16500	568	1	2007	2007	NUM
ihlr-16500	568	2	]	]	PUNCT
ihlr-16500	569	1	puli.jng	puli.jng	NOUN
ihlr-16500	569	2	a	a	DET
ihlr-16500	569	3	blockbuster	blockbuster	ADJ
ihlr-16500	569	4	drug	drug	NOUN
ihlr-16500	569	5	off	off	ADP
ihlr-16500	569	6	the	the	DET
ihlr-16500	569	7	market	market	NOUN
ihlr-16500	569	8	141	141	NUM
ihlr-16500	569	9	whether	whether	SCONJ
ihlr-16500	569	10	the	the	DET
ihlr-16500	569	11	chances	chance	NOUN
ihlr-16500	569	12	of	of	ADP
ihlr-16500	569	13	being	be	AUX
ihlr-16500	569	14	hanned	hanne	VERB
ihlr-16500	569	15	by	by	ADP
ihlr-16500	569	16	a	a	DET
ihlr-16500	569	17	side	side	ADJ
ihlr-16500	569	18	effect	effect	NOUN
ihlr-16500	569	19	of	of	ADP
ihlr-16500	569	20	a	a	DET
ihlr-16500	569	21	withdrawn	withdraw	VERB
ihlr-16500	569	22	drug	drug	NOUN
ihlr-16500	569	23	out­	out­	NOUN
ihlr-16500	569	24	weigh	weigh	VERB
ihlr-16500	569	25	the	the	DET
ihlr-16500	569	26	increased	increase	VERB
ihlr-16500	569	27	quality	quality	NOUN
ihlr-16500	569	28	oflife	oflife	NOUN
ihlr-16500	569	29	associated	associate	VERB
ihlr-16500	569	30	with	with	ADP
ihlr-16500	569	31	using	use	VERB
ihlr-16500	569	32	the	the	DET
ihlr-16500	569	33	withdrawn	withdraw	VERB
ihlr-16500	569	34	block­	block­	NOUN
ihlr-16500	569	35	buster	buster	VERB
ihlr-16500	569	36	drug.144	drug.144	PROPN
ihlr-16500	569	37	c.	c.	NOUN
ihlr-16500	569	38	balancing	balance	VERB
ihlr-16500	569	39	ethical	ethical	ADJ
ihlr-16500	569	40	considerations	consideration	NOUN
ihlr-16500	569	41	with	with	ADP
ihlr-16500	569	42	the	the	DET
ihlr-16500	569	43	company	company	NOUN
ihlr-16500	569	44	's	's	PART
ihlr-16500	569	45	stated	state	VERB
ihlr-16500	569	46	goal	goal	NOUN
ihlr-16500	569	47	of	of	ADP
ihlr-16500	569	48	profitability	profitability	NOUN
ihlr-16500	569	49	most	most	ADJ
ihlr-16500	569	50	phannaceutical	phannaceutical	ADJ
ihlr-16500	569	51	companies	company	NOUN
ihlr-16500	569	52	must	must	AUX
ihlr-16500	569	53	consider	consider	VERB
ihlr-16500	569	54	the	the	DET
ihlr-16500	569	55	ethics	ethic	NOUN
ihlr-16500	569	56	of	of	ADP
ihlr-16500	569	57	putting	put	VERB
ihlr-16500	569	58	profits	profit	NOUN
ihlr-16500	569	59	before	before	ADP
ihlr-16500	569	60	patient	patient	ADJ
ihlr-16500	569	61	safety	safety	NOUN
ihlr-16500	569	62	.	.	PUNCT
ihlr-16500	570	1	in	in	ADP
ihlr-16500	570	2	the	the	DET
ihlr-16500	570	3	1950s	1950s	NUM
ihlr-16500	570	4	,	,	PUNCT
ihlr-16500	570	5	merck	merck	PROPN
ihlr-16500	570	6	patriarch	patriarch	PROPN
ihlr-16500	570	7	and	and	CCONJ
ihlr-16500	570	8	president	president	PROPN
ihlr-16500	570	9	george	george	PROPN
ihlr-16500	570	10	merck	merck	PROPN
ihlr-16500	570	11	remarked	remark	VERB
ihlr-16500	570	12	,	,	PUNCT
ihlr-16500	570	13	"	"	PUNCT
ihlr-16500	570	14	medicine	medicine	NOUN
ihlr-16500	570	15	is	be	AUX
ihlr-16500	570	16	for	for	ADP
ihlr-16500	570	17	the	the	DET
ihlr-16500	570	18	people	people	NOUN
ihlr-16500	570	19	.	.	PUNCT
ihlr-16500	571	1	it	it	PRON
ihlr-16500	571	2	is	be	AUX
ihlr-16500	571	3	not	not	PART
ihlr-16500	571	4	for	for	ADP
ihlr-16500	571	5	profits	profit	NOUN
ihlr-16500	571	6	.	.	PUNCT
ihlr-16500	572	1	"	"	PUNCT
ihlr-16500	572	2	145	145	NUM
ihlr-16500	572	3	in	in	ADP
ihlr-16500	572	4	recent	recent	ADJ
ihlr-16500	572	5	months	month	NOUN
ihlr-16500	572	6	,	,	PUNCT
ihlr-16500	572	7	his	his	PRON
ihlr-16500	572	8	company	company	NOUN
ihlr-16500	572	9	has	have	AUX
ihlr-16500	572	10	been	be	AUX
ihlr-16500	572	11	criticized	criticize	VERB
ihlr-16500	572	12	for	for	ADP
ihlr-16500	572	13	hiding	hide	VERB
ihlr-16500	572	14	the	the	DET
ihlr-16500	572	15	problems	problem	NOUN
ihlr-16500	572	16	associated	associate	VERB
ihlr-16500	572	17	with	with	ADP
ihlr-16500	572	18	vioxx	vioxx	NOUN
ihlr-16500	572	19	in	in	ADP
ihlr-16500	572	20	order	order	NOUN
ihlr-16500	572	21	to	to	PART
ihlr-16500	572	22	increase	increase	VERB
ihlr-16500	572	23	profits.146	profits.146	NOUN
ihlr-16500	572	24	although	although	SCONJ
ihlr-16500	572	25	such	such	ADJ
ihlr-16500	572	26	allegations	allegation	NOUN
ihlr-16500	572	27	have	have	AUX
ihlr-16500	572	28	not	not	PART
ihlr-16500	572	29	been	be	AUX
ihlr-16500	572	30	substantially	substantially	ADV
ihlr-16500	572	31	proven	prove	VERB
ihlr-16500	572	32	,	,	PUNCT
ihlr-16500	572	33	companies	company	NOUN
ihlr-16500	572	34	that	that	PRON
ihlr-16500	572	35	fail	fail	VERB
ihlr-16500	572	36	to	to	PART
ihlr-16500	572	37	consider	consider	VERB
ihlr-16500	572	38	the	the	DET
ihlr-16500	572	39	plight	plight	NOUN
ihlr-16500	572	40	of	of	ADP
ihlr-16500	572	41	patients	patient	NOUN
ihlr-16500	572	42	and	and	CCONJ
ihlr-16500	572	43	their	their	PRON
ihlr-16500	572	44	families	family	NOUN
ihlr-16500	572	45	are	be	AUX
ihlr-16500	572	46	likely	likely	ADJ
ihlr-16500	572	47	to	to	PART
ihlr-16500	572	48	suffer	suffer	VERB
ihlr-16500	572	49	from	from	ADP
ihlr-16500	572	50	negative	negative	ADJ
ihlr-16500	572	51	public	public	ADJ
ihlr-16500	572	52	perception	perception	NOUN
ihlr-16500	572	53	that	that	PRON
ihlr-16500	572	54	may	may	AUX
ihlr-16500	572	55	affect	affect	VERB
ihlr-16500	572	56	the	the	DET
ihlr-16500	572	57	company	company	NOUN
ihlr-16500	572	58	for	for	ADP
ihlr-16500	572	59	years	year	NOUN
ihlr-16500	572	60	to	to	PART
ihlr-16500	572	61	follow	follow	VERB
ihlr-16500	572	62	.	.	PUNCT
ihlr-16500	573	1	in	in	ADP
ihlr-16500	573	2	addition	addition	NOUN
ihlr-16500	573	3	,	,	PUNCT
ihlr-16500	573	4	such	such	ADJ
ihlr-16500	573	5	companies	company	NOUN
ihlr-16500	573	6	would	would	AUX
ihlr-16500	573	7	likely	likely	ADV
ihlr-16500	573	8	face	face	VERB
ihlr-16500	573	9	endless	endless	ADJ
ihlr-16500	573	10	litigation	litigation	NOUN
ihlr-16500	573	11	and	and	CCONJ
ihlr-16500	573	12	claims	claim	NOUN
ihlr-16500	573	13	of	of	ADP
ihlr-16500	573	14	negligence	negligence	NOUN
ihlr-16500	573	15	,	,	PUNCT
ihlr-16500	573	16	which	which	PRON
ihlr-16500	573	17	could	could	AUX
ihlr-16500	573	18	continue	continue	VERB
ihlr-16500	573	19	for	for	ADP
ihlr-16500	573	20	a	a	DET
ihlr-16500	573	21	seemingly	seemingly	ADV
ihlr-16500	573	22	indefinite	indefinite	ADJ
ihlr-16500	573	23	period	period	NOUN
ihlr-16500	573	24	of	of	ADP
ihlr-16500	573	25	time	time	NOUN
ihlr-16500	573	26	.	.	PUNCT
ihlr-16500	574	1	when	when	SCONJ
ihlr-16500	574	2	making	make	VERB
ihlr-16500	574	3	the	the	DET
ihlr-16500	574	4	decision	decision	NOUN
ihlr-16500	574	5	to	to	PART
ihlr-16500	574	6	withdraw	withdraw	VERB
ihlr-16500	574	7	a	a	DET
ihlr-16500	574	8	drug	drug	NOUN
ihlr-16500	574	9	from	from	ADP
ihlr-16500	574	10	the	the	DET
ihlr-16500	574	11	market	market	NOUN
ihlr-16500	574	12	,	,	PUNCT
ihlr-16500	574	13	a	a	DET
ihlr-16500	574	14	phanna­	phanna­	NOUN
ihlr-16500	574	15	ceutical	ceutical	ADJ
ihlr-16500	574	16	company	company	NOUN
ihlr-16500	574	17	must	must	AUX
ihlr-16500	574	18	first	first	ADV
ihlr-16500	574	19	consider	consider	VERB
ihlr-16500	574	20	the	the	DET
ihlr-16500	574	21	patient	patient	NOUN
ihlr-16500	574	22	.	.	PUNCT
ihlr-16500	575	1	often	often	ADV
ihlr-16500	575	2	,	,	PUNCT
ihlr-16500	575	3	a	a	DET
ihlr-16500	575	4	company	company	NOUN
ihlr-16500	575	5	is	be	AUX
ihlr-16500	575	6	forced	force	VERB
ihlr-16500	575	7	to	to	PART
ihlr-16500	575	8	confront	confront	VERB
ihlr-16500	575	9	the	the	DET
ihlr-16500	575	10	families	family	NOUN
ihlr-16500	575	11	of	of	ADP
ihlr-16500	575	12	the	the	DET
ihlr-16500	575	13	patients	patient	NOUN
ihlr-16500	575	14	who	who	PRON
ihlr-16500	575	15	died	die	VERB
ihlr-16500	575	16	or	or	CCONJ
ihlr-16500	575	17	were	be	AUX
ihlr-16500	575	18	injured	injure	VERB
ihlr-16500	575	19	as	as	ADP
ihlr-16500	575	20	a	a	DET
ihlr-16500	575	21	result	result	NOUN
ihlr-16500	575	22	of	of	ADP
ihlr-16500	575	23	us­	us­	NOUN
ihlr-16500	575	24	ing	e	VERB
ihlr-16500	575	25	the	the	DET
ihlr-16500	575	26	blockbuster	blockbuster	NOUN
ihlr-16500	575	27	drug	drug	NOUN
ihlr-16500	575	28	in	in	ADP
ihlr-16500	575	29	question	question	NOUN
ihlr-16500	575	30	.	.	PUNCT
ihlr-16500	576	1	but	but	CCONJ
ihlr-16500	576	2	the	the	DET
ihlr-16500	576	3	company	company	NOUN
ihlr-16500	576	4	must	must	AUX
ihlr-16500	576	5	also	also	ADV
ihlr-16500	576	6	consider	consider	VERB
ihlr-16500	576	7	the	the	DET
ihlr-16500	576	8	plight	plight	NOUN
ihlr-16500	576	9	of	of	ADP
ihlr-16500	576	10	those	those	DET
ihlr-16500	576	11	patients	patient	NOUN
ihlr-16500	576	12	who	who	PRON
ihlr-16500	576	13	have	have	AUX
ihlr-16500	576	14	not	not	PART
ihlr-16500	576	15	experienced	experience	VERB
ihlr-16500	576	16	side	side	NOUN
ihlr-16500	576	17	effects	effect	NOUN
ihlr-16500	576	18	in	in	ADP
ihlr-16500	576	19	connection	connection	NOUN
ihlr-16500	576	20	with	with	ADP
ihlr-16500	576	21	use	use	NOUN
ihlr-16500	576	22	of	of	ADP
ihlr-16500	576	23	the	the	DET
ihlr-16500	576	24	drug	drug	NOUN
ihlr-16500	576	25	.	.	PUNCT
ihlr-16500	577	1	such	such	ADJ
ihlr-16500	577	2	patients	patient	NOUN
ihlr-16500	577	3	may	may	AUX
ihlr-16500	577	4	be	be	AUX
ihlr-16500	577	5	banned	ban	VERB
ihlr-16500	577	6	as	as	ADP
ihlr-16500	577	7	a	a	DET
ihlr-16500	577	8	result	result	NOUN
ihlr-16500	577	9	of	of	ADP
ihlr-16500	577	10	the	the	DET
ihlr-16500	577	11	drug	drug	NOUN
ihlr-16500	577	12	being	be	AUX
ihlr-16500	577	13	withdrawn	withdraw	VERB
ihlr-16500	577	14	from	from	ADP
ihlr-16500	577	15	the	the	DET
ihlr-16500	577	16	market	market	NOUN
ihlr-16500	577	17	,	,	PUNCT
ihlr-16500	577	18	particularly	particularly	ADV
ihlr-16500	577	19	if	if	SCONJ
ihlr-16500	577	20	there	there	PRON
ihlr-16500	577	21	is	be	VERB
ihlr-16500	577	22	a	a	DET
ihlr-16500	577	23	lack	lack	NOUN
ihlr-16500	577	24	of	of	ADP
ihlr-16500	577	25	efficacious	efficacious	ADJ
ihlr-16500	577	26	substi­	substi­	NOUN
ihlr-16500	577	27	tutes	tute	NOUN
ihlr-16500	577	28	.	.	PUNCT
ihlr-16500	578	1	therefore	therefore	ADV
ihlr-16500	578	2	,	,	PUNCT
ihlr-16500	578	3	the	the	DET
ihlr-16500	578	4	ethical	ethical	ADJ
ihlr-16500	578	5	ramifications	ramification	NOUN
ihlr-16500	578	6	of	of	ADP
ihlr-16500	578	7	withdrawing	withdraw	VERB
ihlr-16500	578	8	a	a	DET
ihlr-16500	578	9	blockbuster	blockbuster	ADJ
ihlr-16500	578	10	drug	drug	NOUN
ihlr-16500	578	11	from	from	ADP
ihlr-16500	578	12	the	the	DET
ihlr-16500	578	13	market	market	NOUN
ihlr-16500	578	14	are	be	AUX
ihlr-16500	578	15	numerous	numerous	ADJ
ihlr-16500	578	16	and	and	CCONJ
ihlr-16500	578	17	affect	affect	VERB
ihlr-16500	578	18	all	all	DET
ihlr-16500	578	19	parties	party	NOUN
ihlr-16500	578	20	involved	involve	VERB
ihlr-16500	578	21	.	.	PUNCT
ihlr-16500	579	1	vii	vii	PROPN
ihlr-16500	579	2	.	.	PUNCT
ihlr-16500	579	3	considerations	consideration	NOUN
ihlr-16500	579	4	of	of	ADP
ihlr-16500	579	5	culpabll	culpabll	NOUN
ihlr-16500	579	6	..	..	PUNCT
ihlr-16500	579	7	l'iy	l'iy	NOUN
ihlr-16500	579	8	in	in	ADP
ihlr-16500	579	9	pulling	pull	VERB
ihlr-16500	579	10	a	a	DET
ihlr-16500	579	11	drug	drug	NOUN
ihlr-16500	579	12	off	off	ADP
ihlr-16500	579	13	the	the	DET
ihlr-16500	579	14	market	market	NOUN
ihlr-16500	579	15	the	the	DET
ihlr-16500	579	16	question	question	NOUN
ihlr-16500	579	17	of	of	ADP
ihlr-16500	579	18	who	who	PRON
ihlr-16500	579	19	is	be	AUX
ihlr-16500	579	20	at	at	ADP
ihlr-16500	579	21	fault	fault	NOUN
ihlr-16500	579	22	when	when	SCONJ
ihlr-16500	579	23	a	a	DET
ihlr-16500	579	24	drug	drug	NOUN
ihlr-16500	579	25	is	be	AUX
ihlr-16500	579	26	withdrawn	withdraw	VERB
ihlr-16500	579	27	from	from	ADP
ihlr-16500	579	28	the	the	DET
ihlr-16500	579	29	market	market	NOUN
ihlr-16500	579	30	is	be	AUX
ihlr-16500	579	31	not	not	PART
ihlr-16500	579	32	easily	easily	ADV
ihlr-16500	579	33	discernible	discernible	ADJ
ihlr-16500	579	34	,	,	PUNCT
ihlr-16500	579	35	even	even	ADV
ihlr-16500	579	36	though	though	SCONJ
ihlr-16500	579	37	the	the	DET
ihlr-16500	579	38	parties	party	NOUN
ihlr-16500	579	39	who	who	PRON
ihlr-16500	579	40	are	be	AUX
ihlr-16500	579	41	responsible	responsible	ADJ
ihlr-16500	579	42	can	can	AUX
ihlr-16500	579	43	be	be	AUX
ihlr-16500	579	44	easily	easily	ADV
ihlr-16500	579	45	identified	identify	VERB
ihlr-16500	579	46	.	.	PUNCT
ihlr-16500	580	1	most	most	ADJ
ihlr-16500	580	2	of	of	ADP
ihlr-16500	580	3	the	the	DET
ihlr-16500	580	4	time	time	NOUN
ihlr-16500	580	5	,	,	PUNCT
ihlr-16500	580	6	the	the	DET
ihlr-16500	580	7	party	party	NOUN
ihlr-16500	580	8	held	hold	VERB
ihlr-16500	580	9	responsible	responsible	ADJ
ihlr-16500	580	10	is	be	AUX
ihlr-16500	580	11	the	the	DET
ihlr-16500	580	12	most	most	ADV
ihlr-16500	580	13	visible	visible	ADJ
ihlr-16500	580	14	party	party	NOUN
ihlr-16500	580	15	,	,	PUNCT
ihlr-16500	580	16	usually	usually	ADV
ihlr-16500	580	17	the	the	DET
ihlr-16500	580	18	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	580	19	company	company	NOUN
ihlr-16500	580	20	that	that	PRON
ihlr-16500	580	21	developed	develop	VERB
ihlr-16500	580	22	and	and	CCONJ
ihlr-16500	580	23	marketed	market	VERB
ihlr-16500	580	24	the	the	DET
ihlr-16500	580	25	failed	fail	VERB
ihlr-16500	580	26	product	product	NOUN
ihlr-16500	580	27	.	.	PUNCT
ihlr-16500	581	1	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	581	2	companies	company	NOUN
ihlr-16500	581	3	,	,	PUNCT
ihlr-16500	581	4	however	however	ADV
ihlr-16500	581	5	,	,	PUNCT
ihlr-16500	581	6	are	be	AUX
ihlr-16500	581	7	large	large	ADJ
ihlr-16500	581	8	conglomerates	conglomerate	NOUN
ihlr-16500	581	9	with	with	ADP
ihlr-16500	581	10	multi	multi	ADJ
ihlr-16500	581	11	-	-	ADJ
ihlr-16500	581	12	tiered	tiered	ADJ
ihlr-16500	581	13	management	management	NOUN
ihlr-16500	581	14	cotntn\ttees	cotntn\ttee	NOUN
ihlr-16500	581	15	and	and	CCONJ
ihlr-16500	581	16	divisions	division	NOUN
ihlr-16500	581	17	.	.	PUNCT
ihlr-16500	582	1	as	as	ADP
ihlr-16500	582	2	a	a	DET
ihlr-16500	582	3	result	result	NOUN
ihlr-16500	582	4	,	,	PUNCT
ihlr-16500	582	5	assigning	assign	VERB
ihlr-16500	582	6	the	the	DET
ihlr-16500	582	7	blame	blame	NOUN
ihlr-16500	582	8	to	to	ADP
ihlr-16500	582	9	a	a	DET
ihlr-16500	582	10	particular	particular	ADJ
ihlr-16500	582	11	individual	individual	NOUN
ihlr-16500	582	12	or	or	CCONJ
ihlr-16500	582	13	division	division	NOUN
ihlr-16500	582	14	of	of	ADP
ihlr-16500	582	15	the	the	DET
ihlr-16500	582	16	com144	com144	PROPN
ihlr-16500	582	17	see	see	VERB
ihlr-16500	582	18	vioxx	vioxx	NOUN
ihlr-16500	582	19	could	could	AUX
ihlr-16500	582	20	be	be	AUX
ihlr-16500	582	21	sold	sell	VERB
ihlr-16500	582	22	again	again	ADV
ihlr-16500	582	23	,	,	PUNCT
ihlr-16500	582	24	supra	supra	PROPN
ihlr-16500	582	25	note	note	VERB
ihlr-16500	582	26	143	143	NUM
ihlr-16500	582	27	.	.	PUNCT
ihlr-16500	582	28	145	145	NUM
ihlr-16500	583	1	raymond	raymond	PROPN
ihlr-16500	583	2	v.	v.	PROPN
ihlr-16500	583	3	gilmartin	gilmartin	PROPN
ihlr-16500	583	4	,	,	PUNCT
ihlr-16500	583	5	chairman	chairman	NOUN
ihlr-16500	583	6	.	.	PUNCT
ihlr-16500	584	1	president	president	PROPN
ihlr-16500	584	2	,	,	PUNCT
ihlr-16500	584	3	and	and	CCONJ
ihlr-16500	584	4	chiefexecutive	chiefexecutive	ADJ
ihlr-16500	584	5	officer	officer	NOUN
ihlr-16500	584	6	,	,	PUNCT
ihlr-16500	584	7	merck	merck	PROPN
ihlr-16500	584	8	&	&	CCONJ
ihlr-16500	584	9	co.	co.	PROPN
ihlr-16500	584	10	inc	inc	PROPN
ihlr-16500	584	11	.	.	PROPN
ihlr-16500	584	12	,	,	PUNCT
ihlr-16500	584	13	remarks	remark	NOUN
ihlr-16500	584	14	of	of	ADP
ihlr-16500	584	15	raymond	raymond	PROPN
ihlr-16500	584	16	v.	v.	PROPN
ihlr-16500	584	17	gilmartin	gilmartin	PROPN
ihlr-16500	584	18	,	,	PUNCT
ihlr-16500	584	19	chairman	chairman	NOUN
ihlr-16500	584	20	,	,	PUNCT
ihlr-16500	584	21	president	president	NOUN
ihlr-16500	584	22	,	,	PUNCT
ihlr-16500	584	23	and	and	CCONJ
ihlr-16500	584	24	chiefexecutive	chiefexecutive	ADJ
ihlr-16500	584	25	officer	officer	NOUN
ihlr-16500	584	26	,	,	PUNCT
ihlr-16500	584	27	merck	merck	PROPN
ihlr-16500	584	28	&	&	CCONJ
ihlr-16500	584	29	co.	co.	PROPN
ihlr-16500	584	30	,	,	PUNCT
ihlr-16500	584	31	inc	inc	PROPN
ihlr-16500	584	32	.	.	PROPN
ihlr-16500	585	1	at	at	ADP
ihlr-16500	585	2	town	town	NOUN
ihlr-16500	585	3	hall	hall	PROPN
ihlr-16500	585	4	los	los	PROPN
ihlr-16500	585	5	angeles	angeles	PROPN
ihlr-16500	585	6	,	,	PUNCT
ihlr-16500	585	7	july	july	PROPN
ihlr-16500	585	8	29	29	NUM
ihlr-16500	585	9	,	,	PUNCT
ihlr-16500	585	10	2004	2004	NUM
ihlr-16500	585	11	,	,	PUNCT
ihlr-16500	585	12	available	available	ADJ
ihlr-16500	585	13	at	at	ADP
ihlr-16500	585	14	http://www.merck	http://www.merck	PROPN
ihlr-16500	585	15	.com	.com	PROPN
ihlr-16500	585	16	/	/	SYM
ihlr-16500	585	17	newsroom	newsroom	NOUN
ihlr-16500	585	18	/	/	SYM
ihlr-16500	585	19	executive	executive	NOUN
ihlr-16500	585	20	_	_	PUNCT
ihlr-16500	585	21	speeches/072904.html	speeches/072904.html	NOUN
ihlr-16500	585	22	.	.	PUNCT
ihlr-16500	586	1	146	146	NUM
ihlr-16500	586	2	see	see	VERB
ihlr-16500	586	3	medical	medical	ADJ
ihlr-16500	586	4	journal	journal	PROPN
ihlr-16500	586	5	revelation	revelation	NOUN
ihlr-16500	586	6	that	that	SCONJ
ihlr-16500	586	7	study	study	NOUN
ihlr-16500	586	8	omitted	omit	VERB
ihlr-16500	586	9	3	3	NUM
ihlr-16500	586	10	deaths	death	NOUN
ihlr-16500	586	11	prompts	prompt	NOUN
ihlr-16500	586	12	call	call	VERB
ihlr-16500	586	13	for	for	ADP
ihlr-16500	586	14	mzs­	mzs­	ADJ
ihlr-16500	586	15	trial	trial	NOUN
ihlr-16500	586	16	,	,	PUNCT
ihlr-16500	586	17	mealey	mealey	PROPN
ihlr-16500	586	18	's	's	PART
ihlr-16500	586	19	lmo	lmo	PROPN
ihlr-16500	586	20	.	.	PUNCT
ihlr-16500	586	21	rep	rep	PROPN
ihlr-16500	586	22	.	.	PROPN
ihlr-16500	586	23	arthritis	arthritis	NOUN
ihlr-16500	586	24	drugs	drug	NOUN
ihlr-16500	586	25	,	,	PUNCT
ihlr-16500	586	26	dec	dec	PROPN
ihlr-16500	586	27	.	.	PROPN
ihlr-16500	586	28	1	1	NUM
ihlr-16500	586	29	,	,	PUNCT
ihlr-16500	586	30	2005	2005	NUM
ihlr-16500	586	31	,	,	PUNCT
ihlr-16500	586	32	at	at	ADP
ihlr-16500	586	33	5	5	NUM
ihlr-16500	586	34	,	,	PUNCT
ihlr-16500	586	35	6	6	NUM
ihlr-16500	586	36	.	.	NOUN
ihlr-16500	586	37	142	142	NUM
ihlr-16500	586	38	thidmnah	thidmnah	NOUN
ihlr-16500	586	39	~	~	SYM
ihlr-16500	586	40	thlawrevmw	thlawrevmw	NOUN
ihlr-16500	586	41	[	[	X
ihlr-16500	586	42	vol	vol	NOUN
ihlr-16500	586	43	.	.	PUNCT
ihlr-16500	587	1	4:115	4:115	NUM
ihlr-16500	587	2	pany	pany	NOUN
ihlr-16500	587	3	can	can	AUX
ihlr-16500	587	4	be	be	AUX
ihlr-16500	587	5	almost	almost	ADV
ihlr-16500	587	6	impossible	impossible	ADJ
ihlr-16500	587	7	and	and	CCONJ
ihlr-16500	587	8	requires	require	VERB
ihlr-16500	587	9	proof	proof	NOUN
ihlr-16500	587	10	that	that	SCONJ
ihlr-16500	587	11	certain	certain	ADJ
ihlr-16500	587	12	individuals	individual	NOUN
ihlr-16500	587	13	had	have	AUX
ihlr-16500	587	14	knowledge	knowledge	NOUN
ihlr-16500	587	15	of	of	ADP
ihlr-16500	587	16	the	the	DET
ihlr-16500	587	17	drug	drug	NOUN
ihlr-16500	587	18	's	's	PART
ihlr-16500	587	19	safety	safety	NOUN
ihlr-16500	587	20	failures	failure	NOUN
ihlr-16500	587	21	and	and	CCONJ
ihlr-16500	587	22	subsequently	subsequently	ADV
ihlr-16500	587	23	failed	fail	VERB
ihlr-16500	587	24	to	to	PART
ihlr-16500	587	25	report	report	VERB
ihlr-16500	587	26	them	they	PRON
ihlr-16500	587	27	.	.	PUNCT
ihlr-16500	588	1	a.	a.	NOUN
ihlr-16500	588	2	to	to	ADP
ihlr-16500	588	3	what	what	DET
ihlr-16500	588	4	extent	extent	NOUN
ihlr-16500	588	5	is	be	AUX
ihlr-16500	588	6	the	the	DET
ihlr-16500	588	7	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	588	8	company	company	NOUN
ihlr-16500	588	9	at	at	ADP
ihlr-16500	588	10	fault	fault	NOUN
ihlr-16500	588	11	?	?	PUNCT
ihlr-16500	589	1	the	the	DET
ihlr-16500	589	2	proof	proof	NOUN
ihlr-16500	589	3	required	require	VERB
ihlr-16500	589	4	to	to	PART
ihlr-16500	589	5	hold	hold	VERB
ihlr-16500	589	6	a	a	DET
ihlr-16500	589	7	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	589	8	company	company	NOUN
ihlr-16500	589	9	liable	liable	ADJ
ihlr-16500	589	10	for	for	ADP
ihlr-16500	589	11	marketing	marketing	NOUN
ihlr-16500	589	12	and	and	CCONJ
ihlr-16500	589	13	distributing	distribute	VERB
ihlr-16500	589	14	an	an	DET
ihlr-16500	589	15	unsafe	unsafe	ADJ
ihlr-16500	589	16	product	product	NOUN
ihlr-16500	589	17	is	be	AUX
ihlr-16500	589	18	difficult	difficult	ADJ
ihlr-16500	589	19	to	to	PART
ihlr-16500	589	20	produce	produce	VERB
ihlr-16500	589	21	.	.	PUNCT
ihlr-16500	590	1	after	after	SCONJ
ihlr-16500	590	2	a	a	DET
ihlr-16500	590	3	drug	drug	NOUN
ihlr-16500	590	4	has	have	AUX
ihlr-16500	590	5	been	be	AUX
ihlr-16500	590	6	pulled	pull	VERB
ihlr-16500	590	7	off	off	ADP
ihlr-16500	590	8	the	the	DET
ihlr-16500	590	9	market	market	NOUN
ihlr-16500	590	10	,	,	PUNCT
ihlr-16500	590	11	both	both	CCONJ
ihlr-16500	590	12	the	the	DET
ihlr-16500	590	13	fda	fda	PROPN
ihlr-16500	590	14	and	and	CCONJ
ihlr-16500	590	15	the	the	DET
ihlr-16500	590	16	respective	respective	ADJ
ihlr-16500	590	17	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	590	18	com­	com­	NOUN
ihlr-16500	590	19	pany	pany	NOUN
ihlr-16500	590	20	incur	incur	VERB
ihlr-16500	590	21	significant	significant	ADJ
ihlr-16500	590	22	expenses	expense	NOUN
ihlr-16500	590	23	in	in	ADP
ihlr-16500	590	24	order	order	NOUN
ihlr-16500	590	25	to	to	PART
ihlr-16500	590	26	investigate	investigate	VERB
ihlr-16500	590	27	how	how	SCONJ
ihlr-16500	590	28	such	such	DET
ihlr-16500	590	29	a	a	DET
ihlr-16500	590	30	safety	safety	NOUN
ihlr-16500	590	31	failure	failure	NOUN
ihlr-16500	590	32	transpired	transpire	VERB
ihlr-16500	590	33	.	.	PUNCT
ihlr-16500	591	1	such	such	ADJ
ihlr-16500	591	2	investigations	investigation	NOUN
ihlr-16500	591	3	can	can	AUX
ihlr-16500	591	4	take	take	VERB
ihlr-16500	591	5	years	year	NOUN
ihlr-16500	591	6	and	and	CCONJ
ihlr-16500	591	7	may	may	AUX
ihlr-16500	591	8	cost	cost	VERB
ihlr-16500	591	9	millions	million	NOUN
ihlr-16500	591	10	of	of	ADP
ihlr-16500	591	11	dollars	dollar	NOUN
ihlr-16500	591	12	;	;	PUNCT
ihlr-16500	591	13	nonetheless	nonetheless	ADV
ihlr-16500	591	14	,	,	PUNCT
ihlr-16500	591	15	they	they	PRON
ihlr-16500	591	16	produce	produce	VERB
ihlr-16500	591	17	valuable	valuable	ADJ
ihlr-16500	591	18	evidence	evidence	NOUN
ihlr-16500	591	19	-	-	PUNCT
ihlr-16500	591	20	based	base	VERB
ihlr-16500	591	21	answers	answer	NOUN
ihlr-16500	591	22	regarding	regard	VERB
ihlr-16500	591	23	the	the	DET
ihlr-16500	591	24	drug	drug	NOUN
ihlr-16500	591	25	's	's	PART
ihlr-16500	591	26	failure	failure	NOUN
ihlr-16500	591	27	.	.	PUNCT
ihlr-16500	592	1	any	any	DET
ihlr-16500	592	2	information	information	NOUN
ihlr-16500	592	3	regarding	regard	VERB
ihlr-16500	592	4	management	management	NOUN
ihlr-16500	592	5	malfeasance	malfeasance	NOUN
ihlr-16500	592	6	and	and	CCONJ
ihlr-16500	592	7	a	a	DET
ihlr-16500	592	8	fail­	fail­	PROPN
ihlr-16500	592	9	ure	ure	NOUN
ihlr-16500	592	10	to	to	PART
ihlr-16500	592	11	report	report	VERB
ihlr-16500	592	12	important	important	ADJ
ihlr-16500	592	13	safety	safety	NOUN
ihlr-16500	592	14	information	information	NOUN
ihlr-16500	592	15	is	be	AUX
ihlr-16500	592	16	not	not	PART
ihlr-16500	592	17	easily	easily	ADV
ihlr-16500	592	18	discoverable	discoverable	ADJ
ihlr-16500	592	19	.	.	PUNCT
ihlr-16500	593	1	therefore	therefore	ADV
ihlr-16500	593	2	,	,	PUNCT
ihlr-16500	593	3	even	even	ADV
ihlr-16500	593	4	though	though	SCONJ
ihlr-16500	593	5	a	a	DET
ihlr-16500	593	6	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	593	7	company	company	NOUN
ihlr-16500	593	8	may	may	AUX
ihlr-16500	593	9	be	be	AUX
ihlr-16500	593	10	held	hold	VERB
ihlr-16500	593	11	liable	liable	ADJ
ihlr-16500	593	12	for	for	ADP
ihlr-16500	593	13	continuing	continue	VERB
ihlr-16500	593	14	to	to	PART
ihlr-16500	593	15	mass	mass	VERB
ihlr-16500	593	16	market	market	NOUN
ihlr-16500	593	17	and	and	CCONJ
ihlr-16500	593	18	produce	produce	VERB
ihlr-16500	593	19	an	an	DET
ihlr-16500	593	20	unsafe	unsafe	ADJ
ihlr-16500	593	21	product	product	NOUN
ihlr-16500	593	22	,	,	PUNCT
ihlr-16500	593	23	it	it	PRON
ihlr-16500	593	24	may	may	AUX
ihlr-16500	593	25	escape	escape	VERB
ihlr-16500	593	26	any	any	DET
ihlr-16500	593	27	punitive	punitive	ADJ
ihlr-16500	593	28	liability	liability	NOUN
ihlr-16500	593	29	because	because	SCONJ
ihlr-16500	593	30	the	the	DET
ihlr-16500	593	31	opposing	oppose	VERB
ihlr-16500	593	32	party	party	NOUN
ihlr-16500	593	33	will	will	AUX
ihlr-16500	593	34	likely	likely	ADV
ihlr-16500	593	35	be	be	AUX
ihlr-16500	593	36	unable	unable	ADJ
ihlr-16500	593	37	to	to	PART
ihlr-16500	593	38	produce	produce	VERB
ihlr-16500	593	39	sufficient	sufficient	ADJ
ihlr-16500	593	40	proof	proof	NOUN
ihlr-16500	593	41	that	that	SCONJ
ihlr-16500	593	42	the	the	DET
ihlr-16500	593	43	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	593	44	company	company	NOUN
ihlr-16500	593	45	's	's	PART
ihlr-16500	593	46	management	management	NOUN
ihlr-16500	593	47	knowingly	knowingly	ADV
ihlr-16500	593	48	and	and	CCONJ
ihlr-16500	593	49	intentionally	intentionally	ADV
ihlr-16500	593	50	pro­	pro­	VERB
ihlr-16500	593	51	duced	duce	VERB
ihlr-16500	593	52	the	the	DET
ihlr-16500	593	53	harmful	harmful	ADJ
ihlr-16500	593	54	drug	drug	NOUN
ihlr-16500	593	55	.	.	PUNCT
ihlr-16500	594	1	moreover	moreover	ADV
ihlr-16500	594	2	,	,	PUNCT
ihlr-16500	594	3	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	594	4	companies	company	NOUN
ihlr-16500	594	5	argue	argue	VERB
ihlr-16500	594	6	that	that	SCONJ
ihlr-16500	594	7	it	it	PRON
ihlr-16500	594	8	is	be	AUX
ihlr-16500	594	9	difficult	difficult	ADJ
ihlr-16500	594	10	to	to	PART
ihlr-16500	594	11	predict	predict	VERB
ihlr-16500	594	12	how	how	SCONJ
ihlr-16500	594	13	a	a	DET
ihlr-16500	594	14	patient	patient	NOUN
ihlr-16500	594	15	will	will	AUX
ihlr-16500	594	16	react	react	VERB
ihlr-16500	594	17	to	to	ADP
ihlr-16500	594	18	a	a	DET
ihlr-16500	594	19	drug	drug	NOUN
ihlr-16500	594	20	after	after	ADP
ihlr-16500	594	21	years	year	NOUN
ihlr-16500	594	22	of	of	ADP
ihlr-16500	594	23	concomitant	concomitant	ADJ
ihlr-16500	594	24	treatment	treatment	NOUN
ihlr-16500	594	25	with	with	ADP
ihlr-16500	594	26	other	other	ADJ
ihlr-16500	594	27	drugs	drug	NOUN
ihlr-16500	594	28	.	.	PUNCT
ihlr-16500	595	1	for	for	ADP
ihlr-16500	595	2	instance	instance	NOUN
ihlr-16500	595	3	,	,	PUNCT
ihlr-16500	595	4	most	most	ADJ
ihlr-16500	595	5	drugs	drug	NOUN
ihlr-16500	595	6	are	be	AUX
ihlr-16500	595	7	tested	test	VERB
ihlr-16500	595	8	under	under	ADP
ihlr-16500	595	9	rigid	rigid	ADJ
ihlr-16500	595	10	clinical	clinical	ADJ
ihlr-16500	595	11	conditions	condition	NOUN
ihlr-16500	595	12	.	.	PUNCT
ihlr-16500	596	1	when	when	SCONJ
ihlr-16500	596	2	placed	place	VERB
ihlr-16500	596	3	on	on	ADP
ihlr-16500	596	4	the	the	DET
ihlr-16500	596	5	market	market	NOUN
ihlr-16500	596	6	,	,	PUNCT
ihlr-16500	596	7	however	however	ADV
ihlr-16500	596	8	,	,	PUNCT
ihlr-16500	596	9	a	a	DET
ihlr-16500	596	10	patient	patient	NOUN
ihlr-16500	596	11	may	may	AUX
ihlr-16500	596	12	fail	fail	VERB
ihlr-16500	596	13	to	to	PART
ihlr-16500	596	14	read	read	VERB
ihlr-16500	596	15	the	the	DET
ihlr-16500	596	16	prescnbing	prescnbing	ADJ
ihlr-16500	596	17	information	information	NOUN
ihlr-16500	596	18	circular147	circular147	PROPN
ihlr-16500	596	19	carefully	carefully	ADV
ihlr-16500	596	20	.	.	PUNCT
ihlr-16500	597	1	often	often	ADV
ihlr-16500	597	2	times	time	NOUN
ihlr-16500	597	3	,	,	PUNCT
ihlr-16500	597	4	patients	patient	NOUN
ihlr-16500	597	5	ingest	ingest	VERB
ihlr-16500	597	6	a	a	DET
ihlr-16500	597	7	drug	drug	NOUN
ihlr-16500	597	8	concur­	concur­	ADV
ihlr-16500	597	9	rently	rently	ADV
ihlr-16500	597	10	with	with	ADP
ihlr-16500	597	11	other	other	ADJ
ihlr-16500	597	12	substances	substance	NOUN
ihlr-16500	597	13	,	,	PUNCT
ihlr-16500	597	14	such	such	ADJ
ihlr-16500	597	15	as	as	ADP
ihlr-16500	597	16	food	food	NOUN
ihlr-16500	597	17	,	,	PUNCT
ihlr-16500	597	18	drinks	drink	NOUN
ihlr-16500	597	19	,	,	PUNCT
ihlr-16500	597	20	or	or	CCONJ
ihlr-16500	597	21	other	other	ADJ
ihlr-16500	597	22	drugs	drug	NOUN
ihlr-16500	597	23	,	,	PUNCT
ihlr-16500	597	24	which	which	PRON
ihlr-16500	597	25	is	be	AUX
ihlr-16500	597	26	strictly	strictly	ADV
ihlr-16500	597	27	forbidden	forbid	VERB
ihlr-16500	597	28	in	in	ADP
ihlr-16500	597	29	the	the	DET
ihlr-16500	597	30	drug	drug	NOUN
ihlr-16500	597	31	's	's	PART
ihlr-16500	597	32	prescribing	prescribing	NOUN
ihlr-16500	597	33	information	information	NOUN
ihlr-16500	597	34	.	.	PUNCT
ihlr-16500	598	1	in	in	ADP
ihlr-16500	598	2	addition	addition	NOUN
ihlr-16500	598	3	,	,	PUNCT
ihlr-16500	598	4	most	most	ADJ
ihlr-16500	598	5	drugs	drug	NOUN
ihlr-16500	598	6	have	have	VERB
ihlr-16500	598	7	long	long	ADJ
ihlr-16500	598	8	half	half	ADJ
ihlr-16500	598	9	-	-	PUNCT
ihlr-16500	598	10	lives.148	lives.148	NOUN
ihlr-16500	598	11	as	as	ADP
ihlr-16500	598	12	a	a	DET
ihlr-16500	598	13	result	result	NOUN
ihlr-16500	598	14	,	,	PUNCT
ihlr-16500	598	15	a	a	DET
ihlr-16500	598	16	drug	drug	NOUN
ihlr-16500	598	17	can	can	AUX
ihlr-16500	598	18	be	be	AUX
ihlr-16500	598	19	present	present	ADJ
ihlr-16500	598	20	in	in	ADP
ihlr-16500	598	21	a	a	DET
ihlr-16500	598	22	patient	patient	NOUN
ihlr-16500	598	23	's	's	PART
ihlr-16500	598	24	body	body	NOUN
ihlr-16500	598	25	for	for	ADP
ihlr-16500	598	26	many	many	ADJ
ihlr-16500	598	27	years	year	NOUN
ihlr-16500	598	28	.	.	PUNCT
ihlr-16500	599	1	149	149	NUM
ihlr-16500	599	2	because	because	SCONJ
ihlr-16500	599	3	of	of	ADP
ihlr-16500	599	4	this	this	PRON
ihlr-16500	599	5	,	,	PUNCT
ihlr-16500	599	6	it	it	PRON
ihlr-16500	599	7	is	be	AUX
ihlr-16500	599	8	difficult	difficult	ADJ
ihlr-16500	599	9	to	to	PART
ihlr-16500	599	10	assess	assess	VERB
ihlr-16500	599	11	the	the	DET
ihlr-16500	599	12	long	long	ADJ
ihlr-16500	599	13	-	-	PUNCT
ihlr-16500	599	14	term	term	NOUN
ihlr-16500	599	15	effects	effect	NOUN
ihlr-16500	599	16	of	of	ADP
ihlr-16500	599	17	the	the	DET
ihlr-16500	599	18	drug	drug	NOUN
ihlr-16500	599	19	because	because	SCONJ
ihlr-16500	599	20	the	the	DET
ihlr-16500	599	21	drug	drug	NOUN
ihlr-16500	599	22	usually	usually	ADV
ihlr-16500	599	23	is	be	AUX
ihlr-16500	599	24	not	not	PART
ihlr-16500	599	25	tested	test	VERB
ihlr-16500	599	26	for	for	ADP
ihlr-16500	599	27	that	that	DET
ihlr-16500	599	28	length	length	NOUN
ihlr-16500	599	29	of	of	ADP
ihlr-16500	599	30	time	time	NOUN
ihlr-16500	599	31	during	during	ADP
ihlr-16500	599	32	147	147	NUM
ihlr-16500	599	33	a	a	DET
ihlr-16500	599	34	prescribing	prescribe	VERB
ihlr-16500	599	35	information	information	NOUN
ihlr-16500	599	36	circular	circular	NOUN
ihlr-16500	599	37	is	be	AUX
ihlr-16500	599	38	a	a	DET
ihlr-16500	599	39	sheet	sheet	NOUN
ihlr-16500	599	40	of	of	ADP
ihlr-16500	599	41	paper	paper	NOUN
ihlr-16500	599	42	that	that	PRON
ihlr-16500	599	43	is	be	AUX
ihlr-16500	599	44	included	include	VERB
ihlr-16500	599	45	when	when	SCONJ
ihlr-16500	599	46	a	a	DET
ihlr-16500	599	47	drug	drug	NOUN
ihlr-16500	599	48	is	be	AUX
ihlr-16500	599	49	prescribed	prescribe	VERB
ihlr-16500	599	50	to	to	ADP
ihlr-16500	599	51	a	a	DET
ihlr-16500	599	52	patient	patient	NOUN
ihlr-16500	599	53	and	and	CCONJ
ihlr-16500	599	54	is	be	AUX
ihlr-16500	599	55	required	require	VERB
ihlr-16500	599	56	to	to	PART
ihlr-16500	599	57	contain	contain	VERB
ihlr-16500	599	58	,	,	PUNCT
ihlr-16500	599	59	among	among	ADP
ihlr-16500	599	60	other	other	ADJ
ihlr-16500	599	61	requirements	requirement	NOUN
ihlr-16500	599	62	,	,	PUNCT
ihlr-16500	599	63	"	"	PUNCT
ihlr-16500	599	64	a	a	DET
ihlr-16500	599	65	summary	summary	NOUN
ihlr-16500	599	66	of	of	ADP
ihlr-16500	599	67	the	the	DET
ihlr-16500	599	68	essential	essential	ADJ
ihlr-16500	599	69	scientific	scientific	ADJ
ihlr-16500	599	70	information	information	NOUN
ihlr-16500	599	71	"	"	PUNCT
ihlr-16500	599	72	and	and	CCONJ
ihlr-16500	599	73	comprehensive	comprehensive	ADJ
ihlr-16500	599	74	prescribing	prescribing	NOUN
ihlr-16500	599	75	information	information	NOUN
ihlr-16500	599	76	.	.	PUNCT
ihlr-16500	600	1	labeling	labeling	NOUN
ihlr-16500	600	2	re­	re­	PROPN
ihlr-16500	600	3	quirements	quirement	NOUN
ihlr-16500	600	4	for	for	ADP
ihlr-16500	600	5	prescription	prescription	NOUN
ihlr-16500	600	6	drugs	drug	NOUN
ihlr-16500	600	7	and/or	and/or	CCONJ
ihlr-16500	600	8	insulin	insulin	NOUN
ihlr-16500	600	9	,	,	PUNCT
ihlr-16500	600	10	21	21	NUM
ihlr-16500	600	11	c.p.r	c.p.r	NOUN
ihlr-16500	600	12	.	.	PUNCT
ihlr-16500	601	1	§	§	PROPN
ihlr-16500	601	2	§	§	PROPN
ihlr-16500	601	3	201.56	201.56	NUM
ihlr-16500	601	4	to	to	ADP
ihlr-16500	601	5	201.57	201.57	NUM
ihlr-16500	601	6	(	(	PUNCT
ihlr-16500	601	7	2006	2006	NUM
ihlr-16500	601	8	)	)	PUNCT
ihlr-16500	601	9	.	.	PUNCT
ihlr-16500	602	1	it	it	PRON
ihlr-16500	602	2	also	also	ADV
ihlr-16500	602	3	provides	provide	VERB
ihlr-16500	602	4	the	the	DET
ihlr-16500	602	5	patient	patient	NOUN
ihlr-16500	602	6	with	with	ADP
ihlr-16500	602	7	other	other	ADJ
ihlr-16500	602	8	information	information	NOUN
ihlr-16500	602	9	,	,	PUNCT
ihlr-16500	602	10	such	such	ADJ
ihlr-16500	602	11	as	as	ADP
ihlr-16500	602	12	concomitant	concomitant	ADJ
ihlr-16500	602	13	use	use	NOUN
ihlr-16500	602	14	and	and	CCONJ
ihlr-16500	602	15	the	the	DET
ihlr-16500	602	16	drug	drug	NOUN
ihlr-16500	602	17	's	's	PART
ihlr-16500	602	18	mechanism	mechanism	NOUN
ihlr-16500	602	19	of	of	ADP
ihlr-16500	602	20	action	action	NOUN
ihlr-16500	602	21	.	.	PUNCT
ihlr-16500	603	1	ld	ld	PROPN
ihlr-16500	603	2	§	§	PROPN
ihlr-16500	603	3	201.57	201.57	NUM
ihlr-16500	603	4	.	.	PUNCT
ihlr-16500	604	1	it	it	PRON
ihlr-16500	604	2	is	be	AUX
ihlr-16500	604	3	"	"	PUNCT
ihlr-16500	604	4	also	also	ADV
ihlr-16500	604	5	referred	refer	VERB
ihlr-16500	604	6	to	to	ADP
ihlr-16500	604	7	as	as	ADP
ihlr-16500	604	8	a	a	DET
ihlr-16500	604	9	package	package	NOUN
ihlr-16500	604	10	insert	insert	NOUN
ihlr-16500	604	11	,	,	PUNCT
ihlr-16500	604	12	product	product	NOUN
ihlr-16500	604	13	label	label	NOUN
ihlr-16500	604	14	,	,	PUNCT
ihlr-16500	604	15	or	or	CCONJ
ihlr-16500	604	16	product	product	NOUN
ihlr-16500	604	17	in­	in­	NOUN
ihlr-16500	604	18	formation	formation	NOUN
ihlr-16500	604	19	.	.	PUNCT
ihlr-16500	604	20	"	"	PUNCT
ihlr-16500	605	1	hepititisbhelp.com	hepititisbhelp.com	X
ihlr-16500	605	2	,	,	PUNCT
ihlr-16500	605	3	glossary	glossary	NOUN
ihlr-16500	605	4	,	,	PUNCT
ihlr-16500	605	5	http://www.hepatitisbhelp.com/hepatitis	http://www.hepatitisbhelp.com/hepatitis	PROPN
ihlr-16500	605	6	_	_	NOUN
ihlr-16500	605	7	b_glossary.html	b_glossary.html	NOUN
ihlr-16500	605	8	(	(	PUNCT
ihlr-16500	605	9	last	last	ADV
ihlr-16500	605	10	visited	visit	VERB
ihlr-16500	605	11	feb	feb	PROPN
ihlr-16500	605	12	.	.	PROPN
ihlr-16500	605	13	24	24	NUM
ihlr-16500	605	14	,	,	PUNCT
ihlr-16500	605	15	2007	2007	NUM
ihlr-16500	605	16	)	)	PUNCT
ihlr-16500	605	17	.	.	PUNCT
ihlr-16500	606	1	148	148	NUM
ihlr-16500	606	2	answers	answer	NOUN
ihlr-16500	606	3	.	.	PUNCT
ihlr-16500	607	1	com	com	NOUN
ihlr-16500	607	2	,	,	PUNCT
ihlr-16500	607	3	dictionary	dictionary	ADJ
ihlr-16500	607	4	,	,	PUNCT
ihlr-16500	607	5	half	half	ADJ
ihlr-16500	607	6	-	-	PUNCT
ihlr-16500	607	7	life	life	NOUN
ihlr-16500	607	8	,	,	PUNCT
ihlr-16500	607	9	http:/lwww.answers.com	http:/lwww.answers.com	PROPN
ihlr-16500	607	10	/	/	SYM
ihlr-16500	607	11	topiclhalf	topiclhalf	NOUN
ihlr-16500	607	12	-	-	PUNCT
ihlr-16500	607	13	life	life	NOUN
ihlr-16500	607	14	(	(	PUNCT
ihlr-16500	607	15	last	last	ADJ
ihlr-16500	607	16	vis­	vis­	NOUN
ihlr-16500	607	17	ited	ite	VERB
ihlr-16500	607	18	feb	feb	PROPN
ihlr-16500	607	19	.	.	PROPN
ihlr-16500	607	20	24	24	NUM
ihlr-16500	607	21	,	,	PUNCT
ihlr-16500	607	22	2007	2007	NUM
ihlr-16500	607	23	)	)	PUNCT
ihlr-16500	607	24	.	.	PUNCT
ihlr-16500	608	1	the	the	DET
ihlr-16500	608	2	half	half	ADJ
ihlr-16500	608	3	-	-	PUNCT
ihlr-16500	608	4	life	life	NOUN
ihlr-16500	608	5	of	of	ADP
ihlr-16500	608	6	a	a	DET
ihlr-16500	608	7	substance	substance	NOUN
ihlr-16500	608	8	subject	subject	NOUN
ihlr-16500	608	9	to	to	ADP
ihlr-16500	608	10	exponential	exponential	ADJ
ihlr-16500	608	11	decay	decay	NOUN
ihlr-16500	608	12	is	be	AUX
ihlr-16500	608	13	"	"	PUNCT
ihlr-16500	608	14	[	[	X
ihlr-16500	608	15	t]he	t]he	ADV
ihlr-16500	608	16	time	time	NOUN
ihlr-16500	608	17	required	require	VERB
ihlr-16500	608	18	for	for	ADP
ihlr-16500	608	19	half	half	NOUN
ihlr-16500	608	20	of	of	ADP
ihlr-16500	608	21	the	the	DET
ihlr-16500	608	22	quantity	quantity	NOUN
ihlr-16500	608	23	of	of	ADP
ihlr-16500	608	24	a	a	DET
ihlr-16500	608	25	drug	drug	NOUN
ihlr-16500	608	26	•	•	NOUN
ihlr-16500	608	27	•	•	NOUN
ihlr-16500	608	28	.to	.to	PUNCT
ihlr-16500	608	29	be	be	AUX
ihlr-16500	608	30	metabolized	metabolize	VERB
ihlr-16500	608	31	or	or	CCONJ
ihlr-16500	608	32	eliminated	eliminate	VERB
ihlr-16500	608	33	by	by	ADP
ihlr-16500	608	34	normal	normal	ADJ
ihlr-16500	608	35	biological	biological	ADJ
ihlr-16500	608	36	processes	process	NOUN
ihlr-16500	608	37	.	.	PUNCT
ihlr-16500	608	38	"	"	PUNCT
ihlr-16500	609	1	/d	/d	PUNCT
ihlr-16500	609	2	.	.	PROPN
ihlr-16500	609	3	149	149	NUM
ihlr-16500	609	4	see	see	VERB
ihlr-16500	609	5	,	,	PUNCT
ihlr-16500	609	6	e.g.	e.g.	ADV
ihlr-16500	609	7	,	,	PUNCT
ihlr-16500	609	8	julienne	julienne	PROPN
ihlr-16500	609	9	k.	k.	PROPN
ihlr-16500	609	10	kirk	kirk	PROPN
ihlr-16500	609	11	&	&	CCONJ
ihlr-16500	609	12	john	john	PROPN
ihlr-16500	609	13	g.	g.	PROPN
ihlr-16500	609	14	spangler	spangler	PROPN
ihlr-16500	609	15	,	,	PUNCT
ihlr-16500	609	16	alendronate	alendronate	NOUN
ihlr-16500	609	17	:	:	PUNCT
ihlr-16500	609	18	a	a	DET
ihlr-16500	609	19	bisphosphonate	bisphosphonate	NOUN
ihlr-16500	609	20	for	for	ADP
ihlr-16500	609	21	treatment	treatment	NOUN
ihlr-16500	609	22	of	of	ADP
ihlr-16500	609	23	osteoporosis	osteoporosis	NOUN
ihlr-16500	609	24	,	,	PUNCT
ihlr-16500	609	25	am	be	AUX
ihlr-16500	609	26	.	.	PUNCT
ihlr-16500	610	1	family	family	NOUN
ihlr-16500	610	2	physician	physician	NOUN
ihlr-16500	610	3	,	,	PUNCT
ihlr-16500	610	4	nov	nov	PROPN
ihlr-16500	610	5	.	.	PROPN
ihlr-16500	610	6	1	1	NUM
ihlr-16500	610	7	,	,	PUNCT
ihlr-16500	610	8	1996	1996	NUM
ihlr-16500	610	9	,	,	PUNCT
ihlr-16500	610	10	available	available	ADJ
ihlr-16500	610	11	at	at	ADP
ihlr-16500	610	12	http://www	http://www	PROPN
ihlr-16500	610	13	.	.	PUNCT
ihlr-16500	611	1	findarticles.com/p/articles/mi	findarticles.com/p/articles/mi	NOUN
ihlr-16500	612	1	_	_	PUNCT
ihlr-16500	613	1	m3225	m3225	NOUN
ihlr-16500	613	2	/	/	SYM
ihlr-16500	613	3	is	be	AUX
ihlr-16500	613	4	_	_	PROPN
ihlr-16500	613	5	n6	n6	PROPN
ihlr-16500	613	6	_	_	PUNCT
ihlr-16500	613	7	v54	v54	PROPN
ihlr-16500	613	8	/	/	SYM
ihlr-16500	613	9	ai	ai	VERB
ihlr-16500	613	10	_	_	NOUN
ihlr-16500	613	11	18890140	18890140	NUM
ihlr-16500	613	12	.	.	PUNCT
ihlr-16500	614	1	for	for	ADP
ihlr-16500	614	2	instance	instance	NOUN
ihlr-16500	614	3	,	,	PUNCT
ihlr-16500	614	4	the	the	DET
ihlr-16500	614	5	terminal	terminal	NOUN
ihlr-16500	614	6	half­	half­	PROPN
ihlr-16500	614	7	life	life	NOUN
ihlr-16500	614	8	offosamax	offosamax	NOUN
ihlr-16500	614	9	,	,	PUNCT
ihlr-16500	614	10	a	a	DET
ihlr-16500	614	11	drug	drug	NOUN
ihlr-16500	614	12	that	that	PRON
ihlr-16500	614	13	helps	help	VERB
ihlr-16500	614	14	treat	treat	VERB
ihlr-16500	614	15	osteoporosis	osteoporosis	NOUN
ihlr-16500	614	16	in	in	ADP
ihlr-16500	614	17	men	man	NOUN
ihlr-16500	614	18	and	and	CCONJ
ihlr-16500	614	19	women	woman	NOUN
ihlr-16500	614	20	,	,	PUNCT
ihlr-16500	614	21	is	be	AUX
ihlr-16500	614	22	estimated	estimate	VERB
ihlr-16500	614	23	to	to	PART
ihlr-16500	614	24	exceed	exceed	VERB
ihlr-16500	614	25	ten	ten	NUM
ihlr-16500	614	26	years	year	NOUN
ihlr-16500	614	27	.	.	PUNCT
ihlr-16500	615	1	/d	/d	PUNCT
ihlr-16500	615	2	.	.	PUNCT
ihlr-16500	616	1	2007	2007	NUM
ihlr-16500	616	2	]	]	X
ihlr-16500	616	3	pulung	pulung	PROPN
ihlr-16500	616	4	a	a	DET
ihlr-16500	616	5	blockbuster	blockbuster	ADJ
ihlr-16500	616	6	drug	drug	NOUN
ihlr-16500	616	7	off	off	ADP
ihlr-16500	616	8	the	the	DET
ihlr-16500	616	9	market	market	NOUN
ihlr-16500	616	10	143	143	PRON
ihlr-16500	616	11	clinical	clinical	ADJ
ihlr-16500	616	12	trials	trial	NOUN
ihlr-16500	616	13	.	.	PUNCT
ihlr-16500	617	1	moreover	moreover	ADV
ihlr-16500	617	2	,	,	PUNCT
ihlr-16500	617	3	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	617	4	company	company	NOUN
ihlr-16500	617	5	proponents	proponent	NOUN
ihlr-16500	617	6	argue	argue	VERB
ihlr-16500	617	7	that	that	SCONJ
ihlr-16500	617	8	it	it	PRON
ihlr-16500	617	9	is	be	AUX
ihlr-16500	617	10	unrealistic	unrealistic	ADJ
ihlr-16500	617	11	to	to	PART
ihlr-16500	617	12	expect	expect	VERB
ihlr-16500	617	13	a	a	DET
ihlr-16500	617	14	drug	drug	NOUN
ihlr-16500	617	15	to	to	PART
ihlr-16500	617	16	be	be	AUX
ihlr-16500	617	17	tested	test	VERB
ihlr-16500	617	18	for	for	ADP
ihlr-16500	617	19	every	every	DET
ihlr-16500	617	20	possible	possible	ADJ
ihlr-16500	617	21	side	side	NOUN
ihlr-16500	617	22	effect	effect	NOUN
ihlr-16500	617	23	and	and	CCONJ
ihlr-16500	617	24	ad­	ad­	ADJ
ihlr-16500	617	25	verse	verse	NOUN
ihlr-16500	617	26	event	event	NOUN
ihlr-16500	617	27	because	because	SCONJ
ihlr-16500	617	28	there	there	PRON
ihlr-16500	617	29	are	be	VERB
ihlr-16500	617	30	too	too	ADV
ihlr-16500	617	31	many	many	ADJ
ihlr-16500	617	32	different	different	ADJ
ihlr-16500	617	33	scenarios	scenario	NOUN
ihlr-16500	617	34	under	under	ADP
ihlr-16500	617	35	which	which	PRON
ihlr-16500	617	36	a	a	DET
ihlr-16500	617	37	drug	drug	NOUN
ihlr-16500	617	38	may	may	AUX
ihlr-16500	617	39	be	be	AUX
ihlr-16500	617	40	ingested	ingest	VERB
ihlr-16500	617	41	by	by	ADP
ihlr-16500	617	42	the	the	DET
ihlr-16500	617	43	average	average	ADJ
ihlr-16500	617	44	patient	patient	NOUN
ihlr-16500	617	45	.	.	PUNCT
ihlr-16500	618	1	furthermore	furthermore	ADV
ihlr-16500	618	2	,	,	PUNCT
ihlr-16500	618	3	each	each	DET
ihlr-16500	618	4	patient	patient	NOUN
ihlr-16500	618	5	's	's	PART
ihlr-16500	618	6	body	body	NOUN
ihlr-16500	618	7	re­	re­	PROPN
ihlr-16500	618	8	acts	act	VERB
ihlr-16500	618	9	differently	differently	ADV
ihlr-16500	618	10	to	to	ADP
ihlr-16500	618	11	a	a	DET
ihlr-16500	618	12	drug	drug	NOUN
ihlr-16500	618	13	;	;	PUNCT
ihlr-16500	618	14	an	an	DET
ihlr-16500	618	15	adverse	adverse	ADJ
ihlr-16500	618	16	event	event	NOUN
ihlr-16500	618	17	in	in	ADP
ihlr-16500	618	18	one	one	NUM
ihlr-16500	618	19	patient	patient	NOUN
ihlr-16500	618	20	may	may	AUX
ihlr-16500	618	21	not	not	PART
ihlr-16500	618	22	be	be	AUX
ihlr-16500	618	23	found	find	VERB
ihlr-16500	618	24	in	in	ADP
ihlr-16500	618	25	another	another	PRON
ihlr-16500	618	26	.	.	PUNCT
ihlr-16500	619	1	nevertheless	nevertheless	ADV
ihlr-16500	619	2	,	,	PUNCT
ihlr-16500	619	3	most	most	ADJ
ihlr-16500	619	4	litigation	litigation	NOUN
ihlr-16500	619	5	is	be	AUX
ihlr-16500	619	6	still	still	ADV
ihlr-16500	619	7	directed	direct	VERB
ihlr-16500	619	8	towards	towards	ADP
ihlr-16500	619	9	the	the	DET
ihlr-16500	619	10	pharmaceuti­	pharmaceuti­	NOUN
ihlr-16500	619	11	cal	cal	NOUN
ihlr-16500	619	12	company	company	NOUN
ihlr-16500	619	13	when	when	SCONJ
ihlr-16500	619	14	a	a	DET
ihlr-16500	619	15	drug	drug	NOUN
ihlr-16500	619	16	is	be	AUX
ihlr-16500	619	17	withdrawn	withdraw	VERB
ihlr-16500	619	18	from	from	ADP
ihlr-16500	619	19	the	the	DET
ihlr-16500	619	20	market	market	NOUN
ihlr-16500	619	21	because	because	SCONJ
ihlr-16500	619	22	it	it	PRON
ihlr-16500	619	23	is	be	AUX
ihlr-16500	619	24	the	the	DET
ihlr-16500	619	25	party	party	NOUN
ihlr-16500	619	26	that	that	PRON
ihlr-16500	619	27	marketed	market	VERB
ihlr-16500	619	28	and	and	CCONJ
ihlr-16500	619	29	distributed	distribute	VERB
ihlr-16500	619	30	the	the	DET
ihlr-16500	619	31	failed	fail	VERB
ihlr-16500	619	32	product	product	NOUN
ihlr-16500	619	33	.	.	PUNCT
ihlr-16500	620	1	thus	thus	ADV
ihlr-16500	620	2	,	,	PUNCT
ihlr-16500	620	3	it	it	PRON
ihlr-16500	620	4	can	can	AUX
ihlr-16500	620	5	be	be	AUX
ihlr-16500	620	6	argued	argue	VERB
ihlr-16500	620	7	that	that	SCONJ
ihlr-16500	620	8	just	just	ADV
ihlr-16500	620	9	as	as	SCONJ
ihlr-16500	620	10	a	a	DET
ihlr-16500	620	11	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	620	12	company	company	NOUN
ihlr-16500	620	13	takes	take	VERB
ihlr-16500	620	14	credit	credit	NOUN
ihlr-16500	620	15	for	for	ADP
ihlr-16500	620	16	a	a	DET
ihlr-16500	620	17	successful	successful	ADJ
ihlr-16500	620	18	novel	novel	ADJ
ihlr-16500	620	19	medicine	medicine	NOUN
ihlr-16500	620	20	and	and	CCONJ
ihlr-16500	620	21	as	as	ADP
ihlr-16500	620	22	a	a	DET
ihlr-16500	620	23	result	result	NOUN
ihlr-16500	620	24	reaps	reap	VERB
ihlr-16500	620	25	the	the	DET
ihlr-16500	620	26	financial	financial	ADJ
ihlr-16500	620	27	rewards	reward	NOUN
ihlr-16500	620	28	,	,	PUNCT
ihlr-16500	620	29	it	it	PRON
ihlr-16500	620	30	must	must	AUX
ihlr-16500	620	31	also	also	ADV
ihlr-16500	620	32	be	be	AUX
ihlr-16500	620	33	held	hold	VERB
ihlr-16500	620	34	accountable	accountable	ADJ
ihlr-16500	620	35	and	and	CCONJ
ihlr-16500	620	36	publicly	publicly	ADV
ihlr-16500	620	37	responsible	responsible	ADJ
ihlr-16500	620	38	for	for	ADP
ihlr-16500	620	39	developing	develop	VERB
ihlr-16500	620	40	and	and	CCONJ
ihlr-16500	620	41	marketing	market	VERB
ihlr-16500	620	42	an	an	DET
ihlr-16500	620	43	unsafe	unsafe	ADJ
ihlr-16500	620	44	drug	drug	NOUN
ihlr-16500	620	45	in	in	ADP
ihlr-16500	620	46	order	order	NOUN
ihlr-16500	620	47	to	to	PART
ihlr-16500	620	48	prevent	prevent	VERB
ihlr-16500	620	49	companies	company	NOUN
ihlr-16500	620	50	from	from	ADP
ihlr-16500	620	51	submitting	submit	VERB
ihlr-16500	620	52	drugs	drug	NOUN
ihlr-16500	620	53	to	to	ADP
ihlr-16500	620	54	the	the	DET
ihlr-16500	620	55	market	market	NOUN
ihlr-16500	620	56	that	that	PRON
ihlr-16500	620	57	have	have	AUX
ihlr-16500	620	58	not	not	PART
ihlr-16500	620	59	been	be	AUX
ihlr-16500	620	60	thor­	thor­	PRON
ihlr-16500	620	61	oughly	oughly	ADV
ihlr-16500	620	62	tested	test	VERB
ihlr-16500	620	63	.	.	PUNCT
ihlr-16500	621	1	b.	b.	VERB
ihlr-16500	621	2	to	to	ADP
ihlr-16500	621	3	what	what	DET
ihlr-16500	621	4	extent	extent	NOUN
ihlr-16500	621	5	is	be	AUX
ihlr-16500	621	6	the	the	DET
ihlr-16500	621	7	fda	fda	PROPN
ihlr-16500	621	8	at	at	ADP
ihlr-16500	621	9	fault	fault	NOUN
ihlr-16500	621	10	?	?	PUNCT
ihlr-16500	622	1	another	another	DET
ihlr-16500	622	2	visible	visible	ADJ
ihlr-16500	622	3	party	party	NOUN
ihlr-16500	622	4	who	who	PRON
ihlr-16500	622	5	does	do	AUX
ihlr-16500	622	6	not	not	PART
ihlr-16500	622	7	escape	escape	VERB
ihlr-16500	622	8	liability	liability	NOUN
ihlr-16500	622	9	for	for	ADP
ihlr-16500	622	10	its	its	PRON
ihlr-16500	622	11	failure	failure	NOUN
ihlr-16500	622	12	to	to	ADP
ihlr-16500	622	13	ade­	ade­	NOUN
ihlr-16500	622	14	quately	quately	ADV
ihlr-16500	622	15	monitor	monitor	VERB
ihlr-16500	622	16	the	the	DET
ihlr-16500	622	17	safety	safety	NOUN
ihlr-16500	622	18	issues	issue	NOUN
ihlr-16500	622	19	associated	associate	VERB
ihlr-16500	622	20	with	with	ADP
ihlr-16500	622	21	a	a	DET
ihlr-16500	622	22	withdrawn	withdraw	VERB
ihlr-16500	622	23	drug	drug	NOUN
ihlr-16500	622	24	is	be	AUX
ihlr-16500	622	25	the	the	DET
ihlr-16500	622	26	fda	fda	PROPN
ihlr-16500	622	27	.	.	PUNCT
ihlr-16500	623	1	often	often	ADV
ihlr-16500	623	2	times	time	NOUN
ihlr-16500	623	3	,	,	PUNCT
ihlr-16500	623	4	medical	medical	ADJ
ihlr-16500	623	5	experts	expert	NOUN
ihlr-16500	623	6	and	and	CCONJ
ihlr-16500	623	7	insiders	insider	NOUN
ihlr-16500	623	8	within	within	ADP
ihlr-16500	623	9	the	the	DET
ihlr-16500	623	10	fda	fda	PROPN
ihlr-16500	623	11	will	will	AUX
ihlr-16500	623	12	publicly	publicly	ADV
ihlr-16500	623	13	ridicule	ridicule	VERB
ihlr-16500	623	14	the	the	DET
ihlr-16500	623	15	fda	fda	PROPN
ihlr-16500	623	16	for	for	ADP
ihlr-16500	623	17	a	a	DET
ihlr-16500	623	18	lack	lack	NOUN
ihlr-16500	623	19	of	of	ADP
ihlr-16500	623	20	sustained	sustained	ADJ
ihlr-16500	623	21	scrutiny	scrutiny	NOUN
ihlr-16500	623	22	of	of	ADP
ihlr-16500	623	23	certain	certain	ADJ
ihlr-16500	623	24	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	623	25	drugs	drug	NOUN
ihlr-16500	623	26	after	after	SCONJ
ihlr-16500	623	27	these	these	DET
ihlr-16500	623	28	drugs	drug	NOUN
ihlr-16500	623	29	have	have	AUX
ihlr-16500	623	30	been	be	AUX
ihlr-16500	623	31	approved	approve	VERB
ihlr-16500	623	32	for	for	ADP
ihlr-16500	623	33	sale	sale	NOUN
ihlr-16500	623	34	and	and	CCONJ
ihlr-16500	623	35	distribution	distribution	NOUN
ihlr-16500	623	36	in	in	ADP
ihlr-16500	623	37	the	the	DET
ihlr-16500	623	38	u.s	u.s	PROPN
ihlr-16500	623	39	.	.	PROPN
ihlr-16500	623	40	market	market	NOUN
ihlr-16500	623	41	.	.	PUNCT
ihlr-16500	624	1	for	for	ADP
ihlr-16500	624	2	instance	instance	NOUN
ihlr-16500	624	3	,	,	PUNCT
ihlr-16500	624	4	during	during	ADP
ihlr-16500	624	5	the	the	DET
ihlr-16500	624	6	very	very	ADV
ihlr-16500	624	7	public	public	ADJ
ihlr-16500	624	8	vioxx	vioxx	NOUN
ihlr-16500	624	9	senate	senate	PROPN
ihlr-16500	624	10	hearings	hearing	NOUN
ihlr-16500	624	11	,	,	PUNCT
ihlr-16500	624	12	doctor	doctor	NOUN
ihlr-16500	624	13	david	david	PROPN
ihlr-16500	624	14	gra­	gra­	PROPN
ihlr-16500	624	15	ham	ham	PROPN
ihlr-16500	624	16	testified	testify	VERB
ihlr-16500	624	17	that	that	SCONJ
ihlr-16500	624	18	the	the	DET
ihlr-16500	624	19	fda	fda	PROPN
ihlr-16500	624	20	failed	fail	VERB
ihlr-16500	624	21	in	in	ADP
ihlr-16500	624	22	its	its	PRON
ihlr-16500	624	23	attempt	attempt	NOUN
ihlr-16500	624	24	to	to	PART
ihlr-16500	624	25	protect	protect	VERB
ihlr-16500	624	26	the	the	DET
ihlr-16500	624	27	american	american	ADJ
ihlr-16500	624	28	con­	con­	PROPN
ihlr-16500	624	29	sumer	sumer	PROPN
ihlr-16500	624	30	from	from	ADP
ihlr-16500	624	31	unsafe	unsafe	ADJ
ihlr-16500	624	32	drugs	drug	NOUN
ihlr-16500	624	33	and	and	CCONJ
ihlr-16500	624	34	that	that	SCONJ
ihlr-16500	624	35	as	as	ADP
ihlr-16500	624	36	a	a	DET
ihlr-16500	624	37	result	result	NOUN
ihlr-16500	624	38	,	,	PUNCT
ihlr-16500	624	39	thousands	thousand	NOUN
ihlr-16500	624	40	of	of	ADP
ihlr-16500	624	41	americans	americans	PROPN
ihlr-16500	624	42	suffered	suffer	VERB
ihlr-16500	624	43	cardiovascular	cardiovascular	ADJ
ihlr-16500	624	44	events	event	NOUN
ihlr-16500	624	45	that	that	PRON
ihlr-16500	624	46	may	may	AUX
ihlr-16500	624	47	have	have	AUX
ihlr-16500	624	48	been	be	AUX
ihlr-16500	624	49	avoided.150	avoided.150	DET
ihlr-16500	624	50	other	other	ADJ
ihlr-16500	624	51	experts	expert	NOUN
ihlr-16500	624	52	have	have	AUX
ihlr-16500	624	53	also	also	ADV
ihlr-16500	624	54	testified	testify	VERB
ihlr-16500	624	55	that	that	SCONJ
ihlr-16500	624	56	the	the	DET
ihlr-16500	624	57	fda	fda	PROPN
ihlr-16500	624	58	has	have	AUX
ihlr-16500	624	59	pandered	pander	VERB
ihlr-16500	624	60	to	to	ADP
ihlr-16500	624	61	the	the	DET
ihlr-16500	624	62	interests	interest	NOUN
ihlr-16500	624	63	of	of	ADP
ihlr-16500	624	64	the	the	DET
ihlr-16500	624	65	"	"	PUNCT
ihlr-16500	624	66	big	big	ADJ
ihlr-16500	624	67	pharma	pharma	NOUN
ihlr-16500	624	68	"	"	PUNCT
ihlr-16500	624	69	and	and	CCONJ
ihlr-16500	624	70	as	as	ADP
ihlr-16500	624	71	a	a	DET
ihlr-16500	624	72	result	result	NOUN
ihlr-16500	624	73	has	have	AUX
ihlr-16500	624	74	failed	fail	VERB
ihlr-16500	624	75	to	to	PART
ihlr-16500	624	76	objectively	objectively	ADV
ihlr-16500	624	77	regulate	regulate	VERB
ihlr-16500	624	78	the	the	DET
ihlr-16500	624	79	introduction	introduction	NOUN
ihlr-16500	624	80	of	of	ADP
ihlr-16500	624	81	new	new	ADJ
ihlr-16500	624	82	drugs	drug	NOUN
ihlr-16500	624	83	on	on	ADP
ihlr-16500	624	84	the	the	DET
ihlr-16500	624	85	market.151	market.151	NOUN
ihlr-16500	624	86	this	this	DET
ihlr-16500	624	87	kind	kind	NOUN
ihlr-16500	624	88	of	of	ADP
ihlr-16500	624	89	public	public	ADJ
ihlr-16500	624	90	ridicule	ridicule	NOUN
ihlr-16500	624	91	and	and	CCONJ
ihlr-16500	624	92	testimony	testimony	NOUN
ihlr-16500	624	93	by	by	ADP
ihlr-16500	624	94	respected	respected	ADJ
ihlr-16500	624	95	members	member	NOUN
ihlr-16500	624	96	of	of	ADP
ihlr-16500	624	97	the	the	DET
ihlr-16500	624	98	medical	medical	ADJ
ihlr-16500	624	99	profession	profession	NOUN
ihlr-16500	624	100	is	be	AUX
ihlr-16500	624	101	extremely	extremely	ADV
ihlr-16500	624	102	damaging	damaging	ADJ
ihlr-16500	624	103	,	,	PUNCT
ihlr-16500	624	104	especially	especially	ADV
ihlr-16500	624	105	to	to	ADP
ihlr-16500	624	106	a	a	DET
ihlr-16500	624	107	regulatory	regulatory	ADJ
ihlr-16500	624	108	agency	agency	NOUN
ihlr-16500	624	109	charged	charge	VERB
ihlr-16500	624	110	with	with	ADP
ihlr-16500	624	111	protecting	protect	VERB
ihlr-16500	624	112	u.s	u.s	PROPN
ihlr-16500	624	113	.	.	PROPN
ihlr-16500	624	114	citizens	citizen	NOUN
ihlr-16500	624	115	from	from	ADP
ihlr-16500	624	116	harmful	harmful	ADJ
ihlr-16500	624	117	products	product	NOUN
ihlr-16500	624	118	,	,	PUNCT
ihlr-16500	624	119	and	and	CCONJ
ihlr-16500	624	120	it	it	PRON
ihlr-16500	624	121	could	could	AUX
ihlr-16500	624	122	lead	lead	VERB
ihlr-16500	624	123	to	to	ADP
ihlr-16500	624	124	future	future	ADJ
ihlr-16500	624	125	congressional	congressional	ADJ
ihlr-16500	624	126	action	action	NOUN
ihlr-16500	624	127	and	and	CCONJ
ihlr-16500	624	128	examination	examination	NOUN
ihlr-16500	624	129	into	into	ADP
ihlr-16500	624	130	drug	drug	NOUN
ihlr-16500	624	131	approval	approval	NOUN
ihlr-16500	624	132	practices.152	practices.152	PROPN
ihlr-16500	624	133	150	150	NUM
ihlr-16500	624	134	see	see	VERB
ihlr-16500	624	135	risa	risa	PROPN
ihlr-16500	624	136	l.	l.	PROPN
ihlr-16500	624	137	lieberwitz	lieberwitz	PROPN
ihlr-16500	624	138	.	.	PUNCT
ihlr-16500	625	1	education	education	NOUN
ihlr-16500	625	2	law	law	NOUN
ihlr-16500	625	3	:	:	PUNCT
ihlr-16500	625	4	the	the	DET
ihlr-16500	625	5	corporatization	corporatization	NOUN
ihlr-16500	625	6	of	of	ADP
ihlr-16500	625	7	academic	academic	ADJ
ihlr-16500	625	8	research	research	NOUN
ihlr-16500	625	9	:	:	PUNCT
ihlr-16500	625	10	whose	whose	DET
ihlr-16500	625	11	interests	interest	NOUN
ihlr-16500	625	12	are	be	AUX
ihlr-16500	625	13	served	serve	VERB
ihlr-16500	625	14	?	?	PUNCT
ihlr-16500	625	15	,	,	PUNCT
ihlr-16500	625	16	38	38	NUM
ihlr-16500	625	17	akron	akron	PROPN
ihlr-16500	625	18	l.	l.	PROPN
ihlr-16500	625	19	rev	rev	PROPN
ihlr-16500	625	20	.	.	PROPN
ihlr-16500	625	21	759	759	NUM
ihlr-16500	625	22	,	,	PUNCT
ihlr-16500	625	23	768	768	NUM
ihlr-16500	625	24	(	(	PUNCT
ihlr-16500	625	25	2005	2005	NUM
ihlr-16500	625	26	)	)	PUNCT
ihlr-16500	625	27	;	;	PUNCT
ihlr-16500	625	28	see	see	VERB
ihlr-16500	625	29	also	also	ADV
ihlr-16500	625	30	lisa	lisa	PROPN
ihlr-16500	625	31	richwine	richwine	PROPN
ihlr-16500	625	32	,	,	PUNCT
ihlr-16500	625	33	fda	fda	PROPN
ihlr-16500	625	34	failed	fail	VERB
ihlr-16500	625	35	public	public	ADJ
ihlr-16500	625	36	on	on	ADP
ihlr-16500	625	37	vioxx	vioxx	NOUN
ihlr-16500	625	38	,	,	PUNCT
ihlr-16500	625	39	reuters	reuters	PROPN
ihlr-16500	625	40	,	,	PUNCT
ihlr-16500	625	41	nov	nov	PROPN
ihlr-16500	625	42	.	.	PROPN
ihlr-16500	625	43	18	18	NUM
ihlr-16500	625	44	,	,	PUNCT
ihlr-16500	625	45	2004	2004	NUM
ihlr-16500	625	46	,	,	PUNCT
ihlr-16500	625	47	available	available	ADJ
ihlr-16500	625	48	athttp://www.lexisnexis.com	athttp://www.lexisnexis.com	X
ihlr-16500	625	49	(	(	PUNCT
ihlr-16500	625	50	click	click	VERB
ihlr-16500	625	51	on	on	ADP
ihlr-16500	625	52	news	news	NOUN
ihlr-16500	625	53	and	and	CCONJ
ihlr-16500	625	54	business	business	NOUN
ihlr-16500	625	55	,	,	PUNCT
ihlr-16500	625	56	click	click	VERB
ihlr-16500	625	57	on	on	ADP
ihlr-16500	625	58	individual	individual	ADJ
ihlr-16500	625	59	publications	publication	NOUN
ihlr-16500	625	60	,	,	PUNCT
ihlr-16500	625	61	click	click	VERB
ihlr-16500	625	62	on	on	ADP
ihlr-16500	625	63	r	r	NOUN
ihlr-16500	625	64	,	,	PUNCT
ihlr-16500	625	65	click	click	VERB
ihlr-16500	625	66	on	on	ADP
ihlr-16500	625	67	reuters	reuters	PROPN
ihlr-16500	625	68	news	news	PROPN
ihlr-16500	625	69	)	)	PUNCT
ihlr-16500	625	70	.	.	PUNCT
ihlr-16500	626	1	151	151	NUM
ihlr-16500	626	2	lieberwitz	lieberwitz	NOUN
ihlr-16500	626	3	,	,	PUNCT
ihlr-16500	626	4	supra	supra	PROPN
ihlr-16500	626	5	note	note	NOUN
ihlr-16500	626	6	150	150	NUM
ihlr-16500	626	7	,	,	PUNCT
ihlr-16500	626	8	at	at	ADP
ihlr-16500	626	9	768	768	NUM
ihlr-16500	626	10	-	-	SYM
ihlr-16500	626	11	69	69	NUM
ihlr-16500	626	12	.	.	PUNCT
ihlr-16500	627	1	during	during	ADP
ihlr-16500	627	2	the	the	DET
ihlr-16500	627	3	vioxx	vioxx	PROPN
ihlr-16500	627	4	house	house	PROPN
ihlr-16500	627	5	committee	committee	PROPN
ihlr-16500	627	6	hearings	hearing	NOUN
ihlr-16500	627	7	,	,	PUNCT
ihlr-16500	627	8	minnesota	minnesota	PROPN
ihlr-16500	627	9	congressman	congressman	PROPN
ihlr-16500	627	10	gil	gil	PROPN
ihlr-16500	627	11	gutknecht	gutknecht	PROPN
ihlr-16500	627	12	commented	comment	VERB
ihlr-16500	627	13	,	,	PUNCT
ihlr-16500	627	14	"	"	PUNCT
ihlr-16500	627	15	[	[	X
ihlr-16500	627	16	j]ust	j]ust	NOUN
ihlr-16500	627	17	who	who	PRON
ihlr-16500	627	18	is	be	AUX
ihlr-16500	627	19	the	the	DET
ihlr-16500	627	20	fda	fda	PROPN
ihlr-16500	627	21	protecting	protecting	NOUN
ihlr-16500	627	22	,	,	PUNCT
ihlr-16500	627	23	and	and	CCONJ
ihlr-16500	627	24	what	what	PRON
ihlr-16500	627	25	are	be	AUX
ihlr-16500	627	26	the	the	DET
ihlr-16500	627	27	ethical	ethical	ADJ
ihlr-16500	627	28	responsibilities	responsibility	NOUN
ihlr-16500	627	29	of	of	ADP
ihlr-16500	627	30	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	627	31	companies	company	NOUN
ihlr-16500	627	32	?	?	PUNCT
ihlr-16500	628	1	both	both	CCONJ
ihlr-16500	628	2	the	the	DET
ihlr-16500	628	3	fda	fda	PROPN
ihlr-16500	628	4	and	and	CCONJ
ihlr-16500	628	5	the	the	DET
ihlr-16500	628	6	phar­	phar­	PROPN
ihlr-16500	628	7	maceutical	maceutical	ADJ
ihlr-16500	628	8	company	company	NOUN
ihlr-16500	628	9	sort	sort	ADV
ihlr-16500	628	10	of	of	ADV
ihlr-16500	628	11	missed	miss	VERB
ihlr-16500	628	12	the	the	DET
ihlr-16500	628	13	mark	mark	NOUN
ihlr-16500	628	14	.	.	PUNCT
ihlr-16500	628	15	"	"	PUNCT
ihlr-16500	629	1	bernadette	bernadette	PROPN
ihlr-16500	629	2	tansey	tansey	NOUN
ihlr-16500	629	3	,	,	PUNCT
ihlr-16500	629	4	v"wxx	v"wxx	VERB
ihlr-16500	629	5	:	:	PUNCT
ihlr-16500	629	6	how	how	SCONJ
ihlr-16500	629	7	marketing	marketing	NOUN
ihlr-16500	629	8	drives	drive	VERB
ihlr-16500	629	9	the	the	DET
ihlr-16500	629	10	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	629	11	industry	industry	NOUN
ihlr-16500	629	12	:	:	PUNCT
ihlr-16500	629	13	firm	firm	NOUN
ihlr-16500	629	14	misled	mislead	VERB
ihlr-16500	629	15	doctors	doctor	NOUN
ihlr-16500	629	16	on	on	ADP
ihlr-16500	629	17	vioxx	vioxx	NOUN
ihlr-16500	629	18	,	,	PUNCT
ihlr-16500	629	19	panel	panel	NOUN
ihlr-16500	629	20	says	say	VERB
ihlr-16500	629	21	sales	sale	NOUN
ihlr-16500	629	22	stajjtold	stajjtold	VERB
ihlr-16500	629	23	not	not	PART
ihlr-16500	629	24	to	to	PART
ihlr-16500	629	25	discuss	discuss	VERB
ihlr-16500	629	26	risk	risk	NOUN
ihlr-16500	629	27	study	study	NOUN
ihlr-16500	629	28	,	,	PUNCT
ihlr-16500	629	29	s.	s.	PROPN
ihlr-16500	629	30	f.	f.	PROPN
ihlr-16500	629	31	chronicle	chronicle	PROPN
ihlr-16500	629	32	,	,	PUNCT
ihlr-16500	629	33	may	may	AUX
ihlr-16500	629	34	6	6	NUM
ihlr-16500	629	35	,	,	PUNCT
ihlr-16500	629	36	2005	2005	NUM
ihlr-16500	629	37	,	,	PUNCT
ihlr-16500	629	38	at	at	ADP
ihlr-16500	629	39	ai	ai	NOUN
ihlr-16500	629	40	.	.	PROPN
ihlr-16500	629	41	152	152	NUM
ihlr-16500	629	42	see	see	VERB
ihlr-16500	629	43	evaluating	evaluate	VERB
ihlr-16500	629	44	the	the	DET
ihlr-16500	629	45	effectiveness	effectiveness	NOUN
ihlr-16500	629	46	of	of	ADP
ihlr-16500	629	47	the	the	DET
ihlr-16500	629	48	food	food	NOUN
ihlr-16500	629	49	and	and	CCONJ
ihlr-16500	629	50	drug	drug	NOUN
ihlr-16500	629	51	admin	admin	PROPN
ihlr-16500	629	52	.	.	PUNCT
ihlr-16500	630	1	modernization	modernization	NOUN
ihlr-16500	630	2	act	act	PROPN
ihlr-16500	630	3	beforethesubcomm	beforethesubcomm	NOUN
ihlr-16500	630	4	.	.	PUNCT
ihlr-16500	631	1	onhealthoftheh	onhealthoftheh	ADJ
ihlr-16500	631	2	.	.	PUNCT
ihlr-16500	632	1	comm	comm	NOUN
ihlr-16500	632	2	.	.	PUNCT
ihlr-16500	633	1	onenergyandcommerce	onenergyandcommerce	PROPN
ihlr-16500	633	2	,	,	PUNCT
ihlr-16500	633	3	i01thcong.51,at	i01thcong.51,at	VERB
ihlr-16500	633	4	16	16	NUM
ihlr-16500	633	5	-	-	SYM
ihlr-16500	633	6	17	17	NUM
ihlr-16500	633	7	(	(	PUNCT
ihlr-16500	633	8	2001	2001	NUM
ihlr-16500	633	9	)	)	PUNCT
ihlr-16500	633	10	(	(	PUNCT
ihlr-16500	633	11	statement	statement	NOUN
ihlr-16500	633	12	ofw.j	ofw.j	PROPN
ihlr-16500	633	13	.	.	PUNCT
ihlr-16500	634	1	"	"	PUNCT
ihlr-16500	634	2	billy	billy	ADJ
ihlr-16500	634	3	"	"	PUNCT
ihlr-16500	634	4	tauzin	tauzin	PROPN
ihlr-16500	634	5	,	,	PUNCT
ihlr-16500	634	6	chairman	chairman	NOUN
ihlr-16500	634	7	,	,	PUNCT
ihlr-16500	634	8	committee	committee	NOUN
ihlr-16500	634	9	on	on	ADP
ihlr-16500	634	10	energy	energy	NOUN
ihlr-16500	634	11	and	and	CCONJ
ihlr-16500	634	12	com­	com­	PROPN
ihlr-16500	634	13	merce	merce	PROPN
ihlr-16500	634	14	)	)	PUNCT
ihlr-16500	634	15	.	.	PUNCT
ihlr-16500	635	1	tauzin	tauzin	PROPN
ihlr-16500	635	2	,	,	PUNCT
ihlr-16500	635	3	the	the	DET
ihlr-16500	635	4	chairman	chairman	NOUN
ihlr-16500	635	5	of	of	ADP
ihlr-16500	635	6	the	the	DET
ihlr-16500	635	7	committee	committee	NOUN
ihlr-16500	635	8	on	on	ADP
ihlr-16500	635	9	energy	energy	NOUN
ihlr-16500	635	10	and	and	CCONJ
ihlr-16500	635	11	commerce	commerce	NOUN
ihlr-16500	635	12	,	,	PUNCT
ihlr-16500	635	13	was	be	AUX
ihlr-16500	635	14	optimistic	optimistic	ADJ
ihlr-16500	636	1	144	144	NUM
ihlr-16500	636	2	indiana	indiana	PROPN
ihlr-16500	636	3	realm	realm	PROPN
ihlr-16500	636	4	law	law	PROPN
ihlr-16500	636	5	review	review	NOUN
ihlr-16500	636	6	[	[	X
ihlr-16500	636	7	vol	vol	NOUN
ihlr-16500	636	8	.	.	PUNCT
ihlr-16500	637	1	4:115	4:115	NUM
ihlr-16500	637	2	c.	c.	NOUN
ihlr-16500	637	3	to	to	ADP
ihlr-16500	637	4	what	what	DET
ihlr-16500	637	5	extent	extent	NOUN
ihlr-16500	637	6	is	be	AUX
ihlr-16500	637	7	the	the	DET
ihlr-16500	637	8	health	health	NOUN
ihlr-16500	637	9	care	care	NOUN
ihlr-16500	637	10	professional	professional	ADJ
ihlr-16500	637	11	at	at	ADP
ihlr-16500	637	12	fault	fault	NOUN
ihlr-16500	637	13	?	?	PUNCT
ihlr-16500	638	1	while	while	SCONJ
ihlr-16500	638	2	the	the	DET
ihlr-16500	638	3	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	638	4	company	company	NOUN
ihlr-16500	638	5	and	and	CCONJ
ihlr-16500	638	6	the	the	DET
ihlr-16500	638	7	fda	fda	PROPN
ihlr-16500	638	8	share	share	VERB
ihlr-16500	638	9	the	the	DET
ihlr-16500	638	10	brunt	brunt	NOUN
ihlr-16500	638	11	of	of	ADP
ihlr-16500	638	12	the	the	DET
ihlr-16500	638	13	blame	blame	NOUN
ihlr-16500	638	14	,	,	PUNCT
ihlr-16500	638	15	in	in	ADP
ihlr-16500	638	16	some	some	DET
ihlr-16500	638	17	cases	case	NOUN
ihlr-16500	638	18	,	,	PUNCT
ihlr-16500	638	19	other	other	ADJ
ihlr-16500	638	20	smaller	small	ADJ
ihlr-16500	638	21	groups	group	NOUN
ihlr-16500	638	22	are	be	AUX
ihlr-16500	638	23	also	also	ADV
ihlr-16500	638	24	blamed	blame	VERB
ihlr-16500	638	25	for	for	ADP
ihlr-16500	638	26	failing	fail	VERB
ihlr-16500	638	27	to	to	PART
ihlr-16500	638	28	ade­	ade­	VERB
ihlr-16500	638	29	quately	quately	ADV
ihlr-16500	638	30	warn	warn	VERB
ihlr-16500	638	31	.	.	PUNCT
ihlr-16500	639	1	some	some	DET
ihlr-16500	639	2	claim	claim	NOUN
ihlr-16500	639	3	that	that	SCONJ
ihlr-16500	639	4	the	the	DET
ihlr-16500	639	5	onus	onus	NOUN
ihlr-16500	639	6	falls	fall	VERB
ihlr-16500	639	7	on	on	ADP
ihlr-16500	639	8	the	the	DET
ihlr-16500	639	9	doctor	doctor	NOUN
ihlr-16500	639	10	to	to	PART
ihlr-16500	639	11	adequately	adequately	ADV
ihlr-16500	639	12	treat	treat	VERB
ihlr-16500	639	13	his	his	PRON
ihlr-16500	639	14	or	or	CCONJ
ihlr-16500	639	15	her	her	PRON
ihlr-16500	639	16	patients	patient	NOUN
ihlr-16500	639	17	and	and	CCONJ
ihlr-16500	639	18	,	,	PUNCT
ihlr-16500	639	19	as	as	ADP
ihlr-16500	639	20	a	a	DET
ihlr-16500	639	21	result	result	NOUN
ihlr-16500	639	22	,	,	PUNCT
ihlr-16500	639	23	to	to	PART
ihlr-16500	639	24	choose	choose	VERB
ihlr-16500	639	25	the	the	DET
ihlr-16500	639	26	medicine	medicine	NOUN
ihlr-16500	639	27	that	that	PRON
ihlr-16500	639	28	is	be	AUX
ihlr-16500	639	29	right	right	ADJ
ihlr-16500	639	30	for	for	ADP
ihlr-16500	639	31	each	each	DET
ihlr-16500	639	32	individual	individual	ADJ
ihlr-16500	639	33	patient	patient	NOUN
ihlr-16500	639	34	.	.	PUNCT
ihlr-16500	640	1	in	in	ADP
ihlr-16500	640	2	most	most	ADJ
ihlr-16500	640	3	cases	case	NOUN
ihlr-16500	640	4	,	,	PUNCT
ihlr-16500	640	5	however	however	ADV
ihlr-16500	640	6	,	,	PUNCT
ihlr-16500	640	7	physicians	physician	NOUN
ihlr-16500	640	8	will	will	AUX
ihlr-16500	640	9	prescribe	prescribe	VERB
ihlr-16500	640	10	a	a	DET
ihlr-16500	640	11	drug	drug	NOUN
ihlr-16500	640	12	even	even	ADV
ihlr-16500	640	13	with	with	ADP
ihlr-16500	640	14	the	the	DET
ihlr-16500	640	15	knowledge	knowledge	NOUN
ihlr-16500	640	16	that	that	SCONJ
ihlr-16500	640	17	it	it	PRON
ihlr-16500	640	18	has	have	VERB
ihlr-16500	640	19	certain	certain	ADJ
ihlr-16500	640	20	adverse	adverse	ADJ
ihlr-16500	640	21	side	side	NOUN
ihlr-16500	640	22	effects	effect	NOUN
ihlr-16500	640	23	because	because	SCONJ
ihlr-16500	640	24	the	the	DET
ihlr-16500	640	25	in­	in­	NOUN
ihlr-16500	640	26	formation	formation	NOUN
ihlr-16500	640	27	available	available	ADJ
ihlr-16500	640	28	to	to	ADP
ihlr-16500	640	29	them	they	PRON
ihlr-16500	640	30	,	,	PUNCT
ihlr-16500	640	31	from	from	ADP
ihlr-16500	640	32	medical	medical	ADJ
ihlr-16500	640	33	journals	journal	NOUN
ihlr-16500	640	34	and	and	CCONJ
ihlr-16500	640	35	clinical	clinical	ADJ
ihlr-16500	640	36	trials	trial	NOUN
ihlr-16500	640	37	outlined	outline	VERB
ihlr-16500	640	38	in	in	ADP
ihlr-16500	640	39	the	the	DET
ihlr-16500	640	40	drug	drug	NOUN
ihlr-16500	640	41	's	's	PART
ihlr-16500	640	42	prescribing	prescribing	NOUN
ihlr-16500	640	43	information	information	NOUN
ihlr-16500	640	44	,	,	PUNCT
ihlr-16500	640	45	describes	describe	VERB
ihlr-16500	640	46	the	the	DET
ihlr-16500	640	47	risk	risk	NOUN
ihlr-16500	640	48	of	of	ADP
ihlr-16500	640	49	any	any	DET
ihlr-16500	640	50	adverse	adverse	ADJ
ihlr-16500	640	51	event	event	NOUN
ihlr-16500	640	52	occurring	occur	VERB
ihlr-16500	640	53	as	as	ADV
ihlr-16500	640	54	miniscule	miniscule	ADJ
ihlr-16500	640	55	;	;	PUNCT
ihlr-16500	640	56	as	as	ADP
ihlr-16500	640	57	a	a	DET
ihlr-16500	640	58	result	result	NOUN
ihlr-16500	640	59	,	,	PUNCT
ihlr-16500	640	60	the	the	DET
ihlr-16500	640	61	benefit	benefit	NOUN
ihlr-16500	640	62	to	to	ADP
ihlr-16500	640	63	the	the	DET
ihlr-16500	640	64	patient	patient	NOUN
ihlr-16500	640	65	exceeds	exceed	VERB
ihlr-16500	640	66	the	the	DET
ihlr-16500	640	67	health	health	NOUN
ihlr-16500	640	68	risk	risk	NOUN
ihlr-16500	640	69	posed	pose	VERB
ihlr-16500	640	70	by	by	ADP
ihlr-16500	640	71	such	such	DET
ihlr-16500	640	72	a	a	DET
ihlr-16500	640	73	drug	drug	NOUN
ihlr-16500	640	74	.	.	PUNCT
ihlr-16500	641	1	thus	thus	ADV
ihlr-16500	641	2	,	,	PUNCT
ihlr-16500	641	3	it	it	PRON
ihlr-16500	641	4	is	be	AUX
ihlr-16500	641	5	difficult	difficult	ADJ
ihlr-16500	641	6	to	to	PART
ihlr-16500	641	7	blame	blame	VERB
ihlr-16500	641	8	physicians	physician	NOUN
ihlr-16500	641	9	for	for	ADP
ihlr-16500	641	10	using	use	VERB
ihlr-16500	641	11	the	the	DET
ihlr-16500	641	12	information	information	NOUN
ihlr-16500	641	13	proffered	proffer	VERB
ihlr-16500	641	14	by	by	ADP
ihlr-16500	641	15	the	the	DET
ihlr-16500	641	16	respective	respective	ADJ
ihlr-16500	641	17	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	641	18	company	company	NOUN
ihlr-16500	641	19	claiming	claim	VERB
ihlr-16500	641	20	that	that	SCONJ
ihlr-16500	641	21	the	the	DET
ihlr-16500	641	22	drug	drug	NOUN
ihlr-16500	641	23	is	be	AUX
ihlr-16500	641	24	safe	safe	ADJ
ihlr-16500	641	25	in	in	ADP
ihlr-16500	641	26	making	make	VERB
ihlr-16500	641	27	informed	informed	ADJ
ihlr-16500	641	28	decisions	decision	NOUN
ihlr-16500	641	29	regarding	regard	VERB
ihlr-16500	641	30	the	the	DET
ihlr-16500	641	31	health	health	NOUN
ihlr-16500	641	32	of	of	ADP
ihlr-16500	641	33	their	their	PRON
ihlr-16500	641	34	pa­	pa­	ADJ
ihlr-16500	641	35	tients	tient	NOUN
ihlr-16500	641	36	.	.	PUNCT
ihlr-16500	642	1	conversely	conversely	ADV
ihlr-16500	642	2	,	,	PUNCT
ihlr-16500	642	3	many	many	ADJ
ihlr-16500	642	4	physician	physician	NOUN
ihlr-16500	642	5	advocacy	advocacy	NOUN
ihlr-16500	642	6	groups	group	NOUN
ihlr-16500	642	7	blame	blame	VERB
ihlr-16500	642	8	the	the	DET
ihlr-16500	642	9	vharmaceutical	vharmaceutical	ADJ
ihlr-16500	642	10	companies	company	NOUN
ihlr-16500	642	11	'	'	PART
ihlr-16500	642	12	desire	desire	NOUN
ihlr-16500	642	13	to	to	PART
ihlr-16500	642	14	gain	gain	VERB
ihlr-16500	642	15	the	the	DET
ihlr-16500	642	16	most	most	ADJ
ihlr-16500	642	17	market	market	NOUN
ihlr-16500	642	18	share	share	NOUN
ihlr-16500	642	19	and	and	CCONJ
ihlr-16500	642	20	revenues	revenue	NOUN
ihlr-16500	642	21	.	.	PUNCT
ihlr-16500	643	1	53	53	NUM
ihlr-16500	643	2	they	they	PRON
ihlr-16500	643	3	claim	claim	VERB
ihlr-16500	643	4	that	that	SCONJ
ihlr-16500	643	5	the	the	DET
ihlr-16500	643	6	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	643	7	companies	company	NOUN
ihlr-16500	643	8	continually	continually	ADV
ihlr-16500	643	9	mislead	mislead	VERB
ihlr-16500	643	10	physicians	physician	NOUN
ihlr-16500	643	11	by	by	ADP
ihlr-16500	643	12	feeding	feed	VERB
ihlr-16500	643	13	them	they	PRON
ihlr-16500	643	14	erroneous	erroneous	ADJ
ihlr-16500	643	15	information	information	NOUN
ihlr-16500	643	16	through	through	ADP
ihlr-16500	643	17	their	their	PRON
ihlr-16500	643	18	sales	sale	NOUN
ihlr-16500	643	19	representatives	representative	NOUN
ihlr-16500	643	20	or	or	CCONJ
ihlr-16500	643	21	failing	fail	VERB
ihlr-16500	643	22	to	to	PART
ihlr-16500	643	23	dis­	dis­	VERB
ihlr-16500	643	24	close	close	ADJ
ihlr-16500	643	25	vital	vital	ADJ
ihlr-16500	643	26	information	information	NOUN
ihlr-16500	643	27	refsarding	refsarde	VERB
ihlr-16500	643	28	the	the	DET
ihlr-16500	643	29	drug	drug	NOUN
ihlr-16500	643	30	's	's	PART
ihlr-16500	643	31	safety.154	safety.154	NOUN
ihlr-16500	643	32	for	for	ADP
ihlr-16500	643	33	instance	instance	NOUN
ihlr-16500	643	34	,	,	PUNCT
ihlr-16500	643	35	during	during	ADP
ihlr-16500	643	36	the	the	DET
ihlr-16500	643	37	vioxx	vioxx	NOUN
ihlr-16500	643	38	senate	senate	PROPN
ihlr-16500	643	39	hearings	hearing	NOUN
ihlr-16500	643	40	,	,	PUNCT
ihlr-16500	643	41	1	1	NUM
ihlr-16500	643	42	critics	critic	NOUN
ihlr-16500	643	43	claimed	claim	VERB
ihlr-16500	643	44	that	that	SCONJ
ihlr-16500	643	45	merck	merck	PROPN
ihlr-16500	643	46	purposely	purposely	ADV
ihlr-16500	643	47	misled	mislead	VERB
ihlr-16500	643	48	physi­	physi­	PROPN
ihlr-16500	643	49	cians	cian	NOUN
ihlr-16500	643	50	by	by	ADP
ihlr-16500	643	51	compensating	compensate	VERB
ihlr-16500	643	52	their	their	PRON
ihlr-16500	643	53	sales	sale	NOUN
ihlr-16500	643	54	representatives	representative	NOUN
ihlr-16500	643	55	with	with	ADP
ihlr-16500	643	56	a	a	DET
ihlr-16500	643	57	bonus	bonus	NOUN
ihlr-16500	643	58	program	program	NOUN
ihlr-16500	643	59	,	,	PUNCT
ihlr-16500	643	60	which	which	PRON
ihlr-16500	643	61	provided	provide	VERB
ihlr-16500	643	62	the	the	DET
ihlr-16500	643	63	representatives	representative	NOUN
ihlr-16500	643	64	with	with	ADP
ihlr-16500	643	65	an	an	DET
ihlr-16500	643	66	incentive	incentive	NOUN
ihlr-16500	643	67	not	not	PART
ihlr-16500	643	68	to	to	PART
ihlr-16500	643	69	disclose	disclose	VERB
ihlr-16500	643	70	fully	fully	ADV
ihlr-16500	643	71	vioxx	vioxx	NOUN
ihlr-16500	643	72	's	's	PART
ihlr-16500	643	73	safety	safety	NOUN
ihlr-16500	643	74	issues	issue	NOUN
ihlr-16500	643	75	in	in	ADP
ihlr-16500	643	76	an	an	DET
ihlr-16500	643	77	effort	effort	NOUN
ihlr-16500	643	78	to	to	PART
ihlr-16500	643	79	increase	increase	VERB
ihlr-16500	643	80	the	the	DET
ihlr-16500	643	81	drug	drug	NOUN
ihlr-16500	643	82	's	's	PART
ihlr-16500	643	83	market	market	NOUN
ihlr-16500	643	84	share.156	share.156	NOUN
ihlr-16500	643	85	this	this	DET
ihlr-16500	643	86	program	program	NOUN
ihlr-16500	643	87	allegedly	allegedly	ADV
ihlr-16500	643	88	directed	direct	VERB
ihlr-16500	643	89	representatives	representative	NOUN
ihlr-16500	643	90	to	to	PART
ihlr-16500	643	91	find	find	VERB
ihlr-16500	643	92	ways	way	NOUN
ihlr-16500	643	93	to	to	PART
ihlr-16500	643	94	avoid	avoid	VERB
ihlr-16500	643	95	safety	safety	NOUN
ihlr-16500	643	96	related	relate	VERB
ihlr-16500	643	97	questions	question	NOUN
ihlr-16500	643	98	from	from	ADP
ihlr-16500	643	99	physicians	physician	NOUN
ihlr-16500	643	100	and	and	CCONJ
ihlr-16500	643	101	handle	handle	VERB
ihlr-16500	643	102	these	these	DET
ihlr-16500	643	103	"	"	PUNCT
ihlr-16500	643	104	obstacles	obstacle	NOUN
ihlr-16500	643	105	"	"	PUNCT
ihlr-16500	643	106	before	before	ADP
ihlr-16500	643	107	reverting	revert	VERB
ihlr-16500	643	108	to	to	ADP
ihlr-16500	643	109	the	the	DET
ihlr-16500	643	110	message	message	NOUN
ihlr-16500	643	111	promoting	promote	VERB
ihlr-16500	643	112	the	the	DET
ihlr-16500	643	113	drug	drug	NOUN
ihlr-16500	643	114	's	's	PART
ihlr-16500	643	115	efficacy.157	efficacy.157	NOUN
ihlr-16500	643	116	in	in	ADP
ihlr-16500	643	117	response	response	NOUN
ihlr-16500	643	118	to	to	ADP
ihlr-16500	643	119	such	such	ADJ
ihlr-16500	643	120	criticism	criticism	NOUN
ihlr-16500	643	121	,	,	PUNCT
ihlr-16500	643	122	a	a	DET
ihlr-16500	643	123	merck	merck	NOUN
ihlr-16500	643	124	about	about	ADP
ihlr-16500	643	125	the	the	DET
ihlr-16500	643	126	changes	change	NOUN
ihlr-16500	643	127	at	at	ADP
ihlr-16500	643	128	the	the	DET
ihlr-16500	643	129	fda	fda	PROPN
ihlr-16500	643	130	over	over	ADP
ihlr-16500	643	131	the	the	DET
ihlr-16500	643	132	years	year	NOUN
ihlr-16500	643	133	,	,	PUNCT
ihlr-16500	643	134	but	but	CCONJ
ihlr-16500	643	135	also	also	ADV
ihlr-16500	643	136	warned	warn	VERB
ihlr-16500	643	137	that	that	SCONJ
ihlr-16500	643	138	"	"	PUNCT
ihlr-16500	643	139	approval	approval	NOUN
ihlr-16500	643	140	times	time	NOUN
ihlr-16500	643	141	have	have	AUX
ihlr-16500	643	142	been	be	AUX
ihlr-16500	643	143	cut	cut	VERB
ihlr-16500	643	144	in	in	ADP
ihlr-16500	643	145	half	half	NOUN
ihlr-16500	643	146	,	,	PUNCT
ihlr-16500	643	147	and	and	CCONJ
ihlr-16500	643	148	the	the	DET
ihlr-16500	643	149	percentage	percentage	NOUN
ihlr-16500	643	150	of	of	ADP
ihlr-16500	643	151	new	new	ADJ
ihlr-16500	643	152	drugs	drug	NOUN
ihlr-16500	643	153	being	be	AUX
ihlr-16500	643	154	introduced	introduce	VERB
ihlr-16500	643	155	in	in	ADP
ihlr-16500	643	156	the	the	DET
ihlr-16500	643	157	united	united	PROPN
ihlr-16500	643	158	states	states	PROPN
ihlr-16500	643	159	before	before	ADP
ihlr-16500	643	160	being	be	AUX
ihlr-16500	643	161	in­	in­	ADV
ihlr-16500	643	162	troduced	troduce	VERB
ihlr-16500	643	163	in	in	ADP
ihlr-16500	643	164	other	other	ADJ
ihlr-16500	643	165	countries	country	NOUN
ihlr-16500	643	166	has	have	AUX
ihlr-16500	643	167	nearly	nearly	ADV
ihlr-16500	643	168	doubled	double	VERB
ihlr-16500	643	169	.	.	PUNCT
ihlr-16500	643	170	"	"	PUNCT
ihlr-16500	644	1	i	i	PRON
ihlr-16500	644	2	d	d	PROPN
ihlr-16500	644	3	153	153	NUM
ihlr-16500	644	4	see	see	VERB
ihlr-16500	644	5	,	,	PUNCT
ihlr-16500	644	6	e.g.	e.g.	ADV
ihlr-16500	644	7	,	,	PUNCT
ihlr-16500	644	8	i	i	PRON
ihlr-16500	644	9	d.	d.	VERB
ihlr-16500	644	10	at	at	ADP
ihlr-16500	644	11	82	82	NUM
ihlr-16500	644	12	-	-	SYM
ihlr-16500	644	13	87	87	NUM
ihlr-16500	644	14	(	(	PUNCT
ihlr-16500	644	15	statement	statement	NOUN
ihlr-16500	644	16	of	of	ADP
ihlr-16500	644	17	abbeys	abbey	NOUN
ihlr-16500	644	18	.	.	PUNCT
ihlr-16500	645	1	meyers	meyer	NOUN
ihlr-16500	645	2	,	,	PUNCT
ihlr-16500	645	3	president	president	NOUN
ihlr-16500	645	4	,	,	PUNCT
ihlr-16500	645	5	the	the	DET
ihlr-16500	645	6	national	national	PROPN
ihlr-16500	645	7	organi­	organi­	PROPN
ihlr-16500	645	8	zation	zation	NOUN
ihlr-16500	645	9	of	of	ADP
ihlr-16500	645	10	rare	rare	ADJ
ihlr-16500	645	11	disorders	disorder	NOUN
ihlr-16500	645	12	)	)	PUNCT
ihlr-16500	645	13	(	(	PUNCT
ihlr-16500	645	14	discussing	discuss	VERB
ihlr-16500	645	15	problems	problem	NOUN
ihlr-16500	645	16	with	with	ADP
ihlr-16500	645	17	the	the	DET
ihlr-16500	645	18	prescription	prescription	NOUN
ihlr-16500	645	19	drog	drog	NOUN
ihlr-16500	645	20	user	user	PROPN
ihlr-16500	645	21	fee	fee	PROPN
ihlr-16500	645	22	act	act	PROPN
ihlr-16500	645	23	)	)	PUNCT
ihlr-16500	645	24	.	.	PUNCT
ihlr-16500	646	1	154	154	NUM
ihlr-16500	646	2	tansey	tansey	NOUN
ihlr-16500	646	3	,	,	PUNCT
ihlr-16500	646	4	supra	supra	PROPN
ihlr-16500	646	5	note	note	PROPN
ihlr-16500	646	6	151	151	NUM
ihlr-16500	646	7	.	.	PUNCT
ihlr-16500	647	1	iss	iss	PROPN
ihlr-16500	647	2	i	i	PRON
ihlr-16500	647	3	d.	d.	PROPN
ihlr-16500	647	4	representative	representative	PROPN
ihlr-16500	647	5	henry	henry	PROPN
ihlr-16500	647	6	waxman	waxman	PROPN
ihlr-16500	647	7	(	(	PUNCT
ihlr-16500	647	8	democrat	democrat	PROPN
ihlr-16500	647	9	)	)	PUNCT
ihlr-16500	647	10	of	of	ADP
ihlr-16500	647	11	los	los	PROPN
ihlr-16500	647	12	angeles	angeles	PROPN
ihlr-16500	647	13	,	,	PUNCT
ihlr-16500	647	14	california	california	PROPN
ihlr-16500	647	15	,	,	PUNCT
ihlr-16500	647	16	stated	state	VERB
ihlr-16500	647	17	at	at	ADP
ihlr-16500	647	18	a	a	DET
ihlr-16500	647	19	hearing	hearing	NOUN
ihlr-16500	647	20	of	of	ADP
ihlr-16500	647	21	the	the	DET
ihlr-16500	647	22	house	house	NOUN
ihlr-16500	647	23	government	government	PROPN
ihlr-16500	647	24	reform	reform	PROPN
ihlr-16500	647	25	committee	committee	PROPN
ihlr-16500	647	26	that	that	PRON
ihlr-16500	647	27	vioxx	vioxx	PROPN
ihlr-16500	647	28	"	"	PUNCT
ihlr-16500	647	29	built	build	VERB
ihlr-16500	647	30	up	up	ADP
ihlr-16500	647	31	sales	sale	NOUN
ihlr-16500	647	32	topping	top	VERB
ihlr-16500	647	33	$	$	SYM
ihlr-16500	647	34	2	2	NUM
ihlr-16500	647	35	billion	billion	NUM
ihlr-16500	647	36	during	during	ADP
ihlr-16500	647	37	a	a	DET
ihlr-16500	647	38	period	period	NOUN
ihlr-16500	647	39	when	when	SCONJ
ihlr-16500	647	40	safety	safety	NOUN
ihlr-16500	647	41	concerns	concern	NOUN
ihlr-16500	647	42	were	be	AUX
ihlr-16500	647	43	mounting	mount	VERB
ihlr-16500	647	44	among	among	ADP
ihlr-16500	647	45	scientific	scientific	ADJ
ihlr-16500	647	46	experts	expert	NOUN
ihlr-16500	647	47	and	and	CCONJ
ihlr-16500	647	48	fed­	fed­	ADJ
ihlr-16500	647	49	eral	eral	ADJ
ihlr-16500	647	50	regulators	regulator	NOUN
ihlr-16500	647	51	.	.	PUNCT
ihlr-16500	647	52	"	"	PUNCT
ihlr-16500	648	1	i	i	PRON
ihlr-16500	648	2	d.	d.	PROPN
ihlr-16500	648	3	representative	representative	PROPN
ihlr-16500	648	4	waxman	waxman	PROPN
ihlr-16500	648	5	,	,	PUNCT
ihlr-16500	648	6	whose	whose	DET
ihlr-16500	648	7	staff	staff	NOUN
ihlr-16500	648	8	analyzed	analyze	VERB
ihlr-16500	648	9	20,000	20,000	NUM
ihlr-16500	648	10	documents	document	NOUN
ihlr-16500	648	11	related	relate	VERB
ihlr-16500	648	12	to	to	ADP
ihlr-16500	648	13	the	the	DET
ihlr-16500	648	14	sales	sale	NOUN
ihlr-16500	648	15	promotion	promotion	NOUN
ihlr-16500	648	16	ofvi!>xx	ofvi!>xx	NOUN
ihlr-16500	648	17	,	,	PUNCT
ihlr-16500	648	18	also	also	ADV
ihlr-16500	648	19	claimed	claim	VERB
ihlr-16500	648	20	that	that	SCONJ
ihlr-16500	648	21	physicians	physician	NOUN
ihlr-16500	648	22	wrote	write	VERB
ihlr-16500	648	23	millions	million	NOUN
ihlr-16500	648	24	ofvioxx	ofvioxx	ADJ
ihlr-16500	648	25	prescriptions	prescription	NOUN
ihlr-16500	648	26	due	due	ADJ
ihlr-16500	648	27	to	to	ADP
ihlr-16500	648	28	''	''	PUNCT
ihlr-16500	648	29	merck	merck	ADJ
ihlr-16500	648	30	sales	sale	NOUN
ihlr-16500	648	31	strategies	strategy	NOUN
ihlr-16500	648	32	that	that	PRON
ihlr-16500	648	33	amounted	amount	VERB
ihlr-16500	648	34	to	to	ADP
ihlr-16500	648	35	'	'	PUNCT
ihlr-16500	648	36	disinformation	disinformation	NOUN
ihlr-16500	648	37	and	and	CCONJ
ihlr-16500	648	38	censorship	censorship	NOUN
ihlr-16500	648	39	'	'	PUNCT
ihlr-16500	648	40	.	.	PUNCT
ihlr-16500	648	41	"	"	PUNCT
ihlr-16500	649	1	i	i	PRON
ihlr-16500	649	2	d.	d.	PROPN
ihlr-16500	649	3	1s6	1s6	NUM
ihlr-16500	649	4	/d	/d	PUNCT
ihlr-16500	649	5	.	.	PUNCT
ihlr-16500	649	6	is	be	AUX
ihlr-16500	649	7	?	?	PUNCT
ihlr-16500	650	1	i	i	PRON
ihlr-16500	650	2	d.	d.	PROPN
ihlr-16500	650	3	in	in	ADP
ihlr-16500	650	4	addition	addition	NOUN
ihlr-16500	650	5	,	,	PUNCT
ihlr-16500	650	6	the	the	DET
ihlr-16500	650	7	committee	committee	NOUN
ihlr-16500	650	8	analysis	analysis	NOUN
ihlr-16500	650	9	found	find	VERB
ihlr-16500	650	10	that	that	SCONJ
ihlr-16500	650	11	sales	sale	NOUN
ihlr-16500	650	12	representatives	representative	NOUN
ihlr-16500	650	13	were	be	AUX
ihlr-16500	650	14	not	not	PART
ihlr-16500	650	15	to	to	PART
ihlr-16500	650	16	initiate	initiate	VERB
ihlr-16500	650	17	discussions	discussion	NOUN
ihlr-16500	650	18	of	of	ADP
ihlr-16500	650	19	the	the	DET
ihlr-16500	650	20	vioxx	vioxx	NOUN
ihlr-16500	650	21	vigor	vigor	NOUN
ihlr-16500	650	22	study	study	NOUN
ihlr-16500	650	23	with	with	ADP
ihlr-16500	650	24	physicians	physician	NOUN
ihlr-16500	650	25	and	and	CCONJ
ihlr-16500	650	26	"	"	PUNCT
ihlr-16500	650	27	[	[	X
ihlr-16500	650	28	i]nstead	i]nstead	NOUN
ihlr-16500	650	29	,	,	PUNCT
ihlr-16500	650	30	they	they	PRON
ihlr-16500	650	31	were	be	AUX
ihlr-16500	650	32	to	to	PART
ihlr-16500	650	33	offer	offer	VERB
ihlr-16500	650	34	information	information	NOUN
ihlr-16500	650	35	from	from	ADP
ihlr-16500	650	36	a	a	DET
ihlr-16500	650	37	company	company	NOUN
ihlr-16500	650	38	-	-	PUNCT
ihlr-16500	650	39	prepared	prepare	VERB
ihlr-16500	650	40	'	'	PUNCT
ihlr-16500	650	41	cardiovascular	cardiovascular	ADJ
ihlr-16500	650	42	card	card	NOUN
ihlr-16500	650	43	'	'	PUNCT
ihlr-16500	650	44	that	that	PRON
ihlr-16500	650	45	indicated	indicate	VERB
ihlr-16500	650	46	vioxx	vioxx	NOUN
ihlr-16500	650	47	was	be	AUX
ihlr-16500	650	48	eight	eight	NUM
ihlr-16500	650	49	to	to	PART
ihlr-16500	650	50	[	[	X
ihlr-16500	650	51	eleven	eleven	NUM
ihlr-16500	650	52	]	]	X
ihlr-16500	650	53	times	time	NOUN
ihlr-16500	650	54	safer	safe	ADJ
ihlr-16500	650	55	than	than	ADP
ihlr-16500	650	56	other	other	ADJ
ihlr-16500	650	57	anti	anti	ADJ
ihlr-16500	650	58	-	-	ADJ
ihlr-16500	650	59	inflammatory	inflammatory	ADJ
ihlr-16500	650	60	painkillers	painkiller	NOUN
ihlr-16500	650	61	.	.	PUNCT
ihlr-16500	650	62	"	"	PUNCT
ihlr-16500	651	1	/d	/d	PUNCT
ihlr-16500	651	2	.	.	PUNCT
ihlr-16500	652	1	the	the	DET
ihlr-16500	652	2	vigor	vigor	ADJ
ihlr-16500	652	3	study	study	NOUN
ihlr-16500	652	4	showed	show	VERB
ihlr-16500	652	5	that	that	SCONJ
ihlr-16500	652	6	although	although	SCONJ
ihlr-16500	652	7	efficacious	efficacious	ADJ
ihlr-16500	652	8	,	,	PUNCT
ihlr-16500	652	9	vioxx	vioxx	PROPN
ihlr-16500	652	10	did	do	AUX
ihlr-16500	652	11	have	have	VERB
ihlr-16500	652	12	a	a	DET
ihlr-16500	652	13	higher	high	ADJ
ihlr-16500	652	14	risk	risk	NOUN
ihlr-16500	652	15	of	of	ADP
ihlr-16500	652	16	causing	cause	VERB
ihlr-16500	652	17	cardiovascular	cardiovascular	ADJ
ihlr-16500	652	18	events	event	NOUN
ihlr-16500	652	19	than	than	ADP
ihlr-16500	652	20	naproxen	naproxen	NOUN
ihlr-16500	652	21	.	.	PUNCT
ihlr-16500	653	1	press	press	NOUN
ihlr-16500	653	2	release	release	NOUN
ihlr-16500	653	3	,	,	PUNCT
ihlr-16500	653	4	peters	peters	PROPN
ihlr-16500	653	5	.	.	PUNCT
ihlr-16500	654	1	kim	kim	PROPN
ihlr-16500	654	2	,	,	PUNCT
ihlr-16500	654	3	president	president	NOUN
ihlr-16500	654	4	,	,	PUNCT
ihlr-16500	654	5	merck	merck	PROPN
ihlr-16500	654	6	research	research	NOUN
ihlr-16500	654	7	laboratories	laboratory	NOUN
ihlr-16500	654	8	(	(	PUNCT
ihlr-16500	654	9	oct	oct	PROPN
ihlr-16500	654	10	.	.	PROPN
ihlr-16500	654	11	13	13	NUM
ihlr-16500	654	12	,	,	PUNCT
ihlr-16500	654	13	2004	2004	NUM
ihlr-16500	654	14	)	)	PUNCT
ihlr-16500	654	15	,	,	PUNCT
ihlr-16500	654	16	available	available	ADJ
ihlr-16500	654	17	at	at	ADP
ihlr-16500	654	18	http://www.merck.com/newsroomlvioxx_withdrawal	http://www.merck.com/newsroomlvioxx_withdrawal	PROPN
ihlr-16500	654	19	2007	2007	NUM
ihlr-16500	654	20	]	]	PUNCT
ihlr-16500	654	21	pulling	pull	VERB
ihlr-16500	654	22	a	a	DET
ihlr-16500	654	23	blockbuster	blockbuster	ADJ
ihlr-16500	654	24	drug	drug	NOUN
ihlr-16500	654	25	off	off	ADP
ihlr-16500	654	26	the	the	DET
ihlr-16500	654	27	market	market	NOUN
ihlr-16500	654	28	145	145	NUM
ihlr-16500	654	29	spokesman	spokesman	NOUN
ihlr-16500	654	30	further	far	ADV
ihlr-16500	654	31	reiterated	reiterate	VERB
ihlr-16500	654	32	that	that	SCONJ
ihlr-16500	654	33	the	the	DET
ihlr-16500	654	34	company	company	NOUN
ihlr-16500	654	35	's	's	PART
ihlr-16500	654	36	marketing	marketing	NOUN
ihlr-16500	654	37	practices	practice	NOUN
ihlr-16500	654	38	were	be	AUX
ihlr-16500	654	39	fair	fair	ADJ
ihlr-16500	654	40	and	and	CCONJ
ihlr-16500	654	41	balanced	balanced	ADJ
ihlr-16500	654	42	,	,	PUNCT
ihlr-16500	654	43	noting	note	VERB
ihlr-16500	654	44	that	that	SCONJ
ihlr-16500	654	45	ihysicians	ihysician	NOUN
ihlr-16500	654	46	have	have	VERB
ihlr-16500	654	47	the	the	DET
ihlr-16500	654	48	opportunity	opportunity	NOUN
ihlr-16500	654	49	to	to	PART
ihlr-16500	654	50	read	read	VERB
ihlr-16500	654	51	every	every	DET
ihlr-16500	654	52	clinical	clinical	ADJ
ihlr-16500	654	53	study	study	NOUN
ihlr-16500	654	54	including	include	VERB
ihlr-16500	654	55	vioxx	vioxx	NOUN
ihlr-16500	654	56	.	.	PUNCT
ihlr-16500	655	1	1	1	NUM
ihlr-16500	655	2	8	8	NUM
ihlr-16500	655	3	fu	fu	NOUN
ihlr-16500	655	4	addition	addition	NOUN
ihlr-16500	655	5	,	,	PUNCT
ihlr-16500	655	6	these	these	DET
ihlr-16500	655	7	sales	sale	NOUN
ihlr-16500	655	8	practices	practice	NOUN
ihlr-16500	655	9	are	be	AUX
ihlr-16500	655	10	common	common	ADJ
ihlr-16500	655	11	throughout	throughout	ADP
ihlr-16500	655	12	the	the	DET
ihlr-16500	655	13	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	655	14	industry	industry	NOUN
ihlr-16500	655	15	where	where	SCONJ
ihlr-16500	655	16	sales	sale	NOUN
ihlr-16500	655	17	representatives	representative	NOUN
ihlr-16500	655	18	attempt	attempt	VERB
ihlr-16500	655	19	to	to	PART
ihlr-16500	655	20	persuade	persuade	VERB
ihlr-16500	655	21	busy	busy	ADJ
ihlr-16500	655	22	physicians	physician	NOUN
ihlr-16500	655	23	to	to	PART
ihlr-16500	655	24	use	use	VERB
ihlr-16500	655	25	their	their	PRON
ihlr-16500	655	26	products	product	NOUN
ihlr-16500	655	27	and	and	CCONJ
ihlr-16500	655	28	as	as	ADP
ihlr-16500	655	29	a	a	DET
ihlr-16500	655	30	result	result	NOUN
ihlr-16500	655	31	often	often	ADV
ihlr-16500	655	32	fail	fail	VERB
ihlr-16500	655	33	to	to	PART
ihlr-16500	655	34	be	be	AUX
ihlr-16500	655	35	objective	objective	ADJ
ihlr-16500	655	36	.	.	PUNCT
ihlr-16500	656	1	nevertheless	nevertheless	ADV
ihlr-16500	656	2	,	,	PUNCT
ihlr-16500	656	3	the	the	DET
ihlr-16500	656	4	fda	fda	PROPN
ihlr-16500	656	5	found	find	VERB
ihlr-16500	656	6	that	that	SCONJ
ihlr-16500	656	7	merck	merck	PROPN
ihlr-16500	656	8	's	's	PART
ihlr-16500	656	9	sales	sale	NOUN
ihlr-16500	656	10	practices	practice	NOUN
ihlr-16500	656	11	were	be	AUX
ihlr-16500	656	12	legal	legal	ADJ
ihlr-16500	656	13	and	and	CCONJ
ihlr-16500	656	14	appropriate	appropriate	ADJ
ihlr-16500	656	15	.	.	PUNCT
ihlr-16500	657	1	159	159	NUM
ihlr-16500	657	2	d.	d.	PROPN
ihlr-16500	657	3	shared	share	VERB
ihlr-16500	657	4	culpability	culpability	NOUN
ihlr-16500	657	5	among	among	ADP
ihlr-16500	657	6	all	all	DET
ihlr-16500	657	7	parties	party	NOUN
ihlr-16500	657	8	involved	involve	VERB
ihlr-16500	657	9	?	?	PUNCT
ihlr-16500	658	1	inevitably	inevitably	ADV
ihlr-16500	658	2	,	,	PUNCT
ihlr-16500	658	3	the	the	DET
ihlr-16500	658	4	party	party	NOUN
ihlr-16500	658	5	solely	solely	ADV
ihlr-16500	658	6	responsible	responsible	ADJ
ihlr-16500	658	7	for	for	ADP
ihlr-16500	658	8	a	a	DET
ihlr-16500	658	9	drug	drug	NOUN
ihlr-16500	658	10	withdrawal	withdrawal	NOUN
ihlr-16500	658	11	is	be	AUX
ihlr-16500	658	12	not	not	PART
ihlr-16500	658	13	easily	easily	ADV
ihlr-16500	658	14	discerned	discern	VERB
ihlr-16500	658	15	.	.	PUNCT
ihlr-16500	659	1	as	as	SCONJ
ihlr-16500	659	2	evidenced	evidence	VERB
ihlr-16500	659	3	by	by	ADP
ihlr-16500	659	4	the	the	DET
ihlr-16500	659	5	vioxx	vioxx	NOUN
ihlr-16500	659	6	case	case	NOUN
ihlr-16500	659	7	and	and	CCONJ
ihlr-16500	659	8	other	other	ADJ
ihlr-16500	659	9	recent	recent	ADJ
ihlr-16500	659	10	drug	drug	NOUN
ihlr-16500	659	11	withdrawals	withdrawal	NOUN
ihlr-16500	659	12	,	,	PUNCT
ihlr-16500	659	13	it	it	PRON
ihlr-16500	659	14	is	be	AUX
ihlr-16500	659	15	usually	usually	ADV
ihlr-16500	659	16	a	a	DET
ihlr-16500	659	17	combination	combination	NOUN
ihlr-16500	659	18	of	of	ADP
ihlr-16500	659	19	missteps	misstep	NOUN
ihlr-16500	659	20	by	by	ADP
ihlr-16500	659	21	both	both	CCONJ
ihlr-16500	659	22	the	the	DET
ihlr-16500	659	23	drug	drug	NOUN
ihlr-16500	659	24	's	's	PART
ihlr-16500	659	25	manufacturer	manufacturer	NOUN
ihlr-16500	659	26	and	and	CCONJ
ihlr-16500	659	27	the	the	DET
ihlr-16500	659	28	fda	fda	PROPN
ihlr-16500	659	29	.	.	PUNCT
ihlr-16500	660	1	ultimately	ultimately	ADV
ihlr-16500	660	2	,	,	PUNCT
ihlr-16500	660	3	it	it	PRON
ihlr-16500	660	4	is	be	AUX
ihlr-16500	660	5	difficult	difficult	ADJ
ihlr-16500	660	6	to	to	PART
ihlr-16500	660	7	assess	assess	VERB
ihlr-16500	660	8	blame	blame	NOUN
ihlr-16500	660	9	but	but	CCONJ
ihlr-16500	660	10	easy	easy	ADJ
ihlr-16500	660	11	to	to	PART
ihlr-16500	660	12	identify	identify	VERB
ihlr-16500	660	13	those	those	PRON
ihlr-16500	660	14	who	who	PRON
ihlr-16500	660	15	are	be	AUX
ihlr-16500	660	16	adversely	adversely	ADV
ihlr-16500	660	17	affected	affect	VERB
ihlr-16500	660	18	.	.	PUNCT
ihlr-16500	661	1	for	for	ADP
ihlr-16500	661	2	instance	instance	NOUN
ihlr-16500	661	3	,	,	PUNCT
ihlr-16500	661	4	it	it	PRON
ihlr-16500	661	5	may	may	AUX
ihlr-16500	661	6	be	be	AUX
ihlr-16500	661	7	the	the	DET
ihlr-16500	661	8	patients	patient	NOUN
ihlr-16500	661	9	who	who	PRON
ihlr-16500	661	10	relied	rely	VERB
ihlr-16500	661	11	on	on	ADP
ihlr-16500	661	12	the	the	DET
ihlr-16500	661	13	information	information	NOUN
ihlr-16500	661	14	provided	provide	VERB
ihlr-16500	661	15	to	to	ADP
ihlr-16500	661	16	them	they	PRON
ihlr-16500	661	17	by	by	ADP
ihlr-16500	661	18	doctors	doctor	NOUN
ihlr-16500	661	19	.	.	PUNCT
ihlr-16500	662	1	additionally	additionally	ADV
ihlr-16500	662	2	,	,	PUNCT
ihlr-16500	662	3	it	it	PRON
ihlr-16500	662	4	may	may	AUX
ihlr-16500	662	5	be	be	AUX
ihlr-16500	662	6	the	the	DET
ihlr-16500	662	7	doctor	doctor	NOUN
ihlr-16500	662	8	who	who	PRON
ihlr-16500	662	9	relied	rely	VERB
ihlr-16500	662	10	on	on	ADP
ihlr-16500	662	11	information	information	NOUN
ihlr-16500	662	12	provided	provide	VERB
ihlr-16500	662	13	to	to	ADP
ihlr-16500	662	14	him	he	PRON
ihlr-16500	662	15	or	or	CCONJ
ihlr-16500	662	16	her	she	PRON
ihlr-16500	662	17	by	by	ADP
ihlr-16500	662	18	the	the	DET
ihlr-16500	662	19	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	662	20	com­	com­	NOUN
ihlr-16500	662	21	pany	pany	NOUN
ihlr-16500	662	22	.	.	PUNCT
ihlr-16500	663	1	finally	finally	ADV
ihlr-16500	663	2	,	,	PUNCT
ihlr-16500	663	3	it	it	PRON
ihlr-16500	663	4	may	may	AUX
ihlr-16500	663	5	be	be	AUX
ihlr-16500	663	6	the	the	DET
ihlr-16500	663	7	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	663	8	company	company	NOUN
ihlr-16500	663	9	and	and	CCONJ
ihlr-16500	663	10	the	the	DET
ihlr-16500	663	11	appropriate	appropriate	ADJ
ihlr-16500	663	12	regu­	regu­	NUM
ihlr-16500	663	13	latory	latory	ADJ
ihlr-16500	663	14	agency	agency	NOUN
ihlr-16500	663	15	that	that	PRON
ihlr-16500	663	16	were	be	AUX
ihlr-16500	663	17	unaware	unaware	ADJ
ihlr-16500	663	18	of	of	ADP
ihlr-16500	663	19	the	the	DET
ihlr-16500	663	20	dangers	danger	NOUN
ihlr-16500	663	21	of	of	ADP
ihlr-16500	663	22	a	a	DET
ihlr-16500	663	23	drug	drug	NOUN
ihlr-16500	663	24	that	that	PRON
ihlr-16500	663	25	had	have	AUX
ihlr-16500	663	26	not	not	PART
ihlr-16500	663	27	yet	yet	ADV
ihlr-16500	663	28	been	be	AUX
ihlr-16500	663	29	fully	fully	ADV
ihlr-16500	663	30	investigated	investigate	VERB
ihlr-16500	663	31	.	.	PUNCT
ihlr-16500	664	1	viti	viti	NOUN
ihlr-16500	664	2	.	.	PUNCT
ihlr-16500	665	1	possible	possible	ADJ
ihlr-16500	665	2	solutions	solution	NOUN
ihlr-16500	665	3	there	there	PRON
ihlr-16500	665	4	are	be	VERB
ihlr-16500	665	5	several	several	ADJ
ihlr-16500	665	6	possible	possible	ADJ
ihlr-16500	665	7	solutions	solution	NOUN
ihlr-16500	665	8	in	in	ADP
ihlr-16500	665	9	order	order	NOUN
ihlr-16500	665	10	to	to	PART
ihlr-16500	665	11	minimize	minimize	VERB
ihlr-16500	665	12	the	the	DET
ihlr-16500	665	13	numerous	numerous	ADJ
ihlr-16500	665	14	ways	way	NOUN
ihlr-16500	665	15	in	in	ADP
ihlr-16500	665	16	which	which	PRON
ihlr-16500	665	17	a	a	DET
ihlr-16500	665	18	drug	drug	NOUN
ihlr-16500	665	19	withdrawal	withdrawal	NOUN
ihlr-16500	665	20	may	may	AUX
ihlr-16500	665	21	affect	affect	VERB
ihlr-16500	665	22	multiple	multiple	ADJ
ihlr-16500	665	23	parties	party	NOUN
ihlr-16500	665	24	.	.	PUNCT
ihlr-16500	666	1	first	first	ADV
ihlr-16500	666	2	,	,	PUNCT
ihlr-16500	666	3	although	although	SCONJ
ihlr-16500	666	4	a	a	DET
ihlr-16500	666	5	drug	drug	NOUN
ihlr-16500	666	6	may	may	AUX
ihlr-16500	666	7	negatively	negatively	ADV
ihlr-16500	666	8	affect	affect	VERB
ihlr-16500	666	9	certain	certain	ADJ
ihlr-16500	666	10	patients	patient	NOUN
ihlr-16500	666	11	,	,	PUNCT
ihlr-16500	666	12	other	other	ADJ
ihlr-16500	666	13	patients	patient	NOUN
ihlr-16500	666	14	who	who	PRON
ihlr-16500	666	15	are	be	AUX
ihlr-16500	666	16	positively	positively	ADV
ihlr-16500	666	17	affected	affect	VERB
ihlr-16500	666	18	by	by	ADP
ihlr-16500	666	19	the	the	DET
ihlr-16500	666	20	drug	drug	NOUN
ihlr-16500	666	21	are	be	AUX
ihlr-16500	666	22	faced	face	VERB
ihlr-16500	666	23	with	with	ADP
ihlr-16500	666	24	a	a	DET
ihlr-16500	666	25	lesser	less	ADJ
ihlr-16500	666	26	quality	quality	NOUN
ihlr-16500	666	27	of	of	ADP
ihlr-16500	666	28	life	life	NOUN
ihlr-16500	666	29	as	as	ADP
ihlr-16500	666	30	a	a	DET
ihlr-16500	666	31	result	result	NOUN
ihlr-16500	666	32	of	of	ADP
ihlr-16500	666	33	the	the	DET
ihlr-16500	666	34	drug	drug	NOUN
ihlr-16500	666	35	withdrawal	withdrawal	NOUN
ihlr-16500	666	36	.	.	PUNCT
ihlr-16500	667	1	these	these	DET
ihlr-16500	667	2	patients	patient	NOUN
ihlr-16500	667	3	might	might	AUX
ihlr-16500	667	4	be	be	AUX
ihlr-16500	667	5	able	able	ADJ
ihlr-16500	667	6	to	to	PART
ihlr-16500	667	7	fmd	fmd	VERB
ihlr-16500	667	8	some	some	DET
ihlr-16500	667	9	relief	relief	NOUN
ihlr-16500	667	10	if	if	SCONJ
ihlr-16500	667	11	the	the	DET
ihlr-16500	667	12	withdrawn	withdraw	VERB
ihlr-16500	667	13	drug	drug	NOUN
ihlr-16500	667	14	could	could	AUX
ihlr-16500	667	15	still	still	ADV
ihlr-16500	667	16	be	be	AUX
ihlr-16500	667	17	prescribed	prescribe	VERB
ihlr-16500	667	18	to	to	ADP
ihlr-16500	667	19	them	they	PRON
ihlr-16500	667	20	.	.	PUNCT
ihlr-16500	668	1	for	for	ADP
ihlr-16500	668	2	instance	instance	NOUN
ihlr-16500	668	3	,	,	PUNCT
ihlr-16500	668	4	in	in	ADP
ihlr-16500	668	5	the	the	DET
ihlr-16500	668	6	vigor	vigor	NOUN
ihlr-16500	668	7	trial	trial	NOUN
ihlr-16500	668	8	,	,	PUNCT
ihlr-16500	668	9	vioxx	vioxx	NOUN
ihlr-16500	668	10	was	be	AUX
ihlr-16500	668	11	administered	administer	VERB
ihlr-16500	668	12	to	to	ADP
ihlr-16500	668	13	4,000	4,000	NUM
ihlr-16500	668	14	patients	patient	NOUN
ihlr-16500	668	15	,	,	PUNCT
ihlr-16500	668	16	some	some	DET
ihlr-16500	668	17	elderly	elderly	ADJ
ihlr-16500	668	18	,	,	PUNCT
ihlr-16500	668	19	at	at	ADP
ihlr-16500	668	20	the	the	DET
ihlr-16500	668	21	highest	high	ADJ
ihlr-16500	668	22	possible	possible	ADJ
ihlr-16500	668	23	dose	dose	NOUN
ihlr-16500	668	24	of	of	ADP
ihlr-16500	668	25	fifty	fifty	NUM
ihlr-16500	668	26	milligrams.160	milligrams.160	NUM
ihlr-16500	668	27	most	most	ADJ
ihlr-16500	668	28	patients	patient	NOUN
ihlr-16500	668	29	who	who	PRON
ihlr-16500	668	30	were	be	AUX
ihlr-16500	668	31	prescribed	prescribe	VERB
ihlr-16500	668	32	vioxx	vioxx	NOUN
ihlr-16500	668	33	,	,	PUNCT
ihlr-16500	668	34	however	however	ADV
ihlr-16500	668	35	,	,	PUNCT
ihlr-16500	668	36	were	be	AUX
ihlr-16500	668	37	often	often	ADV
ihlr-16500	668	38	younger	young	ADJ
ihlr-16500	668	39	patients	patient	NOUN
ihlr-16500	668	40	and	and	CCONJ
ihlr-16500	668	41	were	be	AUX
ihlr-16500	668	42	prescribed	prescribe	VERB
ihlr-16500	668	43	much	much	ADV
ihlr-16500	668	44	lower	low	ADJ
ihlr-16500	668	45	doses	dose	NOUN
ihlr-16500	668	46	,	,	PUNCT
ihlr-16500	668	47	specifically	specifically	ADV
ihlr-16500	668	48	at	at	ADP
ihlr-16500	668	49	12.5	12.5	NUM
ihlr-16500	668	50	and	and	CCONJ
ihlr-16500	668	51	25	25	NUM
ihlr-16500	668	52	milligrams.161	milligrams.161	ADJ
ihlr-16500	668	53	therefore	therefore	ADV
ihlr-16500	668	54	,	,	PUNCT
ihlr-16500	668	55	many	many	ADJ
ihlr-16500	668	56	of	of	ADP
ihlr-16500	668	57	the	the	DET
ihlr-16500	668	58	patients	patient	NOUN
ihlr-16500	668	59	who	who	PRON
ihlr-16500	668	60	were	be	AUX
ihlr-16500	668	61	previ­	previ­	PRON
ihlr-16500	668	62	ously	ously	ADV
ihlr-16500	668	63	prescribed	prescribe	VERB
ihlr-16500	668	64	vioxx	vioxx	NOUN
ihlr-16500	668	65	did	do	AUX
ihlr-16500	668	66	not	not	PART
ihlr-16500	668	67	fall	fall	VERB
ihlr-16500	668	68	into	into	ADP
ihlr-16500	668	69	the	the	DET
ihlr-16500	668	70	category	category	NOUN
ihlr-16500	668	71	of	of	ADP
ihlr-16500	668	72	patients	patient	NOUN
ihlr-16500	668	73	who	who	PRON
ihlr-16500	668	74	experi­	experi­	VERB
ihlr-16500	668	75	enced	ence	VERB
ihlr-16500	668	76	problems	problem	NOUN
ihlr-16500	668	77	in	in	ADP
ihlr-16500	668	78	the	the	DET
ihlr-16500	668	79	vigor	vigor	ADJ
ihlr-16500	668	80	trial	trial	NOUN
ihlr-16500	668	81	and	and	CCONJ
ihlr-16500	668	82	arguably	arguably	ADV
ihlr-16500	668	83	should	should	AUX
ihlr-16500	668	84	be	be	AUX
ihlr-16500	668	85	allowed	allow	VERB
ihlr-16500	668	86	to	to	PART
ihlr-16500	668	87	continue	continue	VERB
ihlr-16500	668	88	using	use	VERB
ihlr-16500	668	89	it	it	PRON
ihlr-16500	668	90	at	at	ADP
ihlr-16500	668	91	the	the	DET
ihlr-16500	668	92	lower	low	ADJ
ihlr-16500	668	93	dose	dose	NOUN
ihlr-16500	668	94	.	.	PUNCT
ihlr-16500	669	1	/pd£11	/pd£11	PUNCT
ihlr-16500	669	2	0	0	PUNCT
ihlr-16500	670	1	_	_	NOUN
ihlr-16500	670	2	13	13	NUM
ihlr-16500	670	3	_	_	NOUN
ihlr-16500	670	4	2004	2004	NUM
ihlr-16500	671	1	_	_	PUNCT
ihlr-16500	671	2	psk.pdf	psk.pdf	NOUN
ihlr-16500	671	3	.	.	PUNCT
ihlr-16500	672	1	158	158	NUM
ihlr-16500	672	2	tansey	tansey	NOUN
ihlr-16500	672	3	,	,	PUNCT
ihlr-16500	672	4	supra	supra	PROPN
ihlr-16500	672	5	note	note	PROPN
ihlr-16500	672	6	151	151	NUM
ihlr-16500	672	7	.	.	NOUN
ihlr-16500	672	8	159	159	NUM
ihlr-16500	673	1	i	i	PROPN
ihlr-16500	673	2	d.	d.	PROPN
ihlr-16500	673	3	160	160	NUM
ihlr-16500	673	4	letter	letter	NOUN
ihlr-16500	673	5	from	from	ADP
ihlr-16500	673	6	thomas	thomas	PROPN
ihlr-16500	673	7	w.	w.	PROPN
ihlr-16500	673	8	abrams	abrams	PROPN
ihlr-16500	673	9	,	,	PUNCT
ihlr-16500	673	10	dir	dir	PROPN
ihlr-16500	673	11	.	.	PUNCT
ihlr-16500	673	12	of	of	ADP
ihlr-16500	673	13	div	div	PROPN
ihlr-16500	673	14	.	.	PUNCT
ihlr-16500	673	15	of	of	ADP
ihlr-16500	673	16	drug	drug	NOUN
ihlr-16500	673	17	marketing	marketing	NOUN
ihlr-16500	673	18	,	,	PUNCT
ihlr-16500	673	19	adver	adver	ADJ
ihlr-16500	673	20	.	.	PROPN
ihlr-16500	673	21	,	,	PUNCT
ihlr-16500	673	22	&	&	CCONJ
ihlr-16500	673	23	commc'ns	commc'ns	PROPN
ihlr-16500	673	24	,	,	PUNCT
ihlr-16500	673	25	u.s	u.s	PROPN
ihlr-16500	673	26	.	.	PROPN
ihlr-16500	673	27	dep't	dep't	PROPN
ihlr-16500	673	28	health	health	PROPN
ihlr-16500	673	29	&	&	CCONJ
ihlr-16500	673	30	human	human	PROPN
ihlr-16500	673	31	servs	servs	PROPN
ihlr-16500	673	32	.	.	PUNCT
ihlr-16500	673	33	,	,	PUNCT
ihlr-16500	673	34	to	to	ADP
ihlr-16500	673	35	raymond	raymond	PROPN
ihlr-16500	673	36	v.	v.	PROPN
ihlr-16500	673	37	gilmartin	gilmartin	PROPN
ihlr-16500	673	38	,	,	PUNCT
ihlr-16500	673	39	president	president	NOUN
ihlr-16500	673	40	and	and	CCONJ
ihlr-16500	673	41	ceo	ceo	PROPN
ihlr-16500	673	42	ofmerck	ofmerck	PROPN
ihlr-16500	673	43	&	&	CCONJ
ihlr-16500	673	44	co.	co.	PROPN
ihlr-16500	673	45	inc	inc	PROPN
ihlr-16500	673	46	.	.	PROPN
ihlr-16500	674	1	(	(	PUNCT
ihlr-16500	674	2	sept	sept	PROPN
ihlr-16500	674	3	.	.	PROPN
ihlr-16500	674	4	17	17	NUM
ihlr-16500	674	5	,	,	PUNCT
ihlr-16500	674	6	2001	2001	NUM
ihlr-16500	674	7	)	)	PUNCT
ihlr-16500	674	8	,	,	PUNCT
ihlr-16500	674	9	http://www.fda.gov/foilwaming_letters/gl751d.pdf	http://www.fda.gov/foilwaming_letters/gl751d.pdf	PROPN
ihlr-16500	674	10	.	.	PUNCT
ihlr-16500	675	1	161	161	NUM
ihlr-16500	675	2	fda.gov	fda.gov	NUM
ihlr-16500	675	3	,	,	PUNCT
ihlr-16500	675	4	vioxx	vioxx	NOUN
ihlr-16500	675	5	(	(	PUNCT
ihlr-16500	675	6	rofecoxib	rofecoxib	VERB
ihlr-16500	675	7	tablets	tablet	NOUN
ihlr-16500	675	8	and	and	CCONJ
ihlr-16500	675	9	oral	oral	ADJ
ihlr-16500	675	10	suspension	suspension	NOUN
ihlr-16500	675	11	)	)	PUNCT
ihlr-16500	675	12	,	,	PUNCT
ihlr-16500	675	13	http://www.fda.gov	http://www.fda.gov	NOUN
ihlr-16500	675	14	/medwatch!safety	/medwatch!safety	NOUN
ihlr-16500	675	15	/2002	/2002	PUNCT
ihlr-16500	675	16	/	/	SYM
ihlr-16500	675	17	vioxx	vioxx	NOUN
ihlr-16500	675	18	_	_	PUNCT
ihlr-16500	676	1	pi.pdf	pi.pdf	NOUN
ihlr-16500	676	2	(	(	PUNCT
ihlr-16500	676	3	last	last	ADV
ihlr-16500	676	4	visited	visit	VERB
ihlr-16500	676	5	feb	feb	PROPN
ihlr-16500	676	6	.	.	PROPN
ihlr-16500	676	7	24	24	NUM
ihlr-16500	676	8	,	,	PUNCT
ihlr-16500	676	9	2007	2007	NUM
ihlr-16500	676	10	)	)	PUNCT
ihlr-16500	676	11	(	(	PUNCT
ihlr-16500	676	12	prescribing	prescribe	VERB
ihlr-16500	676	13	information	information	NOUN
ihlr-16500	676	14	circular	circular	ADJ
ihlr-16500	676	15	)	)	PUNCT
ihlr-16500	676	16	.	.	PUNCT
ihlr-16500	677	1	146	146	NUM
ihlr-16500	677	2	indiana	indiana	PROPN
ihlr-16500	677	3	health	health	PROPN
ihlr-16500	677	4	law	law	PROPN
ihlr-16500	677	5	review	review	NOUN
ihlr-16500	677	6	[	[	X
ihlr-16500	677	7	vol	vol	NOUN
ihlr-16500	677	8	.	.	PUNCT
ihlr-16500	677	9	4:115	4:115	NUM
ihlr-16500	677	10	in	in	ADP
ihlr-16500	677	11	fact	fact	NOUN
ihlr-16500	677	12	,	,	PUNCT
ihlr-16500	677	13	several	several	ADJ
ihlr-16500	677	14	months	month	NOUN
ihlr-16500	677	15	after	after	SCONJ
ihlr-16500	677	16	vioxx	vioxx	NOUN
ihlr-16500	677	17	was	be	AUX
ihlr-16500	677	18	withdrawn	withdraw	VERB
ihlr-16500	677	19	from	from	ADP
ihlr-16500	677	20	the	the	DET
ihlr-16500	677	21	market	market	NOUN
ihlr-16500	677	22	,	,	PUNCT
ihlr-16500	677	23	a	a	DET
ihlr-16500	677	24	joint	joint	ADJ
ihlr-16500	677	25	advisory	advisory	ADJ
ihlr-16500	677	26	committee	committee	NOUN
ihlr-16500	677	27	of	of	ADP
ihlr-16500	677	28	the	the	DET
ihlr-16500	677	29	fda	fda	PROPN
ihlr-16500	677	30	,	,	PUNCT
ihlr-16500	677	31	including	include	VERB
ihlr-16500	677	32	thirty	thirty	NUM
ihlr-16500	677	33	-	-	PUNCT
ihlr-16500	677	34	two	two	NUM
ihlr-16500	677	35	experts	expert	NOUN
ihlr-16500	677	36	,	,	PUNCT
ihlr-16500	677	37	concluded	conclude	VERB
ihlr-16500	677	38	that	that	SCONJ
ihlr-16500	677	39	vioxx	vioxx	NOUN
ihlr-16500	677	40	should	should	AUX
ihlr-16500	677	41	be	be	AUX
ihlr-16500	677	42	permitted	permit	VERB
ihlr-16500	677	43	to	to	PART
ihlr-16500	677	44	reenter	reenter	VERB
ihlr-16500	677	45	the	the	DET
ihlr-16500	677	46	market	market	NOUN
ihlr-16500	677	47	with	with	ADP
ihlr-16500	677	48	a	a	DET
ihlr-16500	677	49	stronger	strong	ADJ
ihlr-16500	677	50	wam­	wam­	NOUN
ihlr-16500	677	51	ing.162	ing.162	ADP
ihlr-16500	677	52	the	the	DET
ihlr-16500	677	53	committee	committee	NOUN
ihlr-16500	677	54	put	put	VERB
ihlr-16500	677	55	forth	forth	ADP
ihlr-16500	677	56	such	such	DET
ihlr-16500	677	57	a	a	DET
ihlr-16500	677	58	recommendation	recommendation	NOUN
ihlr-16500	677	59	because	because	SCONJ
ihlr-16500	677	60	it	it	PRON
ihlr-16500	677	61	concluded	conclude	VERB
ihlr-16500	677	62	that	that	SCONJ
ihlr-16500	677	63	in	in	ADP
ihlr-16500	677	64	certain	certain	ADJ
ihlr-16500	677	65	patient	patient	ADJ
ihlr-16500	677	66	populations	population	NOUN
ihlr-16500	677	67	,	,	PUNCT
ihlr-16500	677	68	the	the	DET
ihlr-16500	677	69	benefits	benefit	NOUN
ihlr-16500	677	70	may	may	AUX
ihlr-16500	677	71	outweigh	outweigh	VERB
ihlr-16500	677	72	the	the	DET
ihlr-16500	677	73	risk	risk	NOUN
ihlr-16500	677	74	:	:	PUNCT
ihlr-16500	677	75	s.	s.	PROPN
ihlr-16500	677	76	163	163	NUM
ihlr-16500	677	77	a.	a.	NOUN
ihlr-16500	677	78	allow	allow	VERB
ihlr-16500	677	79	the	the	DET
ihlr-16500	677	80	withdrawn	withdraw	VERB
ihlr-16500	677	81	drug	drug	NOUN
ihlr-16500	677	82	to	to	PART
ihlr-16500	677	83	reenter	reenter	VERB
ihlr-16500	677	84	the	the	DET
ihlr-16500	677	85	market	market	NOUN
ihlr-16500	677	86	under	under	ADP
ihlr-16500	677	87	restricted	restricted	ADJ
ihlr-16500	677	88	conditions	condition	NOUN
ihlr-16500	677	89	there	there	PRON
ihlr-16500	677	90	has	have	AUX
ihlr-16500	677	91	only	only	ADV
ihlr-16500	677	92	been	be	AUX
ihlr-16500	677	93	one	one	NUM
ihlr-16500	677	94	case	case	NOUN
ihlr-16500	677	95	in	in	ADP
ihlr-16500	677	96	u.s	u.s	PROPN
ihlr-16500	677	97	.	.	PROPN
ihlr-16500	677	98	history	history	NOUN
ihlr-16500	677	99	where	where	SCONJ
ihlr-16500	677	100	a	a	DET
ihlr-16500	677	101	drug	drug	NOUN
ihlr-16500	677	102	that	that	PRON
ihlr-16500	677	103	was	be	AUX
ihlr-16500	677	104	previ­	previ­	NOUN
ihlr-16500	677	105	ously	ously	ADV
ihlr-16500	677	106	withdrawn	withdraw	VERB
ihlr-16500	677	107	from	from	ADP
ihlr-16500	677	108	the	the	DET
ihlr-16500	677	109	market	market	NOUN
ihlr-16500	677	110	was	be	AUX
ihlr-16500	677	111	allowed	allow	VERB
ihlr-16500	677	112	to	to	PART
ihlr-16500	677	113	reenter	reenter	VERB
ihlr-16500	677	114	.	.	PUNCT
ihlr-16500	678	1	in	in	ADP
ihlr-16500	678	2	2000	2000	NUM
ihlr-16500	678	3	,	,	PUNCT
ihlr-16500	678	4	glaxo	glaxo	NOUN
ihlr-16500	678	5	phar­	phar­	PROPN
ihlr-16500	678	6	maceuticals	maceutical	NOUN
ihlr-16500	678	7	introduced	introduce	VERB
ihlr-16500	678	8	lotronex	lotronex	NOUN
ihlr-16500	678	9	,	,	PUNCT
ihlr-16500	678	10	which	which	PRON
ihlr-16500	678	11	treated	treat	VERB
ihlr-16500	678	12	irritable	irritable	ADJ
ihlr-16500	678	13	bowel	bowel	NOUN
ihlr-16500	678	14	syndrome	syndrome	NOUN
ihlr-16500	678	15	and	and	CCONJ
ihlr-16500	678	16	as	as	ADP
ihlr-16500	678	17	a	a	DET
ihlr-16500	678	18	result	result	NOUN
ihlr-16500	678	19	helped	help	VERB
ihlr-16500	678	20	millions	million	NOUN
ihlr-16500	678	21	of	of	ADP
ihlr-16500	678	22	americans	americans	PROPN
ihlr-16500	678	23	inflicted	inflict	VERB
ihlr-16500	678	24	with	with	ADP
ihlr-16500	678	25	this.painful	this.painful	ADJ
ihlr-16500	678	26	illness.164	illness.164	NOUN
ihlr-16500	678	27	just	just	ADV
ihlr-16500	678	28	nine	nine	NUM
ihlr-16500	678	29	months	month	NOUN
ihlr-16500	678	30	after	after	SCONJ
ihlr-16500	678	31	it	it	PRON
ihlr-16500	678	32	had	have	AUX
ihlr-16500	678	33	received	receive	VERB
ihlr-16500	678	34	fda	fda	PROPN
ihlr-16500	678	35	approval	approval	NOUN
ihlr-16500	678	36	,	,	PUNCT
ihlr-16500	678	37	however	however	ADV
ihlr-16500	678	38	,	,	PUNCT
ihlr-16500	678	39	the	the	DET
ihlr-16500	678	40	drug	drug	NOUN
ihlr-16500	678	41	was	be	AUX
ihlr-16500	678	42	connected	connect	VERB
ihlr-16500	678	43	with	with	ADP
ihlr-16500	678	44	the	the	DET
ihlr-16500	678	45	deaths	death	NOUN
ihlr-16500	678	46	of	of	ADP
ihlr-16500	678	47	seven	seven	NUM
ihlr-16500	678	48	individuals	individual	NOUN
ihlr-16500	678	49	,	,	PUNCT
ihlr-16500	678	50	and	and	CCONJ
ihlr-16500	678	51	it	it	PRON
ihlr-16500	678	52	was	be	AUX
ihlr-16500	678	53	pulled	pull	VERB
ihlr-16500	678	54	from	from	ADP
ihlr-16500	678	55	the	the	DET
ihlr-16500	678	56	mar­	mar­	NOUN
ihlr-16500	678	57	ket.165	ket.165	NOUN
ihlr-16500	678	58	nevertheless	nevertheless	ADV
ihlr-16500	678	59	,	,	PUNCT
ihlr-16500	678	60	after	after	ADP
ihlr-16500	678	61	heavy	heavy	ADJ
ihlr-16500	678	62	lobbying	lobbying	NOUN
ihlr-16500	678	63	from	from	ADP
ihlr-16500	678	64	desperate	desperate	ADJ
ihlr-16500	678	65	patients	patient	NOUN
ihlr-16500	678	66	claiming	claim	VERB
ihlr-16500	678	67	it	it	PRON
ihlr-16500	678	68	to	to	PART
ihlr-16500	678	69	be	be	AUX
ihlr-16500	678	70	the	the	DET
ihlr-16500	678	71	only	only	ADJ
ihlr-16500	678	72	drug	drug	NOUN
ihlr-16500	678	73	that	that	PRON
ihlr-16500	678	74	ever	ever	ADV
ihlr-16500	678	75	relieved	relieve	VERB
ihlr-16500	678	76	their	their	PRON
ihlr-16500	678	77	constant	constant	ADJ
ihlr-16500	678	78	misery	misery	NOUN
ihlr-16500	678	79	,	,	PUNCT
ihlr-16500	678	80	the	the	DET
ihlr-16500	678	81	fda	fda	PROPN
ihlr-16500	678	82	permitted	permit	VERB
ihlr-16500	678	83	glaxo	glaxo	NOUN
ihlr-16500	678	84	to	to	PART
ihlr-16500	678	85	reintroduce	reintroduce	VERB
ihlr-16500	678	86	the	the	DET
ihlr-16500	678	87	drug	drug	NOUN
ihlr-16500	678	88	into	into	ADP
ihlr-16500	678	89	the	the	DET
ihlr-16500	678	90	u.s	u.s	PROPN
ihlr-16500	678	91	.	.	PROPN
ihlr-16500	678	92	market	market	NOUN
ihlr-16500	678	93	under	under	ADP
ihlr-16500	678	94	careful	careful	ADJ
ihlr-16500	678	95	scrutiny	scrutiny	NOUN
ihlr-16500	678	96	and	and	CCONJ
ihlr-16500	678	97	only	only	ADV
ihlr-16500	678	98	if	if	SCONJ
ihlr-16500	678	99	the	the	DET
ihlr-16500	678	100	company	company	NOUN
ihlr-16500	678	101	agreed	agree	VERB
ihlr-16500	678	102	to	to	PART
ihlr-16500	678	103	increased	increase	VERB
ihlr-16500	678	104	monitoring.166	monitoring.166	ADJ
ihlr-16500	678	105	currently	currently	ADV
ihlr-16500	678	106	,	,	PUNCT
ihlr-16500	678	107	"	"	PUNCT
ihlr-16500	678	108	lotronex	lotronex	NOUN
ihlr-16500	678	109	may	may	AUX
ihlr-16500	678	110	be	be	AUX
ihlr-16500	678	111	prescribed	prescribe	VERB
ihlr-16500	678	112	only	only	ADV
ihlr-16500	678	113	by	by	ADP
ihlr-16500	678	114	certain	certain	ADJ
ihlr-16500	678	115	doctors	doctor	NOUN
ihlr-16500	678	116	enrolled	enrol	VERB
ihlr-16500	678	117	in	in	ADP
ihlr-16500	678	118	a	a	DET
ihlr-16500	678	119	special	special	ADJ
ihlr-16500	678	120	program	program	NOUN
ihlr-16500	678	121	,	,	PUNCT
ihlr-16500	678	122	and	and	CCONJ
ihlr-16500	678	123	given	give	VERB
ihlr-16500	678	124	only	only	ADV
ihlr-16500	678	125	to	to	ADP
ihlr-16500	678	126	the	the	DET
ihlr-16500	678	127	sickest	sick	ADJ
ihlr-16500	678	128	patients	patient	NOUN
ihlr-16500	678	129	fewer	few	ADJ
ihlr-16500	678	130	than	than	ADP
ihlr-16500	678	131	5	5	NUM
ihlr-16500	678	132	%	%	NOUN
ihlr-16500	678	133	of	of	ADP
ihlr-16500	678	134	sufferers	sufferer	NOUN
ihlr-16500	678	135	who	who	PRON
ihlr-16500	678	136	have	have	AUX
ihlr-16500	678	137	failed	fail	VERB
ihlr-16500	678	138	other	other	ADJ
ihlr-16500	678	139	therapies	therapy	NOUN
ihlr-16500	678	140	.	.	PUNCT
ihlr-16500	679	1	"167	"167	ADJ
ihlr-16500	679	2	the	the	DET
ihlr-16500	679	3	lotronex	lotronex	PROPN
ihlr-16500	679	4	incident	incident	NOUN
ihlr-16500	679	5	proved	prove	VERB
ihlr-16500	679	6	that	that	SCONJ
ihlr-16500	679	7	a	a	DET
ihlr-16500	679	8	withdrawn	withdraw	VERB
ihlr-16500	679	9	drug	drug	NOUN
ihlr-16500	679	10	may	may	AUX
ihlr-16500	679	11	be	be	AUX
ihlr-16500	679	12	allowed	allow	VERB
ihlr-16500	679	13	to	to	PART
ihlr-16500	679	14	reenter	reenter	VERB
ihlr-16500	679	15	the	the	DET
ihlr-16500	679	16	market	market	NOUN
ihlr-16500	679	17	under	under	ADP
ihlr-16500	679	18	careful	careful	ADJ
ihlr-16500	679	19	scrutiny	scrutiny	NOUN
ihlr-16500	679	20	because	because	SCONJ
ihlr-16500	679	21	certain	certain	ADJ
ihlr-16500	679	22	patient	patient	ADJ
ihlr-16500	679	23	demographics	demographic	NOUN
ihlr-16500	679	24	whose	whose	DET
ihlr-16500	679	25	quality	quality	NOUN
ihlr-16500	679	26	of	of	ADP
ihlr-16500	679	27	life	life	NOUN
ihlr-16500	679	28	is	be	AUX
ihlr-16500	679	29	negatively	negatively	ADV
ihlr-16500	679	30	affected	affect	VERB
ihlr-16500	679	31	by	by	ADP
ihlr-16500	679	32	the	the	DET
ihlr-16500	679	33	drug	drug	NOUN
ihlr-16500	679	34	's	's	PART
ihlr-16500	679	35	withdrawal	withdrawal	NOUN
ihlr-16500	679	36	may	may	AUX
ihlr-16500	679	37	suffer	suffer	VERB
ihlr-16500	679	38	less	less	ADJ
ihlr-16500	679	39	harm	harm	NOUN
ihlr-16500	679	40	with	with	ADP
ihlr-16500	679	41	the	the	DET
ihlr-16500	679	42	drug	drug	NOUN
ihlr-16500	679	43	than	than	ADP
ihlr-16500	679	44	without	without	ADP
ihlr-16500	679	45	it	it	PRON
ihlr-16500	679	46	.	.	PUNCT
ihlr-16500	680	1	nonetheless	nonetheless	ADV
ihlr-16500	680	2	,	,	PUNCT
ihlr-16500	680	3	the	the	DET
ihlr-16500	680	4	manner	manner	NOUN
ihlr-16500	680	5	in	in	ADP
ihlr-16500	680	6	which	which	PRON
ihlr-16500	680	7	the	the	DET
ihlr-16500	680	8	drug	drug	NOUN
ihlr-16500	680	9	will	will	AUX
ihlr-16500	680	10	be	be	AUX
ihlr-16500	680	11	tested	test	VERB
ihlr-16500	680	12	and	and	CCONJ
ihlr-16500	680	13	scrutinized	scrutinize	VERB
ihlr-16500	680	14	must	must	AUX
ihlr-16500	680	15	be	be	AUX
ihlr-16500	680	16	carefully	carefully	ADV
ihlr-16500	680	17	evaluated	evaluate	VERB
ihlr-16500	680	18	before	before	SCONJ
ihlr-16500	680	19	the	the	DET
ihlr-16500	680	20	drug	drug	NOUN
ihlr-16500	680	21	can	can	AUX
ihlr-16500	680	22	be	be	AUX
ihlr-16500	680	23	placed	place	VERB
ihlr-16500	680	24	back	back	ADV
ihlr-16500	680	25	on	on	ADP
ihlr-16500	680	26	the	the	DET
ihlr-16500	680	27	market	market	NOUN
ihlr-16500	680	28	.	.	PUNCT
ihlr-16500	681	1	also	also	ADV
ihlr-16500	681	2	,	,	PUNCT
ihlr-16500	681	3	the	the	DET
ihlr-16500	681	4	fda	fda	PROPN
ihlr-16500	681	5	must	must	AUX
ihlr-16500	681	6	conclusively	conclusively	ADV
ihlr-16500	681	7	find	find	VERB
ihlr-16500	681	8	that	that	SCONJ
ihlr-16500	681	9	the	the	DET
ihlr-16500	681	10	drug	drug	NOUN
ihlr-16500	681	11	is	be	AUX
ihlr-16500	681	12	safe	safe	ADJ
ihlr-16500	681	13	for	for	ADP
ihlr-16500	681	14	the	the	DET
ihlr-16500	681	15	patient	patient	ADJ
ihlr-16500	681	16	populations	population	NOUN
ihlr-16500	681	17	that	that	PRON
ihlr-16500	681	18	would	would	AUX
ihlr-16500	681	19	be	be	AUX
ihlr-16500	681	20	allowed	allow	VERB
ihlr-16500	681	21	to	to	PART
ihlr-16500	681	22	use	use	VERB
ihlr-16500	681	23	the	the	DET
ihlr-16500	681	24	drug	drug	NOUN
ihlr-16500	681	25	.	.	PUNCT
ihlr-16500	682	1	finally	finally	ADV
ihlr-16500	682	2	,	,	PUNCT
ihlr-16500	682	3	the	the	DET
ihlr-16500	682	4	fda	fda	PROPN
ihlr-16500	682	5	must	must	AUX
ihlr-16500	682	6	still	still	ADV
ihlr-16500	682	7	be	be	AUX
ihlr-16500	682	8	willing	willing	ADJ
ihlr-16500	682	9	to	to	PART
ihlr-16500	682	10	re	re	VERB
ihlr-16500	682	11	-	-	VERB
ihlr-16500	682	12	pull	pull	VERB
ihlr-16500	682	13	the	the	DET
ihlr-16500	682	14	drug	drug	NOUN
ihlr-16500	682	15	back	back	ADV
ihlr-16500	682	16	off	off	ADP
ihlr-16500	682	17	the	the	DET
ihlr-16500	682	18	market	market	NOUN
ihlr-16500	682	19	if	if	SCONJ
ihlr-16500	682	20	there	there	PRON
ihlr-16500	682	21	is	be	VERB
ihlr-16500	682	22	even	even	ADV
ihlr-16500	682	23	a	a	DET
ihlr-16500	682	24	remote	remote	ADJ
ihlr-16500	682	25	chance	chance	NOUN
ihlr-16500	682	26	that	that	SCONJ
ihlr-16500	682	27	the	the	DET
ihlr-16500	682	28	drug	drug	NOUN
ihlr-16500	682	29	will	will	AUX
ihlr-16500	682	30	pose	pose	VERB
ihlr-16500	682	31	any	any	DET
ihlr-16500	682	32	health	health	NOUN
ihlr-16500	682	33	risk	risk	NOUN
ihlr-16500	682	34	to	to	ADP
ihlr-16500	682	35	these	these	DET
ihlr-16500	682	36	patients	patient	NOUN
ihlr-16500	682	37	.	.	PUNCT
ihlr-16500	683	1	162	162	NUM
ihlr-16500	683	2	vioxx	vioxx	NOUN
ihlr-16500	683	3	could	could	AUX
ihlr-16500	683	4	be	be	AUX
ihlr-16500	683	5	sold	sell	VERB
ihlr-16500	683	6	again	again	ADV
ihlr-16500	683	7	,	,	PUNCT
ihlr-16500	683	8	supra	supra	PROPN
ihlr-16500	683	9	note	note	VERB
ihlr-16500	683	10	143	143	NUM
ihlr-16500	683	11	.	.	PUNCT
ihlr-16500	684	1	a	a	DET
ihlr-16500	684	2	stronger	strong	ADJ
ihlr-16500	684	3	warning	warning	NOUN
ihlr-16500	684	4	may	may	AUX
ihlr-16500	684	5	be	be	AUX
ihlr-16500	684	6	in	in	ADP
ihlr-16500	684	7	the	the	DET
ihlr-16500	684	8	form	form	NOUN
ihlr-16500	684	9	of	of	ADP
ihlr-16500	684	10	a	a	DET
ihlr-16500	684	11	black	black	ADJ
ihlr-16500	684	12	box	box	NOUN
ihlr-16500	684	13	warning	warning	NOUN
ihlr-16500	684	14	,	,	PUNCT
ihlr-16500	684	15	which	which	PRON
ihlr-16500	684	16	is	be	AUX
ihlr-16500	684	17	placed	place	VERB
ihlr-16500	684	18	in	in	ADP
ihlr-16500	684	19	the	the	DET
ihlr-16500	684	20	drug	drug	NOUN
ihlr-16500	684	21	's	's	PART
ihlr-16500	684	22	prescribing	prescribing	NOUN
ihlr-16500	684	23	information	information	NOUN
ihlr-16500	684	24	regarding	regard	VERB
ihlr-16500	684	25	a	a	DET
ihlr-16500	684	26	possi­	possi­	PROPN
ihlr-16500	684	27	ble	ble	ADJ
ihlr-16500	684	28	adverse	adverse	ADJ
ihlr-16500	684	29	side	side	NOUN
ihlr-16500	684	30	effect	effect	NOUN
ihlr-16500	684	31	from	from	ADP
ihlr-16500	684	32	use	use	NOUN
ihlr-16500	684	33	of	of	ADP
ihlr-16500	684	34	the	the	DET
ihlr-16500	684	35	drug	drug	NOUN
ihlr-16500	684	36	.	.	PUNCT
ihlr-16500	685	1	other	other	ADJ
ihlr-16500	685	2	such	such	ADJ
ihlr-16500	685	3	warnings	warning	NOUN
ihlr-16500	685	4	also	also	ADV
ihlr-16500	685	5	include	include	VERB
ihlr-16500	685	6	"	"	PUNCT
ihlr-16500	685	7	dear	dear	ADJ
ihlr-16500	685	8	doctor	doctor	NOUN
ihlr-16500	685	9	,	,	PUNCT
ihlr-16500	685	10	.	.	PUNCT
ihlr-16500	686	1	letters	letter	NOUN
ihlr-16500	686	2	,	,	PUNCT
ihlr-16500	686	3	whereby	whereby	SCONJ
ihlr-16500	686	4	the	the	DET
ihlr-16500	686	5	fda	fda	PROPN
ihlr-16500	686	6	informs	inform	VERB
ihlr-16500	686	7	any	any	DET
ihlr-16500	686	8	prescribing	prescribing	NOUN
ihlr-16500	686	9	physician	physician	NOUN
ihlr-16500	686	10	of	of	ADP
ihlr-16500	686	11	the	the	DET
ihlr-16500	686	12	possible	possible	ADJ
ihlr-16500	686	13	dangers	danger	NOUN
ihlr-16500	686	14	associated	associate	VERB
ihlr-16500	686	15	with	with	ADP
ihlr-16500	686	16	the	the	DET
ihlr-16500	686	17	drug	drug	NOUN
ihlr-16500	686	18	in	in	ADP
ihlr-16500	686	19	question	question	NOUN
ihlr-16500	686	20	.	.	PUNCT
ihlr-16500	687	1	163	163	NUM
ihlr-16500	687	2	!	!	PUNCT
ihlr-16500	688	1	d.	d.	NOUN
ihlr-16500	688	2	164	164	NUM
ihlr-16500	688	3	bowel	bowel	NOUN
ihlr-16500	688	4	drug	drug	NOUN
ihlr-16500	688	5	returns	return	NOUN
ihlr-16500	688	6	to	to	ADP
ihlr-16500	688	7	market	market	NOUN
ihlr-16500	688	8	with	with	ADP
ihlr-16500	688	9	restrictions	restriction	NOUN
ihlr-16500	688	10	,	,	PUNCT
ihlr-16500	688	11	usa	usa	PROPN
ihlr-16500	688	12	today	today	NOUN
ihlr-16500	688	13	,	,	PUNCT
ihlr-16500	688	14	june	june	PROPN
ihlr-16500	688	15	7	7	NUM
ihlr-16500	688	16	,	,	PUNCT
ihlr-16500	688	17	2002	2002	NUM
ihlr-16500	688	18	,	,	PUNCT
ihlr-16500	688	19	http://www.usatoday.com/newslhealth/2002-06-07-bowel-drug.htm	http://www.usatoday.com/newslhealth/2002-06-07-bowel-drug.htm	PROPN
ihlr-16500	688	20	.	.	PUNCT
ihlr-16500	689	1	165	165	NUM
ihlr-16500	689	2	!	!	PUNCT
ihlr-16500	690	1	d.	d.	PROPN
ihlr-16500	690	2	166	166	NUM
ihlr-16500	690	3	!	!	PUNCT
ihlr-16500	691	1	d.	d.	PROPN
ihlr-16500	691	2	167	167	NUM
ihlr-16500	691	3	!	!	PUNCT
ihlr-16500	692	1	d.	d.	NOUN
ihlr-16500	692	2	2007	2007	NUM
ihlr-16500	692	3	]	]	PUNCT
ihlr-16500	693	1	pulling	pull	VERB
ihlr-16500	693	2	a	a	DET
ihlr-16500	693	3	blockbuster	blockbuster	ADJ
ihlr-16500	693	4	drug	drug	NOUN
ihlr-16500	693	5	off	off	ADP
ihlr-16500	693	6	the	the	DET
ihlr-16500	693	7	market	market	NOUN
ihlr-16500	693	8	147	147	NUM
ihlr-16500	693	9	b.	b.	NOUN
ihlr-16500	693	10	create	create	VERB
ihlr-16500	693	11	medical	medical	ADJ
ihlr-16500	693	12	liability	liability	NOUN
ihlr-16500	693	13	review	review	NOUN
ihlr-16500	693	14	panels	panel	NOUN
ihlr-16500	693	15	in	in	ADP
ihlr-16500	693	16	order	order	NOUN
ihlr-16500	693	17	to	to	PART
ihlr-16500	693	18	reduce	reduce	VERB
ihlr-16500	693	19	the	the	DET
ihlr-16500	693	20	number	number	NOUN
ihlr-16500	693	21	of	of	ADP
ihlr-16500	693	22	frivolous	frivolous	ADJ
ihlr-16500	693	23	lawsuits	lawsuit	NOUN
ihlr-16500	693	24	usually	usually	ADV
ihlr-16500	693	25	,	,	PUNCT
ihlr-16500	693	26	after	after	SCONJ
ihlr-16500	693	27	a	a	DET
ihlr-16500	693	28	drug	drug	NOUN
ihlr-16500	693	29	is	be	AUX
ihlr-16500	693	30	withdrawn	withdraw	VERB
ihlr-16500	693	31	from	from	ADP
ihlr-16500	693	32	the	the	DET
ihlr-16500	693	33	market	market	NOUN
ihlr-16500	693	34	,	,	PUNCT
ihlr-16500	693	35	plaintiffs	plaintiff	NOUN
ihlr-16500	693	36	'	'	PART
ihlr-16500	693	37	attorneys	attorney	NOUN
ihlr-16500	693	38	create	create	VERB
ihlr-16500	693	39	a	a	DET
ihlr-16500	693	40	public	public	ADJ
ihlr-16500	693	41	hysteria	hysteria	NOUN
ihlr-16500	693	42	of	of	ADP
ihlr-16500	693	43	sorts	sort	NOUN
ihlr-16500	693	44	by	by	ADP
ihlr-16500	693	45	soliciting	solicit	VERB
ihlr-16500	693	46	past	past	ADJ
ihlr-16500	693	47	users	user	NOUN
ihlr-16500	693	48	of	of	ADP
ihlr-16500	693	49	the	the	DET
ihlr-16500	693	50	drug	drug	NOUN
ihlr-16500	693	51	.	.	PUNCT
ihlr-16500	694	1	as	as	ADP
ihlr-16500	694	2	a	a	DET
ihlr-16500	694	3	result	result	NOUN
ihlr-16500	694	4	,	,	PUNCT
ihlr-16500	694	5	many	many	ADJ
ihlr-16500	694	6	frivolous	frivolous	ADJ
ihlr-16500	694	7	lawsuits	lawsuit	NOUN
ihlr-16500	694	8	are	be	AUX
ihlr-16500	694	9	filed	file	VERB
ihlr-16500	694	10	,	,	PUNCT
ihlr-16500	694	11	costing	cost	VERB
ihlr-16500	694	12	the	the	DET
ihlr-16500	694	13	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	694	14	company	company	NOUN
ihlr-16500	694	15	millions	million	NOUN
ihlr-16500	694	16	of	of	ADP
ihlr-16500	694	17	dollars	dollar	NOUN
ihlr-16500	694	18	in	in	ADP
ihlr-16500	694	19	litigation	litigation	NOUN
ihlr-16500	694	20	costs	cost	NOUN
ihlr-16500	694	21	and	and	CCONJ
ihlr-16500	694	22	negative	negative	ADJ
ihlr-16500	694	23	publicity	publicity	NOUN
ihlr-16500	694	24	.	.	PUNCT
ihlr-16500	695	1	in	in	ADP
ihlr-16500	695	2	order	order	NOUN
ihlr-16500	695	3	to	to	PART
ihlr-16500	695	4	reduce	reduce	VERB
ihlr-16500	695	5	the	the	DET
ihlr-16500	695	6	num­	num­	ADJ
ihlr-16500	695	7	ber	ber	NOUN
ihlr-16500	695	8	of	of	ADP
ihlr-16500	695	9	frivolous	frivolous	ADJ
ihlr-16500	695	10	lawsuits	lawsuit	NOUN
ihlr-16500	695	11	that	that	PRON
ihlr-16500	695	12	are	be	AUX
ihlr-16500	695	13	filed	file	VERB
ihlr-16500	695	14	,	,	PUNCT
ihlr-16500	695	15	many	many	ADJ
ihlr-16500	695	16	states	state	NOUN
ihlr-16500	695	17	either	either	CCONJ
ihlr-16500	695	18	require	require	VERB
ihlr-16500	695	19	or	or	CCONJ
ihlr-16500	695	20	permit	permit	VERB
ihlr-16500	695	21	that	that	SCONJ
ihlr-16500	695	22	the	the	DET
ihlr-16500	695	23	claim	claim	NOUN
ihlr-16500	695	24	first	first	ADV
ihlr-16500	695	25	be	be	AUX
ihlr-16500	695	26	submitted	submit	VERB
ihlr-16500	695	27	to	to	ADP
ihlr-16500	695	28	a	a	DET
ihlr-16500	695	29	medical	medical	ADJ
ihlr-16500	695	30	liability	liability	NOUN
ihlr-16500	695	31	review	review	NOUN
ihlr-16500	695	32	panel	panel	NOUN
ihlr-16500	695	33	that	that	PRON
ihlr-16500	695	34	will	will	AUX
ihlr-16500	695	35	deter­	deter­	PROPN
ihlr-16500	695	36	mine	mine	VERB
ihlr-16500	695	37	the	the	DET
ihlr-16500	695	38	credibility	credibility	NOUN
ihlr-16500	695	39	of	of	ADP
ihlr-16500	695	40	the	the	DET
ihlr-16500	695	41	claim	claim	NOUN
ihlr-16500	695	42	and	and	CCONJ
ihlr-16500	695	43	whether	whether	SCONJ
ihlr-16500	695	44	standing	standing	NOUN
ihlr-16500	695	45	may	may	AUX
ihlr-16500	695	46	be	be	AUX
ihlr-16500	695	47	established	establish	VERB
ihlr-16500	695	48	in	in	ADP
ihlr-16500	695	49	order	order	NOUN
ihlr-16500	695	50	to	to	PART
ihlr-16500	695	51	further	far	ADV
ihlr-16500	695	52	pursue	pursue	VERB
ihlr-16500	695	53	litigation.168	litigation.168	PROPN
ihlr-16500	695	54	this	this	DET
ihlr-16500	695	55	approach	approach	NOUN
ihlr-16500	695	56	,	,	PUNCT
ihlr-16500	695	57	requiring	require	VERB
ihlr-16500	695	58	submission	submission	NOUN
ihlr-16500	695	59	of	of	ADP
ihlr-16500	695	60	cases	case	NOUN
ihlr-16500	695	61	to	to	PART
ihlr-16500	695	62	review	review	VERB
ihlr-16500	695	63	panels	panel	NOUN
ihlr-16500	695	64	consisting	consist	VERB
ihlr-16500	695	65	of	of	ADP
ihlr-16500	695	66	doctors	doctor	NOUN
ihlr-16500	695	67	and	and	CCONJ
ihlr-16500	695	68	lawyers	lawyer	NOUN
ihlr-16500	695	69	,	,	PUNCT
ihlr-16500	695	70	was	be	AUX
ihlr-16500	695	71	first	first	ADV
ihlr-16500	695	72	enacted	enact	VERB
ihlr-16500	695	73	b~	b~	ADP
ihlr-16500	695	74	a	a	DET
ihlr-16500	695	75	number	number	NOUN
ihlr-16500	695	76	of	of	ADP
ihlr-16500	695	77	state	state	NOUN
ihlr-16500	695	78	legislatures	legislature	NOUN
ihlr-16500	695	79	in	in	ADP
ihlr-16500	695	80	order	order	NOUN
ihlr-16500	695	81	to	to	PART
ihlr-16500	695	82	"	"	PUNCT
ihlr-16500	695	83	aid	aid	VERB
ihlr-16500	695	84	the	the	DET
ihlr-16500	695	85	early	early	ADJ
ihlr-16500	695	86	settlement	settlement	NOUN
ihlr-16500	695	87	of	of	ADP
ihlr-16500	695	88	cases	case	NOUN
ihlr-16500	695	89	.	.	PUNCT
ihlr-16500	695	90	"	"	PUNCT
ihlr-16500	696	1	69	69	NUM
ihlr-16500	696	2	as	as	ADP
ihlr-16500	696	3	a	a	DET
ihlr-16500	696	4	result	result	NOUN
ihlr-16500	696	5	,	,	PUNCT
ihlr-16500	696	6	the	the	DET
ihlr-16500	696	7	state	state	NOUN
ihlr-16500	696	8	legislature	legislature	NOUN
ihlr-16500	696	9	will	will	AUX
ihlr-16500	696	10	ensure	ensure	VERB
ihlr-16500	696	11	that	that	SCONJ
ihlr-16500	696	12	the	the	DET
ihlr-16500	696	13	court	court	NOUN
ihlr-16500	696	14	's	's	PART
ihlr-16500	696	15	time	time	NOUN
ihlr-16500	696	16	is	be	AUX
ihlr-16500	696	17	not	not	PART
ihlr-16500	696	18	being	be	AUX
ihlr-16500	696	19	wasted	waste	VERB
ihlr-16500	696	20	and	and	CCONJ
ihlr-16500	696	21	that	that	SCONJ
ihlr-16500	696	22	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	696	23	companies	company	NOUN
ihlr-16500	696	24	are	be	AUX
ihlr-16500	696	25	not	not	PART
ihlr-16500	696	26	subjected	subject	VERB
ihlr-16500	696	27	to	to	ADP
ihlr-16500	696	28	the	the	DET
ihlr-16500	696	29	added	add	VERB
ihlr-16500	696	30	costs	cost	NOUN
ihlr-16500	696	31	of	of	ADP
ihlr-16500	696	32	defending	defend	VERB
ihlr-16500	696	33	against	against	ADP
ihlr-16500	696	34	frivolous	frivolous	ADJ
ihlr-16500	696	35	claims	claim	NOUN
ihlr-16500	696	36	.	.	PUNCT
ihlr-16500	697	1	c.	c.	NOUN
ihlr-16500	697	2	create	create	VERB
ihlr-16500	697	3	an	an	DET
ihlr-16500	697	4	independent	independent	ADJ
ihlr-16500	697	5	drug	drug	NOUN
ihlr-16500	697	6	monitoring	monitoring	NOUN
ihlr-16500	697	7	board	board	NOUN
ihlr-16500	697	8	another	another	DET
ihlr-16500	697	9	possible	possible	ADJ
ihlr-16500	697	10	preventive	preventive	ADJ
ihlr-16500	697	11	solution	solution	NOUN
ihlr-16500	697	12	is	be	AUX
ihlr-16500	697	13	to	to	PART
ihlr-16500	697	14	institute	institute	VERB
ihlr-16500	697	15	a	a	DET
ihlr-16500	697	16	drug	drug	NOUN
ihlr-16500	697	17	monitoring	monitoring	NOUN
ihlr-16500	697	18	board	board	NOUN
ihlr-16500	697	19	independent	independent	ADJ
ihlr-16500	697	20	of	of	ADP
ihlr-16500	697	21	the	the	DET
ihlr-16500	697	22	fda.170	fda.170	NOUN
ihlr-16500	697	23	this	this	DET
ihlr-16500	697	24	board	board	NOUN
ihlr-16500	697	25	would	would	AUX
ihlr-16500	697	26	only	only	ADV
ihlr-16500	697	27	be	be	AUX
ihlr-16500	697	28	in	in	ADP
ihlr-16500	697	29	charge	charge	NOUN
ihlr-16500	697	30	of	of	ADP
ihlr-16500	697	31	moni­	moni­	NOUN
ihlr-16500	697	32	toring	tore	VERB
ihlr-16500	697	33	drug	drug	NOUN
ihlr-16500	697	34	safety	safety	NOUN
ihlr-16500	697	35	for	for	ADP
ihlr-16500	697	36	high	high	ADJ
ihlr-16500	697	37	volume	volume	NOUN
ihlr-16500	697	38	drugs	drug	NOUN
ihlr-16500	697	39	on	on	ADP
ihlr-16500	697	40	the	the	DET
ihlr-16500	697	41	market	market	NOUN
ihlr-16500	697	42	.	.	PUNCT
ihlr-16500	698	1	it	it	PRON
ihlr-16500	698	2	would	would	AUX
ihlr-16500	698	3	monitor	monitor	VERB
ihlr-16500	698	4	the	the	DET
ihlr-16500	698	5	appropriate	appropriate	ADJ
ihlr-16500	698	6	clinical	clinical	ADJ
ihlr-16500	698	7	trials	trial	NOUN
ihlr-16500	698	8	and	and	CCONJ
ihlr-16500	698	9	submit	submit	VERB
ihlr-16500	698	10	reports	report	NOUN
ihlr-16500	698	11	to	to	ADP
ihlr-16500	698	12	both	both	CCONJ
ihlr-16500	698	13	the	the	DET
ihlr-16500	698	14	fda	fda	PROPN
ihlr-16500	698	15	and	and	CCONJ
ihlr-16500	698	16	phrma	phrma	NOUN
ihlr-16500	698	17	in	in	ADP
ihlr-16500	698	18	order	order	NOUN
ihlr-16500	698	19	to	to	PART
ihlr-16500	698	20	ensure	ensure	VERB
ihlr-16500	698	21	compliance	compliance	NOUN
ihlr-16500	698	22	with	with	ADP
ihlr-16500	698	23	recommendations	recommendation	NOUN
ihlr-16500	698	24	.	.	PUNCT
ihlr-16500	699	1	nevertheless	nevertheless	ADV
ihlr-16500	699	2	,	,	PUNCT
ihlr-16500	699	3	the	the	DET
ihlr-16500	699	4	goal	goal	NOUN
ihlr-16500	699	5	of	of	ADP
ihlr-16500	699	6	such	such	DET
ihlr-16500	699	7	a	a	DET
ihlr-16500	699	8	board	board	NOUN
ihlr-16500	699	9	would	would	AUX
ihlr-16500	699	10	be	be	AUX
ihlr-16500	699	11	to	to	PART
ihlr-16500	699	12	decrease	decrease	VERB
ihlr-16500	699	13	the	the	DET
ihlr-16500	699	14	fda	fda	PROPN
ihlr-16500	699	15	's	's	PART
ihlr-16500	699	16	workload	workload	NOUN
ihlr-16500	699	17	and	and	CCONJ
ihlr-16500	699	18	create	create	VERB
ihlr-16500	699	19	an	an	DET
ihlr-16500	699	20	inde­	inde­	NOUN
ihlr-16500	699	21	pendent	pendent	ADJ
ihlr-16500	699	22	body	body	NOUN
ihlr-16500	699	23	,	,	PUNCT
ihlr-16500	699	24	detached	detach	VERB
ihlr-16500	699	25	from	from	ADP
ihlr-16500	699	26	the	the	DET
ihlr-16500	699	27	pharmaceutical	pharmaceutical	NOUN
ihlr-16500	699	28	industry	industry	NOUN
ihlr-16500	699	29	and	and	CCONJ
ihlr-16500	699	30	the	the	DET
ihlr-16500	699	31	fda	fda	PROPN
ihlr-16500	699	32	,	,	PUNCT
ihlr-16500	699	33	that	that	PRON
ihlr-16500	699	34	would	would	AUX
ihlr-16500	699	35	be	be	AUX
ihlr-16500	699	36	able	able	ADJ
ihlr-16500	699	37	to	to	PART
ihlr-16500	699	38	monitor	monitor	VERB
ihlr-16500	699	39	objectively	objectively	ADV
ihlr-16500	699	40	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	699	41	drugs	drug	NOUN
ihlr-16500	699	42	from	from	ADP
ihlr-16500	699	43	beyond	beyond	ADP
ihlr-16500	699	44	the	the	DET
ihlr-16500	699	45	reach	reach	NOUN
ihlr-16500	699	46	of	of	ADP
ihlr-16500	699	47	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	699	48	lobbyists	lobbyist	NOUN
ihlr-16500	699	49	.	.	PUNCT
ihlr-16500	700	1	171	171	NUM
ihlr-16500	700	2	this	this	DET
ihlr-16500	700	3	board	board	NOUN
ihlr-16500	700	4	could	could	AUX
ihlr-16500	700	5	also	also	ADV
ihlr-16500	700	6	ensure	ensure	VERB
ihlr-16500	700	7	that	that	SCONJ
ihlr-16500	700	8	money	money	NOUN
ihlr-16500	700	9	is	be	AUX
ihlr-16500	700	10	being	be	AUX
ihlr-16500	700	11	spent	spend	VERB
ihlr-16500	700	12	on	on	ADP
ihlr-16500	700	13	improving	improve	VERB
ihlr-16500	700	14	existing	exist	VERB
ihlr-16500	700	15	products	product	NOUN
ihlr-16500	700	16	.	.	PUNCT
ihlr-16500	701	1	as	as	ADP
ihlr-16500	701	2	the	the	DET
ihlr-16500	701	3	president	president	NOUN
ihlr-16500	701	4	of	of	ADP
ihlr-16500	701	5	phrma	phrma	PROPN
ihlr-16500	701	6	,	,	PUNCT
ihlr-16500	701	7	alan	alan	PROPN
ihlr-16500	701	8	f.	f.	PROPN
ihlr-16500	701	9	holmer	holmer	PROPN
ihlr-16500	701	10	,	,	PUNCT
ihlr-16500	701	11	stated	state	VERB
ihlr-16500	701	12	during	during	ADP
ihlr-16500	701	13	his	his	PRON
ihlr-16500	701	14	congressional	congressional	ADJ
ihlr-16500	701	15	testimony	testimony	NOUN
ihlr-16500	701	16	:	:	PUNCT
ihlr-16500	701	17	the	the	DET
ihlr-16500	701	18	industry	industry	NOUN
ihlr-16500	701	19	is	be	AUX
ihlr-16500	701	20	spending	spend	VERB
ihlr-16500	701	21	more	more	ADJ
ihlr-16500	701	22	than	than	ADP
ihlr-16500	701	23	$	$	SYM
ihlr-16500	701	24	30	30	NUM
ihlr-16500	701	25	billion	billion	NUM
ihlr-16500	701	26	annually	annually	ADV
ihlr-16500	701	27	on	on	ADP
ihlr-16500	701	28	research	research	NOUN
ihlr-16500	701	29	and	and	CCONJ
ihlr-16500	701	30	development	development	NOUN
ihlr-16500	702	1	[	[	X
ihlr-16500	702	2	referring	refer	VERB
ihlr-16500	702	3	to	to	ADP
ihlr-16500	702	4	the	the	DET
ihlr-16500	702	5	2002	2002	NUM
ihlr-16500	702	6	year	year	NOUN
ihlr-16500	702	7	]	]	PUNCT
ihlr-16500	702	8	,	,	PUNCT
ihlr-16500	702	9	with	with	ADP
ihlr-16500	702	10	about	about	ADV
ihlr-16500	702	11	eighty	eighty	NUM
ihlr-16500	702	12	percent	percent	NOUN
ihlr-16500	702	13	of	of	ADP
ihlr-16500	702	14	this	this	DET
ihlr-16500	702	15	investment	investment	NOUN
ihlr-16500	702	16	dedi­	dedi­	NOUN
ihlr-16500	702	17	cated	cat	VERB
ihlr-16500	702	18	to	to	ADP
ihlr-16500	702	19	the	the	DET
ihlr-16500	702	20	advancement	advancement	NOUN
ihlr-16500	702	21	of	of	ADP
ihlr-16500	702	22	scientific	scientific	ADJ
ihlr-16500	702	23	knowledge	knowledge	NOUN
ihlr-16500	702	24	and	and	CCONJ
ihlr-16500	702	25	the	the	DET
ihlr-16500	702	26	development	development	NOUN
ihlr-16500	702	27	of	of	ADP
ihlr-16500	702	28	products	product	NOUN
ihlr-16500	702	29	,	,	PUNCT
ihlr-16500	702	30	compared	compare	VERB
ihlr-16500	702	31	to	to	ADP
ihlr-16500	702	32	about	about	ADV
ihlr-16500	702	33	twenty	twenty	NUM
ihlr-16500	702	34	percent	percent	NOUN
ihlr-16500	702	35	that	that	PRON
ihlr-16500	702	36	is	be	AUX
ihlr-16500	702	37	devoted	devote	VERB
ihlr-16500	702	38	to	to	ADP
ihlr-16500	702	39	improving	improve	VERB
ihlr-16500	702	40	and/or	and/or	CCONJ
ihlr-16500	702	41	modifying	modify	VERB
ihlr-16500	702	42	168	168	NUM
ihlr-16500	702	43	frank	frank	ADJ
ihlr-16500	702	44	p.	p.	PROPN
ihlr-16500	702	45	grad	grad	PROPN
ihlr-16500	702	46	,	,	PUNCT
ihlr-16500	702	47	medical	medical	ADJ
ihlr-16500	702	48	malpractice	malpractice	NOUN
ihlr-16500	702	49	and	and	CCONJ
ihlr-16500	702	50	the	the	DET
ihlr-16500	702	51	crisis	crisis	NOUN
ihlr-16500	702	52	of	of	ADP
ihlr-16500	702	53	insurance	insurance	NOUN
ihlr-16500	702	54	availability	availability	NOUN
ihlr-16500	702	55	:	:	PUNCT
ihlr-16500	702	56	the	the	DET
ihlr-16500	702	57	waning	wane	VERB
ihlr-16500	702	58	options	option	NOUN
ihlr-16500	702	59	,	,	PUNCT
ihlr-16500	702	60	36	36	NUM
ihlr-16500	702	61	case	case	NOUN
ihlr-16500	702	62	w.	w.	NOUN
ihlr-16500	702	63	res	re	NOUN
ihlr-16500	702	64	.	.	PROPN
ihlr-16500	702	65	1058	1058	NUM
ihlr-16500	702	66	,	,	PUNCT
ihlr-16500	702	67	1082	1082	NUM
ihlr-16500	702	68	(	(	PUNCT
ihlr-16500	702	69	1986	1986	NUM
ihlr-16500	702	70	)	)	PUNCT
ihlr-16500	702	71	.	.	PUNCT
ihlr-16500	703	1	169	169	NUM
ihlr-16500	703	2	jd	jd	PROPN
ihlr-16500	703	3	.	.	PROPN
ihlr-16500	703	4	170	170	NUM
ihlr-16500	703	5	jerry	jerry	NOUN
ihlr-16500	703	6	a	a	DET
ihlr-16500	703	7	vorn	vorn	ADJ
ihlr-16500	703	8	,	,	PUNCT
ihlr-16500	703	9	powerful	powerful	ADJ
ihlr-16500	703	10	medicines	medicine	NOUN
ihlr-16500	703	11	:	:	PUNCT
ihlr-16500	703	12	the	the	DET
ihlr-16500	703	13	benefits	benefit	NOUN
ihlr-16500	703	14	,	,	PUNCT
ihlr-16500	703	15	risks	risk	NOUN
ihlr-16500	703	16	,	,	PUNCT
ihlr-16500	703	17	and	and	CCONJ
ihlr-16500	703	18	costs	cost	NOUN
ihlr-16500	703	19	of	of	ADP
ihlr-16500	703	20	prescription	prescription	NOUN
ihlr-16500	703	21	drugs	drug	NOUN
ihlr-16500	703	22	373	373	NUM
ihlr-16500	703	23	(	(	PUNCT
ihlr-16500	703	24	2004	2004	NUM
ihlr-16500	703	25	)	)	PUNCT
ihlr-16500	703	26	.	.	PUNCT
ihlr-16500	704	1	171	171	NUM
ihlr-16500	704	2	matthew	matthew	PROPN
ihlr-16500	704	3	harper	harper	PROPN
ihlr-16500	704	4	,	,	PUNCT
ihlr-16500	704	5	david	david	PROPN
ihlr-16500	704	6	graham	graham	PROPN
ihlr-16500	704	7	on	on	ADP
ihlr-16500	704	8	the	the	DET
ihlr-16500	704	9	vioxx	vioxx	NOUN
ihlr-16500	704	10	verdict	verdict	NOUN
ihlr-16500	704	11	,	,	PUNCT
ihlr-16500	704	12	forbes.com	forbes.com	X
ihlr-16500	704	13	,	,	PUNCT
ihlr-16500	704	14	aug	aug	PROPN
ihlr-16500	704	15	.	.	PROPN
ihlr-16500	704	16	19	19	NUM
ihlr-16500	704	17	,	,	PUNCT
ihlr-16500	704	18	2005	2005	NUM
ihlr-16500	704	19	,	,	PUNCT
ihlr-16500	704	20	http://www.vioxx-recall-lawsuit.com/news/graham.pdf	http://www.vioxx-recall-lawsuit.com/news/graham.pdf	NOUN
ihlr-16500	704	21	.	.	PUNCT
ihlr-16500	705	1	148	148	NUM
ihlr-16500	705	2	indiana	indiana	PROPN
ihlr-16500	705	3	health	health	NOUN
ihlr-16500	705	4	law	law	NOUN
ihlr-16500	705	5	revjew	revjew	NOUN
ihlr-16500	706	1	[	[	X
ihlr-16500	706	2	vol	vol	NOUN
ihlr-16500	706	3	.	.	PUNCT
ihlr-16500	707	1	4:115	4:115	NUM
ihlr-16500	707	2	.	.	PUNCT
ihlr-16500	707	3	.	.	PUNCT
ihlr-16500	708	1	rod	rod	VERB
ihlr-16500	708	2	172	172	NUM
ihlr-16500	708	3	existing	exist	VERB
ihlr-16500	708	4	p	p	NOUN
ihlr-16500	708	5	ucts	uct	NOUN
ihlr-16500	708	6	.	.	PUNCT
ihlr-16500	709	1	currently	currently	ADV
ihlr-16500	709	2	,	,	PUNCT
ihlr-16500	709	3	the	the	DET
ihlr-16500	709	4	fda	fda	PROPN
ihlr-16500	709	5	is	be	AUX
ihlr-16500	709	6	charged	charge	VERB
ihlr-16500	709	7	with	with	ADP
ihlr-16500	709	8	monitoring	monitor	VERB
ihlr-16500	709	9	more	more	ADJ
ihlr-16500	709	10	than	than	ADP
ihlr-16500	709	11	10,000	10,000	NUM
ihlr-16500	709	12	drugs	drug	NOUN
ihlr-16500	709	13	,	,	PUNCT
ihlr-16500	709	14	in	in	ADP
ihlr-16500	709	15	addition	addition	NOUN
ihlr-16500	709	16	to	to	ADP
ihlr-16500	709	17	performing	perform	VERB
ihlr-16500	709	18	other	other	ADJ
ihlr-16500	709	19	re	re	NOUN
ihlr-16500	709	20	~	~	NOUN
ihlr-16500	709	21	duties	duty	NOUN
ihlr-16500	709	22	such	such	ADJ
ihlr-16500	709	23	as	as	ADP
ihlr-16500	709	24	new	new	ADJ
ihlr-16500	709	25	drug	drug	NOUN
ihlr-16500	709	26	approval	approval	NOUN
ihlr-16500	709	27	and	and	CCONJ
ihlr-16500	709	28	post	post	ADJ
ihlr-16500	709	29	-	-	ADJ
ihlr-16500	709	30	approval	approval	ADJ
ihlr-16500	709	31	marketing	marketing	NOUN
ihlr-16500	709	32	surveillance.1	surveillance.1	VERB
ihlr-16500	709	33	an	an	DET
ihlr-16500	709	34	independent	independent	ADJ
ihlr-16500	709	35	monitoring	monitoring	NOUN
ihlr-16500	709	36	board	board	NOUN
ihlr-16500	709	37	would	would	AUX
ihlr-16500	709	38	therefore	therefore	ADV
ihlr-16500	709	39	mean	mean	VERB
ihlr-16500	709	40	that	that	SCONJ
ihlr-16500	709	41	there	there	PRON
ihlr-16500	709	42	are	be	VERB
ihlr-16500	709	43	some	some	DET
ihlr-16500	709	44	checks	check	NOUN
ihlr-16500	709	45	and	and	CCONJ
ihlr-16500	709	46	balances	balance	NOUN
ihlr-16500	709	47	in	in	ADP
ihlr-16500	709	48	the	the	DET
ihlr-16500	709	49	system	system	NOUN
ihlr-16500	709	50	and	and	CCONJ
ihlr-16500	709	51	would	would	AUX
ihlr-16500	709	52	allow	allow	VERB
ihlr-16500	709	53	for	for	ADP
ihlr-16500	709	54	closer	close	ADJ
ihlr-16500	709	55	scrutiny	scrutiny	NOUN
ihlr-16500	709	56	of	of	ADP
ihlr-16500	709	57	post	post	ADJ
ihlr-16500	709	58	-	-	ADJ
ihlr-16500	709	59	approval	approval	ADJ
ihlr-16500	709	60	clinical	clinical	ADJ
ihlr-16500	709	61	studies	study	NOUN
ihlr-16500	709	62	.	.	PUNCT
ihlr-16500	710	1	therefore	therefore	ADV
ihlr-16500	710	2	,	,	PUNCT
ihlr-16500	710	3	there	there	PRON
ihlr-16500	710	4	are	be	VERB
ihlr-16500	710	5	several	several	ADJ
ihlr-16500	710	6	possible	possible	ADJ
ihlr-16500	710	7	solutions	solution	NOUN
ihlr-16500	710	8	to	to	PART
ihlr-16500	710	9	reduce	reduce	VERB
ihlr-16500	710	10	the	the	DET
ihlr-16500	710	11	devastating	devastating	ADJ
ihlr-16500	710	12	impact	impact	NOUN
ihlr-16500	710	13	such	such	ADJ
ihlr-16500	710	14	withdrawals	withdrawal	NOUN
ihlr-16500	710	15	have	have	VERB
ihlr-16500	710	16	on	on	ADP
ihlr-16500	710	17	all	all	DET
ihlr-16500	710	18	the	the	DET
ihlr-16500	710	19	affected	affected	ADJ
ihlr-16500	710	20	parties	party	NOUN
ihlr-16500	710	21	.	.	PUNCT
ihlr-16500	711	1	ix	ix	INTJ
ihlr-16500	711	2	.	.	PUNCT
ihlr-16500	712	1	conclusion	conclusion	NOUN
ihlr-16500	712	2	the	the	DET
ihlr-16500	712	3	pharmaceutical	pharmaceutical	NOUN
ihlr-16500	712	4	industry	industry	NOUN
ihlr-16500	712	5	has	have	AUX
ihlr-16500	712	6	played	play	VERB
ihlr-16500	712	7	a	a	DET
ihlr-16500	712	8	prevalent	prevalent	ADJ
ihlr-16500	712	9	role	role	NOUN
ihlr-16500	712	10	in	in	ADP
ihlr-16500	712	11	both	both	CCONJ
ihlr-16500	712	12	united	united	PROPN
ihlr-16500	712	13	states	states	PROPN
ihlr-16500	712	14	and	and	CCONJ
ihlr-16500	712	15	world	world	NOUN
ihlr-16500	712	16	history	history	NOUN
ihlr-16500	712	17	.	.	PUNCT
ihlr-16500	713	1	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	713	2	companies	company	NOUN
ihlr-16500	713	3	have	have	AUX
ihlr-16500	713	4	been	be	AUX
ihlr-16500	713	5	credited	credit	VERB
ihlr-16500	713	6	with	with	ADP
ihlr-16500	713	7	eliminating	eliminate	VERB
ihlr-16500	713	8	many	many	ADJ
ihlr-16500	713	9	diseases	disease	NOUN
ihlr-16500	713	10	through	through	ADP
ihlr-16500	713	11	the	the	DET
ihlr-16500	713	12	introduction	introduction	NOUN
ihlr-16500	713	13	of	of	ADP
ihlr-16500	713	14	novel	novel	ADJ
ihlr-16500	713	15	medicines	medicine	NOUN
ihlr-16500	713	16	and	and	CCONJ
ihlr-16500	713	17	,	,	PUNCT
ihlr-16500	713	18	as	as	ADP
ihlr-16500	713	19	a	a	DET
ihlr-16500	713	20	result	result	NOUN
ihlr-16500	713	21	,	,	PUNCT
ihlr-16500	713	22	are	be	AUX
ihlr-16500	713	23	helping	help	VERB
ihlr-16500	713	24	to	to	PART
ihlr-16500	713	25	increase	increase	VERB
ihlr-16500	713	26	life	life	NOUN
ihlr-16500	713	27	expectancy	expectancy	NOUN
ihlr-16500	713	28	rates	rate	NOUN
ihlr-16500	713	29	throughout	throughout	ADP
ihlr-16500	713	30	the	the	DET
ihlr-16500	713	31	world	world	NOUN
ihlr-16500	713	32	.	.	PUNCT
ihlr-16500	714	1	in	in	ADP
ihlr-16500	714	2	order	order	NOUN
ihlr-16500	714	3	to	to	PART
ihlr-16500	714	4	continue	continue	VERB
ihlr-16500	714	5	to	to	PART
ihlr-16500	714	6	develop	develop	VERB
ihlr-16500	714	7	novel	novel	ADJ
ihlr-16500	714	8	medicines	medicine	NOUN
ihlr-16500	714	9	,	,	PUNCT
ihlr-16500	714	10	however	however	ADV
ihlr-16500	714	11	,	,	PUNCT
ihlr-16500	714	12	pharmaceutical	pharmaceutical	NOUN
ihlr-16500	714	13	compa­	compa­	NOUN
ihlr-16500	714	14	nies	ny	NOUN
ihlr-16500	714	15	place	place	VERB
ihlr-16500	714	16	a	a	DET
ihlr-16500	714	17	great	great	ADJ
ihlr-16500	714	18	deal	deal	NOUN
ihlr-16500	714	19	of	of	ADP
ihlr-16500	714	20	emphasis	emphasis	NOUN
ihlr-16500	714	21	on	on	ADP
ihlr-16500	714	22	research	research	NOUN
ihlr-16500	714	23	and	and	CCONJ
ihlr-16500	714	24	development	development	NOUN
ihlr-16500	714	25	research	research	NOUN
ihlr-16500	714	26	and	and	CCONJ
ihlr-16500	714	27	development	development	NOUN
ihlr-16500	714	28	cost	cost	VERB
ihlr-16500	714	29	a	a	DET
ihlr-16500	714	30	company	company	NOUN
ihlr-16500	714	31	millions	million	NOUN
ihlr-16500	714	32	of	of	ADP
ihlr-16500	714	33	dollars	dollar	NOUN
ihlr-16500	714	34	every	every	DET
ihlr-16500	714	35	year	year	NOUN
ihlr-16500	714	36	in	in	ADP
ihlr-16500	714	37	its	its	PRON
ihlr-16500	714	38	search	search	NOUN
ihlr-16500	714	39	for	for	ADP
ihlr-16500	714	40	the	the	DET
ihlr-16500	714	41	next	next	ADJ
ihlr-16500	714	42	blockbuster	blockbuster	NOUN
ihlr-16500	714	43	drug	drug	NOUN
ihlr-16500	714	44	.	.	PUNCT
ihlr-16500	715	1	much	much	ADJ
ihlr-16500	715	2	expense	expense	NOUN
ihlr-16500	715	3	is	be	AUX
ihlr-16500	715	4	placed	place	VERB
ihlr-16500	715	5	on	on	ADP
ihlr-16500	715	6	obtaining	obtain	VERB
ihlr-16500	715	7	the	the	DET
ihlr-16500	715	8	best	good	ADJ
ihlr-16500	715	9	and	and	CCONJ
ihlr-16500	715	10	brightest	bright	ADJ
ihlr-16500	715	11	scientists	scientist	NOUN
ihlr-16500	715	12	and	and	CCONJ
ihlr-16500	715	13	providing	provide	VERB
ihlr-16500	715	14	them	they	PRON
ihlr-16500	715	15	with	with	ADP
ihlr-16500	715	16	the	the	DET
ihlr-16500	715	17	requisite	requisite	ADJ
ihlr-16500	715	18	resources	resource	NOUN
ihlr-16500	715	19	to	to	PART
ihlr-16500	715	20	produce	produce	VERB
ihlr-16500	715	21	a	a	DET
ihlr-16500	715	22	blockbuster	blockbuster	ADJ
ihlr-16500	715	23	drug	drug	NOUN
ihlr-16500	715	24	.	.	PUNCT
ihlr-16500	716	1	in	in	ADP
ihlr-16500	716	2	order	order	NOUN
ihlr-16500	716	3	to	to	PART
ihlr-16500	716	4	provide	provide	VERB
ihlr-16500	716	5	scientists	scientist	NOUN
ihlr-16500	716	6	with	with	ADP
ihlr-16500	716	7	the	the	DET
ihlr-16500	716	8	resources	resource	NOUN
ihlr-16500	716	9	required	require	VERB
ihlr-16500	716	10	to	to	PART
ihlr-16500	716	11	produce	produce	VERB
ihlr-16500	716	12	the	the	DET
ihlr-16500	716	13	next	next	ADJ
ihlr-16500	716	14	blockbuster	blockbuster	NOUN
ihlr-16500	716	15	drug	drug	NOUN
ihlr-16500	716	16	,	,	PUNCT
ihlr-16500	716	17	a	a	DET
ihlr-16500	716	18	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	716	19	company	company	NOUN
ihlr-16500	716	20	must	must	AUX
ihlr-16500	716	21	gain	gain	VERB
ihlr-16500	716	22	suffi­	suffi­	PROPN
ihlr-16500	716	23	cient	cient	VERB
ihlr-16500	716	24	revenue	revenue	NOUN
ihlr-16500	716	25	from	from	ADP
ihlr-16500	716	26	its	its	PRON
ihlr-16500	716	27	existing	exist	VERB
ihlr-16500	716	28	pipeline	pipeline	NOUN
ihlr-16500	716	29	of	of	ADP
ihlr-16500	716	30	drugs	drug	NOUN
ihlr-16500	716	31	.	.	PUNCT
ihlr-16500	717	1	hence	hence	ADV
ihlr-16500	717	2	,	,	PUNCT
ihlr-16500	717	3	a	a	DET
ihlr-16500	717	4	cycle	cycle	NOUN
ihlr-16500	717	5	in	in	ADP
ihlr-16500	717	6	which	which	PRON
ihlr-16500	717	7	a	a	DET
ihlr-16500	717	8	company	company	NOUN
ihlr-16500	717	9	is	be	AUX
ihlr-16500	717	10	forced	force	VERB
ihlr-16500	717	11	to	to	PART
ihlr-16500	717	12	produce	produce	VERB
ihlr-16500	717	13	blockbuster	blockbuster	ADJ
ihlr-16500	717	14	drugs	drug	NOUN
ihlr-16500	717	15	in	in	ADP
ihlr-16500	717	16	order	order	NOUN
ihlr-16500	717	17	to	to	PART
ihlr-16500	717	18	offset	offset	VERB
ihlr-16500	717	19	the	the	DET
ihlr-16500	717	20	costs	cost	NOUN
ihlr-16500	717	21	of	of	ADP
ihlr-16500	717	22	previous	previous	ADJ
ihlr-16500	717	23	blockbuster	blockbuster	NOUN
ihlr-16500	717	24	drugs	drug	NOUN
ihlr-16500	717	25	.	.	PUNCT
ihlr-16500	718	1	today	today	NOUN
ihlr-16500	718	2	,	,	PUNCT
ihlr-16500	718	3	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	718	4	conglomerates	conglomerate	NOUN
ihlr-16500	718	5	are	be	AUX
ihlr-16500	718	6	bigger	big	ADJ
ihlr-16500	718	7	than	than	ADP
ihlr-16500	718	8	ever	ever	ADV
ihlr-16500	718	9	.	.	PUNCT
ihlr-16500	719	1	presently	presently	ADV
ihlr-16500	719	2	,	,	PUNCT
ihlr-16500	719	3	more	more	ADJ
ihlr-16500	719	4	money	money	NOUN
ihlr-16500	719	5	is	be	AUX
ihlr-16500	719	6	spent	spend	VERB
ihlr-16500	719	7	on	on	ADP
ihlr-16500	719	8	obtaining	obtain	VERB
ihlr-16500	719	9	the	the	DET
ihlr-16500	719	10	brightest	bright	ADJ
ihlr-16500	719	11	executives	executive	NOUN
ihlr-16500	719	12	and	and	CCONJ
ihlr-16500	719	13	providing	provide	VERB
ihlr-16500	719	14	sales	sale	NOUN
ihlr-16500	719	15	personnel	personnel	NOUN
ihlr-16500	719	16	with	with	ADP
ihlr-16500	719	17	all	all	DET
ihlr-16500	719	18	the	the	DET
ihlr-16500	719	19	resources	resource	NOUN
ihlr-16500	719	20	necessary	necessary	ADJ
ihlr-16500	719	21	to	to	PART
ihlr-16500	719	22	obtain	obtain	VERB
ihlr-16500	719	23	the	the	DET
ihlr-16500	719	24	greatest	great	ADJ
ihlr-16500	719	25	possible	possible	ADJ
ihlr-16500	719	26	market	market	NOUN
ihlr-16500	719	27	share	share	NOUN
ihlr-16500	719	28	in	in	ADP
ihlr-16500	719	29	this	this	DET
ihlr-16500	719	30	very	very	ADV
ihlr-16500	719	31	competitive	competitive	ADJ
ihlr-16500	719	32	industry	industry	NOUN
ihlr-16500	719	33	.	.	PUNCT
ihlr-16500	720	1	the	the	DET
ihlr-16500	720	2	company	company	NOUN
ihlr-16500	720	3	depends	depend	VERB
ihlr-16500	720	4	on	on	ADP
ihlr-16500	720	5	a	a	DET
ihlr-16500	720	6	strong	strong	ADJ
ihlr-16500	720	7	pipe­	pipe­	NOUN
ihlr-16500	720	8	line	line	NOUN
ihlr-16500	720	9	of	of	ADP
ihlr-16500	720	10	drugs	drug	NOUN
ihlr-16500	720	11	that	that	PRON
ihlr-16500	720	12	will	will	AUX
ihlr-16500	720	13	provide	provide	VERB
ihlr-16500	720	14	a	a	DET
ihlr-16500	720	15	continual	continual	ADJ
ihlr-16500	720	16	stream	stream	NOUN
ihlr-16500	720	17	of	of	ADP
ihlr-16500	720	18	revenues	revenue	NOUN
ihlr-16500	720	19	and	and	CCONJ
ihlr-16500	720	20	profits	profit	NOUN
ihlr-16500	720	21	for	for	ADP
ihlr-16500	720	22	this	this	DET
ihlr-16500	720	23	purpose	purpose	NOUN
ihlr-16500	720	24	as	as	ADV
ihlr-16500	720	25	well	well	ADV
ihlr-16500	720	26	.	.	PUNCT
ihlr-16500	721	1	this	this	DET
ihlr-16500	721	2	stream	stream	NOUN
ihlr-16500	721	3	of	of	ADP
ihlr-16500	721	4	revenues	revenue	NOUN
ihlr-16500	721	5	and	and	CCONJ
ihlr-16500	721	6	profits	profit	NOUN
ihlr-16500	721	7	is	be	AUX
ihlr-16500	721	8	required	require	VERB
ihlr-16500	721	9	in	in	ADP
ihlr-16500	721	10	order	order	NOUN
ihlr-16500	721	11	for	for	SCONJ
ihlr-16500	721	12	the	the	DET
ihlr-16500	721	13	company	company	NOUN
ihlr-16500	721	14	to	to	PART
ihlr-16500	721	15	produce	produce	VERB
ihlr-16500	721	16	novel	novel	ADJ
ihlr-16500	721	17	medicines	medicine	NOUN
ihlr-16500	721	18	.	.	PUNCT
ihlr-16500	722	1	as	as	ADP
ihlr-16500	722	2	a	a	DET
ihlr-16500	722	3	result	result	NOUN
ihlr-16500	722	4	ofbeing	ofbee	VERB
ihlr-16500	722	5	a	a	DET
ihlr-16500	722	6	player	player	NOUN
ihlr-16500	722	7	in	in	ADP
ihlr-16500	722	8	a	a	DET
ihlr-16500	722	9	very	very	ADV
ihlr-16500	722	10	competitive	competitive	ADJ
ihlr-16500	722	11	industry	industry	NOUN
ihlr-16500	722	12	,	,	PUNCT
ihlr-16500	722	13	pharmaceuti­	pharmaceuti­	AUX
ihlr-16500	722	14	cal	cal	VERB
ihlr-16500	722	15	companies	company	NOUN
ihlr-16500	722	16	in	in	ADP
ihlr-16500	722	17	the	the	DET
ihlr-16500	722	18	united	united	PROPN
ihlr-16500	722	19	states	states	PROPN
ihlr-16500	722	20	have	have	VERB
ihlr-16500	722	21	the	the	DET
ihlr-16500	722	22	dual	dual	ADJ
ihlr-16500	722	23	objective	objective	NOUN
ihlr-16500	722	24	of	of	ADP
ihlr-16500	722	25	providing	provide	VERB
ihlr-16500	722	26	afford­	afford­	NOUN
ihlr-16500	722	27	able	able	ADJ
ihlr-16500	722	28	health	health	NOUN
ihlr-16500	722	29	care	care	NOUN
ihlr-16500	722	30	to	to	ADP
ihlr-16500	722	31	the	the	DET
ihlr-16500	722	32	general	general	ADJ
ihlr-16500	722	33	public	public	NOUN
ihlr-16500	722	34	and	and	CCONJ
ihlr-16500	722	35	making	make	VERB
ihlr-16500	722	36	a	a	DET
ihlr-16500	722	37	profit	profit	NOUN
ihlr-16500	722	38	for	for	ADP
ihlr-16500	722	39	their	their	PRON
ihlr-16500	722	40	shareholders	shareholder	NOUN
ihlr-16500	722	41	.	.	PUNCT
ihlr-16500	723	1	as	as	SCONJ
ihlr-16500	723	2	consumers	consumer	NOUN
ihlr-16500	723	3	have	have	AUX
ihlr-16500	723	4	demanded	demand	VERB
ihlr-16500	723	5	more	more	ADJ
ihlr-16500	723	6	affordable	affordable	ADJ
ihlr-16500	723	7	medicines	medicine	NOUN
ihlr-16500	723	8	,	,	PUNCT
ihlr-16500	723	9	pharmaceutical	pharmaceutical	NOUN
ihlr-16500	723	10	companies	company	NOUN
ihlr-16500	723	11	and	and	CCONJ
ihlr-16500	723	12	the	the	DET
ihlr-16500	723	13	fda	fda	PROPN
ihlr-16500	723	14	have	have	AUX
ihlr-16500	723	15	developed	develop	VERB
ihlr-16500	723	16	an	an	DET
ihlr-16500	723	17	increasingly	increasingly	ADV
ihlr-16500	723	18	cozy	cozy	ADJ
ihlr-16500	723	19	relationship	relationship	NOUN
ihlr-16500	723	20	and	and	CCONJ
ihlr-16500	723	21	,	,	PUNCT
ihlr-16500	723	22	as	as	ADP
ihlr-16500	723	23	a	a	DET
ihlr-16500	723	24	result	result	NOUN
ihlr-16500	723	25	,	,	PUNCT
ihlr-16500	723	26	have	have	AUX
ihlr-16500	723	27	put	put	VERB
ihlr-16500	723	28	the	the	DET
ihlr-16500	723	29	public	public	NOUN
ihlr-16500	723	30	at	at	ADP
ihlr-16500	723	31	risk	risk	NOUN
ihlr-16500	723	32	.	.	PUNCT
ihlr-16500	724	1	174	174	NUM
ihlr-16500	724	2	this	this	PRON
ihlr-16500	724	3	is	be	AUX
ihlr-16500	724	4	a	a	DET
ihlr-16500	724	5	contentious	contentious	ADJ
ihlr-16500	724	6	proposal	proposal	NOUN
ihlr-16500	724	7	for	for	ADP
ihlr-16500	724	8	172	172	NUM
ihlr-16500	724	9	goozner	goozner	NOUN
ihlr-16500	724	10	,	,	PUNCT
ihlr-16500	724	11	supra	supra	PROPN
ihlr-16500	724	12	note	note	NOUN
ihlr-16500	724	13	12	12	NUM
ihlr-16500	724	14	,	,	PUNCT
ihlr-16500	724	15	at	at	ADP
ihlr-16500	724	16	235	235	NUM
ihlr-16500	724	17	.	.	PUNCT
ihlr-16500	724	18	173	173	NUM
ihlr-16500	724	19	see	see	VERB
ihlr-16500	724	20	michelle	michelle	NOUN
ihlr-16500	724	21	meadows	meadow	NOUN
ihlr-16500	724	22	,	,	PUNCT
ihlr-16500	724	23	why	why	SCONJ
ihlr-16500	724	24	drugs	drug	NOUN
ihlr-16500	724	25	get	get	AUX
ihlr-16500	724	26	pulled	pull	VERB
ihlr-16500	724	27	off	off	ADP
ihlr-16500	724	28	the	the	DET
ihlr-16500	724	29	market	market	NOUN
ihlr-16500	724	30	,	,	PUNCT
ihlr-16500	724	31	fda	fda	PROPN
ihlr-16500	724	32	consumer	consumer	PROPN
ihlr-16500	724	33	,	,	PUNCT
ihlr-16500	724	34	jan.-feb	jan.-feb	PROPN
ihlr-16500	724	35	.	.	PROPN
ihlr-16500	724	36	2002	2002	NUM
ihlr-16500	724	37	,	,	PUNCT
ihlr-16500	724	38	at	at	ADP
ihlr-16500	724	39	11	11	NUM
ihlr-16500	724	40	,	,	PUNCT
ihlr-16500	724	41	11	11	NUM
ihlr-16500	724	42	-	-	SYM
ihlr-16500	724	43	17	17	NUM
ihlr-16500	724	44	,	,	PUNCT
ihlr-16500	724	45	http://www.fda.gov/fdac/features/2002/1	http://www.fda.gov/fdac/features/2002/1	NOUN
ihlr-16500	725	1	02	02	NUM
ihlr-16500	725	2	_	_	PUNCT
ihlr-16500	726	1	drug.htrnl	drug.htrnl	X
ihlr-16500	726	2	.	.	PUNCT
ihlr-16500	726	3	174	174	NUM
ihlr-16500	726	4	see	see	VERB
ihlr-16500	726	5	,	,	PUNCT
ihlr-16500	726	6	e.g.	e.g.	ADV
ihlr-16500	726	7	,	,	PUNCT
ihlr-16500	726	8	eric	eric	PROPN
ihlr-16500	726	9	j.	j.	PROPN
ihlr-16500	726	10	topol	topol	PROPN
ihlr-16500	726	11	,	,	PUNCT
ihlr-16500	726	12	failing	fail	VERB
ihlr-16500	726	13	the	the	DET
ihlr-16500	726	14	public	public	ADJ
ihlr-16500	726	15	health	health	NOUN
ihlr-16500	726	16	rofecoxib	rofecoxib	PROPN
ihlr-16500	726	17	,	,	PUNCT
ihlr-16500	726	18	merck	merck	NOUN
ihlr-16500	726	19	,	,	PUNCT
ihlr-16500	726	20	and	and	CCONJ
ihlr-16500	726	21	the	the	DET
ihlr-16500	726	22	fda	fda	PROPN
ihlr-16500	726	23	,	,	PUNCT
ihlr-16500	726	24	2007	2007	NUM
ihlr-16500	726	25	]	]	PUNCT
ihlr-16500	726	26	pulling	pull	VERB
ihlr-16500	726	27	a	a	DET
ihlr-16500	726	28	blockbuster	blockbuster	ADJ
ihlr-16500	726	29	drug	drug	NOUN
ihlr-16500	726	30	off	off	ADP
ihlr-16500	726	31	the	the	DET
ihlr-16500	726	32	market	market	NOUN
ihlr-16500	726	33	149	149	NUM
ihlr-16500	726	34	many	many	ADJ
ihlr-16500	726	35	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	726	36	executives	executive	NOUN
ihlr-16500	726	37	,	,	PUNCT
ihlr-16500	726	38	knowing	know	VERB
ihlr-16500	726	39	that	that	SCONJ
ihlr-16500	726	40	they	they	PRON
ihlr-16500	726	41	are	be	AUX
ihlr-16500	726	42	only	only	ADV
ihlr-16500	726	43	as	as	ADV
ihlr-16500	726	44	secure	secure	ADJ
ihlr-16500	726	45	as	as	ADP
ihlr-16500	726	46	the	the	DET
ihlr-16500	726	47	next	next	ADJ
ihlr-16500	726	48	dividend	dividend	NOUN
ihlr-16500	726	49	payment	payment	NOUN
ihlr-16500	726	50	to	to	ADP
ihlr-16500	726	51	their	their	PRON
ihlr-16500	726	52	shareholders	shareholder	NOUN
ihlr-16500	726	53	.	.	PUNCT
ihlr-16500	727	1	therefore	therefore	ADV
ihlr-16500	727	2	,	,	PUNCT
ihlr-16500	727	3	such	such	ADJ
ihlr-16500	727	4	executives	executive	NOUN
ihlr-16500	727	5	must	must	AUX
ihlr-16500	727	6	produce	produce	VERB
ihlr-16500	727	7	more	more	ADV
ihlr-16500	727	8	profitable	profitable	ADJ
ihlr-16500	727	9	blockbuster	blockbuster	ADJ
ihlr-16500	727	10	drugs	drug	NOUN
ihlr-16500	727	11	or	or	CCONJ
ihlr-16500	727	12	else	else	ADV
ihlr-16500	727	13	find	find	VERB
ihlr-16500	727	14	other	other	ADJ
ihlr-16500	727	15	employment	employment	NOUN
ihlr-16500	727	16	.	.	PUNCT
ihlr-16500	728	1	the	the	DET
ihlr-16500	728	2	continual	continual	ADJ
ihlr-16500	728	3	desire	desire	NOUN
ihlr-16500	728	4	to	to	PART
ihlr-16500	728	5	produce	produce	VERB
ihlr-16500	728	6	the	the	DET
ihlr-16500	728	7	next	next	ADJ
ihlr-16500	728	8	great	great	ADJ
ihlr-16500	728	9	blockbuster	blockbuster	NOUN
ihlr-16500	728	10	drug	drug	NOUN
ihlr-16500	728	11	can	can	AUX
ihlr-16500	728	12	lead	lead	VERB
ihlr-16500	728	13	to	to	ADP
ihlr-16500	728	14	many	many	ADJ
ihlr-16500	728	15	legal	legal	ADJ
ihlr-16500	728	16	,	,	PUNCT
ihlr-16500	728	17	business	business	NOUN
ihlr-16500	728	18	,	,	PUNCT
ihlr-16500	728	19	and	and	CCONJ
ihlr-16500	728	20	ethical	ethical	ADJ
ihlr-16500	728	21	problems	problem	NOUN
ihlr-16500	728	22	.	.	PUNCT
ihlr-16500	729	1	as	as	ADP
ihlr-16500	729	2	a	a	DET
ihlr-16500	729	3	result	result	NOUN
ihlr-16500	729	4	,	,	PUNCT
ihlr-16500	729	5	when	when	SCONJ
ihlr-16500	729	6	a	a	DET
ihlr-16500	729	7	pharmaceu­	pharmaceu­	X
ihlr-16500	729	8	tical	tical	ADJ
ihlr-16500	729	9	company	company	NOUN
ihlr-16500	729	10	produces	produce	VERB
ihlr-16500	729	11	a	a	DET
ihlr-16500	729	12	blockbuster	blockbuster	ADJ
ihlr-16500	729	13	drug	drug	NOUN
ihlr-16500	729	14	that	that	PRON
ihlr-16500	729	15	is	be	AUX
ihlr-16500	729	16	later	later	ADV
ihlr-16500	729	17	pulled	pull	VERB
ihlr-16500	729	18	off	off	ADP
ihlr-16500	729	19	the	the	DET
ihlr-16500	729	20	market	market	NOUN
ihlr-16500	729	21	because	because	SCONJ
ihlr-16500	729	22	of	of	ADP
ihlr-16500	729	23	safety	safety	NOUN
ihlr-16500	729	24	concerns	concern	NOUN
ihlr-16500	729	25	,	,	PUNCT
ihlr-16500	729	26	the	the	DET
ihlr-16500	729	27	question	question	NOUN
ihlr-16500	729	28	arises	arise	VERB
ihlr-16500	729	29	as	as	ADP
ihlr-16500	729	30	to	to	ADP
ihlr-16500	729	31	whether	whether	SCONJ
ihlr-16500	729	32	the	the	DET
ihlr-16500	729	33	lure	lure	NOUN
ihlr-16500	729	34	of	of	ADP
ihlr-16500	729	35	making	make	VERB
ihlr-16500	729	36	a	a	DET
ihlr-16500	729	37	profit	profit	NOUN
ihlr-16500	729	38	blinded	blind	VERB
ihlr-16500	729	39	the	the	DET
ihlr-16500	729	40	company	company	NOUN
ihlr-16500	729	41	into	into	ADP
ihlr-16500	729	42	approving	approve	VERB
ihlr-16500	729	43	a	a	DET
ihlr-16500	729	44	drug	drug	NOUN
ihlr-16500	729	45	wrought	work	VERB
ihlr-16500	729	46	with	with	ADP
ihlr-16500	729	47	safety	safety	NOUN
ihlr-16500	729	48	issues	issue	NOUN
ihlr-16500	729	49	.	.	PUNCT
ihlr-16500	730	1	regardless	regardless	ADV
ihlr-16500	730	2	of	of	ADP
ihlr-16500	730	3	the	the	DET
ihlr-16500	730	4	circumstances	circumstance	NOUN
ihlr-16500	730	5	prompting	prompt	VERB
ihlr-16500	730	6	a	a	DET
ihlr-16500	730	7	company	company	NOUN
ihlr-16500	730	8	to	to	PART
ihlr-16500	730	9	pull	pull	VERB
ihlr-16500	730	10	a	a	DET
ihlr-16500	730	11	drug	drug	NOUN
ihlr-16500	730	12	off	off	ADP
ihlr-16500	730	13	the	the	DET
ihlr-16500	730	14	market	market	NOUN
ihlr-16500	730	15	,	,	PUNCT
ihlr-16500	730	16	the	the	DET
ihlr-16500	730	17	ramifications	ramification	NOUN
ihlr-16500	730	18	of	of	ADP
ihlr-16500	730	19	such	such	DET
ihlr-16500	730	20	a	a	DET
ihlr-16500	730	21	decision	decision	NOUN
ihlr-16500	730	22	can	can	AUX
ihlr-16500	730	23	affect	affect	VERB
ihlr-16500	730	24	all	all	PRON
ihlr-16500	730	25	involved	involve	VERB
ihlr-16500	730	26	,	,	PUNCT
ihlr-16500	730	27	including	include	VERB
ihlr-16500	730	28	company	company	NOUN
ihlr-16500	730	29	employees	employee	NOUN
ihlr-16500	730	30	,	,	PUNCT
ihlr-16500	730	31	physicians	physician	NOUN
ihlr-16500	730	32	,	,	PUNCT
ihlr-16500	730	33	patients	patient	NOUN
ihlr-16500	730	34	,	,	PUNCT
ihlr-16500	730	35	and	and	CCONJ
ihlr-16500	730	36	the	the	DET
ihlr-16500	730	37	appropriate	appropriate	ADJ
ihlr-16500	730	38	regulatory	regulatory	ADJ
ihlr-16500	730	39	agen­	agen­	NOUN
ihlr-16500	730	40	cies	cie	NOUN
ihlr-16500	730	41	.	.	PUNCT
ihlr-16500	731	1	the	the	DET
ihlr-16500	731	2	legal	legal	ADJ
ihlr-16500	731	3	,	,	PUNCT
ihlr-16500	731	4	business	business	NOUN
ihlr-16500	731	5	,	,	PUNCT
ihlr-16500	731	6	and	and	CCONJ
ihlr-16500	731	7	ethical	ethical	ADJ
ihlr-16500	731	8	ramifications	ramification	NOUN
ihlr-16500	731	9	of	of	ADP
ihlr-16500	731	10	pulling	pull	VERB
ihlr-16500	731	11	a	a	DET
ihlr-16500	731	12	drug	drug	NOUN
ihlr-16500	731	13	off	off	ADP
ihlr-16500	731	14	the	the	DET
ihlr-16500	731	15	market	market	NOUN
ihlr-16500	731	16	can	can	AUX
ihlr-16500	731	17	be	be	AUX
ihlr-16500	731	18	severe	severe	ADJ
ihlr-16500	731	19	.	.	PUNCT
ihlr-16500	732	1	this	this	DET
ihlr-16500	732	2	removal	removal	NOUN
ihlr-16500	732	3	can	can	AUX
ihlr-16500	732	4	cost	cost	VERB
ihlr-16500	732	5	the	the	DET
ihlr-16500	732	6	company	company	NOUN
ihlr-16500	732	7	millions	million	NOUN
ihlr-16500	732	8	of	of	ADP
ihlr-16500	732	9	dollars	dollar	NOUN
ihlr-16500	732	10	in	in	ADP
ihlr-16500	732	11	litigation	litigation	NOUN
ihlr-16500	732	12	as	as	ADP
ihlr-16500	732	13	a	a	DET
ihlr-16500	732	14	result	result	NOUN
ihlr-16500	732	15	of	of	ADP
ihlr-16500	732	16	the	the	DET
ihlr-16500	732	17	multitude	multitude	NOUN
ihlr-16500	732	18	oflawsuits	oflawsuit	NOUN
ihlr-16500	732	19	brought	bring	VERB
ihlr-16500	732	20	by	by	ADP
ihlr-16500	732	21	the	the	DET
ihlr-16500	732	22	alleged	allege	VERB
ihlr-16500	732	23	victim­	victim­	NOUN
ihlr-16500	732	24	ized	ized	ADJ
ihlr-16500	732	25	plaintiffs	plaintiff	NOUN
ihlr-16500	732	26	claiming	claim	VERB
ihlr-16500	732	27	that	that	SCONJ
ihlr-16500	732	28	the	the	DET
ihlr-16500	732	29	company	company	NOUN
ihlr-16500	732	30	produced	produce	VERB
ihlr-16500	732	31	an	an	DET
ihlr-16500	732	32	unsafe	unsafe	ADJ
ihlr-16500	732	33	product	product	NOUN
ihlr-16500	732	34	.	.	PUNCT
ihlr-16500	733	1	175	175	NUM
ihlr-16500	733	2	the	the	DET
ihlr-16500	733	3	costs	cost	NOUN
ihlr-16500	733	4	of	of	ADP
ihlr-16500	733	5	a	a	DET
ihlr-16500	733	6	drug	drug	NOUN
ihlr-16500	733	7	withdrawal	withdrawal	NOUN
ihlr-16500	733	8	can	can	AUX
ihlr-16500	733	9	affect	affect	VERB
ihlr-16500	733	10	the	the	DET
ihlr-16500	733	11	company	company	NOUN
ihlr-16500	733	12	in	in	ADP
ihlr-16500	733	13	more	more	ADJ
ihlr-16500	733	14	ways	way	NOUN
ihlr-16500	733	15	than	than	ADP
ihlr-16500	733	16	just	just	ADV
ihlr-16500	733	17	its	its	PRON
ihlr-16500	733	18	bottom	bottom	ADJ
ihlr-16500	733	19	line	line	NOUN
ihlr-16500	733	20	.	.	PUNCT
ihlr-16500	734	1	for	for	ADP
ihlr-16500	734	2	instance	instance	NOUN
ihlr-16500	734	3	,	,	PUNCT
ihlr-16500	734	4	it	it	PRON
ihlr-16500	734	5	can	can	AUX
ihlr-16500	734	6	affect	affect	VERB
ihlr-16500	734	7	a	a	DET
ihlr-16500	734	8	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	734	9	company	company	NOUN
ihlr-16500	734	10	's	's	PART
ihlr-16500	734	11	perception	perception	NOUN
ihlr-16500	734	12	on	on	ADP
ihlr-16500	734	13	wall	wall	PROPN
ihlr-16500	734	14	street	street	PROPN
ihlr-16500	734	15	and	and	CCONJ
ihlr-16500	734	16	,	,	PUNCT
ihlr-16500	734	17	as	as	ADP
ihlr-16500	734	18	a	a	DET
ihlr-16500	734	19	result	result	NOUN
ihlr-16500	734	20	,	,	PUNCT
ihlr-16500	734	21	affect	affect	VERB
ihlr-16500	734	22	investor	investor	NOUN
ihlr-16500	734	23	confidence	confidence	NOUN
ihlr-16500	734	24	.	.	PUNCT
ihlr-16500	735	1	since	since	SCONJ
ihlr-16500	735	2	most	most	ADJ
ihlr-16500	735	3	large	large	ADJ
ihlr-16500	735	4	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	735	5	conglomerates	conglomerate	NOUN
ihlr-16500	735	6	are	be	AUX
ihlr-16500	735	7	traded	trade	VERB
ihlr-16500	735	8	on	on	ADP
ihlr-16500	735	9	publicly	publicly	ADV
ihlr-16500	735	10	accessible	accessible	ADJ
ihlr-16500	735	11	stock	stock	NOUN
ihlr-16500	735	12	ex­	ex­	NOUN
ihlr-16500	735	13	changes	change	NOUN
ihlr-16500	735	14	,	,	PUNCT
ihlr-16500	735	15	a	a	DET
ihlr-16500	735	16	major	major	ADJ
ihlr-16500	735	17	drug	drug	NOUN
ihlr-16500	735	18	withdrawal	withdrawal	NOUN
ihlr-16500	735	19	can	can	AUX
ihlr-16500	735	20	cause	cause	VERB
ihlr-16500	735	21	a	a	DET
ihlr-16500	735	22	decrease	decrease	NOUN
ihlr-16500	735	23	in	in	ADP
ihlr-16500	735	24	stock	stock	NOUN
ihlr-16500	735	25	price	price	NOUN
ihlr-16500	735	26	.	.	PUNCT
ihlr-16500	736	1	there­	there­	NUM
ihlr-16500	736	2	fore	fore	NOUN
ihlr-16500	736	3	,	,	PUNCT
ihlr-16500	736	4	the	the	DET
ihlr-16500	736	5	loss	loss	NOUN
ihlr-16500	736	6	in	in	ADP
ihlr-16500	736	7	investor	investor	NOUN
ihlr-16500	736	8	confidence	confidence	NOUN
ihlr-16500	736	9	ultimately	ultimately	ADV
ihlr-16500	736	10	leads	lead	VERB
ihlr-16500	736	11	to	to	ADP
ihlr-16500	736	12	a	a	DET
ihlr-16500	736	13	variety	variety	NOUN
ihlr-16500	736	14	of	of	ADP
ihlr-16500	736	15	changes	change	NOUN
ihlr-16500	736	16	within	within	ADP
ihlr-16500	736	17	the	the	DET
ihlr-16500	736	18	respective	respective	ADJ
ihlr-16500	736	19	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	736	20	company	company	NOUN
ihlr-16500	736	21	.	.	PUNCT
ihlr-16500	737	1	restructuring	restructure	VERB
ihlr-16500	737	2	leadership	leadership	NOUN
ihlr-16500	737	3	posi­	posi­	PROPN
ihlr-16500	737	4	tions	tion	NOUN
ihlr-16500	737	5	can	can	AUX
ihlr-16500	737	6	include	include	VERB
ihlr-16500	737	7	layoffs	layoff	NOUN
ihlr-16500	737	8	and	and	CCONJ
ihlr-16500	737	9	termination	termination	NOUN
ihlr-16500	737	10	of	of	ADP
ihlr-16500	737	11	many	many	ADJ
ihlr-16500	737	12	executive	executive	ADJ
ihlr-16500	737	13	positions	position	NOUN
ihlr-16500	737	14	.	.	PUNCT
ihlr-16500	738	1	finally	finally	ADV
ihlr-16500	738	2	,	,	PUNCT
ihlr-16500	738	3	there	there	PRON
ihlr-16500	738	4	are	be	VERB
ihlr-16500	738	5	significant	significant	ADJ
ihlr-16500	738	6	ethical	ethical	ADJ
ihlr-16500	738	7	questions	question	NOUN
ihlr-16500	738	8	to	to	PART
ihlr-16500	738	9	be	be	AUX
ihlr-16500	738	10	answered	answer	VERB
ihlr-16500	738	11	after	after	SCONJ
ihlr-16500	738	12	a	a	DET
ihlr-16500	738	13	drug	drug	NOUN
ihlr-16500	738	14	has	have	AUX
ihlr-16500	738	15	been	be	AUX
ihlr-16500	738	16	withdrawn	withdraw	VERB
ihlr-16500	738	17	from	from	ADP
ihlr-16500	738	18	the	the	DET
ihlr-16500	738	19	market	market	NOUN
ihlr-16500	738	20	.	.	PUNCT
ihlr-16500	739	1	specifically	specifically	ADV
ihlr-16500	739	2	,	,	PUNCT
ihlr-16500	739	3	how	how	SCONJ
ihlr-16500	739	4	are	be	AUX
ihlr-16500	739	5	patients	patient	NOUN
ihlr-16500	739	6	to	to	PART
ihlr-16500	739	7	cope	cope	VERB
ihlr-16500	739	8	when	when	SCONJ
ihlr-16500	739	9	they	they	PRON
ihlr-16500	739	10	have	have	AUX
ihlr-16500	739	11	depended	depend	VERB
ihlr-16500	739	12	on	on	ADP
ihlr-16500	739	13	the	the	DET
ihlr-16500	739	14	withdrawn	withdraw	VERB
ihlr-16500	739	15	drug	drug	NOUN
ihlr-16500	739	16	to	to	PART
ihlr-16500	739	17	provide	provide	VERB
ihlr-16500	739	18	them	they	PRON
ihlr-16500	739	19	with	with	ADP
ihlr-16500	739	20	a	a	DET
ihlr-16500	739	21	quality	quality	NOUN
ihlr-16500	739	22	of	of	ADP
ihlr-16500	739	23	life	life	NOUN
ihlr-16500	739	24	that	that	PRON
ihlr-16500	739	25	they	they	PRON
ihlr-16500	739	26	did	do	AUX
ihlr-16500	739	27	not	not	PART
ihlr-16500	739	28	possess	possess	VERB
ihlr-16500	739	29	prior	prior	ADV
ihlr-16500	739	30	to	to	ADP
ihlr-16500	739	31	the	the	DET
ihlr-16500	739	32	drug	drug	NOUN
ihlr-16500	739	33	's	's	PART
ihlr-16500	739	34	introduction	introduction	NOUN
ihlr-16500	739	35	in	in	ADP
ihlr-16500	739	36	the	the	DET
ihlr-16500	739	37	market­	market­	PROPN
ihlr-16500	739	38	place	place	NOUN
ihlr-16500	739	39	?	?	PUNCT
ihlr-16500	740	1	moreover	moreover	ADV
ihlr-16500	740	2	,	,	PUNCT
ihlr-16500	740	3	when	when	SCONJ
ihlr-16500	740	4	did	do	AUX
ihlr-16500	740	5	the	the	DET
ihlr-16500	740	6	fda	fda	PROPN
ihlr-16500	740	7	and	and	CCONJ
ihlr-16500	740	8	the	the	DET
ihlr-16500	740	9	respective	respective	ADJ
ihlr-16500	740	10	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	740	11	com­	com­	NOUN
ihlr-16500	740	12	pany	pany	NOUN
ihlr-16500	740	13	know	know	PROPN
ihlr-16500	740	14	of	of	ADP
ihlr-16500	740	15	the	the	DET
ihlr-16500	740	16	drug	drug	NOUN
ihlr-16500	740	17	's	's	PART
ihlr-16500	740	18	safety	safety	NOUN
ihlr-16500	740	19	issues	issue	NOUN
ihlr-16500	740	20	and	and	CCONJ
ihlr-16500	740	21	was	be	AUX
ihlr-16500	740	22	the	the	DET
ihlr-16500	740	23	response	response	NOUN
ihlr-16500	740	24	swift	swift	ADJ
ihlr-16500	740	25	and	and	CCONJ
ihlr-16500	740	26	appropriate	appropriate	ADJ
ihlr-16500	740	27	?	?	PUNCT
ihlr-16500	741	1	the	the	DET
ihlr-16500	741	2	ideal	ideal	ADJ
ihlr-16500	741	3	solution	solution	NOUN
ihlr-16500	741	4	would	would	AUX
ihlr-16500	741	5	be	be	AUX
ihlr-16500	741	6	for	for	SCONJ
ihlr-16500	741	7	the	the	DET
ihlr-16500	741	8	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	741	9	companies	company	NOUN
ihlr-16500	741	10	to	to	PART
ihlr-16500	741	11	take	take	VERB
ihlr-16500	741	12	these	these	DET
ihlr-16500	741	13	questions	question	NOUN
ihlr-16500	741	14	into	into	ADP
ihlr-16500	741	15	account	account	NOUN
ihlr-16500	741	16	both	both	PRON
ihlr-16500	741	17	prior	prior	ADV
ihlr-16500	741	18	to	to	ADP
ihlr-16500	741	19	marketing	market	VERB
ihlr-16500	741	20	the	the	DET
ihlr-16500	741	21	blockbuster	blockbuster	NOUN
ihlr-16500	741	22	drug	drug	NOUN
ihlr-16500	741	23	and	and	CCONJ
ihlr-16500	741	24	every	every	DET
ihlr-16500	741	25	step	step	NOUN
ihlr-16500	741	26	of	of	ADP
ihlr-16500	741	27	the	the	DET
ihlr-16500	741	28	way	way	NOUN
ihlr-16500	741	29	after	after	ADP
ihlr-16500	741	30	initially	initially	ADV
ihlr-16500	741	31	marketing	market	VERB
ihlr-16500	741	32	it	it	PRON
ihlr-16500	741	33	.	.	PUNCT
ihlr-16500	742	1	after	after	ADP
ihlr-16500	742	2	examining	examine	VERB
ihlr-16500	742	3	the	the	DET
ihlr-16500	742	4	different	different	ADJ
ihlr-16500	742	5	parties	party	NOUN
ihlr-16500	742	6	affected	affect	VERB
ihlr-16500	742	7	by	by	ADP
ihlr-16500	742	8	a	a	DET
ihlr-16500	742	9	drug	drug	NOUN
ihlr-16500	742	10	withdrawal	withdrawal	NOUN
ihlr-16500	742	11	,	,	PUNCT
ihlr-16500	742	12	there	there	PRON
ihlr-16500	742	13	is	be	VERB
ihlr-16500	742	14	no	no	DET
ihlr-16500	742	15	one	one	NUM
ihlr-16500	742	16	party	party	NOUN
ihlr-16500	742	17	who	who	PRON
ihlr-16500	742	18	is	be	AUX
ihlr-16500	742	19	clearly	clearly	ADV
ihlr-16500	742	20	culpable	culpable	ADJ
ihlr-16500	742	21	.	.	PUNCT
ihlr-16500	743	1	although	although	SCONJ
ihlr-16500	743	2	at	at	ADP
ihlr-16500	743	3	first	first	ADV
ihlr-16500	743	4	it	it	PRON
ihlr-16500	743	5	seems	seem	VERB
ihlr-16500	743	6	as	as	SCONJ
ihlr-16500	743	7	if	if	SCONJ
ihlr-16500	743	8	the	the	DET
ihlr-16500	743	9	pharmaceutical	pharmaceutical	ADJ
ihlr-16500	743	10	company	company	NOUN
ihlr-16500	743	11	must	must	AUX
ihlr-16500	743	12	be	be	AUX
ihlr-16500	743	13	blamed	blame	VERB
ihlr-16500	743	14	,	,	PUNCT
ihlr-16500	743	15	176	176	NUM
ihlr-16500	743	16	in	in	ADP
ihlr-16500	743	17	essence	essence	NOUN
ihlr-16500	743	18	,	,	PUNCT
ihlr-16500	743	19	there	there	PRON
ihlr-16500	743	20	are	be	VERB
ihlr-16500	743	21	many	many	ADJ
ihlr-16500	743	22	parties	party	NOUN
ihlr-16500	743	23	that	that	PRON
ihlr-16500	743	24	are	be	AUX
ihlr-16500	743	25	blameworthy	blameworthy	ADJ
ihlr-16500	743	26	.	.	PUNCT
ihlr-16500	744	1	to	to	PART
ihlr-16500	744	2	solely	solely	ADV
ihlr-16500	744	3	blame	blame	VERB
ihlr-16500	744	4	one	one	NUM
ihlr-16500	744	5	party	party	NOUN
ihlr-16500	744	6	over	over	ADP
ihlr-16500	744	7	another	another	PRON
ihlr-16500	744	8	,	,	PUNCT
ihlr-16500	744	9	however	however	ADV
ihlr-16500	744	10	,	,	PUNCT
ihlr-16500	744	11	would	would	AUX
ihlr-16500	744	12	be	be	AUX
ihlr-16500	744	13	erroneous	erroneous	ADJ
ihlr-16500	744	14	because	because	SCONJ
ihlr-16500	744	15	,	,	PUNCT
ihlr-16500	744	16	ultimately	ultimately	ADV
ihlr-16500	744	17	,	,	PUNCT
ihlr-16500	744	18	the	the	DET
ihlr-16500	744	19	parties	party	NOUN
ihlr-16500	744	20	negatively	negatively	ADV
ihlr-16500	744	21	affected	affect	VERB
ihlr-16500	744	22	by	by	ADP
ihlr-16500	744	23	a	a	DET
ihlr-16500	744	24	drug	drug	NOUN
ihlr-16500	744	25	351	351	NUM
ihlr-16500	744	26	new	new	ADJ
ihlr-16500	744	27	eng	eng	PROPN
ihlr-16500	744	28	.	.	PUNCT
ihlr-16500	745	1	j.	j.	PROPN
ihlr-16500	745	2	med	med	PROPN
ihlr-16500	745	3	.	.	PROPN
ihlr-16500	745	4	1707	1707	NUM
ihlr-16500	745	5	,	,	PUNCT
ihlr-16500	745	6	1707	1707	NUM
ihlr-16500	745	7	-	-	SYM
ihlr-16500	745	8	09	09	NUM
ihlr-16500	745	9	(	(	PUNCT
ihlr-16500	745	10	2004	2004	NUM
ihlr-16500	745	11	)	)	PUNCT
ihlr-16500	745	12	;	;	PUNCT
ihlr-16500	745	13	thomas	thomas	PROPN
ihlr-16500	745	14	l.	l.	PROPN
ihlr-16500	745	15	friedman	friedman	PROPN
ihlr-16500	745	16	,	,	PUNCT
ihlr-16500	745	17	the	the	DET
ihlr-16500	745	18	world	world	NOUN
ihlr-16500	745	19	is	be	AUX
ihlr-16500	745	20	fiat	fiat	ADJ
ihlr-16500	745	21	:	:	PUNCT
ihlr-16500	745	22	a	a	DET
ihlr-16500	745	23	brief	brief	ADJ
ihlr-16500	745	24	history	history	NOUN
ihlr-16500	745	25	of	of	ADP
ihlr-16500	745	26	the	the	DET
ihlr-16500	745	27	twenty	twenty	NUM
ihlr-16500	745	28	-	-	PUNCT
ihlr-16500	745	29	first	first	ADJ
ihlr-16500	745	30	century	century	NOUN
ihlr-16500	745	31	252	252	NUM
ihlr-16500	745	32	(	(	PUNCT
ihlr-16500	745	33	2006	2006	NUM
ihlr-16500	745	34	)	)	PUNCT
ihlr-16500	745	35	.	.	PUNCT
ihlr-16500	746	1	175	175	NUM
ihlr-16500	746	2	on	on	ADP
ihlr-16500	746	3	the	the	DET
ihlr-16500	746	4	other	other	ADJ
ihlr-16500	746	5	hand	hand	NOUN
ihlr-16500	746	6	,	,	PUNCT
ihlr-16500	746	7	patients	patient	NOUN
ihlr-16500	746	8	who	who	PRON
ihlr-16500	746	9	were	be	AUX
ihlr-16500	746	10	negatively	negatively	ADV
ihlr-16500	746	11	affected	affect	VERB
ihlr-16500	746	12	by	by	ADP
ihlr-16500	746	13	the	the	DET
ihlr-16500	746	14	drug	drug	NOUN
ihlr-16500	746	15	must	must	AUX
ihlr-16500	746	16	spend	spend	VERB
ihlr-16500	746	17	con­	con­	NOUN
ihlr-16500	746	18	siderable	siderable	ADJ
ihlr-16500	746	19	time	time	NOUN
ihlr-16500	746	20	and	and	CCONJ
ihlr-16500	746	21	money	money	NOUN
ihlr-16500	746	22	to	to	PART
ihlr-16500	746	23	sue	sue	VERB
ihlr-16500	746	24	a	a	DET
ihlr-16500	746	25	defendant	defendant	NOUN
ihlr-16500	746	26	who	who	PRON
ihlr-16500	746	27	more	more	ADV
ihlr-16500	746	28	often	often	ADV
ihlr-16500	746	29	has	have	VERB
ihlr-16500	746	30	considerably	considerably	ADV
ihlr-16500	746	31	greater	great	ADJ
ihlr-16500	746	32	resources	resource	NOUN
ihlr-16500	746	33	.	.	PUNCT
ihlr-16500	747	1	176	176	NUM
ihlr-16500	747	2	see	see	VERB
ihlr-16500	747	3	generally	generally	ADV
ihlr-16500	747	4	barry	barry	PROPN
ihlr-16500	747	5	werth	werth	PROPN
ihlr-16500	747	6	,	,	PUNCT
ihlr-16500	747	7	the	the	DET
ihlr-16500	747	8	billion	billion	NUM
ihlr-16500	747	9	dollar	dollar	NOUN
ihlr-16500	747	10	molecule	molecule	NOUN
ihlr-16500	747	11	:	:	PUNCT
ihlr-16500	747	12	one	one	NUM
ihlr-16500	747	13	company	company	NOUN
ihlr-16500	747	14	's	's	PART
ihlr-16500	747	15	quest	quest	NOUN
ihlr-16500	747	16	for	for	ADP
ihlr-16500	747	17	the	the	DET
ihlr-16500	747	18	perfect	perfect	ADJ
ihlr-16500	747	19	drug	drug	NOUN
ihlr-16500	747	20	(	(	PUNCT
ihlr-16500	747	21	1994	1994	NUM
ihlr-16500	747	22	)	)	PUNCT
ihlr-16500	747	23	(	(	PUNCT
ihlr-16500	747	24	illustrating	illustrate	VERB
ihlr-16500	747	25	the	the	DET
ihlr-16500	747	26	importance	importance	NOUN
ihlr-16500	747	27	that	that	SCONJ
ihlr-16500	747	28	a	a	DET
ihlr-16500	747	29	company	company	NOUN
ihlr-16500	747	30	places	place	VERB
ihlr-16500	747	31	on	on	ADP
ihlr-16500	747	32	profits	profit	NOUN
ihlr-16500	747	33	and	and	CCONJ
ihlr-16500	747	34	finding	find	VERB
ihlr-16500	747	35	the	the	DET
ihlr-16500	747	36	next	next	ADJ
ihlr-16500	747	37	blockbuster	blockbuster	NOUN
ihlr-16500	747	38	drug	drug	NOUN
ihlr-16500	747	39	)	)	PUNCT
ihlr-16500	747	40	.	.	PUNCT
ihlr-16500	748	1	150	150	NUM
ihlr-16500	748	2	indiana	indiana	PROPN
ihlr-16500	748	3	health	health	PROPN
ihlr-16500	748	4	law	law	NOUN
ihlr-16500	748	5	review	review	NOUN
ihlr-16500	748	6	[	[	X
ihlr-16500	748	7	vol	vol	NOUN
ihlr-16500	748	8	.	.	PUNCT
ihlr-16500	749	1	4:115	4:115	NUM
ihlr-16500	749	2	withdrawal	withdrawal	NOUN
ihlr-16500	749	3	are	be	AUX
ihlr-16500	749	4	also	also	ADV
ihlr-16500	749	5	those	those	PRON
ihlr-16500	749	6	in	in	ADP
ihlr-16500	749	7	fervent	fervent	ADJ
ihlr-16500	749	8	support	support	NOUN
ihlr-16500	749	9	of	of	ADP
ihlr-16500	749	10	developing	develop	VERB
ihlr-16500	749	11	and	and	CCONJ
ihlr-16500	749	12	distributing	distribute	VERB
ihlr-16500	749	13	ef­	ef­	NOUN
ihlr-16500	749	14	fective	fective	ADJ
ihlr-16500	749	15	drugs	drug	NOUN
ihlr-16500	749	16	.	.	PUNCT